<!DOCTYPE html>

<html>

<head>

<meta name="robots" content="noindex, nofollow">
<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>nanaokunote</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>
<script>/*! jQuery v3.6.0 | (c) OpenJS Foundation and other contributors | jquery.org/license */
!function(e,t){"use strict";"object"==typeof module&&"object"==typeof module.exports?module.exports=e.document?t(e,!0):function(e){if(!e.document)throw new Error("jQuery requires a window with a document");return t(e)}:t(e)}("undefined"!=typeof window?window:this,function(C,e){"use strict";var t=[],r=Object.getPrototypeOf,s=t.slice,g=t.flat?function(e){return t.flat.call(e)}:function(e){return t.concat.apply([],e)},u=t.push,i=t.indexOf,n={},o=n.toString,v=n.hasOwnProperty,a=v.toString,l=a.call(Object),y={},m=function(e){return"function"==typeof e&&"number"!=typeof e.nodeType&&"function"!=typeof e.item},x=function(e){return null!=e&&e===e.window},E=C.document,c={type:!0,src:!0,nonce:!0,noModule:!0};function b(e,t,n){var r,i,o=(n=n||E).createElement("script");if(o.text=e,t)for(r in c)(i=t[r]||t.getAttribute&&t.getAttribute(r))&&o.setAttribute(r,i);n.head.appendChild(o).parentNode.removeChild(o)}function w(e){return null==e?e+"":"object"==typeof e||"function"==typeof e?n[o.call(e)]||"object":typeof e}var f="3.6.0",S=function(e,t){return new S.fn.init(e,t)};function p(e){var t=!!e&&"length"in e&&e.length,n=w(e);return!m(e)&&!x(e)&&("array"===n||0===t||"number"==typeof t&&0<t&&t-1 in e)}S.fn=S.prototype={jquery:f,constructor:S,length:0,toArray:function(){return s.call(this)},get:function(e){return null==e?s.call(this):e<0?this[e+this.length]:this[e]},pushStack:function(e){var t=S.merge(this.constructor(),e);return t.prevObject=this,t},each:function(e){return S.each(this,e)},map:function(n){return this.pushStack(S.map(this,function(e,t){return n.call(e,t,e)}))},slice:function(){return this.pushStack(s.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},even:function(){return this.pushStack(S.grep(this,function(e,t){return(t+1)%2}))},odd:function(){return this.pushStack(S.grep(this,function(e,t){return t%2}))},eq:function(e){var t=this.length,n=+e+(e<0?t:0);return this.pushStack(0<=n&&n<t?[this[n]]:[])},end:function(){return this.prevObject||this.constructor()},push:u,sort:t.sort,splice:t.splice},S.extend=S.fn.extend=function(){var e,t,n,r,i,o,a=arguments[0]||{},s=1,u=arguments.length,l=!1;for("boolean"==typeof a&&(l=a,a=arguments[s]||{},s++),"object"==typeof a||m(a)||(a={}),s===u&&(a=this,s--);s<u;s++)if(null!=(e=arguments[s]))for(t in e)r=e[t],"__proto__"!==t&&a!==r&&(l&&r&&(S.isPlainObject(r)||(i=Array.isArray(r)))?(n=a[t],o=i&&!Array.isArray(n)?[]:i||S.isPlainObject(n)?n:{},i=!1,a[t]=S.extend(l,o,r)):void 0!==r&&(a[t]=r));return a},S.extend({expando:"jQuery"+(f+Math.random()).replace(/\D/g,""),isReady:!0,error:function(e){throw new Error(e)},noop:function(){},isPlainObject:function(e){var t,n;return!(!e||"[object Object]"!==o.call(e))&&(!(t=r(e))||"function"==typeof(n=v.call(t,"constructor")&&t.constructor)&&a.call(n)===l)},isEmptyObject:function(e){var t;for(t in e)return!1;return!0},globalEval:function(e,t,n){b(e,{nonce:t&&t.nonce},n)},each:function(e,t){var n,r=0;if(p(e)){for(n=e.length;r<n;r++)if(!1===t.call(e[r],r,e[r]))break}else for(r in e)if(!1===t.call(e[r],r,e[r]))break;return e},makeArray:function(e,t){var n=t||[];return null!=e&&(p(Object(e))?S.merge(n,"string"==typeof e?[e]:e):u.call(n,e)),n},inArray:function(e,t,n){return null==t?-1:i.call(t,e,n)},merge:function(e,t){for(var n=+t.length,r=0,i=e.length;r<n;r++)e[i++]=t[r];return e.length=i,e},grep:function(e,t,n){for(var r=[],i=0,o=e.length,a=!n;i<o;i++)!t(e[i],i)!==a&&r.push(e[i]);return r},map:function(e,t,n){var r,i,o=0,a=[];if(p(e))for(r=e.length;o<r;o++)null!=(i=t(e[o],o,n))&&a.push(i);else for(o in e)null!=(i=t(e[o],o,n))&&a.push(i);return g(a)},guid:1,support:y}),"function"==typeof Symbol&&(S.fn[Symbol.iterator]=t[Symbol.iterator]),S.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(e,t){n["[object "+t+"]"]=t.toLowerCase()});var d=function(n){var e,d,b,o,i,h,f,g,w,u,l,T,C,a,E,v,s,c,y,S="sizzle"+1*new Date,p=n.document,k=0,r=0,m=ue(),x=ue(),A=ue(),N=ue(),j=function(e,t){return e===t&&(l=!0),0},D={}.hasOwnProperty,t=[],q=t.pop,L=t.push,H=t.push,O=t.slice,P=function(e,t){for(var n=0,r=e.length;n<r;n++)if(e[n]===t)return n;return-1},R="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",M="[\\x20\\t\\r\\n\\f]",I="(?:\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\[^\\r\\n\\f]|[\\w-]|[^\0-\\x7f])+",W="\\["+M+"*("+I+")(?:"+M+"*([*^$|!~]?=)"+M+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+I+"))|)"+M+"*\\]",F=":("+I+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+W+")*)|.*)\\)|)",B=new RegExp(M+"+","g"),$=new RegExp("^"+M+"+|((?:^|[^\\\\])(?:\\\\.)*)"+M+"+$","g"),_=new RegExp("^"+M+"*,"+M+"*"),z=new RegExp("^"+M+"*([>+~]|"+M+")"+M+"*"),U=new RegExp(M+"|>"),X=new RegExp(F),V=new RegExp("^"+I+"$"),G={ID:new RegExp("^#("+I+")"),CLASS:new RegExp("^\\.("+I+")"),TAG:new RegExp("^("+I+"|[*])"),ATTR:new RegExp("^"+W),PSEUDO:new RegExp("^"+F),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+M+"*(even|odd|(([+-]|)(\\d*)n|)"+M+"*(?:([+-]|)"+M+"*(\\d+)|))"+M+"*\\)|)","i"),bool:new RegExp("^(?:"+R+")$","i"),needsContext:new RegExp("^"+M+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+M+"*((?:-\\d)?\\d*)"+M+"*\\)|)(?=[^-]|$)","i")},Y=/HTML$/i,Q=/^(?:input|select|textarea|button)$/i,J=/^h\d$/i,K=/^[^{]+\{\s*\[native \w/,Z=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,ee=/[+~]/,te=new RegExp("\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\([^\\r\\n\\f])","g"),ne=function(e,t){var n="0x"+e.slice(1)-65536;return t||(n<0?String.fromCharCode(n+65536):String.fromCharCode(n>>10|55296,1023&n|56320))},re=/([\0-\x1f\x7f]|^-?\d)|^-$|[^\0-\x1f\x7f-\uFFFF\w-]/g,ie=function(e,t){return t?"\0"===e?"\ufffd":e.slice(0,-1)+"\\"+e.charCodeAt(e.length-1).toString(16)+" ":"\\"+e},oe=function(){T()},ae=be(function(e){return!0===e.disabled&&"fieldset"===e.nodeName.toLowerCase()},{dir:"parentNode",next:"legend"});try{H.apply(t=O.call(p.childNodes),p.childNodes),t[p.childNodes.length].nodeType}catch(e){H={apply:t.length?function(e,t){L.apply(e,O.call(t))}:function(e,t){var n=e.length,r=0;while(e[n++]=t[r++]);e.length=n-1}}}function se(t,e,n,r){var i,o,a,s,u,l,c,f=e&&e.ownerDocument,p=e?e.nodeType:9;if(n=n||[],"string"!=typeof t||!t||1!==p&&9!==p&&11!==p)return n;if(!r&&(T(e),e=e||C,E)){if(11!==p&&(u=Z.exec(t)))if(i=u[1]){if(9===p){if(!(a=e.getElementById(i)))return n;if(a.id===i)return n.push(a),n}else if(f&&(a=f.getElementById(i))&&y(e,a)&&a.id===i)return n.push(a),n}else{if(u[2])return H.apply(n,e.getElementsByTagName(t)),n;if((i=u[3])&&d.getElementsByClassName&&e.getElementsByClassName)return H.apply(n,e.getElementsByClassName(i)),n}if(d.qsa&&!N[t+" "]&&(!v||!v.test(t))&&(1!==p||"object"!==e.nodeName.toLowerCase())){if(c=t,f=e,1===p&&(U.test(t)||z.test(t))){(f=ee.test(t)&&ye(e.parentNode)||e)===e&&d.scope||((s=e.getAttribute("id"))?s=s.replace(re,ie):e.setAttribute("id",s=S)),o=(l=h(t)).length;while(o--)l[o]=(s?"#"+s:":scope")+" "+xe(l[o]);c=l.join(",")}try{return H.apply(n,f.querySelectorAll(c)),n}catch(e){N(t,!0)}finally{s===S&&e.removeAttribute("id")}}}return g(t.replace($,"$1"),e,n,r)}function ue(){var r=[];return function e(t,n){return r.push(t+" ")>b.cacheLength&&delete e[r.shift()],e[t+" "]=n}}function le(e){return e[S]=!0,e}function ce(e){var t=C.createElement("fieldset");try{return!!e(t)}catch(e){return!1}finally{t.parentNode&&t.parentNode.removeChild(t),t=null}}function fe(e,t){var n=e.split("|"),r=n.length;while(r--)b.attrHandle[n[r]]=t}function pe(e,t){var n=t&&e,r=n&&1===e.nodeType&&1===t.nodeType&&e.sourceIndex-t.sourceIndex;if(r)return r;if(n)while(n=n.nextSibling)if(n===t)return-1;return e?1:-1}function de(t){return function(e){return"input"===e.nodeName.toLowerCase()&&e.type===t}}function he(n){return function(e){var t=e.nodeName.toLowerCase();return("input"===t||"button"===t)&&e.type===n}}function ge(t){return function(e){return"form"in e?e.parentNode&&!1===e.disabled?"label"in e?"label"in e.parentNode?e.parentNode.disabled===t:e.disabled===t:e.isDisabled===t||e.isDisabled!==!t&&ae(e)===t:e.disabled===t:"label"in e&&e.disabled===t}}function ve(a){return le(function(o){return o=+o,le(function(e,t){var n,r=a([],e.length,o),i=r.length;while(i--)e[n=r[i]]&&(e[n]=!(t[n]=e[n]))})})}function ye(e){return e&&"undefined"!=typeof e.getElementsByTagName&&e}for(e in d=se.support={},i=se.isXML=function(e){var t=e&&e.namespaceURI,n=e&&(e.ownerDocument||e).documentElement;return!Y.test(t||n&&n.nodeName||"HTML")},T=se.setDocument=function(e){var t,n,r=e?e.ownerDocument||e:p;return r!=C&&9===r.nodeType&&r.documentElement&&(a=(C=r).documentElement,E=!i(C),p!=C&&(n=C.defaultView)&&n.top!==n&&(n.addEventListener?n.addEventListener("unload",oe,!1):n.attachEvent&&n.attachEvent("onunload",oe)),d.scope=ce(function(e){return a.appendChild(e).appendChild(C.createElement("div")),"undefined"!=typeof e.querySelectorAll&&!e.querySelectorAll(":scope fieldset div").length}),d.attributes=ce(function(e){return e.className="i",!e.getAttribute("className")}),d.getElementsByTagName=ce(function(e){return e.appendChild(C.createComment("")),!e.getElementsByTagName("*").length}),d.getElementsByClassName=K.test(C.getElementsByClassName),d.getById=ce(function(e){return a.appendChild(e).id=S,!C.getElementsByName||!C.getElementsByName(S).length}),d.getById?(b.filter.ID=function(e){var t=e.replace(te,ne);return function(e){return e.getAttribute("id")===t}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n=t.getElementById(e);return n?[n]:[]}}):(b.filter.ID=function(e){var n=e.replace(te,ne);return function(e){var t="undefined"!=typeof e.getAttributeNode&&e.getAttributeNode("id");return t&&t.value===n}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n,r,i,o=t.getElementById(e);if(o){if((n=o.getAttributeNode("id"))&&n.value===e)return[o];i=t.getElementsByName(e),r=0;while(o=i[r++])if((n=o.getAttributeNode("id"))&&n.value===e)return[o]}return[]}}),b.find.TAG=d.getElementsByTagName?function(e,t){return"undefined"!=typeof t.getElementsByTagName?t.getElementsByTagName(e):d.qsa?t.querySelectorAll(e):void 0}:function(e,t){var n,r=[],i=0,o=t.getElementsByTagName(e);if("*"===e){while(n=o[i++])1===n.nodeType&&r.push(n);return r}return o},b.find.CLASS=d.getElementsByClassName&&function(e,t){if("undefined"!=typeof t.getElementsByClassName&&E)return t.getElementsByClassName(e)},s=[],v=[],(d.qsa=K.test(C.querySelectorAll))&&(ce(function(e){var t;a.appendChild(e).innerHTML="<a id='"+S+"'></a><select id='"+S+"-\r\\' msallowcapture=''><option selected=''></option></select>",e.querySelectorAll("[msallowcapture^='']").length&&v.push("[*^$]="+M+"*(?:''|\"\")"),e.querySelectorAll("[selected]").length||v.push("\\["+M+"*(?:value|"+R+")"),e.querySelectorAll("[id~="+S+"-]").length||v.push("~="),(t=C.createElement("input")).setAttribute("name",""),e.appendChild(t),e.querySelectorAll("[name='']").length||v.push("\\["+M+"*name"+M+"*="+M+"*(?:''|\"\")"),e.querySelectorAll(":checked").length||v.push(":checked"),e.querySelectorAll("a#"+S+"+*").length||v.push(".#.+[+~]"),e.querySelectorAll("\\\f"),v.push("[\\r\\n\\f]")}),ce(function(e){e.innerHTML="<a href='' disabled='disabled'></a><select disabled='disabled'><option/></select>";var t=C.createElement("input");t.setAttribute("type","hidden"),e.appendChild(t).setAttribute("name","D"),e.querySelectorAll("[name=d]").length&&v.push("name"+M+"*[*^$|!~]?="),2!==e.querySelectorAll(":enabled").length&&v.push(":enabled",":disabled"),a.appendChild(e).disabled=!0,2!==e.querySelectorAll(":disabled").length&&v.push(":enabled",":disabled"),e.querySelectorAll("*,:x"),v.push(",.*:")})),(d.matchesSelector=K.test(c=a.matches||a.webkitMatchesSelector||a.mozMatchesSelector||a.oMatchesSelector||a.msMatchesSelector))&&ce(function(e){d.disconnectedMatch=c.call(e,"*"),c.call(e,"[s!='']:x"),s.push("!=",F)}),v=v.length&&new RegExp(v.join("|")),s=s.length&&new RegExp(s.join("|")),t=K.test(a.compareDocumentPosition),y=t||K.test(a.contains)?function(e,t){var n=9===e.nodeType?e.documentElement:e,r=t&&t.parentNode;return e===r||!(!r||1!==r.nodeType||!(n.contains?n.contains(r):e.compareDocumentPosition&&16&e.compareDocumentPosition(r)))}:function(e,t){if(t)while(t=t.parentNode)if(t===e)return!0;return!1},j=t?function(e,t){if(e===t)return l=!0,0;var n=!e.compareDocumentPosition-!t.compareDocumentPosition;return n||(1&(n=(e.ownerDocument||e)==(t.ownerDocument||t)?e.compareDocumentPosition(t):1)||!d.sortDetached&&t.compareDocumentPosition(e)===n?e==C||e.ownerDocument==p&&y(p,e)?-1:t==C||t.ownerDocument==p&&y(p,t)?1:u?P(u,e)-P(u,t):0:4&n?-1:1)}:function(e,t){if(e===t)return l=!0,0;var n,r=0,i=e.parentNode,o=t.parentNode,a=[e],s=[t];if(!i||!o)return e==C?-1:t==C?1:i?-1:o?1:u?P(u,e)-P(u,t):0;if(i===o)return pe(e,t);n=e;while(n=n.parentNode)a.unshift(n);n=t;while(n=n.parentNode)s.unshift(n);while(a[r]===s[r])r++;return r?pe(a[r],s[r]):a[r]==p?-1:s[r]==p?1:0}),C},se.matches=function(e,t){return se(e,null,null,t)},se.matchesSelector=function(e,t){if(T(e),d.matchesSelector&&E&&!N[t+" "]&&(!s||!s.test(t))&&(!v||!v.test(t)))try{var n=c.call(e,t);if(n||d.disconnectedMatch||e.document&&11!==e.document.nodeType)return n}catch(e){N(t,!0)}return 0<se(t,C,null,[e]).length},se.contains=function(e,t){return(e.ownerDocument||e)!=C&&T(e),y(e,t)},se.attr=function(e,t){(e.ownerDocument||e)!=C&&T(e);var n=b.attrHandle[t.toLowerCase()],r=n&&D.call(b.attrHandle,t.toLowerCase())?n(e,t,!E):void 0;return void 0!==r?r:d.attributes||!E?e.getAttribute(t):(r=e.getAttributeNode(t))&&r.specified?r.value:null},se.escape=function(e){return(e+"").replace(re,ie)},se.error=function(e){throw new Error("Syntax error, unrecognized expression: "+e)},se.uniqueSort=function(e){var t,n=[],r=0,i=0;if(l=!d.detectDuplicates,u=!d.sortStable&&e.slice(0),e.sort(j),l){while(t=e[i++])t===e[i]&&(r=n.push(i));while(r--)e.splice(n[r],1)}return u=null,e},o=se.getText=function(e){var t,n="",r=0,i=e.nodeType;if(i){if(1===i||9===i||11===i){if("string"==typeof e.textContent)return e.textContent;for(e=e.firstChild;e;e=e.nextSibling)n+=o(e)}else if(3===i||4===i)return e.nodeValue}else while(t=e[r++])n+=o(t);return n},(b=se.selectors={cacheLength:50,createPseudo:le,match:G,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(e){return e[1]=e[1].replace(te,ne),e[3]=(e[3]||e[4]||e[5]||"").replace(te,ne),"~="===e[2]&&(e[3]=" "+e[3]+" "),e.slice(0,4)},CHILD:function(e){return e[1]=e[1].toLowerCase(),"nth"===e[1].slice(0,3)?(e[3]||se.error(e[0]),e[4]=+(e[4]?e[5]+(e[6]||1):2*("even"===e[3]||"odd"===e[3])),e[5]=+(e[7]+e[8]||"odd"===e[3])):e[3]&&se.error(e[0]),e},PSEUDO:function(e){var t,n=!e[6]&&e[2];return G.CHILD.test(e[0])?null:(e[3]?e[2]=e[4]||e[5]||"":n&&X.test(n)&&(t=h(n,!0))&&(t=n.indexOf(")",n.length-t)-n.length)&&(e[0]=e[0].slice(0,t),e[2]=n.slice(0,t)),e.slice(0,3))}},filter:{TAG:function(e){var t=e.replace(te,ne).toLowerCase();return"*"===e?function(){return!0}:function(e){return e.nodeName&&e.nodeName.toLowerCase()===t}},CLASS:function(e){var t=m[e+" "];return t||(t=new RegExp("(^|"+M+")"+e+"("+M+"|$)"))&&m(e,function(e){return t.test("string"==typeof e.className&&e.className||"undefined"!=typeof e.getAttribute&&e.getAttribute("class")||"")})},ATTR:function(n,r,i){return function(e){var t=se.attr(e,n);return null==t?"!="===r:!r||(t+="","="===r?t===i:"!="===r?t!==i:"^="===r?i&&0===t.indexOf(i):"*="===r?i&&-1<t.indexOf(i):"$="===r?i&&t.slice(-i.length)===i:"~="===r?-1<(" "+t.replace(B," ")+" ").indexOf(i):"|="===r&&(t===i||t.slice(0,i.length+1)===i+"-"))}},CHILD:function(h,e,t,g,v){var y="nth"!==h.slice(0,3),m="last"!==h.slice(-4),x="of-type"===e;return 1===g&&0===v?function(e){return!!e.parentNode}:function(e,t,n){var r,i,o,a,s,u,l=y!==m?"nextSibling":"previousSibling",c=e.parentNode,f=x&&e.nodeName.toLowerCase(),p=!n&&!x,d=!1;if(c){if(y){while(l){a=e;while(a=a[l])if(x?a.nodeName.toLowerCase()===f:1===a.nodeType)return!1;u=l="only"===h&&!u&&"nextSibling"}return!0}if(u=[m?c.firstChild:c.lastChild],m&&p){d=(s=(r=(i=(o=(a=c)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1])&&r[2],a=s&&c.childNodes[s];while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if(1===a.nodeType&&++d&&a===e){i[h]=[k,s,d];break}}else if(p&&(d=s=(r=(i=(o=(a=e)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1]),!1===d)while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if((x?a.nodeName.toLowerCase()===f:1===a.nodeType)&&++d&&(p&&((i=(o=a[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]=[k,d]),a===e))break;return(d-=v)===g||d%g==0&&0<=d/g}}},PSEUDO:function(e,o){var t,a=b.pseudos[e]||b.setFilters[e.toLowerCase()]||se.error("unsupported pseudo: "+e);return a[S]?a(o):1<a.length?(t=[e,e,"",o],b.setFilters.hasOwnProperty(e.toLowerCase())?le(function(e,t){var n,r=a(e,o),i=r.length;while(i--)e[n=P(e,r[i])]=!(t[n]=r[i])}):function(e){return a(e,0,t)}):a}},pseudos:{not:le(function(e){var r=[],i=[],s=f(e.replace($,"$1"));return s[S]?le(function(e,t,n,r){var i,o=s(e,null,r,[]),a=e.length;while(a--)(i=o[a])&&(e[a]=!(t[a]=i))}):function(e,t,n){return r[0]=e,s(r,null,n,i),r[0]=null,!i.pop()}}),has:le(function(t){return function(e){return 0<se(t,e).length}}),contains:le(function(t){return t=t.replace(te,ne),function(e){return-1<(e.textContent||o(e)).indexOf(t)}}),lang:le(function(n){return V.test(n||"")||se.error("unsupported lang: "+n),n=n.replace(te,ne).toLowerCase(),function(e){var t;do{if(t=E?e.lang:e.getAttribute("xml:lang")||e.getAttribute("lang"))return(t=t.toLowerCase())===n||0===t.indexOf(n+"-")}while((e=e.parentNode)&&1===e.nodeType);return!1}}),target:function(e){var t=n.location&&n.location.hash;return t&&t.slice(1)===e.id},root:function(e){return e===a},focus:function(e){return e===C.activeElement&&(!C.hasFocus||C.hasFocus())&&!!(e.type||e.href||~e.tabIndex)},enabled:ge(!1),disabled:ge(!0),checked:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&!!e.checked||"option"===t&&!!e.selected},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,!0===e.selected},empty:function(e){for(e=e.firstChild;e;e=e.nextSibling)if(e.nodeType<6)return!1;return!0},parent:function(e){return!b.pseudos.empty(e)},header:function(e){return J.test(e.nodeName)},input:function(e){return Q.test(e.nodeName)},button:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&"button"===e.type||"button"===t},text:function(e){var t;return"input"===e.nodeName.toLowerCase()&&"text"===e.type&&(null==(t=e.getAttribute("type"))||"text"===t.toLowerCase())},first:ve(function(){return[0]}),last:ve(function(e,t){return[t-1]}),eq:ve(function(e,t,n){return[n<0?n+t:n]}),even:ve(function(e,t){for(var n=0;n<t;n+=2)e.push(n);return e}),odd:ve(function(e,t){for(var n=1;n<t;n+=2)e.push(n);return e}),lt:ve(function(e,t,n){for(var r=n<0?n+t:t<n?t:n;0<=--r;)e.push(r);return e}),gt:ve(function(e,t,n){for(var r=n<0?n+t:n;++r<t;)e.push(r);return e})}}).pseudos.nth=b.pseudos.eq,{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})b.pseudos[e]=de(e);for(e in{submit:!0,reset:!0})b.pseudos[e]=he(e);function me(){}function xe(e){for(var t=0,n=e.length,r="";t<n;t++)r+=e[t].value;return r}function be(s,e,t){var u=e.dir,l=e.next,c=l||u,f=t&&"parentNode"===c,p=r++;return e.first?function(e,t,n){while(e=e[u])if(1===e.nodeType||f)return s(e,t,n);return!1}:function(e,t,n){var r,i,o,a=[k,p];if(n){while(e=e[u])if((1===e.nodeType||f)&&s(e,t,n))return!0}else while(e=e[u])if(1===e.nodeType||f)if(i=(o=e[S]||(e[S]={}))[e.uniqueID]||(o[e.uniqueID]={}),l&&l===e.nodeName.toLowerCase())e=e[u]||e;else{if((r=i[c])&&r[0]===k&&r[1]===p)return a[2]=r[2];if((i[c]=a)[2]=s(e,t,n))return!0}return!1}}function we(i){return 1<i.length?function(e,t,n){var r=i.length;while(r--)if(!i[r](e,t,n))return!1;return!0}:i[0]}function Te(e,t,n,r,i){for(var o,a=[],s=0,u=e.length,l=null!=t;s<u;s++)(o=e[s])&&(n&&!n(o,r,i)||(a.push(o),l&&t.push(s)));return a}function Ce(d,h,g,v,y,e){return v&&!v[S]&&(v=Ce(v)),y&&!y[S]&&(y=Ce(y,e)),le(function(e,t,n,r){var i,o,a,s=[],u=[],l=t.length,c=e||function(e,t,n){for(var r=0,i=t.length;r<i;r++)se(e,t[r],n);return n}(h||"*",n.nodeType?[n]:n,[]),f=!d||!e&&h?c:Te(c,s,d,n,r),p=g?y||(e?d:l||v)?[]:t:f;if(g&&g(f,p,n,r),v){i=Te(p,u),v(i,[],n,r),o=i.length;while(o--)(a=i[o])&&(p[u[o]]=!(f[u[o]]=a))}if(e){if(y||d){if(y){i=[],o=p.length;while(o--)(a=p[o])&&i.push(f[o]=a);y(null,p=[],i,r)}o=p.length;while(o--)(a=p[o])&&-1<(i=y?P(e,a):s[o])&&(e[i]=!(t[i]=a))}}else p=Te(p===t?p.splice(l,p.length):p),y?y(null,t,p,r):H.apply(t,p)})}function Ee(e){for(var i,t,n,r=e.length,o=b.relative[e[0].type],a=o||b.relative[" "],s=o?1:0,u=be(function(e){return e===i},a,!0),l=be(function(e){return-1<P(i,e)},a,!0),c=[function(e,t,n){var r=!o&&(n||t!==w)||((i=t).nodeType?u(e,t,n):l(e,t,n));return i=null,r}];s<r;s++)if(t=b.relative[e[s].type])c=[be(we(c),t)];else{if((t=b.filter[e[s].type].apply(null,e[s].matches))[S]){for(n=++s;n<r;n++)if(b.relative[e[n].type])break;return Ce(1<s&&we(c),1<s&&xe(e.slice(0,s-1).concat({value:" "===e[s-2].type?"*":""})).replace($,"$1"),t,s<n&&Ee(e.slice(s,n)),n<r&&Ee(e=e.slice(n)),n<r&&xe(e))}c.push(t)}return we(c)}return me.prototype=b.filters=b.pseudos,b.setFilters=new me,h=se.tokenize=function(e,t){var n,r,i,o,a,s,u,l=x[e+" "];if(l)return t?0:l.slice(0);a=e,s=[],u=b.preFilter;while(a){for(o in n&&!(r=_.exec(a))||(r&&(a=a.slice(r[0].length)||a),s.push(i=[])),n=!1,(r=z.exec(a))&&(n=r.shift(),i.push({value:n,type:r[0].replace($," ")}),a=a.slice(n.length)),b.filter)!(r=G[o].exec(a))||u[o]&&!(r=u[o](r))||(n=r.shift(),i.push({value:n,type:o,matches:r}),a=a.slice(n.length));if(!n)break}return t?a.length:a?se.error(e):x(e,s).slice(0)},f=se.compile=function(e,t){var n,v,y,m,x,r,i=[],o=[],a=A[e+" "];if(!a){t||(t=h(e)),n=t.length;while(n--)(a=Ee(t[n]))[S]?i.push(a):o.push(a);(a=A(e,(v=o,m=0<(y=i).length,x=0<v.length,r=function(e,t,n,r,i){var o,a,s,u=0,l="0",c=e&&[],f=[],p=w,d=e||x&&b.find.TAG("*",i),h=k+=null==p?1:Math.random()||.1,g=d.length;for(i&&(w=t==C||t||i);l!==g&&null!=(o=d[l]);l++){if(x&&o){a=0,t||o.ownerDocument==C||(T(o),n=!E);while(s=v[a++])if(s(o,t||C,n)){r.push(o);break}i&&(k=h)}m&&((o=!s&&o)&&u--,e&&c.push(o))}if(u+=l,m&&l!==u){a=0;while(s=y[a++])s(c,f,t,n);if(e){if(0<u)while(l--)c[l]||f[l]||(f[l]=q.call(r));f=Te(f)}H.apply(r,f),i&&!e&&0<f.length&&1<u+y.length&&se.uniqueSort(r)}return i&&(k=h,w=p),c},m?le(r):r))).selector=e}return a},g=se.select=function(e,t,n,r){var i,o,a,s,u,l="function"==typeof e&&e,c=!r&&h(e=l.selector||e);if(n=n||[],1===c.length){if(2<(o=c[0]=c[0].slice(0)).length&&"ID"===(a=o[0]).type&&9===t.nodeType&&E&&b.relative[o[1].type]){if(!(t=(b.find.ID(a.matches[0].replace(te,ne),t)||[])[0]))return n;l&&(t=t.parentNode),e=e.slice(o.shift().value.length)}i=G.needsContext.test(e)?0:o.length;while(i--){if(a=o[i],b.relative[s=a.type])break;if((u=b.find[s])&&(r=u(a.matches[0].replace(te,ne),ee.test(o[0].type)&&ye(t.parentNode)||t))){if(o.splice(i,1),!(e=r.length&&xe(o)))return H.apply(n,r),n;break}}}return(l||f(e,c))(r,t,!E,n,!t||ee.test(e)&&ye(t.parentNode)||t),n},d.sortStable=S.split("").sort(j).join("")===S,d.detectDuplicates=!!l,T(),d.sortDetached=ce(function(e){return 1&e.compareDocumentPosition(C.createElement("fieldset"))}),ce(function(e){return e.innerHTML="<a href='#'></a>","#"===e.firstChild.getAttribute("href")})||fe("type|href|height|width",function(e,t,n){if(!n)return e.getAttribute(t,"type"===t.toLowerCase()?1:2)}),d.attributes&&ce(function(e){return e.innerHTML="<input/>",e.firstChild.setAttribute("value",""),""===e.firstChild.getAttribute("value")})||fe("value",function(e,t,n){if(!n&&"input"===e.nodeName.toLowerCase())return e.defaultValue}),ce(function(e){return null==e.getAttribute("disabled")})||fe(R,function(e,t,n){var r;if(!n)return!0===e[t]?t.toLowerCase():(r=e.getAttributeNode(t))&&r.specified?r.value:null}),se}(C);S.find=d,S.expr=d.selectors,S.expr[":"]=S.expr.pseudos,S.uniqueSort=S.unique=d.uniqueSort,S.text=d.getText,S.isXMLDoc=d.isXML,S.contains=d.contains,S.escapeSelector=d.escape;var h=function(e,t,n){var r=[],i=void 0!==n;while((e=e[t])&&9!==e.nodeType)if(1===e.nodeType){if(i&&S(e).is(n))break;r.push(e)}return r},T=function(e,t){for(var n=[];e;e=e.nextSibling)1===e.nodeType&&e!==t&&n.push(e);return n},k=S.expr.match.needsContext;function A(e,t){return e.nodeName&&e.nodeName.toLowerCase()===t.toLowerCase()}var N=/^<([a-z][^\/\0>:\x20\t\r\n\f]*)[\x20\t\r\n\f]*\/?>(?:<\/\1>|)$/i;function j(e,n,r){return m(n)?S.grep(e,function(e,t){return!!n.call(e,t,e)!==r}):n.nodeType?S.grep(e,function(e){return e===n!==r}):"string"!=typeof n?S.grep(e,function(e){return-1<i.call(n,e)!==r}):S.filter(n,e,r)}S.filter=function(e,t,n){var r=t[0];return n&&(e=":not("+e+")"),1===t.length&&1===r.nodeType?S.find.matchesSelector(r,e)?[r]:[]:S.find.matches(e,S.grep(t,function(e){return 1===e.nodeType}))},S.fn.extend({find:function(e){var t,n,r=this.length,i=this;if("string"!=typeof e)return this.pushStack(S(e).filter(function(){for(t=0;t<r;t++)if(S.contains(i[t],this))return!0}));for(n=this.pushStack([]),t=0;t<r;t++)S.find(e,i[t],n);return 1<r?S.uniqueSort(n):n},filter:function(e){return this.pushStack(j(this,e||[],!1))},not:function(e){return this.pushStack(j(this,e||[],!0))},is:function(e){return!!j(this,"string"==typeof e&&k.test(e)?S(e):e||[],!1).length}});var D,q=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]+))$/;(S.fn.init=function(e,t,n){var r,i;if(!e)return this;if(n=n||D,"string"==typeof e){if(!(r="<"===e[0]&&">"===e[e.length-1]&&3<=e.length?[null,e,null]:q.exec(e))||!r[1]&&t)return!t||t.jquery?(t||n).find(e):this.constructor(t).find(e);if(r[1]){if(t=t instanceof S?t[0]:t,S.merge(this,S.parseHTML(r[1],t&&t.nodeType?t.ownerDocument||t:E,!0)),N.test(r[1])&&S.isPlainObject(t))for(r in t)m(this[r])?this[r](t[r]):this.attr(r,t[r]);return this}return(i=E.getElementById(r[2]))&&(this[0]=i,this.length=1),this}return e.nodeType?(this[0]=e,this.length=1,this):m(e)?void 0!==n.ready?n.ready(e):e(S):S.makeArray(e,this)}).prototype=S.fn,D=S(E);var L=/^(?:parents|prev(?:Until|All))/,H={children:!0,contents:!0,next:!0,prev:!0};function O(e,t){while((e=e[t])&&1!==e.nodeType);return e}S.fn.extend({has:function(e){var t=S(e,this),n=t.length;return this.filter(function(){for(var e=0;e<n;e++)if(S.contains(this,t[e]))return!0})},closest:function(e,t){var n,r=0,i=this.length,o=[],a="string"!=typeof e&&S(e);if(!k.test(e))for(;r<i;r++)for(n=this[r];n&&n!==t;n=n.parentNode)if(n.nodeType<11&&(a?-1<a.index(n):1===n.nodeType&&S.find.matchesSelector(n,e))){o.push(n);break}return this.pushStack(1<o.length?S.uniqueSort(o):o)},index:function(e){return e?"string"==typeof e?i.call(S(e),this[0]):i.call(this,e.jquery?e[0]:e):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(e,t){return this.pushStack(S.uniqueSort(S.merge(this.get(),S(e,t))))},addBack:function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}}),S.each({parent:function(e){var t=e.parentNode;return t&&11!==t.nodeType?t:null},parents:function(e){return h(e,"parentNode")},parentsUntil:function(e,t,n){return h(e,"parentNode",n)},next:function(e){return O(e,"nextSibling")},prev:function(e){return O(e,"previousSibling")},nextAll:function(e){return h(e,"nextSibling")},prevAll:function(e){return h(e,"previousSibling")},nextUntil:function(e,t,n){return h(e,"nextSibling",n)},prevUntil:function(e,t,n){return h(e,"previousSibling",n)},siblings:function(e){return T((e.parentNode||{}).firstChild,e)},children:function(e){return T(e.firstChild)},contents:function(e){return null!=e.contentDocument&&r(e.contentDocument)?e.contentDocument:(A(e,"template")&&(e=e.content||e),S.merge([],e.childNodes))}},function(r,i){S.fn[r]=function(e,t){var n=S.map(this,i,e);return"Until"!==r.slice(-5)&&(t=e),t&&"string"==typeof t&&(n=S.filter(t,n)),1<this.length&&(H[r]||S.uniqueSort(n),L.test(r)&&n.reverse()),this.pushStack(n)}});var P=/[^\x20\t\r\n\f]+/g;function R(e){return e}function M(e){throw e}function I(e,t,n,r){var i;try{e&&m(i=e.promise)?i.call(e).done(t).fail(n):e&&m(i=e.then)?i.call(e,t,n):t.apply(void 0,[e].slice(r))}catch(e){n.apply(void 0,[e])}}S.Callbacks=function(r){var e,n;r="string"==typeof r?(e=r,n={},S.each(e.match(P)||[],function(e,t){n[t]=!0}),n):S.extend({},r);var i,t,o,a,s=[],u=[],l=-1,c=function(){for(a=a||r.once,o=i=!0;u.length;l=-1){t=u.shift();while(++l<s.length)!1===s[l].apply(t[0],t[1])&&r.stopOnFalse&&(l=s.length,t=!1)}r.memory||(t=!1),i=!1,a&&(s=t?[]:"")},f={add:function(){return s&&(t&&!i&&(l=s.length-1,u.push(t)),function n(e){S.each(e,function(e,t){m(t)?r.unique&&f.has(t)||s.push(t):t&&t.length&&"string"!==w(t)&&n(t)})}(arguments),t&&!i&&c()),this},remove:function(){return S.each(arguments,function(e,t){var n;while(-1<(n=S.inArray(t,s,n)))s.splice(n,1),n<=l&&l--}),this},has:function(e){return e?-1<S.inArray(e,s):0<s.length},empty:function(){return s&&(s=[]),this},disable:function(){return a=u=[],s=t="",this},disabled:function(){return!s},lock:function(){return a=u=[],t||i||(s=t=""),this},locked:function(){return!!a},fireWith:function(e,t){return a||(t=[e,(t=t||[]).slice?t.slice():t],u.push(t),i||c()),this},fire:function(){return f.fireWith(this,arguments),this},fired:function(){return!!o}};return f},S.extend({Deferred:function(e){var o=[["notify","progress",S.Callbacks("memory"),S.Callbacks("memory"),2],["resolve","done",S.Callbacks("once memory"),S.Callbacks("once memory"),0,"resolved"],["reject","fail",S.Callbacks("once memory"),S.Callbacks("once memory"),1,"rejected"]],i="pending",a={state:function(){return i},always:function(){return s.done(arguments).fail(arguments),this},"catch":function(e){return a.then(null,e)},pipe:function(){var i=arguments;return S.Deferred(function(r){S.each(o,function(e,t){var n=m(i[t[4]])&&i[t[4]];s[t[1]](function(){var e=n&&n.apply(this,arguments);e&&m(e.promise)?e.promise().progress(r.notify).done(r.resolve).fail(r.reject):r[t[0]+"With"](this,n?[e]:arguments)})}),i=null}).promise()},then:function(t,n,r){var u=0;function l(i,o,a,s){return function(){var n=this,r=arguments,e=function(){var e,t;if(!(i<u)){if((e=a.apply(n,r))===o.promise())throw new TypeError("Thenable self-resolution");t=e&&("object"==typeof e||"function"==typeof e)&&e.then,m(t)?s?t.call(e,l(u,o,R,s),l(u,o,M,s)):(u++,t.call(e,l(u,o,R,s),l(u,o,M,s),l(u,o,R,o.notifyWith))):(a!==R&&(n=void 0,r=[e]),(s||o.resolveWith)(n,r))}},t=s?e:function(){try{e()}catch(e){S.Deferred.exceptionHook&&S.Deferred.exceptionHook(e,t.stackTrace),u<=i+1&&(a!==M&&(n=void 0,r=[e]),o.rejectWith(n,r))}};i?t():(S.Deferred.getStackHook&&(t.stackTrace=S.Deferred.getStackHook()),C.setTimeout(t))}}return S.Deferred(function(e){o[0][3].add(l(0,e,m(r)?r:R,e.notifyWith)),o[1][3].add(l(0,e,m(t)?t:R)),o[2][3].add(l(0,e,m(n)?n:M))}).promise()},promise:function(e){return null!=e?S.extend(e,a):a}},s={};return S.each(o,function(e,t){var n=t[2],r=t[5];a[t[1]]=n.add,r&&n.add(function(){i=r},o[3-e][2].disable,o[3-e][3].disable,o[0][2].lock,o[0][3].lock),n.add(t[3].fire),s[t[0]]=function(){return s[t[0]+"With"](this===s?void 0:this,arguments),this},s[t[0]+"With"]=n.fireWith}),a.promise(s),e&&e.call(s,s),s},when:function(e){var n=arguments.length,t=n,r=Array(t),i=s.call(arguments),o=S.Deferred(),a=function(t){return function(e){r[t]=this,i[t]=1<arguments.length?s.call(arguments):e,--n||o.resolveWith(r,i)}};if(n<=1&&(I(e,o.done(a(t)).resolve,o.reject,!n),"pending"===o.state()||m(i[t]&&i[t].then)))return o.then();while(t--)I(i[t],a(t),o.reject);return o.promise()}});var W=/^(Eval|Internal|Range|Reference|Syntax|Type|URI)Error$/;S.Deferred.exceptionHook=function(e,t){C.console&&C.console.warn&&e&&W.test(e.name)&&C.console.warn("jQuery.Deferred exception: "+e.message,e.stack,t)},S.readyException=function(e){C.setTimeout(function(){throw e})};var F=S.Deferred();function B(){E.removeEventListener("DOMContentLoaded",B),C.removeEventListener("load",B),S.ready()}S.fn.ready=function(e){return F.then(e)["catch"](function(e){S.readyException(e)}),this},S.extend({isReady:!1,readyWait:1,ready:function(e){(!0===e?--S.readyWait:S.isReady)||(S.isReady=!0)!==e&&0<--S.readyWait||F.resolveWith(E,[S])}}),S.ready.then=F.then,"complete"===E.readyState||"loading"!==E.readyState&&!E.documentElement.doScroll?C.setTimeout(S.ready):(E.addEventListener("DOMContentLoaded",B),C.addEventListener("load",B));var $=function(e,t,n,r,i,o,a){var s=0,u=e.length,l=null==n;if("object"===w(n))for(s in i=!0,n)$(e,t,s,n[s],!0,o,a);else if(void 0!==r&&(i=!0,m(r)||(a=!0),l&&(a?(t.call(e,r),t=null):(l=t,t=function(e,t,n){return l.call(S(e),n)})),t))for(;s<u;s++)t(e[s],n,a?r:r.call(e[s],s,t(e[s],n)));return i?e:l?t.call(e):u?t(e[0],n):o},_=/^-ms-/,z=/-([a-z])/g;function U(e,t){return t.toUpperCase()}function X(e){return e.replace(_,"ms-").replace(z,U)}var V=function(e){return 1===e.nodeType||9===e.nodeType||!+e.nodeType};function G(){this.expando=S.expando+G.uid++}G.uid=1,G.prototype={cache:function(e){var t=e[this.expando];return t||(t={},V(e)&&(e.nodeType?e[this.expando]=t:Object.defineProperty(e,this.expando,{value:t,configurable:!0}))),t},set:function(e,t,n){var r,i=this.cache(e);if("string"==typeof t)i[X(t)]=n;else for(r in t)i[X(r)]=t[r];return i},get:function(e,t){return void 0===t?this.cache(e):e[this.expando]&&e[this.expando][X(t)]},access:function(e,t,n){return void 0===t||t&&"string"==typeof t&&void 0===n?this.get(e,t):(this.set(e,t,n),void 0!==n?n:t)},remove:function(e,t){var n,r=e[this.expando];if(void 0!==r){if(void 0!==t){n=(t=Array.isArray(t)?t.map(X):(t=X(t))in r?[t]:t.match(P)||[]).length;while(n--)delete r[t[n]]}(void 0===t||S.isEmptyObject(r))&&(e.nodeType?e[this.expando]=void 0:delete e[this.expando])}},hasData:function(e){var t=e[this.expando];return void 0!==t&&!S.isEmptyObject(t)}};var Y=new G,Q=new G,J=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,K=/[A-Z]/g;function Z(e,t,n){var r,i;if(void 0===n&&1===e.nodeType)if(r="data-"+t.replace(K,"-$&").toLowerCase(),"string"==typeof(n=e.getAttribute(r))){try{n="true"===(i=n)||"false"!==i&&("null"===i?null:i===+i+""?+i:J.test(i)?JSON.parse(i):i)}catch(e){}Q.set(e,t,n)}else n=void 0;return n}S.extend({hasData:function(e){return Q.hasData(e)||Y.hasData(e)},data:function(e,t,n){return Q.access(e,t,n)},removeData:function(e,t){Q.remove(e,t)},_data:function(e,t,n){return Y.access(e,t,n)},_removeData:function(e,t){Y.remove(e,t)}}),S.fn.extend({data:function(n,e){var t,r,i,o=this[0],a=o&&o.attributes;if(void 0===n){if(this.length&&(i=Q.get(o),1===o.nodeType&&!Y.get(o,"hasDataAttrs"))){t=a.length;while(t--)a[t]&&0===(r=a[t].name).indexOf("data-")&&(r=X(r.slice(5)),Z(o,r,i[r]));Y.set(o,"hasDataAttrs",!0)}return i}return"object"==typeof n?this.each(function(){Q.set(this,n)}):$(this,function(e){var t;if(o&&void 0===e)return void 0!==(t=Q.get(o,n))?t:void 0!==(t=Z(o,n))?t:void 0;this.each(function(){Q.set(this,n,e)})},null,e,1<arguments.length,null,!0)},removeData:function(e){return this.each(function(){Q.remove(this,e)})}}),S.extend({queue:function(e,t,n){var r;if(e)return t=(t||"fx")+"queue",r=Y.get(e,t),n&&(!r||Array.isArray(n)?r=Y.access(e,t,S.makeArray(n)):r.push(n)),r||[]},dequeue:function(e,t){t=t||"fx";var n=S.queue(e,t),r=n.length,i=n.shift(),o=S._queueHooks(e,t);"inprogress"===i&&(i=n.shift(),r--),i&&("fx"===t&&n.unshift("inprogress"),delete o.stop,i.call(e,function(){S.dequeue(e,t)},o)),!r&&o&&o.empty.fire()},_queueHooks:function(e,t){var n=t+"queueHooks";return Y.get(e,n)||Y.access(e,n,{empty:S.Callbacks("once memory").add(function(){Y.remove(e,[t+"queue",n])})})}}),S.fn.extend({queue:function(t,n){var e=2;return"string"!=typeof t&&(n=t,t="fx",e--),arguments.length<e?S.queue(this[0],t):void 0===n?this:this.each(function(){var e=S.queue(this,t,n);S._queueHooks(this,t),"fx"===t&&"inprogress"!==e[0]&&S.dequeue(this,t)})},dequeue:function(e){return this.each(function(){S.dequeue(this,e)})},clearQueue:function(e){return this.queue(e||"fx",[])},promise:function(e,t){var n,r=1,i=S.Deferred(),o=this,a=this.length,s=function(){--r||i.resolveWith(o,[o])};"string"!=typeof e&&(t=e,e=void 0),e=e||"fx";while(a--)(n=Y.get(o[a],e+"queueHooks"))&&n.empty&&(r++,n.empty.add(s));return s(),i.promise(t)}});var ee=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,te=new RegExp("^(?:([+-])=|)("+ee+")([a-z%]*)$","i"),ne=["Top","Right","Bottom","Left"],re=E.documentElement,ie=function(e){return S.contains(e.ownerDocument,e)},oe={composed:!0};re.getRootNode&&(ie=function(e){return S.contains(e.ownerDocument,e)||e.getRootNode(oe)===e.ownerDocument});var ae=function(e,t){return"none"===(e=t||e).style.display||""===e.style.display&&ie(e)&&"none"===S.css(e,"display")};function se(e,t,n,r){var i,o,a=20,s=r?function(){return r.cur()}:function(){return S.css(e,t,"")},u=s(),l=n&&n[3]||(S.cssNumber[t]?"":"px"),c=e.nodeType&&(S.cssNumber[t]||"px"!==l&&+u)&&te.exec(S.css(e,t));if(c&&c[3]!==l){u/=2,l=l||c[3],c=+u||1;while(a--)S.style(e,t,c+l),(1-o)*(1-(o=s()/u||.5))<=0&&(a=0),c/=o;c*=2,S.style(e,t,c+l),n=n||[]}return n&&(c=+c||+u||0,i=n[1]?c+(n[1]+1)*n[2]:+n[2],r&&(r.unit=l,r.start=c,r.end=i)),i}var ue={};function le(e,t){for(var n,r,i,o,a,s,u,l=[],c=0,f=e.length;c<f;c++)(r=e[c]).style&&(n=r.style.display,t?("none"===n&&(l[c]=Y.get(r,"display")||null,l[c]||(r.style.display="")),""===r.style.display&&ae(r)&&(l[c]=(u=a=o=void 0,a=(i=r).ownerDocument,s=i.nodeName,(u=ue[s])||(o=a.body.appendChild(a.createElement(s)),u=S.css(o,"display"),o.parentNode.removeChild(o),"none"===u&&(u="block"),ue[s]=u)))):"none"!==n&&(l[c]="none",Y.set(r,"display",n)));for(c=0;c<f;c++)null!=l[c]&&(e[c].style.display=l[c]);return e}S.fn.extend({show:function(){return le(this,!0)},hide:function(){return le(this)},toggle:function(e){return"boolean"==typeof e?e?this.show():this.hide():this.each(function(){ae(this)?S(this).show():S(this).hide()})}});var ce,fe,pe=/^(?:checkbox|radio)$/i,de=/<([a-z][^\/\0>\x20\t\r\n\f]*)/i,he=/^$|^module$|\/(?:java|ecma)script/i;ce=E.createDocumentFragment().appendChild(E.createElement("div")),(fe=E.createElement("input")).setAttribute("type","radio"),fe.setAttribute("checked","checked"),fe.setAttribute("name","t"),ce.appendChild(fe),y.checkClone=ce.cloneNode(!0).cloneNode(!0).lastChild.checked,ce.innerHTML="<textarea>x</textarea>",y.noCloneChecked=!!ce.cloneNode(!0).lastChild.defaultValue,ce.innerHTML="<option></option>",y.option=!!ce.lastChild;var ge={thead:[1,"<table>","</table>"],col:[2,"<table><colgroup>","</colgroup></table>"],tr:[2,"<table><tbody>","</tbody></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:[0,"",""]};function ve(e,t){var n;return n="undefined"!=typeof e.getElementsByTagName?e.getElementsByTagName(t||"*"):"undefined"!=typeof e.querySelectorAll?e.querySelectorAll(t||"*"):[],void 0===t||t&&A(e,t)?S.merge([e],n):n}function ye(e,t){for(var n=0,r=e.length;n<r;n++)Y.set(e[n],"globalEval",!t||Y.get(t[n],"globalEval"))}ge.tbody=ge.tfoot=ge.colgroup=ge.caption=ge.thead,ge.th=ge.td,y.option||(ge.optgroup=ge.option=[1,"<select multiple='multiple'>","</select>"]);var me=/<|&#?\w+;/;function xe(e,t,n,r,i){for(var o,a,s,u,l,c,f=t.createDocumentFragment(),p=[],d=0,h=e.length;d<h;d++)if((o=e[d])||0===o)if("object"===w(o))S.merge(p,o.nodeType?[o]:o);else if(me.test(o)){a=a||f.appendChild(t.createElement("div")),s=(de.exec(o)||["",""])[1].toLowerCase(),u=ge[s]||ge._default,a.innerHTML=u[1]+S.htmlPrefilter(o)+u[2],c=u[0];while(c--)a=a.lastChild;S.merge(p,a.childNodes),(a=f.firstChild).textContent=""}else p.push(t.createTextNode(o));f.textContent="",d=0;while(o=p[d++])if(r&&-1<S.inArray(o,r))i&&i.push(o);else if(l=ie(o),a=ve(f.appendChild(o),"script"),l&&ye(a),n){c=0;while(o=a[c++])he.test(o.type||"")&&n.push(o)}return f}var be=/^([^.]*)(?:\.(.+)|)/;function we(){return!0}function Te(){return!1}function Ce(e,t){return e===function(){try{return E.activeElement}catch(e){}}()==("focus"===t)}function Ee(e,t,n,r,i,o){var a,s;if("object"==typeof t){for(s in"string"!=typeof n&&(r=r||n,n=void 0),t)Ee(e,s,n,r,t[s],o);return e}if(null==r&&null==i?(i=n,r=n=void 0):null==i&&("string"==typeof n?(i=r,r=void 0):(i=r,r=n,n=void 0)),!1===i)i=Te;else if(!i)return e;return 1===o&&(a=i,(i=function(e){return S().off(e),a.apply(this,arguments)}).guid=a.guid||(a.guid=S.guid++)),e.each(function(){S.event.add(this,t,i,r,n)})}function Se(e,i,o){o?(Y.set(e,i,!1),S.event.add(e,i,{namespace:!1,handler:function(e){var t,n,r=Y.get(this,i);if(1&e.isTrigger&&this[i]){if(r.length)(S.event.special[i]||{}).delegateType&&e.stopPropagation();else if(r=s.call(arguments),Y.set(this,i,r),t=o(this,i),this[i](),r!==(n=Y.get(this,i))||t?Y.set(this,i,!1):n={},r!==n)return e.stopImmediatePropagation(),e.preventDefault(),n&&n.value}else r.length&&(Y.set(this,i,{value:S.event.trigger(S.extend(r[0],S.Event.prototype),r.slice(1),this)}),e.stopImmediatePropagation())}})):void 0===Y.get(e,i)&&S.event.add(e,i,we)}S.event={global:{},add:function(t,e,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.get(t);if(V(t)){n.handler&&(n=(o=n).handler,i=o.selector),i&&S.find.matchesSelector(re,i),n.guid||(n.guid=S.guid++),(u=v.events)||(u=v.events=Object.create(null)),(a=v.handle)||(a=v.handle=function(e){return"undefined"!=typeof S&&S.event.triggered!==e.type?S.event.dispatch.apply(t,arguments):void 0}),l=(e=(e||"").match(P)||[""]).length;while(l--)d=g=(s=be.exec(e[l])||[])[1],h=(s[2]||"").split(".").sort(),d&&(f=S.event.special[d]||{},d=(i?f.delegateType:f.bindType)||d,f=S.event.special[d]||{},c=S.extend({type:d,origType:g,data:r,handler:n,guid:n.guid,selector:i,needsContext:i&&S.expr.match.needsContext.test(i),namespace:h.join(".")},o),(p=u[d])||((p=u[d]=[]).delegateCount=0,f.setup&&!1!==f.setup.call(t,r,h,a)||t.addEventListener&&t.addEventListener(d,a)),f.add&&(f.add.call(t,c),c.handler.guid||(c.handler.guid=n.guid)),i?p.splice(p.delegateCount++,0,c):p.push(c),S.event.global[d]=!0)}},remove:function(e,t,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.hasData(e)&&Y.get(e);if(v&&(u=v.events)){l=(t=(t||"").match(P)||[""]).length;while(l--)if(d=g=(s=be.exec(t[l])||[])[1],h=(s[2]||"").split(".").sort(),d){f=S.event.special[d]||{},p=u[d=(r?f.delegateType:f.bindType)||d]||[],s=s[2]&&new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"),a=o=p.length;while(o--)c=p[o],!i&&g!==c.origType||n&&n.guid!==c.guid||s&&!s.test(c.namespace)||r&&r!==c.selector&&("**"!==r||!c.selector)||(p.splice(o,1),c.selector&&p.delegateCount--,f.remove&&f.remove.call(e,c));a&&!p.length&&(f.teardown&&!1!==f.teardown.call(e,h,v.handle)||S.removeEvent(e,d,v.handle),delete u[d])}else for(d in u)S.event.remove(e,d+t[l],n,r,!0);S.isEmptyObject(u)&&Y.remove(e,"handle events")}},dispatch:function(e){var t,n,r,i,o,a,s=new Array(arguments.length),u=S.event.fix(e),l=(Y.get(this,"events")||Object.create(null))[u.type]||[],c=S.event.special[u.type]||{};for(s[0]=u,t=1;t<arguments.length;t++)s[t]=arguments[t];if(u.delegateTarget=this,!c.preDispatch||!1!==c.preDispatch.call(this,u)){a=S.event.handlers.call(this,u,l),t=0;while((i=a[t++])&&!u.isPropagationStopped()){u.currentTarget=i.elem,n=0;while((o=i.handlers[n++])&&!u.isImmediatePropagationStopped())u.rnamespace&&!1!==o.namespace&&!u.rnamespace.test(o.namespace)||(u.handleObj=o,u.data=o.data,void 0!==(r=((S.event.special[o.origType]||{}).handle||o.handler).apply(i.elem,s))&&!1===(u.result=r)&&(u.preventDefault(),u.stopPropagation()))}return c.postDispatch&&c.postDispatch.call(this,u),u.result}},handlers:function(e,t){var n,r,i,o,a,s=[],u=t.delegateCount,l=e.target;if(u&&l.nodeType&&!("click"===e.type&&1<=e.button))for(;l!==this;l=l.parentNode||this)if(1===l.nodeType&&("click"!==e.type||!0!==l.disabled)){for(o=[],a={},n=0;n<u;n++)void 0===a[i=(r=t[n]).selector+" "]&&(a[i]=r.needsContext?-1<S(i,this).index(l):S.find(i,this,null,[l]).length),a[i]&&o.push(r);o.length&&s.push({elem:l,handlers:o})}return l=this,u<t.length&&s.push({elem:l,handlers:t.slice(u)}),s},addProp:function(t,e){Object.defineProperty(S.Event.prototype,t,{enumerable:!0,configurable:!0,get:m(e)?function(){if(this.originalEvent)return e(this.originalEvent)}:function(){if(this.originalEvent)return this.originalEvent[t]},set:function(e){Object.defineProperty(this,t,{enumerable:!0,configurable:!0,writable:!0,value:e})}})},fix:function(e){return e[S.expando]?e:new S.Event(e)},special:{load:{noBubble:!0},click:{setup:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click",we),!1},trigger:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click"),!0},_default:function(e){var t=e.target;return pe.test(t.type)&&t.click&&A(t,"input")&&Y.get(t,"click")||A(t,"a")}},beforeunload:{postDispatch:function(e){void 0!==e.result&&e.originalEvent&&(e.originalEvent.returnValue=e.result)}}}},S.removeEvent=function(e,t,n){e.removeEventListener&&e.removeEventListener(t,n)},S.Event=function(e,t){if(!(this instanceof S.Event))return new S.Event(e,t);e&&e.type?(this.originalEvent=e,this.type=e.type,this.isDefaultPrevented=e.defaultPrevented||void 0===e.defaultPrevented&&!1===e.returnValue?we:Te,this.target=e.target&&3===e.target.nodeType?e.target.parentNode:e.target,this.currentTarget=e.currentTarget,this.relatedTarget=e.relatedTarget):this.type=e,t&&S.extend(this,t),this.timeStamp=e&&e.timeStamp||Date.now(),this[S.expando]=!0},S.Event.prototype={constructor:S.Event,isDefaultPrevented:Te,isPropagationStopped:Te,isImmediatePropagationStopped:Te,isSimulated:!1,preventDefault:function(){var e=this.originalEvent;this.isDefaultPrevented=we,e&&!this.isSimulated&&e.preventDefault()},stopPropagation:function(){var e=this.originalEvent;this.isPropagationStopped=we,e&&!this.isSimulated&&e.stopPropagation()},stopImmediatePropagation:function(){var e=this.originalEvent;this.isImmediatePropagationStopped=we,e&&!this.isSimulated&&e.stopImmediatePropagation(),this.stopPropagation()}},S.each({altKey:!0,bubbles:!0,cancelable:!0,changedTouches:!0,ctrlKey:!0,detail:!0,eventPhase:!0,metaKey:!0,pageX:!0,pageY:!0,shiftKey:!0,view:!0,"char":!0,code:!0,charCode:!0,key:!0,keyCode:!0,button:!0,buttons:!0,clientX:!0,clientY:!0,offsetX:!0,offsetY:!0,pointerId:!0,pointerType:!0,screenX:!0,screenY:!0,targetTouches:!0,toElement:!0,touches:!0,which:!0},S.event.addProp),S.each({focus:"focusin",blur:"focusout"},function(e,t){S.event.special[e]={setup:function(){return Se(this,e,Ce),!1},trigger:function(){return Se(this,e),!0},_default:function(){return!0},delegateType:t}}),S.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(e,i){S.event.special[e]={delegateType:i,bindType:i,handle:function(e){var t,n=e.relatedTarget,r=e.handleObj;return n&&(n===this||S.contains(this,n))||(e.type=r.origType,t=r.handler.apply(this,arguments),e.type=i),t}}}),S.fn.extend({on:function(e,t,n,r){return Ee(this,e,t,n,r)},one:function(e,t,n,r){return Ee(this,e,t,n,r,1)},off:function(e,t,n){var r,i;if(e&&e.preventDefault&&e.handleObj)return r=e.handleObj,S(e.delegateTarget).off(r.namespace?r.origType+"."+r.namespace:r.origType,r.selector,r.handler),this;if("object"==typeof e){for(i in e)this.off(i,t,e[i]);return this}return!1!==t&&"function"!=typeof t||(n=t,t=void 0),!1===n&&(n=Te),this.each(function(){S.event.remove(this,e,n,t)})}});var ke=/<script|<style|<link/i,Ae=/checked\s*(?:[^=]|=\s*.checked.)/i,Ne=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g;function je(e,t){return A(e,"table")&&A(11!==t.nodeType?t:t.firstChild,"tr")&&S(e).children("tbody")[0]||e}function De(e){return e.type=(null!==e.getAttribute("type"))+"/"+e.type,e}function qe(e){return"true/"===(e.type||"").slice(0,5)?e.type=e.type.slice(5):e.removeAttribute("type"),e}function Le(e,t){var n,r,i,o,a,s;if(1===t.nodeType){if(Y.hasData(e)&&(s=Y.get(e).events))for(i in Y.remove(t,"handle events"),s)for(n=0,r=s[i].length;n<r;n++)S.event.add(t,i,s[i][n]);Q.hasData(e)&&(o=Q.access(e),a=S.extend({},o),Q.set(t,a))}}function He(n,r,i,o){r=g(r);var e,t,a,s,u,l,c=0,f=n.length,p=f-1,d=r[0],h=m(d);if(h||1<f&&"string"==typeof d&&!y.checkClone&&Ae.test(d))return n.each(function(e){var t=n.eq(e);h&&(r[0]=d.call(this,e,t.html())),He(t,r,i,o)});if(f&&(t=(e=xe(r,n[0].ownerDocument,!1,n,o)).firstChild,1===e.childNodes.length&&(e=t),t||o)){for(s=(a=S.map(ve(e,"script"),De)).length;c<f;c++)u=e,c!==p&&(u=S.clone(u,!0,!0),s&&S.merge(a,ve(u,"script"))),i.call(n[c],u,c);if(s)for(l=a[a.length-1].ownerDocument,S.map(a,qe),c=0;c<s;c++)u=a[c],he.test(u.type||"")&&!Y.access(u,"globalEval")&&S.contains(l,u)&&(u.src&&"module"!==(u.type||"").toLowerCase()?S._evalUrl&&!u.noModule&&S._evalUrl(u.src,{nonce:u.nonce||u.getAttribute("nonce")},l):b(u.textContent.replace(Ne,""),u,l))}return n}function Oe(e,t,n){for(var r,i=t?S.filter(t,e):e,o=0;null!=(r=i[o]);o++)n||1!==r.nodeType||S.cleanData(ve(r)),r.parentNode&&(n&&ie(r)&&ye(ve(r,"script")),r.parentNode.removeChild(r));return e}S.extend({htmlPrefilter:function(e){return e},clone:function(e,t,n){var r,i,o,a,s,u,l,c=e.cloneNode(!0),f=ie(e);if(!(y.noCloneChecked||1!==e.nodeType&&11!==e.nodeType||S.isXMLDoc(e)))for(a=ve(c),r=0,i=(o=ve(e)).length;r<i;r++)s=o[r],u=a[r],void 0,"input"===(l=u.nodeName.toLowerCase())&&pe.test(s.type)?u.checked=s.checked:"input"!==l&&"textarea"!==l||(u.defaultValue=s.defaultValue);if(t)if(n)for(o=o||ve(e),a=a||ve(c),r=0,i=o.length;r<i;r++)Le(o[r],a[r]);else Le(e,c);return 0<(a=ve(c,"script")).length&&ye(a,!f&&ve(e,"script")),c},cleanData:function(e){for(var t,n,r,i=S.event.special,o=0;void 0!==(n=e[o]);o++)if(V(n)){if(t=n[Y.expando]){if(t.events)for(r in t.events)i[r]?S.event.remove(n,r):S.removeEvent(n,r,t.handle);n[Y.expando]=void 0}n[Q.expando]&&(n[Q.expando]=void 0)}}}),S.fn.extend({detach:function(e){return Oe(this,e,!0)},remove:function(e){return Oe(this,e)},text:function(e){return $(this,function(e){return void 0===e?S.text(this):this.empty().each(function(){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||(this.textContent=e)})},null,e,arguments.length)},append:function(){return He(this,arguments,function(e){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||je(this,e).appendChild(e)})},prepend:function(){return He(this,arguments,function(e){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var t=je(this,e);t.insertBefore(e,t.firstChild)}})},before:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this)})},after:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this.nextSibling)})},empty:function(){for(var e,t=0;null!=(e=this[t]);t++)1===e.nodeType&&(S.cleanData(ve(e,!1)),e.textContent="");return this},clone:function(e,t){return e=null!=e&&e,t=null==t?e:t,this.map(function(){return S.clone(this,e,t)})},html:function(e){return $(this,function(e){var t=this[0]||{},n=0,r=this.length;if(void 0===e&&1===t.nodeType)return t.innerHTML;if("string"==typeof e&&!ke.test(e)&&!ge[(de.exec(e)||["",""])[1].toLowerCase()]){e=S.htmlPrefilter(e);try{for(;n<r;n++)1===(t=this[n]||{}).nodeType&&(S.cleanData(ve(t,!1)),t.innerHTML=e);t=0}catch(e){}}t&&this.empty().append(e)},null,e,arguments.length)},replaceWith:function(){var n=[];return He(this,arguments,function(e){var t=this.parentNode;S.inArray(this,n)<0&&(S.cleanData(ve(this)),t&&t.replaceChild(e,this))},n)}}),S.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(e,a){S.fn[e]=function(e){for(var t,n=[],r=S(e),i=r.length-1,o=0;o<=i;o++)t=o===i?this:this.clone(!0),S(r[o])[a](t),u.apply(n,t.get());return this.pushStack(n)}});var Pe=new RegExp("^("+ee+")(?!px)[a-z%]+$","i"),Re=function(e){var t=e.ownerDocument.defaultView;return t&&t.opener||(t=C),t.getComputedStyle(e)},Me=function(e,t,n){var r,i,o={};for(i in t)o[i]=e.style[i],e.style[i]=t[i];for(i in r=n.call(e),t)e.style[i]=o[i];return r},Ie=new RegExp(ne.join("|"),"i");function We(e,t,n){var r,i,o,a,s=e.style;return(n=n||Re(e))&&(""!==(a=n.getPropertyValue(t)||n[t])||ie(e)||(a=S.style(e,t)),!y.pixelBoxStyles()&&Pe.test(a)&&Ie.test(t)&&(r=s.width,i=s.minWidth,o=s.maxWidth,s.minWidth=s.maxWidth=s.width=a,a=n.width,s.width=r,s.minWidth=i,s.maxWidth=o)),void 0!==a?a+"":a}function Fe(e,t){return{get:function(){if(!e())return(this.get=t).apply(this,arguments);delete this.get}}}!function(){function e(){if(l){u.style.cssText="position:absolute;left:-11111px;width:60px;margin-top:1px;padding:0;border:0",l.style.cssText="position:relative;display:block;box-sizing:border-box;overflow:scroll;margin:auto;border:1px;padding:1px;width:60%;top:1%",re.appendChild(u).appendChild(l);var e=C.getComputedStyle(l);n="1%"!==e.top,s=12===t(e.marginLeft),l.style.right="60%",o=36===t(e.right),r=36===t(e.width),l.style.position="absolute",i=12===t(l.offsetWidth/3),re.removeChild(u),l=null}}function t(e){return Math.round(parseFloat(e))}var n,r,i,o,a,s,u=E.createElement("div"),l=E.createElement("div");l.style&&(l.style.backgroundClip="content-box",l.cloneNode(!0).style.backgroundClip="",y.clearCloneStyle="content-box"===l.style.backgroundClip,S.extend(y,{boxSizingReliable:function(){return e(),r},pixelBoxStyles:function(){return e(),o},pixelPosition:function(){return e(),n},reliableMarginLeft:function(){return e(),s},scrollboxSize:function(){return e(),i},reliableTrDimensions:function(){var e,t,n,r;return null==a&&(e=E.createElement("table"),t=E.createElement("tr"),n=E.createElement("div"),e.style.cssText="position:absolute;left:-11111px;border-collapse:separate",t.style.cssText="border:1px solid",t.style.height="1px",n.style.height="9px",n.style.display="block",re.appendChild(e).appendChild(t).appendChild(n),r=C.getComputedStyle(t),a=parseInt(r.height,10)+parseInt(r.borderTopWidth,10)+parseInt(r.borderBottomWidth,10)===t.offsetHeight,re.removeChild(e)),a}}))}();var Be=["Webkit","Moz","ms"],$e=E.createElement("div").style,_e={};function ze(e){var t=S.cssProps[e]||_e[e];return t||(e in $e?e:_e[e]=function(e){var t=e[0].toUpperCase()+e.slice(1),n=Be.length;while(n--)if((e=Be[n]+t)in $e)return e}(e)||e)}var Ue=/^(none|table(?!-c[ea]).+)/,Xe=/^--/,Ve={position:"absolute",visibility:"hidden",display:"block"},Ge={letterSpacing:"0",fontWeight:"400"};function Ye(e,t,n){var r=te.exec(t);return r?Math.max(0,r[2]-(n||0))+(r[3]||"px"):t}function Qe(e,t,n,r,i,o){var a="width"===t?1:0,s=0,u=0;if(n===(r?"border":"content"))return 0;for(;a<4;a+=2)"margin"===n&&(u+=S.css(e,n+ne[a],!0,i)),r?("content"===n&&(u-=S.css(e,"padding"+ne[a],!0,i)),"margin"!==n&&(u-=S.css(e,"border"+ne[a]+"Width",!0,i))):(u+=S.css(e,"padding"+ne[a],!0,i),"padding"!==n?u+=S.css(e,"border"+ne[a]+"Width",!0,i):s+=S.css(e,"border"+ne[a]+"Width",!0,i));return!r&&0<=o&&(u+=Math.max(0,Math.ceil(e["offset"+t[0].toUpperCase()+t.slice(1)]-o-u-s-.5))||0),u}function Je(e,t,n){var r=Re(e),i=(!y.boxSizingReliable()||n)&&"border-box"===S.css(e,"boxSizing",!1,r),o=i,a=We(e,t,r),s="offset"+t[0].toUpperCase()+t.slice(1);if(Pe.test(a)){if(!n)return a;a="auto"}return(!y.boxSizingReliable()&&i||!y.reliableTrDimensions()&&A(e,"tr")||"auto"===a||!parseFloat(a)&&"inline"===S.css(e,"display",!1,r))&&e.getClientRects().length&&(i="border-box"===S.css(e,"boxSizing",!1,r),(o=s in e)&&(a=e[s])),(a=parseFloat(a)||0)+Qe(e,t,n||(i?"border":"content"),o,r,a)+"px"}function Ke(e,t,n,r,i){return new Ke.prototype.init(e,t,n,r,i)}S.extend({cssHooks:{opacity:{get:function(e,t){if(t){var n=We(e,"opacity");return""===n?"1":n}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,gridArea:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnStart:!0,gridRow:!0,gridRowEnd:!0,gridRowStart:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{},style:function(e,t,n,r){if(e&&3!==e.nodeType&&8!==e.nodeType&&e.style){var i,o,a,s=X(t),u=Xe.test(t),l=e.style;if(u||(t=ze(s)),a=S.cssHooks[t]||S.cssHooks[s],void 0===n)return a&&"get"in a&&void 0!==(i=a.get(e,!1,r))?i:l[t];"string"===(o=typeof n)&&(i=te.exec(n))&&i[1]&&(n=se(e,t,i),o="number"),null!=n&&n==n&&("number"!==o||u||(n+=i&&i[3]||(S.cssNumber[s]?"":"px")),y.clearCloneStyle||""!==n||0!==t.indexOf("background")||(l[t]="inherit"),a&&"set"in a&&void 0===(n=a.set(e,n,r))||(u?l.setProperty(t,n):l[t]=n))}},css:function(e,t,n,r){var i,o,a,s=X(t);return Xe.test(t)||(t=ze(s)),(a=S.cssHooks[t]||S.cssHooks[s])&&"get"in a&&(i=a.get(e,!0,n)),void 0===i&&(i=We(e,t,r)),"normal"===i&&t in Ge&&(i=Ge[t]),""===n||n?(o=parseFloat(i),!0===n||isFinite(o)?o||0:i):i}}),S.each(["height","width"],function(e,u){S.cssHooks[u]={get:function(e,t,n){if(t)return!Ue.test(S.css(e,"display"))||e.getClientRects().length&&e.getBoundingClientRect().width?Je(e,u,n):Me(e,Ve,function(){return Je(e,u,n)})},set:function(e,t,n){var r,i=Re(e),o=!y.scrollboxSize()&&"absolute"===i.position,a=(o||n)&&"border-box"===S.css(e,"boxSizing",!1,i),s=n?Qe(e,u,n,a,i):0;return a&&o&&(s-=Math.ceil(e["offset"+u[0].toUpperCase()+u.slice(1)]-parseFloat(i[u])-Qe(e,u,"border",!1,i)-.5)),s&&(r=te.exec(t))&&"px"!==(r[3]||"px")&&(e.style[u]=t,t=S.css(e,u)),Ye(0,t,s)}}}),S.cssHooks.marginLeft=Fe(y.reliableMarginLeft,function(e,t){if(t)return(parseFloat(We(e,"marginLeft"))||e.getBoundingClientRect().left-Me(e,{marginLeft:0},function(){return e.getBoundingClientRect().left}))+"px"}),S.each({margin:"",padding:"",border:"Width"},function(i,o){S.cssHooks[i+o]={expand:function(e){for(var t=0,n={},r="string"==typeof e?e.split(" "):[e];t<4;t++)n[i+ne[t]+o]=r[t]||r[t-2]||r[0];return n}},"margin"!==i&&(S.cssHooks[i+o].set=Ye)}),S.fn.extend({css:function(e,t){return $(this,function(e,t,n){var r,i,o={},a=0;if(Array.isArray(t)){for(r=Re(e),i=t.length;a<i;a++)o[t[a]]=S.css(e,t[a],!1,r);return o}return void 0!==n?S.style(e,t,n):S.css(e,t)},e,t,1<arguments.length)}}),((S.Tween=Ke).prototype={constructor:Ke,init:function(e,t,n,r,i,o){this.elem=e,this.prop=n,this.easing=i||S.easing._default,this.options=t,this.start=this.now=this.cur(),this.end=r,this.unit=o||(S.cssNumber[n]?"":"px")},cur:function(){var e=Ke.propHooks[this.prop];return e&&e.get?e.get(this):Ke.propHooks._default.get(this)},run:function(e){var t,n=Ke.propHooks[this.prop];return this.options.duration?this.pos=t=S.easing[this.easing](e,this.options.duration*e,0,1,this.options.duration):this.pos=t=e,this.now=(this.end-this.start)*t+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),n&&n.set?n.set(this):Ke.propHooks._default.set(this),this}}).init.prototype=Ke.prototype,(Ke.propHooks={_default:{get:function(e){var t;return 1!==e.elem.nodeType||null!=e.elem[e.prop]&&null==e.elem.style[e.prop]?e.elem[e.prop]:(t=S.css(e.elem,e.prop,""))&&"auto"!==t?t:0},set:function(e){S.fx.step[e.prop]?S.fx.step[e.prop](e):1!==e.elem.nodeType||!S.cssHooks[e.prop]&&null==e.elem.style[ze(e.prop)]?e.elem[e.prop]=e.now:S.style(e.elem,e.prop,e.now+e.unit)}}}).scrollTop=Ke.propHooks.scrollLeft={set:function(e){e.elem.nodeType&&e.elem.parentNode&&(e.elem[e.prop]=e.now)}},S.easing={linear:function(e){return e},swing:function(e){return.5-Math.cos(e*Math.PI)/2},_default:"swing"},S.fx=Ke.prototype.init,S.fx.step={};var Ze,et,tt,nt,rt=/^(?:toggle|show|hide)$/,it=/queueHooks$/;function ot(){et&&(!1===E.hidden&&C.requestAnimationFrame?C.requestAnimationFrame(ot):C.setTimeout(ot,S.fx.interval),S.fx.tick())}function at(){return C.setTimeout(function(){Ze=void 0}),Ze=Date.now()}function st(e,t){var n,r=0,i={height:e};for(t=t?1:0;r<4;r+=2-t)i["margin"+(n=ne[r])]=i["padding"+n]=e;return t&&(i.opacity=i.width=e),i}function ut(e,t,n){for(var r,i=(lt.tweeners[t]||[]).concat(lt.tweeners["*"]),o=0,a=i.length;o<a;o++)if(r=i[o].call(n,t,e))return r}function lt(o,e,t){var n,a,r=0,i=lt.prefilters.length,s=S.Deferred().always(function(){delete u.elem}),u=function(){if(a)return!1;for(var e=Ze||at(),t=Math.max(0,l.startTime+l.duration-e),n=1-(t/l.duration||0),r=0,i=l.tweens.length;r<i;r++)l.tweens[r].run(n);return s.notifyWith(o,[l,n,t]),n<1&&i?t:(i||s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l]),!1)},l=s.promise({elem:o,props:S.extend({},e),opts:S.extend(!0,{specialEasing:{},easing:S.easing._default},t),originalProperties:e,originalOptions:t,startTime:Ze||at(),duration:t.duration,tweens:[],createTween:function(e,t){var n=S.Tween(o,l.opts,e,t,l.opts.specialEasing[e]||l.opts.easing);return l.tweens.push(n),n},stop:function(e){var t=0,n=e?l.tweens.length:0;if(a)return this;for(a=!0;t<n;t++)l.tweens[t].run(1);return e?(s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l,e])):s.rejectWith(o,[l,e]),this}}),c=l.props;for(!function(e,t){var n,r,i,o,a;for(n in e)if(i=t[r=X(n)],o=e[n],Array.isArray(o)&&(i=o[1],o=e[n]=o[0]),n!==r&&(e[r]=o,delete e[n]),(a=S.cssHooks[r])&&"expand"in a)for(n in o=a.expand(o),delete e[r],o)n in e||(e[n]=o[n],t[n]=i);else t[r]=i}(c,l.opts.specialEasing);r<i;r++)if(n=lt.prefilters[r].call(l,o,c,l.opts))return m(n.stop)&&(S._queueHooks(l.elem,l.opts.queue).stop=n.stop.bind(n)),n;return S.map(c,ut,l),m(l.opts.start)&&l.opts.start.call(o,l),l.progress(l.opts.progress).done(l.opts.done,l.opts.complete).fail(l.opts.fail).always(l.opts.always),S.fx.timer(S.extend(u,{elem:o,anim:l,queue:l.opts.queue})),l}S.Animation=S.extend(lt,{tweeners:{"*":[function(e,t){var n=this.createTween(e,t);return se(n.elem,e,te.exec(t),n),n}]},tweener:function(e,t){m(e)?(t=e,e=["*"]):e=e.match(P);for(var n,r=0,i=e.length;r<i;r++)n=e[r],lt.tweeners[n]=lt.tweeners[n]||[],lt.tweeners[n].unshift(t)},prefilters:[function(e,t,n){var r,i,o,a,s,u,l,c,f="width"in t||"height"in t,p=this,d={},h=e.style,g=e.nodeType&&ae(e),v=Y.get(e,"fxshow");for(r in n.queue||(null==(a=S._queueHooks(e,"fx")).unqueued&&(a.unqueued=0,s=a.empty.fire,a.empty.fire=function(){a.unqueued||s()}),a.unqueued++,p.always(function(){p.always(function(){a.unqueued--,S.queue(e,"fx").length||a.empty.fire()})})),t)if(i=t[r],rt.test(i)){if(delete t[r],o=o||"toggle"===i,i===(g?"hide":"show")){if("show"!==i||!v||void 0===v[r])continue;g=!0}d[r]=v&&v[r]||S.style(e,r)}if((u=!S.isEmptyObject(t))||!S.isEmptyObject(d))for(r in f&&1===e.nodeType&&(n.overflow=[h.overflow,h.overflowX,h.overflowY],null==(l=v&&v.display)&&(l=Y.get(e,"display")),"none"===(c=S.css(e,"display"))&&(l?c=l:(le([e],!0),l=e.style.display||l,c=S.css(e,"display"),le([e]))),("inline"===c||"inline-block"===c&&null!=l)&&"none"===S.css(e,"float")&&(u||(p.done(function(){h.display=l}),null==l&&(c=h.display,l="none"===c?"":c)),h.display="inline-block")),n.overflow&&(h.overflow="hidden",p.always(function(){h.overflow=n.overflow[0],h.overflowX=n.overflow[1],h.overflowY=n.overflow[2]})),u=!1,d)u||(v?"hidden"in v&&(g=v.hidden):v=Y.access(e,"fxshow",{display:l}),o&&(v.hidden=!g),g&&le([e],!0),p.done(function(){for(r in g||le([e]),Y.remove(e,"fxshow"),d)S.style(e,r,d[r])})),u=ut(g?v[r]:0,r,p),r in v||(v[r]=u.start,g&&(u.end=u.start,u.start=0))}],prefilter:function(e,t){t?lt.prefilters.unshift(e):lt.prefilters.push(e)}}),S.speed=function(e,t,n){var r=e&&"object"==typeof e?S.extend({},e):{complete:n||!n&&t||m(e)&&e,duration:e,easing:n&&t||t&&!m(t)&&t};return S.fx.off?r.duration=0:"number"!=typeof r.duration&&(r.duration in S.fx.speeds?r.duration=S.fx.speeds[r.duration]:r.duration=S.fx.speeds._default),null!=r.queue&&!0!==r.queue||(r.queue="fx"),r.old=r.complete,r.complete=function(){m(r.old)&&r.old.call(this),r.queue&&S.dequeue(this,r.queue)},r},S.fn.extend({fadeTo:function(e,t,n,r){return this.filter(ae).css("opacity",0).show().end().animate({opacity:t},e,n,r)},animate:function(t,e,n,r){var i=S.isEmptyObject(t),o=S.speed(e,n,r),a=function(){var e=lt(this,S.extend({},t),o);(i||Y.get(this,"finish"))&&e.stop(!0)};return a.finish=a,i||!1===o.queue?this.each(a):this.queue(o.queue,a)},stop:function(i,e,o){var a=function(e){var t=e.stop;delete e.stop,t(o)};return"string"!=typeof i&&(o=e,e=i,i=void 0),e&&this.queue(i||"fx",[]),this.each(function(){var e=!0,t=null!=i&&i+"queueHooks",n=S.timers,r=Y.get(this);if(t)r[t]&&r[t].stop&&a(r[t]);else for(t in r)r[t]&&r[t].stop&&it.test(t)&&a(r[t]);for(t=n.length;t--;)n[t].elem!==this||null!=i&&n[t].queue!==i||(n[t].anim.stop(o),e=!1,n.splice(t,1));!e&&o||S.dequeue(this,i)})},finish:function(a){return!1!==a&&(a=a||"fx"),this.each(function(){var e,t=Y.get(this),n=t[a+"queue"],r=t[a+"queueHooks"],i=S.timers,o=n?n.length:0;for(t.finish=!0,S.queue(this,a,[]),r&&r.stop&&r.stop.call(this,!0),e=i.length;e--;)i[e].elem===this&&i[e].queue===a&&(i[e].anim.stop(!0),i.splice(e,1));for(e=0;e<o;e++)n[e]&&n[e].finish&&n[e].finish.call(this);delete t.finish})}}),S.each(["toggle","show","hide"],function(e,r){var i=S.fn[r];S.fn[r]=function(e,t,n){return null==e||"boolean"==typeof e?i.apply(this,arguments):this.animate(st(r,!0),e,t,n)}}),S.each({slideDown:st("show"),slideUp:st("hide"),slideToggle:st("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(e,r){S.fn[e]=function(e,t,n){return this.animate(r,e,t,n)}}),S.timers=[],S.fx.tick=function(){var e,t=0,n=S.timers;for(Ze=Date.now();t<n.length;t++)(e=n[t])()||n[t]!==e||n.splice(t--,1);n.length||S.fx.stop(),Ze=void 0},S.fx.timer=function(e){S.timers.push(e),S.fx.start()},S.fx.interval=13,S.fx.start=function(){et||(et=!0,ot())},S.fx.stop=function(){et=null},S.fx.speeds={slow:600,fast:200,_default:400},S.fn.delay=function(r,e){return r=S.fx&&S.fx.speeds[r]||r,e=e||"fx",this.queue(e,function(e,t){var n=C.setTimeout(e,r);t.stop=function(){C.clearTimeout(n)}})},tt=E.createElement("input"),nt=E.createElement("select").appendChild(E.createElement("option")),tt.type="checkbox",y.checkOn=""!==tt.value,y.optSelected=nt.selected,(tt=E.createElement("input")).value="t",tt.type="radio",y.radioValue="t"===tt.value;var ct,ft=S.expr.attrHandle;S.fn.extend({attr:function(e,t){return $(this,S.attr,e,t,1<arguments.length)},removeAttr:function(e){return this.each(function(){S.removeAttr(this,e)})}}),S.extend({attr:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return"undefined"==typeof e.getAttribute?S.prop(e,t,n):(1===o&&S.isXMLDoc(e)||(i=S.attrHooks[t.toLowerCase()]||(S.expr.match.bool.test(t)?ct:void 0)),void 0!==n?null===n?void S.removeAttr(e,t):i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:(e.setAttribute(t,n+""),n):i&&"get"in i&&null!==(r=i.get(e,t))?r:null==(r=S.find.attr(e,t))?void 0:r)},attrHooks:{type:{set:function(e,t){if(!y.radioValue&&"radio"===t&&A(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}}},removeAttr:function(e,t){var n,r=0,i=t&&t.match(P);if(i&&1===e.nodeType)while(n=i[r++])e.removeAttribute(n)}}),ct={set:function(e,t,n){return!1===t?S.removeAttr(e,n):e.setAttribute(n,n),n}},S.each(S.expr.match.bool.source.match(/\w+/g),function(e,t){var a=ft[t]||S.find.attr;ft[t]=function(e,t,n){var r,i,o=t.toLowerCase();return n||(i=ft[o],ft[o]=r,r=null!=a(e,t,n)?o:null,ft[o]=i),r}});var pt=/^(?:input|select|textarea|button)$/i,dt=/^(?:a|area)$/i;function ht(e){return(e.match(P)||[]).join(" ")}function gt(e){return e.getAttribute&&e.getAttribute("class")||""}function vt(e){return Array.isArray(e)?e:"string"==typeof e&&e.match(P)||[]}S.fn.extend({prop:function(e,t){return $(this,S.prop,e,t,1<arguments.length)},removeProp:function(e){return this.each(function(){delete this[S.propFix[e]||e]})}}),S.extend({prop:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return 1===o&&S.isXMLDoc(e)||(t=S.propFix[t]||t,i=S.propHooks[t]),void 0!==n?i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:e[t]=n:i&&"get"in i&&null!==(r=i.get(e,t))?r:e[t]},propHooks:{tabIndex:{get:function(e){var t=S.find.attr(e,"tabindex");return t?parseInt(t,10):pt.test(e.nodeName)||dt.test(e.nodeName)&&e.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),y.optSelected||(S.propHooks.selected={get:function(e){var t=e.parentNode;return t&&t.parentNode&&t.parentNode.selectedIndex,null},set:function(e){var t=e.parentNode;t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex)}}),S.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){S.propFix[this.toLowerCase()]=this}),S.fn.extend({addClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).addClass(t.call(this,e,gt(this)))});if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])r.indexOf(" "+o+" ")<0&&(r+=o+" ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},removeClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).removeClass(t.call(this,e,gt(this)))});if(!arguments.length)return this.attr("class","");if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])while(-1<r.indexOf(" "+o+" "))r=r.replace(" "+o+" "," ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},toggleClass:function(i,t){var o=typeof i,a="string"===o||Array.isArray(i);return"boolean"==typeof t&&a?t?this.addClass(i):this.removeClass(i):m(i)?this.each(function(e){S(this).toggleClass(i.call(this,e,gt(this),t),t)}):this.each(function(){var e,t,n,r;if(a){t=0,n=S(this),r=vt(i);while(e=r[t++])n.hasClass(e)?n.removeClass(e):n.addClass(e)}else void 0!==i&&"boolean"!==o||((e=gt(this))&&Y.set(this,"__className__",e),this.setAttribute&&this.setAttribute("class",e||!1===i?"":Y.get(this,"__className__")||""))})},hasClass:function(e){var t,n,r=0;t=" "+e+" ";while(n=this[r++])if(1===n.nodeType&&-1<(" "+ht(gt(n))+" ").indexOf(t))return!0;return!1}});var yt=/\r/g;S.fn.extend({val:function(n){var r,e,i,t=this[0];return arguments.length?(i=m(n),this.each(function(e){var t;1===this.nodeType&&(null==(t=i?n.call(this,e,S(this).val()):n)?t="":"number"==typeof t?t+="":Array.isArray(t)&&(t=S.map(t,function(e){return null==e?"":e+""})),(r=S.valHooks[this.type]||S.valHooks[this.nodeName.toLowerCase()])&&"set"in r&&void 0!==r.set(this,t,"value")||(this.value=t))})):t?(r=S.valHooks[t.type]||S.valHooks[t.nodeName.toLowerCase()])&&"get"in r&&void 0!==(e=r.get(t,"value"))?e:"string"==typeof(e=t.value)?e.replace(yt,""):null==e?"":e:void 0}}),S.extend({valHooks:{option:{get:function(e){var t=S.find.attr(e,"value");return null!=t?t:ht(S.text(e))}},select:{get:function(e){var t,n,r,i=e.options,o=e.selectedIndex,a="select-one"===e.type,s=a?null:[],u=a?o+1:i.length;for(r=o<0?u:a?o:0;r<u;r++)if(((n=i[r]).selected||r===o)&&!n.disabled&&(!n.parentNode.disabled||!A(n.parentNode,"optgroup"))){if(t=S(n).val(),a)return t;s.push(t)}return s},set:function(e,t){var n,r,i=e.options,o=S.makeArray(t),a=i.length;while(a--)((r=i[a]).selected=-1<S.inArray(S.valHooks.option.get(r),o))&&(n=!0);return n||(e.selectedIndex=-1),o}}}}),S.each(["radio","checkbox"],function(){S.valHooks[this]={set:function(e,t){if(Array.isArray(t))return e.checked=-1<S.inArray(S(e).val(),t)}},y.checkOn||(S.valHooks[this].get=function(e){return null===e.getAttribute("value")?"on":e.value})}),y.focusin="onfocusin"in C;var mt=/^(?:focusinfocus|focusoutblur)$/,xt=function(e){e.stopPropagation()};S.extend(S.event,{trigger:function(e,t,n,r){var i,o,a,s,u,l,c,f,p=[n||E],d=v.call(e,"type")?e.type:e,h=v.call(e,"namespace")?e.namespace.split("."):[];if(o=f=a=n=n||E,3!==n.nodeType&&8!==n.nodeType&&!mt.test(d+S.event.triggered)&&(-1<d.indexOf(".")&&(d=(h=d.split(".")).shift(),h.sort()),u=d.indexOf(":")<0&&"on"+d,(e=e[S.expando]?e:new S.Event(d,"object"==typeof e&&e)).isTrigger=r?2:3,e.namespace=h.join("."),e.rnamespace=e.namespace?new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,e.result=void 0,e.target||(e.target=n),t=null==t?[e]:S.makeArray(t,[e]),c=S.event.special[d]||{},r||!c.trigger||!1!==c.trigger.apply(n,t))){if(!r&&!c.noBubble&&!x(n)){for(s=c.delegateType||d,mt.test(s+d)||(o=o.parentNode);o;o=o.parentNode)p.push(o),a=o;a===(n.ownerDocument||E)&&p.push(a.defaultView||a.parentWindow||C)}i=0;while((o=p[i++])&&!e.isPropagationStopped())f=o,e.type=1<i?s:c.bindType||d,(l=(Y.get(o,"events")||Object.create(null))[e.type]&&Y.get(o,"handle"))&&l.apply(o,t),(l=u&&o[u])&&l.apply&&V(o)&&(e.result=l.apply(o,t),!1===e.result&&e.preventDefault());return e.type=d,r||e.isDefaultPrevented()||c._default&&!1!==c._default.apply(p.pop(),t)||!V(n)||u&&m(n[d])&&!x(n)&&((a=n[u])&&(n[u]=null),S.event.triggered=d,e.isPropagationStopped()&&f.addEventListener(d,xt),n[d](),e.isPropagationStopped()&&f.removeEventListener(d,xt),S.event.triggered=void 0,a&&(n[u]=a)),e.result}},simulate:function(e,t,n){var r=S.extend(new S.Event,n,{type:e,isSimulated:!0});S.event.trigger(r,null,t)}}),S.fn.extend({trigger:function(e,t){return this.each(function(){S.event.trigger(e,t,this)})},triggerHandler:function(e,t){var n=this[0];if(n)return S.event.trigger(e,t,n,!0)}}),y.focusin||S.each({focus:"focusin",blur:"focusout"},function(n,r){var i=function(e){S.event.simulate(r,e.target,S.event.fix(e))};S.event.special[r]={setup:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r);t||e.addEventListener(n,i,!0),Y.access(e,r,(t||0)+1)},teardown:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r)-1;t?Y.access(e,r,t):(e.removeEventListener(n,i,!0),Y.remove(e,r))}}});var bt=C.location,wt={guid:Date.now()},Tt=/\?/;S.parseXML=function(e){var t,n;if(!e||"string"!=typeof e)return null;try{t=(new C.DOMParser).parseFromString(e,"text/xml")}catch(e){}return n=t&&t.getElementsByTagName("parsererror")[0],t&&!n||S.error("Invalid XML: "+(n?S.map(n.childNodes,function(e){return e.textContent}).join("\n"):e)),t};var Ct=/\[\]$/,Et=/\r?\n/g,St=/^(?:submit|button|image|reset|file)$/i,kt=/^(?:input|select|textarea|keygen)/i;function At(n,e,r,i){var t;if(Array.isArray(e))S.each(e,function(e,t){r||Ct.test(n)?i(n,t):At(n+"["+("object"==typeof t&&null!=t?e:"")+"]",t,r,i)});else if(r||"object"!==w(e))i(n,e);else for(t in e)At(n+"["+t+"]",e[t],r,i)}S.param=function(e,t){var n,r=[],i=function(e,t){var n=m(t)?t():t;r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(null==n?"":n)};if(null==e)return"";if(Array.isArray(e)||e.jquery&&!S.isPlainObject(e))S.each(e,function(){i(this.name,this.value)});else for(n in e)At(n,e[n],t,i);return r.join("&")},S.fn.extend({serialize:function(){return S.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var e=S.prop(this,"elements");return e?S.makeArray(e):this}).filter(function(){var e=this.type;return this.name&&!S(this).is(":disabled")&&kt.test(this.nodeName)&&!St.test(e)&&(this.checked||!pe.test(e))}).map(function(e,t){var n=S(this).val();return null==n?null:Array.isArray(n)?S.map(n,function(e){return{name:t.name,value:e.replace(Et,"\r\n")}}):{name:t.name,value:n.replace(Et,"\r\n")}}).get()}});var Nt=/%20/g,jt=/#.*$/,Dt=/([?&])_=[^&]*/,qt=/^(.*?):[ \t]*([^\r\n]*)$/gm,Lt=/^(?:GET|HEAD)$/,Ht=/^\/\//,Ot={},Pt={},Rt="*/".concat("*"),Mt=E.createElement("a");function It(o){return function(e,t){"string"!=typeof e&&(t=e,e="*");var n,r=0,i=e.toLowerCase().match(P)||[];if(m(t))while(n=i[r++])"+"===n[0]?(n=n.slice(1)||"*",(o[n]=o[n]||[]).unshift(t)):(o[n]=o[n]||[]).push(t)}}function Wt(t,i,o,a){var s={},u=t===Pt;function l(e){var r;return s[e]=!0,S.each(t[e]||[],function(e,t){var n=t(i,o,a);return"string"!=typeof n||u||s[n]?u?!(r=n):void 0:(i.dataTypes.unshift(n),l(n),!1)}),r}return l(i.dataTypes[0])||!s["*"]&&l("*")}function Ft(e,t){var n,r,i=S.ajaxSettings.flatOptions||{};for(n in t)void 0!==t[n]&&((i[n]?e:r||(r={}))[n]=t[n]);return r&&S.extend(!0,e,r),e}Mt.href=bt.href,S.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:bt.href,type:"GET",isLocal:/^(?:about|app|app-storage|.+-extension|file|res|widget):$/.test(bt.protocol),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Rt,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":JSON.parse,"text xml":S.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(e,t){return t?Ft(Ft(e,S.ajaxSettings),t):Ft(S.ajaxSettings,e)},ajaxPrefilter:It(Ot),ajaxTransport:It(Pt),ajax:function(e,t){"object"==typeof e&&(t=e,e=void 0),t=t||{};var c,f,p,n,d,r,h,g,i,o,v=S.ajaxSetup({},t),y=v.context||v,m=v.context&&(y.nodeType||y.jquery)?S(y):S.event,x=S.Deferred(),b=S.Callbacks("once memory"),w=v.statusCode||{},a={},s={},u="canceled",T={readyState:0,getResponseHeader:function(e){var t;if(h){if(!n){n={};while(t=qt.exec(p))n[t[1].toLowerCase()+" "]=(n[t[1].toLowerCase()+" "]||[]).concat(t[2])}t=n[e.toLowerCase()+" "]}return null==t?null:t.join(", ")},getAllResponseHeaders:function(){return h?p:null},setRequestHeader:function(e,t){return null==h&&(e=s[e.toLowerCase()]=s[e.toLowerCase()]||e,a[e]=t),this},overrideMimeType:function(e){return null==h&&(v.mimeType=e),this},statusCode:function(e){var t;if(e)if(h)T.always(e[T.status]);else for(t in e)w[t]=[w[t],e[t]];return this},abort:function(e){var t=e||u;return c&&c.abort(t),l(0,t),this}};if(x.promise(T),v.url=((e||v.url||bt.href)+"").replace(Ht,bt.protocol+"//"),v.type=t.method||t.type||v.method||v.type,v.dataTypes=(v.dataType||"*").toLowerCase().match(P)||[""],null==v.crossDomain){r=E.createElement("a");try{r.href=v.url,r.href=r.href,v.crossDomain=Mt.protocol+"//"+Mt.host!=r.protocol+"//"+r.host}catch(e){v.crossDomain=!0}}if(v.data&&v.processData&&"string"!=typeof v.data&&(v.data=S.param(v.data,v.traditional)),Wt(Ot,v,t,T),h)return T;for(i in(g=S.event&&v.global)&&0==S.active++&&S.event.trigger("ajaxStart"),v.type=v.type.toUpperCase(),v.hasContent=!Lt.test(v.type),f=v.url.replace(jt,""),v.hasContent?v.data&&v.processData&&0===(v.contentType||"").indexOf("application/x-www-form-urlencoded")&&(v.data=v.data.replace(Nt,"+")):(o=v.url.slice(f.length),v.data&&(v.processData||"string"==typeof v.data)&&(f+=(Tt.test(f)?"&":"?")+v.data,delete v.data),!1===v.cache&&(f=f.replace(Dt,"$1"),o=(Tt.test(f)?"&":"?")+"_="+wt.guid+++o),v.url=f+o),v.ifModified&&(S.lastModified[f]&&T.setRequestHeader("If-Modified-Since",S.lastModified[f]),S.etag[f]&&T.setRequestHeader("If-None-Match",S.etag[f])),(v.data&&v.hasContent&&!1!==v.contentType||t.contentType)&&T.setRequestHeader("Content-Type",v.contentType),T.setRequestHeader("Accept",v.dataTypes[0]&&v.accepts[v.dataTypes[0]]?v.accepts[v.dataTypes[0]]+("*"!==v.dataTypes[0]?", "+Rt+"; q=0.01":""):v.accepts["*"]),v.headers)T.setRequestHeader(i,v.headers[i]);if(v.beforeSend&&(!1===v.beforeSend.call(y,T,v)||h))return T.abort();if(u="abort",b.add(v.complete),T.done(v.success),T.fail(v.error),c=Wt(Pt,v,t,T)){if(T.readyState=1,g&&m.trigger("ajaxSend",[T,v]),h)return T;v.async&&0<v.timeout&&(d=C.setTimeout(function(){T.abort("timeout")},v.timeout));try{h=!1,c.send(a,l)}catch(e){if(h)throw e;l(-1,e)}}else l(-1,"No Transport");function l(e,t,n,r){var i,o,a,s,u,l=t;h||(h=!0,d&&C.clearTimeout(d),c=void 0,p=r||"",T.readyState=0<e?4:0,i=200<=e&&e<300||304===e,n&&(s=function(e,t,n){var r,i,o,a,s=e.contents,u=e.dataTypes;while("*"===u[0])u.shift(),void 0===r&&(r=e.mimeType||t.getResponseHeader("Content-Type"));if(r)for(i in s)if(s[i]&&s[i].test(r)){u.unshift(i);break}if(u[0]in n)o=u[0];else{for(i in n){if(!u[0]||e.converters[i+" "+u[0]]){o=i;break}a||(a=i)}o=o||a}if(o)return o!==u[0]&&u.unshift(o),n[o]}(v,T,n)),!i&&-1<S.inArray("script",v.dataTypes)&&S.inArray("json",v.dataTypes)<0&&(v.converters["text script"]=function(){}),s=function(e,t,n,r){var i,o,a,s,u,l={},c=e.dataTypes.slice();if(c[1])for(a in e.converters)l[a.toLowerCase()]=e.converters[a];o=c.shift();while(o)if(e.responseFields[o]&&(n[e.responseFields[o]]=t),!u&&r&&e.dataFilter&&(t=e.dataFilter(t,e.dataType)),u=o,o=c.shift())if("*"===o)o=u;else if("*"!==u&&u!==o){if(!(a=l[u+" "+o]||l["* "+o]))for(i in l)if((s=i.split(" "))[1]===o&&(a=l[u+" "+s[0]]||l["* "+s[0]])){!0===a?a=l[i]:!0!==l[i]&&(o=s[0],c.unshift(s[1]));break}if(!0!==a)if(a&&e["throws"])t=a(t);else try{t=a(t)}catch(e){return{state:"parsererror",error:a?e:"No conversion from "+u+" to "+o}}}return{state:"success",data:t}}(v,s,T,i),i?(v.ifModified&&((u=T.getResponseHeader("Last-Modified"))&&(S.lastModified[f]=u),(u=T.getResponseHeader("etag"))&&(S.etag[f]=u)),204===e||"HEAD"===v.type?l="nocontent":304===e?l="notmodified":(l=s.state,o=s.data,i=!(a=s.error))):(a=l,!e&&l||(l="error",e<0&&(e=0))),T.status=e,T.statusText=(t||l)+"",i?x.resolveWith(y,[o,l,T]):x.rejectWith(y,[T,l,a]),T.statusCode(w),w=void 0,g&&m.trigger(i?"ajaxSuccess":"ajaxError",[T,v,i?o:a]),b.fireWith(y,[T,l]),g&&(m.trigger("ajaxComplete",[T,v]),--S.active||S.event.trigger("ajaxStop")))}return T},getJSON:function(e,t,n){return S.get(e,t,n,"json")},getScript:function(e,t){return S.get(e,void 0,t,"script")}}),S.each(["get","post"],function(e,i){S[i]=function(e,t,n,r){return m(t)&&(r=r||n,n=t,t=void 0),S.ajax(S.extend({url:e,type:i,dataType:r,data:t,success:n},S.isPlainObject(e)&&e))}}),S.ajaxPrefilter(function(e){var t;for(t in e.headers)"content-type"===t.toLowerCase()&&(e.contentType=e.headers[t]||"")}),S._evalUrl=function(e,t,n){return S.ajax({url:e,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,converters:{"text script":function(){}},dataFilter:function(e){S.globalEval(e,t,n)}})},S.fn.extend({wrapAll:function(e){var t;return this[0]&&(m(e)&&(e=e.call(this[0])),t=S(e,this[0].ownerDocument).eq(0).clone(!0),this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstElementChild)e=e.firstElementChild;return e}).append(this)),this},wrapInner:function(n){return m(n)?this.each(function(e){S(this).wrapInner(n.call(this,e))}):this.each(function(){var e=S(this),t=e.contents();t.length?t.wrapAll(n):e.append(n)})},wrap:function(t){var n=m(t);return this.each(function(e){S(this).wrapAll(n?t.call(this,e):t)})},unwrap:function(e){return this.parent(e).not("body").each(function(){S(this).replaceWith(this.childNodes)}),this}}),S.expr.pseudos.hidden=function(e){return!S.expr.pseudos.visible(e)},S.expr.pseudos.visible=function(e){return!!(e.offsetWidth||e.offsetHeight||e.getClientRects().length)},S.ajaxSettings.xhr=function(){try{return new C.XMLHttpRequest}catch(e){}};var Bt={0:200,1223:204},$t=S.ajaxSettings.xhr();y.cors=!!$t&&"withCredentials"in $t,y.ajax=$t=!!$t,S.ajaxTransport(function(i){var o,a;if(y.cors||$t&&!i.crossDomain)return{send:function(e,t){var n,r=i.xhr();if(r.open(i.type,i.url,i.async,i.username,i.password),i.xhrFields)for(n in i.xhrFields)r[n]=i.xhrFields[n];for(n in i.mimeType&&r.overrideMimeType&&r.overrideMimeType(i.mimeType),i.crossDomain||e["X-Requested-With"]||(e["X-Requested-With"]="XMLHttpRequest"),e)r.setRequestHeader(n,e[n]);o=function(e){return function(){o&&(o=a=r.onload=r.onerror=r.onabort=r.ontimeout=r.onreadystatechange=null,"abort"===e?r.abort():"error"===e?"number"!=typeof r.status?t(0,"error"):t(r.status,r.statusText):t(Bt[r.status]||r.status,r.statusText,"text"!==(r.responseType||"text")||"string"!=typeof r.responseText?{binary:r.response}:{text:r.responseText},r.getAllResponseHeaders()))}},r.onload=o(),a=r.onerror=r.ontimeout=o("error"),void 0!==r.onabort?r.onabort=a:r.onreadystatechange=function(){4===r.readyState&&C.setTimeout(function(){o&&a()})},o=o("abort");try{r.send(i.hasContent&&i.data||null)}catch(e){if(o)throw e}},abort:function(){o&&o()}}}),S.ajaxPrefilter(function(e){e.crossDomain&&(e.contents.script=!1)}),S.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(e){return S.globalEval(e),e}}}),S.ajaxPrefilter("script",function(e){void 0===e.cache&&(e.cache=!1),e.crossDomain&&(e.type="GET")}),S.ajaxTransport("script",function(n){var r,i;if(n.crossDomain||n.scriptAttrs)return{send:function(e,t){r=S("<script>").attr(n.scriptAttrs||{}).prop({charset:n.scriptCharset,src:n.url}).on("load error",i=function(e){r.remove(),i=null,e&&t("error"===e.type?404:200,e.type)}),E.head.appendChild(r[0])},abort:function(){i&&i()}}});var _t,zt=[],Ut=/(=)\?(?=&|$)|\?\?/;S.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var e=zt.pop()||S.expando+"_"+wt.guid++;return this[e]=!0,e}}),S.ajaxPrefilter("json jsonp",function(e,t,n){var r,i,o,a=!1!==e.jsonp&&(Ut.test(e.url)?"url":"string"==typeof e.data&&0===(e.contentType||"").indexOf("application/x-www-form-urlencoded")&&Ut.test(e.data)&&"data");if(a||"jsonp"===e.dataTypes[0])return r=e.jsonpCallback=m(e.jsonpCallback)?e.jsonpCallback():e.jsonpCallback,a?e[a]=e[a].replace(Ut,"$1"+r):!1!==e.jsonp&&(e.url+=(Tt.test(e.url)?"&":"?")+e.jsonp+"="+r),e.converters["script json"]=function(){return o||S.error(r+" was not called"),o[0]},e.dataTypes[0]="json",i=C[r],C[r]=function(){o=arguments},n.always(function(){void 0===i?S(C).removeProp(r):C[r]=i,e[r]&&(e.jsonpCallback=t.jsonpCallback,zt.push(r)),o&&m(i)&&i(o[0]),o=i=void 0}),"script"}),y.createHTMLDocument=((_t=E.implementation.createHTMLDocument("").body).innerHTML="<form></form><form></form>",2===_t.childNodes.length),S.parseHTML=function(e,t,n){return"string"!=typeof e?[]:("boolean"==typeof t&&(n=t,t=!1),t||(y.createHTMLDocument?((r=(t=E.implementation.createHTMLDocument("")).createElement("base")).href=E.location.href,t.head.appendChild(r)):t=E),o=!n&&[],(i=N.exec(e))?[t.createElement(i[1])]:(i=xe([e],t,o),o&&o.length&&S(o).remove(),S.merge([],i.childNodes)));var r,i,o},S.fn.load=function(e,t,n){var r,i,o,a=this,s=e.indexOf(" ");return-1<s&&(r=ht(e.slice(s)),e=e.slice(0,s)),m(t)?(n=t,t=void 0):t&&"object"==typeof t&&(i="POST"),0<a.length&&S.ajax({url:e,type:i||"GET",dataType:"html",data:t}).done(function(e){o=arguments,a.html(r?S("<div>").append(S.parseHTML(e)).find(r):e)}).always(n&&function(e,t){a.each(function(){n.apply(this,o||[e.responseText,t,e])})}),this},S.expr.pseudos.animated=function(t){return S.grep(S.timers,function(e){return t===e.elem}).length},S.offset={setOffset:function(e,t,n){var r,i,o,a,s,u,l=S.css(e,"position"),c=S(e),f={};"static"===l&&(e.style.position="relative"),s=c.offset(),o=S.css(e,"top"),u=S.css(e,"left"),("absolute"===l||"fixed"===l)&&-1<(o+u).indexOf("auto")?(a=(r=c.position()).top,i=r.left):(a=parseFloat(o)||0,i=parseFloat(u)||0),m(t)&&(t=t.call(e,n,S.extend({},s))),null!=t.top&&(f.top=t.top-s.top+a),null!=t.left&&(f.left=t.left-s.left+i),"using"in t?t.using.call(e,f):c.css(f)}},S.fn.extend({offset:function(t){if(arguments.length)return void 0===t?this:this.each(function(e){S.offset.setOffset(this,t,e)});var e,n,r=this[0];return r?r.getClientRects().length?(e=r.getBoundingClientRect(),n=r.ownerDocument.defaultView,{top:e.top+n.pageYOffset,left:e.left+n.pageXOffset}):{top:0,left:0}:void 0},position:function(){if(this[0]){var e,t,n,r=this[0],i={top:0,left:0};if("fixed"===S.css(r,"position"))t=r.getBoundingClientRect();else{t=this.offset(),n=r.ownerDocument,e=r.offsetParent||n.documentElement;while(e&&(e===n.body||e===n.documentElement)&&"static"===S.css(e,"position"))e=e.parentNode;e&&e!==r&&1===e.nodeType&&((i=S(e).offset()).top+=S.css(e,"borderTopWidth",!0),i.left+=S.css(e,"borderLeftWidth",!0))}return{top:t.top-i.top-S.css(r,"marginTop",!0),left:t.left-i.left-S.css(r,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var e=this.offsetParent;while(e&&"static"===S.css(e,"position"))e=e.offsetParent;return e||re})}}),S.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(t,i){var o="pageYOffset"===i;S.fn[t]=function(e){return $(this,function(e,t,n){var r;if(x(e)?r=e:9===e.nodeType&&(r=e.defaultView),void 0===n)return r?r[i]:e[t];r?r.scrollTo(o?r.pageXOffset:n,o?n:r.pageYOffset):e[t]=n},t,e,arguments.length)}}),S.each(["top","left"],function(e,n){S.cssHooks[n]=Fe(y.pixelPosition,function(e,t){if(t)return t=We(e,n),Pe.test(t)?S(e).position()[n]+"px":t})}),S.each({Height:"height",Width:"width"},function(a,s){S.each({padding:"inner"+a,content:s,"":"outer"+a},function(r,o){S.fn[o]=function(e,t){var n=arguments.length&&(r||"boolean"!=typeof e),i=r||(!0===e||!0===t?"margin":"border");return $(this,function(e,t,n){var r;return x(e)?0===o.indexOf("outer")?e["inner"+a]:e.document.documentElement["client"+a]:9===e.nodeType?(r=e.documentElement,Math.max(e.body["scroll"+a],r["scroll"+a],e.body["offset"+a],r["offset"+a],r["client"+a])):void 0===n?S.css(e,t,i):S.style(e,t,n,i)},s,n?e:void 0,n)}})}),S.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(e,t){S.fn[t]=function(e){return this.on(t,e)}}),S.fn.extend({bind:function(e,t,n){return this.on(e,null,t,n)},unbind:function(e,t){return this.off(e,null,t)},delegate:function(e,t,n,r){return this.on(t,e,n,r)},undelegate:function(e,t,n){return 1===arguments.length?this.off(e,"**"):this.off(t,e||"**",n)},hover:function(e,t){return this.mouseenter(e).mouseleave(t||e)}}),S.each("blur focus focusin focusout resize scroll click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup contextmenu".split(" "),function(e,n){S.fn[n]=function(e,t){return 0<arguments.length?this.on(n,null,e,t):this.trigger(n)}});var Xt=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g;S.proxy=function(e,t){var n,r,i;if("string"==typeof t&&(n=e[t],t=e,e=n),m(e))return r=s.call(arguments,2),(i=function(){return e.apply(t||this,r.concat(s.call(arguments)))}).guid=e.guid=e.guid||S.guid++,i},S.holdReady=function(e){e?S.readyWait++:S.ready(!0)},S.isArray=Array.isArray,S.parseJSON=JSON.parse,S.nodeName=A,S.isFunction=m,S.isWindow=x,S.camelCase=X,S.type=w,S.now=Date.now,S.isNumeric=function(e){var t=S.type(e);return("number"===t||"string"===t)&&!isNaN(e-parseFloat(e))},S.trim=function(e){return null==e?"":(e+"").replace(Xt,"")},"function"==typeof define&&define.amd&&define("jquery",[],function(){return S});var Vt=C.jQuery,Gt=C.$;return S.noConflict=function(e){return C.$===S&&(C.$=Gt),e&&C.jQuery===S&&(C.jQuery=Vt),S},"undefined"==typeof e&&(C.jQuery=C.$=S),S});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:700}dfn{font-style:italic}h1{margin:.67em 0;font-size:2em}mark{color:#000;background:#ff0}small{font-size:80%}sub,sup{position:relative;font-size:75%;line-height:0;vertical-align:baseline}sup{top:-.5em}sub{bottom:-.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{height:0;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace,monospace;font-size:1em}button,input,optgroup,select,textarea{margin:0;font:inherit;color:inherit}button{overflow:visible}button,select{text-transform:none}button,html input[type=button],input[type=reset],input[type=submit]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{padding:0;border:0}input{line-height:normal}input[type=checkbox],input[type=radio]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type=number]::-webkit-inner-spin-button,input[type=number]::-webkit-outer-spin-button{height:auto}input[type=search]{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;-webkit-appearance:textfield}input[type=search]::-webkit-search-cancel-button,input[type=search]::-webkit-search-decoration{-webkit-appearance:none}fieldset{padding:.35em .625em .75em;margin:0 2px;border:1px solid silver}legend{padding:0;border:0}textarea{overflow:auto}optgroup{font-weight:700}table{border-spacing:0;border-collapse:collapse}td,th{padding:0}@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="javascript:"]:after,a[href^="#"]:after{content:""}blockquote,pre{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}img,tr{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000!important}.label{border:1px solid #000}.table{border-collapse:collapse!important}.table td,.table th{background-color:#fff!important}.table-bordered td,.table-bordered th{border:1px solid #ddd!important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:application/font-woff;base64,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) format('woff'),url(data:application/font-sfnt;base64,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) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:400;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\2a"}.glyphicon-plus:before{content:"\2b"}.glyphicon-eur:before,.glyphicon-euro:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}button,input,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.carousel-inner>.item>a>img,.carousel-inner>.item>img,.img-responsive,.thumbnail a>img,.thumbnail>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:6px}.img-thumbnail{display:inline-block;max-width:100%;height:auto;padding:4px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out}.img-circle{border-radius:50%}hr{margin-top:20px;margin-bottom:20px;border:0;border-top:1px solid #eee}.sr-only{position:absolute;width:1px;height:1px;padding:0;margin:-1px;overflow:hidden;clip:rect(0,0,0,0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role=button]{cursor:pointer}.h1,.h2,.h3,.h4,.h5,.h6,h1,h2,h3,h4,h5,h6{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-weight:400;line-height:1;color:#777}.h1,.h2,.h3,h1,h2,h3{margin-top:20px;margin-bottom:10px}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small{font-size:65%}.h4,.h5,.h6,h4,h5,h6{margin-top:10px;margin-bottom:10px}.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-size:75%}.h1,h1{font-size:36px}.h2,h2{font-size:30px}.h3,h3{font-size:24px}.h4,h4{font-size:18px}.h5,h5{font-size:14px}.h6,h6{font-size:12px}p{margin:0 0 10px}.lead{margin-bottom:20px;font-size:16px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:21px}}.small,small{font-size:85%}.mark,mark{padding:.2em;background-color:#fcf8e3}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#777}.text-primary{color:#337ab7}a.text-primary:focus,a.text-primary:hover{color:#286090}.text-success{color:#3c763d}a.text-success:focus,a.text-success:hover{color:#2b542c}.text-info{color:#31708f}a.text-info:focus,a.text-info:hover{color:#245269}.text-warning{color:#8a6d3b}a.text-warning:focus,a.text-warning:hover{color:#66512c}.text-danger{color:#a94442}a.text-danger:focus,a.text-danger:hover{color:#843534}.bg-primary{color:#fff;background-color:#337ab7}a.bg-primary:focus,a.bg-primary:hover{background-color:#286090}.bg-success{background-color:#dff0d8}a.bg-success:focus,a.bg-success:hover{background-color:#c1e2b3}.bg-info{background-color:#d9edf7}a.bg-info:focus,a.bg-info:hover{background-color:#afd9ee}.bg-warning{background-color:#fcf8e3}a.bg-warning:focus,a.bg-warning:hover{background-color:#f7ecb5}.bg-danger{background-color:#f2dede}a.bg-danger:focus,a.bg-danger:hover{background-color:#e4b9b9}.page-header{padding-bottom:9px;margin:40px 0 20px;border-bottom:1px solid #eee}ol,ul{margin-top:0;margin-bottom:10px}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;margin-left:-5px;list-style:none}.list-inline>li{display:inline-block;padding-right:5px;padding-left:5px}dl{margin-top:0;margin-bottom:20px}dd,dt{line-height:1.42857143}dt{font-weight:700}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;overflow:hidden;clear:left;text-align:right;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[data-original-title],abbr[title]{cursor:help;border-bottom:1px dotted #777}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:10px 20px;margin:0 0 20px;font-size:17.5px;border-left:5px solid #eee}blockquote ol:last-child,blockquote p:last-child,blockquote ul:last-child{margin-bottom:0}blockquote .small,blockquote footer,blockquote small{display:block;font-size:80%;line-height:1.42857143;color:#777}blockquote .small:before,blockquote footer:before,blockquote small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;text-align:right;border-right:5px solid #eee;border-left:0}.blockquote-reverse .small:before,.blockquote-reverse footer:before,.blockquote-reverse small:before,blockquote.pull-right .small:before,blockquote.pull-right footer:before,blockquote.pull-right small:before{content:''}.blockquote-reverse .small:after,.blockquote-reverse footer:after,.blockquote-reverse small:after,blockquote.pull-right .small:after,blockquote.pull-right footer:after,blockquote.pull-right small:after{content:'\00A0 \2014'}address{margin-bottom:20px;font-style:normal;line-height:1.42857143}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:4px}kbd{padding:2px 4px;font-size:90%;color:#fff;background-color:#333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,.25)}kbd kbd{padding:0;font-size:100%;font-weight:700;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:9.5px;margin:0 0 10px;font-size:13px;line-height:1.42857143;color:#333;word-break:break-all;word-wrap:break-word;background-color:#f5f5f5;border:1px solid #ccc;border-radius:4px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{position:relative;min-height:1px;padding-right:15px;padding-left:15px}.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0}@media (min-width:768px){.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0}}@media (min-width:992px){.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0}}@media (min-width:1200px){.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#777;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:20px}.table>tbody>tr>td,.table>tbody>tr>th,.table>tfoot>tr>td,.table>tfoot>tr>th,.table>thead>tr>td,.table>thead>tr>th{padding:8px;line-height:1.42857143;vertical-align:top;border-top:1px solid #ddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #ddd}.table>caption+thead>tr:first-child>td,.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>td,.table>thead:first-child>tr:first-child>th{border-top:0}.table>tbody+tbody{border-top:2px solid #ddd}.table .table{background-color:#fff}.table-condensed>tbody>tr>td,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>td,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>thead>tr>th{padding:5px}.table-bordered{border:1px solid #ddd}.table-bordered>tbody>tr>td,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>td,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border:1px solid #ddd}.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*=col-]{position:static;display:table-column;float:none}table td[class*=col-],table th[class*=col-]{position:static;display:table-cell;float:none}.table>tbody>tr.active>td,.table>tbody>tr.active>th,.table>tbody>tr>td.active,.table>tbody>tr>th.active,.table>tfoot>tr.active>td,.table>tfoot>tr.active>th,.table>tfoot>tr>td.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>thead>tr.active>th,.table>thead>tr>td.active,.table>thead>tr>th.active{background-color:#f5f5f5}.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr.active:hover>th,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover{background-color:#e8e8e8}.table>tbody>tr.success>td,.table>tbody>tr.success>th,.table>tbody>tr>td.success,.table>tbody>tr>th.success,.table>tfoot>tr.success>td,.table>tfoot>tr.success>th,.table>tfoot>tr>td.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>thead>tr.success>th,.table>thead>tr>td.success,.table>thead>tr>th.success{background-color:#dff0d8}.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr.success:hover>th,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover{background-color:#d0e9c6}.table>tbody>tr.info>td,.table>tbody>tr.info>th,.table>tbody>tr>td.info,.table>tbody>tr>th.info,.table>tfoot>tr.info>td,.table>tfoot>tr.info>th,.table>tfoot>tr>td.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>thead>tr.info>th,.table>thead>tr>td.info,.table>thead>tr>th.info{background-color:#d9edf7}.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr.info:hover>th,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover{background-color:#c4e3f3}.table>tbody>tr.warning>td,.table>tbody>tr.warning>th,.table>tbody>tr>td.warning,.table>tbody>tr>th.warning,.table>tfoot>tr.warning>td,.table>tfoot>tr.warning>th,.table>tfoot>tr>td.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>thead>tr.warning>th,.table>thead>tr>td.warning,.table>thead>tr>th.warning{background-color:#fcf8e3}.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr.warning:hover>th,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover{background-color:#faf2cc}.table>tbody>tr.danger>td,.table>tbody>tr.danger>th,.table>tbody>tr>td.danger,.table>tbody>tr>th.danger,.table>tfoot>tr.danger>td,.table>tfoot>tr.danger>th,.table>tfoot>tr>td.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>thead>tr.danger>th,.table>thead>tr>td.danger,.table>thead>tr>th.danger{background-color:#f2dede}.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr.danger:hover>th,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover{background-color:#ebcccc}.table-responsive{min-height:.01%;overflow-x:auto}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:15px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #ddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>td,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>thead>tr>th{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}}fieldset{min-width:0;padding:0;margin:0;border:0}legend{display:block;width:100%;padding:0;margin-bottom:20px;font-size:21px;line-height:inherit;color:#333;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:700}input[type=search]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type=checkbox],input[type=radio]{margin:4px 0 0;margin-top:1px\9;line-height:normal}input[type=file]{display:block}input[type=range]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type=file]:focus,input[type=checkbox]:focus,input[type=radio]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:14px;line-height:1.42857143;color:#555}.form-control{display:block;width:100%;height:34px;padding:6px 12px;font-size:14px;line-height:1.42857143;color:#555;background-color:#fff;background-image:none;border:1px solid #ccc;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6);box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6)}.form-control::-moz-placeholder{color:#999;opacity:1}.form-control:-ms-input-placeholder{color:#999}.form-control::-webkit-input-placeholder{color:#999}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:#eee;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type=search]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type=date].form-control,input[type=time].form-control,input[type=datetime-local].form-control,input[type=month].form-control{line-height:34px}.input-group-sm input[type=date],.input-group-sm input[type=time],.input-group-sm input[type=datetime-local],.input-group-sm input[type=month],input[type=date].input-sm,input[type=time].input-sm,input[type=datetime-local].input-sm,input[type=month].input-sm{line-height:30px}.input-group-lg input[type=date],.input-group-lg input[type=time],.input-group-lg input[type=datetime-local],.input-group-lg input[type=month],input[type=date].input-lg,input[type=time].input-lg,input[type=datetime-local].input-lg,input[type=month].input-lg{line-height:46px}}.form-group{margin-bottom:15px}.checkbox,.radio{position:relative;display:block;margin-top:10px;margin-bottom:10px}.checkbox label,.radio label{min-height:20px;padding-left:20px;margin-bottom:0;font-weight:400;cursor:pointer}.checkbox input[type=checkbox],.checkbox-inline input[type=checkbox],.radio input[type=radio],.radio-inline input[type=radio]{position:absolute;margin-top:4px\9;margin-left:-20px}.checkbox+.checkbox,.radio+.radio{margin-top:-5px}.checkbox-inline,.radio-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;font-weight:400;vertical-align:middle;cursor:pointer}.checkbox-inline+.checkbox-inline,.radio-inline+.radio-inline{margin-top:0;margin-left:10px}fieldset[disabled] input[type=checkbox],fieldset[disabled] input[type=radio],input[type=checkbox].disabled,input[type=checkbox][disabled],input[type=radio].disabled,input[type=radio][disabled]{cursor:not-allowed}.checkbox-inline.disabled,.radio-inline.disabled,fieldset[disabled] .checkbox-inline,fieldset[disabled] .radio-inline{cursor:not-allowed}.checkbox.disabled label,.radio.disabled label,fieldset[disabled] .checkbox label,fieldset[disabled] .radio label{cursor:not-allowed}.form-control-static{min-height:34px;padding-top:7px;padding-bottom:7px;margin-bottom:0}.form-control-static.input-lg,.form-control-static.input-sm{padding-right:0;padding-left:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}select[multiple].input-sm,textarea.input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm select[multiple].form-control,.form-group-sm textarea.form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:32px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-lg{height:46px;line-height:46px}select[multiple].input-lg,textarea.input-lg{height:auto}.form-group-lg .form-control{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.form-group-lg select.form-control{height:46px;line-height:46px}.form-group-lg select[multiple].form-control,.form-group-lg textarea.form-control{height:auto}.form-group-lg .form-control-static{height:46px;min-height:38px;padding:11px 16px;font-size:18px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:42.5px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:34px;height:34px;line-height:34px;text-align:center;pointer-events:none}.form-group-lg .form-control+.form-control-feedback,.input-group-lg+.form-control-feedback,.input-lg+.form-control-feedback{width:46px;height:46px;line-height:46px}.form-group-sm .form-control+.form-control-feedback,.input-group-sm+.form-control-feedback,.input-sm+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .checkbox,.has-success .checkbox-inline,.has-success .control-label,.has-success .help-block,.has-success .radio,.has-success .radio-inline,.has-success.checkbox label,.has-success.checkbox-inline label,.has-success.radio label,.has-success.radio-inline label{color:#3c763d}.has-success .form-control{border-color:#3c763d;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-success .form-control:focus{border-color:#2b542c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168}.has-success .input-group-addon{color:#3c763d;background-color:#dff0d8;border-color:#3c763d}.has-success .form-control-feedback{color:#3c763d}.has-warning .checkbox,.has-warning .checkbox-inline,.has-warning .control-label,.has-warning .help-block,.has-warning .radio,.has-warning .radio-inline,.has-warning.checkbox label,.has-warning.checkbox-inline label,.has-warning.radio label,.has-warning.radio-inline label{color:#8a6d3b}.has-warning .form-control{border-color:#8a6d3b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-warning .form-control:focus{border-color:#66512c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b}.has-warning .input-group-addon{color:#8a6d3b;background-color:#fcf8e3;border-color:#8a6d3b}.has-warning .form-control-feedback{color:#8a6d3b}.has-error .checkbox,.has-error .checkbox-inline,.has-error .control-label,.has-error .help-block,.has-error .radio,.has-error .radio-inline,.has-error.checkbox label,.has-error.checkbox-inline label,.has-error.radio label,.has-error.radio-inline label{color:#a94442}.has-error .form-control{border-color:#a94442;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-error .form-control:focus{border-color:#843534;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483}.has-error .input-group-addon{color:#a94442;background-color:#f2dede;border-color:#a94442}.has-error .form-control-feedback{color:#a94442}.has-feedback label~.form-control-feedback{top:25px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#737373}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .form-control,.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .checkbox,.form-inline .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .checkbox label,.form-inline .radio label{padding-left:0}.form-inline .checkbox input[type=checkbox],.form-inline .radio input[type=radio]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .checkbox,.form-horizontal .checkbox-inline,.form-horizontal .radio,.form-horizontal .radio-inline{padding-top:7px;margin-top:0;margin-bottom:0}.form-horizontal .checkbox,.form-horizontal .radio{min-height:27px}.form-horizontal .form-group{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.form-horizontal .control-label{padding-top:7px;margin-bottom:0;text-align:right}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:14.33px;font-size:18px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;padding:6px 12px;margin-bottom:0;font-size:14px;font-weight:400;line-height:1.42857143;text-align:center;white-space:nowrap;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;background-image:none;border:1px solid transparent;border-radius:4px}.btn.active.focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn:active:focus,.btn:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn.focus,.btn:focus,.btn:hover{color:#333;text-decoration:none}.btn.active,.btn:active{background-image:none;outline:0;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none;opacity:.65}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#333;background-color:#fff;border-color:#ccc}.btn-default.focus,.btn-default:focus{color:#333;background-color:#e6e6e6;border-color:#8c8c8c}.btn-default:hover{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active.focus,.btn-default.active:focus,.btn-default.active:hover,.btn-default:active.focus,.btn-default:active:focus,.btn-default:active:hover,.open>.dropdown-toggle.btn-default.focus,.open>.dropdown-toggle.btn-default:focus,.open>.dropdown-toggle.btn-default:hover{color:#333;background-color:#d4d4d4;border-color:#8c8c8c}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled,.btn-default.disabled.active,.btn-default.disabled.focus,.btn-default.disabled:active,.btn-default.disabled:focus,.btn-default.disabled:hover,.btn-default[disabled],.btn-default[disabled].active,.btn-default[disabled].focus,.btn-default[disabled]:active,.btn-default[disabled]:focus,.btn-default[disabled]:hover,fieldset[disabled] .btn-default,fieldset[disabled] .btn-default.active,fieldset[disabled] .btn-default.focus,fieldset[disabled] .btn-default:active,fieldset[disabled] .btn-default:focus,fieldset[disabled] .btn-default:hover{background-color:#fff;border-color:#ccc}.btn-default .badge{color:#fff;background-color:#333}.btn-primary{color:#fff;background-color:#337ab7;border-color:#2e6da4}.btn-primary.focus,.btn-primary:focus{color:#fff;background-color:#286090;border-color:#122b40}.btn-primary:hover{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active.focus,.btn-primary.active:focus,.btn-primary.active:hover,.btn-primary:active.focus,.btn-primary:active:focus,.btn-primary:active:hover,.open>.dropdown-toggle.btn-primary.focus,.open>.dropdown-toggle.btn-primary:focus,.open>.dropdown-toggle.btn-primary:hover{color:#fff;background-color:#204d74;border-color:#122b40}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled,.btn-primary.disabled.active,.btn-primary.disabled.focus,.btn-primary.disabled:active,.btn-primary.disabled:focus,.btn-primary.disabled:hover,.btn-primary[disabled],.btn-primary[disabled].active,.btn-primary[disabled].focus,.btn-primary[disabled]:active,.btn-primary[disabled]:focus,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary,fieldset[disabled] .btn-primary.active,fieldset[disabled] .btn-primary.focus,fieldset[disabled] .btn-primary:active,fieldset[disabled] .btn-primary:focus,fieldset[disabled] .btn-primary:hover{background-color:#337ab7;border-color:#2e6da4}.btn-primary .badge{color:#337ab7;background-color:#fff}.btn-success{color:#fff;background-color:#5cb85c;border-color:#4cae4c}.btn-success.focus,.btn-success:focus{color:#fff;background-color:#449d44;border-color:#255625}.btn-success:hover{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active.focus,.btn-success.active:focus,.btn-success.active:hover,.btn-success:active.focus,.btn-success:active:focus,.btn-success:active:hover,.open>.dropdown-toggle.btn-success.focus,.open>.dropdown-toggle.btn-success:focus,.open>.dropdown-toggle.btn-success:hover{color:#fff;background-color:#398439;border-color:#255625}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled,.btn-success.disabled.active,.btn-success.disabled.focus,.btn-success.disabled:active,.btn-success.disabled:focus,.btn-success.disabled:hover,.btn-success[disabled],.btn-success[disabled].active,.btn-success[disabled].focus,.btn-success[disabled]:active,.btn-success[disabled]:focus,.btn-success[disabled]:hover,fieldset[disabled] .btn-success,fieldset[disabled] .btn-success.active,fieldset[disabled] .btn-success.focus,fieldset[disabled] .btn-success:active,fieldset[disabled] .btn-success:focus,fieldset[disabled] .btn-success:hover{background-color:#5cb85c;border-color:#4cae4c}.btn-success .badge{color:#5cb85c;background-color:#fff}.btn-info{color:#fff;background-color:#5bc0de;border-color:#46b8da}.btn-info.focus,.btn-info:focus{color:#fff;background-color:#31b0d5;border-color:#1b6d85}.btn-info:hover{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active.focus,.btn-info.active:focus,.btn-info.active:hover,.btn-info:active.focus,.btn-info:active:focus,.btn-info:active:hover,.open>.dropdown-toggle.btn-info.focus,.open>.dropdown-toggle.btn-info:focus,.open>.dropdown-toggle.btn-info:hover{color:#fff;background-color:#269abc;border-color:#1b6d85}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled,.btn-info.disabled.active,.btn-info.disabled.focus,.btn-info.disabled:active,.btn-info.disabled:focus,.btn-info.disabled:hover,.btn-info[disabled],.btn-info[disabled].active,.btn-info[disabled].focus,.btn-info[disabled]:active,.btn-info[disabled]:focus,.btn-info[disabled]:hover,fieldset[disabled] .btn-info,fieldset[disabled] .btn-info.active,fieldset[disabled] .btn-info.focus,fieldset[disabled] .btn-info:active,fieldset[disabled] .btn-info:focus,fieldset[disabled] .btn-info:hover{background-color:#5bc0de;border-color:#46b8da}.btn-info .badge{color:#5bc0de;background-color:#fff}.btn-warning{color:#fff;background-color:#f0ad4e;border-color:#eea236}.btn-warning.focus,.btn-warning:focus{color:#fff;background-color:#ec971f;border-color:#985f0d}.btn-warning:hover{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active.focus,.btn-warning.active:focus,.btn-warning.active:hover,.btn-warning:active.focus,.btn-warning:active:focus,.btn-warning:active:hover,.open>.dropdown-toggle.btn-warning.focus,.open>.dropdown-toggle.btn-warning:focus,.open>.dropdown-toggle.btn-warning:hover{color:#fff;background-color:#d58512;border-color:#985f0d}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled,.btn-warning.disabled.active,.btn-warning.disabled.focus,.btn-warning.disabled:active,.btn-warning.disabled:focus,.btn-warning.disabled:hover,.btn-warning[disabled],.btn-warning[disabled].active,.btn-warning[disabled].focus,.btn-warning[disabled]:active,.btn-warning[disabled]:focus,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning,fieldset[disabled] .btn-warning.active,fieldset[disabled] .btn-warning.focus,fieldset[disabled] .btn-warning:active,fieldset[disabled] .btn-warning:focus,fieldset[disabled] .btn-warning:hover{background-color:#f0ad4e;border-color:#eea236}.btn-warning .badge{color:#f0ad4e;background-color:#fff}.btn-danger{color:#fff;background-color:#d9534f;border-color:#d43f3a}.btn-danger.focus,.btn-danger:focus{color:#fff;background-color:#c9302c;border-color:#761c19}.btn-danger:hover{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active.focus,.btn-danger.active:focus,.btn-danger.active:hover,.btn-danger:active.focus,.btn-danger:active:focus,.btn-danger:active:hover,.open>.dropdown-toggle.btn-danger.focus,.open>.dropdown-toggle.btn-danger:focus,.open>.dropdown-toggle.btn-danger:hover{color:#fff;background-color:#ac2925;border-color:#761c19}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled,.btn-danger.disabled.active,.btn-danger.disabled.focus,.btn-danger.disabled:active,.btn-danger.disabled:focus,.btn-danger.disabled:hover,.btn-danger[disabled],.btn-danger[disabled].active,.btn-danger[disabled].focus,.btn-danger[disabled]:active,.btn-danger[disabled]:focus,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger,fieldset[disabled] .btn-danger.active,fieldset[disabled] .btn-danger.focus,fieldset[disabled] .btn-danger:active,fieldset[disabled] .btn-danger:focus,fieldset[disabled] .btn-danger:hover{background-color:#d9534f;border-color:#d43f3a}.btn-danger .badge{color:#d9534f;background-color:#fff}.btn-link{font-weight:400;color:#337ab7;border-radius:0}.btn-link,.btn-link.active,.btn-link:active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:active,.btn-link:focus,.btn-link:hover{border-color:transparent}.btn-link:focus,.btn-link:hover{color:#23527c;text-decoration:underline;background-color:transparent}.btn-link[disabled]:focus,.btn-link[disabled]:hover,fieldset[disabled] .btn-link:focus,fieldset[disabled] .btn-link:hover{color:#777;text-decoration:none}.btn-group-lg>.btn,.btn-lg{padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.btn-group-sm>.btn,.btn-sm{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-group-xs>.btn,.btn-xs{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type=button].btn-block,input[type=reset].btn-block,input[type=submit].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity .15s linear;-o-transition:opacity .15s linear;transition:opacity .15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease;-webkit-transition-duration:.35s;-o-transition-duration:.35s;transition-duration:.35s;-webkit-transition-property:height,visibility;-o-transition-property:height,visibility;transition-property:height,visibility}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid\9;border-right:4px solid transparent;border-left:4px solid transparent}.dropdown,.dropup{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;font-size:14px;text-align:left;list-style:none;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.15);border-radius:4px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,.175);box-shadow:0 6px 12px rgba(0,0,0,.175)}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:400;line-height:1.42857143;color:#333;white-space:nowrap}.dropdown-menu>li>a:focus,.dropdown-menu>li>a:hover{color:#262626;text-decoration:none;background-color:#f5f5f5}.dropdown-menu>.active>a,.dropdown-menu>.active>a:focus,.dropdown-menu>.active>a:hover{color:#fff;text-decoration:none;background-color:#337ab7;outline:0}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{color:#777}.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{text-decoration:none;cursor:not-allowed;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false)}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{right:0;left:auto}.dropdown-menu-left{right:auto;left:0}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.42857143;color:#777;white-space:nowrap}.dropdown-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{content:"";border-top:0;border-bottom:4px dashed;border-bottom:4px solid\9}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{right:0;left:auto}.navbar-right .dropdown-menu-left{right:auto;left:0}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group-vertical>.btn,.btn-group>.btn{position:relative;float:left}.btn-group-vertical>.btn.active,.btn-group-vertical>.btn:active,.btn-group-vertical>.btn:focus,.btn-group-vertical>.btn:hover,.btn-group>.btn.active,.btn-group>.btn:active,.btn-group>.btn:focus,.btn-group>.btn:hover{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-top-left-radius:0;border-bottom-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-bottom-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-right:8px;padding-left:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-right:12px;padding-left:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-left-radius:0;border-top-right-radius:0;border-bottom-left-radius:4px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-top-right-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{display:table-cell;float:none;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle=buttons]>.btn input[type=checkbox],[data-toggle=buttons]>.btn input[type=radio],[data-toggle=buttons]>.btn-group>.btn input[type=checkbox],[data-toggle=buttons]>.btn-group>.btn input[type=radio]{position:absolute;clip:rect(0,0,0,0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*=col-]{float:none;padding-right:0;padding-left:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:46px;line-height:46px}select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn,textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn,textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn{height:auto}.input-group .form-control,.input-group-addon,.input-group-btn{display:table-cell}.input-group .form-control:not(:first-child):not(:last-child),.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 12px;font-size:14px;font-weight:400;line-height:1;color:#555;text-align:center;background-color:#eee;border:1px solid #ccc;border-radius:4px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:18px;border-radius:6px}.input-group-addon input[type=checkbox],.input-group-addon input[type=radio]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn-group:not(:last-child)>.btn,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:first-child>.btn-group:not(:first-child)>.btn,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle{border-top-left-radius:0;border-bottom-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:active,.input-group-btn>.btn:focus,.input-group-btn>.btn:hover{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.nav>li.disabled>a{color:#777}.nav>li.disabled>a:focus,.nav>li.disabled>a:hover{color:#777;text-decoration:none;cursor:not-allowed;background-color:transparent}.nav .open>a,.nav .open>a:focus,.nav .open>a:hover{background-color:#eee;border-color:#337ab7}.nav .nav-divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid #ddd}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.42857143;border:1px solid transparent;border-radius:4px 4px 0 0}.nav-tabs>li>a:hover{border-color:#eee #eee #ddd}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus,.nav-tabs>li.active>a:hover{color:#555;cursor:default;background-color:#fff;border:1px solid #ddd;border-bottom-color:transparent}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border-bottom-color:#fff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:4px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:focus,.nav-pills>li.active>a:hover{color:#fff;background-color:#337ab7}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border-bottom-color:#fff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-left-radius:0;border-top-right-radius:0}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse{padding-right:0;padding-left:0}}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:200px}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-bottom,.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-bottom,.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;padding:9px 10px;margin-top:8px;margin-right:15px;margin-bottom:8px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:4px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu .dropdown-header,.navbar-nav .open .dropdown-menu>li>a{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:20px}.navbar-nav .open .dropdown-menu>li>a:focus,.navbar-nav .open .dropdown-menu>li>a:hover{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}.navbar-form{padding:10px 15px;margin-top:8px;margin-right:-15px;margin-bottom:8px;margin-left:-15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .form-control,.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .checkbox,.navbar-form .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .checkbox label,.navbar-form .radio label{padding-left:0}.navbar-form .checkbox input[type=checkbox],.navbar-form .radio input[type=radio]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;padding-top:0;padding-bottom:0;margin-right:0;margin-left:0;border:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-left-radius:0;border-top-right-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-left-radius:4px;border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:8px;margin-bottom:8px}.navbar-btn.btn-sm{margin-top:10px;margin-bottom:10px}.navbar-btn.btn-xs{margin-top:14px;margin-bottom:14px}.navbar-text{margin-top:15px;margin-bottom:15px}@media (min-width:768px){.navbar-text{float:left;margin-right:15px;margin-left:15px}}@media (min-width:768px){.navbar-left{float:left!important}.navbar-right{float:right!important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-text{color:#777}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:focus,.navbar-default .navbar-nav>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:focus,.navbar-default .navbar-nav>.disabled>a:hover{color:#ccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:#ddd}.navbar-default .navbar-toggle:focus,.navbar-default .navbar-toggle:hover{background-color:#ddd}.navbar-default .navbar-toggle .icon-bar{background-color:#888}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:#e7e7e7}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:focus,.navbar-default .navbar-nav>.open>a:hover{color:#555;background-color:#e7e7e7}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#777}.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#ccc;background-color:transparent}}.navbar-default .navbar-link{color:#777}.navbar-default .navbar-link:hover{color:#333}.navbar-default .btn-link{color:#777}.navbar-default .btn-link:focus,.navbar-default .btn-link:hover{color:#333}.navbar-default .btn-link[disabled]:focus,.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:focus,fieldset[disabled] .navbar-default .btn-link:hover{color:#ccc}.navbar-inverse{background-color:#222;border-color:#080808}.navbar-inverse .navbar-brand{color:#9d9d9d}.navbar-inverse .navbar-brand:focus,.navbar-inverse .navbar-brand:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-text{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a:focus,.navbar-inverse .navbar-nav>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:focus,.navbar-inverse .navbar-nav>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:focus,.navbar-inverse .navbar-nav>.disabled>a:hover{color:#444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:#333}.navbar-inverse .navbar-toggle:focus,.navbar-inverse .navbar-toggle:hover{background-color:#333}.navbar-inverse .navbar-toggle .icon-bar{background-color:#fff}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#101010}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:focus,.navbar-inverse .navbar-nav>.open>a:hover{color:#fff;background-color:#080808}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#444;background-color:transparent}}.navbar-inverse .navbar-link{color:#9d9d9d}.navbar-inverse .navbar-link:hover{color:#fff}.navbar-inverse .btn-link{color:#9d9d9d}.navbar-inverse .btn-link:focus,.navbar-inverse .btn-link:hover{color:#fff}.navbar-inverse .btn-link[disabled]:focus,.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:focus,fieldset[disabled] .navbar-inverse .btn-link:hover{color:#444}.breadcrumb{padding:8px 15px;margin-bottom:20px;list-style:none;background-color:#f5f5f5;border-radius:4px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{padding:0 5px;color:#ccc;content:"/\00a0"}.breadcrumb>.active{color:#777}.pagination{display:inline-block;padding-left:0;margin:20px 0;border-radius:4px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 12px;margin-left:-1px;line-height:1.42857143;color:#337ab7;text-decoration:none;background-color:#fff;border:1px solid #ddd}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-top-left-radius:4px;border-bottom-left-radius:4px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-top-right-radius:4px;border-bottom-right-radius:4px}.pagination>li>a:focus,.pagination>li>a:hover,.pagination>li>span:focus,.pagination>li>span:hover{z-index:3;color:#23527c;background-color:#eee;border-color:#ddd}.pagination>.active>a,.pagination>.active>a:focus,.pagination>.active>a:hover,.pagination>.active>span,.pagination>.active>span:focus,.pagination>.active>span:hover{z-index:2;color:#fff;cursor:default;background-color:#337ab7;border-color:#337ab7}.pagination>.disabled>a,.pagination>.disabled>a:focus,.pagination>.disabled>a:hover,.pagination>.disabled>span,.pagination>.disabled>span:focus,.pagination>.disabled>span:hover{color:#777;cursor:not-allowed;background-color:#fff;border-color:#ddd}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:18px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-top-left-radius:6px;border-bottom-left-radius:6px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-top-right-radius:6px;border-bottom-right-radius:6px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-top-left-radius:3px;border-bottom-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-top-right-radius:3px;border-bottom-right-radius:3px}.pager{padding-left:0;margin:20px 0;text-align:center;list-style:none}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#fff;border:1px solid #ddd;border-radius:15px}.pager li>a:focus,.pager li>a:hover{text-decoration:none;background-color:#eee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:focus,.pager .disabled>a:hover,.pager .disabled>span{color:#777;cursor:not-allowed;background-color:#fff}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:focus,a.label:hover{color:#fff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#777}.label-default[href]:focus,.label-default[href]:hover{background-color:#5e5e5e}.label-primary{background-color:#337ab7}.label-primary[href]:focus,.label-primary[href]:hover{background-color:#286090}.label-success{background-color:#5cb85c}.label-success[href]:focus,.label-success[href]:hover{background-color:#449d44}.label-info{background-color:#5bc0de}.label-info[href]:focus,.label-info[href]:hover{background-color:#31b0d5}.label-warning{background-color:#f0ad4e}.label-warning[href]:focus,.label-warning[href]:hover{background-color:#ec971f}.label-danger{background-color:#d9534f}.label-danger[href]:focus,.label-danger[href]:hover{background-color:#c9302c}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:middle;background-color:#777;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-group-xs>.btn .badge,.btn-xs .badge{top:0;padding:1px 5px}a.badge:focus,a.badge:hover{color:#fff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#337ab7;background-color:#fff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#eee}.jumbotron .h1,.jumbotron h1{color:inherit}.jumbotron p{margin-bottom:15px;font-size:21px;font-weight:200}.jumbotron>hr{border-top-color:#d5d5d5}.container .jumbotron,.container-fluid .jumbotron{border-radius:6px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-right:60px;padding-left:60px}.jumbotron .h1,.jumbotron h1{font-size:63px}}.thumbnail{display:block;padding:4px;margin-bottom:20px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail a>img,.thumbnail>img{margin-right:auto;margin-left:auto}a.thumbnail.active,a.thumbnail:focus,a.thumbnail:hover{border-color:#337ab7}.thumbnail .caption{padding:9px;color:#333}.alert{padding:15px;margin-bottom:20px;border:1px solid transparent;border-radius:4px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:700}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#2b542c}.alert-info{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.alert-info hr{border-top-color:#a6e1ec}.alert-info .alert-link{color:#245269}.alert-warning{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.alert-warning hr{border-top-color:#f7e1b5}.alert-warning .alert-link{color:#66512c}.alert-danger{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.alert-danger hr{border-top-color:#e4b9c0}.alert-danger .alert-link{color:#843534}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{height:20px;margin-bottom:20px;overflow:hidden;background-color:#f5f5f5;border-radius:4px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,.1);box-shadow:inset 0 1px 2px rgba(0,0,0,.1)}.progress-bar{float:left;width:0;height:100%;font-size:12px;line-height:20px;color:#fff;text-align:center;background-color:#337ab7;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);-webkit-transition:width .6s ease;-o-transition:width .6s ease;transition:width .6s ease}.progress-bar-striped,.progress-striped .progress-bar{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress-bar.active,.progress.active .progress-bar{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#5cb85c}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-info{background-color:#5bc0de}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-warning{background-color:#f0ad4e}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-danger{background-color:#d9534f}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{overflow:hidden;zoom:1}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-body,.media-left,.media-right{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{padding-left:0;margin-bottom:20px}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#fff;border:1px solid #ddd}.list-group-item:first-child{border-top-left-radius:4px;border-top-right-radius:4px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:4px;border-bottom-left-radius:4px}a.list-group-item,button.list-group-item{color:#555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333}a.list-group-item:focus,a.list-group-item:hover,button.list-group-item:focus,button.list-group-item:hover{color:#555;text-decoration:none;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:focus,.list-group-item.disabled:hover{color:#777;cursor:not-allowed;background-color:#eee}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text{color:#777}.list-group-item.active,.list-group-item.active:focus,.list-group-item.active:hover{z-index:2;color:#fff;background-color:#337ab7;border-color:#337ab7}.list-group-item.active .list-group-item-heading,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:focus .list-group-item-text,.list-group-item.active:hover .list-group-item-text{color:#c7ddef}.list-group-item-success{color:#3c763d;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#3c763d}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:focus,a.list-group-item-success:hover,button.list-group-item-success:focus,button.list-group-item-success:hover{color:#3c763d;background-color:#d0e9c6}a.list-group-item-success.active,a.list-group-item-success.active:focus,a.list-group-item-success.active:hover,button.list-group-item-success.active,button.list-group-item-success.active:focus,button.list-group-item-success.active:hover{color:#fff;background-color:#3c763d;border-color:#3c763d}.list-group-item-info{color:#31708f;background-color:#d9edf7}a.list-group-item-info,button.list-group-item-info{color:#31708f}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:focus,a.list-group-item-info:hover,button.list-group-item-info:focus,button.list-group-item-info:hover{color:#31708f;background-color:#c4e3f3}a.list-group-item-info.active,a.list-group-item-info.active:focus,a.list-group-item-info.active:hover,button.list-group-item-info.active,button.list-group-item-info.active:focus,button.list-group-item-info.active:hover{color:#fff;background-color:#31708f;border-color:#31708f}.list-group-item-warning{color:#8a6d3b;background-color:#fcf8e3}a.list-group-item-warning,button.list-group-item-warning{color:#8a6d3b}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:focus,a.list-group-item-warning:hover,button.list-group-item-warning:focus,button.list-group-item-warning:hover{color:#8a6d3b;background-color:#faf2cc}a.list-group-item-warning.active,a.list-group-item-warning.active:focus,a.list-group-item-warning.active:hover,button.list-group-item-warning.active,button.list-group-item-warning.active:focus,button.list-group-item-warning.active:hover{color:#fff;background-color:#8a6d3b;border-color:#8a6d3b}.list-group-item-danger{color:#a94442;background-color:#f2dede}a.list-group-item-danger,button.list-group-item-danger{color:#a94442}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:focus,a.list-group-item-danger:hover,button.list-group-item-danger:focus,button.list-group-item-danger:hover{color:#a94442;background-color:#ebcccc}a.list-group-item-danger.active,a.list-group-item-danger.active:focus,a.list-group-item-danger.active:hover,button.list-group-item-danger.active,button.list-group-item-danger.active:focus,button.list-group-item-danger.active:hover{color:#fff;background-color:#a94442;border-color:#a94442}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:20px;background-color:#fff;border:1px solid transparent;border-radius:4px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,.05);box-shadow:0 1px 1px rgba(0,0,0,.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-left-radius:3px;border-top-right-radius:3px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:16px;color:inherit}.panel-title>.small,.panel-title>.small>a,.panel-title>a,.panel-title>small,.panel-title>small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #ddd;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-left-radius:3px;border-top-right-radius:3px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-left-radius:0;border-top-right-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.panel-collapse>.table,.panel>.table,.panel>.table-responsive>.table{margin-bottom:0}.panel>.panel-collapse>.table caption,.panel>.table caption,.panel>.table-responsive>.table caption{padding-right:15px;padding-left:15px}.panel>.table-responsive:first-child>.table:first-child,.panel>.table:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table:first-child>thead:first-child>tr:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child{border-top-left-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child{border-top-right-radius:3px}.panel>.table-responsive:last-child>.table:last-child,.panel>.table:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:3px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #ddd}.panel>.table>tbody:first-child>tr:first-child td,.panel>.table>tbody:first-child>tr:first-child th{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{margin-bottom:0;border:0}.panel-group{margin-bottom:20px}.panel-group .panel{margin-bottom:0;border-radius:4px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.list-group,.panel-group .panel-heading+.panel-collapse>.panel-body{border-top:1px solid #ddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #ddd}.panel-default{border-color:#ddd}.panel-default>.panel-heading{color:#333;background-color:#f5f5f5;border-color:#ddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#333}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ddd}.panel-primary{border-color:#337ab7}.panel-primary>.panel-heading{color:#fff;background-color:#337ab7;border-color:#337ab7}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#337ab7}.panel-primary>.panel-heading .badge{color:#337ab7;background-color:#fff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#337ab7}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#dff0d8;background-color:#3c763d}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#bce8f1}.panel-info>.panel-heading{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#bce8f1}.panel-info>.panel-heading .badge{color:#d9edf7;background-color:#31708f}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#bce8f1}.panel-warning{border-color:#faebcc}.panel-warning>.panel-heading{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#faebcc}.panel-warning>.panel-heading .badge{color:#fcf8e3;background-color:#8a6d3b}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#faebcc}.panel-danger{border-color:#ebccd1}.panel-danger>.panel-heading{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ebccd1}.panel-danger>.panel-heading .badge{color:#f2dede;background-color:#a94442}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ebccd1}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive embed,.embed-responsive iframe,.embed-responsive object,.embed-responsive video{position:absolute;top:0;bottom:0;left:0;width:100%;height:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f5f5f5;border:1px solid #e3e3e3;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.05);box-shadow:inset 0 1px 1px rgba(0,0,0,.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,.15)}.well-lg{padding:24px;border-radius:6px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:21px;font-weight:700;line-height:1;color:#000;text-shadow:0 1px 0 #fff;filter:alpha(opacity=20);opacity:.2}.close:focus,.close:hover{color:#000;text-decoration:none;cursor:pointer;filter:alpha(opacity=50);opacity:.5}button.close{-webkit-appearance:none;padding:0;cursor:pointer;background:0 0;border:0}.modal-open{overflow:hidden}.modal{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;display:none;overflow:hidden;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out;-webkit-transform:translate(0,-25%);-ms-transform:translate(0,-25%);-o-transform:translate(0,-25%);transform:translate(0,-25%)}.modal.in .modal-dialog{-webkit-transform:translate(0,0);-ms-transform:translate(0,0);-o-transform:translate(0,0);transform:translate(0,0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #999;border:1px solid rgba(0,0,0,.2);border-radius:6px;outline:0;-webkit-box-shadow:0 3px 9px rgba(0,0,0,.5);box-shadow:0 3px 9px rgba(0,0,0,.5)}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000}.modal-backdrop.fade{filter:alpha(opacity=0);opacity:0}.modal-backdrop.in{filter:alpha(opacity=50);opacity:.5}.modal-header{min-height:16.43px;padding:15px;border-bottom:1px solid #e5e5e5}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.42857143}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid #e5e5e5}.modal-footer .btn+.btn{margin-bottom:0;margin-left:5px}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,.5);box-shadow:0 5px 15px rgba(0,0,0,.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:12px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;filter:alpha(opacity=0);opacity:0;line-break:auto}.tooltip.in{filter:alpha(opacity=90);opacity:.9}.tooltip.top{padding:5px 0;margin-top:-3px}.tooltip.right{padding:0 5px;margin-left:3px}.tooltip.bottom{padding:5px 0;margin-top:3px}.tooltip.left{padding:0 5px;margin-left:-3px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#fff;text-align:center;background-color:#000;border-radius:4px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-left .tooltip-arrow{right:5px;bottom:0;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#000}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#000}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.2);border-radius:6px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,.2);box-shadow:0 5px 10px rgba(0,0,0,.2);line-break:auto}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{padding:8px 14px;margin:0;font-size:14px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:5px 5px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{content:"";border-width:10px}.popover.top>.arrow{bottom:-11px;left:50%;margin-left:-11px;border-top-color:#999;border-top-color:rgba(0,0,0,.25);border-bottom-width:0}.popover.top>.arrow:after{bottom:1px;margin-left:-10px;content:" ";border-top-color:#fff;border-bottom-width:0}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-right-color:#999;border-right-color:rgba(0,0,0,.25);border-left-width:0}.popover.right>.arrow:after{bottom:-10px;left:1px;content:" ";border-right-color:#fff;border-left-width:0}.popover.bottom>.arrow{top:-11px;left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:#999;border-bottom-color:rgba(0,0,0,.25)}.popover.bottom>.arrow:after{top:1px;margin-left:-10px;content:" ";border-top-width:0;border-bottom-color:#fff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:#999;border-left-color:rgba(0,0,0,.25)}.popover.left>.arrow:after{right:1px;bottom:-10px;content:" ";border-right-width:0;border-left-color:#fff}.carousel{position:relative}.carousel-inner{position:relative;width:100%;overflow:hidden}.carousel-inner>.item{position:relative;display:none;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>a>img,.carousel-inner>.item>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.active.right,.carousel-inner>.item.next{left:0;-webkit-transform:translate3d(100%,0,0);transform:translate3d(100%,0,0)}.carousel-inner>.item.active.left,.carousel-inner>.item.prev{left:0;-webkit-transform:translate3d(-100%,0,0);transform:translate3d(-100%,0,0)}.carousel-inner>.item.active,.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right{left:0;-webkit-transform:translate3d(0,0,0);transform:translate3d(0,0,0)}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;bottom:0;left:0;width:15%;font-size:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6);filter:alpha(opacity=50);opacity:.5}.carousel-control.left{background-image:-webkit-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.5)),to(rgba(0,0,0,.0001)));background-image:linear-gradient(to right,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1);background-repeat:repeat-x}.carousel-control.right{right:0;left:auto;background-image:-webkit-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.0001)),to(rgba(0,0,0,.5)));background-image:linear-gradient(to right,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1);background-repeat:repeat-x}.carousel-control:focus,.carousel-control:hover{color:#fff;text-decoration:none;filter:alpha(opacity=90);outline:0;opacity:.9}.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{position:absolute;top:50%;z-index:5;display:inline-block;margin-top:-10px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{left:50%;margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{right:50%;margin-right:-10px}.carousel-control .icon-next,.carousel-control .icon-prev{width:20px;height:20px;font-family:serif;line-height:1}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;padding-left:0;margin-left:-30%;text-align:center;list-style:none}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;cursor:pointer;background-color:#000\9;background-color:rgba(0,0,0,0);border:1px solid #fff;border-radius:10px}.carousel-indicators .active{width:12px;height:12px;margin:0;background-color:#fff}.carousel-caption{position:absolute;right:15%;bottom:20px;left:15%;z-index:10;padding-top:20px;padding-bottom:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{width:30px;height:30px;margin-top:-15px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-15px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-15px}.carousel-caption{right:20%;left:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.btn-group-vertical>.btn-group:after,.btn-group-vertical>.btn-group:before,.btn-toolbar:after,.btn-toolbar:before,.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.dl-horizontal dd:after,.dl-horizontal dd:before,.form-horizontal .form-group:after,.form-horizontal .form-group:before,.modal-footer:after,.modal-footer:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.pager:after,.pager:before,.panel-body:after,.panel-body:before,.row:after,.row:before{display:table;content:" "}.btn-group-vertical>.btn-group:after,.btn-toolbar:after,.clearfix:after,.container-fluid:after,.container:after,.dl-horizontal dd:after,.form-horizontal .form-group:after,.modal-footer:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.pager:after,.panel-body:after,.row:after{clear:both}.center-block{display:block;margin-right:auto;margin-left:auto}.pull-right{float:right!important}.pull-left{float:left!important}.hide{display:none!important}.show{display:block!important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none!important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-lg,.visible-md,.visible-sm,.visible-xs{display:none!important}.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block{display:none!important}@media (max-width:767px){.visible-xs{display:block!important}table.visible-xs{display:table!important}tr.visible-xs{display:table-row!important}td.visible-xs,th.visible-xs{display:table-cell!important}}@media (max-width:767px){.visible-xs-block{display:block!important}}@media (max-width:767px){.visible-xs-inline{display:inline!important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block!important}table.visible-sm{display:table!important}tr.visible-sm{display:table-row!important}td.visible-sm,th.visible-sm{display:table-cell!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block!important}table.visible-md{display:table!important}tr.visible-md{display:table-row!important}td.visible-md,th.visible-md{display:table-cell!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block!important}}@media (min-width:1200px){.visible-lg{display:block!important}table.visible-lg{display:table!important}tr.visible-lg{display:table-row!important}td.visible-lg,th.visible-lg{display:table-cell!important}}@media (min-width:1200px){.visible-lg-block{display:block!important}}@media (min-width:1200px){.visible-lg-inline{display:inline!important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block!important}}@media (max-width:767px){.hidden-xs{display:none!important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none!important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none!important}}@media (min-width:1200px){.hidden-lg{display:none!important}}.visible-print{display:none!important}@media print{.visible-print{display:block!important}table.visible-print{display:table!important}tr.visible-print{display:table-row!important}td.visible-print,th.visible-print{display:table-cell!important}}.visible-print-block{display:none!important}@media print{.visible-print-block{display:block!important}}.visible-print-inline{display:none!important}@media print{.visible-print-inline{display:inline!important}}.visible-print-inline-block{display:none!important}@media print{.visible-print-inline-block{display:inline-block!important}}@media print{.hidden-print{display:none!important}}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<style type="text/css">.hljs-literal {
color: #990073;
}
.hljs-number {
color: #099;
}
.hljs-comment {
color: #998;
font-style: italic;
}
.hljs-keyword {
color: #900;
font-weight: bold;
}
.hljs-string {
color: #d14;
}
</style>
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>



<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div id="header">



<h1 class="title toc-ignore">nanaokunote</h1>

</div>


<div id="section" class="section level1">
<h1>700022404</h1>
<div id="section-1" class="section level2">
<h2>220328</h2>
<p>{CNS DLBCL}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2021-12-22 CT - Brain: Right temporoparietal tumors (lymphoma?) with
progression mass effect as compare with CT study on 20211205, suggest
clinical correlation.</li>
<li>2021-12-09 MRI - Brain: Recurrent brain lymphoma. Old insults in
left caudate head and splenium, stationary and mild general brain
atrophy.</li>
<li>2021-12-05 CT - Brain: Ill-defined heteregeneous lesions in right
temporoparietal lobes. Brain metastasis or contusion hemorrhage, suggest
clinical correlation. Focal hyperdensity along left frontal horn,
suspected focal hematoma.</li>
<li>2021-09-09 MRI - Brain: old insults in left caudate head and
splenium, stationary as comapred with MRI on 20210609.</li>
<li>2021-06-09 MRI - Brain: focal increased enhancement in the
periventricular region of the right parietal lobe.</li>
<li>2020-07-09 CT, MRI: showed no definite evidence of extra-crainial
metastasis. (TMUH)</li>
<li>2020-06-20 MRI: CNS lesion, then biopsy revealed DLBCL. (TMUH)</li>
<li>2020H1 Initial presentation with blurred vision, especially, right
eye, and personality change. (TMUH)</li>
</ul></li>
<li>lab data
<ul>
<li>Methotrexate (Toxic: 24hr &gt; 10, 48hr &gt; 1, 72h &gt; 0.1)
<ul>
<li>2022-03-11 0.041 umol/L</li>
<li>2022-03-10 0.133 umol/L</li>
<li>2022-03-09 1.181 umol/L</li>
<li>2022-02-14 0.045</li>
<li>2022-02-13 0.119</li>
<li>2022-02-12 2.548</li>
<li>2022-01-25 0.061</li>
<li>2022-01-24 1.784</li>
<li>2022-01-23 0.091</li>
<li>2021-12-31 0.043</li>
<li>2021-12-30 0.160</li>
<li>2021-12-29 2.552</li>
<li>2021-03-05 0.071</li>
<li>2021-03-04 0.214</li>
<li>2021-03-03 1.141</li>
<li>2021-01-26 0.046</li>
<li>2021-01-25 0.175</li>
<li>2021-01-25 1.032</li>
<li>2020-12-30 &lt;0.040</li>
<li>2020-12-29 0.058</li>
<li>2020-12-28 1.379</li>
<li>2020-12-28 0.218</li>
<li>2020-12-02 &lt;0.040</li>
<li>2020-12-01 0.065</li>
<li>2020-11-30 0.239</li>
<li>2020-11-30 0.902</li>
<li>2020-11-05 0.083</li>
<li>2020-11-04 0.151</li>
<li>2020-11-03 0.333</li>
<li>2020-11-02 1.185</li>
</ul></li>
</ul></li>
<li>treatment
<ul>
<li>2021-12 ~ ongoing - methotrexate + temozolomide</li>
<li>2020-07 ~ 2021-03 - methotrexate + temozolomide + rituximab</li>
</ul></li>
<li>underlying diseases
<ul>
<li>DM and HTN are under medication management.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Recurrent DLBCL with brain mets, in progression (2021-12-22
CT).</li>
<li>The patient got good response with methotrexate + temozolomide +
rituximab during July 2020 to March 2021, and he is now on methotrexate
+ temozolomide since December 2021.</li>
<li>No IHC or Karyotype or FISH results found in HIS5.</li>
<li>The frequency of CNS involvement in systemic NHL varies depending at
least partially upon the aggressiveness of the NHL subtype.
Approximately 2 to 10 percent of patients with aggressive subtypes of
systemic NHL (eg, DLBCL) will experience direct involvement of the CNS
at some time during their course. The incidence is much higher in highly
aggressive NHL (eg, Burkitt lymphoma/leukemia, lymphoblastic lymphoma)
and lower in indolent NHL (eg, follicular lymphoma). Peripheral nervous
system (PNS) involvement by lymphoma is rare.</li>
<li>It is unknown whether the risk of CNS relapse has changed as initial
treatment of these diseases has evolved. Several retrospective studies
have suggested that the incidence may be lower among patients with B
cell NHL treated with rituximab-containing therapy [20,21] or
etoposide-containing therapy. Other studies have found no difference in
the incidence of CNS relapse in the pre- versus post-rituximab era.
<ul>
<li><a href="https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-secondary-central-nervous-system-lymphoma" class="uri">https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-secondary-central-nervous-system-lymphoma</a></li>
</ul></li>
<li>Diffuse large B-cell lymphoma with secondary involvement of the
central nervous system treated with R-IDARAM (rituximab 375 mg/m2 IV day
1; methotrexate 12.5 mg by intrathecal injection day 1; idarubicin 10
mg/m2/day IV days 1 and 2; dexamethasone 100 mg/day IV infusion over 12
h days 1-3; cytosine arabinoside 1000 mg/m2/day IV over 1 h days 1 and
2; and methotrexate 2000 mg/m2 IV over 2 h day 3.) and median follow-up
for surviving patients was 49 months. At 2 years, estimated
progression-free survival (PFS) was 39% and overall survival (OS) was
52%. Encouraging outcomes were reported in patients with new disease,
with 5-year estimated PFS of 50% and OS 75%.
<ul>
<li><a href="https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13867" class="uri">https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.13867</a></li>
</ul></li>
</ul>
</div>
<div id="section-2" class="section level2">
<h2>220211</h2>
<p>{CNS DLBCL}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2021-12-22 CT - Brain: Right temporoparietal tumors (lymphoma?) with
progression mass effect as compare with CT study on 20211205, suggest
clinical correlation.</li>
<li>2021-12-09 MRI - Brain: Recurrent brain lymphoma. Old insults in
left caudate head and splenium, stationary and mild general brain
atrophy.</li>
<li>2021-12-05 CT - Brain: Ill-defined heteregeneous lesions in right
temporoparietal lobes. Brain metastasis or contusion hemorrhage, suggest
clinical correlation. Focal hyperdensity along left frontal horn,
suspected focal hematoma.</li>
<li>2021-09-09 MRI - Brain: old insults in left caudate head and
splenium, stationary as comapred with MRI on 20210609.</li>
<li>2021-06-09 MRI - Brain: focal increased enhancement in the
periventricular region of the right parietal lobe.</li>
<li>2020-07-09 CT, MRI: showed no definite evidence of extra-crainial
metastasis. (TMUH)</li>
<li>2020-06-20 MRI: CNS lesion, then biopsy revealed DLBCL. (TMUH)</li>
<li>2020H1 Initial presentation with blurred vision, especially, right
eye, and personality change. (TMUH)</li>
</ul></li>
<li>treatment
<ul>
<li>2021-12 ~ ongoing - methotrexate + temozolomide</li>
<li>2020-07 ~ 2021-03 - methotrexate + temozolomide + rituximab</li>
</ul></li>
<li>underlying diseases
<ul>
<li>DM and HTN are under medication management.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>brain DLBCL recurrence, in progression.</li>
<li>the patient got good response with MTR when first introduced since
2020H2, he is now on the same regimen.
<ul>
<li>reference: Therapy of primary CNS lymphoma: role of intensity,
radiation, and novel agents - <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142584/pdf/bloodbook-2017-565.pdf" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142584/pdf/bloodbook-2017-565.pdf</a></li>
</ul></li>
<li>autologous stem cell transplatation could be a worth trying
alternative option if the patient younger.
<ul>
<li>reference: The role of autologous stem cell transplantation in
primary central nervous system lymphoma - <a href="https://ashpublications.org/blood/article/127/13/1642/34766/The-role-of-autologous-stem-cell-transplantation" class="uri">https://ashpublications.org/blood/article/127/13/1642/34766/The-role-of-autologous-stem-cell-transplantation</a></li>
</ul></li>
<li>if poor response proved under current regimen, then Ibrutinib might
be an opt-in to the regimen.</li>
</ul>
</div>
<div id="section-3" class="section level2">
<h2>220124</h2>
<p>{hyperglycemia}</p>
<p>[objective]</p>
<ul>
<li>lab data
<ul>
<li>blood sugar 2022-01-20 ~ 2022-02-24 around 200+/-30</li>
<li>urine Glu 2022-01-20 2+</li>
<li>HbA1c 2022-01-13 7.3%</li>
</ul></li>
<li>medication
<ul>
<li>metformin 500mg PO BID</li>
<li>sitagliptin 100mg PO QD</li>
<li>glimepiride 1mg PO QDAC</li>
</ul></li>
</ul>
<p>[assessment, suggestion]</p>
<ul>
<li>blood sugar lab readings are above normal range under current mix of
biguanide (metformin), DPP4i (sitagliptin) and sulfonylurea
(glimepiride).</li>
<li>if a rapid increase of blood sugar is found, then some regular
insulin might be considered.</li>
</ul>
</div>
</div>
<div id="section-4" class="section level1">
<h1>700026574</h1>
<div id="section-5" class="section level2">
<h2>220411</h2>
<p>{Left renal cell carcinoma with metastatic mediastinal
lymphadenopathies and suspecious RUL lung metastasis, liver and bone
metastases s/p chemotherapy and radiotherapy}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-10 Pelvis THR &amp; Rt Hip Lat; KUB &amp; L-spine
<ul>
<li>Lucent lesions in L5, S1, right acetabulum.</li>
</ul></li>
<li>2022-04-10 CT - abdomen
<ul>
<li>Bony metastases.</li>
<li>Dilatation of A- and T-colon.</li>
<li>Collapse of gallbladder with small stones (2-3mm). Small CBD stones
(2-3mm).</li>
</ul></li>
<li>2022-04-10 Chest
<ul>
<li>Presence of ileus.</li>
<li>Fracture of right ribs with union.</li>
<li>Ground glass opacity in right lung.</li>
</ul></li>
<li>2022-04-01 Chest
<ul>
<li>Several nodular opacity projecting in the right upper lung are
suspected. Please correlate with CT.</li>
<li>Left hemi-diaphragm elevation was noted that is compatible with
bronchiectasis with collapse after correlate with CT.</li>
<li>Atherosclerotic change of aortic arch.</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura thickening.</li>
</ul></li>
<li>2022-02-23 Tc-99m MDP bone scan with SPECT
<ul>
<li>In comparison with the previous study on 20200911, some new bone
lesions in both rib cages are noted, suggesting multiple bone metastases
in progression. However, several previous bone lesions in multiple T-
and L-spine, sternum, right humeral head, and right iliac bone become
less evident, indicating partial respopnse to current therapy.</li>
<li>Suspected benign lesions at bilateral knees.</li>
</ul></li>
<li>2022-02-22 CT - abdomen, pelvis
<ul>
<li>Bone meta at left rib, L5 and right acetabulum, Suggest further
treatment.</li>
</ul></li>
<li>2022-02-21 KUB
<ul>
<li>Fracture of right acetabulum is suspected.</li>
</ul></li>
<li>2020-09-11 Tc-99m MDP bone scan
<ul>
<li>In comparison with the previous study on 20200407, some new bone
lesions are noted and some of the previous bone lesions are more
evident, suggesting multiple bone metastases in progression.</li>
<li>No prominent change is noted in the lower C-spine and right
sternoclavicular junction. Degenerative change may show this
picture.</li>
</ul></li>
<li>2020-04-22 Chest
<ul>
<li>A nodular opacity projecting in the ventral aspect of RUL of the
lung is suspected that is compatible with metastasis after correlate
with chest CT.</li>
<li>Band-like atelectasis in RLL and LUL of the lung.</li>
<li>Patchy opacity projecting at the left lower medial lung zone and
Left hemi-diaphragm elevation was noted that is compatible with
bronchiectasis with collapse after correlate with CT.</li>
<li>Atherosclerotic change of aortic arch.</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura thickening.</li>
</ul></li>
<li>2020-04-07 Tc-99m MDP bone scan
<ul>
<li>Prominently increased activity in the L5 spine, sternum and right
iliac bone. Bone metastases should be considered. Please correlate with
other imaging modalities for further evaluation.</li>
<li>Increased activity in the lower C-spine, some middle and lower
T-spines, right sternoclavicular junction and right humeral head. Either
degenerative change or bone metastases may show this picture. Please
keep follow-up for further evaluation.</li>
<li>Some hot and faint spots in bilateral rib cages and mildly increased
activity in the lesser trochanter of right femur. The nature is to be
determined (post-traumatic change? bone metastasis? other nature?).</li>
</ul></li>
<li>2020-03-18 MRI - L-spine
<ul>
<li>tumors in the L5 and right iliac bone.</li>
</ul></li>
<li>2019-12-13 CT - lung/pleura, chest and upper abdomen
<ul>
<li>Compatible with RCC lung meta and mediastinal lymph nodes,
stable.</li>
</ul></li>
<li>2019-09-11 CT - lung/pleura, chest and upper abdomen
<ul>
<li>no mediastinal LAP and no lung nodule on this F/U study.</li>
<li>stationary atelectatic basal segments with air-bronchograms of the
LLL.</li>
</ul></li>
<li>2019-06-06 CT - lung/pleura, chest and upper abdomen
<ul>
<li>no mediastinal LAP and no lung nodule on this F/U study.</li>
<li>stationary atelectatic basal segments with air-bronchograms of the
LLL.</li>
</ul></li>
<li>2019-03-06 CT - chest and upper abdomen
<ul>
<li>RCC with resolution of left lung and mediastinal LNs metastasis as
compared with previous CT study.</li>
</ul></li>
<li>2018-11-21 CT - chest and upper abdomen
<ul>
<li>RCC with left lung and mediastinal LNs metastasis, further in
regression as compared with previous CT study.</li>
</ul></li>
<li>2018-08-23 CT - chest and upper abdomen
<ul>
<li>RCC with lung and mediastinal LNs metastasis, further in regression
as compared with previous CT study.</li>
</ul></li>
<li>2018-05-09 CT - chest and upper abdomen
<ul>
<li>RCC with lung and mediastinal LNs metastasis, in regression compared
with previous CT study.</li>
</ul></li>
<li>2018-02-13 CT - chest and upper abdomen
<ul>
<li>Metastatic mediastinal and left hilar LAPs and Lt Main bronchus with
left lung atelectasis.</li>
</ul></li>
<li>2017-10-14 Renal Echo
<ul>
<li>Absence of left kidney with hypertrophy of right side kidney</li>
<li>History of RCC s/p left side nephrectomy</li>
</ul></li>
<li>2017-10-11 CT - chest and upper abdomen
<ul>
<li>suspected endobronchial CA in left main bronchus with obstructive
pneumonitis.</li>
</ul></li>
<li>2017-08-03 MRI - kidney, adrenals
<ul>
<li>S/P left nephrectomy with residual minimal fatty infiltrates in left
renal fossa.</li>
<li>GB stones.</li>
</ul></li>
<li>2017-05-06 CT - abdomen
<ul>
<li>S/P left nephrectomy with fluid density in left renal fossa, seroma,
abscess or hematoma?<br />
</li>
<li>Thickening/edema of small bowel loops around surgical region.</li>
</ul></li>
<li>2017-03-24 CT - abdomen
<ul>
<li>Left renal tumor, suspected RCC, suspicious renal venous branch
invasion. Cstage T3N0Mx.</li>
</ul></li>
<li>2017-03-22 Renal Echo
<ul>
<li>Left renal tumor was noted at Taipei CGMH</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-03-02 ~ 2022-03-15 - 3000cGy/10 fractions (IMRT) to Rt iliac
bone, palliative</li>
<li>2020-03-27 ~ 2020-04-06 - 3000cGy/10 fractions (6 MV photon) to L5,
&amp; 3000cGy/10 fractions to Rt hip</li>
<li>2018-08-16 ~ 2018-08-31 - 3600cGy/12 fractions (6 MV photon) to Rt
humeral head</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-03-17 ~ 2022-04-11 - everolimus</li>
<li>2022-03-17 - denosumab</li>
<li>2022-02-19 ~ 2022-02-26 - axitinib</li>
<li>2018-03-02 ~ 2020-06-17 - axitinib</li>
<li>tried oral sunitinib, axitinib (Cheng Hsin General Hospital)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient was diagnosed with RCC with metastatic mediastinal LAPs,
suspected RUL lung metastases, liver and bone metastases and is
currently enrolled in hospice combined care (since 2022-03-11).</li>
<li>He is now taking everolimus (since 2022-03-17 s/p axitinib) and has
tried denosumab to prevent pathological spontaneous fractures, as well
as opioid analgesics to relieve pain.</li>
<li>Serum calcium 1.55mmol/L (normal 2.2 ~ 2.65) and magnesium 1.8mg/dL
(normal 1.9 ~ 2.7) reported on 2022-04-10. In patients with
hypomagnesemia, hypocalcemia is difficult to correct without first
normalizing the serum magnesium concentration. The patients serum
magnesium was just slight below normal range and currently treated with
oral magnesium oxide and calcium carbonate without issues.</li>
<li>Urine bacteria (1+) were reported on 2022-04-10; since everolimus is
also an immunosuppressive agent, some ABX might be considered to prevent
an infection from worsening.</li>
</ul>
</div>
<div id="section-6" class="section level2">
<h2>220318</h2>
<p>{RCC with multiple bone metastases}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-23 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>In comparison with the previous study on 20200911, some new bone
lesions in both rib cages are noted, suggesting multiple bone metastases
in progression. However, several previous bone lesions in multiple T-
and L-spine, sternum, right humeral head, and right iliac bone become
less evident, indicating partial respopnse to current therapy.</li>
<li>Suspected benign lesions at bilateral knees.</li>
</ul></li>
<li>2022-02-22 CT - whole abdomen, pelvis
<ul>
<li>Bone mets at left rib, L5 and right acetabulum, suggest further
treatment.</li>
</ul></li>
<li>2022-02-19 KUB + L-spine Lat
<ul>
<li>L5 compression fracture</li>
<li>suspected an osteolytic lesion with bone destruction at right
pelvis.</li>
</ul></li>
<li>2020-09-10 Chest PA
<ul>
<li>Band-like atelectasis in RLL of the lung is suspected. Please
correlate with CT.</li>
<li>Left hemi-diaphragm elevation was noted that is compatible with
bronchiectasis with collapse after correlate with CT.</li>
<li>Atherosclerotic change of aortic arch.</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura thickening.</li>
</ul></li>
<li>2020-09-11 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20200407, some new bone
lesions are noted and some of the previous bone lesions are more
evident, suggesting multiple bone metastases in progression.</li>
</ul></li>
<li>2020-04-07 Tc-99m MDP whole body bone scan
<ul>
<li>Prominently increased activity in the L5 spine, sternum and right
iliac bone. Bone metastases should be considered. Please correlate with
other imaging modalities for further evaluation.</li>
<li>Increased activity in the lower C-spine, some middle and lower
T-spines, right sternoclavicular junction and right humeral head. Either
degenerative change or bone metastases may show this picture. Please
keep follow-up for further evaluation.</li>
<li>Some hot and faint spots in bilateral rib cages and mildly increased
activity in the lesser trochanter of right femur. The nature is to be
determined (post-traumatic change? bone metastasis? other nature?).</li>
</ul></li>
<li>2020-03-18 MRI - L-spine
<ul>
<li>Tumors in the L5 and right iliac bone.</li>
</ul></li>
<li>2019-12-13 CT - lung/pleura
<ul>
<li>Compatible with RCC lung meta and mediastinal lymph nodes,
stable.</li>
</ul></li>
<li>2019-09-11 CT - lung/pleura
<ul>
<li>No mediastinal LAP and no lung nodule on this F/U study.</li>
<li>Stationary atelectatic basal segments with air-bronchograms of the
LLL.</li>
</ul></li>
<li>2019-03-06 CT - lung/pleura
<ul>
<li>RCC with resolution of left lung and mediastinal LNs metastasis as
compared with previous CT study.</li>
</ul></li>
<li>2018-11-21 CT - lung/pleura
<ul>
<li>RCC with left lung and mediastinal LNs metastasis, further in
regression as compared with previous CT study.</li>
</ul></li>
<li>2018-08-23 CT - lung/pleura
<ul>
<li>RCC with lung and mediastinal LNs metastasis, further in regression
as compared with previous CT study.</li>
</ul></li>
<li>2018-05-09 CT - lung/pleura
<ul>
<li>RCC with lung and mediastinal LNs metastasis, in regression compared
with previous CT study.</li>
</ul></li>
<li>2018-02-13 CT - lung/pleura
<ul>
<li>Metastatic mediastinal and left hilar LAPs and Lt Main bronchus with
left lung atelectasis.</li>
</ul></li>
<li>2017-10-11 CT - lung/pleura
<ul>
<li>suspected endobronchial CA in left main bronchus with obstructive
pneumonitis.</li>
</ul></li>
<li>2017-08-03 MRI - kidney, adrenals
<ul>
<li>S/P left nephrectomy with residual minimal fatty infiltrates in left
renal fossa.</li>
<li>GB stones.</li>
</ul></li>
<li>2017-05-06 CT - whole abdomen
<ul>
<li>S/P left nephrectomy with fluid density in left renal fossa, seroma,
abscess or hematoma?<br />
</li>
<li>Thickening/edema of small bowel loops around surgical region.</li>
</ul></li>
<li>2017-03-24 CT - whole abdomen
<ul>
<li>Imaging Report Form for Renal Cell Carcinoma</li>
<li>Left renal tumor, suspected RCC, suspicious renal venous branch
invasion. Cstage T3N0Mx.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2017-08-14 Left inguinal hernia</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-03-02 ~ 2022-03-15 - 3000cGy/8~10fx to Rt iliac bone</li>
<li>2020-03-27 ~ 2020-04-06 - 3000cGy/10fx (6 MV photon) to L5,
3000cGy/10fx to Rt hip</li>
<li>2018-08-16 ~ 2018-08-31 - 3600cGy/12fx (6 MV photon) to Rt humeral
head</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-19 ~ 2022-02-26 axitinib</li>
<li>2018-03-02 ~ 2020-05-20 axitinib</li>
<li>2018-02-03 ~ 2020-01-17 sunitinib</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The RCC patient with multiple bone metastases in progression
(2022-02-23 CT), has been treated with axitinib and sunitinib.</li>
<li>If the conditions are covered by the national health insurance or a
commercial insurance, or the patient is financially able to afford the
medication, immunotherapy might also be considered as an add-on
treatment.</li>
<li>Some regimens in which drug used in immunotherapy can be found,
including but not limited to:
<ul>
<li>axitinib + pembrolizumab</li>
<li>cabozantinib + nivolumab</li>
<li>lenvatinib + pembrolizumab</li>
<li>ipilimumab + pembrolizumab</li>
</ul></li>
<li>Hospice care is being considered by the patient and his family.</li>
<li>Caregivers have an urgent problem of controlling pain for patients
at home that needs to be resolved. Besides analgesics,
non-pharmacological interventions that can control pain over a longer
period of time might also be considered.</li>
<li>The following interventions are available to treat metastatic bone
cancer pain (not exhaustive, reference: <a href="https://pubmed.ncbi.nlm.nih.gov/31140913/" class="uri">https://pubmed.ncbi.nlm.nih.gov/31140913/</a>):
<ul>
<li>Epidural and selective nerve root block</li>
<li>Radiofrequency ablation and cryoablation</li>
<li>Vertebral augmentation</li>
<li>Intrathecal drug delivery</li>
<li>Spinal cord stimulation</li>
<li>Dorsal root ganglion stimulation</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-7" class="section level1">
<h1>700029300</h1>
<div id="section-8" class="section level2">
<h2>210930</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 13 items.</p>
<p>the 9 identified items are listed as following, however, the other 4
items still remain unknown:</p>
<ul>
<li>Galvus Met (Metformin HCl 850mg, Vildagliptin 50mg)</li>
<li>Betmiga (Mirabegron 25mg)</li>
<li>Avodart (Dutasteride 0.5mg)</li>
<li>Mequitine (Mequitazine 5mg)</li>
<li>Co-Tareg (Valsartan 80mg, Hydrochlorothiazide 12.5mg)</li>
<li>Nonin (Glimepiride 2mg)</li>
<li>Bokey (Aspirin 100mg)</li>
<li>Crestor (Rosuvastatin 10mg)</li>
<li>Levozine (Levocetirizine 5mg)</li>
</ul>
<p>these drugs will be sent back to ward by the in-hospital porter.</p>
</div>
</div>
<div id="section-9" class="section level1">
<h1>700031883</h1>
<div id="section-10" class="section level2">
<h2>210830</h2>
<p>{esophageal scc with lung and stomach mets}</p>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2018-04-26 surgical pathology level IV
<ul>
<li>esophagus, 26 cm below incisor, biopsy - moderately differentiated
squamous cell carcinoma</li>
<li>IHC stains P40(+), p63(+), CK(+), CDX-2(-).</li>
</ul></li>
<li>2018-05-07 CT - mediastinum
<ul>
<li>imp: M/3 esophageal tumor T1N0Mx.</li>
</ul></li>
<li>2019-08-20 CT - mediastinum
<ul>
<li>LUL cancer T1aN0MO stage IA1.</li>
</ul></li>
<li>2019-11-21 CT - mediastinum
<ul>
<li>s/p esophagectomy with gastric tube reconstruction.</li>
<li>left upper lobe nodule.</li>
</ul></li>
<li>2021-06-03 PET whole body scan
<ul>
<li>glucose hypermetabolic lesion in the left paratracheal area,
compatible with recurrent malignancy.</li>
<li>mild glucose hypermetabolism in a right submandibular lymph node, a
right neck level III lymph node, bilateral pulmonry hilar regions and in
some focal areas in bilateral buttocks.</li>
</ul></li>
<li>2021-06-25 cell block cytology &amp; needle aspiration cytology
<ul>
<li>stypical hyperchromatic pleomorphic tumor cells with focal
keratinization.</li>
<li>metastatic squamous cell carcinoma is favored.</li>
</ul></li>
<li>2021-06-25 patho - stomach biopsy
<ul>
<li>nests of hyperchromatic tumor cells infiltration in fibrous tissue.
keratinization is focally present.</li>
<li>IHC stains CK5/6(+), p40(+), TTF-1(-), Napsin A(-), CD56(-), and
Synaptophyin(-).</li>
<li>the results are in favor of metastatic squamous cell carcinoma.</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2018-06-04 op for scc of middle third esophagus
<ul>
<li>the esophagus was dissected, and retrosternal route was created and
connected to abdomen.</li>
<li>the gastric tube was draw up to the cervical incision via
retrosternal route.</li>
</ul></li>
<li>2019-11-29 VATS left upper lobe wedge resection, lobectomy with
RLND.</li>
<li>2021-07 up to now: CCRT
<ul>
<li>chemo part - PF 2021-07-29, -08-27
<ul>
<li>75mg/m2 day 1</li>
<li>1000mg/m2 day 1~4</li>
</ul></li>
<li>radio part - 3440Gy/19fx 2021-07-01 ~ -07-27</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>visiting the patient at around 16:40 on 2021-08-30. he said the
treatments were generally well-tolerated and he did not experience any
side effects need intervention during this hospitalization.</li>
<li>overall good, no issue on medication.</li>
</ul>
</div>
</div>
<div id="section-11" class="section level1">
<h1>700035817</h1>
<div id="section-12" class="section level2">
<h2>220505</h2>
<p>He was admitted for hemoptysis with blood clot from oral and nasal
cavity for more than a week. History of NPC and CT imaging revealed
possible tumor recurrence in Jan 2022.</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-16 Chest PA/AP view
<ul>
<li>S/P tracheostomy.</li>
<li>S/P port-A insertion via right subclavian vein.</li>
<li>Right lower lung infiltrates.</li>
<li>No cardiomegaly.</li>
<li>Intimal calcification of thoracic aorta.</li>
</ul></li>
<li>2022-04-16 KUB
<ul>
<li>Calcifications in the pelvic cavity, could be due to
phleboliths.</li>
<li>Non-specific bowel gas pattern.</li>
<li>Mild lumbar spondylosis.</li>
<li>Old fractures at left proximal femur.</li>
</ul></li>
<li>2022-01-13 Patho - polyps, inflammatory nasal/sinonasal
<ul>
<li>Labeled as Granulation tissue at nasopharynx, biopsy  benign
squamous mucosa lined tissue with granulation tissue.</li>
<li>Labeled as Granulation tissue at soft palate, poterior pharyngeal
wall, biopsy  squamous cell carcinoma, granulation tissue and necrotic
tissue.
<ul>
<li>IHC stain: p16 (-).</li>
</ul></li>
<li>Labeled as Granulation tissue around stoma, biopsy  necrotic
tissue.</li>
</ul></li>
<li>2022-01-11 CT - CTA, brain (head, neck)
<ul>
<li>Post graft stent (Viabahn, 8x50mm x2) placement at right
ICA-CCA.</li>
<li>Total occlusion of right ICA and upper-middle part of CCA.</li>
<li>But seems with well blood collateral circulation to right ICA, MCA
from left AcomA.</li>
<li>Presence of soft tissue swelling over right neck, carotid space, and
skull base, recurrent tumor with infection?</li>
<li>Old right fronto-temporal insult with brain tissue loss due to
ICH.</li>
<li>S/P tracheostomy in position.</li>
<li>S/P Port-A infusion catheter insertion at right jugular/subclavian
region.</li>
</ul></li>
<li>2021-04-26 KUB
<ul>
<li>Osteopenia of the bony structure is noted.</li>
<li>The psoas shadow is clear.</li>
<li>Degenerative change of the bony structure with marginal osteophyte
formation is identified.</li>
<li>Stool impaction at the abdominal cavity is noted.</li>
<li>Phlebolith at pelvic cavity is also found.</li>
<li>Suggest clinical correlation</li>
</ul></li>
<li>2021-04-18 Sinuses
<ul>
<li>Waters view of the paranasal sinuses showed
<ul>
<li>obliteration of the bilateral paranasal sinuses</li>
<li>no evidence of destructive bone lesions</li>
</ul></li>
</ul></li>
<li>2021-04-18 Neck soft tissue
<ul>
<li>s/p tracheostomy<br />
</li>
<li>increased soft tissue thickness in the prevertebral soft tissue</li>
<li>s/p stenting at the right neck</li>
</ul></li>
<li>2021-04-18 CT - neck
<ul>
<li>s/p tracheostomy.</li>
<li>s/p stenting at the right ICA and right CCA with air in the luminal
region</li>
<li>Diffuse soft tissue densities in nasalpharynx, oropharynx; and
bilateral retropharyngeal, right carotid and right masticator spaces
with diffuse subcutaneous fatty infiltrates and abscess formation in the
right masticator space. Recurrent tumor with abscess, or stent
extravasation? Suggest clinical correlation.</li>
<li>bilateral CPS.</li>
</ul></li>
<li>2020-12-06 CT - abdomen, pelvis
<ul>
<li>PE abdomen: Muscle guarding</li>
<li>Without contrast Abdomen CT showed
<ul>
<li>unremarkable change in the solid organs, such as liver, pancreas,
spleen, and both kidneys, except multiple GB stones, up to 22mm in the
largest one.</li>
<li>gastrostomy</li>
</ul></li>
<li>IMP: GB stones.</li>
</ul></li>
<li>2020-12-04 Bronchoscopy
<ul>
<li>Bronchitis</li>
<li>Tracheomalasia</li>
<li>Profuse purulent bronchorrhea s/p bronchial toilet</li>
<li>suspected nasopharyngeal tumor with nearly total obstruction</li>
</ul></li>
<li>2020-11-17 Nasopharyngoscopy
<ul>
<li>NPC s/p treatment</li>
<li>Trachea granulation</li>
</ul></li>
<li>2020-10-28 Whole body PET scan
<ul>
<li>In comparison with the previous study on 2018/12/19, glucose
hypermetabolism in the right nasopharyngeal wall disappears, indicating
NPC with good response to previous therapy. However, there is a new
lesion of glucose hypermetabolism in the left vocal cord in this study,
suggesting tumor recurrence with hypopharynx involvement.<br />
</li>
<li>Glucose hypermetabolism in the left level II cervical lymphh nodes,
probably reactive change in response to locoregional inflammation.<br />
</li>
<li>Glucose hypermetabolism in the right pleura and right axillary lymph
nodes, the nature is to be determined (inflammation/ infection process,
NPC with distant metastasis, or others ?), suggesting follow-up.</li>
<li>Glucose hypermetabolism in the right neck, suggesting s/p
tracheostomy with inflammation/infection process.</li>
<li>Glucose hypermetabolism in hepatic flexure of colon, bilateral
shoulders, and left hip, probably benign in nature.</li>
<li>Nasopharyngeal cancer s/p treatment with tumor recurrence,
rcT4NxM0-1, stage IVA at least (AJCC 8th ed.), by this F-18-FDG PET/CT
scan.</li>
</ul></li>
<li>2020-10-18 CT - neck
<ul>
<li>S/P tracheostomy.</li>
<li>S/P vascular stenting in right CCA with intraluminal and
perivascualr air densities, suspected infection/inflammation.<br />
</li>
<li>R/O tumor recurrence in nasalpharynx, oropharynx and carotid and
masticator spaces (mainly in right side), with cellulitis? Suggest
clinical correlation.</li>
<li>Multiple enlarged lymph nodes in neck, mediastinum and right
axillary regions.</li>
</ul></li>
<li>2020-09-09 CT - CTA, brain (head, neck)
<ul>
<li>Total occlusion from the right proximal CCA to the cavernous ICA
with air in the stent graft. suspected inflammatory process.</li>
</ul></li>
<li>2020-05-27 CT - abdomen, pelvis
<ul>
<li>findings
<ul>
<li>There is an ill-defined mild poor enhancing lesion measuring 3.4 x
1.4 cm in S4 of the liver (Srs:3, Img:23) that may be abscess? please
correlate with clinical condition and sonography.</li>
<li>There are several gallstones, the size  1.8 cm), but no evidence
of wall thickening, distension or surrounding fatty stranding.</li>
<li>Mild swelling of the pancreatic head is suspected. Please correlate
with amylase and lipase level.</li>
<li>Left adrenal hyperplasia shows stationary.</li>
<li>Hyperdense hard Fecal material in the S-colon and rectum.</li>
<li>Status post feeding gastrostomy.</li>
<li>There is no focal abnormality in the biliary system, spleen &amp;
both kidney.</li>
<li>There is no ascites or lymphadenopathy.</li>
<li>There is no bowel wall thickening, and no bowel obstruction.<br />
</li>
<li>There is no evidence of intrinsic or extrinsic bladder mass.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.</li>
<li>There is no focal lesion in the mesentery and omentum.</li>
</ul></li>
<li>IMP:
<ul>
<li>Liver abscess is suspected. please correlate with clinical condition
and sonography.</li>
</ul></li>
</ul></li>
<li>2020-01-06 Carotid angiography bilat
<ul>
<li>IMP: Right distal CCA blow-out with a large pseudoaneurysm and
massive active bleeding.</li>
</ul></li>
<li>2020-01-05 Embolization (TAE) - neuro
<ul>
<li>Indication: Massive bleeding from the oral cavity</li>
<li>Angiography of bilateral ECA shows oozing of the mucosa at right
side supplied by branches of rigth ECA and active bleeding is found at
left side by left ECA.</li>
<li>Embolization was done with fine gelatine sponge from bilateral ECAs
till decreased blood flow.</li>
</ul></li>
<li>2020-01-05 Carotid angiography bilat
<ul>
<li>Right distal CCA blow-out with one pseudo-aneurysm formation.
Suggest covered-stent insertion.</li>
</ul></li>
<li>2020-01-05 CT - lung/pleura (chest and upper abdomen) (with and
without contrast)
<ul>
<li>Ind: hemoptysis, suspected lung hemorrhage, suspected NPC with tumor
bleeding</li>
<li>Imp:
<ul>
<li>probably oozing or bleeding at hypopharyngeal region.</li>
<li>single nodule at left apical lung. suggest follow up.</li>
<li>s/p gastrostomy.</li>
<li>s/p tracheal tube placement with its tip in place.</li>
</ul></li>
</ul></li>
<li>2019-11-25 Abdominal Ultrasonography
<ul>
<li>liver parenchyma disease/ incomplete exam of liver</li>
<li>gallstones, GB wall thickening</li>
<li>pancreas masked</li>
<li>spleen not seen</li>
</ul></li>
<li>2019-11-25 Phleborheograph, PRG
<ul>
<li>Venous thrombosis at right internal jugular vein; patent right
external jugular vein; patent right subclavian vein.</li>
</ul></li>
<li>2019-11-13 CT - sinuses for navigator
<ul>
<li>Increased soft tissue in the bilateral posterior nostrils and the
nasopharynx. Nature?<br />
</li>
<li>CPS</li>
</ul></li>
<li>2019-11-05 Nasopharyngolaryngoscopy
<ul>
<li>finding: bi sinus s/p FESS, right choana total synechiae (fibrosis
between septum, right inferior T and nasal floor), left NP whitish mass,
biopsy done</li>
<li>diagnosis
<ul>
<li>NPC s/p treatement</li>
<li>Nasopharyngeal lesion, suspect post-RT necrosis, suspected tumor
recurrence</li>
</ul></li>
</ul></li>
<li>2019-10-08 Nasopharyngolaryngoscopy
<ul>
<li>finding: right choana synechiae, left NP mass with whitish exudate
coating</li>
<li>diagnosis
<ul>
<li>Nasopharyngeal lesion, suspect post-RT necrosis, suspected tumor
recurrence</li>
<li>suggest debridement/excision of nasopharyngeal lesion + choana-plasy
+- FESS for CPS</li>
</ul></li>
</ul></li>
<li>2019-09-20 Repetitive stimulation test
<ul>
<li>Blink Reflex Studies</li>
<li>The repetitive stimulation study at frequency of 2Hz showed no
typical decremental responses in the examined muscles.</li>
<li>Sympathetic Skin Response (SSR)</li>
</ul></li>
<li>2019-09-06 MRA - brain
<ul>
<li>General brain atrophy.</li>
<li>Hydrocephalus.</li>
<li>Bilateral chronic paranasal sinusitis.</li>
<li>Bilateral mastoiditis.</li>
</ul></li>
<li>2019-08-30 CT - brain
<ul>
<li>Brain atrophy.</li>
<li>Paranasal sinusitis, nasal polyps and mastoiditis.</li>
<li>Nasopharyngeal and oropharyngeal lesion. DDX: prolapse of nasal
polyps, nasopharyngeal tumor. Suggest ENT check up.</li>
</ul></li>
<li>2019-07-26 MRI - nasopharynx
<ul>
<li>post-CCRT change with dissue swelling in the bilateral nasopharynx,
oropharynx, amd hypopharyn; and anterior neck. Please f/u 3 months
later.</li>
</ul></li>
<li>2019-05-24 CT - abdomen
<ul>
<li>Senile fibrotic change is noted at lung fields. Some bronchovascular
bundle infiltration at right lower lobe is found.</li>
<li>Gallstones with borderline wall thickening but the GB is not
distended.</li>
</ul></li>
<li>2019-05-15 Myocardial perfusion SPECT with persantin
<ul>
<li>Probably attenuating artifact or mild myocardial ischemia at the
inferoseptal wall of LV.</li>
<li>No post-stress dilatation of the left ventricle.</li>
</ul></li>
<li>2019-05-15 Carotid phonoangiograph, CPA
<ul>
<li>Sonographic diagnosis:
<ul>
<li>Mild to moderate atherosclerosis in Rt CCA.</li>
<li>Imcomplete study due to poor temporal windows for transcranial
insonation.</li>
<li>Partial venous thrombus formation or venous stasis was noted in Rt
IVJ with blood flow.</li>
<li>Adequate total VA flow volume (126 ml/min), indicating absence of
Vertebrobasilar insufficiency.</li>
</ul></li>
<li>Advise clinical correlation.</li>
</ul></li>
<li>2018-12-20 MRI - nasopharynx
<ul>
<li>Image staging(AJCC,8th edition): NPC, T1N1Mx, stage II.</li>
</ul></li>
<li>2018-12-19 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the right nasopharyngeal wall, compatible
with the primary lesion of nasopharyngeal cancer.</li>
<li>Glucose hypermetabolism in the right level II and III cervical lymph
nodes, suggesting cancer with regional lymph node involvement.</li>
<li>Mild glucose hypermetabolism in the left level IIa cervical lymphh
nodes, reactive change in response to locoregional inflammation may show
such a picture.</li>
<li>Glucose hypermetabolism in both lobes of the thyroid gland,
inflammatory change is more likely. Please correlate with other work-up
studies if further evaluation is warranted.</li>
<li>Nasopharyngeal cancer, cT1N1M0, stage II (AJCC 8th ed.), by this
F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2018-12-10 Surgical pathology level IV
<ul>
<li>Nasopharynx, left, biopsy  Non-keratinizing squamous cell
carcinoma</li>
<li>The sections show non-keratinizing squamous cell carcinoma,
undifferentiated subtype, composed of sheets and scattered
spindle-shaped neoplastic cells in lymphoid stroma.</li>
<li>IHC: CK(+), p63(+).</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-12-08 ENT
<ul>
<li>Minimal oozing from tracheal wound</li>
<li>Portable fiber through tracheal tube: patent airway, no active
bleeding site</li>
<li>Local treatment done</li>
<li>Suggestion:
<ul>
<li>Curam + Paran for Rt. facial cellulitis</li>
<li>ENT OPD f/u if needed</li>
</ul></li>
</ul></li>
<li>2021-05-06 ENT
<ul>
<li>we had changed the trachea already this night but I could not help
him to clean the cerumen because the patuient could noy obey our order
and he is too heavy that the nurse was hard to move his head</li>
<li>we suggested back yo our OPD for crumen removed</li>
</ul></li>
<li>2021-05-03 Family Medicine
<ul>
<li>The patient is a case of NPC. This time, he was admitted due to deep
neck infection with abscess formation. Due to poor prognosis, we were
consulted for further evaluation.</li>
<li>When I visited, the patien lied on bed. I asked the nurse about the
familys decision for hospice care. The nurse said that the patients
wife still need to take the message to other family members. And they
didnt make decision. As a result, I arranged hospice combine care for
the patient.</li>
<li>Assessment
<ul>
<li>Indication for hospice combine care : NPC with severe infection</li>
<li>ECOG 4</li>
</ul></li>
</ul></li>
<li>2021-04-19 Radiation Oncology
<ul>
<li>Q
<ul>
<li>This 67 year old man is a case of NPC, old CVA, tracheostomy with
vewntilation. He suffer form deep neck infection with abscess formation.
We need your expertise for pigtail drainage!</li>
</ul></li>
<li>A
<ul>
<li>According to the clinical condition and imaging findings, drainage
is indicated.</li>
</ul></li>
</ul></li>
<li>2021-04-18 ENT
<ul>
<li>Impression: Deep neck infection with abscess formation,
nasopharyngeal carcinoma.</li>
<li>Plan:
<ul>
<li>Surgical intervention at the moment is not appropriate owing to high
mortality and morbidity rate.</li>
<li>Please arrange admission to INFECTION IPD for broad-spectrum
antibiotic treatment.</li>
</ul></li>
<li>Already told the patient to consider hospice care.</li>
</ul></li>
<li>2021-03-30 ENT
<ul>
<li>Local finding via portable fiberoscopy:
<ul>
<li>Bil. nasal mucopus and cannot see N-P well, favor post-RT CPS</li>
<li>Rt. auricle swelling and EAC cerumen impaction</li>
<li>Diffused redness and swelling of Rt. facial, neck and shoulder
skin</li>
</ul></li>
<li>Imp
<ul>
<li>Favor diffused soft tissue infection, suspected post-R/T caused poor
circulation</li>
</ul></li>
<li>Suggestion
<ul>
<li>Keep current Abx</li>
<li>If no improvement or even progression, may consider CT for r/o
abscess formation</li>
</ul></li>
</ul></li>
<li>2020-12-24 Rehabilitation
<ul>
<li>Assessment
<ul>
<li>Acute respiratory failure with ventilator support</li>
<li>NPC s/p CCRT with airway stenosis s/p tracheostomy</li>
<li>Right distal CCA blow-out with a large pseudoaneurysm and massive
active bleeding s/p TAE with stent</li>
<li>COPD with AE</li>
<li>DM</li>
<li>HTN</li>
<li>old CVA with bedridden status</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation programs</li>
</ul></li>
<li>Goal: recondition, improve endurance and muscle strength, remove
endo tube</li>
</ul></li>
<li>2020-10-26 Radiation Oncology
<ul>
<li>Assessment: Non-keratinizing squamous cell carcinoma of the
nasopharynx, stage cT1N1M0 (stage II), s/p CCRT.</li>
<li>Plan: There is no tissue proven of the suspicious area at the
present. ENT further evaluation was suggested.</li>
</ul></li>
<li>2020-03-18 Mental Health
<ul>
<li>Psychiatric impression
<ul>
<li>Depressive DISORDER WITH SUICIDE ATTEMPT</li>
<li>ADJUSTMENT DISORDER WITH DEPRESSED MOOD,</li>
</ul></li>
<li>Psychiatric history
<ul>
<li>This 66-year-old male patient was brought to this ER due to
self-remove trachia this morning. According to his wife, notable
depressed mood and insomnia with initial type since diagnosed with NPC.
However, his depression was progressed in recent 3 months since he
suffered form hemiparesis due to hemoregic stroke. He also note
cooperative for rehabilitation and other treatment. Few and nearly no
interpersonal interaction. Previosly, he had self-remove trachia during
hospitalization.</li>
<li>GIVEN-UP COMPLEX, HELPLESSNESS AND HOPELESSNESS</li>
</ul></li>
<li>Medical history:
<ul>
<li>Nasopharyngeal, left, non-keratinizing squamous cell carcinoma,
cT1N1M0, stage II, with right neck LNs, s/p CCRT and Chemotherapy.
Intake form grastostomy</li>
<li>Diabetes Mellitus type II.</li>
<li>Chronic obstructive pulmonary disease.</li>
<li>Right distal common carotid artery pseudoaneurysm status
transcatheter arterial chemoembolization and stent on 2020/01/06.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>prevent suicide, well inform the risk and prevention to his
family</li>
<li>emotional support</li>
<li>correct his medical problem as your expertise</li>
<li>may give Mirtapine 1# hs for his depression</li>
<li>arrange psychiatric OPD follow up</li>
</ul></li>
</ul></li>
<li>2020-01-12 General and Gastroenterological Surgery
<ul>
<li>Inform the family members (his wife) of the CT results of the brain,
and inform that if the anticoagulant continues to be used, it may
aggravate the cerebral hemorrhage, but if the anticoagulant is not used,
the stent placed in the aneurysm may be blocked.</li>
</ul></li>
<li>2020-01-07 Neurology
<ul>
<li>impression: left hemiplegia, suspect R hemisphere subcortical
infarction</li>
<li>suggestion:
<ul>
<li>agree with current dual antiplatelet agent therapy if no
contraindication such as active bleeding</li>
<li>arrange brain MRA (without contrast) for stroke survey (consider
contrast enhancement for brain metastasis survey)</li>
</ul></li>
</ul></li>
<li>2020-01-07 Family Medicine
<ul>
<li>When I visited patient, he lied on the bed and his consicousness was
drowsy. Interminttent oozing from oral and trochea were found.
Tachycardia was found (HR: 120-130/minute). Breathing sound showed no
rhonchi or no wheezing. CT on 20200105 showed tumor local invasion and
angiography on 20200106 showed no pneudoaneurym formation. Stent for
carotid bleeding was done at that time. Due to NPC with local invasion
and persisted bleeding, we will arrange hospice combine care for patient
first. If his family prefer to receive palliative care, we will discuss
with family about further management or PCU admission issue. If family
still want to receive aggressive treatment/management, we will keep
current combine care first.</li>
</ul></li>
<li>2020-01-07 Infectious Disease
<ul>
<li>Bleeding is the major problem now.</li>
<li>Despite there is leukocytosis, no definite infection is found at the
present time.</li>
<li>Because of repeated embolization, temporary coverage of
staphylococci, including MRSA/MRSE possibility, is acceptable.</li>
<li>Empirical anti-fungal therapy seems not necessary for him.</li>
<li>Please repeat CxR film to see if there is newly-developed pneumonia
or not.</li>
</ul></li>
<li>2020-01-07 Radiation Oncology
<ul>
<li>We have arranged emergent angiography for this patient 20200106
19:00, which revealed right distal CCA blowout, with active bleeding
from pseodoaneurysm. Two stents were placed crossing distal CCA and
proximal ICA. No more active bleeding is noted after stenting.</li>
<li>Medication: Plavix and Bockey 1# QD at least 3 month, after 3 month
Bockey 1# QD life long.</li>
</ul></li>
<li>2020-01-07 ENT
<ul>
<li>Local finding: Oozing from oral cavity but cannot see the bleeding
origin</li>
<li>No epistaxis nor bleeding from tracheostomy</li>
<li>s/p 10 pieces Bosmin gauze compression, but may still need TAE
again</li>
</ul></li>
<li>2020-01-04 ENT
<ul>
<li>Scope: should suspect bleeding from tracheal or lung
<ul>
<li>Yellowish mass over bil. nasopharynx, suspected pus (CPS) or
tumor</li>
<li>Cannot passed the scope into hypopharynx.</li>
</ul></li>
<li>However, the patient was using tracheal tube without side hole
-&gt; less likely from nasal or oral cavity</li>
<li>Suggestion: consult chest men for lung CT or bronchoscopy</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-12
<ul>
<li>Surgery
<ul>
<li>debride the granulation tissue</li>
<li>change gastrostomy tube 20fr for him</li>
</ul></li>
<li>Finding
<ul>
<li>grandulation tissue around the gastrostomy</li>
</ul></li>
</ul></li>
<li>2022-01-12
<ul>
<li>Surgery
<ul>
<li>Stomaplasty</li>
<li>Biopsy of oropharynx and nasopharynx mucosal lesion</li>
</ul></li>
<li>Finding
<ul>
<li>Granulation around the stoma except inferior part</li>
<li>Yellowish semisolid necrotic substance at soft palate, posterior
pharyngeal wall, and bilateral nasopharynx; Diffuse mucosal edema and
touch bleeding was noted at above areas</li>
</ul></li>
</ul></li>
<li>2020-11-11 excision - granuloma around gastrostomy, easy
bleeding(+), pain(+)</li>
<li>2020-04-29 Stomaplasty
<ul>
<li>Surgery
<ul>
<li>Stomaplasty + Nasopharyngeal lesion biopsy</li>
</ul></li>
<li>Finding
<ul>
<li>Stoma stenosis with granulation formation.</li>
<li>Whitish exudate like lesion at bilateral nasopharynx.</li>
</ul></li>
</ul></li>
<li>2021-04-28
<ul>
<li>Surgery
<ul>
<li>Incision and drainage of right masticator space</li>
</ul></li>
<li>Finding
<ul>
<li>Much bloody discharge and few pus over right masticator space</li>
</ul></li>
</ul></li>
<li>2020-04-02
<ul>
<li>Surgery
<ul>
<li>laparoscopic gastrostomy</li>
</ul></li>
<li>Finding
<ul>
<li>NPC</li>
<li>difficulty in NG tube insertion</li>
</ul></li>
</ul></li>
<li>2020-01-06 Embolization (TAE) - neuro
<ul>
<li>Indication: Right distal CCA blow-out with a large pseudoaneurysm
and massive active bleeding.</li>
<li>TAE was done with two 8x50 mm stent graft (Viabahn Endoprothesis,
overlapped on distal CCA), no more contrast leak after this
procedure.</li>
<li>Imp: Post stent grafting of the large right CCA pseudoaneurysm.</li>
<li>Medication: Plavix and Bockey 1# QD at least 3 month, after 3 month
Bockey 1# QD life long.</li>
</ul></li>
<li>2019-11-20 Nasopharyngeal necrosis and right choana atresia</li>
<li>2019-08-27 Tracheostomy for respiratory failure
<ul>
<li>neck shortness and stiffness, tracheostomy done with Shily #6</li>
</ul></li>
<li>2019-06-10 Jejunostomy - Nasopharyngeal cancer post op, for feeding
jejunostomy creation</li>
<li>2017-12-26 Rt soft palate tumor
<ul>
<li>1.3x2mm granular lesion at right soft palate</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Lab data on 2022-05-04 showed PT 10.6 sec, INR 1.02, APTT 40.4 sec,
Fibrinogen 474.5 mg/dL, D-dimer 982 ng/mL(FEU).</li>
<li>Aspirin, warfarin, vitamin K antagonists, DOACs records found in NHI
PharmaCloud.</li>
<li>Tranexamic acid 500mg IVD Q8H has been prescribed since
2022-05-05.</li>
<li>Hemoptysis no longer appears in the problem list. No issue with
current medication.</li>
</ul>
</div>
</div>
<div id="section-13" class="section level1">
<h1>700039230</h1>
<div id="section-14" class="section level2">
<h2>210729</h2>
<p>{post IPP meeting following up}</p>
<ul>
<li><p>the schedule and regimen for PBSCT for the patient was disclosed
in the meeting held on 2021-07-28 10:30.</p></li>
<li><p>the estimated total amount of busulfan used in the time table is
15 vials.</p>
<ul>
<li>based on busulfan 60mg/10mL/vial, dose 3.2mg/kg, body weight
75kg</li>
<li>5 vials per day for 3 days (2021-07-28, 2021-07-29, 2021-07-30)</li>
</ul></li>
<li><p>staff dispensing regimen during weekend are arranged.</p></li>
<li><p>preparation and administration precautions:</p>
<ul>
<li>busulfan:
<ul>
<li>do not use polycarbonate syringes or polycarbonate filter needles
with the drug.</li>
</ul></li>
<li>etoposide:
<ul>
<li>precipitation may be exacerbated at concentrations of 0.4 mg/mL or
above.</li>
<li>etoposide 400mg/m2 x body surface area 1.9m2 -&gt; amount
760mg.</li>
<li>total solution containing 760mg etoposide will be no less than
1900mL.</li>
</ul></li>
</ul></li>
</ul>
<p>{mesna administration rate}</p>
<ul>
<li>where ifosfamide or cyclophosphamide is used (like this patient) as
an iv bolus: mesna is given by intravenous injection over 15-30 minutes
at 20% of the simultaneously administered oxazaphosphorine on a weight
for weight basis (w/w). the same dose of mesna is repeated after 4 and 8
hours (as listed in the regimen schedule).
<ul>
<li>reference: <a href="https://www.medicines.org.uk/emc/product/1838/smpc" class="uri">https://www.medicines.org.uk/emc/product/1838/smpc</a></li>
<li>reference: drug package insert</li>
</ul></li>
<li>taking a conservative approach as conclusion, 30 minutes should be
safe for adult.</li>
</ul>
</div>
</div>
<div id="section-15" class="section level1">
<h1>700042050</h1>
<div id="section-16" class="section level2">
<h2>220119</h2>
<p>[objective]</p>
<ul>
<li>lab data:
<ul>
<li>Na 2022-01-18 125mmol/L</li>
<li>K 2022-01-18 2.7mmol/L</li>
<li>Mg 2022-01-18 1.8mg/dL</li>
<li>Free T4
<ul>
<li>2021-10-15 1.3ng/dL</li>
<li>2021-08-17 0.95ng/dL</li>
</ul></li>
<li>TSH
<ul>
<li>2021-10-15 14.46uIU/mL</li>
<li>2021-08-17 0.117uIU/mL</li>
</ul></li>
</ul></li>
<li>medication
<ul>
<li>Radi-K (potassium gluconate)</li>
<li>MgO</li>
<li>Eltroxin (levothyroxine)</li>
</ul></li>
</ul>
<p>[assessment, suggestion]</p>
<ul>
<li>In addition to current Radi-K administration, the low serum K might
be induced by low serum Mg, bioavailability of Mg from oral MgO is
around 5~10%, MgSO4 Inj might be considered to pump up serum Mg more
rapidly.</li>
<li>Last thyroid hormone related lab records were taken more than 3
months ago, there is no updated data to follow up the hyped TSH, which
could be ordered if no contraindication.</li>
</ul>
</div>
</div>
<div id="section-17" class="section level1">
<h1>700043762</h1>
<div id="section-18" class="section level2">
<h2>210928</h2>
<p>{potential drug interactions, vitamin supplement}</p>
<p>[objective]</p>
<ul>
<li>items listed in active medication including:
<ul>
<li>emetrol (domperidone 10mg/tab) 2 tab PO TIDAC</li>
<li>rivotril (clonazepam 0.5mg/tab) 1 tab PO HS</li>
<li>keppra (levetiracetam 100mg/ml) 3 ml PO BID</li>
<li>calquene (acalabrutinib 100mg) 1 tab PO Q12H</li>
</ul></li>
<li>lab data reported on 2021-09-25
<ul>
<li>gastric juice OB 3+</li>
<li>RBC 2.78*10^6/mL</li>
<li>HGB 9.8g/dL</li>
<li>MCV 101fL</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>there are drugs in active medication might have potential
interactions:
<ul>
<li>acalabrutinib &lt;&gt; lansoprazole
<ul>
<li>PPI might decrease the serum concentration of acalabrutinib.</li>
<li>with the long-lasting effect of PPIs, separation of doses might not
eliminate the interaction.</li>
<li>acalabrutinib AUC was decreased by 43% when co-administered with the
PPI omeprazole (40 mg for 5 days) according to studies of healthy
subjects. this decreases in acalabrutinib concentrations might reduce
acalabrutinib activity, so the acalabrutinib labeling recommends that if
treatment with a gastric acid reducing agent is required, a histamine-2
receptor antagonist (H2RA) or an antacid should be considered, with
separation of administration to minimize the likelihood of a significant
interaction.
<ul>
<li>reference: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf" class="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf</a></li>
</ul></li>
</ul></li>
<li>clonazepam &lt;&gt; levetiracetam
<ul>
<li>CNS depressants may enhance the adverse/toxic effect of other CNS
depressant</li>
</ul></li>
</ul></li>
<li>emetrol (domperidone) dosing
<ul>
<li>10mg x 3 times (max) a day stated in package insert, however,
prescirbed daily dose is 60mg.</li>
</ul></li>
<li>suspected GI bleeding
<ul>
<li>somewhat anemia, MCV reading above upper limit of normal.</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>H2 antagonists such as cimetidine (stogamet 300mg/tab, tagamet
200mg/2ml/amp available in stock), famotidine (ulstop 20mg/tab, ulcertin
20mg/2ml/amp available), ranitidine (not available in hospital),
nizatidine (not available) could be considered to shift PPI off.</li>
<li>please monitor for additive CNS-depressant effects whenever two or
more CNS depressants are concomitantly used.</li>
<li>symptoms of domperidone overdosage may include agitation, altered
consciousness, convulsions, disorientation, somnolence and
extrapyramidal reactions. there is no specific antidote to domperidone,
but in the event of overdose, standard symptomatic treatment should be
given.</li>
<li>some vit B12, folic acid might help to increase HGB.</li>
</ul>
<p>thanks and regards,</p>
</div>
</div>
<div id="section-19" class="section level1">
<h1>700045553</h1>
<div id="section-20" class="section level2">
<h2>220315</h2>
<p>{Metastatic colon adenocarcinoma in liver S4-5-8 &amp; S6, pTxN0M1a
StageIVA,post segmental hepatectomy on 2019-06-05}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-15 MRI - nasopharynx
<ul>
<li>Metastastic LAPs at left neck. An extra-axial tumor (37 mm) at
anterior cranial fossa and pituitary fossa. R/O meningioma. D/D:
craniopharyngioma, pituitary adenoma, metastasis.</li>
</ul></li>
<li>2022-01-14 CT - whole abdomen, pelvis
<ul>
<li>Metastasis in S7 liver S/P C/T shows progressive disease.</li>
<li>Metastatic lymphadenopathy in para-aortic space and para-cava space
S/P C/T show partial response.</li>
</ul></li>
<li>2021-11-10 MRI - nasopharynx
<ul>
<li>multiple enlarged and necrotic lymph nodes in the left lower neck
and left supraclavicular fossa.</li>
</ul></li>
<li>2021-11-09 CT - whole abdomen, pelvis
<ul>
<li>Hepatic meta at S7, in progression.</li>
<li>Extensive paraaortic lymphadenopathy, enlarged.</li>
<li>Tiny left upper lobe nodule. Stable.</li>
</ul></li>
<li>2021-09-16 CT - whole abdomen, pelvis
<ul>
<li>Progression of liver/LNs metastases.</li>
</ul></li>
<li>2021-07-19 Patho - peritoneum biopsy
<ul>
<li>newly developed retroperitoneal LNs, R/I recurrence.</li>
<li>malignant neoplasm of descending colon</li>
<li>Retroperitoneal lymph node, CT-guide biopsy - Adenocarcinoma,
metastatic</li>
<li>IHC: CK(+), CK20(-), CDX2(+) and CD31 highlights endothelial cell,
compatible with metastatic colonic adenocarcinoma.</li>
</ul></li>
<li>2020-10-14 CT - whole abdomen, pelvis
<ul>
<li>A metastasis 2.9 x 2 cm in S7 of the liver S/P C/T with partial
response. Follow up is indicated.</li>
</ul></li>
<li>2020-08-25 CT - whole abdomen, pelvis
<ul>
<li>Post-op at the liver with loculated fluid in right subphrenic
region, stationary.</li>
<li>Stationary of S7 liver tumor.</li>
</ul></li>
<li>2020-06-15 MRI - brain
<ul>
<li>A pituitary macroadenoma. No evidence of brain metastasis.</li>
</ul></li>
<li>2020-06-13 CT - whole abdomen, pelvis
<ul>
<li>Post-op at the liver with loculated fluid in right subphrenic region
with progression. Post-op biloma or associated with recurrenct, suggest
tissue study.</li>
<li>Stationary of S7 liver tumor.</li>
<li>Small bilateral renal stones.</li>
</ul></li>
<li>2020-04-01 CT
<ul>
<li>A metastasis 3.9 x 2 cm in S7 of the liver S/P C/T with stable
disease.</li>
</ul></li>
<li>2019-11-21 Whole body PET scan
<ul>
<li>Three glucose hypermetabolic lesions in the segment 8 of liver, in
the segment 7 of liver and in the right upper abdomen just in the
inferomedial aspect of the right lobe of liver respectively. Metastatic
lesions should be considered.</li>
<li>Mild glucose hypermetabolism in bilateral pulmonary hilar regions
and in the soft tissues around bilateral hips. Inflammatory process is
more likely.</li>
<li>Glucose hypermetabolism in the midline anterior abdominal wall. The
nature is to be determined (post-operative change? other nature?).</li>
<li>A glucose hypermetabolic lesion the pituitary fossa. The nature is
to be determined (some kind of pituitary tumor? other nature?).</li>
</ul></li>
<li>2019-11-11 CT - abdomen
<ul>
<li>S/P liver operation. A low attenuation lesion (1.8cm) in S7 of liver
without interval change.</li>
</ul></li>
<li>2019-08-14 Tc-99m MDP whole body bone scan
<ul>
<li>A faint hot spot in the anterolateral aspect of the right 8th rib,
the nature is to be determined (post-traumatic change or other nature
?), suggesting follow-up with bone scna in 3 months for further
evaluation.</li>
<li>Suspected benign lesions in the left zygomatic bone, inferior angle
of the right scapula, bilateral shoulders, and S-I joints.</li>
</ul></li>
<li>2019-08-03 MRI - liver, spleen
<ul>
<li>s/p pigtail placement at previous op. region. Some fluid
accumulation at previous op. region with tiny air bubble is found. The
adjacent liver parenchyma is hyperemic, suspected regional residual
abscess formation.</li>
</ul></li>
<li>2019-06-06 Surgical pathology Level V
<ul>
<li>pathologic diagnosis
<ul>
<li>Liver, S4-5-8, segmental hepatectomy  Metastatic colonic
adenocarcinoma<br />
</li>
<li>Liver, S7, segmental hepatectomy  Metastatic colonic
adenocarcinoma<br />
</li>
<li>Tumor regression grade: Grade 4/5 (cancer cells &gt; fibrosis)<br />
</li>
<li>Lymph nodes, group 12, lymphadenectomy  Negative (0/3)</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Diagnosis: Metastatic colonic adenoarcinoma x2</li>
<li>Histologic grade: Moderately differentiated<br />
</li>
<li>Tumor growth pattern: Pushing<br />
</li>
<li>Tumor pseudocapsule: Present<br />
</li>
<li>Tumor necrosis: Marked (60%)<br />
</li>
<li>Parenchymal margin: Uninvolved by carcinoma<br />
</li>
<li>Distance of invasive carcinoma from closest margins: 0.1 cm (S4-5-8)
and 0.1 cm (S7), respectively<br />
</li>
<li>Vascular invasion: Present<br />
</li>
<li>Perineural invasion: Not identified<br />
</li>
<li>Tumor regression grade: Grade 4/5 (residual cancer cells predominate
over fibrosis)</li>
<li>Lymph nodes, group 12: Negative (0/3) (LN involved/LN
examined)<br />
</li>
<li>Non-neoplastic liver parenchyma: Perivenular congestion, and mild
portal lymphocytic infiltration<br />
</li>
<li>Fatty Change: Moderate (50%)</li>
</ul></li>
</ul></li>
<li>2019-06-08 CT - abdomen
<ul>
<li>S/P operation. Bil. pleural effusion with adjacent lung
collapse.</li>
<li>Some air and fluid collection in upper peritoneal cavity and right
subphrenic region.</li>
<li>Inhomogeneous enhancement of right hepatic lobe.</li>
</ul></li>
<li>2019-05-20 CT - abdomen
<ul>
<li>Metastasis 4 cm in size at S4 of the liver is noted and it shows
indentation or invasion of the gallbladder wall.</li>
</ul></li>
<li>2018-11-16 CT
<ul>
<li>S/P left hemicolectomy. Suggest follow up.</li>
</ul></li>
<li>2018-07-07 CT
<ul>
<li>S/P operation. Presence of incisional hernia. Focal fat stranding of
abdominal wound.</li>
</ul></li>
<li>2018-06-28 Surgical pathology Level III
<ul>
<li>Soft tissue, site?, debridement  Ulcer with granulation tissue</li>
</ul></li>
<li>2018-04-26 Surgical pathology Level VI
<ul>
<li>Pathologic diagnosis
<ul>
<li>Descending colon, left hemicolectomy  Adenocarcinoma, moderately
differentiated<br />
</li>
<li>Resection margins: Free<br />
</li>
<li>Lymph nodes, mesocolic, dissection  Metastatic adenocarcinoma
(2/16)</li>
<li>Pathology stage: pT4aN1b(cMx); Stage IIIB at least</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histology: Adenocarcinoma<br />
</li>
<li>Histology Grade: Moderately differentiated</li>
<li>Depth of invasion: Mesocolic soft tissue<br />
</li>
<li>Angiolymphatic invasion: Present<br />
</li>
<li>Perineural invasion: Present<br />
</li>
<li>Discontinuous extramural tumor extension: Not identified<br />
</li>
<li>Serosal margin status of colon: Involved<br />
</li>
<li>Lymph nodes metastasis, mesocolic: Metastatic adenocarcinoma (2/16)
(No.Positive / No.Total)</li>
<li>Extranodal involvement: Present<br />
</li>
<li>IHC: EGFR(+), MLH1(+), PMS2(+), MSH2(+), MSH6(+)</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2019-06-05
<ul>
<li>Segmental hepatectomy</li>
<li>Secondary liver malignant neoplasm</li>
</ul></li>
<li>2018-06-27
<ul>
<li>Colon cancer s/p op with enterocutaneous fistula</li>
</ul></li>
<li>2018-06-22
<ul>
<li>Malignant colon neoplasm, desc</li>
<li>8.5 Fr.B. braun port, left cephalic vein, cut-down method.</li>
</ul></li>
<li>2018-05-01
<ul>
<li>D-colon cancer obstruction post op</li>
<li>Smoe necrotic tissue at colostomy opened wound</li>
<li>Debridement and closure and set a penrose drain</li>
</ul></li>
<li>2018-04-25
<ul>
<li>D-colon cancer obstruction s/p colostomy</li>
<li>D-colon cancer with complete obstruction 7<em>4</em>4cm</li>
<li>Peristoma dense adhesion with omentum and small intestine</li>
</ul></li>
<li>2018-04-10
<ul>
<li>D-colon cancer obstruction</li>
<li>Severe dilatation of T-colon and short mesentary</li>
<li>Asites (+)</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-11-11 ~ ongoing: FOLFOXIRI (plus cetuximab since
2022-02-10)</li>
<li>2021-11-06 ~ 2021-11-11: regorafenib</li>
<li>2021-07-29 ~ 2021-09-03: FOLFOX</li>
<li>2020-01-13 ~ 2020-08-24: FOLFIRI (plus bevacizumab since
2020-02-17)</li>
<li>2019-12-06 ~ 2019-12-28: capecitabine</li>
<li>2018-06-08 ~ 2018-06-18: capecitabine</li>
</ul></li>
<li>lab data
<ul>
<li>CEA
<ul>
<li>2022-02-18 886ng/mL</li>
<li>2021-11-23 1261</li>
<li>2021-11-09 913</li>
<li>2021-09-14 817</li>
<li>2021-07-30 440</li>
<li>2021-07-23 323</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>CT and MRI in mid January 2022 showed the disease progressed
compared to previous images.</li>
<li>CEA readings since July 2021 at intervals of two to three months
showed a peak in November 2021 (1261ng/mL) and a slight fall in February
2022 (886ng/mL), possibly caused by the introduction of FOLFOXIRI from
November 2021 (ongoing).</li>
</ul>
</div>
</div>
<div id="section-21" class="section level1">
<h1>700051397</h1>
<div id="section-22" class="section level2">
<h2>220329</h2>
<p>{SCC of esophagus, lower third, with mediastinal &amp; SCF LAPs and
multiple brain metastases, stage IV}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-10 Patho - esophageal biopsy
<ul>
<li>Esophagus, 30 cm below the incisor, biopsy - Compatible with
squamous cell carcinoma</li>
<li>IHC: CK(+); P16(-), P63(+) and P53 (+, focal) for atypical
cells.</li>
<li>According to histopathologic finding and past history, it is
compatible with poorly-differentiated squamous cell carcinoma, although
no convincing stromal invasion.</li>
</ul></li>
<li>2022-03-01 Esophagography
<ul>
<li>Severe stenosis at middle esophagus</li>
</ul></li>
<li>2022-01-17 MRI - brain
<ul>
<li>Small poor enhancing nodules in left frontal and right occipital
lobes, regressed. Regressed size and edema of left occipital
nodule.</li>
</ul></li>
<li>2022-01-14 CT - lung/mediastinum/pleura
<ul>
<li>Compatible with middle third esophageal cancer and mediastinal lymph
nodes, in regression.</li>
</ul></li>
<li>2021-10-11 CT - lung/mediastinum/pleura
<ul>
<li>Esophageal cancer with mediastinal lymph nodes metastasis, in
regression post CCRT, but a suspect new RLL nodular metastasis and
inflammation or infection in LLL of lungs, compared with CT on
20210428.</li>
</ul></li>
<li>2021-10-08 CT - brain
<ul>
<li>Multiple brain metastases, size slightly smaller as compared to that
in previous CT done on 20210705.</li>
</ul></li>
<li>2021-04-28 Whole body PET scan
<ul>
<li>A glucose-hypermetabolic lesion in the esophagus, L/3, compatible
with the primary esophageal cancer.<br />
</li>
<li>Glucose-hypermetabolic lesions in bilateral mediastinal lymph nodes,
probably cancer with regional lymph nodes involvement.<br />
</li>
<li>Glucose-hypermetabolic lesions in the right lower lung, probably
benign in nature.<br />
</li>
<li>Increased FDG uptake in the colon, probably physiological uptake of
FDG.<br />
</li>
<li>Esophageal cancer, cTxN3M0, by this F-18 FDG PET scan.</li>
</ul></li>
<li>2021-04-28 CT - lung/mediastinum/pleura
<ul>
<li>lower third esophageal cancer T3N3M0 IVA</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-07-26 ~ 2021-08-30 - 5040cGy/28 fractions (15 MV photon) to
esophageeal tumor and LAPs</li>
<li>2021-07-08 ~ 2021-07-23 - 3600cGy/12 fractions (6 MV photon) to
brain metastasis</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12-06 ~ undergoing - fluorouracil + leucovorin + cisplatin</li>
<li>2021-07-14 ~ 2021-11-18 - FOLFOX</li>
</ul></li>
<li>diagnosis
<ul>
<li>Esophageal cancer, SqCC, L/3, diagnosed by FuJen Catholic University
Hospital in 2019-10.</li>
</ul></li>
</ul>
<p>[tube feeding]</p>
<ul>
<li>Nexium (esomeprazole) must not be ground. Instead, it should be
dissolved in adequate drinking water prior to tube feeding.</li>
</ul>
</div>
</div>
<div id="section-23" class="section level1">
<h1>700054780</h1>
<div id="section-24" class="section level2">
<h2>210920</h2>
<p>{mesna compatibility for common solutions}</p>
<p>reply for the consultation from the ward, mesna is compatible with: -
D5W (Dextrose 5% in water) - D5NS (Dextrose 5% in sodium chloride 0.9%)
- D5W - 1/2 NS (Dextrose 5% in sodium chloride 0.45%) - NS (Normal
saline (Sodium chloride 0.9%)) - Lactated Ringers Injection</p>
</div>
<div id="section-25" class="section level2">
<h2>210915</h2>
<p>{post IPP meeting following up}</p>
<p>[busulfan inventory]</p>
<ul>
<li>the schedule and regimen for PBSCT for the patient was disclosed in
the meeting (with his spouse) held on 2021-09-15 10:30 in the ward.</li>
<li>the estimated total amount of busulfan used in the time table is 12
vials.
<ul>
<li>based on busulfan 60mg/10mL/vial, dose 3.2mg/kg, body weight
64.8kg</li>
<li>4 vials per day for 3 days (2021-09-16, 2021-09-17, 2021-09-18)</li>
<li>staff to dispense regimen during weekend are arranged.</li>
<li>stock in medicine storeroom has been confirmed enough in
quantity.</li>
</ul></li>
</ul>
<p>[preparation and administration precautions]</p>
<ul>
<li>busulfan:
<ul>
<li>do not use polycarbonate syringes or polycarbonate filter needles
with the drug.</li>
</ul></li>
<li>etoposide:
<ul>
<li>precipitation may be exacerbated at concentrations of 0.4 mg/mL or
above.</li>
<li>etoposide 400mg/m2 x body surface area 1.79m2 -&gt; amount
716mg.</li>
<li>total solution containing 716mg etoposide should be no less than
1790mL.</li>
</ul></li>
<li>mesna administration rate
<ul>
<li>where ifosfamide or cyclophosphamide is used (like this patient) as
an iv bolus:
<ul>
<li>mesna is given by intravenous injection over 15-30 minutes at 20% of
the simultaneously administered oxazaphosphorine on a weight for weight
basis (w/w). the same dose of mesna is repeated after 4 and 8 hours (as
listed in the regimen schedule).
<ul>
<li>reference: <a href="https://www.medicines.org.uk/emc/product/1838/smpc" class="uri">https://www.medicines.org.uk/emc/product/1838/smpc</a></li>
<li>reference: drug package insert</li>
</ul></li>
</ul></li>
<li>taking a conservative approach as conclusion, 30 minutes should be
safe for adult.</li>
</ul></li>
</ul>
<p>[underlying diseases]</p>
<ul>
<li>underlying diseases are managed with corresponding medicine without
issues.
<ul>
<li>HTN and CAD s/p stent splacement
<ul>
<li>concor (bisoprolol) 2.5mg PO QD</li>
<li>norvasc (amlodipine) 2.5mg PO QD</li>
<li>tulip (atorvastatin) 10mg PO QOD</li>
</ul></li>
<li>HBV infected
<ul>
<li>baraclude (entecavir) 0.5mg PO QDAC</li>
</ul></li>
<li>SLE
<ul>
<li>plaquenil (hydroxychloroquine) 200mg PO QOD</li>
</ul></li>
</ul></li>
</ul>
<p>[medical compliance]</p>
<ul>
<li>the patient showed somewhat self-assertive in the meeting, pleading
with tactful words might be needed to prevent potential undesired
events.</li>
</ul>
</div>
</div>
<div id="section-26" class="section level1">
<h1>700061689</h1>
<div id="section-27" class="section level2">
<h2>210517</h2>
<p>{tube feeding}</p>
<p>the oral drug takepron (lansoprazole, 30mg/tab) in active medication
should not be grinded, while it can be peeled in half.</p>
<p>there is also an iv version takepron (lansoprazole, 30mg/vial) can be
the alternative.</p>
</div>
</div>
<div id="section-28" class="section level1">
<h1>700068505</h1>
<div id="section-29" class="section level2">
<h2>220331</h2>
<p>[subjective]</p>
<ul>
<li>low back pain since Feb 2021, pain aggravated when changing
position</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-01-06 CT
<ul>
<li>Much regression of S-colon cancer, regional/non-regional LNs,
peritoneal seeding, bony/liver and lung metastases.</li>
</ul></li>
<li>2021-10-06 Tc-99m MDP whole body bone scan
<ul>
<li>Multiple hot spots in bilateral rib cages and increased activity in
the sacrum, bilateral S-I joints, and right acetabulum, cancer with bone
metastasis is highly suspected.</li>
<li>Suspected benign lesions in the maxilla, sternum, middle T-spine,
L3-4 spine, bilateral shoulders and right foot.</li>
</ul></li>
<li>2021-10-05 CT
<ul>
<li>Diffuse metastatic tumors in the liver, peritoneum, bones,
metastatic lymph nodes in paraaortic and left neck.</li>
<li>Regression as compare with CT study on 2021-6-21.</li>
<li>Mild pericardial effusion.</li>
</ul></li>
<li>2021-06-25 Patho - Colon biopsy
<ul>
<li>Colon, sigmoid 20cm above anal verge, biopsy - Adenocarcinoma.<br />
</li>
<li>IHC: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+).</li>
</ul></li>
<li>2021-06-22 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the sacrum, right S-I joint and right iliac
bone. Bone metastases should be considered first.</li>
<li>Increased activity in the middle T-spines and L4 spine. Either
degenerative change or bone metastases may show this picture. Please
correlate with other imaging modalities for further evaluation.</li>
<li>Multiple hot spots in the sternum and bilateral rib cages and mildly
increased activity in bilateral femoral trochanters. The nature is to be
determined (bone metastases? post-traumatic change? other nature?).</li>
<li>Increased activity in bilateral shoulders. Benign joint lesions is
more likely.</li>
</ul></li>
<li>2021-06-21 CT
<ul>
<li>Impression (Imaging stage): T3N2aM1c, stage IVC</li>
</ul></li>
<li>2021-06-15 Patho - Bone pathologic fragment, at right first sacral
tumor/mass.
<ul>
<li>Labeled as sacrum, CT guided biopsy - adenocarcinoma.</li>
<li>IHC:
<ul>
<li>CK20(+), CDX2(+): please check gastrointestinal tract first.</li>
<li>PSA(-): dis-favor prostatic origin.</li>
<li>TTF-1(-), Napsin-A(-): dis-favor pulmonary origin.</li>
</ul></li>
</ul></li>
<li>2021-06-02 MRI - L-spine:
<ul>
<li>tumors in the sacrum.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2021-07-20
<ul>
<li>All-RAS mutation detected</li>
<li>BRAF mutation not detected</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-08 ~ undergoing: FOLFIRI + bevacizumab</li>
<li>2021-07: FOLFOX</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>According to latest CT images on 2022-01-06, the disease showed
response to current regimen which has been introduced since 2021-08,
compared with the images on 2021-10-25, 2021-06-21.</li>
<li>There has been an increase in biomarker readings since 2022 [CEA
10.39(2022-03-29) &lt;- 8.55(2022-02-23) &lt;- 6.69(2022-01-18); CA199
92.15(2022-03-29) &lt;- 82.61(2022-02-23) &lt;- 72.41(2022-01-18)],
which is not consistent with the CT images that are updated not so
frequently.</li>
<li>When the disease becomes resistant to current treatment, since this
patient is on irinotecan-based therapy without oxaliplatin, the next
regimen candidates might be FOLFOX or CAPEOX.</li>
</ul>
</div>
<div id="section-30" class="section level2">
<h2>220225</h2>
<p>[subjective]</p>
<ul>
<li>low back pain since Feb 2021, pain aggravated when changing
position</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-01-06 CT
<ul>
<li>Much regression of S-colon cancer, regional/non-regional LNs,
peritoneal seeding, bony/liver and lung metastases.</li>
</ul></li>
<li>2021-10-06 Tc-99m MDP whole body bone scan
<ul>
<li>Multiple hot spots in bilateral rib cages and increased activity in
the sacrum, bilateral S-I joints, and right acetabulum, cancer with bone
metastasis is highly suspected.</li>
<li>Suspected benign lesions in the maxilla, sternum, middle T-spine,
L3-4 spine, bilateral shoulders and right foot.</li>
</ul></li>
<li>2021-10-05 CT
<ul>
<li>Diffuse metastatic tumors in the liver, peritoneum, bones,
metastatic lymph nodes in paraaortic and left neck.</li>
<li>Regression as compare with CT study on 2021-6-21.</li>
<li>Mild pericardial effusion.</li>
</ul></li>
<li>2021-06-25 Patho - Colon biopsy
<ul>
<li>Colon, sigmoid 20cm above anal verge, biopsy - Adenocarcinoma.<br />
</li>
<li>IHC: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+).</li>
</ul></li>
<li>2021-06-22 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the sacrum, right S-I joint and right iliac
bone. Bone metastases should be considered first.</li>
<li>Increased activity in the middle T-spines and L4 spine. Either
degenerative change or bone metastases may show this picture. Please
correlate with other imaging modalities for further evaluation.</li>
<li>Multiple hot spots in the sternum and bilateral rib cages and mildly
increased activity in bilateral femoral trochanters. The nature is to be
determined (bone metastases? post-traumatic change? other nature?).</li>
<li>Increased activity in bilateral shoulders. Benign joint lesions is
more likely.</li>
</ul></li>
<li>2021-06-21 CT
<ul>
<li>Impression (Imaging stage): T3N2aM1c, stage IVC</li>
</ul></li>
<li>2021-06-15 Patho - Bone pathologic fragment, at right first sacral
tumor/mass.
<ul>
<li>Labeled as sacrum, CT guided biopsy - adenocarcinoma.</li>
<li>IHC:
<ul>
<li>CK20(+), CDX2(+): please check gastrointestinal tract first.</li>
<li>PSA(-): dis-favor prostatic origin.</li>
<li>TTF-1(-), Napsin-A(-): dis-favor pulmonary origin.</li>
</ul></li>
</ul></li>
<li>2021-06-02 MRI - L-spine:
<ul>
<li>tumors in the sacrum.</li>
</ul></li>
</ul></li>
<li>Chemotherapy
<ul>
<li>2021-08 ~ ongoing: FOLFIRI + bevacizumab</li>
<li>2021-07: FOLFOX</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>according to CT image on 2022-01-06, the disease showed response to
current regimen which has been introduced since 2021-08, compared with
the images on 2021-10-25, 2021-06-21.</li>
</ul>
</div>
<div id="section-31" class="section level2">
<h2>210630</h2>
<p>{colon cancer}</p>
<p>[initial presentation]</p>
<ul>
<li>low back pain since Feb 2021, pain aggravated when changing
position</li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2021-06-02 MRI, L-spine:
<ul>
<li>degenerative lumbar spondylosis, intermittent claudicationright
thigh muscle atrophy</li>
<li>tumors in the sacrum.</li>
<li>enlarged lymph nodes in the paraaortic region.</li>
</ul></li>
<li>2021-06-15 CT guide biopsy Patho, bone fragment/pathologic fracture
<ul>
<li>IHC stains:
<ul>
<li>CK20 (+), CDX2 (+): should check gastrointestinal tract</li>
<li>PSA (-): dis-favor prostatic origin.</li>
<li>TTF-1 (-), Napsin-A (-): dis-favor pulmonary origin.</li>
</ul></li>
</ul></li>
<li>2021-06-22 Tc-99m bone scan
<ul>
<li>increased activity in the middle T-spines and L4 spine. either
degenerative change or bone metastases may show this picture.</li>
<li>multiple hot spots in the sternum and bilateral rib cages and mildly
increased activity in bilateral femoral trochanters.</li>
</ul></li>
<li>2021-06-24 colonoscopy: sigmoid colon cancer without obstruction,
20cm above AV</li>
<li>2021-06-25 Patho, colon biopsy: adenocarcinoma, IHC stains: EGFR
(+); PMS2 (+), MSH6 (+), MSH2(+), MLH1 (+).</li>
</ul>
<p>[disease extent]</p>
<ul>
<li>2021-06-21 CT, ABD: T3N2aM1c, stage IVC</li>
</ul>
<p>[treatment/plan]</p>
<ul>
<li>lab data on 2021-06-25 indicate past hepatitis B infection and being
protected against the hepatitis B virus now.
<ul>
<li>Anti-HBc Reactive</li>
<li>Anti-HBs &gt;1000mIU/mL</li>
<li>HBsAg Nonreactive</li>
<li>AntiHCV Nonreactive</li>
</ul></li>
<li>EGFR (+)
<ul>
<li>anti-EGFR agent e.g.cetuximab or panitumumab might be indicated,
KRAS/NRAS test is recommended.</li>
</ul></li>
<li>PMS2 (+), MSH6 (+), MSH2(+), MLH1 (+)
<ul>
<li>MMR proficient, pembrolizumab might not be indicated.</li>
</ul></li>
<li>BRAF (V600E) not found in lab data, not sure if
vemurafenib/dabrafenib should be applicable.</li>
<li>being having bone mets and no obstruction in colon, systemic (chemo)
therapy e.g.bevacizumab plus FOLFOX might be considered.</li>
</ul>
<p>[effect and side effect]</p>
<ul>
<li>2021-06-25
<ul>
<li>CEA 111ng/mL</li>
<li>CA199 709U/mL</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<p><pain></p>
<ul>
<li>managed with neurontin (gabapentin), tramacet (tramadol,
acetaminophen)</li>
</ul>
<p><hypertension></p>
<ul>
<li>managed with concor (bisoprolol), atanaal (nifedipine), zanidip
(lercanidipine), hyzaar (losartan, hydrochlorothiazide)</li>
<li>above normal range but no excess 200/110 during this
hospitalization.</li>
</ul>
<p><hyperlipidemia></p>
<ul>
<li>managed with pravafen (pravastatin, fenofibrate)</li>
<li>last lab data was reported in 2020 Sep, might need to be
updated.</li>
</ul>
<p>&lt;diabetes mellitus, type 2&gt;</p>
<ul>
<li>managed with forxiga (dapagliflozin)</li>
<li>stable than 3 months ago.</li>
</ul>
</div>
</div>
<div id="section-32" class="section level1">
<h1>700070771</h1>
<div id="section-33" class="section level2">
<h2>220325</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-12 CT - abdomen, pelvis
<ul>
<li>S/P liver and colon operation. No evidence of tumor recurrence.</li>
</ul></li>
<li>2022-02-07 SONO - abdomen
<ul>
<li>Post-op at right lobe liver. Calcified spot in the liver.<br />
</li>
<li>Right renal cyst.</li>
<li>Left renal stone.</li>
</ul></li>
<li>2011-11-04 CT - abdomen, pelvis
<ul>
<li>S/P liver and colon operation. Some fluid and air collection at
right subphrenic region. Bil. pleural effusion with adjacent lung
collapse.</li>
</ul></li>
<li>2021-10-29 Patho - liver partial resection
<ul>
<li>Liver, S6-7, segmental hepatectomy  Metastatic adenocarcinoma,
consistent with colonic primary<br />
</li>
<li>Tumor regression grade: Grade 4/5 (cancer cells &gt; fibrosis)</li>
</ul></li>
<li>2021-09-22 CT - abdomen, pelvis
<ul>
<li>S/P right hemicolectomy. There is no evidence of tumor
recurrence.</li>
<li>Two metastasis in S7 and S4 S/P C/T show partial response.</li>
<li>A newly-developed metastasis or flow artifact 0.5 cm in S6 liver is
suspected.</li>
</ul></li>
<li>2021-05-20 NRAS/KRAS, BRAF not detected</li>
<li>2021-05-17 MRI - liver, spleen
<ul>
<li>Two poor enhancing tumors (0.4cm, 2.6cm) in S8 of liver suspected
metastases.</li>
</ul></li>
<li>2021-04-28 Patho - colon segmental resection for tumor
<ul>
<li>Pathologic diagnosis
<ul>
<li>Tumor, ascending colon, SILS Rt hemicolectomy  Adenocarcinoma</li>
<li>Resection margins, bilateral, ditto  Free from tumor invasion</li>
<li>Lymph node, mesocolic, dissection  Free from tumor metastasis
(0/23)<br />
</li>
<li>Appendix, excision  Fecalith and free from tumor<br />
</li>
<li>AJCC pathologic stage  pT3N0, cM1a, compatible with stage IVA</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histology: adenocarcinoma<br />
</li>
<li>Histology Grade: G2: moderately differentiated<br />
</li>
<li>Depth of invasion: pericolonic fat<br />
</li>
<li>Angiolymphatic invasion: Present<br />
</li>
<li>Perineural invasion: Present<br />
</li>
<li>Discontinuous extramural tumor extension: NOT present<br />
</li>
<li>Circumferential (radial) margin of rectosigmoid: NOT involved<br />
</li>
<li>Lymph node metastasis, mesocolic: free from tumor metastasis
(0/23)<br />
</li>
<li>Lymph node metastasis, IMA / SMA: N/A<br />
</li>
<li>Extranodal involvement: N/A<br />
</li>
<li>Pathological TNM Stage: pT3N0, but cM1a (liver meta), compatible
with stage IVA<br />
</li>
<li>Type of polyp in which invasive carcinoma arose: N/A<br />
</li>
<li>Additional pathologic findings: focal necrosis and abscess<br />
</li>
<li>TNM descriptors: N/A<br />
</li>
<li>Tumor regression grading S/P CCRT: N/A<br />
</li>
</ul></li>
</ul></li>
<li>2021-04-22 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the proxinal portion of the ascending
colon and some adjacent lymph nodes, compatible with primary colon
malignancy with some adjacent lymph node metastases.</li>
<li>A glucose hypermetabolic lesion in the segment 7 of the liver. A
metastatic lesion may show this picture.</li>
<li>Mild glucose hypermetabolism in bilateral pulmonary hilar regions.
Inflammatory process may show this picture.</li>
</ul></li>
<li>2021-04-19 CT - abdomen, pelvis
<ul>
<li>T3N2aM1a, stage IVA</li>
</ul></li>
<li>2021-04-16 Patho - colorectal polyp
<ul>
<li>Colon, ascending, biopsy  Adenocarcinoma.</li>
<li>IHC: EGFR(focal +); PMS2(+), MSH6(+), MSH2(+), MLH1(+).</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-28 laparoscope S6-7 resection
<ul>
<li>solid tumor at S7</li>
<li>suspected small nodule at S6.</li>
</ul></li>
<li>2021-04-28 SILS Right-hemicolectomy
<ul>
<li>Adenocarcinoma of ascending colon, cT3N2aM1a (liver mets) stage
IVa</li>
<li>Huge tumor with tissue edema suspecting as T4 lesion.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2021-06 ~ ongoing - FOLFIRI plus bevacizumab since</li>
</ul></li>
<li>initial presentation
<ul>
<li>unintentional body weight loss 6 kgs in half year before diagnosed
with cancer.</li>
<li>exertional dyspnea and intermittent right abdomen pain were noted
without bowel habit change.</li>
<li>iOFBT(+)</li>
</ul></li>
<li>underlying disease
<ul>
<li>type 2 diabetes</li>
<li>chronic hepatitis B</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Patient with colon cancer with liver mets after SILS right
hemicolectomy (2021-04-28) and liver S6/S7 resection (2021-10-28) is
receiving FOLFIRI plus bevacizumab since June 2021. Recent CT
(2022-02-12) and SONO (2022-02-07) have revealed no signs of
recurrence.</li>
<li>Lab results reported on 2022-03-15 indicated no abnormality in liver
or kidney functions, but a slight pancytopenia was detected. The lower
blood counts should not affect the application of chemoimmunotherapy
during this hospital stay.</li>
<li>Chronic hepatitis B and type 2 diabetes are managed with
corresponding drugs.</li>
<li>No issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-34" class="section level1">
<h1>700072194</h1>
<div id="section-35" class="section level2">
<h2>220110</h2>
<p>[Teicoplanin Dose]</p>
<p>blood creatinine readings reported:</p>
<p>2022-01-10 1.64mg/dL 2022-01-08 1.83mg/dL 2022-01-06 1.72mg/dL
2022-01-03 1.31mg/dL</p>
<p>teicoplanin has been administered since 2022-01-06, the elevated
serum creatinine maintains stable for half week, no dose adjustment
needed for now, keep monitoring renal function as regular.</p>
</div>
</div>
<div id="section-36" class="section level1">
<h1>700072580</h1>
<div id="section-37" class="section level2">
<h2>210512</h2>
<p>{post IPP meeting following up}</p>
<ul>
<li><p>the schedule with regimen for PBSCT for the patient is disclosed
in the meeting.</p></li>
<li><p>the estimated total amount of busulfan used in the time table is
15 vials.</p>
<ul>
<li>based on busulfan 60mg/10mL/vial, dose 3.2mg/kg, body weight
85kg</li>
<li>5 vials per day for 3 days (2021-05-12, 2021-05-13, 2021-05-14)</li>
<li>pharmacy staff in charge of drug purchasing will get the inventory
ready before the coming prescribing.</li>
</ul></li>
<li><p>people for dispensing regimen during weekend are also
arranged.</p></li>
<li><p>preparation and administration precautions:</p>
<ul>
<li>busulfan:
<ul>
<li>do not use polycarbonate syringes or polycarbonate filter needles
with the drug.</li>
</ul></li>
<li>etoposide:
<ul>
<li>precipitation may be exacerbated at concentrations of 0.4 mg/mL or
above.</li>
<li>etoposide 400mg/m2 x body surface area 2m2 -&gt; amount 800mg.</li>
<li>total solution containing 800mg etoposide will be no less than
2000mL.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-38" class="section level1">
<h1>700073358</h1>
<div id="section-39" class="section level2">
<h2>220119</h2>
<ul>
<li><p>no drug allergy recorded in database.</p></li>
<li><p>CBC reported on 2022-01-18 showed items below normal ranges:</p>
<ul>
<li>WBC 2.96*10^3/uL</li>
<li>RBC 3.47*10^6/uL</li>
<li>HGB 11.8g/dL</li>
</ul></li>
<li><p>no liver or kidney dysfuncion shown in recent lab data.</p></li>
<li><p>the drugs prescribed at neurology OPD have been included in
active medication, no issue found.</p></li>
</ul>
</div>
</div>
<div id="section-40" class="section level1">
<h1>700081580</h1>
<div id="section-41" class="section level2">
<h2>999999</h2>
<p>[initial presentation]</p>
<ul>
<li>2021-07-15 left inguinal mass for 3 weeks refer from LMD.</li>
<li>2021-07-16 CT - abdomen, pelvis:
<ul>
<li>a well-defined soft tissue mass measuring 2.6 x 2.3 cm in left
inguinal area.</li>
<li>differential diagnosis include undescended testis.</li>
</ul></li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2021-07-28 patho - lymph node regiion resection:
<ul>
<li>labeled as inguinal tumor, tumor excision - in situ follicular
neoplasm.
<ul>
<li>IHC stains: CD3 and CD20: a predominant B cell subpopulation;</li>
<li>bcl-2 (+), bcl-6 (+), CD10 (+) of the follicules.<br />
</li>
<li>CD23 (-), cyclin-D (-).<br />
</li>
</ul></li>
<li>sections show lymph node with proliferative lymphocytes
deminstrating pseudofollicles.</li>
</ul></li>
</ul>
<p>[disease extent]</p>
<ul>
<li>2021-08-10 CT - abdomen, pelvis:
<ul>
<li>only one enhanced lymph node at left inguinal region.</li>
<li>the rest of the body part is free of lymphadenopathy.</li>
</ul></li>
</ul>
<p>[plan &amp; treatment]</p>
<p>[effect &amp; side effect]</p>
<p>[ongoing problem]</p>
</div>
<div id="section-42" class="section level2">
<h2>210810</h2>
<p>{renal glucosuria?}</p>
<p>[objective]</p>
<ul>
<li>2021-07-27 lab data:
<ul>
<li>urine glucose 4+</li>
<li>urine bacteria 1+</li>
<li>serum glucose 103mg/dL</li>
</ul></li>
<li>creatinine WNL:
<ul>
<li>2021-08-08 0.83mg/dL</li>
<li>2021-07-27 0.74mg/dL</li>
<li>2021-07-15 0.85mg/dL</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>patients with renal glycosuria, glucose is excreted in the urine in
the presence of normal or low concentrations of blood glucose.</li>
<li>there is a lowered renal threshold to glucose and, in some cases, a
reduction in the rate at which the renal tubules are able to reabsorb
glucose.</li>
<li>in most affected individuals, renal glycosuria is a benign
condition, resulting in no apparent symptoms. however, in some cases,
glycosuria may be pronounced enough to result in excessive urination
(polyuria), excessive thirst (polydipsia), and other associated
symptoms.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>if any symptomatic sign is observed, appropriate testing should be
conducted to rule out diabetes and to regularly monitor those with
confirmed renal glycosuria.</li>
<li>genetic counseling will be of benefit for affected individuals and
their families. other treatment for this condition is symptomatic and
supportive.</li>
</ul>
</div>
</div>
<div id="section-43" class="section level1">
<h1>700098157</h1>
<div id="section-44" class="section level2">
<h2>220106</h2>
<p>High Serum glucose 235mg/dL (2022-01-05), Lactic Acid 4.9mmol/L
(2022-01-06), NAKO NO.5 500mL IVD BID and Saline 500mL IVD QD are
prescribed.</p>
<p>High CRP 13.47mg/dL (2022-01-05), Procalcitonin (PCT) 8.37ng/mL
(2022-01-06) suggest (probable bacterial) infectious process with
systemic consequences. Tapimycin and Targocid are prescribed.</p>
</div>
</div>
<div id="section-45" class="section level1">
<h1>700105459</h1>
<div id="section-46" class="section level2">
<h2>220223</h2>
<p>{SCC of tongue, cT4N1M0, s/p total glossectomy, right mandibular
osteotomy, right marginal mandibulectomy, selective neck dissection,
wide excision of malignant left lower gum SCC and marginal
mandibulectomy, teeth extraction of #46, tracheotomy and free flap
reconstruction}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-02-10 CT - Lung/Mediastinum/Pleura
<ul>
<li>Impression: Bilateral lung meta, in progression.</li>
<li>S/p tracheal tube placement with its tip in place.</li>
<li>S/P NG tube placement.</li>
</ul></li>
<li>2021-10-25 Chect PA (Erect) view
<ul>
<li>Few nodular opacity projecting in the right upper and left lower
lung is noted.</li>
</ul></li>
<li>2021-10-22 CT - Lung/Mediastinum/Pleura
<ul>
<li>Right upper lobe and left lower lobe lung meta.</li>
<li>Recurrent lymphadenopathy at right level II and level III and left
parapharyngeal space.</li>
</ul></li>
<li>2021-10-19 CT - Neck
<ul>
<li>Status post tracheostomy.</li>
<li>Postoperative change in the oral cavity and neck, and
post-irradiation change.</li>
<li>Suspect tumor recurrence or infection at left parapharyngeal space
involving medial pterygoid muscle.</li>
<li>Necrotic nodal recurrence at right level II and left level III.</li>
<li>RUL nodule (2.1cm), suspect lung metastasis.</li>
</ul></li>
<li>2021-10-18 LN aspiration
<ul>
<li>Left neck mass: Positive for malignancy
<ul>
<li>Two wet smears show multiple dysplastic sqaumous cell clusters,
compatible with metastatic squamous cell carcinoma.</li>
</ul></li>
</ul></li>
<li>2021-08-16 Patho - oral cancer (wide excision + lymph node)
<ul>
<li>pathologic diagnosis
<ul>
<li>Tongue, total glossectomy - Moderately differentiated squamous cell
carcinoma</li>
<li>Oral cavity, right retromolar region, right marginal mandibulectomy
- Moderately differentiated squamous cell carcinoma</li>
<li>Oral cavity, left mandible region, wide excision - Severe dysplasia
with ulcer</li>
<li>Pathology stage: pT4a(m)N0(if cM0); AJCC stage IVA</li>
</ul></li>
</ul></li>
<li>2021-08-03 PET
<ul>
<li>Glucose hypermetabolism in the left aspect of the tonge with
invasion to the mouth floor and left aspect of soft palate, compatible
with malignancy involving these regions.</li>
<li>Glucose hypermetabolism in the some left neck level II, left
submandibular and left level IV lymph nodes, compatible with metastatic
lymph nodes.</li>
<li>Mild glucose hypermetabolism in some right neck level II and right
submandibular lymph nodes. The nature is to be determined (inflammatory
process? other nature?).</li>
<li>Glucose hypermetabolism in a focal area in the right aspect of
mandible. The nature is to be determined (dental problem? other
nature?).</li>
<li>Glucose hypermetabolism in the right shoulder and in the right
pulmonary hilar region, compatible with inflammatory process.</li>
</ul></li>
<li>2021-08-02 Patho - Gingival/oral mucosa biopsy
<ul>
<li>Labeled as left lateral tongue, biopsy - squamous cell
carcinoma.</li>
<li>IHC: P16(-, 0%); p40(+).</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>SCC
<ul>
<li>2022-02-08 5.7ng/mL</li>
<li>2021-08-04 6.1</li>
<li>2021-08-03 5.8</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-08-13
<ul>
<li>Total glossectomy</li>
<li>R mandibular osteotomy</li>
<li>R marginal mandibulectomy</li>
<li>Selective neck dissection</li>
<li>Wide excision of malignant L lower gum SCC+ marginal
mandibulectomy</li>
<li>Extraction of #46 (at anterior margin of skip L lower gum SCC)</li>
<li>Tracheotomy</li>
<li>Free left anterolateral thigh flap resurfacing to the intra-oral
defect</li>
<li>Open reduction of mandible and internal fixation with reconstruction
plates</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-10-04 ~ 2021-11-22: bil. neck 50Gy/25fx. The tongue preOP tumor
site: 66Gy/33fx. The gross LAPs: 70Gy/35fx</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-03 ~ ongoing: 5-Fu + cisplatin + cetuximab, biweekly</li>
<li>2021-10-27 ~ 2021-11-22: cisplatin weekly</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-47" class="section level1">
<h1>700126665</h1>
<div id="section-48" class="section level2">
<h2>220427</h2>
<p>{synchronous double (breast and colon) primary tumors s/p MRM s/p
hemicolectomy}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-03-16 CT - abdomen, pelvis
<ul>
<li>Liver metastases S/P C/T show progressive disease.</li>
<li>Mechanical small bowel obstruction is noted. However, the transition
zone is hard to identify. The differential diagnosis include tumor
seeding or adhesion.</li>
<li>A soft tissue nodule 5 mm in LUQ omentum is noted that may be tumor
seeding. Ascites in right subphrenic space and Morison pouch.</li>
</ul></li>
<li>2022-02-08 ultrasound - abdomen
<ul>
<li>Hepatic tumor, nature to be determinated</li>
<li>Hepatic cyst, GB stone</li>
</ul></li>
<li>2022-01-20 esophagogastroduodenoscopy
<ul>
<li>suspected gastric intestinal metaplasia, antrum and low body, s/p
biopsy at antrum, GC</li>
</ul></li>
<li>2021-11-30 CT - ABD
<ul>
<li>Post-op at the colon and small bowel loops.</li>
<li>RLQ peritoneal soft tissue tumors, suspected carcinomatosis.</li>
<li>Newly developed liver tumors, suspected liver metastasis.</li>
<li>Liver and renal cysts.</li>
</ul></li>
<li>2021-08-03 patho - small intestine resection for tumor
<ul>
<li>mucinous adenocarcinoma, colonic origin</li>
<li>IHC: CK7(-), CK20(+), CDX2(+) and GATA-3(-), colonic origin</li>
</ul></li>
<li>2021-07-27 whole body PET scan
<ul>
<li>two glucose hypermetabolic lesions in the liver, some glucose
hypermetabolic lesions in the abdominal cavity and a glucose
hypermetabolic lesion in the umbilicus. metastatic lesions should be
considered first.</li>
</ul></li>
<li>2021-01-20 patho - colon segmental resection for tumor
<ul>
<li>tumor, transverse colon, SILS left hemicolectomy - mucinous
adenocarcinoma - pT3N0 (if cM0), stage IIA</li>
</ul></li>
<li>2021-01-19 patho - breast mastectomy with regional lymph nodes
<ul>
<li>breast, right, modified radical mastectomy - invasive carcinoma.
grade 2.</li>
<li>lymph node, right axilla, lymphadenecomy - metastatic
carcinoma.</li>
<li>pathology stage: pT2 pN2 (if cM0); anatomic stage: IIIA, pathology
prognostic stage: IIIA</li>
</ul></li>
<li>2021-01-12 patho - colorectal polyp
<ul>
<li>adenocarcinoma. IHC stain: EGFR(+); PMS2(+), MSH6(+), MSH2(+),
MLH1(+).</li>
</ul></li>
<li>2020-12-28 patho - lymphnode biopsy
<ul>
<li>axilla, right, core biopsy - invasive carcinoma.</li>
<li>IHC stains: CK (+).</li>
</ul></li>
<li>2020-12-28 patho - breast biopsy (no margin)
<ul>
<li>invasive carcinoma, no special type.</li>
<li>IHC stains: ER (+, strong intensity, 95%), PR(-), Her2/neu: negative
(score=0), Ki-67(&lt;2%).</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-01-18 Rehabilitation
<ul>
<li>Imp
<ul>
<li>Right breast invasive carcinoma with axillary metastasis</li>
<li>Lymphoma 30+ yrs ago</li>
<li>T-colon cancer found in 2020/12</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation and home program
education</li>
<li>Goal: Functional ability ID, maintain ROM, prevent post-OP
complications</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operations
<ul>
<li>2021-08-02 surgical operation
<ul>
<li>local excision abdominal wall tumor + small bowel resection with
anastomosis</li>
</ul></li>
<li>2021-01-19 surgical operation
<ul>
<li>right breast MRM (modified radical mastectomy)</li>
<li>SILS (single incision laparoscopic surgery) left hemicolectomy +
laparoscopic adhesionolysis</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-07-15 ~ -07-30
<ul>
<li>2400cGy/12 fractions (6 MV photon) to rt chestwall and SCF lymph
nodes</li>
</ul></li>
</ul></li>
<li>chemo regimen
<ul>
<li>2022-03-18 ~ undergoing - FOLFOX</li>
<li>2021-11-16 ~ 2022-03-02 - FOLFIRI</li>
<li>2021-08-20, -11-03
<ul>
<li>5-Fu (fluorouracil) + Covorin (leucovorin)</li>
</ul></li>
<li>2021-04-28, -05-19, -05-26
<ul>
<li>Nolbaxol (docetaxel)</li>
</ul></li>
<li>2021-02-02, -02-24, -03-17, -04-08
<ul>
<li>Lipo-Dox (liposome doxorubicin) + Endoxan (cyclophosphamide)</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient admitted to receive FOLFOX treatment, the current
regimen being used since 2022-03-18.</li>
<li>No images have been updated since last hospitalization. The lab data
reported on 2022-04-25 showed slightly elevated levels of BUN (43
mg/dL), creatinine (1.32 mg/dL), bilirubin total (1.26 mg/dL) and
decreased level of potassium (3.2 mmol/L); these results should not
affect the chemotherapy procedure.</li>
<li>TPR 36/106/17, BP 105/59 recorded at 19:50 2022-04-26. Insufficient
blood pressure caused a faster pulse?</li>
<li>Drugs prescribed in the OPD have been put as self-carried items in
the list of active medications.</li>
</ul>
</div>
<div id="section-49" class="section level2">
<h2>220412</h2>
<p>[assessment]</p>
<ul>
<li>A patient with synchronous double primary cancers s/p surgery;
systemic therapy was initially focused on breast cancer from 2021-02 to
2021-05, and then refocused on colon cancer from 2021-08 based on
clinical judgment.</li>
<li>The CEA and CA199 levels have been trending upward from 43ng/mL and
59U/mL (2021-12-13) to 130ng/mL and 83U/mL (2022-04-07) respectively.
Abdominal CT on 2022-03-16 showed progression of liver mets and possible
peritoneal seeding.</li>
<li>As a result of the disease being resistant to FOLFIRI, the regimen
has switched to FOLFOX since 2022-03-18.</li>
<li>Sundowning-like behaviors were observed during last hospital stay
(2022-03-12 ~ 2022-03-31). According to nursing notes, these behaviors
did not occur since this admission.</li>
<li>Lab data reported on 2022-04-06 showed normal liver and kidney
function and no obvious abnormalities with CBC and WBC readings.</li>
</ul>
</div>
<div id="section-50" class="section level2">
<h2>220315</h2>
<ul>
<li>Lab data reported on 2022-03-15 showed stool OB 3+, stool glutamate
dehydrogenase (GDH) positive, Clostridium difficile toxin A/B
negative.</li>
<li>Colonization with nontoxinogenic strains also affords protection.
This observation suggests that the initial colonizing strain may occupy
a microbial niche in the large intestine that is protective against
superinfection with a new toxin-producing C. difficile strain</li>
<li>The antibiotics most frequently implicated in predisposition to C.
difficile infection (CDI) include fluoroquinolones, clindamycin,
penicillins, and cephalosporins.</li>
</ul>
</div>
<div id="section-51" class="section level2">
<h2>220225</h2>
<ul>
<li>no updated exam findings as of last hospitalization
(2022-02-10).</li>
<li>new lab data showed lower serum potassium 3.2mmol/L (reported on
2022-02-22) is treated with 0.298% KCl in NaCl 500mL IVD QD.</li>
<li>neutrophil is just above 1500/uL (WBC 2910/uL, Neutrophil 58%,
2022-02-22) should be regularly monitored.</li>
</ul>
</div>
<div id="section-52" class="section level2">
<h2>220210</h2>
<p>{synchronous double (breast and colon) primary tumors s/p MRM s/p
hemicolectomy}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-02-08 ultrasound - abd
<ul>
<li>Hepatic tumor, nature to be determinated</li>
<li>Hepatic cyst, GB stone</li>
</ul></li>
<li>2022-01-20 esophagogastroduodenoscopy
<ul>
<li>suspected gastric intestinal metaplasia, antrum and low body, s/p
biopsy at antrum, GC</li>
</ul></li>
<li>2021-11-30 CT - ABD
<ul>
<li>Post-op at the colon and small bowel loops.</li>
<li>RLQ peritoneal soft tissue tumors, suspected carcinomatosis.</li>
<li>Newly developed liver tumors, suspected liver metastasis.</li>
<li>Liver and renal cysts.</li>
</ul></li>
<li>2021-08-03 patho - small intestine resection for tumor
<ul>
<li>mucinous adenocarcinoma, colonic origin</li>
<li>IHC: CK7(-), CK20(+), CDX2(+) and GATA-3(-), colonic origin</li>
</ul></li>
<li>2021-07-27 whole body PET scan
<ul>
<li>two glucose hypermetabolic lesions in the liver, some glucose
hypermetabolic lesions in the abdominal cavity and a glucose
hypermetabolic lesion in the umbilicus. metastatic lesions should be
considered first.</li>
</ul></li>
<li>2021-01-20 patho - colon segmental resection for tumor
<ul>
<li>tumor, transverse colon, SILS left hemicolectomy - mucinous
adenocarcinoma - pT3N0 (if cM0), stage IIA</li>
</ul></li>
<li>2021-01-19 patho - breast mastectomy with regional lymph nodes
<ul>
<li>breast, right, modified radical mastectomy - invasive carcinoma.
grade 2.</li>
<li>lymph node, right axilla, lymphadenecomy - metastatic
carcinoma.</li>
<li>pathology stage: pT2 pN2 (if cM0); anatomic stage: IIIA, pathology
prognostic stage: IIIA</li>
</ul></li>
<li>2021-01-12 patho - colorectal polyp
<ul>
<li>adenocarcinoma. IHC stain: EGFR(+); PMS2(+), MSH6(+), MSH2(+),
MLH1(+).</li>
</ul></li>
<li>2020-12-28 patho - lymphnode biopsy
<ul>
<li>axilla, right, core biopsy - invasive carcinoma.</li>
<li>IHC stains: CK (+).</li>
</ul></li>
<li>2020-12-28 patho - breast biopsy (no margin)
<ul>
<li>invasive carcinoma, no special type.</li>
<li>IHC stains: ER (+, strong intensity, 95%), PR(-), Her2/neu: negative
(score=0), Ki-67(&lt;2%).</li>
</ul></li>
</ul></li>
<li>surgical operations
<ul>
<li>2021-08-02 surgical operation
<ul>
<li>local excision abdominal wall tumor + small bowel resection with
anastomosis</li>
</ul></li>
<li>2021-01-19 surgical operation
<ul>
<li>right breast MRM (modified radical mastectomy)</li>
<li>SILS (single incision laparoscopic surgery) left hemicolectomy +
laparoscopic adhesionolysis</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-07-15 ~ -07-30
<ul>
<li>2400cGy/12 fractions (6 MV photon) to rt chestwall and SCF lymph
nodes</li>
</ul></li>
</ul></li>
<li>chemo regimen
<ul>
<li>2021-11-16 ~ ongoing FOLFIRI</li>
<li>2021-08-20, -11-03
<ul>
<li>5-Fu (fluorouracil) + Covorin (leucovorin)</li>
</ul></li>
<li>2021-04-28, -05-19, -05-26
<ul>
<li>Nolbaxol (docetaxel)</li>
</ul></li>
<li>2021-02-02, -02-24, -03-17, -04-08
<ul>
<li>Lipo-Dox (liposome doxorubicin) + Endoxan (cyclophosphamide)</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>synchronous double primary cancers s/p surgical operation
<ul>
<li>systemic therapy had been focused on breast cancer from 2021-02 to
2021-05, then refocused on colon cancer since 2021-08 based on clinical
judgement.</li>
<li>time serial CEA readings trend up slowly from 2021-07-27 25.48ng/mL
to 2022-02-07 66.56ng/mL during last half year.</li>
<li>newly found liver tumor could be another metastatic lesion.</li>
</ul></li>
<li>drugs approved by FDA for both breast cancer and colon cancer
include: 5-FU, capecitabine, pembrolizumab.
<ul>
<li>polyp patho showed pMMR, pembrolizumab might not be indicated.</li>
<li>bevacizumab might be considered if no contraindication.</li>
</ul></li>
<li>EGFR overexpression (up-regulation or amplification) or mutation is
usually associated with progression and resistance of epithelial tumors.
<ul>
<li>reference: Wang Z. ErbB receptors and cancer. Methods Mol Biol.
(2017)1652:3-35. <a href="doi:10.1007/978-1-4939-7219-7_1" class="uri">doi:10.1007/978-1-4939-7219-7_1</a></li>
<li>cetuximab or panitumumab might be considered if no
contraindication.</li>
</ul></li>
<li>liver and kidney functions showed no abnormality based on ALT, AST,
and creatinine reported on 2022-02-07.
<ul>
<li>introduction of irinotecan should not likely to be restricted.</li>
</ul></li>
<li>no drug allergy recorded in database, no issue found in current
medication.</li>
</ul>
</div>
<div id="section-53" class="section level2">
<h2>210908</h2>
<p>{synchronous double (breast and colon) primary tumors s/p MRM s/p
hemicolectomy}</p>
<p>[history]</p>
<ul>
<li>lymphoma at appendix s/p C/T 30+ years ago at Taipei City Hospital
RenAi Branch</li>
</ul>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2020-12-28 patho - breast biopsy (no margin)
<ul>
<li>diagnosis
<ul>
<li>invasive carcinoma, no special type.</li>
<li>IHC stains: ER (+, strong intensity, 95%), PR(-), Her2/neu: negative
(score=0), Ki-67(&lt;2%).</li>
</ul></li>
<li>microscopic description
<ul>
<li>fragments of breast tissue with irregular neoplastic ducts
infiltration.</li>
</ul></li>
</ul></li>
<li>2020-12-28 patho - lymphnode biopsy
<ul>
<li>diagnosis
<ul>
<li>axilla, right, core biopsy - invasive carcinoma.</li>
<li>IHC stains: CK (+).</li>
</ul></li>
<li>microscopic description
<ul>
<li>soft tissue with necrotic neoplastic ducts infiltration.</li>
</ul></li>
</ul></li>
<li>2021-01-12 patho - colorectal polyp
<ul>
<li>diagnosis
<ul>
<li>adenocarcinoma.</li>
<li>IHC stain: EGFR (+); PMS2 (+), MSH6 (+), MSH2(+), MLH1 (+).</li>
</ul></li>
<li>microscopic description
<ul>
<li>colonic tissue with invasive irregular neoplastic glands.</li>
</ul></li>
</ul></li>
<li>2021-01-19 patho - breast mastectomy with regional lymph nodes
<ul>
<li>pathologic diagnosis
<ul>
<li>breast, right, modified radical mastectomy - invasive carcinoma.
grade 2.</li>
<li>lymph node, right axilla, lymphadenecomy - metastatic
carcinoma.</li>
<li>pathology stage: pT2 pN2 (if cM0); anatomic stage: IIIA, pathology
prognostic stage: IIIA</li>
</ul></li>
<li>microscopic examination
<ul>
<li>histologic type: invasive carcinoma with approximtely 20-25%
mucinous component</li>
<li>histologic grade (Nottingham histologic score): grade II (score
6,7)</li>
</ul></li>
</ul></li>
<li>2021-01-20 patho - colon segmental resection for tumor
<ul>
<li>pathologic diagnosis
<ul>
<li>tumor, transverse colon, SILS left hemicolectomy - mucinous
adenocarcinoma</li>
<li>AJCC pathologic stage - pT3N0 (if cM0), stage IIA</li>
</ul></li>
<li>microscopic examination
<ul>
<li>histology: mucinous adenocarcinoma</li>
<li>histology grade: G2, moderately differentiated</li>
<li>depth of invasion: pericolonic fat</li>
<li>angiolymphatic invasion: present</li>
</ul></li>
</ul></li>
<li>2021-07-27 whole body PET scan
<ul>
<li>two glucose hypermetabolic lesions in the liver, some glucose
hypermetabolic lesions in the abdominal cavity and a glucose
hypermetabolic lesion in the umbilicus. metastatic lesions should be
considered first.</li>
</ul></li>
<li>2021-08-03 patho - small intestine resection for tumor
<ul>
<li>pathologic diagnosis
<ul>
<li>tumor, under umbilicus, excision with small bowel resection -
mucinous adenocarcinoma, colonic origin</li>
<li>small intestine, segmental resection - tumor invasion to subserosal
fat</li>
<li>skin, umbilicus, excision - tumor invasion</li>
<li>hard nodule, small intestine, segmental resection - submucosal
hematoma</li>
<li>lymph node, dissection - free from tumor metastasis (0/1)</li>
</ul></li>
<li>microscopic examination
<ul>
<li>histology: mucinous adenocarcinoma. After discussing with surgeon,
it is compatible with carcinomatosis</li>
<li>histology Grade: G2: moderately differentiated</li>
<li>depth of invasion: umbilical skin and subserosal fat of small
bowel</li>
<li>angiolymphatic invasion: present</li>
<li>perineural invasion: present</li>
<li>pathological TNM Stage: compatible with carcinomatosis</li>
<li>IHC: CK7(-), CK20(+), CDX2(+) and GATA-3(-), colonic origin</li>
</ul></li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2021-01-19 surgical operation
<ul>
<li>right breast MRM (modified radical mastectomy)</li>
<li>SILS (single incision laparoscopic surgery) left hemicolectomy +
laparoscopic adhesionolysis</li>
</ul></li>
<li>2021-02-02, -02-24, -03-17, -04-08 chemotherapy
<ul>
<li>Lipo-Dox (liposome doxorubicin) + Endoxan (cyclophosphamide)</li>
</ul></li>
<li>2021-04-28, -05-19, -05-26 chemotherapy
<ul>
<li>Nolbaxol (docetaxel)</li>
</ul></li>
<li>2021-07-15 ~ -07-30 radiotherapy
<ul>
<li>2400cGy/12 fractions (6 MV photon) to rt chestwall and SCF lymph
nodes</li>
</ul></li>
<li>2021-08-02 surgical operation
<ul>
<li>local excision abdominal wall tumor + small bowel resection with
anastomosis</li>
</ul></li>
<li>2021-08-20, -09-06 chemotherapy
<ul>
<li>5-Fu (fluorouracil) + Covorin (leucovorin)</li>
<li>irinotecan and bevacizumab are supposed to be added</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>synchronous double primary cancers s/p surgical operation
<ul>
<li>systemic therapy had been focused on breast cancer from 2021-02 to
2021-05, refocused on colon cancer since 2021-08 based on clinical
judgement.</li>
</ul></li>
<li>drugs approved by FDA for both breast cancer and colon cancer
include: 5-FU, capecitabine, pembrolizumab.
<ul>
<li>polyp patho showed pMMR, pembrolizumab might not be indicated.</li>
</ul></li>
<li>liver and kidney functions showed no obvious abnormality based on
ALT, AST, and creatinine reported on 2021-09-02.
<ul>
<li>introduction of irinotecan should not likely to be restricted
because of hepatic dysfunction.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-54" class="section level1">
<h1>700127430</h1>
<div id="section-55" class="section level2">
<h2>220106</h2>
<p>Objective:</p>
<ul>
<li>Lab data reported on 2021-09-01
<ul>
<li>HBsAg Nonreactive</li>
<li>HBsAg Value 0.36 S/CO</li>
<li>Anti-HBc Reactive</li>
<li>Anti-HBc Value 4.02 S/CO</li>
<li>Anti-HBc IgM Nonreactive</li>
<li>Anti-HBs &gt;1,000mIU/mL</li>
</ul></li>
</ul>
<p>Assessment:</p>
<ul>
<li>Hepatitis B virus might reactivate in the setting of
chemotherapy.</li>
</ul>
<p>Suggestion:</p>
<ul>
<li>Baraclude (Entecavir) might be prescribed prior to next
chemo-dose.</li>
</ul>
</div>
</div>
<div id="section-56" class="section level1">
<h1>700127501</h1>
<div id="section-57" class="section level2">
<h2>220419</h2>
<p>{tube feeding}</p>
<ul>
<li>All oral PPIs should not be ground.</li>
<li>PPIs are easily protonated and therefore unstable at acid pH. In
gastric juice, this would result in inactivation before absorption. This
is why some PPIs are enteric coated. Following absorption, they
partition by ionic trapping into the acidic environment of the parietal
cell cytoplasm, where the unstable sulphonamide/sulphenic acid species
that result from protonation form irreversible disulphide bonds with
cysteine residues in the proton pump.</li>
<li>Pariet FC (rabeprazole 20mg/tab) is film-coated and not intended for
tube feeding. It could be replaced with Takepron (lansoprazole
30mg/tab), Nexium (esomeprazole 40mg/tab) or Dexilant (Dexlansoprazole
60mg/cap), with opening the capsule and pouring out the small granules
into drinking water prior to tube feeding.</li>
</ul>
</div>
<div id="section-58" class="section level2">
<h2>220418</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-30 Esophagogastroduodenoscopy
<ul>
<li>Diagnosis:
<ul>
<li>Reflux esophagitis LA grade A</li>
<li>Superficial gastritis</li>
<li>Gastric erosions, body, GC</li>
<li>Doudenal ulcers with duodenitis, bulb to 3rd portion</li>
<li>Incomplete study of esophagus due to residual food</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Pursue CLO test result</li>
</ul></li>
</ul></li>
<li>2022-03-27 Sacrum &amp; coccyx
<ul>
<li>mild spondylolisthesis at L5-S1</li>
<li>moderate decreased L5/S1 joint space</li>
</ul></li>
<li>2022-03-27 L-spine Lat
<ul>
<li>loss of the natural curvature of the spine</li>
<li>mild spondylolisthesis at L5-S1</li>
<li>severe decreased disc space in the L5/S1 disc</li>
<li>unremarkable change in the paravertebral region</li>
<li>compression racture at T11 vertebral body</li>
</ul></li>
<li>2022-03-27 CT - abdomen, pelvis
<ul>
<li>suspected duodenal perforation</li>
</ul></li>
<li>2022-02-16 CT - lung/mediastinum/pleura
<ul>
<li>breast cancer with hematogeneous and lymphatic metastases in both
lungs, and spine metastasis, and bilateral pleural effusions, in
progression as compared with previous CT on 20210921.</li>
<li>suspect associated with infection or drug toxicity in the
lungs.</li>
</ul></li>
<li>2022-02-15 Chest
<ul>
<li>S/P port-A implantation.</li>
<li>Multiple nodular opacity projecting in the both lung are noted that
may be metastases. Please correlate with CT.</li>
<li>Presence of old fracture(s) at the bil. ribs and right clavicle are
noted that may be bony metastases? Please correlate with CT.</li>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura thickening or effusion?</li>
<li>Atherosclerotic change of aortic arch</li>
</ul></li>
<li>2021-09-21 CT - chest
<ul>
<li>S/P right breast operation. Bil. lung metastases.</li>
<li>Suspected metastases at T10.</li>
</ul></li>
<li>2021-09-10 Chest
<ul>
<li>Port-A catheter inserted into cavo-atrial junction via left
subclavian vein.</li>
<li>Multiple ill-defined nodules of variable sizes and reticular
abndormality throughout in both lungs due to metastases.</li>
<li>A large increased opacity shadow over lateral Rt hemithorax,
extrapulmonary lesion</li>
<li>Absence of medial half of Rt clavicle and focal bone defects at Rt
humeral head</li>
<li>Old fracture of many Lt ribs</li>
<li>Osteoblastic metastasis in spine</li>
</ul></li>
<li>2021-08-16 KUB
<ul>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2021-05-21 CT - lung/mediastinum/pleura
<ul>
<li>S/P mastectomy at right side.</li>
<li>Diffuse lung meta, stationary.</li>
<li>Right humoral head bony invasion. Stable.</li>
<li>Bone mets at lumbar spine</li>
</ul></li>
<li>2021-02-06 CT - lung/mediastinum/pleura
<ul>
<li>Compatible with breast cancer lung meta, stationary in lung
mets.</li>
<li>Bone mets at right clavicle. stable.</li>
</ul></li>
<li>2020-12-14 Pathology - bronchus biopsy
<ul>
<li>Diagnosis
<ul>
<li>Lung, side?, CT-guide biopsy  metastatic breast carcinoma of no
special type<br />
</li>
</ul></li>
<li>Microscopic Description
<ul>
<li>Section shows cores of alveolar lung tissue with irregular
neoplastic glands infiltration.</li>
<li>IHC: GATA3(+) and TTF-1(-). The results are consistent with
metastatic breast carcinoma of no special type.</li>
</ul></li>
<li>Immunohistochemical Study
<ul>
<li>ER (Ab): Positive(95%, strong)<br />
</li>
<li>PR (Ab): Negative<br />
</li>
<li>Her-2/neu (Ab): Negative (1+)<br />
</li>
<li>Ki-67: 20%</li>
</ul></li>
</ul></li>
<li>2020-10-23 CT - lung/mediastinum/pleura
<ul>
<li>Breast cancer with bilatral lung mets and right clavicle mets.</li>
</ul></li>
<li>2020-10-15 CT - brain
<ul>
<li>Mild brain atrophy and intracranial atherosclerotic disease</li>
</ul></li>
<li>2020-09-14 ABR, Auditory brainstem evoked response
<ul>
<li>Rt 60 dB nHL</li>
<li>Lt 55 dB nHL</li>
</ul></li>
<li>2020-03-13 CT - lung/mediastinum/pleura
<ul>
<li>Diffuse lung mets and bone mets. In progression.</li>
</ul></li>
<li>2019-07-17 CT - lung/mediastinum/pleura
<ul>
<li>Breast cancer with lung metastasis with fibrosis, slightly in
progression.</li>
</ul></li>
<li>2018-01-30 CT - lung/mediastinum/pleura
<ul>
<li>Breast cancer with lung metastasis, stationary.</li>
</ul></li>
<li>2017-10-25 CT - lung/mediastinum/pleura
<ul>
<li>Lung metastasis still present.</li>
</ul></li>
<li>2017-03-23 SONO - breast
<ul>
<li>A small right breast calcification.</li>
<li>Post OP with Edema at right axillary region.</li>
<li>Small left breast nodules and cysts.</li>
<li>BI-RADS: 2, Benign findings</li>
</ul></li>
<li>2017-03-21 CT - lung/mediastinum/pleura
<ul>
<li>D/D lung edema and/or pulmonary lymphagitic carcinomatosis.</li>
<li>LVD of heart.</li>
<li>Rt shoulder and arm post treatment change or edema.</li>
</ul></li>
<li>2017-02-17 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the lower C-spine and lower L-spines.
Degenerative change may show this picture. Please correlate with other
imaging modalities for further evaluation.</li>
<li>Increased activity in the maxilla. Dental problem and/or sinusitis
may show this picture.</li>
<li>Increased activity in the right shoulder, left sternoclavicular
junction, right elbow, right wrist, bilateral knees and right foot.
Either benign joint lesion such as arthritis or post-traumatic change
may show this picture. However, please correlate with other clinical
findings for further evaluation and to rule out other
possibilities.</li>
<li>No prominent bone abnormality was noted elsewhere.</li>
</ul></li>
<li>2008-07-14 CT
<ul>
<li>bilateral multiple pulmonary metastasis</li>
<li>pT2N2M1, stage IV</li>
</ul></li>
<li>2008-06 Pathology
<ul>
<li>Infiltrating ductal carcinoma, grade II with pectoralis major muscle
invasion</li>
<li>IHC: ER(+) 5% score 1, PR(+) 20% score 1, Her2(-)</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2008-06-16 MRM at Taipei City Hospital FuYou Branch</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-15 ~ undergoing - ribociclib</li>
<li>2020-12-25 ~ undergoing - exemestane</li>
<li>2017-02-03 ~ 2020-12-18 - letrozole</li>
<li>2008-07-10 ~ 2008-09-16 doxorubicin + cyclophosphamide; (then
docetaxel, letrozole, vinorelbine?)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient was diagnosed with breast cancer (ER+ PR- HER2-,
2020-12-14 pathology, s/p MRM) with lung and spine mets in progress
(2022-02-16 CT) and was treated with exemestane since 2020-12-25, and
with ribociclib since 2022-03-15.</li>
<li>The current regimen (aromatase inhibitor and CDK4/6 inhibitor) is a
treatment of choice for HR+ HER2- postmenopausal recurrent or stage IV
breast cancer.</li>
<li>All the listed underlying health conditions have been managed with
corresponding drugs. As TPR readings remain relatively stable, blood
sugar readings fluctuate at a higher range, which should be
addressed.</li>
<li>Kisqali (ribociclib) prescribed at 2022-04-15 OPD has been filled to
2022-04-29. Severe, life-threatening, and/or fatal interstitial lung
disease (ILD) and/or pneumonitis may occur with ribociclib (and other
cyclin-dependent kinase inhibitors). Symptoms of ILD/pneumonitis may
include hypoxia, cough, dyspnea, or interstitial infiltrates on
radiologic exam. (exclude infectious, neoplastic, and other causes for
pulmonary toxicity.) Kisqali (ribociclib) is currently suspended.</li>
</ul>
</div>
</div>
<div id="section-59" class="section level1">
<h1>700130863</h1>
<div id="section-60" class="section level2">
<h2>999999</h2>
<p>[definite diagnose, disease extent, effect]</p>
<ul>
<li><p>2021-06-09 patho - peritoneum biopsy</p>
<ul>
<li>pathologic diagnosis: tumor, Rt diaphragm, biopsy  metastatic
colonic adenocarcinoma.</li>
<li>metastatic adenocarcinoma characterized by glandular tumor cells
infiltrating with desmoplasia.</li>
<li>IHC stains CK7(-), CK20(+), CDX2(+) and TTF-1(-) indicated
metastatic colonic adenocarcinoma.</li>
</ul></li>
<li><p>2021-05-31 CT - whole abdomen, pelvis</p>
<ul>
<li>multiple metastases at peritoneal cavity.</li>
</ul></li>
<li><p>2021-05-17 PET - whole body</p>
<ul>
<li>Glucose-hypermetabolism in the right mediastinal lymph nodes,
probably recurrent lung cancer with regional lymph nodes
involvement.<br />
</li>
<li>Glucose-hypermetabolism in the left mediastinal lymph nodes and left
pulmonary hilar lymph nodes, probably reactive nodes or recurrent lung
cancer with regional lymph nodes involvement.<br />
</li>
<li>Glucose-hypermetabolism in bilateral adrenal regions, probably
recurrent lung cancer with bilateral adrenal glands metastases.</li>
<li>Glucose-hypermetabolism in peritoneal lymph nodes in the epigastric
region, right hypochondriac region, and bilateral lumbar regions of
abdomen, probably recurrent colon cancer with peritoneal
metastases.<br />
</li>
<li>S-colon cancer s/p treatment with tumor recurrence, rcTxNxM1c, stage
IVC; right lung cancer s/p treatment with tumor recurrence, rcTxN2-3M1c,
stage IVB.</li>
</ul></li>
<li><p>2021-05-14 MRI - cholangiography</p>
<ul>
<li>multiple cysts on both hepatic lobes.</li>
<li>no focal lesion in the pancreas.</li>
</ul></li>
<li><p>2021-04-07 CT - lung/mediastinum/pleura</p>
<ul>
<li>post treatment change in Rt hemithorax. no new lung nodule or
metastatic lung tumor.</li>
<li>compared with CT dated on 2020-03-19
<ul>
<li>Lungs: s/p right upper lobe lobectomy.
<ul>
<li>a linear opacity in LUL, may be a fibrotic scar.</li>
<li>linear opacities in archiectural distorted RML and superior aspect
of RLL due to fibrosis.</li>
</ul></li>
<li>Mediastinum: no enlarged LN or mass.</li>
<li>Pleura: a small loculated Rt apical effusion with parietal pleural
thickening.</li>
<li>Visible abdominal contents: Hyperplasia of left adrenal gland
multiple hepatic cysts up to 2.6 cm (longest axial diamter).</li>
<li>Visualized bones: marginal spurs of vertebrae.</li>
</ul></li>
</ul></li>
<li><p>2020-11-05 CT - whole abdomen, pelvis</p>
<ul>
<li>s/p right upper lung operation. some encapsulated fluid collection
at RUL.</li>
<li>colon cancer s/p operation.</li>
</ul></li>
<li><p>2020-09-25 thyroid sonography: no detectable local recurrent
tumor mass of bilateral thyroid bed.</p></li>
<li><p>2020-06-23 CT - whole abdomen, pelvis</p>
<ul>
<li>post-op at the colon.</li>
<li>liver cysts and renal cysts.</li>
<li>loculated effusion in right lung apex.</li>
</ul></li>
<li><p>2020-05-26 patho - thyroid total: nodular goiter</p></li>
<li><p>2020-04-10 thyroid sonography: multiple, main tumor, solid
tumor</p></li>
<li><p>2020-03-19 CT - lung/pleura</p>
<ul>
<li>s/p right upper lobe lobectomy. no evidence of recurrent tumor in
the study.</li>
</ul></li>
<li><p>2020-02-15 CT - liver, spleen, biliary duct</p>
<ul>
<li>post-op at the colon.</li>
<li>liver cysts.</li>
</ul></li>
<li><p>2019-10-01 patho</p>
<ul>
<li>lung, right upper lobe, lobectomy  Minimally invasive
adenocarcinoma<br />
</li>
<li>lymph nodes, group 2+4, 7, 11; RLND  No metastatic carcinoma<br />
</li>
<li>pT1miN0(cMx), Stage IA1 if cM0</li>
</ul></li>
<li><p>2019-09-12 patho</p>
<ul>
<li>sigmoid colon, LAR  adenocarcinoma, moderately differentiated</li>
<li>proximal &amp; distal cutting ends, ditto  free of tumor
invasion</li>
<li>lymph node, mesocolic, dissection  positive for tumor metastasis
(4/16) with extracapsular extension (3/4)</li>
<li>pT4bN2aMx, stage IIIC at least</li>
</ul></li>
<li><p>2019-09-02 CT - liver, spleen, iliary duct</p>
<ul>
<li>s-colon cancer</li>
<li>cT3N2aMx</li>
</ul></li>
<li><p>2019-08-29 PET - whole body</p>
<ul>
<li>a glucose hypermetabolic lesion in the sigmoid colon, compatible
with colon malignancy.</li>
<li>a faint glucose hypermetabolic lesion in the upper lobe of right
lung. the nature is to be determined (inflammatory process? malignancy
of faint FDG uptake? other nature?)</li>
<li>glucose hypermetabolism in the right pulmonary hilar region. the
nature is to be determined.</li>
<li>mild glucose hypermetabolism in the left lobe of the thyroid gland.
benign thyroid lesion may show this picture. further evaluation to rule
out the possibility of thyroid malignancy of low FDG uptake.</li>
</ul></li>
<li><p>2019-08-26 surgical pathology</p>
<ul>
<li>colon cancer</li>
<li>IHC stains: EGFR (+); PMS2 (+), MSH6 (+), MSH2(+), MLH1 (+).</li>
</ul></li>
<li><p>2019-08-26 CT - lung cancer screening</p>
<ul>
<li>fibrotic change at both apical lungs.</li>
<li>RUL part solid nodule seems stationary compared with CT on
2018-08-15, favors malignant nodule, suggest surgical removal or tissue
sampling for histolopathological diagnosis.</li>
<li>thyroid goiter or tumor.</li>
</ul></li>
<li><p>2019-08-26 echo - liver, gall bladder, pancreas, spleen</p>
<ul>
<li>there are several hepatic cysts on both lobe</li>
</ul></li>
<li><p>2019-08-26 colon fiberoscopy</p>
<ul>
<li>colon cancer, sigmoid colon or rectosigmoid junction with stenosis
s/p biopsy</li>
<li>mixed hemorrhoid</li>
</ul></li>
<li><p>2018-08-15 CT - mediastinum</p>
<ul>
<li>ground-glass nodule, RUL, fibrotic change at LUL and RUL.</li>
<li>thyroid mass or goiter.</li>
</ul></li>
<li><p>2017-02-13 surgical pathology - gastric polyp, fundus, biopsy:
hyperplastic polyp, benign</p></li>
<li><p>2017-02-09 kidney ultrasound - left renal cyst</p></li>
</ul>
<p>[treatment] - 2019-09-11 op - laparoscopic anterior resection and
enterolysis - 2019-09-30 op - radical lymph node dissection -
peribronchial lymph nodes - thereafter CCRT 5040cGy/2frac until
2019-11-14 - FOLFOX 2019-12 ~ 2020-04</p>
<ul>
<li>2020-05-26 Lt lobectomy + right partial thyroidectomy
<ul>
<li>thereafter applied FOLFIRI up to now</li>
</ul></li>
<li>2021-06-09 laparoscope Rt diaphram tumor ecision - HIPEC with
Oxalip 300mg/m2 for 60mins</li>
</ul>
<p>210813</p>
<p>{loss of appetite}</p>
<p>visiting the patient (with her daughter accompanied) at around 16:20
on 2021-08-13.</p>
<p>[subjective] - the patient does not feel like to eat these days.</p>
<p>[objective] - poor appetite, not eat much. - cachexia still in
problem list.</p>
<p>[assessment] - chemo not applied yet since this hospitalization, not
chemo induced poor appetite for sure, could be psychogenic. -
psychological counselor had visited the patient on 2021-08-09. - some
appetite stimulant could be of help.</p>
<p>[suggestion] - Megejohn (megestrol 160mg/tab) PO QD could be an
option to serve as appetite stimulant. - dronabinol and oxandrolone are
not available in the hospital.</p>
</div>
<div id="section-61" class="section level2">
<h2>220311</h2>
<p>the last exam report is dated on 2021-12-23, no updated image; CEA,
CA199 readings remain stable around 9ng/mL, 53U/mL, respectively; most
WBC and CBC items and all the liver, kidney function tests (reported on
2022-03-09) were in normal range; the systolic blood pressure was
slightly higher (159mmHg) at 13:14 2022-03-11.</p>
<p>the underlying diseases are treated with the drugs in the current
medication list without issue.</p>
</div>
<div id="section-62" class="section level2">
<h2>220208</h2>
<p>{S-colon cancer, cT3N2aM0 s/p laparoscopic anterior resection and
enterolysis on 2019-09-11 s/p post-Op adjuvant chemotherapy FOLFOX
finishing in 2020-04 with periotneal seeding s/p laparoscope rt diaphram
tumor excision 2021-06-09}</p>
<p>[objective]</p>
<ul>
<li>lab findings
<ul>
<li>2021-12-03 CT
<ul>
<li>Multiple omentum metastases S/P C/T show stable disease.</li>
</ul></li>
<li>2021-09-03 CT
<ul>
<li>Multiple omentum metastases S/P C/T show stable disease.</li>
<li>Metastasis or post-operative change in left upper pelic wall?</li>
</ul></li>
<li>2021-06-09 Patho - colon ca s/p at 2018 with intraabd recurrent,
including bilat diaphragm, T-colon stomach surface and rt liver surface
<ul>
<li>Tumor, Rt diaphragm, biopsy - Metastatic colonic
adenocarcinoma</li>
<li>IHC: CK7(-), CK20(+), CDX2(+) and TTF-1(-) for tumor.</li>
<li>IHC: EGFR (+, weakly); PMS2 (+), MSH6 (+), MSH2(+), MLH1 (+)</li>
<li>According to clinical information and above histopathologic
findings, it indicated a case of metastatic colonic adenocarcinoma.</li>
</ul></li>
<li>2021-05-31 CT - whole abdomen, pelvis
<ul>
<li>Imp: S/P colon operation. Multiple metastases at peritoneal
cavity.</li>
</ul></li>
<li>2021-05-17 Whole body PET scan
<ul>
<li>Glucose-hypermetabolism in the right mediastinal lymph nodes,
probably recurrent lung cancer with regional lymph nodes
involvement.<br />
</li>
<li>Glucose-hypermetabolism in the left mediastinal lymph nodes and left
pulmonary hilar lymph nodes, probably reactive nodes or recurrent lung
cancer with regional lymph nodes involvement.<br />
</li>
<li>Glucose-hypermetabolism in bilateral adrenal regions, probably
recurrent lung cancer with bilateral adrenal glands metastases.</li>
<li>Glucose-hypermetabolism in peritoneal lymph nodes in the epigastric
region, right hypochondriac region, and bilateral lumbar regions of
abdomen, probably recurrent colon cancer with peritoneal
metastases.<br />
</li>
<li>S-colon cancer s/p treatment with tumor recurrence, rcTxNxM1c, stage
IVC (AJCC 8th ed.); right lung cancer s/p treatment with tumor
recurrence, rcTxN2-3M1c, stage IVB (AJCC 8th ed.), by this F-18 FDG PET
scan.</li>
</ul></li>
<li>2021-05-14 MRI - MR Cholangiography (MRCP)
<ul>
<li>Imp: Multiple cysts on both hepatic lobes.</li>
</ul></li>
<li>2019-08-26 CT - lung cancer screening (Low-dose CT)
<ul>
<li>Imp: RUL lung cancer TmiNOMO stage IA1</li>
</ul></li>
<li>2019-10-09 Patho - Uterus, cervix, biopsy
<ul>
<li>Chronic cervicitis with reactive aypia</li>
<li>IHC, the epithelial cells are negative for p16 and ki-67
proliferation index &lt;5%.</li>
</ul></li>
<li>2019-10-01 Patho - Lung, right upper lobe, lobectomy
<ul>
<li>Minimally invasive adenocarcinoma<br />
</li>
<li>Lymph nodes, group 2+4, 7, 11; RLND - No metastatic carcinoma<br />
</li>
<li>pTNM Pathology stage: pT1miN0(cMx), Stage IA1 if cM0</li>
</ul></li>
<li>2019-09-12 Patho - Malignant sigmoid colon neoplasm
<ul>
<li>Sigmoid colon, LAR - Adenocarcinoma, moderately differentiated</li>
<li>Lymph node, mesocolic, dissection - Positive for tumor metastasis
(4/16) with extracapsular extension (3/4)</li>
<li>AJCC pathologic stage - pT4bN2aMx, stage IIIC at least</li>
</ul></li>
<li>2019-09-02 CT - liver, spleen, biliary duct
<ul>
<li>T3N2aMx</li>
</ul></li>
<li>2019-08-29 Whole body PET scan
<ul>
<li>A glucose hypermetabolic lesion in the sigmoid colon, compatible
with colon malignancy.</li>
<li>A faint glucose hypermetabolic lesion in the upper lobe of right
lung. The nature is to be determined.</li>
<li>Glucose hypermetabolism in the right pulmonary hilar region. The
nature is to be determined.</li>
<li>Mild glucose hypermetabolism in the left lobe of the thyroid
gland.</li>
</ul></li>
<li>2019-08-26 Patho - colon, sigmoid or rectosigmoid junction, biopsy
<ul>
<li>Ademocarcinoma</li>
<li>IHC: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+).</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-06-09 Laparoscope rt diaphram tumor excision</li>
<li>2020-05-06 Lt lobectomy + right partial thyroidectomy</li>
<li>2019-09-30 Thoracoscopic Lobectomy</li>
<li>2019-09-11 Laparoscopic anterior resection and anastomosis, sigmoid
colon resection, tumor</li>
</ul></li>
<li>medication
<ul>
<li>2021-10 ~ ongoing FOLFIRI + bevacizumab</li>
<li>2021-06 ~ 2021-09 FOLFIRI</li>
<li>2020-01 ~ 2020-04 FOLFOX</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>according to time-serial CT images, CEA, CA199 readings, the disease
remains stable in recent months under current regimen.</li>
<li>no drug allergy recorded in database, no issue found with active
medication.</li>
</ul>
</div>
</div>
<div id="section-63" class="section level1">
<h1>700134931</h1>
<div id="section-64" class="section level2">
<h2>999999</h2>
<p>{colon cancer}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-01-22 RBC 3.42x10^6/uL, HGB 6.6g/dL, blood transfusion pRBC 2U
on 2021-02-12.</li>
<li>2021-02-19 stool occult blood: positive</li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2021-03-15 colonoscopy: probable advanced colon cancer, ascending
colon, ileocecal valve involvement suspected</li>
<li>2021-03-19 patho: adenocarcinoma, IHC stain: EGFR(+), PMS2(-),
MLH-1(-), MSH-2(+), MSH-6(+)</li>
</ul>
<p>[disease extent &amp; staging]</p>
<ul>
<li>2021-03-16 CT, ABD:
<ul>
<li>low density lesions at both lobes of liver is found. liver simple
cysts are considered.</li>
<li>compatible with ascending colon cancer, regional lymphadenopathy,
T2N2aMo -&gt; M1 (with liver mets)</li>
</ul></li>
</ul>
<p>[treatment &amp; plan]</p>
<ul>
<li>biweekly, Q2WK
<ul>
<li>covorin (leucovorin) 400mg/m2, with 250mL N/S, 2hr</li>
<li>5-Fu (fluorouracil) 400mg/m2, with 100mL N/S, 10min</li>
<li>5-Fu (fluorouracil) 2400mg/m2, with 500mL N/S, 46hr</li>
</ul></li>
</ul>
<p>[effect &amp; side effect]</p>
<ul>
<li>NA</li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>chronic ischemic heart disease</li>
<li>type 2 diabetes mellitus</li>
<li>hypercholesterolemia</li>
<li>polyosteoarthritis</li>
</ul>
</div>
</div>
<div id="section-65" class="section level1">
<h1>700142452</h1>
<div id="section-66" class="section level2">
<h2>210915</h2>
<p>{hypoalbuminemia and proteinuria caused by UTI induced nephrotic
syndrome?}</p>
<p>[tube feeding]</p>
<ul>
<li>all the oral drugs in active medication can be administered via NG
tube.</li>
</ul>
<p>[objective]</p>
<ul>
<li>serum Ca 2.03mmol/L 2021-09-15</li>
<li>Creatine kinase-MB 25.7ng/mL 2021-09-14</li>
<li>creatinine 1.67mg/dL 2021-09-14</li>
<li>albumin 2.8g/dL 2021-09-14</li>
<li>CRP 4.87mg/dL 2021-09-14</li>
<li>urine data reported on 2021-09-14
<ul>
<li>PRO 2+</li>
<li>OB 2+</li>
<li>bacteria 3+</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>elevated CKMB reading could mean possible heart muscle damage.
(NT-proBNP 7946pg/mL 2020-02-09)</li>
<li>UTI is treated with Sintrix (Ceftriaxone Na) 1000mg IVD QD since
2021-09-15 for 7 days for now.</li>
<li>in patients with hypoalbuminemia, total serum calcium concentration
will change in parallel to the albumin concentration and may not
accurately reflect the physiologically important ionized (or free)
calcium concentration.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>heart condition might be followed up if no other
considerations.</li>
<li>first priority might be to mitigate UTI, please keep current
medication and monitoring the effects routinely as usual.</li>
<li>urine culture might be of help to choose more adequate antimicrobial
in the coming days.</li>
</ul>
</div>
</div>
<div id="section-67" class="section level1">
<h1>700145757</h1>
<div id="section-68" class="section level2">
<h2>220118</h2>
<p>[objective]</p>
<p>Lab data - Free T4 - 2022-01-14 2.26ng/dL (normal 0.58~1.35) -
2021-10-05 1.94ng/dL - TSH - 2022-01-14 0.027uIU/mL (normal 0.38~5.33) -
2021-10-05 &lt;0.005uIU/mL</p>
<p>PE - body weight - 2022-01-14 65kgw - 2022-01-09 68kgw</p>
<p>Medication - Eltroxin (levothyroxine 50mcg/tab) #1 BIDAC</p>
<p>[assessment]</p>
<ul>
<li>The patient is diagnosed with nontoxic goiter.</li>
<li>Thyroid dysfunction - If the goiter is due to Hashimotos
thyroiditis or severe iodine deficiency, patients may have symptoms of
hypothyroidism (eg, fatigue, constipation, cold intolerance). If due to
multinodular goiter (with autonomy) or Graves disease, patients may
have symptoms of hyperthyroidism (eg, palpitations, dyspnea on exertion,
unexplained weight loss).</li>
<li>Low TSH, high free T4, weight loss reported.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>Eltroxin tapered to QDAC or Q2DAC and then test TSH, free T4 one
week later to check the trend.</li>
</ul>
</div>
</div>
<div id="section-69" class="section level1">
<h1>700148929</h1>
<div id="section-70" class="section level2">
<h2>220406</h2>
<p>{high grade B-cell lymphoma}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-21 MRA - brain
<ul>
<li>Mild Brain atrophy with bilateral periventricular ischemic/aging
white matter change.</li>
</ul></li>
<li>2022-01-28 CT - lung/mediastinum/pleura
<ul>
<li>Minimal left breast soft tissue at lower part, in regression.</li>
<li>LEFT LOWER LOBE nodule. Stable, old insult is favored.</li>
</ul></li>
<li>2021-12-10 MRI - c-spine
<ul>
<li>Degenerative spinal and disc disease.</li>
<li>Herniated disc at posterior central C3-4 level, causing moderate
adjacent spinal cord compression.</li>
<li>Mild C4-5, C5-6, C6-7 spinal cord compression.</li>
<li>Bilateral C4-5, C5-6, C6-7 neuroforaminal narrowing.</li>
</ul></li>
<li>2021-10-12 CT - abdomen, pelvis
<ul>
<li>Residual nodule at left breast, residual tumor activity is
considered.<br />
</li>
<li>No evidence of lymphadenopathy other than left breast.</li>
</ul></li>
<li>2021-06-19 CT - lung/mediastinum/pleura
<ul>
<li>Lymphoma s/p C/T with C/T</li>
<li>Regression of bilateral breast mass with residual mass at left
breast and no visible lymphadenopathy in the current study.</li>
</ul></li>
<li>2021-04-07 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the left nasal cavity, bilateral breasts,
and left lobe of the liver, probably lymphoma with involvement of
multiple extralymphatic organs.<br />
</li>
<li>Glucose hypermetabolism in the right maxilla, bilateral femurs,
tibiae, and left fibia, probably lymphoma with involvement of the bone
marrows.<br />
</li>
<li>Increased FDG accumlation in bilateral renal pelvis and colon,
probably physiological uptake of FDG.</li>
<li>Lymphoma, stage IV (AJCC 8th ed.), by this F-18 FDG PET/CT
scan.</li>
</ul></li>
<li>2021-03-24 Patho - breast biospy
<ul>
<li>diagnosis
<ul>
<li>Breast, right, core biopsy  high grade B-cell lymphoma</li>
<li>Breast, left, core biopsy  high grade B-cell lymphoma</li>
</ul></li>
<li>Section shows cores of breast tissue with diffusely infiltration of
large lymphoid cells.</li>
<li>IHC: CD20(+), CD3(-), CD10(+), BCL2(+), BCL6(+), MUM1(+), cMYC(-),
CD5(-), and CD30(-). The Ki-67 is about 80%.</li>
<li>The results are in favor of high grade B-cell lymphoma.</li>
</ul></li>
<li>2021-03-16 CT - lung/mediastinum/pleura
<ul>
<li>two lt lung nodules up to 6 mm, stationary, favor intrapulmonary
LNs.</li>
<li>regression of Rt inguinal LNs as compare with CT study on
20201027.</li>
<li>post treatment change with calcification in anterior
mediastinum.</li>
<li>bilateral breast masses.</li>
</ul></li>
<li>2020-10-27 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Stationary right inguinal lymph nodes.</li>
<li>Liver cysts.</li>
</ul></li>
<li>2020-06-29 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Some LNs (up to 6mm) at bil. inguinal regions.</li>
</ul></li>
<li>2020-04-30 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy - Hypocellularity and free from lymphoma
involvement<br />
</li>
<li>Sections show 5-20 % cellularity. The M/E ratio is about 1/1 - 2/3.
Megakaryocytes are found about 0-1/HPF. No increase of blasts is noted.
There are no granulomas,foreign malignant cells, nor aggregation of
atypical lymphocytes.</li>
</ul></li>
<li>2020-02-18 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Stationary right inguinal lymph nodes as compare with CT study on
20180802.</li>
<li>Liver cysts.</li>
</ul></li>
<li>2019-10-11 Surgical pathology Level IV
<ul>
<li>In-hospital
<ul>
<li>pathologic diagnosis - Breast, right, excision - Follicular
lymphoma</li>
<li>Histology type: B-cell neoplasms, Follicular lymphoma</li>
<li>Follicular lymphoma - grading: 2, predominantly diffuse pattern</li>
<li>IHC: CK(-), CD3(-), CD20(+), CD10(+), BCL2(+), BCL6(+), CD5(-),
CD21(-), CyclinD1(-), SOX11(-), and cMYC(-)</li>
</ul></li>
<li>Dr.KungChao Chang
<ul>
<li>Breast, right, excision: Extranodal marginal zone lymphoma of
mucosa-associated lymphoid tissue (MALT lymphoma)</li>
<li>Sections show breast parenchyma diffusely replaced by small to
medium-sized lymphoid tumor cells with slightly irregular nuclei,
inconspicuous nucleoli and focally abundant pale cytoplasm.
Lymphoepithelial lesions are present, highlighted by cytokeratin
immunostain.</li>
<li>Immunohistochemically, these cells are positive for CD20, CD79a,
bcl-2 and MNDA (focal) but negative for CD3, CD5, CD10, cyclin D1,
SOX11, IRTA1, HGAL, LMO2, CD21 and c-MYC. Bcl-6 is focally positive for
some cells, probably tumor cells. The Ki-67 proliferative index is
around 40%. The lymphoepithelial lesions are evident but many cells
infiltrating ductal epithelium are negative for CD20 or CD79a but
focally positive for MNDA. The CD10-positive cells are mainly stromal
cells (fibroblasts) not lymphocytes.</li>
</ul></li>
</ul></li>
<li>2019-10-28 SONO - breast
<ul>
<li>Post-op scar in right breast.</li>
<li>Right breast tumor, suspected fibroadenoma.</li>
<li>Left breast nodule with central hyperechoic, suspected intramammary
lymph node, suggest following up.</li>
</ul></li>
<li>2019-10-09 Whole body PET scan
<ul>
<li>Glucose hypermetabolic lesion in the right breast, suggesting
lymphoma involving a single extralymphatic organ in the absence of any
lymph node involvement.</li>
<li>Mild glucose hypermetabolic lesions in bilateral palatine tonsils,
probably chronic inflammation/infection process.<br />
</li>
<li>Mild glucose hypermetabolic lesions in the colon, probably
physiological uptake of FDG.</li>
<li>Lymphoma, c-stage IE (AJCC 8th ed.), by this F-18-FDG PET/CT
scan.</li>
</ul></li>
<li>2018-08-02 CT - abdomen
<ul>
<li>S/P operation. No evidence of tumor recurrence.</li>
<li>Liver cysts (up to 1.2cm). Grade 3 fatty liver.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-06 Left cubital tunnel syndrome for neurolysis/ cubital
tunnel closure and anterior transposition
<ul>
<li>Left ulnar area numbness/ grips muscular atropy and weakness/ claw
hand.</li>
<li>Prominent left epicondyl of humerus. Severe adhesion around ulnar
nerve both at para-epicondyl area, including proxiaml cutibal tunnel
are/ cubital tunnel inside and distal area to FCU area.</li>
</ul></li>
<li>2002-08-03 radical hysterectomy at NTUH</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2021-04-08 ~ 2021-09-08 - R-CHOP (cyclophosphamide, doxorubicin,
vincristine, prednisone plus rituximab)</li>
<li>2020-01-20 ~ 2020-03-11 - R-COP (cyclophosphamide, vincristine,
prednisone plus rituximab)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient underwent R-COP from 2020-01 to 2020-03 after
pathologically proving follicular lymphoma in October 2019, then
received R-CHOP from 2021-04 to 2021-09 after pathologically proving
high grade B-cell lymphoma in March 2021.</li>
<li>There would be an increased risk of CNS involvement for patients
with double-hit or triple-hit high-grade b-cell lymphomas (in this case,
cMYC(-), BCL2(+), BCL6(+)), but CNS involvement was not proven by brain
MRA on 2022-02-21.</li>
<li>While the standard of care is not established, the following
induction regimens have been reported:
<ul>
<li>RCHOP (used in 2021)  - DA-EPOCH-R  - Potentially toxic regimens;
performance status and comorbidities should be considered
<ul>
<li>R-HyperCVAD (rituximab, cyclophosphamide, vincristine, doxorubicin,
and dexamethasone alternating with high-dose methotrexate and
cytarabine)</li>
<li>R-CODOX-M/R-IVAC (rituximab-cyclophosphamide, vincristine,
doxorubicin with methotrexate/ifosfamide, etoposide, and
cytarabine)</li>
</ul></li>
</ul></li>
<li>Laboratory results reported on 2022-03-29 indicated normal liver and
kidney function, along with slightly lower CBC readings.</li>
</ul>
</div>
</div>
<div id="section-71" class="section level1">
<h1>700149178</h1>
<div id="section-72" class="section level2">
<h2>220124</h2>
<p>This 92-year-old woman diagnosed by NTUH in 2021 Dec wtih advanced
ascending colon cancer with lung, paraaortic LN, peritoneal
carcinomatosis, cT4aN2bM1c, stage IVC.</p>
<p>Take into account of the patients age, intensive therapy might not
be most appropriate, a vanilla regimen like FOLFOX could be a candidate
for systematic treatment.</p>
<p>KRAS, NRAS, BRAF, HER2, MSI/MMR, NTRK fusion, dihydropyrimidine
dehydrogenase test might be ordered optionally if related data from NTHU
is not anticipated.</p>
</div>
</div>
<div id="section-73" class="section level1">
<h1>700150240</h1>
<div id="section-74" class="section level2">
<h2>210510</h2>
<p>{problem list}</p>
<p>the active problems listed in the TPR sheet are shown as
following:</p>
<ul>
<li>pneumonia</li>
<li>UTI</li>
<li>hypertension</li>
<li>ileus</li>
<li>hyponatremia</li>
</ul>
<p>[objective]</p>
<ul>
<li>urine OB 1+ (2021-05-08)</li>
<li>urine bacteria 1+ (2021-05-08)</li>
<li>CRP 5.39 (2021-05-08)</li>
<li>D-dimer 1763ng/mL (2021-05-08)</li>
<li>hs-Troponin I 49pg/mL (2021-05-08)</li>
<li>Na 121mmol/L (2021-05-08)</li>
<li>BUN 57mg/dL (2021-05-08)</li>
<li>Creatinine 1.71mg/dL (2021-05-08)</li>
<li>WBC 15.55 (2021-05-08)</li>
<li>RBC 2.68 (2021-05-08)</li>
<li>MCV 97.4 (2021-05-08)</li>
<li>serum glucose 177mg/dL (2021-05-08)</li>
<li>no defecation recorded in these 2 days</li>
</ul>
<p>[assessment]</p>
<ul>
<li>vital signs, including blood pressure, looks relatively stable.</li>
<li>if no other special consideration exists, the first priority should
be controlling the infections.</li>
<li>brosym 2000mg IVD Q12H has been prescribed to control the infection
since 2021-05-09.</li>
<li>the lower serum sodium might be improved by intaking salted
food.</li>
<li>lab data showed a higher serum glucose level, an one-point datum
might not lead to its trend, more data to form a time series of blood
sugar monitoring is recommended.</li>
<li>MCV almost touched the upper limit of the normal range, some folic
acid and/or vit B12 supplements might be helpful for the mild
anemia.</li>
<li>some laxative agent might be helpful for the ileus.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep abx using and monitoring changes of infection signs.</li>
<li>invite dietitian to help the patient to eat more salted diets and to
see if any other diet issue found, then get sodium tested few days
later.</li>
<li>order regular scheduled blood sugar tests to build its trend.</li>
<li>folacin (folic acid 5mg) and/or kentamin (thiamine 50mg, pyridoxine
50mg, cyannocobalamin 500mcg) are available in pharmacy inventory now,
each of them could be administrated QD or BID, which is
recommended.</li>
<li>if still no defecation before 2021-05-11, then dulcolax (bisacodyl
5mg) QD or BID could be considered to prescribe, and administrated until
defecation or 3 days then reevaluate the condition.</li>
</ul>
</div>
</div>
<div id="section-75" class="section level1">
<h1>700154194</h1>
<div id="section-76" class="section level2">
<h2>220304</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2021-12-09 CT - lung/mediastinum/pleura
<ul>
<li>Left upper lobe lung cancer with stationary size.</li>
<li>Liver meta, in enlargement.</li>
</ul></li>
<li>2021-10-25 Patho - soft tissue biopsy, simple excision, non lipoma
<ul>
<li>left pelvic - Adenocarcinoma, metastatic.</li>
<li>IHC: CK7(focal positive), CK20(-), PAX8(+), PR(+), TTF-1(-), Napsin
A(-), p40(-), and CD56(-).</li>
<li>The morphology and immunohistochemical stains are consistent with
S2020-8600 (Endometrioid carcinoma).</li>
</ul></li>
<li>2021-10-21 CT - whhole abdomen, pelvis
<ul>
<li>Partial consolidation at left lingual region.</li>
<li>Tumors in liver, prevertebral region and LLQ tumor metastases.</li>
</ul></li>
<li>2021-09-08 CT - lung/mediastinum/pleura
<ul>
<li>LUL cancer T4M1c, in progression of primary tumor and hepatic
metastases as compared with previous CT study on 2021-06-02</li>
</ul></li>
<li>2021-09-08 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Metastases are highly suspected.</li>
<li>Multiple Cholangiocarcinomas are less likely.</li>
</ul></li>
<li>2021-07-16 Patho - liver biopsy
<ul>
<li>IHC: CK7(+), CK20(-), TTF1(-), Napsin A(-), and p40(focal + in
squamous component).</li>
<li>Primary liver adenocarcinoma (cholangiocarcinoma) can not be
completely excluded.</li>
<li>Metastatic pulmonary adenocarcinoma is less likely in IHC
result.</li>
<li>Additional IHC: ER(focal +), PAX8(focal +)</li>
<li>Comment: The IHC finding is compatible with metastatic endometroid
carcinoma.</li>
</ul></li>
<li>2021-07-07 Tc-99m MDP whole body bone scan
<ul>
<li>A faint hot spot in the lateral aspect of the left 7th rib, the
nature is to be determined (post-traumatic change or other nature ?),
suggesting follow-up with bone scan in 3-6 months for
investigation.</li>
<li>Suspected benign lesions in the maxilla, some C- and L-spine,
bilateral shoulders, S-I joints, hips and knees.</li>
</ul></li>
<li>2020-12-17 ROS1 FISH not detected</li>
<li>2020-12-11 EGFR, ALK IHC, PD-L1(22C3) S2020-18026 (bronchus biopsy)
<ul>
<li>EGFR
<ul>
<li>G719X (-)</li>
<li>Exon19 deletion (+)</li>
<li>S768I (-)</li>
<li>T790M (+)</li>
<li>Exon20 insertion (-)</li>
<li>L858R (-)</li>
<li>L861Q (-)</li>
</ul></li>
<li>ALK IHC (-)</li>
<li>PD-L1 Tumor proportion score TPS &lt; 1%</li>
</ul></li>
<li>2020-11-25 Patho - bronchus biopsy
<ul>
<li>CT-guide biopsy - adenocarcinoma, moderately differentiated</li>
<li>IHC: TTF-1(+).</li>
<li>The result is supportive for the diagnosis of malignant neoplasm of
left bronchus or lung.</li>
</ul></li>
<li>2020-11-13 CT - lung/mediastinum/pleura
<ul>
<li>left upper lobe lung cancer with probably right lung meta. the
primary left upper lobe lung cancer progressed.</li>
</ul></li>
<li>2020-08-12 CT - lung/mediastinum/pleura
<ul>
<li>LUL tumor involving mediastinum and hilum and Rt lung metastasis, in
progression as compared with previous CT study on 20200320.</li>
</ul></li>
<li>2020-06-30 Patho - Ureter resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Ureter, left, frozen section + open nephroureterectomy -
Endometrioid carcinoma with ureter invasion</li>
<li>Kidney, left, ditto - Chronic pyelonephritis</li>
</ul></li>
<li>IHC for tumor cells: CK7(+); CK20 (-); ER(+); GATA-3(-), TTF-1(-),
WT-1(-), PAX-8(+), P63(-) and CDX-2(+, focal) for tumor cells</li>
</ul></li>
<li>2020-06-29 Patho
<ul>
<li>Tumor, urinary tract?, frozen section - Adenocarcinoma, uncertain
origin</li>
</ul></li>
<li>2020-06-13 CT - whole abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Malignant tumors in the pelvic cavity, up to 6.1cm in left side with
left hydronephrosis. Probably metastasis(TCC? GYN or GI tract). Suggest
tissue study.</li>
</ul></li>
<li>2020-03-30 CT - lung/mediastinum/pleura
<ul>
<li>LUL tumor involving mediastinum and hilum, stationary as compared
with previous CT study on 20191230.</li>
</ul></li>
<li>2019-12-30 CT - lung/pleura
<ul>
<li>LUL tumor involving mediastinum and hilum, stationary as compared
with previous CT study on 20190918.</li>
</ul></li>
<li>2019-09-18 CT - lung/pleura
<ul>
<li>LUL tumor involving mediastinum and hilum, stationary as compared
with previous CT study on 20190612.</li>
</ul></li>
<li>2019-06-12 CT - lung/pleura
<ul>
<li>LUL tumor involving mediastinum and hilum, in regression as compared
with previous CT study on 20190312.</li>
</ul></li>
<li>2019-04-11 MRI - L-spine
<ul>
<li>Lumbar spondylosis, canal stenosis and small L1/2 HIVD. No tumor or
metastasis found.</li>
</ul></li>
<li>2019-03-15 MRI - brain
<ul>
<li>No evidence of brian metastasis.</li>
<li>Mild ventriculomegaly.</li>
</ul></li>
<li>2019-03-14 Surgical pathology Level IV
<ul>
<li>indication: Malignant bronchus and lung neoplasm, NOS;</li>
<li>diagnosis: Lung, ? side, needle biopsy - adenocarcinoma, moderately
differentiated</li>
<li>IHC: TTF-1(+), Napsin A(+), and p63(-). The results are supportive
for the diagnosis.</li>
</ul></li>
<li>2019-03-12 CT - lung/pleura
<ul>
<li>Progression of LUL lesion (6.1x7.1cm) with mediastinal LAP. TNM:
T4N2Mx</li>
<li>Right tiny renal stones (1-2mm). Left hydronephrosis.</li>
</ul></li>
<li>2019-03-02 CT - brain
<ul>
<li>No brain lesion.</li>
<li>A 6.4mm dense calcification at left parasagittal region, calcified
meningioma or benign parafalcal calcification.</li>
</ul></li>
<li>2018-06-06 Surgical pathology Level IV
<ul>
<li>indication: bilateral lung nodules</li>
<li>diagnosis: Lung, ? side, needle biopsy - Interstitial fibrosis with
atypical pneumocytes</li>
<li>Sections show alveolar lung tissue with interstitial fibrosis and
atypical pneumocytes proliferating along the alveolar wall. No stromal
invasion is seen. The immunohistochemical stain of CK reveals no
invasive tumor. The TTF-1 is positive. Please correlate with the
clinical presentation and further examination is suggested.</li>
</ul></li>
<li>2018-05-31 Low-dose CT - lung cancer screening
<ul>
<li>A spiculated mass (4.2x6.1cm) at LUL suspected cancer.</li>
</ul></li>
</ul></li>
<li>Medication
<ul>
<li>2021-12 ~ ongoing - paclitaxel + carboplatin (for endometral
cancer)</li>
<li>2021-11 ~ 2021-12 - vinorelbine</li>
<li>2021-09 ~ 2021-11 - durvalumab</li>
<li>2021-09 ~ 2021-09 - pemetrexed</li>
<li>2020-12 ~ ongoing - osimertinib (for NSCLC)</li>
<li>2019-05 ~ 2020-11 - gefitinib</li>
<li>2019-04 ~ 2019-05 - afatinib</li>
<li>2019-03 ~ 2019-04 - vinorelbine</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>targeted therapy or immunotherapy for advanced or metastatic NSCLC
<ul>
<li>EGFR Exon 19 Deletion or L858R
<ul>
<li>First-line therapy -Afatinib -Erlotinib -Dacomitinib -Gefitinib
-Osimertinib -Erlotinib + ramucirumab -Erlotinib + bevacizumabc
(nonsquamous)</li>
<li>Subsequent therapy -Osimertinib9 -EGFR S768I, L861Q, and/or
G719X</li>
<li>First-line therapy -Afatinib -Erlotinib -Dacomitinib -Gefitinib
-Osimertinib</li>
<li>Subsequent therapy -Osimertinib9</li>
</ul></li>
<li>EGFR Exon 20 Insertion Mutation Positive
<ul>
<li>Subsequent therapy -Amivantamab-vmjw -Mobocertinib</li>
</ul></li>
<li>KRAS G12C Mutation Positive
<ul>
<li>Subsequent therapy -Sotorasib</li>
</ul></li>
<li>ALK Rearrangement Positive
<ul>
<li>First-line therapy -Alectinib -Brigatinib -Ceritinib -Crizotinib
-Lorlatinib</li>
<li>Subsequent therapy -Alectinib -Brigatinib -Ceritinib
-Lorlatinib</li>
</ul></li>
<li>ROS1 Rearrangement Positive
<ul>
<li>First-line therapy -Ceritinib -Crizotinib -Entrectinib</li>
<li>Subsequent therapy -Lorlatinib -Entrectinib</li>
</ul></li>
<li>BRAF V600E Mutation Positive
<ul>
<li>First-line therapy -Dabrafenib/trametinib -Dabrafenib
-Vemurafenib</li>
<li>Subsequent therapy -Dabrafenib/trametinib</li>
</ul></li>
<li>NTRK1/2/3 Gene Fusion Positive
<ul>
<li>First-line/Subsequent therapy -Larotrectinib -Entrectinib</li>
</ul></li>
<li>MET Exon 14 Skipping Mutation
<ul>
<li>First-line therapy/Subsequent therapy -Capmatinib -Crizotinib
-Tepotinib</li>
</ul></li>
<li>RET Rearrangement Positive
<ul>
<li>First-line therapy/Subsequent therapy -Selpercatinib -Pralsetinib
-Cabozantinib</li>
</ul></li>
<li>PD-L1 1%
<ul>
<li>First-line therapy -Pembrolizumab -(Carboplatin or
cisplatin)/pemetrexed/pembrolizumab (nonsquamous)
-Carboplatin/paclitaxel/bevacizumab/atezolizumab (nonsquamous)
-Carboplatin/(paclitaxel or albumin-bound paclitaxel)/pembrolizumab
(squamous) -Carboplatin/albumin-bound paclitaxel/atezolizumab
(nonsquamous) -Nivolumab/ipilimumab -Nivolumab/ipilimumab/pemetrexed/
(carboplatin or cisplatin) (nonsquamous)
-Nivolumab/ipilimumab/paclitaxel/carboplatin (squamous)</li>
</ul></li>
<li>PD-L1 &gt;=50% (in addition to above)
<ul>
<li>First-line therapy -Atezolizumab -Cemiplimab-rwlc</li>
</ul></li>
</ul></li>
</ul>
</div>
<div id="section-77" class="section level2">
<h2>220120</h2>
<p>[objective]</p>
<ul>
<li><p>Lab inspection</p>
<ul>
<li>2021-10 Patho - soft tissue biopsy, simple excision, non lipoma,
left pelvic
<ul>
<li>Adenocarcinoma, metastatic.</li>
<li>IHC: CK7(focal positive), CK20(-), PAX8(+), PR(+), TTF-1(-), Napsin
A(-), p40(-), and CD56(-).</li>
<li>The morphology and immunohistochemical stains are consistent with
S2020-8600 (Endometrioid carcinoma).</li>
</ul></li>
<li>2021-07 Patho - liver biopsy
<ul>
<li>IHC: CK7(+), CK20(-), TTF1(-), Napsin A(-), and p40(focal + in
squamous component).</li>
<li>Primary liver adenocarcinoma (cholangiocarcinoma) can not be
completely excluded.</li>
<li>Metastatic pulmonary adenocarcinoma is less likely in IHC
result.</li>
<li>Additional IHC: ER(focal +), PAX8(focal +)</li>
<li>Comment: The IHC finding is compatible with metastatic endometroid
carcinoma.</li>
</ul></li>
<li>2020-12 EGFR, PD-L1(22C3) S2020-18026 (bronchus biopsy)
<ul>
<li>G719X (-)</li>
<li>Exon19 deletion (+)</li>
<li>S768I (-)</li>
<li>T790M (+)</li>
<li>Exon20 insertion (-)</li>
<li>L858R (-)</li>
<li>L861Q (-)</li>
<li>PD-L1 Tumor proportion score TPS &lt; 1%</li>
</ul></li>
<li>2020-11 Patho - bronchus biopsy
<ul>
<li>IHC: TTF-1(+).</li>
<li>The result is supportive for the diagnosis of malignant neoplasm of
left bronchus or lung.</li>
</ul></li>
<li>2020-06 Patho - Ureter resection
<ul>
<li>IHC: CK7(+); CK20 (-); ER(+); GATA-3(-), TTF-1(-), WT-1(-),
PAX-8(+), P63(-) and CDX-2(+, focal) for tumor cells</li>
</ul></li>
</ul></li>
<li><p>Medication</p>
<ul>
<li>2021-12 ~ ongoing - Paclitaxel, Carboplatin</li>
<li>2021-11 ~ 2021-12 - Vinorelbine</li>
<li>2021-09 ~ 2021-11 - Durvalumab</li>
<li>2020-12 ~ 2022-01 - Osimertinib</li>
<li>2019-05 ~ 2020-11 - Gefitinib</li>
<li>2019-04 ~ 2019-05 - Afatinib</li>
<li>2019-03 ~ 2019-04 - Vinorelbine</li>
</ul></li>
</ul>
<p>[assessment, suggestion]</p>
<ul>
<li>drug allergy: alimta (pemetrexed) moderate skin rash recorded in
database as from 2021-12-20.</li>
<li>HER2 test might be tried to opt-in Trastuzumab as a backup
candidate.</li>
</ul>
</div>
</div>
<div id="section-78" class="section level1">
<h1>700167626</h1>
<div id="section-79" class="section level2">
<h2>220503</h2>
<ul>
<li>There is only one item remaining on the list of current active
problems: fever with UTI since 2022-04-29.</li>
<li>Escherichia coli 33000 CFU/cc were found in urine culture, and
Staphylococcus epidermidis were found in blood culture.</li>
<li>Following administration of Flumarin (flomoxef) 1000mg IVD Q12H
since 2022-04-29, the patients temperature became stable on 2022-05-02
afternoon, and no higher than 37 degrees Celsus observed so far.</li>
<li>Underlying diseases are managed with corresponding medicine.</li>
</ul>
</div>
</div>
<div id="section-80" class="section level1">
<h1>700174551</h1>
<div id="section-81" class="section level2">
<h2>220408</h2>
<p>{rectal cancer with liver mets s/p LAR and liver partial
resection}</p>
<p>[objective]</p>
<ul>
<li><p>exam finding</p>
<ul>
<li>2022-04-06 Abdominal sonography
<ul>
<li>post cholecystectomy</li>
<li>parenchymal liver disease</li>
</ul></li>
<li>2022-03-08 CT - abdomen, pelvis
<ul>
<li>Rectal cancer s/p operation. Wall thickening of proximal
A-colon.</li>
<li>Mild regression of liver metastases.</li>
</ul></li>
<li>2021-12-08 CT - abdomen, pelvis
<ul>
<li>Metastasis 1.5 cm in S7 of the liver is highly suspected.</li>
</ul></li>
<li>2021-08-27 Patho - liver partial resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Liver, S2-3, segmental hepatectomy  Metastatic rectal
adenocarcinoma<br />
</li>
<li>Liver, S5, segmental hepatectomy  Metastatic rectal
adenocarcinoma<br />
</li>
<li>Liver, S8, segmental hepatectomy  All specimen taken for section
and no metastatic carcinoma present<br />
</li>
<li>Tumor regression grade: Grade 4/5 (cancer cells &gt; fibrosis)</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Diagnosis: Metastatic rectal adenoarcinoma x3<br />
</li>
<li>Histologic grade: Moderately differentiated<br />
</li>
<li>Tumor growth pattern: Infiltrating<br />
</li>
<li>Tumor pseudocapsule: Present<br />
</li>
<li>Tumor necrosis: Present (50%)<br />
</li>
<li>Parenchymal margin: Uninvolved by carcinoma<br />
</li>
<li>Distance of invasive carcinoma from closest margins: 0.4 cm
(S5)<br />
</li>
<li>Vascular invasion: Not identified<br />
</li>
<li>Perineural invasion: Not identified<br />
</li>
<li>Tumor regression grade: Grade 4 (residual cancer cells predominate
over fibrosis)<br />
</li>
<li>Non-neoplastic liver parenchyma: Perivenular congestion,
regeneration of hepatocytes, mild lymphocytic portal inflammation, and
mild fatty change (10%)</li>
</ul></li>
</ul></li>
<li>2021-06-15 CT - abdomen, pelvis
<ul>
<li>rectal cancer s/p LAR and autosuture with liver mets.</li>
<li>the liver mets regressed.</li>
</ul></li>
<li>2021-02-18 Patho - colon segmental resection for tumor
<ul>
<li>pathologic diagnosis
<ul>
<li>Large intestine, rectum, robotic-assisted low anterior resection -
Adenocarcinoma, moderately differentiated<br />
</li>
<li>Lymph node, mesocolic, dissection - Adenocarcinoma, metastatic
(1/21)<br />
</li>
<li>AJCC 8th edition Pathology stage: pStage IIIB, pT3N1a(if cM0), or
pStage IVA, pT3N1a(if cM1a), Please correlate with the clinical
presentation and image study</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology: adenocarcinoma</li>
<li>Histology Grade: moderately differentiated<br />
</li>
<li>Depth of invasion: mesocolic soft tissue<br />
</li>
<li>Angiolymphatic invasion: Present.<br />
</li>
<li>Perineural invasion: Present.<br />
</li>
<li>Discontinuous extramural tumor extension: Not identified.<br />
</li>
<li>Circumferential (radial) margin of rectum: Uninvolved, 16 mm from
the margin</li>
<li>Lymph node metastasis, mesocolic: 1/21<br />
</li>
<li>Lymph node metastasis, IMA / SMA: not received<br />
</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>Primary Tumor (pT): pT3: Tumor invades through the muscularis
propria into pericolorectal tissues<br />
</li>
<li>Regional Lymph Nodes (pN): pN1a: One regional lymph node is
positive<br />
</li>
<li>Distant Metastasis (pM): if cM0 or cM1a(CT finding)<br />
</li>
</ul></li>
<li>Type of polyp in which invasive carcinoma arose: Tubulovillous
adenoma.<br />
</li>
<li>S2021-02016 IHC: EGFR(+), PMS2(+), MLH1(+), MSH2(+), and
MSH6(+).<br />
</li>
</ul></li>
</ul></li>
<li>2021-02-08 CT - abdomen, pelvis
<ul>
<li>Imaging stage: T2N1bM1a stage IVA</li>
</ul></li>
<li>2021-02-05 Patho - colorectal polyp
<ul>
<li>Large intestine, rectum, 10 cm from anal verge, biopsy 
Adenocarcinoma, moderately differentiated<br />
</li>
<li>IHC: EGFR(+), PMS2(+), MLH1(+), MSH2(+), and MSH6(+).<br />
</li>
</ul></li>
<li>2021-02-04 Colonoscopy
<ul>
<li>A mass was noted in the rectum, size 3cm, 10cm from anal verge,
suspected malignancy.</li>
</ul></li>
<li>2020-09-01 Renal echo
<ul>
<li>parenchymal renal disease</li>
</ul></li>
</ul></li>
<li><p>lab data</p>
<ul>
<li>2021-03-08 NRAS/KRAS mutation not detected</li>
</ul></li>
<li><p>surgical operation</p>
<ul>
<li>2021-08-26
<ul>
<li>surgery
<ul>
<li>S2-3 resection</li>
<li>S8 and S5 partial resection</li>
<li>LC</li>
</ul></li>
<li>finding
<ul>
<li>S2-3 two hypoechoic tumor + 1.5cm in diameter suspected hypoechoic
tumor 1.2cm at S8</li>
<li>superifcal small tumor at S5 near GB</li>
<li>echo didnt find any tumor at right posterior segment</li>
</ul></li>
</ul></li>
<li>2021-02-17
<ul>
<li>surgery
<ul>
<li>Robotic-assisted low anterior resection</li>
</ul></li>
<li>finding
<ul>
<li>Rectal cancer 4<em>3.5</em>2 cm at 10 cm from AV</li>
</ul></li>
</ul></li>
</ul></li>
<li><p>chemoimmunotherapy</p>
<ul>
<li>2021-04-27 ~ undergoing - FOLFIRI + bevacizumab</li>
<li>2021-03-12 ~ 2021-04-12 - FOLFIRI</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient with rectal cancer and liver mets has received FOLFIRI
since 2021-03-12 (plus bevacizumab since 2021-04-27) s/p LAR
(2021-02-17) and liver partial resection (2021-08-26).</li>
<li>Available molecular review results include: pMMR, EGFR(+), NRAS/KRAS
WT; no BRAF, HER2, NTRK results found.</li>
<li>Recent surveillance detected suspected mets in S7 (CT, 2021-12-08)
and proximal A-colon wall thickening (CT, 2022-03-08), CEA fluctuates
within a narrow range of 10 to 13 ng/mL since November 2021.</li>
<li>There is still some progression of the disease (albeit at a slower
rate?)</li>
</ul>
</div>
</div>
<div id="section-82" class="section level1">
<h1>700180657</h1>
<div id="section-83" class="section level2">
<h2>999999</h2>
<p>{colon cancer}</p>
<p>[objective]</p>
<ul>
<li>2018-02 diagnosed with adenocarcinoma of S-colon, cT3N0M0.</li>
<li>2018-02-14 pathology
<ul>
<li>large intestine, sigmoid colon, laparoscopic LAR - Adenocarcinoma,
moderately differentiated.</li>
<li>IHC stains: EGFR (+), PMS2 (+), MSH 6 (+), MSH2 (+), MLH1 (+).</li>
<li>foci of mesenteric endometrosis, CK7 (+) and CK20 (-), with
fibrosis.</li>
<li>AJCC 8th ed.staging: pT3N0 (cMx); pStage: IIA at least (if cM0).
<ul>
<li>primary tumor pT3 - tumor invades through the muscularis propria
into pericolonic tissues</li>
<li>regional lymph nodes pN0 - no regional lymph node metastasis</li>
<li>distant Metastasis pMx<br />
</li>
</ul></li>
</ul></li>
<li>2018-12-25 CT: soft tissue mass with necrotic margin at surface of
uterus up to 2.9cm in largest dimension which is new in comparison to CT
dated on 2018-06-02.</li>
<li>2019-01-03 PET
<ul>
<li>a glucose hypermetabolic lesion on the superior aspect of the
uterus. should be malignancy with pelvic seeding on the uterus.</li>
<li>increased FDG accumulation in the right lateral aspect of the
abdomen and pelvic region and in the anterior aspect of the pelvic
region.</li>
</ul></li>
<li>2019-01-04 sigmoidfiberscopy: an ulcerative tumor, about 1/3
circumferential bowel lumen at 18cm above AV (RS-colon) with easy
contact bleeding previous anastomosis (10cm AAV) looked well.</li>
<li>2019-01-10 low anterior resection (LAR) and hysterectomy plus
bilateral salpingo-oophorectomy (BSO) recurrent 3cm tumor (favor
seeding) involving uterus and upper rectum and a segment of small bowel
was identified.
<ul>
<li>IHC stains: CK20(+), CK7(focal+), vimentine(-)</li>
<li>patho: rT4bN0M1a, stage IVA. 2019-09-20 received 12th Avastin &amp;
14th FOLFOX6, mild fingers and feet numbness, pigmentation on breast
skin. 2019-10-15 refilled Xeloda (capecitabine), mild fatigue, nausea,
abdomen discomfort. 2019-11-26 refilled Xeloda (capecitabine), nail and
finger pigmentation, mild fatigue and numbness. 2020-03-25 CT: a known
newly-developed soft tissue nodule measuring 0.6 cm in right pelvic wall
is noted again, increasing in size. 2020-04-07 PET</li>
<li>a glucose hypermetabolic lesion in the right anterior pelvic wall,
compatible with a metastatic lesion.</li>
<li>multiple glucose hypermetabolic lesions in the left lower abdomen
and in the pelvic cavity and a glucose hypermetabolic lesion in the left
upper abdomen. 2020-11-07 CT: multiple soft tissue nodules in the
peritoneum (upper abdomen and pelvic cavity), up to 1.7cm in left pelvic
cavity, suspected peritoneal carcinomatosis. 2021-02-20 CT: progression
of peritoneal tumors with left lower ureter invasion causing left
hydronephrosis and hydroureter.</li>
</ul></li>
<li>CEA
<ul>
<li>2021-04-28 _8.64</li>
<li>2021-03-29 15.23</li>
<li>2021-03-02 16.89</li>
<li>2021-01-23 13.56</li>
<li>2020-10-28 _5.044</li>
<li>2020-06-22 12.062</li>
<li>2020-03-18 _8.714</li>
<li>2019-12-09 _2.008</li>
<li>2019-08-16 _0.866</li>
<li>2019-04-30 _1.534</li>
<li>2018-12-10 15.635</li>
<li>2018-09-10 _2.047</li>
</ul></li>
<li>regimen
<ul>
<li>2018-03-03 ~ __________: Ufur (tegafur + uracil)</li>
<li>__________ ~ 2020-07-03: FOLFOX + Avastin (bevacizumab)</li>
<li>2020-07-17 ~ 2021-02-19: FOLFIRI + Cyramza (ramucirumab)</li>
<li>2021-03-31 ~ up to now : RegoNivo (Opdivo (nivolumab) + Stivarga
(regorafenib))</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>PMS2 (+), MSH 6 (+), MSH2 (+), MLH1 (+) -&gt; not dMMR, EGFR (+),
pembrolizumab might not be indicated.</li>
<li>no KRAS/NRAS/BRAF lab data found.</li>
<li>after using 5-FU, FOLFOX plus anti-VEGF bevacizumab as adjuvant
first-line therapy for more than one year (2018 Mar ~ 2020 Jul), the
disease progressed, then the regimen was shifted to FOLFIRI plus
anti-VEGFR2 ramucirumab as second-line therapy. the two regimen are
listed in NCCN clinical practice guidelines.</li>
<li>the cancer has been progressed in 2020Q4 ~ 2021Q1, regimen shifted
to RegoNivo since end of 2021 March.
<ul>
<li>nivolumab - anti-PD1, usually used in combination with anti-CTLA4
i.e.ipilimumab, to treat adults with metastatic colorectal cancer that
is microsatellite instability-high (MSI-H) or mismatch repair deficient
(dMMR), and patient have tried treatment with a fluoropyrimidine,
oxaliplatin, and irinotecan.</li>
<li>regorafenib inhibits multiple kinases including VEGF1, VEGF2, VEGF3,
PDGFR, FGFR involved in tumor angiogenesis and KIT, RET, RAF-1, BRAF
involved in oncogenesis.</li>
<li>RegoNivo regimen is supported by articles, e.g.<a href="https://pubmed.ncbi.nlm.nih.gov/32343640/">Regorafenib Plus
Nivolumab in Patients With Advanced Gastric or Colorectal
Cancer</a></li>
</ul></li>
<li>possible toxicity for RegoNivo regimen
<ul>
<li>nivolumab can result in significant immune-mediated adverse
reactions due to T-cell activation and proliferation. These
immune-mediated reactions may involve any organ system, with the most
common reactions being pneumonitis, enterocolitis, hepatitis,
dermatitis, hypophysitis, nephritis, and thyroid dysfunction.</li>
<li>regorafenib:
<ul>
<li>hypertension occurs in nearly 30% of patients. usually occurs within
6 weeks of starting therapy and is well controlled with oral
antihypertensive medications.</li>
<li>skin toxicity in the form of hand-foot syndrome and skin rash occur
in up to 45% and 26%, respectively. generally appears within the first
cycle of drug treatment.</li>
</ul></li>
</ul></li>
</ul>
<p>[suggest/plan]</p>
<ul>
<li>monitor any sign of toxicity caused by nivolumab and
regorafenib.</li>
<li>keep tracking tumor markers including CEA</li>
<li>update chest, abdomen, and pelvic CT (and/or PET) every 3-6
months.</li>
</ul>
</div>
</div>
<div id="section-84" class="section level1">
<h1>700191057</h1>
<div id="section-85" class="section level2">
<h2>220124</h2>
<p>{lung cancer with bone and brain metastasis}</p>
<p>[objective]</p>
<ul>
<li>gene test
<ul>
<li>PD-L1(28-8) 2021-04-08 TC &lt; 1%</li>
<li>ROS1 2021-03-24 not detected</li>
<li>PD-L1(22C3) 2021-03-22 TPS &lt; 1%</li>
<li>EGFR 2021-03-19 G719X not detected</li>
<li>EGFR 2021-03-19 Exon19 deletion not detected</li>
<li>EGFR 2021-03-19 S768I not detected</li>
<li>EGFR 2021-03-19 T790M not detected</li>
<li>EGFR 2021-03-19 Exon20 insertion not detected</li>
<li>EGFR 2021-03-19 L858R not detected</li>
<li>EGFR 2021-03-19 L861Q not detected</li>
<li>ALK IHC 2021-03-18 negative</li>
</ul></li>
<li>systematic treatment
<ul>
<li>2022-01-21 ~ ongoing
<ul>
<li>Nivolumab + Ipilimumab + Pemetrexed + Carboplatin
<ul>
<li>Nivolumab 3mg/kg D1 Q3W</li>
<li>Ipilimumab 1mg/kg D1 Q6W</li>
<li>Pemetrexed 500mg/m2 D1 Q3W*2cycles</li>
<li>Carboplatin AUC 5~6 D1 Q3W*2cycles</li>
</ul></li>
</ul></li>
<li>2021-10-22 ~ 2022-01-04
<ul>
<li>Nivolumab + Ipilimumab
<ul>
<li>Nivolumab 3mg/kg D1 Q3W</li>
<li>Ipilimumab 1mg/kg D1 Q6W</li>
</ul></li>
</ul></li>
<li>2021-03-25 ~ 2021-10-21
<ul>
<li>Gefitinib 250mg QD</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>pembrolizumab is approved for NSCLC with PD-L1 expression levels 
1%, it is not the case here.</li>
<li>for NSCLC with no specific mutations, if progression on PD-1/PD-L1
inh, using a PD-1/PD-L1 inh might not be recommended.</li>
<li>there is no issue found in current medication.</li>
</ul>
</div>
<div id="section-86" class="section level2">
<h2>210217</h2>
<p>{consultation record}</p>
<p>[Brief History and Clinical Findings]</p>
<p>for suspect multiple myeloma, metastases</p>
<p>This 49-year-old female was Dx (1) Leukocytosis, suspect intra
abdominal infection (2) Suspect multiple myeloma, metastases (3)
Hypertension (4) Fracture of 7th ribs in 2020-12. This time, she was
admission because bilateral lower leg edema for two days. She complained
for lower back pain while mobile and right back sorenss for 3 months and
subside while lying down. She has suffered from fracture of left 7th rib
and right little toe pain and local redness. According to the patient,
she has visited Ortho OPD and Rheumatology OPD for the recurrent
multiple joint pain. She came to our ER. CT image revealed retroversion
of uterus with tumors (up to 6.3cm) suspected myomas and Multiple
osteolytic lesions at bony structures. DDX: multiple myeloma,
metastases. Please evaluation her condition by your expertise. Thank you
very much.</p>
<p>[Consultation Findings and Recommandations]</p>
<p>Patient examined and Chart reviewed. A case of multiple bony
destruction is noted. I am consulted for the possible etiolgy.</p>
<p>My suggestions: - Complete CT scan work-up e.g., Chest CT, to rule
out CEA-elevated lung cancer or CEA/CA153-elevated breast cancer -
Please survey breast conditin, using breast sono and/or mammography to
rule out CEA/CA153-elevated breast cancer - Please check Protein EP/IFE,
kappa/lambda chain to rule out myelopma or light chain disease - Please
perform EGD and colonoscopy to rule out CEA-elevated GI cancer - If no
clue from the afroementioned examinations, bone marrow biopsy is
mandatory.</p>
</div>
</div>
<div id="section-87" class="section level1">
<h1>700192852</h1>
<div id="section-88" class="section level2">
<h2>220425</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-22 Esophagogastroduodenoscopy
<ul>
<li>Diagnosis
<ul>
<li>Gastric ulcer, H2, pyloric ring, s/p biopsy</li>
<li>Suboptimal study due to much food residue in stomach and duodenum,
probable due to bowel obstruction below 2nd portion</li>
<li>Reflux esophagitis LA Classification grade A</li>
</ul></li>
<li>Suggestion
<ul>
<li>NG decompression</li>
<li>Small bowel series</li>
</ul></li>
</ul></li>
<li>2022-04-15 KUB
<ul>
<li>Stool retention in the bowel.</li>
</ul></li>
<li>2022-04-01 KUB
<ul>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2022-01-21 Patho - soft tissue debridment
<ul>
<li>Ileum, exploratory laparotomy with segmental bowel resection with
end to end anastomosis  benign perforated ileum with external tumor
seeding and muscular invasion as well as necrotic acute inflammatory
exudates containing tumor nests.
<ul>
<li>One of three peri-ileal lymph nodes (1/3) show tumor metastasis (2 x
1 mm).</li>
<li>IHC stains: CK20 (-): non-intestinal origin, PAX-8 (+), WT-1 (+),
Napsin-A (-), p53 (aberrant type): compatible with serous
carcinoma.</li>
</ul></li>
<li>Labeled as cut end 2, exploratory laparotomy with segmental bowel
resection with end to end anastomosis  Free.</li>
<li>Labeled as cut end, exploratory laparotomy with segmental bowel
resection with end to end anastomosis  Free.</li>
<li>Labeled as peritoneum tumor, excision  serous carcinoma (4 x 3
mm).
<ul>
<li>IHC stains: CK20 (-), PAX-8 (+), WT-1 (+), Napsin-A (-), p53
(aberrant type).<br />
</li>
</ul></li>
</ul></li>
<li>2022-01-20 CT - abdomen, pelvis
<ul>
<li>Pneumoperitoneum. Focal wall thickening of ileum suspected
malignancy.</li>
</ul></li>
<li>2020-12-25 Small Intestinal Series
<ul>
<li>Normal haustration of the jejunum and ileum.</li>
<li>The peristasis of the small intestine is intact.</li>
<li>No evidence of stenotic or obstructive lesion in the study.</li>
<li>The transit time is 120 minutes.</li>
<li>Suggest clinical correlation</li>
</ul></li>
<li>2020-12-11 Gynecologic ultrasonography
<ul>
<li>Suspected Lt ovarian cyst</li>
<li>Uterine myoma</li>
</ul></li>
<li>2020-12-01 KUB
<ul>
<li>Stool retention in the bowel.</li>
</ul></li>
<li>2020-08-19 CT - abdomen, pelvis
<ul>
<li>Infectious colitis is suspected.</li>
<li>Please correlate with stool routine and culture, or
colonoscopy.</li>
</ul></li>
<li>2019-04-01 SONO - breast
<ul>
<li>Right breast cyst and fibroadenoma. Suggest follow up.</li>
<li>BI-RADS2. benign finding</li>
</ul></li>
<li>2018-09-08 EKG
<ul>
<li>Sinus bradycardia with Premature atrial complexes</li>
<li>Prolonged QT</li>
<li>Abnormal ECG</li>
</ul></li>
<li>2018-09-08 SONO - breast
<ul>
<li>Suspected right breast tumor</li>
<li>Right fibroadenoma as described</li>
<li>Suggestion: tissue study</li>
<li>BI-RADS: suspicious abnormality, biopsy should be considered</li>
</ul></li>
<li>2018-09-08 Mammography
<ul>
<li>Dense breast. No mammographic evidence of malignancy, suggest
clinical correlation and regular follow up.</li>
<li>BI-RADS: Category 1: negative.-annual screening.</li>
</ul></li>
<li>2018-09-08 Low-dose CT - lung cancer screening
<ul>
<li>Lungs: Nodular lesion at left upper lobe up to 4.7mm in largest
dimension.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>CA125
<ul>
<li>2022-04-22 823.98 U/ml</li>
<li>2022-02-11 85.56</li>
<li>2020-12-29 254.73</li>
<li>2020-12-11 394.40</li>
<li>2018-09-08 8.20</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-02-09 thoracic surgery
<ul>
<li>Q
<ul>
<li>This 60 year-old female had past history of 1) Myomectomy 20 years
ago. 2) Primary peritoneal serous carcinoma (omentum, ileum, colon,
appendix involvement), pT3cN0M0, FIGO stage IIIC, s/p Optimal (R1)
debulking surgery (TAH + BSO + BPLND + PALNS + OMENTECTOMY + CYTOLOGY) +
CUSA + Right hemicolectomy (Terminal ileum + Appendix +
ascending/transverse colon resection) on 20210111. This time, she
suffered from abdomen pain since 20220120 morning. She was brought to
our ER, her consciousness remained E4V5M6. KUB showed calcification in
LUQ, suspected left renal stone. Abdomen CT revealed pneumoperitoneum
due to hollow organ perforation and carcinomatosis. After GS was
consulted and suggested emergency survey was indicated. She underwent
Exp. lap. with primary repair, lysis of adhesions, segmental bowel
resection with end to end anastomosis excision of peritoneal tumor and
multiple drainage on 20220120.</li>
<li>We need your expertise in evaluation and performing CVC insertion to
facilitate TPN infusion in the immediate future.</li>
</ul></li>
<li>A
<ul>
<li>I will arrange central venous catheterization. Thanks for your
consultation.</li>
</ul></li>
</ul></li>
<li>2022-01-20 gastroenterological surgery
<ul>
<li>Q
<ul>
<li>abdomenial pain VAS 4-7, no fever, nausea +, no diarrhea, deny tarry
or bloody stool</li>
<li>PH: peritoneal cancer s/p op in Jan 2021 at Taipei Veterans General
Hospital</li>
<li>allergy: aspirin</li>
<li>s/p 2 doses of covid vaccine</li>
</ul></li>
<li>A
<ul>
<li>Acute left abdominal pain with fever with chillness for days</li>
<li>P.E showed diffuse local tenderness with muscle guarding esp left
abdomen</li>
<li>Lab and CT in favor of pneumoperitoneum due to hollow organ
perforation and carcinomatosis</li>
<li>Emergency op is indicated</li>
</ul></li>
</ul></li>
</ul></li>
<li>past history
<ul>
<li>Myomectomy 20 years ago.</li>
<li>Primary peritoneal serous carcinoma (omentum, ileum, colon, appendix
involvement), pT3cN0M0, FIGO stage IIIC s/p Optimal (R1) debulking
surgery (TAH + BSO + BPLND + PALNS + OMENTECTOMY + CYTOLOGY) + CUSA +
Right hemicolectomy (Terminal ileum + Appendix + ascending/transverse
colon resection) on 20210111.</li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-20
<ul>
<li>Surgery
<ul>
<li>Exp. lap. with primary repair,lysis of adhesions,segmental bowel
resection with end to end anastomosis excision of peritoneal tumor and
multiple drainage.</li>
</ul></li>
<li>Finding
<ul>
<li>Bowel perforation of upper jejunum, 1.5cm in diameter, cause?</li>
<li>Severe adhesions and desmoplastic reaction over lower abdomen with
focal or segmental bowel ischemic chnage and serosal tear</li>
<li>Multiple small nodules ove peritoneum and mesencary</li>
<li>A lot of turbid fluid over intraabdominal spaces, 100ml in
amount</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Lab data on 2022-04-21, liver and kidney functions, serum
electrolytes and blood cell counts were grossly normal, however the
ca125 level of 823 U/mL was a record high.</li>
<li>The use of a platinum based regimen, specifically
paclitaxel/carboplatin Q3W, is recommended for serous carcinoma of
either low grade or high grade. The addition of bevacizumab can also be
considered.</li>
<li>Acid reflux remains an active issue since 2022-04-22. Some H2
antagonists or PPIs may provide some relief. The prescription for
pantoprazole 40mg IVD QD has been made.</li>
<li>This patient is allergic to aspirin, which is not currently
prescribed.</li>
</ul>
</div>
</div>
<div id="section-89" class="section level1">
<h1>700223143</h1>
<div id="section-90" class="section level2">
<h2>210806</h2>
<p>{flumarin side effect monitoring}</p>
<p>[objective]</p>
<ul>
<li>flumarin (flomoxef sodium) dosing for adult:
<ul>
<li>susceptible infections IV usual dosage: 1 to 2 g per day in 2
divided doses</li>
<li>may increase to 4g per day in 3 to 4 divided doses if needed for
severe or refractory infections.</li>
</ul></li>
<li>flumarin 1g IVD QD is prescribed.</li>
<li>estimated creatinine clearance 10ml/min using the Cockcroft-Gault
equation is based on:
<ul>
<li>age 28 years old</li>
<li>body weight 62.65kg (2021-08-05)</li>
<li>creatinine 7.00mg/dL (2021-08-06)</li>
</ul></li>
<li>according to the drugs package insert, half-life t1/2:
<ul>
<li>healthy adult: 49.6min</li>
<li>patient with 5 &lt; CrCl &lt; 20: 6.95hr</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>half-life for the patient could be 8.4 times long compared to normal
renal function adults.</li>
<li>prescribed dose is a quarter of upper limit of daily use, not as low
as one eighth, might increase the possibility of adverse reactions.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor any signs of adverse reactions possibly caused by
flumarin including:
<ul>
<li>dermatologic: skin rash</li>
<li>endocrine &amp; metabolic: increased gamma-glutamyl transferase</li>
<li>gastrointestinal: diarrhea</li>
<li>hematologic and oncologic: anemia, eosinophilia,
granulocytopenia</li>
<li>hepatic: increased serum alkaline phosphatase, increased serum ALT,
increased serum AST</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-91" class="section level1">
<h1>700261411</h1>
<div id="section-92" class="section level2">
<h2>210901</h2>
<p>{hypophosphatemia, hypokalemia}</p>
<p>[objective]</p>
<ul>
<li>lab data reported on 2021-09-01
<ul>
<li>K(Potassium) 3.0mmol/L, normal 3.5-5.1</li>
<li>P(Phosphous) 1.7mg/dL, normal 2.5-5.0</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>available drug
<ul>
<li>potassium phosphate injection 20mL/amp which contains K 88mEq and P
60mM.</li>
</ul></li>
<li>dosing
<ul>
<li>for patients with mild to moderate hypokalemia (serum potassium 3.0
to 3.4 mEq/L) who do not have ongoing urinary potassium losses, initial
administration of 20 to 80 mEq/day is recommended.</li>
<li>serum phosphate level 1.5 to 2.2 mg/dL, initial 0.16 to 0.32 mmol/kg
(12.8mmol to 25.6mmol for this 80kg patient) over 4 to 6 hours.</li>
</ul></li>
<li>stability
<ul>
<li>must dilute in NS or D5W to a total volume of 100mL or 250mL</li>
<li>for IV infusion only into a central or peripheral vein</li>
<li>do not infuse with calcium-containing intravenous fluids</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>half to one ampoule of 20mL potassium phosphate in no less than
100mL NS or 250mL D5W infusion 4 to 6 hours is recommended.</li>
<li>please monitor serum K, P and EKG routinely to check if the
intervention gets the readings back to normal.</li>
</ul>
</div>
</div>
<div id="section-93" class="section level1">
<h1>700267431</h1>
<div id="section-94" class="section level2">
<h2>220303</h2>
<p>{Compatibility for both Tapimycin and KCl in Suntose}</p>
<ul>
<li>tapimycin in suntose: compatible</li>
<li>potassium chloride in suntose: compatible</li>
<li>both tapimycin and KCl in suntose: no compatibility data availabe
yet, not recommended.</li>
</ul>
</div>
</div>
<div id="section-95" class="section level1">
<h1>700274711</h1>
<div id="section-96" class="section level2">
<h2>210729</h2>
<p>{colon cancer}</p>
<p>[initial presentation]</p>
<ul>
<li>2019-08 intermittent low abdominal cramping pain and fullness, LMD
FOBT positive.</li>
</ul>
<p>[definite diagnosis and disease extent]</p>
<ul>
<li>2019-09-19 patho, hemicolectomy:
<ul>
<li>descending colon, adenocarcinoma, moderately differentiated</li>
<li>IHC stains - EGFR(+), PMS2(+), MLH1(+), MSH2(+), MSH6(+).</li>
<li>pStage IVA, pT3N0M1a</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2019-09-18 laparoscopic left hemicolectomy</li>
<li>2020-01-06 ~ 2020-03-16 FOLFOX x 6 (biweekly for 3 months,
adjuvant)</li>
<li>2021-07-09 VATS RUL wedge resection</li>
<li>2021-07-27 ~ up-to-now FOLFIRI</li>
</ul>
<p>[effect &amp; side effect]</p>
<ul>
<li>2021-07-09 patho, lung wedge biopsy:
<ul>
<li>adenocarcinoma, IHC stains: CK7(-), CK20(+), CDX2(+), TTF-1(-).</li>
<li>the morphology and immunohistochemical stains are consistent with
metastatic colonic tumor.</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>colon cancer
<ul>
<li>assessment
<ul>
<li>FOLFIRI is introduced in the end of July 2021 soon thereafter lung
mets wedge resection</li>
<li>MMR proficient, KRAS/NRAS not detected, BRAF, HER2 lab data not
found.</li>
<li>updated CEA, CA199 within normal limits.</li>
</ul></li>
<li>suggestion
<ul>
<li>keep the ongoing new regimen and surveilling every 3 to 6
months.</li>
<li>bevacizumab might be indicated.</li>
</ul></li>
</ul></li>
<li>HBV
<ul>
<li>lab
<ul>
<li>2021-07-23
<ul>
<li>Anti-HBc reactive</li>
<li>Anti-HBc-Value 5.56 S/CO</li>
</ul></li>
<li>2021-07-22
<ul>
<li>S-GPT/ALT 23 U/L</li>
<li>S-GOT/AST 23 U/L</li>
</ul></li>
</ul></li>
<li>medication
<ul>
<li>baraclude (entecavir 0.5mg) PO QDAC</li>
</ul></li>
<li>assessment
<ul>
<li>in stable condition</li>
</ul></li>
</ul></li>
<li>HTN
<ul>
<li>BP around 130/80 plus or minus 10 the first 2 days this
hospitalization.</li>
<li>medication
<ul>
<li>norvasc (amlodipine 5mg) PO QD</li>
<li>syntrend (carvedilol 25mg) PO QD</li>
</ul></li>
<li>assessment
<ul>
<li>in stable condition</li>
</ul></li>
</ul></li>
<li>BPH
<ul>
<li>medication
<ul>
<li>avodart (dutasteride 0.5mg) PO HS</li>
</ul></li>
<li>assessment
<ul>
<li>in stable condition</li>
</ul></li>
</ul></li>
<li>hypertriglyceridemia
<ul>
<li>lab
<ul>
<li>2021-07-08 494mg/dL</li>
<li>2021-03-31 261mg/dL</li>
<li>2021-01-08 339mg/dL</li>
<li>2020-11-11 322mg/dL</li>
<li>2020-04-13 592mg/dL</li>
</ul></li>
<li>assessment
<ul>
<li>elevated serum TG for at least 1+ year.</li>
</ul></li>
<li>suggestion
<ul>
<li>statin could be considered if not contraindicated.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-97" class="section level1">
<h1>700276060</h1>
<div id="section-98" class="section level2">
<h2>220209</h2>
<p>{Thalidomide/Dexamethasone Interaction}</p>
<p>Dexamethasone might enhance the dermatologic adverse effect and/or
thrombogenic effect of Thalidomide.</p>
<p>Consider using venous thromboembolism prophylaxis in patients with
multiple myeloma who are receiving both thalidomide and dexamethasone,
particularly if the patient is newly diagnosed or has other risk factors
for thromboembolism. Low-molecular-weight heparin or warfarin (at INR of
2.0-3.0) have been proposed as reasonable prophylactic agents. Regarding
the potential dermatologic interaction between thalidomide and
dexamethasone, monitor for any evidence of dermatologic events,
particularly maculopapular or erythematous rash. If evident,
discontinuation of drug therapy or dosage reduction may be required.</p>
</div>
</div>
<div id="section-99" class="section level1">
<h1>700290223</h1>
<div id="section-100" class="section level2">
<h2>999999</h2>
<p>{intrahepatic cholangiocarcinoma}</p>
<p>[initial presentaion]</p>
<ul>
<li>2006-04 Echo
<ul>
<li>Liver cirrhosis (HCV related), liver cysts status post left
lobectomy</li>
<li>Parenchymal renal disease with bilateral renal cysts, GB polyps,
multiple</li>
</ul></li>
<li>2008-10 HCC s/p operation left lobectomy</li>
<li>2010-03-03 Recurrent HCC in S6 s/p S6-segmentectomy</li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2021-04-09 Patho liver biopsy
<ul>
<li>adenocarcinoma, poorly differentiated, compatible with
cholangiocarcinoma</li>
<li>IHC: CK7(+), CK20(focal+), Hepa-1(-) and Arginase-1(-)</li>
</ul></li>
</ul>
<p>[disease extent]</p>
<ul>
<li>cT2N0M0, stage II</li>
</ul>
<p>[treatment]</p>
<ul>
<li>2021-05-26 ~ 2021-05-20 CCRT 3240cGy/18 fractions, gemcitabine</li>
</ul>
<p>[effect and side effect]</p>
<ul>
<li>2021-07-13 CT, ABD
<ul>
<li>s/p op. over left lobe liver with residual choalangiocarcinoma at S4
and liver meta.</li>
<li>the ovarall treatment response is stationary except slghtly increaed
metastatic size.</li>
<li>gallstones.</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<p>HCV, Cirrhosis, Child A - 2021-03-30 - HBsAg Nonreactive - Anti-HBc
Reactive - Anti-HCV Reactive</p>
<p>hypertention, portal hypertension varicose vein GERD type 2 DM</p>
</div>
</div>
<div id="section-101" class="section level1">
<h1>700295989</h1>
<div id="section-102" class="section level2">
<h2>210826</h2>
<p>{duplicated NSAIDs}</p>
<p>[objective]</p>
<ul>
<li>NSAIDs listed in active medication as following:
<ul>
<li>Laston (ketorolac) 30mg IM PRNQ6H</li>
<li>Deflam-K (diclofenac) 25mg PO QID</li>
<li>Deflam-K (diclofenac) 25mg PO QID - patient carried</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>diclofenac could be administered up to 200mg per day.</li>
<li>diclofenac exceeding 100 mg per day might increase risk of vascular
events.</li>
<li>ketorolac is also classified as NSAID.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>either in-hospital prescribed or patient carried diclofenac could be
discontinued if no other clinical considerations.</li>
</ul>
</div>
</div>
<div id="section-103" class="section level1">
<h1>700306021</h1>
<div id="section-104" class="section level2">
<h2>220412</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-14 Patho - pancreas biopsy
<ul>
<li>Labeled as pancreatic head, EUS fine needle biopsy -
adenocarcinoma.</li>
<li>Section shows core of tissue with irregular neoplastic glands and
markedly desmoplastic stroma.</li>
<li>IHC stains: CK19(+), CA19-9(+), CD56(-), p40(-).</li>
</ul></li>
<li>2022-03-14 Fine needle aspiration cytology - pancreas
<ul>
<li>Pancreatic head tumor: adenocarcinoma</li>
</ul></li>
<li>2022-03-11 Endoscopic Retrograde CholangioPancreatography, ERCP
<ul>
<li>Pancreatic head tumor with CBD invasion, s/p TPS, s/p ERBD</li>
<li>Marked dilatation of biliary tree</li>
<li>Inadvertent performance of partial pancreatography</li>
</ul></li>
<li>2022-03-11 Endoscopic ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Pancreatic head tumor, s/p EUS/FNB</li>
<li>Tumor invasion of CBD with marked biliary dilatation</li>
<li>Gastric shallow ulcers and erosions, antrum</li>
<li>Hiatal hernia</li>
</ul></li>
<li>Suggestion
<ul>
<li>Pursue pathology and cytology result</li>
<li>Give PPI after the procedure</li>
</ul></li>
</ul></li>
<li>2022-03-10 MRI - pancreas
<ul>
<li>Pancreatic head cancer (3.3cm) with common hepatic artery, SMA, SMV,
proximal main portal vein, CBD, p-duct. duodenal invasion and LNs
metastases (T4N1M0, stage III).</li>
</ul></li>
<li>2022-03-10 Echocardiography
<ul>
<li>Dilated LA, LV</li>
</ul></li>
<li>2022-03-08 MRI - pancreas
<ul>
<li>In favor of pancreatic head tumor with SMA, SMV, portal vein, distal
CBD, p-duct and duodenal invasion. Some LNs at hepatic hilar
region.</li>
</ul></li>
<li>2022-03-07 Endoscopic ultrasonography
<ul>
<li>Pancreatic tumor with cystic components, head, probable pancreatic
cancer</li>
<li>MPD dilatation</li>
<li>CBD dilatation and sludge</li>
<li>Distended GB with sludge</li>
<li>Esophageal erosion, lower esophagus</li>
</ul></li>
<li>2022-03-07 Abdominal sonography
<ul>
<li>Pancreatic head tumor, suspected cancer</li>
<li>Bilateral IHD and CBD dilatation</li>
<li>Distented gallbladder</li>
</ul></li>
<li>2022-03-05 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Soft tissue mass at uncinate process of the pancreas with
obliteration of the CBD up to 2.09cm is found, causing IHDs and CBD
dilatation. Pancreatic cancer is suspected. The SMV is attached by the
tumor.</li>
</ul></li>
<li>2020-07-06 MRA - brain
<ul>
<li>T2 hyperintensities in bilaetral white matter and periventricular
region, suspected chronic ischemic or other demyelinating white matter
change.</li>
<li>Brain atrophy.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-03-08 Gastroenterology &amp; General Surgery
<ul>
<li>Impression
<ul>
<li>Pancreatic head tumor, IHDs and CBD dilatation</li>
</ul></li>
<li>Suggestions:
<ul>
<li>Insert PTCD/endo stent first due to hyperbilirubinemia.</li>
<li>Check blood sugar HbA1c, glucose AC/PC.</li>
<li>Arrange cardiopulmonary function tests such as cardiac echo and lung
function test due to old age.</li>
<li>We will evaluate the need of the operation after her
hyperbilirubinemia subsided.</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-03-29 ~ 2022-04-11 - 720cGy/4 fractions (15 MV photon) to
pancreatic head tumor and lymphatics</li>
<li>Neoadjuvant C/T and R/T for 5040cGy/28 fractions is sugested for
downstage and tumor control.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-28 ~ undergoing - FOLFIRINOX, pre-Op neoadjuvant C/T
<ul>
<li>oxaliplatin 50mg/m2 2hr</li>
<li>irinotecan 90mg/m2 2hr</li>
<li>leucovorin 400mg/m2</li>
<li>5-Fu 2000mg/m2 46hr</li>
</ul></li>
</ul></li>
</ul>
<p>[reference]</p>
<ul>
<li>FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with
advanced pancreatic cancer: A population-based cohort study. <a href="https://dx.doi.org/10.4251/wjgo.v12.i3.332" class="uri">https://dx.doi.org/10.4251/wjgo.v12.i3.332</a>
<ul>
<li>FOLFIRINOX was administered according to the standard schedule
validated by the PRODIGE 4/ACCORD 11 study. This regimen consisted of a
combination of oxaliplatin (85 mg/m2, over 2 h), followed by leucovorin
(400 mg/m2, over 2 h), with the addition through a Y-connector, after 30
min, of irinotecan (180 mg/m2, over 90 min), followed by 5-FU (400
mg/m2) by intravenous bolus, on Day 1. Then, a continuous intravenous
infusion of 5-FU (2400 mg/m2) was administered over 46 h starting on Day
1.
<ul>
<li>oxaliplatin 85mg/m2 2hr</li>
<li>leucovorin 400mg/m2 2hr</li>
<li>irinotecan 180mg/m2 90min</li>
<li>5-FU 400mg/m2 IV bolus</li>
<li>5-FU 2400mg/m2 46h</li>
</ul></li>
<li>FOLFOXIRI consisted of the same molecules with a reduced dose of
irinotecan and no bolus 5-FU, according to the GONO regimen used in
metastatic colorectal cancer: Irinotecan (165 mg/m2, over 1 h), followed
by oxaliplatin (85 mg/m2) and leucovorin (200 mg/m2) concomitantly over
2 h through a Yconnector, on Day 1; and followed by a continuous
intravenous infusion of 5-FU (3200 mg/m2) over 48 h starting on Day 1.
<ul>
<li>irinotecan 165mg/m2 1hr</li>
<li>oxaliplatin 85mg/m2</li>
<li>leucovorin 200mg/m2 2hr</li>
<li>5-FU 3200mg/m2 48hr</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>There is a case of pancreatic head cancer with common hepatic
artery, superior mesenteric artery, superior mesenteric vein, proximal
main portal vein, CBD, pancreatic duct, duodenal invasion and lymph node
metastases (2022-03-10 MRI).</li>
<li>If jaundice is present, placement of a self-expanding metal stent is
recommended, preferably via ERCP. ERBD was performed via ERCP on
2022-03-11. Bilirubin total decreased from its peak of 13.75mg/dL on
2022-03-07 to 1.86mg/dL on 2022-04-11.</li>
<li>The patient has been given 720cGy/4 fractions (15 MV photon) to
treat the pancreatic head tumor and lymphatics (2022-03-29 to
2022-04-11) and has been receiving neoadjuvant FOLFIRINOX to downstage
the tumor since 2022-03-28.</li>
<li>Tumor/somatic gene profiling is recommended for patients with
locally advanced/metastatic disease who are candidates for anti-cancer
therapy to identify uncommon mutations. Consider specifically testing
for actionable somatic findings including, but not limited to: fusions
(ALK, NRG1, NTRK, ROS1), mutations (BRAF, BRCA1/2, HER2, KRAS, PALB2),
and mismatch repair (MMR) deficiency (detected by tumor IHC, PCR, or
NGS). Testing on tumor tissue is preferred; however, cell-free DNA
testing can be considered if tumor tissue testing is not feasible.</li>
<li>The laboratory results reported on 2022-04-11 showed normal ALT and
creatinine readings as well as lower WBC (2930/uL, Neutrophil 58%),
which should not affect the chemotherapy treatment in this hospital
stay.</li>
<li>No drug allergy records found in database, no issue with current
medication.</li>
</ul>
</div>
</div>
<div id="section-105" class="section level1">
<h1>700309329</h1>
<div id="section-106" class="section level2">
<h2>220309</h2>
<p>{rt breast ca (TNBC), cT2N0M0 stage IB}</p>
<ul>
<li>exam finding
<ul>
<li>2020-11 recurrence</li>
</ul></li>
<li>surgical operation
<ul>
<li>2018-10 at WanFang Hospital</li>
</ul></li>
<li>chemotherapy
<ul>
<li>ongoing oral vinorelbine</li>
<li>2021-05 ~ 2021-10 Eribulin / Xeloda</li>
<li>2021-02 ~ 2021-04: Taxol + Gem</li>
<li>2020-12 ~ 2021-01 EP x 3</li>
<li>2018-18 ~ ?: post-Op adjuvant CAP</li>
<li>2018-07 ~ 2018-09 pre-Op neoadjuvant TAC x 3</li>
<li>2018-05 ~ 2018-06 pre-Op neoadjuvant C/T x CEF x 3</li>
</ul></li>
<li>shared decision making
<ul>
<li>2022-03-01
<ul>
<li>effective Tx option had been tried and failed. hospice care had been
recommended at WanFang Hospital.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Use of preoperative systemic therapy may provide important
prognostic information based on response to therapy. Achieving a
pathologic complete response (pCR) to neoadjuvant therapy is associated
with favorable disease-free and OS in early-stage breast cancer. The
correlation between pathologic response and long-term outcomes in
patients with early-stage breast cancer is strongest for patients with
triple-negative breast cancer.
<ul>
<li>references:
<ul>
<li>Liedtke C, Mazouni C, Hess KR, et al.Response to neoadjuvant
therapy and long-term survival in patients with triple-negative breast
cancer. J Clin Oncol 2008;26:1275-1281. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18250347" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/18250347</a>.</li>
<li>Cortazar P, Zhang L, Untch M, et al.Pathological complete response
and long-term clinical benefit in breast cancer: the CTNeoBC pooled
analysis. Lancet 2014;384:164-172. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24529560" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/24529560</a>.</li>
<li>von Minckwitz G, Untch M, Blohmer JU, et al.Definition and impact
of pathologic complete response on prognosis after neoadjuvant
chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol
2012;30:1796-1804. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22508812" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/22508812</a>.</li>
</ul></li>
</ul></li>
<li>Different subsequent chemotherapy regimen did not yield satisfactory
results for this patient.</li>
<li>Biomarkers such as BRCA1/2, PIK3CA, PD-L1, NTRK, MSI-H/dMMR, or
TMB-H not found in the system, or targeted drugs may provide an
alternative approach.</li>
</ul>
</div>
</div>
<div id="section-107" class="section level1">
<h1>700321047</h1>
<div id="section-108" class="section level2">
<h2>210812</h2>
<p>{statin dose intensity and equivalency}</p>
<p>All the oral drugs in active medication have been reviewed and can be
administered via NG tube.</p>
<p>Pravafen has not been found in active medication yet.</p>
<p>Pravafen should not be grinded or half-peeled. It contains
fenofibrate 160mg and pravastatin 40mg, there is Lipanthyl Supra
(fenofibrate 160mg) available in hospital, however pravastatin 40mg is
out of stock for now.</p>
<p>Fluvastatin 80mg, lovastatin 80mg, simvastatin 20mg, pitavastatin
2mg, atorvastatin 10mg, rosuvastatin 5mg are alternatives for
pravastatin 40mg. reference: <a href="http://www.mqic.org/pdf/UMHS_Statin_Dose_Intensity_and_Equivalency_Chart.pdf" class="uri">http://www.mqic.org/pdf/UMHS_Statin_Dose_Intensity_and_Equivalency_Chart.pdf</a></p>
</div>
</div>
<div id="section-109" class="section level1">
<h1>700334023</h1>
<div id="section-110" class="section level2">
<h2>220303</h2>
<p>{Panceratic carcinoma, cT1N1M1 (left neck subclavicle mets), stage
IV}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-17 CT - lung/mediastinum/pleura
<ul>
<li>distal pancreatic cancer with regression of neck LNs metastases but
progression of retroperitoneal para-aortic LNs metastases, new left
adrenal metastasis, and resolution cystic component at pancreatic tail
as compared with previous chest, neck, and abdominal CT exams.</li>
<li>favor hepatic cysts, cannot totally rule out small metastatic
lesions, stationary</li>
</ul></li>
<li>2021-10-11 CT - neck
<ul>
<li>multiple left low neck and supraclavicular fossa LAPs.</li>
</ul></li>
<li>2021-09-20 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>A soft tissue nodule (2.5cm) at LUQ.</li>
<li>Enlarged LNs at paraaortic region.</li>
</ul></li>
<li>2021-06-12 CT - whole abdomen, pelvis
<ul>
<li>metastatic paraaortic lymph nodes with partial response.</li>
<li>atrophy of pancreatic tail with dilated P-duct.</li>
<li>suspected liver cysts.</li>
</ul></li>
<li>2021-03-05 Patho - lymphnode biopsy
<ul>
<li>tissue, intraabdominal lymph node, biopsy - poorly differentiated
carcinoma</li>
<li>IHC: CK7(+), CDX-2(+), CK(+), CK20(-).</li>
</ul></li>
<li>2021-03-05 Cytology
<ul>
<li>positive for malignancy<br />
</li>
<li>smears show clusters of atypical tumor cells with nuclear
hyperchromasia, pleomorphism and high N/C ratio.</li>
</ul></li>
<li>2021-03-04 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the hypopharynx. The nature is to be
determined (inflammation/infection? malignancy?).</li>
<li>A glucose hypermetabolic in the left upper abdomen just between the
stomach and spleen. Malignancy (colon malignancy?) in this region should
be watched out. However, no prominent abnormal focal FDG uptake was
noted in the pancreas.</li>
<li>Glucose hypermetabolism in multiple left neck level V and left
supraclavicular lymph nodes, a mediastinal A-P window lymph node and
multiple abdominal paraaortic and right plevic lymph nodes, compatible
with multiple metastatic lymph nodes.</li>
<li>Mild glucose hypermetabolism in the stomach, some mediastinal right
paratracheal lymph nodes, right pulmonary hilar lymph nodes and a left
axillary lymph node. Inflammatory process is more likely.</li>
</ul></li>
<li>2021-02-22 Patho - soft tissue
<ul>
<li>Lymph node, left neck, excision - metastatic carcinoma, poorly
differentiated consistent with gastrointestinal or pancreatobiliary
origin</li>
<li>IHC: CK7(focal +), CK20(-), CDX2(+), CK5/6(-), TTF-1(-), CD56(-),
and GATA3(-).</li>
</ul></li>
<li>2021-02-18 CT - lung/mediastinum/pleura
<ul>
<li>Atrophy of the pancreatic tail with dilated distal pancreatic duct
is found. suspected IPMT, suggest EUS/ERCP.</li>
<li>Lymphadenopathy at left thoracic inlet and paraaortic region.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-02-22 Excision- a 1.5x2x2 cm soft tumor over Lt supraclavicle
region.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02 ~ ongoing: 5-Fu + leucovorin + irinotecan liposome, Q2W</li>
<li>2021-04 ~ 2022-01: gemcitabine + nal-paclitaxel, Q2W</li>
<li>2021-03: gemcitabine</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Most recent CT images (2022-01-17) showed regression of neck LNs
metastases, progression of retroperitoneal para-aortic LNs metastases,
new left adrenal metastasis. Each metastasis has its own ups and downs.
In general, the disease is still advancing.</li>
<li>FOLFIRINOX or modified FOLFIRINOX should be limited to those with
ECOG 0-1.</li>
<li>Gemcitabine + albumin-bound paclitaxel is reasonable for patients
with ECOG 0-2. (Apr 2021 to Jan 2022)</li>
<li>5-FU + leucovorin + liposomal irinotecan is a reasonable subsequent
therapy option for patients with ECOG 0-2. (since Feb 2022)</li>
<li>Sympathomimetics for glaucoma prescribed by ophthalmology OPD might
be added as a self-carried item into current medication.</li>
</ul>
</div>
</div>
<div id="section-111" class="section level1">
<h1>700335277</h1>
<div id="section-112" class="section level2">
<h2>220315</h2>
<p>{drug identification}</p>
<p>Two drugs need identification.</p>
<p>the 2 identified items has been shown as following:</p>
<ul>
<li>Duodart (tamsolosin 0.4mg, dutasteride 0.5mg)</li>
<li>Urosin (atenolol 100mg)</li>
</ul>
<p>these drugs will be sent back to ward by an in-hospital porter.</p>
</div>
</div>
<div id="section-113" class="section level1">
<h1>700341500</h1>
<div id="section-114" class="section level2">
<h2>220318</h2>
<p>{colon cancer with liver mets}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-22 Cardiac catheterization
<ul>
<li>Coronary artery disease, 1VD, m-LAD; Syntax score 9 s/p POBA and
stenting with Boston SYNERGY Drug-eluting stent. 4.0 X 48 mm for
proximal LAD to middle LAD.</li>
<li>Patient had take PPI and gastritis history, shift ticagrelor to
clopiodgrel later.</li>
</ul></li>
<li>2021-12-23 Patho - colorectal polyp
<ul>
<li>A. Colon, transverse colon, s/p hot snare polypectomy (E) -
Tubulovillous adenoma with low grade dysplasia.</li>
<li>B. Colon, 10cm to 20cm AAV, s/p biopsy (F) - Adenocarcinoma.
<ul>
<li>IHC: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+).<br />
</li>
</ul></li>
</ul></li>
<li>2021-12-23 Colonoscopy
<ul>
<li>Colon polyp, transverse colon, s/p EMR and clipping.</li>
<li>Highly suspected colon cancer, 1-cm to 20cm AAV, s/p biopsy.</li>
<li>Colon polyps, s/p polypectomy and biopsy, at least four residue
polyps not polypectomized.</li>
</ul></li>
<li>2021-12-21 CT - abdomen - liver, spleen, biliary duct, pancreas
<ul>
<li>Suspected rectosigmoid cancer with liver and left adrenal
metastasis.</li>
<li>Small right lung nodule, suspected lung metastasis.</li>
<li>Right renal stones. Left middle ureteral stone with
hydronephrosis.</li>
</ul></li>
<li>2021-12-17 Abdominal ultrasound
<ul>
<li>Parenchymal liver disease, suspected liver cirrhosis.</li>
<li>Hepatic tumors, HCC with portal vein invasion or metastatic tumor
with vessel compression were suspected.</li>
<li>Left hydronephrosis, mild</li>
<li>Splenomegaly</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-06 ~ ongoing - FOLFIRI (plus bevacizumab since
2022-01-20)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>As reported by the laboratory on 2022-03-17, the patient has normal
liver function, but decreased renal function (creatinine 1.46 mg/dL),
slightly low RBC (3.92*10^6/uL) and HGB (11.3 g/dL) readings.</li>
<li>The patient is currently receiving FOLFIRI plus bevacizumab, and no
reports of diarrhea were found in the nursing notes during this hospital
stay.</li>
<li>5-FU has been associated with cardiac toxicity including myocardial
infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac
failure, sudden death, ECG changes, and cardiomyopathy. There is no
recommended dose for resumption of FU administration following
development of cardiac toxicity.
<ul>
<li>reference:
<ul>
<li><a href="https://www.uptodate.com/contents/image/print?imageKey=ONC%2F76300" class="uri">https://www.uptodate.com/contents/image/print?imageKey=ONC%2F76300</a></li>
<li><a href="https://www.uptodate.com/contents/fluoropyrimidine-associated-cardiotoxicity-incidence-clinical-manifestations-mechanisms-and-management" class="uri">https://www.uptodate.com/contents/fluoropyrimidine-associated-cardiotoxicity-incidence-clinical-manifestations-mechanisms-and-management</a></li>
<li><a href="https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-7-212" class="uri">https://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-7-212</a></li>
<li><a href="https://www.frontiersin.org/articles/10.3389/fcvm.2021.713694/full" class="uri">https://www.frontiersin.org/articles/10.3389/fcvm.2021.713694/full</a></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-115" class="section level1">
<h1>700348580</h1>
<div id="section-116" class="section level2">
<h2>999999</h2>
<ul>
<li><p>2018-10 diarrhea on and off</p></li>
<li><p>2020-11-12 patho - colon biopsy</p>
<ul>
<li>pieces of colonic tissue with invasive irregular neoplastic
glands.</li>
<li>immunohistochemical stains - EGFR(+), PMS2(+), MLH1(+), MSH2(+), and
MSH6(+).</li>
</ul></li>
<li><p>2020-11-12 CT, ABD: cT3N2aMia, stage IVA Re-evaluation on
12/14/2020 slightly decreased in tumor size.</p></li>
<li><p>2020 late Nov ~ 2021 early Jan CCRT, FU/LV 5040 cGy/28Fx in hope
of receiving sphincter preserving surgery (Last RT on 1/5).</p></li>
<li><p>2021 Feb there after chemo FOLFOX</p></li>
<li><p>2021-02-18 CT, ABD: much regression of rectal cancer.</p></li>
</ul>
<p>2021-03-10 Op Method: Abdominoperineal resection (APR)<br />
Finding: 1. Tumor in rectum, cT3N2aM1a (enlarged nodes in left external
iliac chain) 2. End S colostomy is done over LLQ<br />
3. One JV drain at pelvic area</p>
<p>rectal cancer, cT3N2aM1a s/p CCRT, was admitted for scheduled
laparoscopic APR with permanent colostomy. - 2021-03-18 patho -
abdomino-perineum resection - ypT3N1aMia stage IVA</p>
<p>2021-05-13 Self-Monitoring of Blood Glucose,SMBG QDAC</p>
<p>PatMRNo, PatID, PatName, PatBDate, PatGender</p>
<p>Brosym 4g Q12H</p>
<p>assumed 50kg body weight with Cockcroft-Gault formula, the estimated
CrCl is 25mL/min, daily maximal dose is 4g (2g Q12H) according to
package insert.</p>
<p>cefoperazone sulbactam</p>
<p>daily maximal 4g (2g Q12H)</p>
<p>Nexium (esomeprazole) should not be grinded, shifting to Takepron
(lansoprazole) is recommended.</p>
<p>Actein should be dissolved in adequate drinking water prior to tube
feeding.</p>
<p>thanks and regards,</p>
<p>all the oral drugs in active medication can be administrated via NG
tube except Doxaben XL (doxazosin) which is release-controlled.</p>
<p>Urief (silodosin) is recommended as an alternative to switch
Doxaben.</p>
<p>thanks and regards,</p>
<p>omeprazole lansoprazole pantoprazole rabeprazole</p>
</div>
</div>
<div id="section-117" class="section level1">
<h1>700350999</h1>
<div id="section-118" class="section level2">
<h2>210510</h2>
<p>{problem list}</p>
<p>active problems listed in 2021-05-08 14:14 DutyNote containing 2
items: - urinary tract infection - right lower lung pneumonia</p>
<p>[subj/obj]</p>
<ul>
<li>admitted on 2021-05-08 for lethargy, weakness for 5 days and fever
for 1 day.</li>
<li>with underlying HFrEF, bladder cancer s/p TURBT, HCVD, CKD and DM,
been regularly followed up at our cardiology, urology, metabolism
departments.</li>
<li>bladder cancer causing voiding difficulties and UTI</li>
<li>K 3.1mmol/L (2021-05-10), 3.1mmol/L (2021-05-08)</li>
<li>BUN 123mg/dL (2021-05-10), 101mg/dL (2021-05-08)</li>
<li>Creatinine 4mg/dL (2021-05-10), 3mg/dL (2021-05-08)</li>
<li>eGFR 15 (2021-05-10), 20 (2021-05-08)</li>
<li>CRP 8.63 (2021-05-10), 5.31 (2021-05-08)</li>
<li>RBC 4x10^6/uL (2021-05-10), 3.7x10^6/mL (2021-05-08)</li>
<li>HGB 11.6g/dL (2021-05-10), 10.8 (2021-05-08)</li>
<li>MCV 84.8 fL (2021-05-10), 86.2 fL (2021-05-08)</li>
<li>urine OB 2+, sediment-RBC 6-9, sediment-WBC &gt;= 100, Bacteria 3+
(2021-05-08)</li>
<li>hs-Troponin I 385pg/mL (2021-05-08)</li>
<li>serum glucose 177mg/dL (2021-05-08), records fluctuate between
126-226 from 2021-05-08 19:00 to 2021-05-10 11:30.</li>
<li>HbA1c 8.1 (2021-04-27), 8.6 (2021-03-01), 10.1 (2020-12-11), 9.6
(2020-09-17), 9.8 (2020-06-24)</li>
<li>Uric Acid 4.6mg/dL (2021-03-01), 6.1 (2021-01-19), 8.1 (2020-12-11),
9.3 (2020-09-17), 8.6 (2020-06-24)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>vital signs looks relatively stable:
<ul>
<li>body temp no more than 37.5 degrees Celsius since 2021-05-08, the
fever has subsided.</li>
<li>most of time SBP ranges in around 120-130, DBP 60-80, 3-day data
showed BP is under well management.</li>
</ul></li>
<li>if there is no other special consideration, the first priority
should be controlling the infections.
<ul>
<li>avelox (moxifloxacin) 400mg IVD QD has been administrated since
2021-05-09 and scheduled till 2021-05-15.</li>
<li>the patient has poor renal function, but no dosage adjustment
necessary for avelox administration.</li>
</ul></li>
<li>although fever has gone, the rising CRP might hint the infection is
still ongoing.</li>
<li>the lower serum potassium might caused by uretropic
(furosemide).</li>
<li>lab data showed that blood suger flucturates in short-term (serum
glucose), however the management is getting better in mid-term (HbA1c).
<ul>
<li>using humalog mix50 pen (insulin lispro 50%, insulin lispro
protamine 50%) QDAC and QNAC now.</li>
</ul></li>
<li>MCV almost touched the lower limit of the normal range, some iron
supplements might be helpful for boosting up the hemoglobin level.</li>
<li>uric acid seems fell into normal range for months, xanthine oxidase
inhibitor could be no more necessary.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep abx using and monitoring any change of infection signs.</li>
<li>invite dietitian to help the patient to get more
potassium-containing food, and/or consider to shift uretropic
(furosemide) to potassium sparing spironolactone.</li>
<li>foliromin (ferrous sodium citrate, 50mg) BID for 2-4 weeks to
levelup hemoglobin is recommended, administrated in combination with vit
C to help absorption can be considered.</li>
<li>if there is no special consideration, discontinuation feburic
(febuxostat) is recommended.</li>
</ul>
</div>
</div>
<div id="section-119" class="section level1">
<h1>700356362</h1>
<div id="section-120" class="section level2">
<h2>220406</h2>
<p>{Pseudomyxoma peritonei (mucinous carcinoma peritonei), grade 1}</p>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>malignant neoplasm of appendix</li>
<li>secondary malignant neoplasm of retroperitoneum and peritoneum</li>
<li>hypertensive chronic kidney disease with stage 5 chronic kidney
disease or end stage renal disease</li>
<li>anemia, unspecified</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-04-02 Chest PA/AP view
<ul>
<li>Supine chest image shows:
<ul>
<li>elongated and tortuosity of thoracic aorta and calcified
atherosclerotic change at aortic arch</li>
<li>reticular opacities over Lt lower lung zone</li>
<li>marginal spurs of multiple vertebral bodies</li>
</ul></li>
</ul></li>
<li>2022-03-28 Body fluid cytology - ascites
<ul>
<li>Atypia</li>
<li>Smears show mucinous material, neutrophils and reactive mesothelial
cells.</li>
</ul></li>
<li>2022-01-17 Tc-99m MDP whole body bone scan
<ul>
<li>Faint hot spots in the left 11th costovertebral junction and both
rib cages, the nature is to be determined (DJD, post-traumatic change or
other nature ?), suggesting follow-up with bone scan in 3-6 months for
further evaluation.</li>
<li>Suspected benign lesions in the maxilla, some T- and L-spine,
bilateral shoulders, hips, and ankles.</li>
</ul></li>
<li>2022-01-17 MRA - brain
<ul>
<li>Mild general brain atrophy. Left mastoiditis. Bilateral chronic
paranasal sinusitis.</li>
</ul></li>
<li>2022-01-13 CT - CTA, chest
<ul>
<li>Post op. change of the abodominal cavity.</li>
<li>Locualted effusion at RLQ of the abdomen. Nature?</li>
<li>No evidence of pulmonary embolism nor aortic dissection is
found.</li>
<li>Some small patches at both lungs. suspected infection.</li>
</ul></li>
<li>2022-01-13 CT - brain
<ul>
<li>Mild ventriculomegaly. Intracraniaal artherosclerosis.</li>
</ul></li>
<li>2022-01-13 KUB
<ul>
<li>The psoas shadow is clear.</li>
<li>Degenerative change of the bony structure with marginal osteophyte
formation is identified.</li>
<li>Increased intestinal gas is found.</li>
<li>Osteopenia of the bony structure is noted.</li>
</ul></li>
<li>2021-12-31 Patho - soft tissue tumor, extensive resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Peritoneum, RUQ and right flank, peritonectomy - Pseudomyxoma
peritonei (mucinous carcinoma peritonei), grade 1</li>
<li>Round ligament of liver, excision - Pseudomyxoma peritonei (mucinous
carcinoma peritonei), grade 1</li>
<li>Greater omentum, omentectomy - Pseudomyxoma peritonei (mucinous
carcinoma peritonei), grade 1</li>
</ul></li>
<li>microscopic examination
<ul>
<li>The sections show a picture of pseudomyxoma peritonei (mucinous
carcinoma peritonei), grade 1, composed of abundant mucin with scant
cohesive strips of low-grade mucinous epithelium.</li>
</ul></li>
</ul></li>
<li>2021-12-27 Patho - pleural/pericardial biopsy
<ul>
<li>Lung, left, CT-guide biopsy - interstitial fibrosis and chronic
inflammation - atypical pneumocyte present<br />
</li>
<li>Sections show alveolar lung tissue with interstitial fibrosis,
chronic inflammatory cell infiltration and atypical pneumocyte
proliferating along the alveolar wall.</li>
<li>No granuloma or malignancy is found.</li>
<li>IHC: CK7(+), CK20(-), TTF-1(+), Napsin A(+), and CDX2(-).</li>
</ul></li>
<li>2021-12-14 CT - lung/mediastinum/pleura
<ul>
<li>lung infection or aspiration pneumonia.</li>
<li>peritoneal carcinomatosis. RUQ free air due to infection or prior
abdominal intervention.</li>
</ul></li>
<li>2021-12-06 Patho - peritoneum biopsy
<ul>
<li>diagnosis
<ul>
<li>Omentum, biopsy - metastatic mucinous adenocarcinoma, origin?</li>
<li>Peritoneum, biopsy - metastatic mucinous adenocarcinoma,
origin?</li>
</ul></li>
<li>IHC: CK7(-), CK20(+), CDX2(+), and PAX8(-). The results are in favor
of GI tract (including appendix) tumor.</li>
</ul></li>
<li>2021-12-03 Colonoscopy
<ul>
<li>mixed hemorrhoid</li>
<li>no tumor was found in colonic lumen</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-30
<ul>
<li>omentectomy</li>
<li>RUQ and right flank peritonectomy</li>
<li>CAPD (continuous ambulatory peritoneal dialysis)</li>
<li>IP port implantation</li>
</ul></li>
<li>2021-12-06 Laparoscopic exploration and biopsy
<ul>
<li>Post-Op Dx: suspect pseudomyxoma peritoni</li>
<li>Finding
<ul>
<li>Multiple white nodular lesions within omentum and peritoneal surface
were noted. pieces were excised of them for biopsy.</li>
<li>Gelly like ascites about 100 ml and ascites cytology was done.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-09 ~ undergoing - docetaxel + cisplatin + gentamicin + TS-1
(tegafur + gimeracil + oteracil)
<ul>
<li>Neoadjuvant Intraperitoneal Chemotherapy in Patients with
Pseudomyxoma Peritonei - A Novel Treatment Approach
<ul>
<li>Cancers 2020, 12(8), 2212; <a href="https://doi.org/10.3390/cancers12082212" class="uri">https://doi.org/10.3390/cancers12082212</a></li>
</ul></li>
</ul></li>
<li>2021-12-30 - oxaliplatin + gentamicin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This is a patient with pseudomyxoma peritonei (PMP), s/p
omentectomy, RUQ and right flank peritonectomy (2021-12-30) and
hyperthermic intraperitoneal chemotherapy (HIPEC).</li>
<li>From 2022-02-09, he has been receiving intraperitoneal [docetaxel
plus cisplatin + gentamicin] in combination with oral TS-1, a regimen
which was published at <a href="doi:10.3390/cancers12082212" class="uri">doi:10.3390/cancers12082212</a>.</li>
<li>Hypoosmolarity and hypoelectrolytemia are treated with appropriate
electrolyte solutions.</li>
<li>A low WBC reading of 910/uL was recorded on 2022-04-05. G-CSF might
be an option.</li>
</ul>
</div>
</div>
<div id="section-121" class="section level1">
<h1>700358478</h1>
<div id="section-122" class="section level2">
<h2>220428</h2>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>Adenocarcinoma of splenic flexure colon with obstruction, and liver,
lung, bone metastasis with carcinomatosis, cT3N2bM1c, stage IVC status
post colostomy on 2021-10-06</li>
</ul></li>
<li>exam findings
<ul>
<li>2022-04-16 Chest AP - portable
<ul>
<li>S/P port-A implantation.</li>
<li>Multiple osteoblastic bony metastases in the ribs and spine are
noted.</li>
<li>A nodular opacity projecting in the left lower lung is suspected.
Please correlate with CT.</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
</ul></li>
<li>2022-04-15 CT - abdomen, pelvis
<ul>
<li>Splenic flexure colon cancer with multiple metastatic nodes in the
adjacent omentum and mesentery, multiple metastases in the liver, lung
and bone S/P C/T show partial response.</li>
<li>RCC 2.4 cm at left kidney lower pole shows stationary.</li>
<li>The differential diagnosis include angiomyolipoma (lipid-poor).
Follow up is indicated.</li>
</ul></li>
<li>2022-03-31 Chest PA erect view
<ul>
<li>Multiple osteoblastic bony metastases in the ribs and spine are
noted.</li>
<li>A nodular opacity projecting in the left lower lung is suspected.
Please correlate with CT.</li>
<li>Peri-bronchial wall thickening of the right and left lower lung zone
is noted, which may be due to inflammatory process. Please correlate
with clinical history and symptom.</li>
</ul></li>
<li>2022-03-11 Bronchial dilation test
<ul>
<li>Moderate obstructive ventilatoryimpairment without significant
reversibility</li>
<li>FEV1/FVC = 45%, FVC = 96%, FEV1 = 54%</li>
</ul></li>
<li>2022-03-10 Chest PA
<ul>
<li>Multiple osteoblastic bony metastases in the ribs and spine are
noted.</li>
<li>A nodular opacity projecting in the left lower lung is
suspected.</li>
</ul></li>
<li>2022-01-19 CT
<ul>
<li>Findings:
<ul>
<li>Prior CT identified lobulated segmental wall thickening in the
splenic flexure colon is noted again, mild decreasing in size.
<ul>
<li>In addition, prior CT identified multiple metastatic nodes in the
surrounding mesentery and omentum are noted again, decreasing in
size.</li>
</ul></li>
<li>Prior CT identified mutliple metastases on both hepatic lobes are
noted again, decreasing in size.
<ul>
<li>The size of S5 metastasis in prior and current CT is measured 3.1 cm
and 2.5 cm, respectively.</li>
</ul></li>
<li>Prior CT identified mutliple metastases on both lung are noted
again, decreasing in size.
<ul>
<li>The size of LUL metastasis in prior and current CT is measured 2 cm
and 1.5 cm, respectively.</li>
</ul></li>
<li>Prior CT identified multiple osteoblastic bony metastases in the
L-spine and bilateral ilium are noted again, increasing density that may
be bony metastases with progressive disease.</li>
<li>Prior CT suspected renal cell carcinoma measuring 2 cm in left
kidney lower pole is noted again, stable in size.
<ul>
<li>The differential diagnosis include angiomyolipoma (lipid-poor).</li>
</ul></li>
<li>Abdominal aorta aneurysm measuring 3.3 cm in diameter with
atherosclerotic change and mural thrombosis is noted.
<ul>
<li>Right common iliac artery also shows aneurysm 1.7 cm in diameter
with mild mural thrombus formation.</li>
</ul></li>
<li>Adenoma 0.9 cm in left adrenal gland it noted.</li>
</ul></li>
<li>Impression:
<ul>
<li>Splenic flexure colon cancer with multiple metastatic nodes in the
adjacent omentum and mesentery, and multiple metastases in the liver and
lung S/P C/T show partial response.</li>
<li>Multiple bony metastases show more osteoblastic change.</li>
<li>RCC 2 cm at left kidney lower pole shows stationary. The
differential diagnosis include angiomyolipoma (lipid-poor). Follow up is
indicated.</li>
</ul></li>
</ul></li>
<li>2021-09-29 CT
<ul>
<li>Findings:
<ul>
<li>There is lobulated segmental wall thickening in the splenic flexure
colon measuring 1.7 cm in wall thickness, causing lumen narrowing that
is compatible with adenocarcinoma with impending obstruction.
<ul>
<li>In addition, there are multiple metastatic nodes in the surrounding
mesentery and omentum, and the largest one 2.2 cm.</li>
</ul></li>
<li>There are mutliple poor enhancing masses on both hepatic lobes and
the largest one measuring 3.1 cm in S5 that are compatible with liver
metastases.</li>
<li>There are several osteoblastic change of the L-spine and bilateral
ilium that are compatible with bony metastases.</li>
<li>Abdominal aorta aneurysm measuring 3.3 cm in diameter with
atherosclerotic change and mural thrombosis is noted.
<ul>
<li>Right common iliac artery also shows aneurysm 1.7 cm in diameter
with mild mural thrombus formation.</li>
</ul></li>
<li>There are few small soft tissue nodules in both lower lung that are
compatible with lung metastases.</li>
<li>There is a well-defined heterogeneous poor enhancing mass measuring
2 cm in left kidney lower pole that may be RENAL CELL CARCINOMA. The
differential diagnosis include metastasis.
<ul>
<li>Please correlate with contrast enhanced dynamic CT or MRI.</li>
</ul></li>
<li>Adenoma 0.9 cm in left adrenal gland it noted.</li>
<li>Imaging stage: T3N2bM1c stage IVC</li>
</ul></li>
</ul></li>
<li>2021-09-28 Patho - Colon biopsy
<ul>
<li>Colon, splenic flexure, biopsy - Adenocarcinoma, moderately
differentiated</li>
<li>The secvtions show a picture of adenocarcinoma, composed of columnar
neoplastic cells, arranged in glandular patterns with desmoplastic
stromal reaction.</li>
<li>IHC, tumor cells reveal: EGFR(-), MLH1(+), PMS2(+), MSH2(+), and
MSH6(+).</li>
</ul></li>
<li>2021-09-23 CT
<ul>
<li>Imaging stage: T4N2M1</li>
<li>Imp: Colon cancer at splenic flexure with liver, lung and bone
mets.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>CEA
<ul>
<li>2022-04-27 2063ng/mL</li>
<li>2022-03-30 3132</li>
<li>2022-02-16 1956</li>
<li>2022-01-18 771</li>
<li>2021-12-22 980</li>
<li>2021-11-24 2106</li>
<li>2021-10-01 1395</li>
</ul></li>
<li>CA199
<ul>
<li>2022-04-27 2758U/mL</li>
<li>2022-03-30 2837</li>
<li>2022-02-16 2376</li>
<li>2022-01-18 1089</li>
<li>2021-12-22 1898</li>
<li>2021-11-24 5509</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-03-14 Thoracic Medicine
<ul>
<li>Underlying disease:
<ul>
<li>Colon cancer with multiple lung meta, ribs mets, bone mets,
cT3N2M1c, stage IV</li>
<li>Heavy smoking (quited), with COPD, centrilocular emphysema, PFT
showed: moderate obstruction, involving both large and small sized
airways</li>
<li>Baseline hypoxemia, room air SaO2 only 94%</li>
<li>Old TB with LUL calcinfied granuloma.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Favor chest tight due to (1) rib mets with pain, (2) COPD, (3)
abdominal distension with diaphragm dysfunction, (4) possibly GERD</li>
<li>Add Foster 2 puff BID, spiriva 2 puff HS (from
Adult-Aerochamber)</li>
<li>Self-paid Adult-Aerochamber recommended</li>
<li>Try Topaal for GERD</li>
<li>Pain relief</li>
<li>Avoid constipation</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-06 T loop colostomy
<ul>
<li>Splenic flexure colon cancer with obstruction, and liver, lung, bone
metastasis with carcinomatosis, cT3N2bM1c, stage IVC</li>
<li>RUQ stoma with stent</li>
</ul></li>
</ul></li>
<li>chemotherapy regimen
<ul>
<li>2021-10-26 ~ undergoing - FOLFIRI (plus bevacizumab since
2021-11-12)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Recent two consecutive CT scans have indicated a partial response of
splenic flexure colon cancer to the current regimen. However, there is
an enlarged tumor on the lower pole of the left kidney that might need
to be addressed (2.4cm 2022-04-15 &lt;- 2.0cm 2022-01-19, a 20% increase
in diameter in 3 months).</li>
<li>The CEA and CA199 levels on 2022-04-27 fell to 2063ng/mL (from
3132ng/mL on 2022-03-30) and 2758U/mL (from 2837U/mL on 2022-03-30),
which were both positive signs.</li>
<li>In three months, the body weight increased by ten kilograms (81.2
kgw 2022-04-27 &lt;- 71.5 kgw 2022-01-05). According to lab data on
2022-04-27, liver and kidney function, serum electrolytes, and blood
cell counts were all within normal ranges. Cachexia is still a
diagnosis.</li>
<li>The current chemotherapy regimen FOLFIRI plus bevacizumab is
generally well tolerated by the patient and respiratory symptoms have
been managed with corresponding medication.</li>
</ul>
</div>
<div id="section-123" class="section level2">
<h2>220415</h2>
<p>[assessment]</p>
<ul>
<li>Currently there are no new CT images (last 2022-01-19) or CEA or
CA199 readings (last 2022-03-30) since the last hospitalization.</li>
<li>Lab results on 2022-04-12 concerning liver function, renal function,
serum electrolytes, and blood cell counts were grossly normal.</li>
<li>The current chemotherapy regimen FOLFIRI is generally well tolerated
by the patient and respiratory symptoms have been managed with
corresponding medication.</li>
</ul>
</div>
<div id="section-124" class="section level2">
<h2>220330</h2>
<p>[assessment]</p>
<ul>
<li>The evidences were inconsistent, with CT images (2022-01-19) showing
improvement and lab data readings (CEA from 869 to 3132 ng/mL, CA199
from 1089 to 2837 U/mL, since 2022) showing deterioration, following T
loop colostomy (2021-10-06) and FOLFIRI plus bevacizumab (since mid Nov
2021).</li>
<li>pMMR (colon biopsy pathology 2021-09-28), certain kind of drugs
e.g.nivolumab or pembrolizumab might not be preferred.</li>
<li>Cetuximab or panitumumab may be appropriate in this patient with a
left-sided tumor if the RAS WT is confirmed.</li>
<li>When BRAF V600E mutation is proven, then BRAF inhibitors,
e.g.encorafenib, dabrafenib + trametinib, could also be considered
optionally.</li>
</ul>
</div>
<div id="section-125" class="section level2">
<h2>220217</h2>
<p>[assessment]</p>
<ul>
<li>CT images on 2022-01-19 showed some improvement based on decreasing
in mass size and/or density, CEA and CA199 data revealed the same trend
p/s colostomy and FOLFIRI treatment, however both the lab readings
doubled within just a month could hint the disease is acquiring
resistence after 4 months treatment.</li>
<li>pMMR, certain kind of drugs e.g.nivolumab or pembrolizumab might
not be preferred.</li>
<li>if RAS WT proven, cetuximab or panitumumab might be applicable for
this left-sided tumor patient.</li>
</ul>
</div>
</div>
<div id="section-126" class="section level1">
<h1>700360779</h1>
<div id="section-127" class="section level2">
<h2>999999</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-02 Chest AP portable
<ul>
<li>right internal jugular central venous catheter with tip in the
SVC</li>
<li>normal size of heart<br />
</li>
<li>residual hazy areas of increased opacity with reticular opacities in
Lt lung and Rt lower lung zone</li>
</ul></li>
<li>2022-04-29 Renal ultrasound
<ul>
<li>Parenchymal renal disease.</li>
<li>Perirenal fluid accumulation over right lower kidney, suspected
Inflammatory or infectious process.</li>
</ul></li>
<li>2022-04-21 CT - lung/mediastinum/pleura
<ul>
<li>Interstitial pneumonitis at both lungs.</li>
<li>Heart failure.</li>
<li>Calcified coronary arteries is found.</li>
</ul></li>
<li>2022-04-21 Cardiac ultrasound
<ul>
<li>normal chamber size</li>
<li>concentric LV hypertrophy</li>
</ul></li>
<li>2022-04-20 MRI - liver, spleen
<ul>
<li>Lobulated soft tissue lesions, passive atelectasis, or effusions in
bilateral posterior basal CP angle are suspected. Please correlate with
CT.</li>
<li>The liver and spleen shows hypointensity on T2WI that may be iron
deposition. please correlate with clinical condition.</li>
<li>Artifact or fluid collection in right upper abdominal wall is
suspected? Please correlate with CT.</li>
<li>There is no focal abnormality in the gallbladder, biliary system,
pancreas, &amp; both kidney.<br />
</li>
<li>There is no evidence of ascites or lymphadenopathy.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
</ul></li>
<li>2022-04-12 Standing KUB
<ul>
<li>Wedge deformity of L1 vertebral body is suspected. Please correlate
with lateral view.</li>
<li>Spondylosis of the L-spine is noted.</li>
<li>Disc space narrowing with marginal osteophyte formation and vacuum
phenomenon of L4-5.</li>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2022-04-13 Electrocardiography
<ul>
<li>Sinus tachycardia with Premature atrial complexes with Aberrant
conduction</li>
</ul></li>
<li>2022-04-01 CT - lung/mediastinum/pleura
<ul>
<li>Esophageal cancer at middle third esophagus with slightly decreased
in size.</li>
</ul></li>
<li>2022-02-11 CT - lung/mediastinum/pleura
<ul>
<li>Esophageal cancer at middle third esophagus s/p trial with statonary
primary tumor size and extension as well as the mediastinal lymph nodes
s/p jejunostomy.</li>
</ul></li>
<li>2022-01-27 GI series
<ul>
<li>suspected esophageal rupture or ulceration at esophageal tumor,
middle third esophagus.</li>
</ul></li>
<li>2022-01-11 CT - lung/mediastinum/pleura
<ul>
<li>middle third esophageal cancer, significant improvement and
persisted multiple small LNs in visceral and left anterior prevascular
spaces compared with CT on 2021/11/18.</li>
</ul></li>
<li>2021-12-29 Renal ultrasound
<ul>
<li>bilateral chronic change of both kidneys.</li>
</ul></li>
<li>2021-11-18 CT - lung/mediastinum/pleura
<ul>
<li>Esophageal cancer at middle esophagus with main tumor
regression.</li>
<li>Lymphadenopathy in the mediastinum. Stable</li>
<li>s/p jejunostomy.</li>
<li>Calcified coronary arteries is found.</li>
</ul></li>
<li>2021-11-03 Standing KUB
<ul>
<li>Spondylosis of the L-spine is noted.</li>
<li>Disk space narrowing of L4/5.</li>
<li>Compression fracture of L1 vertebral body.</li>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2021-09-27 MRI - brain
<ul>
<li>No evidence of brain metastasis.</li>
</ul></li>
<li>2021-09-23 CT - lung/mediastinum/pleura
<ul>
<li>Esophageal cancer up to 8.9*2.95cm with regional and mediasitnal
lymphadenopathy. Stationary as compared with previous CT on
2021-08-30.</li>
</ul></li>
<li>2021-09-09 Tc-99m MDP whole body bone scan
<ul>
<li>Mildly increased activity in the middle to lower T-spines and some
L-spines. Degenerative change may show this picture. Please correlate
with other imaging modalities for further evaluation.</li>
<li>Some faint hot spots in bilateral rib cages and mildly increased
activity in the right femoal neck. The nature is to be determined
(post-traumatic change? other nature?). Please follow up bone scan for
further evaluation.</li>
<li>Increased activity in bilateral shoulders, left hip, bilateral knees
and left ankle, compatible with benign joint lesions.</li>
</ul></li>
<li>2021-09-08 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in the middle esophagus, compatible with the
primary malignancy of esophagus.<br />
</li>
<li>Glucose hypermetabolism in bilateral mediastinal lymph nodes, cancer
with regional lymph nodes metastases should be considered, suggesting
further investigation.<br />
</li>
<li>Increased FDG uptake in the right upper and right lower lungs, the
nature is to be determined (inflammation/infection process or distant
mets?), suggesting further investigation also.<br />
</li>
<li>Esophageal cancer, cTxN2M0-1, by this F-18 FDG PET/CT scan.</li>
</ul></li>
<li>2021-09-06 Patho - esophageal biopsy
<ul>
<li>Upper esophagus, biopsy  Severe dysplasia at least<br />
</li>
<li>Microscopically, the sections show a picture of severe dysplasia at
least characterized by pleomorphic and hyperchromatic atypical squamous
cells with focal ulceration, lymphoid follicle with germinal center,
without convincing stromal invasion.<br />
</li>
<li>Immunohistochemistry of P16(-), P53(+), P63(+) and CK(+) for
dysplastic cell. However, more advanced lesion can not be excluded
entirely. Closely follow up and repeat biopsy is advised, if clinically
indicated.</li>
</ul></li>
<li>2021-09-04 MRI - brain
<ul>
<li>no evidence of brain metastasis.</li>
</ul></li>
<li>2021-08-30 CT - lung/mediastinum/pleura
<ul>
<li>Imaging Report Form for Esophageal Carcinoma
<ul>
<li>Impression (Imaging stage): T4N2M0</li>
</ul></li>
</ul></li>
<li>2021-08-30 Patho - esophageal biopsy
<ul>
<li>Diffusely circumferential mucosal erosions with frability were noted
at upper esophagus(30cm~20cm below the inscisor). Upper esophageal
tissue peel off spontaneously when endoscopy pass through it. We used
net to removed it out and sent for pathology.</li>
<li>Upper esophagus, 30-20 cm below the incisor, peel removal  Squamous
cell carcinoma<br />
</li>
<li>Immunohistochemistry shows CK(+), P63(+), P53(+) and P16(-) for
tumor cell.</li>
</ul></li>
<li>2021-08-27 Esophagogastroduodenoscopy, EGD
<ul>
<li>Diagnosis
<ul>
<li>Diffuse esophageal erosions with oozing, upper esophagus, s/p
pathology evaluation</li>
<li>Esophageal ulcers, multiple, middle and low esophagus</li>
<li>Superficial gastritis</li>
<li>Suspect Brunners gland hyperplasia, bulb</li>
</ul></li>
<li>Suggestion
<ul>
<li>Admission for observation</li>
<li>Endoscopic hemostasis for upper esophagus was difficult. Consider
angiography if still active bleeding</li>
<li>Persue pathology result</li>
</ul></li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-29 General and Gastroenterological Surgery.
<ul>
<li>Q
<ul>
<li>For TPN</li>
<li>This 66-year-old man patient is a case of squamous cell carcinoma of
upper to middle third esophageal with bilateral mediastinal lymph nodes
metastasis, cT4aN2M1, Stage IVB s/p Port-A and feeding jejunostomy, s/p
BGB-A317, BGB-A1217 and cisplatin plus 5-FU and chronic kidney disease,
stage 3 (Creatinine 2.11 mg/dL). This time, for fever with B/S on
20220403 showed Enterococcus faecium and Acinetobacter baumannii complex
infection and Port-A blood culture showed GPC. Remove Port-A on
20220408. Intabated ETT on 20220421 due to severe metabolic acidosis and
dyspnea. Transferred to ICU for severe sepsis on 20220421. Jejunostomy
created on 20210906. However, ostomy wound reddish and leak, so NPO
since 20220425.</li>
</ul></li>
<li>A
<ul>
<li>obj?
<ul>
<li>A case of esophageal cancer with j-tube leakage who request
nutrition support.</li>
<li>General appearance: ill looking</li>
<li>GI tract: Dysphagia (-), Abd pain (-), Abd distension (-), Nausea
(-), Vomiting (-), Diarrhea (-), Poor appetite (+), Poor digestion (-),
BW loss (-) , stool (+), Bowel sound (-)<br />
</li>
<li>Feeding: NPO</li>
<li>Allergy: NKA</li>
<li>Nutrition assessment: BH 164cm, BW 66.2kg, UBW 56.8 kg, IBW 59.2kg,
96% IBW, BMI 21, BEE (calculated based on IBW) 1251kcal, TEE
1952kcal</li>
<li>Lab data: Alb 2.9, BUN 26, Cr 0.58, Na 133, K 3.6, BS 100</li>
<li>According to the patients present conditions, parenteral nutrition
plus enteral feeding (place ND tube if achieved as tolerance) will be
suitable for nutrition supply. We will follow this case for adjustment
of optimal nutrition support.</li>
</ul></li>
<li>PN suggestion:
<ul>
<li>DC Bfluid 1000mlRI 4Uand D10W 500mlRI 12UQD</li>
<li>DC D50W 80ml Q6HRI 8U each time</li>
<li>D50W 500ml QD run 20.8ml/hradd RI 10U </li>
<li>Amino-Hepa 1000ml QD</li>
<li>Lyo-Povigent 4ml/QDadd in TPN(if out of stock, then use
B-complex 1ml/QD and Vitacicol 2ml/QD in TPN)</li>
<li>Addaven 10ml/QDadd in TPN</li>
</ul></li>
<li>PN monitor items
<ul>
<li>Check BW QW5 and record I/O Q8H</li>
<li>Check one touch Q6H for 2days, if stable QD check</li>
<li>Please control BS &lt; 200 mg/dl with RI sliding scale</li>
<li>QW1 check CBC/DC</li>
<li>QW1 check BUN. Cr. AST. ALT. T/D Bil. TG. ALP. rGT. Na. K. Cl. Ca.
P. Mg. Zinc. Alb. Prealbumin or Transferrin</li>
<li>if TPN not sufficient, use YF5 or D10W instead.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-22 Rheumatology and Immunology
<ul>
<li>Q
<ul>
<li>For IVIG (autoimmune disorders)</li>
<li>Current problem: We need your specialist to evaluate and screen the
patient, to exclude auto-immune disease or suitable administration of
intravenous immune globulin (IVIG).</li>
</ul></li>
<li>A
<ul>
<li>History review were performed. Patient was admitted to ICU due to
acute respiratory failure after receiving check point inhibitor therapy
for esophagus SCC. I was consulted for immunotherapy for possible
drug-related ILD.</li>
<li>Suggestion:
<ul>
<li>Treatment as current your experts management and infection
control.</li>
<li>For IVIG dosage (1-2g/kg), please prescribe IVIG 60g, divided by 3
days therapy as below:
<ul>
<li>Day 1:
<ul>
<li>N/S 250mL for 1 hour</li>
<li>IVIG 20gm (4 bots) in D5W 300mL(total 500mL) IVD for 6 hours</li>
<li>N/S 250mL for 1 hour</li>
</ul></li>
<li>Day 2:
<ul>
<li>N/S 250mL for 1 hour</li>
<li>IVIG 20gm (4 bots) in D5W 300mL(total 500mL) IVD for 6 hours</li>
<li>N/S 250mL for 1 hour</li>
</ul></li>
<li>Day 3:
<ul>
<li>N/S 250mL for 1 hour</li>
<li>IVIG 20gm (4 bots) in D5W 300mL(total 500mL) IVD for 6 hours</li>
<li>N/S 250mL for 1 hour</li>
</ul></li>
</ul></li>
<li>Consider to add actemra 1AMP (162mg) SC as adjunctive therapy for
ILD.</li>
<li>Please monitor clinical condition after therapy. If not effective,
then plasma exchange maybe considered.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-22 Metabolism and Endocrinology
<ul>
<li>Q
<ul>
<li>For abnormal thyroid enzymes</li>
<li>Current problem: We need your specialist to evaluate and
differential diganosis as sick euthyroid or medical advice.</li>
</ul></li>
<li>A
<ul>
<li>O:
<ul>
<li>HR: 66-135</li>
<li>SBP: 110-200+</li>
<li>Possible related medication: methylprednisolone (since
20220418)</li>
<li>AST/ALT: 68/119</li>
<li>BUN/Cr: 69/2.88</li>
<li>Na: 142, K: 3.4</li>
<li>TSH/FT4: 1.952/0.58</li>
<li>FT3: 1.4</li>
<li>ATPO, ATG, TSH receptor Ab: unavailable</li>
<li>ACTH/Cortisol: 5.3/7.86 (20220419), steroid (+)</li>
</ul></li>
<li>A: R/I sick euthyroid syndrome</li>
<li>Suggestions:
<ul>
<li>No need of any treatment at this timing</li>
<li>Recheck TSH/FT4 (biochemistry) 2 weeks later</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-21 Nephrology
<ul>
<li>Q
<ul>
<li>For AKI with metabolic acidosis</li>
<li>Current problem: HD is prefer, We need your specialist to
evaluate.</li>
</ul></li>
<li>A
<ul>
<li>Lab data:
<ul>
<li>PH: 7.18, PCO2: 29, PO2: 146, HCo3:10.8, BE: -16.2</li>
<li>WBC: 21.42, Hb:11.0, PLt: 346</li>
<li>CEA: 9.96, SCC:3.1</li>
<li>GPT: 224, GOT: 105, T.bil: 7.26, D.bil: 4.77, LDH: 330, lipase: 288,
amylase: 150, rGT: 768</li>
<li>BUN/cre : 25/1.68 (20220330) -&gt; 27/2.11 (20220404) -&gt; 29/2.94
(20220414) -&gt; 49/5.00 (20220418) -&gt; 82/4.15(20220420)</li>
<li>U/O: 1420ml -&gt; 56ml</li>
<li>Vital signs: E2V5M4, BP: 179/105mmHg</li>
<li>PE: Under MV ventilator FiO2: 60%, no limb edema</li>
<li>CT chest: interstitial pneumonitis at both lungs</li>
<li>Cardiac echo: LVEF 71.5%, concentric LVH</li>
</ul></li>
<li>Impression:
<ul>
<li>Acute kidney injury stage 3 on CKD with metabolic acidosis</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Check serum lactate, ketone, Cl, FeNa, FeBUN, urine osmolarity,
blood osmolality</li>
<li>Check Urine for analysis</li>
<li>Correct metabolic acidosis and follow up ABG</li>
<li>Adequate IV fluid hydration</li>
<li>Avoid nephrotoxic drugs</li>
<li>If there is refractory metabolic acidosis, electrolyte imbalance,
fluid overload, oliguria, we will arrange RRT if family agree</li>
</ul></li>
<li>20220428 Follow up:
<ul>
<li>Still metabolic acidosis (nonAG)</li>
<li>Check urine AG and add sodium bicarbonate 2# bid</li>
<li>Arrange renal echo</li>
<li>We will follow up this case</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-19 Gastroenterology
<ul>
<li>Q
<ul>
<li>This 66-year-old man patient is case of squamous cell carcinoma of
upper to middle third esophageal with bilateral mediastinal lymph nodes
metastasis, cT4aN2M1, Stage IVB s/p Port-A and feeding jejunostomy, s/p
BGB-A317, BGB-A1217 and cisplatin plus 5-FU.</li>
<li>This time, for progression abnormal liver function, R/O IO therapy
side effect.</li>
</ul></li>
<li>A
<ul>
<li>Rule out other possibilities before considering BGB-A317-,
BGB-A1217-induced hepatitis.
<ul>
<li>Check ALKP, rGT, ALB, PT, APTT, LDH to complete liver study</li>
<li>Check Anti HAV IgM, HBsAg, anti-Hbs Ab, Anti HCV Ab</li>
<li>Check antinuclear antibodies (ANA), smooth muscle antibody (SMA),
Epstein Barr virus (EBV) IgM, cytomegalovirus (CMV) PCR</li>
<li>Check thyroid and adrenal function</li>
<li>Regularly/closely monitor AST/ALT, TBI, PT, APTT, Ammonia, GGT, ALKP
(every two days)</li>
<li>Avoid hepatic toxic agent if possible(or adjust dose), simplify
medication</li>
<li>silymarin 1#~2# TID</li>
</ul></li>
<li>When other possibilities have been excluded or the liver has
decompensated and a checkpoint inhibitor-related immune hepatitis is
suspected, steroids may be administered for immune-mediated hepatitis:
(reference: Sanjeevaiah, A., Kerr, T., &amp; Beg, M. S. (2018). Approach
and management of checkpoint inhibitor-related immune hepatitis. Journal
of gastrointestinal oncology, 9(1), 220224. <a href="https://doi.org/10.21037/jgo.2017.08.14" class="uri">https://doi.org/10.21037/jgo.2017.08.14</a> )
<ul>
<li>Initial dose of 0.5 to 1 mg/kg/day of prednisone for Grade 2
hepatitis</li>
<li>Initial dose of 1 to 2 mg/kg/day of prednisone for Grade 3 or
greater hepatitis, followed by a slowly taper about one month</li>
<li>Based on severity of liver enzyme elevations, withhold or
discontinue BGB-A317, BGB-A1217</li>
<li>Consider liver biopsy for alternate etiology and add mycophenylate
mofetil 1g PO BID if no improvement after 3 days of steroid</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-08 Infectious Disease
<ul>
<li>Q
<ul>
<li>This time, for fever with B/S on 20220403 showed Enterococcus
faecium and Acinetobacter baumannii complex infection and Port-A blood/C
showed GPC. Port-A catheter removed on 20220408.</li>
</ul></li>
<li>A
<ul>
<li>The Enterococcus is susceptible to ampicillin.</li>
<li>The Acinetobacter is susceptible to pip/tazo.</li>
<li>Agree with your use of tapimycin. Adjust the dose to 2.25g iv q6h
according to the renal function.</li>
<li>Recheck B/C 3 days later. Please consider to remove the port-A if
persistent bacteremia.</li>
<li>Arrange CV-echo to exclude endocarditis.</li>
</ul></li>
</ul></li>
<li>2022-03-16 Dermatology
<ul>
<li>This patient suffered from dyskeratotic nails for years.</li>
<li>Imp: Tinea unguim, subacute dermatitis</li>
<li>Suggestion:
<ul>
<li>Excelderm crema 2 tubes, bid</li>
<li>Topsym cream 4 tubes, bid</li>
</ul></li>
</ul></li>
<li>2021-12-28 Nephrology
<ul>
<li>Q
<ul>
<li>Consultation for renal dysfunction (eGFR 20) and electrolyte
imbalance (K 2.5, Mg 4, Ca 1.84, Na 126).</li>
</ul></li>
<li>A
<ul>
<li>Impression:
<ul>
<li>AKI Stage 3, cause to be determined</li>
<li>Hypokalemia suspect extrarenal loss related</li>
<li>Hyponatremia suspect extrarenal loss related</li>
</ul></li>
<li>Suggestions:
<ul>
<li>check FeNa, urine Na, urine osmo, urine K, urine Cl, urine
creatinine, urine Mg</li>
<li>check blood osmo, cortisol, ACTH, thyroid functions, total CO2</li>
<li>potassium supplement</li>
<li>adequate hydration</li>
<li>record I/O and body weight qd</li>
<li>avoid nephrotoxic agents</li>
<li>keep hemodynamic stable</li>
<li>arrange renal echo</li>
<li>recheck electrolytes, renal functions and total CO2</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-12-24 Metabolism and Endocrinology
<ul>
<li>Q
<ul>
<li>For evaluate hypothyroidism therapy</li>
</ul></li>
<li>A
<ul>
<li>O:
<ul>
<li>BH: 166 cm, BW: 61.1 kg</li>
<li>HR: 78-114</li>
<li>Possible related medication: nil</li>
<li>AST/ALT: 16/17</li>
<li>BUN/Cr: 94/3.30</li>
<li>Na: 140, K: 3.9</li>
<li>TSH/FT4: 7.543/1.00</li>
<li>FT3: 3.1</li>
<li>ATPO, ATG, TSH receptor Ab: unavailable</li>
<li>ACTH/Cortisol: unavailable</li>
</ul></li>
<li>A: Subclinical hypothyroidism</li>
<li>Suggestions:
<ul>
<li>Check anti-TPO Ab, anti-thyroglobulin Ab, ACTH/cortisol</li>
<li>Recheck TSH/FT4</li>
<li>No need of thyroxine supplement at this moment</li>
<li>Endocrine OPD F/U</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-09-07 Hemato-Oncology
<ul>
<li>Patient examined anc Chart reviewed. A case of T4N2Mx, Stage IV ESCC
is noted. I am consulted for further evalution and mangmenet.</li>
<li>My suggestions are:
<ul>
<li>Arrange discussion with patient and family (already the afternoon on
2021-09-11)</li>
<li>The patient is preliminarily fit the clinical trial of Phase I BGB
at Cohort 6.</li>
<li>Please do not perform radiotherapy at present, which is requested by
trial.</li>
<li>If necessary, I might take over this case.</li>
</ul></li>
</ul></li>
<li>2021-09-02 Radiation Oncology
<ul>
<li>Subjective:
<ul>
<li>History: This 66-years-old male patient has been drinking alcohol
for 30-40 years (half glass per day). He has suffered from progressive
dysphagia and BW loss of 10 kg for 2 months. He can tolerate soft diet
now. Due to the EGD showed suspicious esophageal lesion, r/i malignancy,
chest CT on 2021/08/30 reported esophageal carcinoma, cT4N2M0. Pathology
report showed squamous cell carcinoma, moderately differentiated.
Staging workup is ongoing.</li>
<li>Previous RT: denied.</li>
<li>Other disease: Gastric ulcer with bleeding and hemorrhoid for 12
years.</li>
<li>Family history: denied.</li>
<li>Habit: smoking, 1 PPD for 30 yr, quitted for 15 yr; alcohol: half
glass per day, just quitted; betel nut: denied.</li>
<li>Married. Caregiver: his wife. Job: retired buffet cook. No or mild
economic stress.</li>
<li>Language: Mandarin, Taiwanese.</li>
</ul></li>
<li>Objective:
<ul>
<li>General Condition-ECOG: 1.</li>
<li>PE, 2021/09/02: No palpable SCF LNs.</li>
<li>Pathology: 2021/8/30, Upper esophagus, 20-30 cm below the incisor,
peel removal  MD squamous cell carcinoma; CK(+), P63(+), P53(+) and
P16(-).</li>
<li>Images:
<ul>
<li>PED, 2021/8/30: diffusely circumferential mucosal erosions with
friability were noted at upper esophagus (20cm~30cm) below the incisor.
Upper esophageal tissue peel off spontaneously when endoscopy pass
through it. We used net to removed it out and sent for pathology.
Multiple ulcers were noted at middle and lower esophagus (from ECJ to
30cm below the incisor). Mucosal active oozing was noted at 23cm below
the incisor.</li>
<li>Chest CT, 2021/08/30: asymmetric esophageal wall thickening of
middle third of thoracic esophagus with severe luminal narrowing (length
7.5 cm, thickness 30 mm), with loss of fat planes between posterior wall
of trachea and left main bronchus. multiple small LNs in visceral and
left anterior prevascular spaces. Hila: no enlarged LN. IMP: middle
third esophageal cancer cT4N2. Nonspecific inflammation in LUL. Moderate
3V-CAD.</li>
<li>EUS, 2021/9/03: pending.</li>
<li>Bone scan, PET, 2021/9/06: pending.</li>
</ul></li>
</ul></li>
<li>Diagnosis: Esophageal cancer, M/3, MD SqCC, cT4N2M0 (pending staging
workup) with loss of fat planes between posterior wall of trachea and
left main bronchus, R &amp; L paratracheal and subcarinal LAP
metastasis; ECOG = 1.</li>
<li>Suggest: Radiotherapy.</li>
<li>Goal: Curative (pre-operative).</li>
<li>RT Plan:
<ul>
<li>Target &amp; Volume: Esophageal tumor and LAPs.</li>
<li>Technique: VMAT &amp; IGRT by linear accelerator.</li>
<li>Dose &amp; Fractionation: 5040cGy/28 fractions with concurrent
chemotherapy.</li>
</ul></li>
<li>Plan: Staging workup, PortA implantation and jejunostomy are
suggested. CCRT is suggested for downstage &amp; downsize. Possible
radiation effects (malaise, radiation esophagitis, pneumonitis) is told.
CT simulation will be arranged on 20210908 after PortA implantation and
jejunostomy are done. Diet education is given.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-24 Endoscopic esophageal dilatation
<ul>
<li>esophageal stenosis noted around 25~30 cm from incision</li>
<li>tumor resolution noted at endoscopic view</li>
<li>esophageal perforation at 9 clock 25 cm from incision due to
fragile esophageal wall</li>
<li>dilatation successful upto 48 Fr.Bougie dilator</li>
</ul></li>
<li>2021-09-06 Feeding jejunostomy + port-A insertion</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-02-04, -02-18 - tislelizumab + ociperlimab</li>
<li>2021-11-03, -11-24, -12-15 - fluorouracial + cisplatin +
tislelizumab + ociperlimab</li>
<li>2021-10-13 - fluorouracil + cisplatin</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-128" class="section level1">
<h1>700371268</h1>
<div id="section-129" class="section level2">
<h2>210824</h2>
<p>{tube feeding}</p>
<p>meitifen (diclofenac Na 75mg) PO QD which is controlled-release
design might be changed to defram-k (diclofenac K 25mg) PO TID</p>
</div>
</div>
<div id="section-130" class="section level1">
<h1>700372070</h1>
<div id="section-131" class="section level2">
<h2>220322</h2>
<p>[assessment]</p>
<ul>
<li>The last medical image update occurred on 28 January 2022. Treatment
with Fluorouracil + Carboplatin + Paclitaxel has been ongoing since
October 2021.</li>
<li>Serum glucose(AC) remained above normal (128mg/dL 2022-03-09),
however HbA1C reading went down to 7.5% (2022-03-09) from 8.0%
(2021-12-06), which is a positive sign.</li>
<li>More than one year of below normal serum magnesium and above normal
serum creatinine.</li>
<li>Cisplatin and, to a much lesser extent, carboplatin therapy, is
associated with hypomagnesemia, more so than any other electrolyte
deficiency. Hypomagnesemia affects 40%~90% of patients on cisplatin; in
contrast, 10% of patients treated with carboplatin or oxaliplatin
experience hypomagnesemia. Platinum-induced hypomagnesemia can persist
for up to 6 years after cessation of treatment and is primarily
attributed to renal Mg wasting.
<ul>
<li>reference: <a href="https://kidney360.asnjournals.org/content/kidney360/2/1/154.full.pdf" class="uri">https://kidney360.asnjournals.org/content/kidney360/2/1/154.full.pdf</a></li>
</ul></li>
<li>It is possible to treat hypomagnesemia without acute symptoms with
oral Mg supplementation and by eliminating medications that may be
contributing to the hypomagnesemia, however, the latter may not be the
optimal option during chemotherapy. MgO is presently in active
medication for the patient.</li>
</ul>
</div>
<div id="section-132" class="section level2">
<h2>220210</h2>
<ul>
<li>exam findings
<ul>
<li>2022-01-28 CT
<ul>
<li>suspected lower third esophageal wall thickening. stable.</li>
</ul></li>
<li>2021-09-24 CT
<ul>
<li>borderline wall thickening at lower third esophagus is found.</li>
</ul></li>
<li>2021-09-24 Esophagogastroduodenoscopy
<ul>
<li>gastric intestinal metaplasia, antrum</li>
</ul></li>
<li>2021-09-09 Patho
<ul>
<li>Diagnosis
<ul>
<li>Lung, left lower lobe, history of hypopharyngeal and eosphaeal
carcinomas, s/p CT and RT, now VATS lobectomy (S2021-12142A) with biopsy
for forzen section (F2021-348FS) - squamous cell carcinomas x2, favor
metastatic.</li>
<li>IHC: CK5/6(+), p40(+), Napsin-A(-), TTF-1(-), CD56(-).<br />
</li>
<li>pM1 pStage: IVC.<br />
</li>
</ul></li>
<li>Microscopic Description
<ul>
<li>Tumor Focality - Separate tumor nodules of same histopathologic type
in same lobe</li>
<li>Histologic Type - Invasive squamous cell carcinoma,
keratinizing</li>
<li>Histologic Grade - G2: Moderately differentiated</li>
<li>Spread Through Air Spaces (STAS) - Present</li>
<li>Visceral Pleura Invasion - Not identified</li>
<li>Lymphovascular Invasion - Present<br />
</li>
</ul></li>
</ul></li>
<li>2021-08-02 Whole body PET scan
<ul>
<li>The lesions of glucose hypermetabolism in the right cervical lymph
nodes are old and show much less prominent compared with the previous
study on 2020-09-21, indicating recurrent tumor with partial response to
current therapy.</li>
<li>Glucose hypermetabolism in the mediastinal lymph nodes and bilateral
pulmonary hilar lymph nodes, probably reactive nodes. Please keep follow
up to exclude the possibility of distant lymph node metastasis in these
regions.</li>
<li>Glucose hypermetabolism in the left lower lung, probably another
primary or secondary lung cancer, suggesting biopsy for further
investigation.</li>
<li>Probably inflammatory change at the left shoulder joint.</li>
<li>Recerrent hypopharyngeal cancer s/p treatment with partial response
to current therapy; another primary or secondary lung cancer in the left
lower lung (if proved), by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2021-07-22 MRI - Larynx
<ul>
<li>focal increased soft tissue in the right hypopharynx. Please
f/u.</li>
<li>focal enhancement in the right maxillary bone, surrounding the
tooth</li>
</ul></li>
<li>2021-07-05 CT
<ul>
<li>minimal emphysema in LUL and RUL.</li>
<li>new solid nodule in LLL, primary tumor or metastasis, suggest
f/u.</li>
</ul></li>
<li>2020-10-02 Patho - Lymph node region resection
<ul>
<li>pStage: rpTXN3b (cM0); rp Stage IVB (2020-10-16 ENT tumor board
consensus)<br />
</li>
</ul></li>
<li>2020-09-21 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in a right level IV cervical lymph node,
suggesting malignant involvement in an ipsilateral regional lymph
node.</li>
<li>Mild to moderate glucose hypermetabolism in bilateral pulmonary
hilar lymph nodes, reactive change from locoregional inflammation may be
considered. Please keep follow up, however, to exclude the possibility
of distant lymph node metastasis in these regions.</li>
<li>Mild glucose hypermetabolism in left lower cervical lymph nodes and
mediastinal lymph nodes, reactive change in response to locoregional
inflammation may show such a picture.</li>
<li>Right hypopharyngeal cancer s/p CCRT with tumor recurrence,
rcTxN1M0, r-stage III at least (AJCC 8th ed.), by this F-18-FDG PET/CT
scan.</li>
</ul></li>
<li>2020-09-10 MRI - Larynx
<ul>
<li>an enlarged lymph node in the right lower carotid space.</li>
</ul></li>
<li>2020-03-10 MRI - Larynx
<ul>
<li>thick soft tissue, tight space, suspected residual/recurrent tumor
in right pyriform sinus.</li>
</ul></li>
<li>2019-12-09 MRI - Nasopharynx
<ul>
<li>residual tumor at right pyriform sinus. no enlarged lymph node. s/p
operation at left tongue and neck.</li>
</ul></li>
<li>2019-07-04 CT - Mediastinum
<ul>
<li>Recurrent tongue base tumor at right pyriform sinus, in regression
as compared with previous PET/CT.</li>
<li>No evidence of tumor recurrence along the course of the
esophagus.</li>
</ul></li>
<li>2019-06-17 Whole body PET scan
<ul>
<li>A glucose hypermetabolic mass in right supraglottic region,
compatible with the primary lesion of laryngeal cancer.</li>
<li>Glucose hypermetabolism in the right level II and III cervical lymph
nodes, suggesting malignant involvement in multiple ipsilateral regional
lymph nodes.</li>
<li>Supraglottic laryngeal cancer, cTxN2bM0, stage IVA (AJCC 8th ed.),
by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2019-06-14 MRI - Larynx
<ul>
<li>Right hypopharynx CA, T4aN2bMx stage IVA</li>
</ul></li>
<li>2019-06-13 Patho
<ul>
<li>Labeled as right supraglottic tumor, biopsy - Squamous cell
carcinoma, moderately differentiated.</li>
<li>IHC stains: p40(+), p16(-, 0%).</li>
</ul></li>
<li>2017-08-02 Patho
<ul>
<li>Diagnosis
<ul>
<li>Paralysis of vocal cords or larynx, bilateral, partial; Malignant
tongue neoplasm, tip and lateral; Inflammatory conditions, abscess,
osteitis, osteomyelitis, periostitis, sequestrum of jaw bone; Acute
gingivitis; Atrophy of salivary gland;</li>
<li>Esophagus, upper, 20cm and 30cm from incisor, biopsy - Squamous cell
carcinoma.</li>
</ul></li>
</ul></li>
</ul></li>
<li>Radiotherapy
<ul>
<li>2020-11-06 ~ 2020-12-02
<ul>
<li>3600cGy/18 fractions of the recurrent nodal with extranodal
extension area.</li>
</ul></li>
<li>2019-09-17 ~ 2019-11-06
<ul>
<li>5000cGy/25 fractions (6MV photon) of the primary hypopharyngeal to
supraglottic tumor, right neck involved nodal, bilateral neck,</li>
<li>7000cGy/35 fractions of the reduced hypopharyngeal to supraglottic
tumor, right neck involved nodal area.</li>
</ul></li>
<li>2017-08-16 ~ 2017-09-22
<ul>
<li>4500cGy/25 fractions (15MV photon) of the esophageal tumor, tract,
to regional lymphatic nodal,</li>
<li>5040cGy/28 fractions of the esophageal tumor area.</li>
</ul></li>
</ul></li>
<li>Chemotherapy
<ul>
<li>2021-10 ~ ongoing Fluorouracil + Carboplatin + Paclitaxel</li>
<li>2021-01 ~ 2021-06 Fluorouracil + Cisplatin + Docetaxel</li>
<li>2020-11 ~ 2020-12 Carboplatin (CCRT)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-133" class="section level1">
<h1>700373891</h1>
<div id="section-134" class="section level2">
<h2>210618</h2>
<p>{tube feeding}</p>
<p>all the oral drugs in active medication have been reviewed, the
following two items can be peeled half but should not be grinded: -
Curam (amoxicillin 875 mg, clavulanic acid 125 mg, tab) - film coated -
Pentop (pentoxifylline 400mg, tab)</p>
<p>and the following item can not be peeled half or grinded: - Nexium
(esomeprazole 40mg, tab)</p>
<p>the alternatives to above items, respectively, could be: - Soonmelt
(amoxicillin 500mg, clavulanic acid 100mg, vial), if half-peeled Curam
still too big to be fed. - there is no other drug containing same active
ingredient with Pentop in the inventory, so please peel it (not too
fine) to fit the tube. - Takepron (lansoprazole 30mg, tab) should not be
grinded but can be peeled half.</p>
</div>
</div>
<div id="section-135" class="section level1">
<h1>700374742</h1>
<div id="section-136" class="section level2">
<h2>220429</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-16 MRI - nasopharynx
<ul>
<li>The current study was compared to the prior one obtained on
20210924.</li>
<li>Knwon a case of right tonsillar cancer S/P treatment. Still mild
mucosal thickening of right palatine fossa. Also swollen change of right
A-E fold with enhancement. Suggest clinical correlation to rule out
inflammatory change or recurrence.</li>
<li>Right mastoiditis.</li>
<li>The bilateral parotid and submandibular glands enhance as before. It
is consistent with post-radiation inflammation.</li>
<li>Clear appearacne of all paranasal sinuses.</li>
</ul></li>
<li>2022-03-15 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20200605, the lesions in
the lower T-spines and some L-spines are stationary. Degenerative change
may show this picture.</li>
<li>Some new faint hot spots in the posterior aspect of right rib cage.
The nature is to be determined (post-traumatic change? other nature?).
Please correlate with the clinical history and follow up bone scan for
further evaluation.</li>
<li>No prominent change is noted in the previous faint hot spots in the
skull and the lesion in the right femoral shaft, possibly more benign in
nature.</li>
<li>Increased activity in bilateral shoulders, right sternoclavicular
junction, bilateral hips and right knee, compatible with benign joint
lesions.</li>
</ul></li>
<li>2022-03-09 Nasopharyngoscopy
<ul>
<li>rt arytenoid swelling, limited airway, suggest tracheostomy</li>
<li>rt tonsil and mouth floor, p16(-), ct2N2bM0, stage IVa + esophagus
ca</li>
</ul></li>
<li>2022-02-22 SONO - abdomen
<ul>
<li>A polyp 4.5 mm and multiple stones (&lt; 6 mm) of the gallbladder
are noted.</li>
</ul></li>
<li>2022-01-12 SONO - head and neck, soft tissue
<ul>
<li>right neck mass, suspected malignancy</li>
<li>right neck level II, large, heterogenous mass lesion (tender+), s/p
FNA</li>
</ul></li>
<li>2021-11-30 MRI - larynx
<ul>
<li>Regressed right tonsil CA, stationary of right carotid and posterior
cervical LAPs with central necrotic change.</li>
</ul></li>
<li>2021-09-30 CT - lung/mediastinum/pleura
<ul>
<li>Consolidation over posterior segment of right upper lobe.</li>
<li>No evidence of metastatic lesion in the current study.</li>
</ul></li>
<li>2021-09-28 Patho - gingival/oral mucosa biopsy
<ul>
<li>Observed
<ul>
<li>Hx of R tonsil + mouth floor, esophageal ca s/p incomplete
CCRT<br />
</li>
<li>Mouth floor lesion</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Labeled as mouth floor lesion, biopsy  squamous cell
carcinoma.<br />
</li>
<li>Section shows squamous cell carcinoma.</li>
</ul></li>
</ul></li>
<li>2021-09-28 L-N aspiration
<ul>
<li>R level V LAP, 3*3cm, firm, hard - squamous cell carcinoma</li>
</ul></li>
<li>2020-10-23 Patho - esophageal biopsy
<ul>
<li>Esophagus, 30 cm below incisor, biopsy - squamous cell
hyperplasia</li>
</ul></li>
<li>2020-10-05 CT - lung/mediastinum/pleura
<ul>
<li>RUL infection D/D includes TB or bacteria severe emphysema and
fibrotic change in lower lobes.</li>
</ul></li>
<li>2020-07-28 Patho - esophageal biopsy
<ul>
<li>A. Labeled as the lesion needed to ablate is localized at the 19 cm
to 35 cm. Random Bx is done (A) as marking at the 19 cm., biopsy 
squamous mucosa with low grade dysplasia and necrosis.<br />
</li>
<li>B. Labeled as There is some ablated esophageal tumor tissue
retrieved for patho exam (B), biopsy - benign squamous mucosa with
moderate acute inflammation.</li>
</ul></li>
<li>2020-06-30 Patho - tonsil biopsy
<ul>
<li>A. Right side tonsil, frozen section + tonsillectomy  Squamous cell
carcinoma, moderately differentiated
<ul>
<li>IHC: CK5/6(+); P16(-), HPV(-) and P63(+) for tumor cells.</li>
</ul></li>
<li>B. Mouth floor tumor, above whartons duct, FS + excision  Squamous
cell carcinoma, moderately differentiated characterized by epithelial
hyperplasia with high grade dysplasia and focal stromal invasion.</li>
</ul></li>
<li>2020-06-30 Frosen section
<ul>
<li>A. Right side tonsil, frozen section  Squamous cell carcinoma<br />
</li>
<li>B. Mouth floor, ditto  Mild to focal moderate dysplasia</li>
</ul></li>
<li>2020-06-29 CT - neck
<ul>
<li>imaging reort form for oropharynx carcinoma</li>
<li>Imaging stage: T2N2bM0, stage IVA</li>
</ul></li>
<li>2020-06-24 Nasopharyngoscopy
<ul>
<li>Rt NP cyst, Rt tonsils with induration, mouth floor tumor?,
hypopharynx cyst.</li>
</ul></li>
<li>2020-06-09 Whole body PET scan
<ul>
<li>Mild glucose hypermetabolism involving the middle portion of the
esophagus, compatible with primary esophageal malignancy of low FDG
uptake. However, no prominent abnormal focal FDG uptake was noted in the
lower portion of the esophagus.</li>
<li>Mild glucose hypermetabolism in the right tonsil and stomach. The
nature is to be determined (inflammatory process? other nature?).</li>
<li>Mildly increased FDG uptake in the right anterior neck muscle.
Either physiological FDG uptake or mild inflammation may show this
picture.</li>
</ul></li>
<li>2020-06-08 Miniprobe Endoscopic Ultrasound
<ul>
<li>Esophageal cancer, middle esophagus, EUS estimated stage
T1b~T2N1Mx</li>
<li>Suspected early esophageal cancer, lower esophagus, EUS estimated
stage T1bN1Mx</li>
</ul></li>
<li>2020-06-06 CT - lung/mediastinum/pleura
<ul>
<li>u/3 thoracic esophageal cancer T? no evidence of mediastinal
invasion, no LAP (N0) and M0.</li>
<li>diffuse emphysema, could be related to smoking and fibrotic change
in LLL, RLL, and LUL, sequela of prior infection?</li>
<li>moderate 3V-CAD.</li>
</ul></li>
<li>2020-06-01 Patho - esophageal biopsy
<ul>
<li>pathologic diagnosis
<ul>
<li>A. Lower esophagus, biopsy  High grade dysplasia at least,
suspicious for malignancy<br />
</li>
<li>B. Middle esophagus, biopsy  Squamous cell carcinoma, moderately
differentiated</li>
</ul></li>
<li>microscopic examination
<ul>
<li>A. Lower esophagus: thick epithelium shows high grade dysplasia and
few subepithelial connective tissue without tumor invasion. It is still
suspicious for malignancy. Repeat biopsy is advised for further
evaluation.<br />
</li>
<li>B. Middle esophagus: squamous cell carcinoma, moderately
differentiated characterized by thick epithelium with high grade
dysplasia and a few tumor nests infiltrated in inflamed stroma.
<ul>
<li>IHC: CK5/6(+); P16(-), HPV(-), CD34(equivocal) and P63 (+) for tumor
cells.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>Magnesium
<ul>
<li>2022-04-28 1.2 mg/dL</li>
</ul></li>
<li>CEA
<ul>
<li>2022-04-28 10.607 ng/ml</li>
<li>2022-02-23 4.299 ng/ml</li>
<li>2021-12-01 3.934 ng/ml</li>
<li>2020-08-11 2.202 ng/ml</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-09-30 Radiation Oncology
<ul>
<li>This 53-year-old man previously:
<ul>
<li>MDSCC of Rt tonsil and mouth floor, p16(-), cT2N2bM0, stage IVa, s/p
CCRT</li>
<li>MDSCC of esophagus M/3, p16(-). cT1b~T2N1M0</li>
</ul></li>
<li>2020-06-06 ~ 2020-09-09 RT to the bil. neck, Rt tonsil, LAPs: 50y/
25fx. The whole esophagus and adjacent lymphatic drainage area: 45y/
25fx. Postponed since 2020-09-10 because he wanted to take a rest.</li>
<li>This time, he suffered from tonsillar fossa tumor with Lateral
pterygoid muscle with lateral nasopharynx invasion, Any node(s) and
clinically overt ENE, T4bN3bM0, stage IVB. FNA were performed on
2021-09-27. The Labeled as mouth floor lesion, biopsy (2021-09-29)
proved squamous cell carcinoma.</li>
<li>Palliative CCRT is indicated. Plan to deliver at least 50 Gy/ 25 fx
to the Rt tonsillar tumor, LAPs, and Rt neck level I~III. However, after
explanation, he is still afraid of the side effects, such as mucositis
or xerostomia, and still need more time to consider whether to have
radiotherapy. If he makes up his mind to have radiotherapy, please
inform us so we can make arrangement for him. Thank you very much.</li>
</ul></li>
<li>2021-09-28 ENT
<ul>
<li>PHx: R tonsil and mouth floor, p16(-), cT2N2bM0, stage IVa;
Esophagus cancer, M/3, p16(-), cT1b-T2N1M0 with incomplete CCRT tx</li>
<li>Oral: mouth floor whitish lesion s/p biopsy</li>
<li>Neck: right level V induration s/p FNA</li>
<li>Imp:
<ul>
<li>Right neck mass, suspect malignancy</li>
<li>Mouth floor lesion, suspect malignancy</li>
</ul></li>
<li>Plan:
<ul>
<li>Pending pathology report</li>
<li>If unsatisfactory, may consider arrange right neck LAP biopsy under
LA</li>
</ul></li>
</ul></li>
<li>2021-09-22 ENT
<ul>
<li>Local finding: a 3-4 cm indurated non-movable mass with tenderness
over R neck level V. A wart-like lesion over midline of floor of
mouth.</li>
<li>Scope: smooth nasopharynx, oropharynx and hypopharynx. Medialization
of right lateral pharyngeal wall. Patent airway.</li>
<li>Neck CT a rim-enhanced irregular mass over R level V, increase in
size compared to previous study in 2020-06.</li>
<li>Neck sono: a heterogenous mass over R neck level V.</li>
<li>Impression: Suspect nodal metastasis with or withour necrosis; Mouth
floor lesion. Poor nutrition and dehydration.</li>
<li>Plan: Admission to Oncology IPD for supportive treatment and further
cancer work-up was suggested.</li>
<li>NG placement is suggested.</li>
</ul></li>
<li>2020-10-27 Radiation Oncology
<ul>
<li>This 52 y/o male patient was diagnosed with
<ul>
<li>MDSCC of Rt tonsil and mouth floor, p16(-), cT2N2bM0, stage IVa</li>
<li>MDSCC of esophagus M/3, p16(-). cT1b~T2N1M0</li>
</ul></li>
<li>s/p incomplete CCRT [20200806 ~ RT to the bil. neck, Rt tonsil,
LAPs: 50y/ 25fx. The whole esophagus and adjacent lymphatic drainage
area: 45y/ 25fx. Postponed since 20200910 because he wanted to take a
rest.]</li>
<li>He was admitted due to poor nutrition and pneumonia.</li>
<li>To resume CCRT is indicated for double cancer treatment. However,
after discussion, he refused to resume CCRT right now and said he will
come back for further treatment when he feels better.</li>
</ul></li>
<li>2020-05-30 Nephrology
<ul>
<li>This 51 y/o man of chronic alcoholism presented with hypokalemia,
hypomagnesemia, and hypocalcemia.</li>
<li>PE revealsed severe malnutrition with muscle wasting. The ABG was
not remarkable.</li>
<li>Hypo-K, hypo-Mg and hypo-Ca are commonly seen in patients with
alcoholism and malnutrition, probably due to chronic low intake.</li>
<li>This triple electrolyte deficiency is not related to renal tubular
dysfunction. Only IV or oral supplements with these electrolytes are
needed.<br />
</li>
<li>I will follow up this patient.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-07-27 Endoscopic radiofrequency ablation with Barrx 360 express
RFA cathether</li>
<li>2020-06-30 Right side tonsil tumor, wide excision; Mouth floor
tumor, above whartons duct, excision</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-10-06 ~ 2021-10-29 RT to the Rt neck LAPs and tonsilar tumor:
36 Gy/ 18 fx</li>
<li>2020-08-06 ~ 2020-09-09 RT to the bil. neck, Rt tonsil, LAPs: 50y/
25fx. The whole esophagus and adjacent lymphatic drainage area: 45y/
25fx.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-17 ~ 2022-04-14 TPF (docetaxel + cisplatin + 5-FU ) <a href="https://pubmed.ncbi.nlm.nih.gov/20878112/" class="uri">https://pubmed.ncbi.nlm.nih.gov/20878112/</a></li>
<li>2021-10-11 ~ 2021-11-03 cisplatin</li>
<li>2020-08-11 ~ 2020-09-01 cisplatin (CCRT)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>After receiving last cisplatin in early November of 2021, this
patient began receiving TPF from 2022-03-17.</li>
<li>Lab data results: serum Mg 1.2 mg/dL (2022-04-28), CEA 10.607 ng/ml
(2022-04-28) &lt;- 4.299 (2022-02-23) &lt;- 3.934 (2021-12-01) &lt;-
2.202 (2020-08-11).</li>
<li>CEA is increasing in trend, which needs to be addressed.</li>
<li>Hypomagnesemia is frequently a result of magnesium depletion, which
is often caused by gastrointestinal or renal losses.
<ul>
<li>One of the main dose-limiting side effects of fluoropyrimidines such
as FU (and its oral prodrugs capecitabine and ftorafur-uracil [UFT]) is
diarrhea.</li>
<li>It is also possible that renal loss could be caused by medications
such as diuretics (loop and thiazide), antibiotics (aminoglycoside,
amphotericin, pentamidine), calcineurin inhibitors, cisplatin,
antibodies targeting epidermal growth factor (EGF) receptors (cetuximab,
panitumumab, matuzumab), which are not prescribed currently. (5-FU and
cisplatin are in recent regimen.)</li>
<li>Alcoholism is also a cause of renal loss. According to the
consultation with mental health clinic 2020-05-30, the patient might be
alcohol dependent.</li>
<li>The use of MgSO4 injection might be considered if there are no
contraindications.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-137" class="section level1">
<h1>700379547</h1>
<div id="section-138" class="section level2">
<h2>220419</h2>
<p>{Recurrent hepatocellular carcinoma with Lung and C-spine, T-spine
and L-spine metastasis cT2N0M1 stage IV}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-01 KUB
<ul>
<li>S/P operation with retention of surgical clips.</li>
<li>Stool retention in the bowel.</li>
<li>Degeneration and spondylosis of L-S spine.</li>
</ul></li>
<li>2022-03-18 CT - abdomen, pelvis
<ul>
<li>Multiple bony metastases on the T-and L-spine, and bilateral ilium
show progressive disease.</li>
<li>Compression fracture of L5 vertebral body is noted.</li>
<li>Right lower Lung metastases show progressive disease.</li>
</ul></li>
<li>2022-02-25 Patho - omentum biopsy
<ul>
<li>diagnosis
<ul>
<li>Tissue, site unspecified, CT-guide biopsy  hepatocellular
carcinoma</li>
<li>Microscopically, it shows hepatocellular carcinoma composed of
neoplatic cells with hyperchromatic nuclei, fine granular cytoplasm,
arranged in trabecular pattern with greater than 3 cell thick
cords.<br />
</li>
<li>IHC: CK7(-), CK19(-), arginase(+), CD10(-), and hepatocytes(+).</li>
</ul></li>
</ul></li>
<li>2022-02-25 Tc-99m MDP whole body bone scan
<ul>
<li>The scintigraphic findings suggest multiple bone metastases.</li>
</ul></li>
<li>2022-02-18 MRI - upper abdomen
<ul>
<li>Multiple HCCs at left hepatic lobe are noted.</li>
<li>Multiple bony metastases on the T-and L-spine are suspected.</li>
<li>Lung metastasis 1.1 cm at RLL is noted.</li>
</ul></li>
<li>2022-01-11 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Post-op at right lobe liver.</li>
<li>Diffuse HCCs, progression.</li>
<li>Lung and bone metastasis.</li>
<li>Suspected left renal cysts, up to 2.1cm.</li>
</ul></li>
<li>2021-12-15 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Multiple HCCs at left hepatic lobe are suspected.</li>
<li>Lung metastasis 1.1 cm at RLL is highly suspected.</li>
</ul></li>
<li>2021-10-14 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>S/P liver operation. Several recurrent HCCs (0.3-0.9) at remnant
liver.</li>
<li>A nodule (9mm) at RLL r/o metastases.</li>
<li>Liver cirrhosis with portal hypertension and splenomegaly.</li>
</ul></li>
<li>2021-09-01 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Two viable HCCs 1.1 cm in S2 and 0.7 cm in S4 are suspected.</li>
<li>Two recurrent HCCs 0.6 cm and 0.5 cm in S4 are suspected.</li>
<li>Cirrhosis of the liver with portal hypertension.</li>
</ul></li>
<li>2021-07-21 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Two recurrent HCCs 1.8 cm in S2 and 0.7 cm in S4 are highly
suspected. Please correlate with AFP.</li>
<li>Cirrhosis of the liver with portal hypertension.</li>
</ul></li>
<li>2021-06-02 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Two recurrent HCCs 1.6 cm in S2 and 0.7 cm in S4/8 are highly
suspected. Please correlate with AFP.</li>
<li>Prior CT identified HCC in S4/8 of the liver S/P TACE on 20210513
shows complete response.</li>
<li>Cirrhosis of the liver with portal hypertension.</li>
</ul></li>
<li>2021-05-19 Abdominal Ultrasonography
<ul>
<li>Liver tumors, suspected recurrent HCCs</li>
<li>Liver cirrhosis with mild splenomegaly</li>
<li>Liver lesions, spspect tumor scars or regeneration nodules</li>
<li>Invisible GB</li>
</ul></li>
<li>2021-05-06 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>S/P liver operation. Two recurrent HCCs (1.1cm, 1.3cm, srs3, img13,
15) at S2 and right liver margin.</li>
<li>A nodule (6mm) at RLL r/o metastases.</li>
<li>Liver cirrhosis with portal hypertension and splenomegaly.</li>
</ul></li>
<li>2021-02-25 Patho - liver partial resection
<ul>
<li>Pathologic diagnosis
<ul>
<li>Liver, S6-7, segmentectomy  Hepatocellular carcinoma,
recurrent<br />
</li>
<li>Pathologic Staging: rpT2Nx(cM0), Stage II at least</li>
</ul></li>
</ul></li>
<li>2021-02-03 MRI - liver, spleen
<ul>
<li>Imaging stage: T2N0M0, stage II</li>
</ul></li>
<li>2020-11-03 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>S/P RFA and S/P cholecystectomy.</li>
<li>Post-op at left lobe liver with focal enhancement at S4 around the
surgical region, probably vascular shunting. Suggest clinical
correlation and follow up study.</li>
<li>Renal cysts.</li>
<li>Minimal ascites in the pelvic cavity.</li>
</ul></li>
<li>2020-09-21 CT - abdomen, pelvis
<ul>
<li>Long segmental wall edema of esophagus and duodenum. Distention of
stomach.</li>
<li>S/P liver operation and cholecystectomy. Liver cirrhosis.</li>
</ul></li>
<li>2020-08-17 MRI - liver, spleen
<ul>
<li>Liver cirrhosis with portal hypertension and splenomegaly. HCC s/p
operation and RFA without tumor recurrence.</li>
</ul></li>
<li>2020-06-17 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Liver cirrhosis with HCC at S6 s/p RFA. No evidence of local
recurrence is found.</li>
</ul></li>
<li>2020-03-16 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>HCCs s/p operation, TACE and RFA. Residual and recurrent HCCs
(3-8mm) at right hepatic lobes.</li>
</ul></li>
<li>2020-02-04 Embolization (TAE) - abdomen
<ul>
<li>HCCs at RIGHT hepatic lobe s/p TACE.</li>
</ul></li>
<li>2019-11-28 MRI - liver, spleen
<ul>
<li>Liver cirrhosis.</li>
<li>HCC at S6 s/p RFA with recurrent tumor adjacent to the lesion.
Suggest further treatment.</li>
</ul></li>
<li>2019-09-18 CT - liver, spleen, biliary duct
<ul>
<li>Liver cirrhosis with HCC s/p RFA and TACE, no evidence of local
recurrence in the study.</li>
</ul></li>
<li>2019-07-03 CT - liver, spleen, biliary duct
<ul>
<li>Liver cirrhosis.</li>
<li>HCC s/p op. and RFA with suspected tumor recurrence at S7. Malignant
liver neoplasm, primary;</li>
</ul></li>
<li>2019-05-20 Surgical pathology Level V
<ul>
<li>Liver, sono-guided biopsy  Consistent with hepatocellular carcinoma
and liver cirrhosis</li>
<li>The sections show a picture liver cirrhosis, composed of
regenerative nodules separated by broad fibrous bands. Scant atypical
cells arranged in thin trabecular pattern can be found.</li>
<li>IHC: Glutamine synthetase(+), HSP70(+), glypican-3(+) and CK7(-).
The IHC finding is consistent with hepatocellular carcinoma.</li>
</ul></li>
<li>2019-03-12 CT - liver, spleen, biliary duct
<ul>
<li>S/P operation. A recurrent HCC (9mm) in S6 of liver.</li>
<li>Liver cirrhosis with portal hypertension and splenomegaly.</li>
</ul></li>
<li>2018-09-07 Surgical pathology Level V
<ul>
<li>pathologic diagnosis
<ul>
<li>Liver, S5, partial hepatectomy  Hepatocellular carcinoma<br />
</li>
<li>Liver, S6, partial hepatectomy  Combined
hepatocellular-cholangiocarcinoma<br />
</li>
<li>Specimen labeled surface tumor, frozen section  Regenerative
nodule<br />
</li>
<li>Pathologic Staging: ypT2Nx(cM0), Stage II at least</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Diagnosis: Hepatocellular carcinoma(S5) and combined
hepatocellular-cholangiocarcinoma(S6)</li>
<li>Histologic Grade: G2 (Moderately differentiated, both tumors)</li>
<li>Tumor Extension: Tumor confined withing liver (both tumors)</li>
<li>Pathologic Stage Classification
<ul>
<li>Primary Tumor (pT): ypT2 (multiple tumors, none &gt;5 cm)<br />
</li>
<li>Regional Lymph Nodes (pN): ypNx (No lymph nodes submitted)<br />
</li>
<li>Distant Metastasis (pM): Not applicable<br />
</li>
</ul></li>
<li>Additional Pathologic Findings: Chronic hepatitis C</li>
<li>Ishak modified staging of fibrosis: Cirrhosis (F6)<br />
</li>
<li>IHC: Cholangiocarcinoma component reveals CK7(+), Hepa1(-),
Arginase-1(-)</li>
</ul></li>
</ul></li>
<li>2017-07-10 MRI - liver, spleen
<ul>
<li>HCC s/p RFA. A poor enhancing nodule (1.5cm) in S6 of liver without
interval change.</li>
<li>Liver cirrhosis with regenerative nodules, portal hypertension and
splenomegaly.</li>
</ul></li>
<li>2017-02-16 CT - liver, spleen, biliary duct
<ul>
<li>HCC s/p RFA. Liver cirrhosis with splenomegaly.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2021-08-13 PIVIKA-II 62.36 mAU/mL (normal &lt; 40)</li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-17 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-11-03 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-09-02 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-07-22 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-06-21 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-05-13 Embolization (TAE) - abdomen for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-02-24
<ul>
<li>surgery - laparoscope assist right posterior segmntectomy S6-7</li>
<li>finding - two hepatic tumors at S7 and scaring at S6 and S6
postresected scarring</li>
</ul></li>
<li>2020-05-29 RFA, Radiofrequency ablation - HCC</li>
<li>2020-05-06 PEIT, Sonography guided percutaneous ethanol
injection</li>
<li>2019-08-23 Embolization (TAE) - abdomen
<ul>
<li>HCCs at RIGHT hepatic lobe s/p TACE.</li>
</ul></li>
<li>2018-09-06 Partial Hepatectomy</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2020-05-05 ~ 2022-01-10 - nivolumab</li>
<li>2020-04-01 ~ 2021-03-19 - lenvatinib</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient underwent partial hepatectomy on 2018-09-06, PEIT on
2020-05-06, RFA on 2020-05-29, 7 times of TACE between 2019-08-23 and
2021-12-17, and Lenvatinib from 2020-04-01 to 2021-03-19 as well as
Nivolumab from 2020-05-05 to 2022-01-10. The patients disease has
progressed based on 2022-03-18 CT.</li>
<li>Historically, traditional chemotherapy agents have not shown great
efficacy in the treatment of HCC when used in advanced stage of disease,
in particular in case of progression after locoregional therapy. FOLFOX
is listed in NCCN HCC guideline as a category 2B regimen. In the event
of MSI-H/dMMR being proven, dostarlimab-gxly might be tried (also
category 2B).</li>
</ul>
</div>
</div>
<div id="section-139" class="section level1">
<h1>700385854</h1>
<div id="section-140" class="section level2">
<h2>210507</h2>
<p>{colon cancer}</p>
<p>[subj/obj]</p>
<ul>
<li>diagnosed with sigmoid adenocarcinoma in 2020 Apr with liver,
paraaortic LNs, and peritoneal carcinomatosis, cT3N2bM1c, stage
IVc.</li>
<li>received FOLFIRI 80% dose and 11 times panitumumab from May to Oct
in 2020 at Taoyuan General Hospital of Ministry of Health and
Welfare.</li>
<li>patho colon biopsy on 2020-11-26 showed one huge tumor was noted at
sigmoid colon (30cm from anal verge) and the lumen was near completely
obstructed.</li>
<li>colonic tissue with invasive irregular neoplastic glands.
immunohistochemical stains reveal CDX2(+) EGFR(+), PMS2(+), MLH1(focal
+), MSH2(+), and MSH6(+).</li>
<li>received FOLFIRI 6 times from 2020 Nov to 2021 Mar (C1D1, C1D15,
C2D1, C2D15, C3D1, C3D15) in our hospital prior to this
hospitalization.</li>
<li>NRAS/KRAS reported on 2020-12-15 showing not detected.</li>
<li>CEA 16.62ng/mL(2021-01-26), 8.52ng/mL(2020-11-17).</li>
<li>BRAF lab data not found.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>patients with tumors originating on the right side of the colon
(hepatic flexure through cecum) are unlikely to respond to cetuximab and
panitumumab in first-line therapy for metastatic disease.</li>
<li>EGFR(+), KRAS/NRAS WT gene and left-sided tumor - panitumumab is
purchased and will be ready for the patient in days.</li>
<li>immune checkpoint inhibitors might not an ideal option for
non-dMMR/MSI-H tumor - MLH1(focal +), MSH2(+), MSH6(+).</li>
<li>according to CEA lab data, the condition might not be improved after
one year FOLFIRI.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>might order CT scan to gather new evidence on treatment effect.</li>
<li>If evidence shows that the cancer is getting more advanced, then
shift FOLFIRI to FOLFOX or CAPEOX (each regimen can be used in
combination with bevacizumab) could be considered.</li>
</ul>
<hr />
<p>{substance dependence}</p>
<p>[subj/obj]</p>
<ul>
<li>lab test showed evidence of using addictive drug.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>should help the patient get rid of those illegal drugs.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>might arrange or refer the patient to an addiction treatment center
or clinic to get some alternative e.g.methadone.</li>
</ul>
<hr />
<p>{returning to society}</p>
<p>[subj/obj]</p>
<ul>
<li>his family members avoid to contact him.</li>
<li>no job, no income</li>
<li>not standing on his own feet yet (financially)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>being not reintegrated to the society will push him closer to the
additive drugs.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>might arrange social work department staff to see if any help could
be offered to him.</li>
</ul>
</div>
</div>
<div id="section-141" class="section level1">
<h1>700404241</h1>
<div id="section-142" class="section level2">
<h2>220107</h2>
<p>[Objective]</p>
<ul>
<li>Adenocarcinoma of descending-sigmoid colon with partial obstruction
status post laparoscopic left hemicolectomy on 2021-10-13, pT3N1aM0,
pStage IIIB.
<ul>
<li>IHC stains: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+) based on
colon segmental resection, reported on 2021-10-20.</li>
</ul></li>
<li>Chronic viral hepatitis B without delta-agent.</li>
<li>Lab data reported on 2022-01-04 showing basically normal readings at
CBC, WBC, ALT, AST, bilirubin total, creatinine, eGFR, and slightly
elevated BUN 30mg/dL.</li>
<li>All RAS and BRAF mutation not detected, reported on 2021-11-03.</li>
</ul>
<p>[Assessment]</p>
<ul>
<li>FOLFOX 3-6 mo or CAPEOX 3 mo is preferred as adjuvant treatment for
T3N1M0 colon cancer patients. This patient is now on FOLFOX course.</li>
<li>Nivolumab or Pembrolizumab might not be preferred for this pMMR
patient.</li>
<li>Panitumumab or Cetuximab might be applicable as RAS and BRAF proved
wildtype for the left-sided patient.</li>
<li>HER2, NTKR data not found yet.</li>
<li>Hepatitis B virus might reactivate in the setting of chemotherapy.
Baraclude (Entecavir) has been prescribed.</li>
</ul>
<p>[Suggestion]</p>
<ul>
<li>No issue found in active medication. Keep tracking CEA, CT as
regular.</li>
</ul>
</div>
</div>
<div id="section-143" class="section level1">
<h1>700464889</h1>
<div id="section-144" class="section level2">
<h2>220325</h2>
<p>{hypopharyngeal and supraglottic cancer, cT4bN2b cM0, stage IV with
recurrent lung mets, progression of mets pulmonary lesions and
mediastinal/hilar LAP}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-10 Laryngoscopy
<ul>
<li>right hypopharyngeal cancer s/p induction chemotherapy + CCRT in
2016</li>
<li>lung mets proved in 2018-11, no local recurrence found according to
PE and fiber</li>
</ul></li>
<li>2022-02-15 CT - lung/mediastinum/pleura
<ul>
<li>progression of metastatic pulmonary lesions and distant metastatic
LAP as compared with previous CT on 20210823.</li>
</ul></li>
<li>2022-01-06 Laryngoscopy
<ul>
<li>right hypopharyngeal cancer s/p induction chemotherapy + CCRT in
2016</li>
<li>lung mets proved in 2018-11, no local recurrence found according to
PE and fiber</li>
</ul></li>
<li>2021-11-30 Nasopharyngoscopy
<ul>
<li>saliva cumulation at hypopharynx and rt. piriform sinus</li>
</ul></li>
<li>2021-10-07 Laryngoscopy
<ul>
<li>right hypopharyngeal cancer s/p induction chemotherapy + CCRT in
2016</li>
</ul></li>
<li>2021-08-23 CT - lung/mediastinum/pleura
<ul>
<li>progression of metastatic pulmonary lesions and mediastinal and
hilar LAP as compared with previous CT on 20210216.</li>
</ul></li>
<li>2021-05-14 MRI - Larynx
<ul>
<li>Post-treatment change at hypopharynx and larynx, without evidence of
recurrence. Less edema as compared with previous MRI on 20181107.</li>
</ul></li>
<li>2021-05-11 SONO - abdomen
<ul>
<li>Few gallstones and the size &lt; 1.15 cm.<br />
</li>
<li>Two renal cyst 2.37 cm in left lower pole and 0.91 cm in right
middle pole are noted.</li>
</ul></li>
<li>2021-02-16 CT - lung/mediastinum/pleura
<ul>
<li>stationary of metastatic pulmonary lesions and progression of
mediastinal and hilar LAP as compared with previous CT on 20200827.</li>
</ul></li>
<li>2020-11-17 SONO - abdomen
<ul>
<li>Few gallstones and the size &lt; 0.68 cm.<br />
</li>
<li>Two renal cyst 1.57 cm in left lower pole and 1 cm in right middle
pole are noted.</li>
</ul></li>
<li>2020-08-27 CT - lung/mediastinum/pleura
<ul>
<li>right upper lobe, left lingula lobe and right lower lobe lung mets,
stable.</li>
</ul></li>
<li>2020-06-02 SONO - abdomen
<ul>
<li>Few gallstones and the size &lt; 0.68 cm.<br />
</li>
<li>A renal cyst measuring 1.38 cm in left lower pole is noted.</li>
</ul></li>
<li>2020-03-10 CT -lung/mediastinum/pleura
<ul>
<li>metastatic tumors in bilateral lungs and medastinal and hilar
lymphadenopathy, stationary as compared with previous CT study on
20191216.</li>
</ul></li>
<li>2019-12-16 CT
<ul>
<li>metastatic tumors in bilateral lungs and medastinal and hilar
lymphadenopathy, in regression as compared with previous CT study on
20190916.</li>
</ul></li>
<li>2019-09-16 CT
<ul>
<li>metastatic tumors in bilateral lungs and medastinal and hilar
lymphadenopathy, in regression as compared with previous CT study on
20190717.</li>
</ul></li>
<li>2019-07-17 CT
<ul>
<li>diffsue lung metastatic lesions and mediastinal lymphadenopathy,
stable.</li>
</ul></li>
<li>2019-06-22 CT
<ul>
<li>metastatic tumors at bilateral lungs and medastinal and hilar
lymphadenopathy, in progression as compared with previous CT study.</li>
</ul></li>
<li>2019-04-19 CT
<ul>
<li>pulmonary necrotic metastatic tumors at bilateral lungs and
medastinal lymphadenopathy, in progression.</li>
</ul></li>
<li>2019-01-25 CT
<ul>
<li>compatible with hypopharyngeal cancer with lung mets. in
regression.</li>
</ul></li>
<li>2018-11-07 MRI - Larynx
<ul>
<li>Post-RT changes at hypopharynx and larynx, without evidence of
recurrence. Stationary as compared with MRI on 20180524.</li>
</ul></li>
<li>2018-11-07 Surgical pathology Level IV
<ul>
<li>Malignant hypopharynx neoplasm, pyriform sinus</li>
<li>Lung, side?, needle biopsy - squamous cell carcinoma, moderately
differentiated, origin?</li>
<li>IHC: p40(+), TTF-1(focal weak positive), and CD56(focal weak
positive). The results are in favor of squamous cell carcinoma.</li>
<li>Please correlate with the clinical presentation to differentiate
primary or metastatic tumor.</li>
</ul></li>
<li>2018-11-06 Surgical pathology Level IV
<ul>
<li>Malignant hypopharynx neoplasm, pyriform sinus</li>
<li>Lung, side?, bronchoscopic biopsy - squamous cell carcinoma,
moderately differentiated, origin?</li>
<li>IHC: p40(+), TTF-1(focal weak positive), and CD56(focal weak
positive). The results are in favor of squamous cell carcinoma.</li>
<li>Please correlate with the clinical presentation to differentiate
primary or metastatic tumor.</li>
</ul></li>
<li>2018-10-30 CT
<ul>
<li>hypopharynx cancer s/p RT s/p CT with lung and mediastinal-hilum LNs
metastasis.</li>
</ul></li>
<li>2018-05-24 MRI - nasopharynx
<ul>
<li>Post R/T and C/T change in right pyriform sinus and adjacent
hypopharynx, stationary.</li>
</ul></li>
<li>2017-11-28 MRI - nasopharynx
<ul>
<li>Post R/T and C/T change in right pyriform sinus and adjacent
hypopharynx, seems stationary.</li>
</ul></li>
<li>2017-05-26 MRI - larynx
<ul>
<li>Right hypopharynx CA, post CT and R/T, stationary in size of
abnormal soft-tissue combined more prominent post R/T change as compared
with MRI on 20161121.</li>
</ul></li>
<li>No earlier data available before 2017.</li>
</ul></li>
<li>Chemoimmunotherapy
<ul>
<li>2022-02-23, -03-24 - 5-FU + cisplatin + gemcitabine + nivolumab</li>
<li>2021-09-10, -10-04, -11-01, -11-30, -12-27, 2022-01-17 - 5-FU +
cisplatin + docetaxel + cetuximab</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>On CT images taken from the second half of 2019 through 2020,
metastatic lesions in bilateral lungs, mediastinal and hilar
lymphadenopathy remained stationary. However, on 2021-02-16 CT images,
progression of mediastinal and hilar LAP was observed, then on
2021-08-23 and 2022-02-15 CT images, metastatic pulmonary lesions and
distant metastatic LAP were observed.</li>
<li>From September 2021 to January 2022, the patient was treated with
chemoimmunotherapy comprising 5-FU + cisplatin + docetaxel + cetuximab,
followed by 5-FU + cisplatin + gemcitabine + nivolumab from February
2022 onwards.</li>
<li>The new regimen has been administered to the patient for the second
time during this hospitalization, and it will take time for the
responses to be confirmed.</li>
<li>The patients low serum magnesium reading on 2022-03-24 was treated
with MgSO4 IVD QD.</li>
</ul>
</div>
</div>
<div id="section-145" class="section level1">
<h1>700466967</h1>
<div id="section-146" class="section level2">
<h2>220421</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-14 MRI - brain
<ul>
<li>A left posterior cerebellar tumor, consistent with metastasis.</li>
</ul></li>
<li>2022-04-14 CT - brain
<ul>
<li>One mass lesion (2.8cm in size) over left cerebellar lobe with
perifocal edema. Compatible with a metastasis.<br />
</li>
<li>Mild dilatation of ventricles.</li>
<li>The posterior structures including the brain stem, cerebellum and CP
angles look normal.</li>
</ul></li>
<li>2022-04-14 Patho - lung transbronchial biopsy
<ul>
<li>Lung, right, CT-guide biopsy  consistent with metastatic
choriocarcinoma</li>
<li>Section shows alveolar tissue with infiltration of large pleomorphic
tumor cells and tumor necrosis.</li>
<li>The immunohistochemical stains reveal CK7(+), CK20(-), beta-hCG(+),
GATA-3(+), TTF-1(-), OCT3(-), PLAP(-), and SALL4(equivocal). The results
are consistent with metastatic choriocarcinoma. Please correlate with
the clinical presentaiton and lab study.</li>
</ul></li>
<li>2022-04-12 CT - chest
<ul>
<li>bilateral lung metastatic tumors.</li>
<li>two hepatic hemangiomas up to 35 mm.</li>
</ul></li>
<li>2022-04-08 MRA - brain
<ul>
<li>Left cerebellar metastasis.</li>
</ul></li>
<li>2022-04-08 CT - brain
<ul>
<li>Probably left cerebellar metastasis.</li>
</ul></li>
<li>2021-12-20 Chest PA/AP view
<ul>
<li>a large consolidation with lobulated contour over Rt lower lobe, in
regression as compared with previous chest image</li>
<li>near complete resolution of the LLL small nodule post transthoracic
needle biopsy</li>
</ul></li>
<li>2021-12-14 Chest PA/AP view</li>
<li>diffuse consolidation in Rt lower lobe stationary as compared with
previous chest image</li>
<li>a nodular opacity (well-defined) over LLL</li>
<li>2021-12-14 Patho - lung transbronchial biopsy
<ul>
<li>Lung, LLL, CT-guide biopsy  Scant atypical cells present<br />
</li>
<li>Sections show alveolar lung tissue with interstitial fibrosis and
scant atypical cells in fibrous stroma.</li>
<li>The immunohistochemical stains reveal CK(+), p40(-), TTF-1(-),
Napsin A(-), CD56(-), SALL4(-), and OCT4(-). Please correlate with the
clinical presentation and lab study. Further examination is
suggested.</li>
</ul></li>
<li>2021-12-07 SONO - chest
<ul>
<li>lung consolidation, suspected abscess</li>
</ul></li>
<li>2021-12-06 Chest PA (erect) view
<ul>
<li>Radiopacity in right middle and lower lung zone, suspected mass or
loculated pleural lesion</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-04-12
<ul>
<li>LDH 776 U/L<br />
</li>
<li>beta-HCG &gt;265200 mIU/mL<br />
</li>
<li>AFP 207.4 ng/mL</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-12 hemato-oncology
<ul>
<li>This 22-year-old male patient had past history of
<ul>
<li>Testis cancer status post operation at Tri-Service General Hospital
for 2 years ago.</li>
<li>Pneumonia and lung abscess in 2021-12 at Taipei Tzu Chi
Hospital</li>
<li>RLL and LLL solid nodules, suspected lung metastases on 20211229 at
Tri-Service General Hospital.<br />
</li>
</ul></li>
<li>This time, he suffered from headache and dizzness for one week. He
was brough to our emergency room for help. Arrival at our emergency
room, initial consciousness remained E4M6V5. Labortory data showed
normal range of WBC, but elevated CRP (11.60mg/dl). Brain CT was done,
which showed a 2.2cm heterogeneous hyperdense nodule at left cerebellum,
associated with vasogenic edema. Brain metastasis is first considered.
Brain MRI was performed, which revealed a 2.2cm rim-enhancing nodule at
left cerebellum, associated with vasogenic edema. Brain metastasis is
first considered. Multiple nodular and mass over bilateral lung were
found. Consulted Neurosurgeon was done cause by suspected brain
metastases of left cerebellum. He then admitted to SICU for neurological
condition monitoring and further management on 2022-04-08. After SICU,
he remained conscious during ICU stay. Under anti-swelling agent as
Mannitol and Medason were used. PPI for ulcer prevention. Anticonvulsant
agent as Keppra was given. He will arrange lung CT this afternoon.
<ul>
<li>Tumor marker: B-HCG: &gt;265200, <a href="AFP:207.4" class="uri">AFP:207.4</a>, LDH:?</li>
<li>Chest CT: pending</li>
<li>Brain CT: left cerebellar metastasis.</li>
<li>Brain MRI: left cerebellar metastasis.</li>
</ul></li>
<li>Impression:
<ul>
<li>Suspect recurrent nonseminal germ cell tumor with lung and brain
metastasis</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Pending chest CT report, check LDH</li>
<li>Arrange CT guide biopsy for suspect lung metastasis</li>
<li>If proof recurrent non seminoma germ cell tumor, arrange port A
insertion</li>
<li>Arrange pulmonary function test: FRC + DLCO</li>
<li>Wait for CT-guided biopsy of lung tumor that will be done on 4/14
22. If recurrent germ cell tumor wt lung mets &amp; L cerebellar mets is
Dx, palliative C/T will be started soon.</li>
<li>Germ cell tumor may be well responsive to palliative C/T wt
BEP.</li>
<li>As for L cerebellar mets tumor, may consult radiation oncologist for
R/T evaluation.</li>
<li>may check AFP, b-HCG as well.</li>
</ul></li>
</ul></li>
<li>2022-04-08 Neurosurgery
<ul>
<li>Q:
<ul>
<li>cough with blood-tinged sputum for 2 weeks</li>
<li>headache with dizziness after waking up for one week</li>
<li>no fever, no sore throat or runny nose, no SOB, no chest pain</li>
<li>PMH: testis cancer s/p op, Rt lung cyst</li>
<li>allergy: denied</li>
</ul></li>
<li>A:
<ul>
<li>A case of 22 y/o male; Testis cancer s/p; Headache/dizziness
progressed for 1+ week;</li>
<li>A brain CT showed a 2.2cm heterogeneous hyperdense nodule at left
cerebellum, associated with vasogenic edema. Brain metastasis is first
considered.</li>
<li>A brain MRI with Gd showed a 2.2cm rim-enhancing nodule at left
cerebellum, associated with vasogenic edema. Brain metastasis is first
considered.</li>
<li>P: ICU care; mannitol/ steroid; Tumor excision indicated;</li>
</ul></li>
</ul></li>
<li>2021-12-13 Radiological Diagnosis
<ul>
<li>Q: 22 year old male with past history of prostate cancer s/p OP 2
years ago admitted this time due to RLL pneumonia (suspected abscess)
and treated with Brosym, Colistin, and Targocid. CT also showed an 1.3
cm nodule over left lower lungs. Thus, we needed your expertise for
CT-giuded biopsy for left lower lung nodule.</li>
<li>A: This 22-year-old patient is a case of LLL nodule, r/o malignancy.
CT-guided biopsy is indicated. Please chek platelet, PT, and aPTT before
this procedure. We will inform the risk of insufficient specimen,
pneumothorax, hemorrhage, infection, and air embolism to the patient and
the family.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Not sure if orchiectomy has been performed.</li>
<li>Bleomycin + Etoposide + Cisplatin might be indicated.</li>
<li>Additionally, opioids may be a viable option for this patients with
moderate to severe pain. (reference: <a href="https://www.ncbi.nlm.nih.gov/books/NBK554435/" class="uri">https://www.ncbi.nlm.nih.gov/books/NBK554435/</a> )</li>
<li>Besides analgesics, non-pharmacological interventions that can
control pain over a longer period of time might also be considered. The
following interventions are available to treat cancer pain (not
exhaustive, reference: <a href="https://pubmed.ncbi.nlm.nih.gov/31140913/" class="uri">https://pubmed.ncbi.nlm.nih.gov/31140913/</a>):
<ul>
<li>Epidural and selective nerve root block</li>
<li>Radiofrequency ablation and cryoablation</li>
<li>Vertebral augmentation</li>
<li>Intrathecal drug delivery</li>
<li>Spinal cord stimulation</li>
<li>Dorsal root ganglion stimulation</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-147" class="section level1">
<h1>700506064</h1>
<div id="section-148" class="section level2">
<h2>220126</h2>
<p>[objective]</p>
<ul>
<li>Lab findings
<ul>
<li>2021-11-09 Patho
<ul>
<li>Diagnosis
<ul>
<li>Ovary, bilateral, debulking surgery - Residual high grade serous
carcinoma</li>
<li>Fallopian tube, bilateral, ditto - High grade serous carcinoma</li>
<li>Endometrium, uterus, ditto - Free from tumor, endometrial polyp</li>
<li>Myometrium, uterus, ditto - Tumor invasion, focal</li>
<li>Tumor on bladder, ditto - Tumor present<br />
</li>
<li>Tumor on rectum, ditto - Tumor present<br />
</li>
<li>Lymph node, Lt iliac artery, dissection - Tumor metastasis (1/4)
without extracapsular extension (0/1)</li>
<li>Lymph node, Rt iliac artery, ditto - Tumor metastasis (1/3) without
extracapsular extension (0/1)</li>
<li>Lymph node, Rt obturator nerve, ditto - Tumor metastasis (1/6)
without extracapsular extension (0/1)</li>
<li>AJCC Pathologic staging: ypT3cN1a, if cM0; stage IIIC<br />
</li>
</ul></li>
<li>Microscopic Exam
<ul>
<li>Histologic type: high-grade serous carcinoma (refer to
S2021-05715)</li>
<li>Histologic grade: high grade</li>
<li>Contralateral ovary involvement: present<br />
</li>
<li>Tumor side ovarian surface involvement: present<br />
</li>
<li>Contralateral ovary involvement: present<br />
</li>
<li>Right tube involvement: present<br />
</li>
<li>Left tube involvement: present<br />
</li>
<li>Right adnexa soft tissue involvement: present<br />
</li>
<li>Left adnexa soft tissue involvement: present<br />
</li>
<li>Uterine serosa involvement: present<br />
</li>
<li>Endometrium involvement: absent, endometrial polyp<br />
</li>
<li>Myometrium involvement: present, focal<br />
</li>
<li>Lymph nodes metastasis: tumor metastasis (3/19) without
extracapsular extension (0/3) in total number</li>
<li>Lymphovascular space invasion: present<br />
</li>
<li>Tumor on bladder: high grade serous carcinoma with necrosis and
microcalcification</li>
<li>Tumor on rectum: high grade serous carcinoma with necrosis and
microcalcification</li>
</ul></li>
</ul></li>
<li>2021-04-15 Patho
<ul>
<li>Diagnosis
<ul>
<li>Peritoneum, debulking -Metastatic serous carcinoma, compatible with
fallopian tube or ovarian origin - Microscopic Exam</li>
<li>The sections show metastatic serous carcinoma, high grade,
compatible with fallopian tube or ovarian origin, composed of nests of
pleomorphic neoplastic cells with numerous mitotic figures, arranged in
solid and papillary patterns. Scattered psammoma bodies and tumor
necrosis are noted.</li>
<li>IHC: ER(+), WT1(+), PAX8 (+), p53(+ with aberrant expression).<br />
</li>
</ul></li>
</ul></li>
<li>2021-04-14 Ascites
<ul>
<li>Smears show clusters of pleomorphic tumor cells. Malignancy is
favored.</li>
</ul></li>
<li>2021-04-14 Frozen Section
<ul>
<li>Peritoneal tumor, frozen section - Malignant, favor serous
carcinoma.</li>
</ul></li>
</ul></li>
<li>Treatments
<ul>
<li>2021-05 ~ 2021-09 - Paclitaxel + Carboplatin</li>
<li>2021-09 ~ 2021-10 - Paclitaxel</li>
<li>2021-11 ~ 2021-11 - Liposome Doxorubicin + Carboplatin</li>
<li>2021-12 ~ ongoing - Paclitaxel + Carboplatin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Paclitaxel + Carboplatin is preferred as an primary systemic therapy
regimen for high-grade serous stage II-IV disease.</li>
<li>Albumin-bound paclitaxel could be substituted for patients
experiencing a hypersensitivity reaction to paclitaxel.</li>
<li>Bevacizumab (or its biosimilar) might be an optional component to
the aforementioned regimen.</li>
<li>for elderly patients and/or those with comorbidities and/or
intolerence, the following adjustment might be considered.
<ul>
<li>paclitaxel 60mg/m2 IV over 1 hour followed by carboplatin AUC 2 IV
over 30 minutes</li>
<li>days 1, 8, 15; repeat every 21 days</li>
</ul></li>
<li>no issue found in active medication.</li>
</ul>
</div>
</div>
<div id="section-149" class="section level1">
<h1>700509991</h1>
<div id="section-150" class="section level2">
<h2>220215</h2>
<p>{gastric cancer, stage IIA, extra-capsular spread (ECS) positive}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2021-12-24 Patho - stomach subtotal/total (tumor)
<ul>
<li>Diagnosis - Tumor, stomach, subtotal gastrectomy -
Adenocarcinoma</li>
<li>AJCC Pathologic staging - pT2N1, if cM0, stage IIA</li>
</ul></li>
<li>2021-12-20 Patho - stomach biopsy
<ul>
<li>Diagnosis
<ul>
<li>Stomach, antrum GC side, s/p biopsy (A) - Adenocarcinoma.
<ul>
<li>IHC: Her2/neu: negative (score=1+).</li>
</ul></li>
<li>Stomach, prepyloric antrum, s/p biopsy (B) - low grade
dysplasia.</li>
</ul></li>
</ul></li>
<li>2021-12-18 CT - abdomen, gastric filling with water
<ul>
<li>Gastric carcinoma
<ul>
<li>T2N1M0, stage IIA</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-23 radical subtotal gastrectomy with D2 lymph nodes
dissection.</li>
</ul></li>
<li>treatment
<ul>
<li>post-Op adjuvant CCRT with 5-FU 24 hr QD x 5 per wk x 6 plus R/T on
2022-02-14.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>several targeted therapeutic agents, trastuzumab,
pembrolizumab/nivolumab, and entrectinib/larotrectinib have been
approved by the FDA for use in gastric cancer.
<ul>
<li>trastuzumab is based on testing for HER2 overexpression.</li>
<li>pembrolizumab/nivolumab are based on testing for MSI by PCR or
NGS/MMR by IHC, PD-L1 immunohistochemical expression, or high tumor
mutational burden (TMB) by NGS.</li>
<li>FDA granted approval for the use of select TRK inhibitors for NTRK
gene fusion-positive solid tumors.</li>
</ul></li>
<li>when limited tissue is available for testing, or the patient is
unable to undergo a traditional biopsy, sequential testing of single
biomarkers or use of limited molecular diagnostic panels may quickly
exhaust the sample. in these scenarios, comprehensive genomic profiling
via a validated NGS assay performed in a CLIA-approved laboratory may be
used for the identification of HER2 amplification, MSI status, MMR
deficiency, TMB, and NTRK gene fusions. the use of IHC/ISH/targeted PCR
should be considered first followed by additional NGS testing as
appropriate.</li>
<li>no drug allergy recorded in database, no issue found with current
medication.</li>
</ul>
</div>
</div>
<div id="section-151" class="section level1">
<h1>700522826</h1>
<div id="section-152" class="section level2">
<h2>210825</h2>
<p>{breast cancer}</p>
<p>[initial presentation]</p>
<ul>
<li>left breast lump found since 2021 May/June</li>
</ul>
<p>[definite diagnose, disease extent]</p>
<ul>
<li>2021-07-23 SONO breast, Mammography
<ul>
<li>hyperdense tumors in left breast, 4.9cm (subareolar region) and
1.7cm (deep central), suspected malignancy, suggest biopsy.</li>
<li>BI-RADS: Category 5: highly suggestive of malignancy-appropriate
action should be taken.</li>
</ul></li>
<li>2021-07-23 Patho - breast biopsy
<ul>
<li>breast, 4/5 and 12 region, left, invasive carcinoma characterized
by proliferation of tumor cells with infiltrative growth pattern, ductal
differentiation and stromal fibrosis.</li>
<li>the tumor cell shows hyperchromatic nuclei, plemorphism and high N/C
ratio.</li>
<li>IHC stain ER(-), PR(-), Her2/neu(3+), p53(+), Ki-67 index 20%.</li>
</ul></li>
<li>2021-08-06 Patho - lymphnode biopsy
<ul>
<li>benigh lymph node tissue, IHC stain CK(-)</li>
</ul></li>
<li>2021-08-09 Tc-99m MDP bone scan
<ul>
<li>no strong evidence of bone metastasis.</li>
</ul></li>
<li>2021-08-09 CT - abdomen, pelvis
<ul>
<li>left breast tumor (2.1cm, 4.9cm) with skin invasion suspected
cancer.</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>chemo regimen AC (doxorubicin/cyclophosphamide) since
2021-08-25.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>cT3N0 her2-positive, tumor &gt; 1cm, chemo with trastuzumab (or
pertuzumab) could be indicated.
<ul>
<li>however, there are limited data to confirm chemo regimen for those
&gt; 70 y of age.</li>
</ul></li>
<li>CBC WNL, liver and kidney function well, based on most recent lab
data.</li>
<li>no drug allergy record found in database.</li>
<li>MSI/MMR, PD-L1, BRCA1/2, PIK3CA tests could also be considered.</li>
</ul>
</div>
</div>
<div id="section-153" class="section level1">
<h1>700522990</h1>
<div id="section-154" class="section level2">
<h2>220506</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-05 Abdominal Ultrasonography
<ul>
<li>Periampullary tumor, causing CBD/MPD obstruction, close to or
invaded to IVC, with PTCD in situ</li>
<li>C/W cholangitis change, lower CBD</li>
<li>C/W A-colon cancer, with luminal stricture but no evidence of
obstruction</li>
<li>Pancreatic cystic lesions, head-body, suspected IPMN</li>
<li>GB polyps</li>
<li>Hepatic cyst, left lobe</li>
<li>Renal cyst, LK</li>
</ul></li>
<li>2022-05-04 CT - abdomen, pelvis
<ul>
<li>suspected colon cancer</li>
<li>suspected pancreatic head or ampulla vater cancer.</li>
</ul></li>
<li>2022-05-04 CT - brain
<ul>
<li>no acute intracranial hemorrhage</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>Bilirubin total
<ul>
<li>2022-05-06 9.97 mg/dL</li>
<li>2022-05-04 16.82</li>
</ul></li>
<li>S-GPT/ALT
<ul>
<li>2022-05-06 55 U/L</li>
<li>2022-05-04 67</li>
</ul></li>
<li>S-GOT/AST
<ul>
<li>2022-05-04 113 U/L</li>
</ul></li>
<li>RBC
<ul>
<li>2022-05-06 3.61 *10^6/uL</li>
<li>2022-05-04 3.92</li>
</ul></li>
<li>HGB
<ul>
<li>2022-05-06 7.9 g/dL</li>
<li>2022-05-04 8.7</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-05-05 PTCD drainage</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>2022-05-06 04:45 vital signs TPR 35.9/68/16, BP 132/64 were
relatively stable, low energy consumption. This patient has been
diagnosed with primary hypertension, her tissue perfusion might be less
than usual. No antihypertensive agents are prescribed currently.</li>
<li>The abdominal ultrasonography performed on 2022-05-05 showed
periampullary tumors causing CBD/MPD obstruction and A-colon tumor with
luminal stricture, which might need further evaluation to determine if
they should/could be resected.</li>
<li>After PTCD drainage on 2022-05-05, bilirubin total decreased to 9
mg/dL (2022-05-06) from 16 mg/dL (2022-05-04).</li>
<li>RBC decreased to 3.61 (2022-05-06) from 3.92 (2022-05-04), HGB
decreased to 7.9 (2022-05-06) from 8.7 (2022-05-04). ABO, Rh typing,
antibody screening have been performed on 2022-05-06.</li>
<li>There are no records of drug allergies in the database. There are no
issues with the current medication.</li>
</ul>
</div>
</div>
<div id="section-155" class="section level1">
<h1>700527901</h1>
<div id="section-156" class="section level2">
<h2>220111</h2>
<p>{Diffuse Large B Cell Lymphoma}</p>
<p>[objective]</p>
<ul>
<li>MRI reported on 2021-12-28
<ul>
<li>Tonsillar fossa, 2cm &lt; size &lt; 4cm, no regional nodal
metastasis, T2N0M0</li>
</ul></li>
<li>patho reported on 2021-12-30 - right tonsil biopsy
<ul>
<li>Diagnosis: diffuse large B cell lymphoma</li>
<li>IHC: CD20(+), CD3(-), CD10(-), CD30(-), CK(-), Bcl-2(+), Bcl-6(+,
focal), C-MYC(+, 30-40%), Ki-67 70-80% for tumor</li>
</ul></li>
<li>LDH reported on 2022-01-10 136U/L (normal 140~271)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>B-cell lymphomas with translocations of MYC and BCL2 and/or BCL6
(double-/triple-hit lymphoma), elevated LDH not seen, bone marrow and
CNS involvement not checked.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>no drug allergy recorded in database, no issue found in active
medication.</li>
<li>if localized high-grade B-cell lymphomas is confirmed, then
consolidative ISRT might be considered.</li>
</ul>
</div>
</div>
<div id="section-157" class="section level1">
<h1>700529746</h1>
<div id="section-158" class="section level2">
<h2>220426</h2>
<ul>
<li>2022-04-25 Chest PA/AP view
<ul>
<li>There are few nodular opacity projecting in both lung that may be
metastases. Please correlate with CT.</li>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>S/P coronary artery stent implantation.</li>
<li>Spondylosis of the T-spine</li>
<li>Compression fracture of L1 vertebral body S/P cement
vertebroplasty.</li>
</ul></li>
<li>2022-04-22 Chest PA/AP view
<ul>
<li>S/P operation.</li>
<li>S/P Port-A infusion catheter insertion.</li>
<li>S/P VP.</li>
<li>Patch density at bil. lungs.</li>
</ul></li>
<li>2022-04-18 MRI - upper abdomen
<ul>
<li>S/P operation.</li>
<li>Multiple LNs, lung and liver metastases.</li>
<li>Bil. pleural effusion.</li>
</ul></li>
<li>2022-04-18 Chest PA + Lat. LT
<ul>
<li>There are few nodular opacity projecting in both lung that may be
metastases. Please correlate with CT.</li>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>S/P coronary artery stent implantation.</li>
<li>Spondylosis of the T-spine</li>
<li>Compression fracture of L1 vertebral body S/P cement
vertebroplasty.</li>
</ul></li>
<li>2022-04-01 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the lower C-spine, lower T- and upper L-spines
and lower L-spines. Degenerative change may show this picture. Please
correlate with other imaging modalities for further evaluation.</li>
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture.</li>
<li>Increased activity in the right shoulder, bilateral hips and right
knee, compatible with benign joint lesions.</li>
</ul></li>
<li>2022-03-31 Patho - lung transbronchial biopsy
<ul>
<li>Lung, right, CT-guide biopsy  adenocarcinoma, moderately
differentiated, consistent with metastatic colonic origin</li>
<li>Sections show neoplastic glandular cells infiltrating in a fibrotic
stroma and proliferating along the alveolar wall with focal tumor
necrosis.</li>
<li>The immunohistochemical stains reveal TTF-1(-) and CDX2(+). The
results are consistent with metastatic colonic adenocarcinoma. Please
correlate with the clinical presentation and image study.</li>
</ul></li>
<li>2022-03-31 Chest PA/AP view
<ul>
<li>no pneumothorax s/p transthoracic needle biopsy of RML nodule.</li>
</ul></li>
<li>2022-03-31 Whole body PET scan
<ul>
<li>Multiple glucose hypermetabolic lesions in bilateral lungs. Multiple
lung metastases should be considered first. Please correlate with other
clinical findings for further evaluation and to rule out other
possibilities.</li>
<li>Some glucose hypermetabolic lesions in the right and left lobes of
the liver. Liver metastases should be watched out.</li>
<li>Glucose hypermetabolism in bilateral pulmonary hilar and multiple
mediastinal lymph nodes and in multiple abdominal lymph nodes,
compatible with metastatic lymph nodes.</li>
<li>Prominent glucose hypermetabolism in a focal area in the right lobe
of the thyroid gland. The nature is to be determined (thyroid
malignancy? other nature?). Please also correlate with other clinical
findings for further evaluation.</li>
<li>Glucose hypermetabolism in a focal area in the right parotid gland
and in a focal area in the left parotid gland. The nature is to be
determined (some kind of parotid lesions? metastases? other
nature).</li>
<li>Mild glucose hypermetabolism in some left lower neck lymph nodes and
glucose hypermetabolism in the left shoulder. Inflammation is more
likely.</li>
</ul></li>
<li>2022-03-31 MRI - brain
<ul>
<li>General brain atrophy. An old infarct in right corona radiata.</li>
<li>No evidence of brain metastases based on this non-contrast MRI.</li>
</ul></li>
<li>2022-03-21 CT - lung/mediastinum/pleura
<ul>
<li>multiple nodules in both lungs, favors metastatic tumors</li>
<li>suspect combined lung edema, pleural effusion, and LAD and LVD of
heart. extensive 3V-CAD.</li>
</ul></li>
<li>2022-03-17 Chest PA erect view
<ul>
<li>Cardiomegaly and tortuosity of the thoracic aorta.</li>
<li>Engorgement of bilateral hilar regions with increased interstitial
lines of both lungs.</li>
<li>Degenerative joint disease of T-spine with marginal
osteophytes.</li>
<li>S/P internal fixation of C-spine.</li>
</ul></li>
<li>2021-11-01 Chest PA erect view
<ul>
<li>A nodular opacity projecting in the right lower lung is suspected.
Please correlate with CT.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>S/P coronary artery stent implantation.</li>
<li>Spondylosis of the T-spine</li>
<li>Compression fracture of L1 vertebral body S/P cement
vertebroplasty.</li>
</ul></li>
<li>2021-10-27 Patho - colorectal polyp
<ul>
<li>Colon, anastomotic site, s/p biopsy.(A)  Tubular adenoma with low
grade dysplasia</li>
<li>Colon, T-colon, s/p biopsy.(B)  Hyperplastic polyp</li>
<li>Colon, D-colon, s/p biopsy.(C)  Hyperplastic polyp</li>
<li>Colon, S-colon, 20 cm from AV, s/p hot snare polypectomy and
S-colon, 18 cm from AV, s/p cold snare polypectomy (D)  Tubulovillous
adenomas with low grade dysplasia.</li>
</ul></li>
<li>2020-11-20 Myocardial perfusion SPECT with persantin
<ul>
<li>Probably moderate myocardial ischemia with possible a small portion
of severe ischemia at the apex and anterior wall and mild to moderate
myocardial ischemia at the anterolateral wall.</li>
<li>Mild reverse redistribution of radioactivity to the basal
inferolateral wall, either normal variant or myocardial ischemia may
show this picture.</li>
</ul></li>
<li>2020-09-26 MRA - brain
<ul>
<li>Moderate stenosis in the bilateral cavernous ICAs, esp, left side.
Please correlate with cerebral angiography.</li>
</ul></li>
<li>2020-06-03 Patho - colon segmental resection for tumor
<ul>
<li>Pathologic diagnosis
<ul>
<li>Large intestine, hepatic flexure colon, SILS right hemicolectomy 
Adenocarcinoma, moderately differentiated<br />
</li>
<li>Resection margins: free<br />
</li>
<li>Lymph node, mesocolic, dissection  metastatic adenocarcinoma
(7/16)<br />
</li>
<li>Lymph node, IMA / SMA, dissection  N/A.<br />
</li>
<li>Pathology stage: pT3N2b(If cM0); pStage IIIC<br />
</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histology: Adenocarcinoma<br />
</li>
<li>Histology Grade: moderately differentiated<br />
</li>
<li>Depth of invasion: pericolorectal tissue<br />
</li>
<li>Angiolymphatic invasion: Present.<br />
</li>
<li>Perineural invasion: Not identified.<br />
</li>
<li>Discontinuous extramural tumor extension: Not identified.</li>
<li>Circumferential (radial) margin of rectum: Uninvolved<br />
</li>
<li>Lymph node metastasis, mesocolic: Positive (7/ 16)<br />
</li>
<li>Lymph node metastasis,, IMA / SMA: N/A.<br />
</li>
<li>Extranodal involvement: Present.<br />
</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>Primary Tumor (pT) pT3: Tumor invades through the muscularis propria
into pericolorectal tissues<br />
</li>
<li>Regional Lymph Nodes (pN) pN2b: Seven or more regional lymph nodes
are positive<br />
</li>
<li>Distant Metastasis (pM) pMX<br />
</li>
</ul></li>
<li>Type of polyp in which invasive carcinoma arose: Not
identified<br />
</li>
<li>Additional pathologic findings: None identified.<br />
</li>
<li>TNM descriptors: N/A.<br />
</li>
<li>Tumor regression grading S/P CCRT: N/A.</li>
</ul></li>
</ul></li>
<li>2020-06-02 CT - abdomen, pelvis
<ul>
<li>Imaging stage: T3N2M0, stage IIIB</li>
</ul></li>
<li>2020-06-02 Patho - colon biopsy
<ul>
<li>Colon, hepatic flexure, biopsy  Adenocarcinoma.</li>
<li>IHC stains: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+).<br />
</li>
<li>Section shows pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
</ul></li>
<li>2020-06-02 Patho - colorectal polyp
<ul>
<li>Colon, transverse, polypectomy  Tubular adenoma with low grade
dysplasia</li>
</ul></li>
<li>2020-02-07 Paho - intradermal nevus
<ul>
<li>Skin, excision biopsy  Basal cell carcinoma, solid type, 0.1 cm
away from the closest (side and deep) margin.</li>
<li>IHC stains: adipophilic(-), EMA(-), Ber-EP4(+).</li>
</ul></li>
<li>2019-11-04 MRA - brain
<ul>
<li>Diffuse arteriosclerosis with multi-focal stenoses.</li>
<li>Brain atrophy.</li>
</ul></li>
<li>2019-04-17 CPA - carotid phonoangiograph
<ul>
<li>Sonographic diagnosis
<ul>
<li>Multi-focal mild stenosis in bil BIF, bil ICA, right ECA; mild
atheromatous lesions in right SCA, right CCA.</li>
<li>Normal extracranial carotid, vertebral, and right intracranial basal
cerebral arterial flows; severe stenotic flow in right ICA, bil ECA,
left SCA; mild to moderate stenotic flow in right PCA and right
ECA.</li>
<li>Poor temporal windows for left transcranial insonation.</li>
<li>Normal bilateral ophthalmic arterial flows.</li>
<li>Suggest MRA (neck+intracranial arteries) for further study if no
contraindication.</li>
</ul></li>
</ul></li>
<li>2018-12-21 KUB
<ul>
<li>Osteoporosis, mild scoliosis and spondylosis of L-spine. S/P VP at
T12. S/P TPS and disc prosthesis at L3-4-5. Mottled bowel gas
pattern.</li>
</ul></li>
<li>2018-10-17 CPA - carotid phonoangiograph
<ul>
<li>Sonographic diagnosis
<ul>
<li>Severe stenosis with severe stenotic flow in right proximal ICA;
moderate to severe stenosis with mildly increased flow velocity in left
proximal ECA; moderate stenosis in right distal CCA and right BIF;
multi-focal mild stenosis in right proximal &amp; mid CCA, left distal
CCA, left BIF and left proximal ICA; moderate atheromatous lesions in
left mid CCA.</li>
<li>Normal extracranial carotid, vertebral, and intracranial vertebral,
basilar arterial flows; severe stenotic flow in right proximal ICA and
BA; mild stenotic flow in left ECA and right intracranial VA; smaller
caliber and decreased flow in right cervical VA, indicated
hypoplasia.</li>
<li>Poor temporal windows for bilateral transcranial insonation.</li>
<li>Normal bilateral ophthalmic arterial flows.</li>
<li>Suggest MRA (neck+intracranial arteries) for further study if no
contraindication.</li>
</ul></li>
</ul></li>
<li>2018-09-03 CT - brain
<ul>
<li>No brain lesion.</li>
<li>Intracranial ICAs and VAs atherosclerosis.</li>
<li>Age-appropriate cerebral atrophy.</li>
</ul></li>
<li>2018-06-27 Upper GI panendoscopy
<ul>
<li>Erosive esophagitis (La Gr A-) - Hiatal hernia</li>
</ul></li>
<li>2018-06-20 Myocardial perfusion SPECT with persantin
<ul>
<li>Probably (1) moderate myocardial ischemia in the apex and anterior
wall (LAD territory) and (2) mild myocardial ischemia in the basal
lateral wall (LCx-M territory) of the left ventricle.</li>
<li>No post-stress dilatation of the left ventricle.</li>
</ul></li>
<li>2017-03-24 Upper GI panendoscopy
<ul>
<li>gastric shallow ulcers and erosions, antrum</li>
</ul></li>
<li>consultation
<ul>
<li>2021-10-21 Gastroenterology
<ul>
<li>PI
<ul>
<li>ADHF, with pulmonary edema, s/p ETT+MV 10/08-10/14</li>
</ul></li>
<li>S
<ul>
<li>still tarry stool today</li>
</ul></li>
<li>O
<ul>
<li>E4V5M6</li>
<li>Hb: 11.7-&gt;8.6-&gt;9.2</li>
<li>EGD: no active bleeder</li>
</ul></li>
<li>A
<ul>
<li>Black with dark green stool, suspected LGIB</li>
</ul></li>
<li>P
<ul>
<li>Arrange colonscopy on 10/23 AM if the patient and family understand
the risk of CFS (organ perforation etc)</li>
<li>Add transamine<br />
</li>
</ul></li>
</ul></li>
<li>2021-10-18 Rehabilitation
<ul>
<li>Q
<ul>
<li>For CHF of cardiopulmonary muscle endurance training and muscle
strengthening exercise.</li>
<li>2021/10/08 heart echo showed: EF = 21.1%; Dilated LA; Poor LV
systolic function, generalized hypokinesis, especiaaly IVS; Concentric
LV hypertrophy, Impaired LV relaxation; Moderate MR.<br />
</li>
<li>This 76 year old female had a past history of
<ul>
<li>NSTEMI, s/p stent placement at ShuangHo Hospital 202109 under Bokey
+ Blingta</li>
<li>3-V-D s/p PTCA and Rota, 2 stents over RCA on 20161019</li>
<li>Pneumonia</li>
<li>Chronic kidney disease stage 4</li>
<li>Hypertension</li>
<li>T2DM control with Humalog Mix25 38u BID</li>
<li>Anemia, gastric OB 3+, UGIB cannot be ruled out</li>
<li>Colon Ca, pT3N2bM0, stage IIIC s/p laparoscopic right colectomy on
20200603</li>
<li>C4-5-6-7 HIVD s/p op in 201310 and L3-4-5 s/p op in 20130529.</li>
<li>PUD hx</li>
</ul></li>
<li>According to her husband, she experienced dyspnea for last weeks.
The symptoms persisted and progressed despite of OPD follow up. Thus she
came to our ED for help. At ER, CXR revealed bilateral pulomonary
inflitration, suggesting acute pulmonary edema. Breathing pattern was
swallow and fast. Intubation was performed after informed consent. Under
the impression of acute decompensated heart failure with pulmonary
edema, she was admitted into ICU for further medical care. After
admitted to MICU, 2D echo was done and showed Dilated LA, Poor LV
systolic function, generalized hypokinesis, especiaaly IVS, Concentric
LV hypertrophy, Impaired LV relaxation, Moderate MR. EF was 21% under
Simpson method. Lasix 40mg Q12H was given and much urine output and BW
loss were noted. Empirical Abx with rocephine was also prescribed since
20211008. Mexiletine and Ivabradine was given. Due to no active bleeding
sign, oral diet was resumed and PPI was shifted to oral. However, acute
on CKD was noted on 20211012, suspected pre-renal AKI. Lasix was tapered
off, minimal IV hydration with 500cc NS QD was given. The ventilator was
tapered smoothly. T-piece was tried on 20211013. On 20211014, extubation
was done and BIPAP support was given. The patient weaning off BIPAP soon
after 1 day. She also tolerated oral diet well. F/u CXR and lab were
both improved with residual left consolidation. No fever was noted thus
Ceftriaxone was discontinued after 1 wk. Under stable condtion, she was
transfered to ward on 20211018.</li>
</ul></li>
<li>A
<ul>
<li>Rehabilitation programs: Bedside PT cardiopulmonary rehabilitation
programs</li>
<li>Goal: recondition, improve endurance and muscle strength</li>
<li>May arrange PM&amp;R OPD follow-up for further phase 2 cardiac
rehabilitation program as needed</li>
</ul></li>
</ul></li>
<li>2021-10-08 Cardiology
<ul>
<li>BILATERAL pulmonary edema noted s/p intuvbation. With her creatine
3.2, no obvious progression compared her last creatinine study.</li>
<li>Received cath at nearby hostpital for LAD. No obvious lower limb
swelling this time.</li>
<li>Last echoc was performd at 202012 with preserved LV function, thus,
the pulmonary edema cause would multi-factorial, pending on admission to
MICU by ER doctor.</li>
</ul></li>
<li>2020-12-16 Nephrology
<ul>
<li>Q
<ul>
<li>Reason: for CKD stage 4 assessment</li>
<li>This is a 75 years old lady who has CAD s/p stent, DM for 20+ years,
Ca colon s/p op in June 2020.</li>
<li>Patient was admitted for planned CAG on 20191216, However, we noted
patient had renal anemia, (Hb : 8.6 with eGFR &lt; 15) (Stool OB:
negative Oct 2020). currently using plavix, progressive renal function
impairment.</li>
<li>We arranged Ca,P, iPTH, Iron profile, Ferritin, renal echo, urine
analysis and proteinuria screening</li>
<li>WE consult you for assessment of EPO SC usage and CKD managment with
your superior profession.</li>
</ul></li>
<li>A
<ul>
<li>Impression
<ul>
<li>CKD stage 4, suspect DM nepropathy relatd</li>
<li>CAD s/p stent</li>
<li>DM</li>
<li>Ca colon s/p op on June 2020.</li>
</ul></li>
<li>Suggestion
<ul>
<li>Stage 4 cannot use EPO</li>
<li>Nephrology OPD follow up was suggested</li>
<li>Treat the underlying diseases as your expertise</li>
<li>Avoid nephrotoxc agents</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-06-03 SILS right hemicolectomy</li>
<li>2020-02-07 skin excision
<ul>
<li>a flesh color papule with hyperpigmented dots on nose for years
-&gt; suspected BCC</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-25 ~ undergoing - FOLFIRI</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This DM related CKD stage 4 patient has advanced colon cancer with
lung mets s/p left hemicolectomy on 2020-06-03. She has been receiving
FOLFIRI as from this hospitalization.</li>
<li>Lab data on 2022-04-25 showed BUN 70mg/dL, urine creatinine
3.95mg/dL, eGFR 11.71, HGB 9.0 g/dL, serum uric acid 8.8 mg/dL.
Hyperuricemia is managed with Feburic (febuxostat) 40mg PO QD
currently.</li>
<li>There are no irinotecan dosage adjustments provided in the
manufacturers labeling (has not been studied) for kidney impairment,
please use with caution and monitor closely. Use of irinotecan in
patients with dialysis is not recommended by the manufacturer; however,
literature suggests reducing weekly dose from 125 mg/m2 to 50 mg/m2 and
administer after hemodialysis or on nondialysis days. Irinotecan is
associated with early and late diarrhea, both of which may be severe
(atropine has been subscribed as a pre-/co-treatment in the regimen). In
the event the patient develops diarrhea, supportive care (e.g.fluid and
electrolyte replacement, loperamide, antibiotics, etc.) should be
provided as needed.</li>
<li>The patient has two stents for her coronary artery disease.
Cardiotoxicity observed with 5-FU includes myocardial
infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac
failure, sudden death, ECG changes, and cardiomyopathy. There is no
recommended dose for resumption of 5-FU administration following
development of cardiac toxicity, and the drug should be discontinued.
She is also taking Plavix (clopidogrel) for her stents, for bevacizumab
has the potential to cause hypertension, hemorrhage, and
thromboembolism, so the patient should be closely monitored if
bevacizumab is also administered.</li>
<li>Erythropoietin 5000U weekly could be considered as an additional
item if no contraindiction, until the reading backs to 11 g/dL.</li>
</ul>
</div>
</div>
<div id="section-159" class="section level1">
<h1>700536529</h1>
<div id="section-160" class="section level2">
<h2>220118</h2>
<p>[objective]</p>
<ul>
<li>Recent lab data
<ul>
<li>2022-01-18 serum glucose 191mg/dL</li>
<li>2022-01-17 serum glucose 164mg/dL</li>
<li>2022-01-11 serum glucose 154mg/dL</li>
<li>2021-11-10 ascites glucose 150mg/dL</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Elevated serum glucose.</li>
<li>This patient has type 2 DM and CVD
<ul>
<li>SGLT2i might be a choice to protect heart while lowering blood
sugar.</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>SGLT2i such as empagliflozin, dapagliflozin, canagliflozin are
available in stock could be prescirbed if UTI is unlikely.</li>
</ul>
</div>
</div>
<div id="section-161" class="section level1">
<h1>700539680</h1>
<div id="section-162" class="section level2">
<h2>210722</h2>
<p>{vaccination for splenectomised patients}</p>
<p>[objective]</p>
<ul>
<li>this patient had splenectomy done on 2021-05-12 (huge spleen,
&gt;30cm in length, weight 2000g)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>splenectomised patients are at risk for severe and overwhelming
infections with encapsulated bacteria, bloodborne parasites.</li>
<li>measures for preventing these infections include patient and family
education, vaccination against encapsulated bacteria.</li>
<li>vaccines are available to against bacteria such as Streptococcus
pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Bordetella
holmesii.</li>
<li>these vaccines are all in inactivated, noncellular form, not
classified as attenuated, relatively safe for patients receiving
chemotherapy.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>as a general guide, vaccine dose could be administered when patient
is in stable condition and during chemo window period. the dose should
be repeated no less than 6 months after chemotherapy.</li>
</ul>
</div>
</div>
<div id="section-163" class="section level1">
<h1>700542356</h1>
<div id="section-164" class="section level2">
<h2>220325</h2>
<ul>
<li>Patient was transferred from Cardinal Tien Hospital with a diagnosis
of suspected MDS and urinary tract infection. Our emergency room did not
note any obvious signs of discomfort, such as fever, chills, chest pain,
dyspnea, or abdominal pain.</li>
<li>The following laboratory results were obtained on 2022-02-24: CRP
4.84 mg/dL, serum glucose 454 mg/dL, WBC 1040/uL, HGB 7.4 g/dL, PLT
3000/uL, NT-proBNP 5006 pg/mL, urine OB 3+, urine bacteria 1+, APTT 38
sec.</li>
<li>The blood culture result is not out yet. Symptomatic treatment is
being provided to the patient currently. No issue is identified with the
current medication.</li>
</ul>
</div>
</div>
<div id="section-165" class="section level1">
<h1>700551138</h1>
<div id="section-166" class="section level2">
<h2>220406</h2>
<p>{serous carcinoma of right fallopian tube with peritoneal and pleural
invastion with tumor recurrent, pT3cN1aM1a, stage IVA}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-02 CT - abdomen, pelvis
<ul>
<li>Pseudomyxoma peritonei with liver and spleen metastases show
stationary.</li>
</ul></li>
<li>2022-02-24 Needle aspiration cytology - liver
<ul>
<li>Smears show histiocytes and clusters of atypical hyperchromatic
papillary tumor. Malignancy is favored.</li>
</ul></li>
<li>2022-02-23 CT - lung/mediastinum/pleura
<ul>
<li>no lung metastasis. pseudomyxoma peritonei and splenic lesion.</li>
</ul></li>
<li>2022-01-28 CT - abdomen, pelvis
<ul>
<li>Pseudomyxoma peritonei is highly suspected. Please correlate with
aspiration cytology.</li>
</ul></li>
<li>2021-11-04 SONO - abdomen
<ul>
<li>Right liver cyst (1.75x2.10cm).</li>
</ul></li>
<li>2021-08-10 CT - abdomen, pelvis
<ul>
<li>s/p LAR and autosuture. No evidence of recurrent/residual tumor in
the current study.</li>
</ul></li>
<li>2021-05-11 SONO - abdomen
<ul>
<li>A hepatic cyst measuring 1.81 cm in S6 is noted.</li>
</ul></li>
<li>2021-02-09 CT - abdomen, pelvis
<ul>
<li>Post-op at the colon. S/P hysterectomy and oophorectomy.</li>
</ul></li>
<li>2020-11-19 Whole body PET scan
<ul>
<li>Mild glucose hypermetabolism in a right axillary lymph node. The
nature is to be determined (inflammation? other nature?). Please
correlate with other clinical findings for further evaluation.</li>
<li>Mild glucose hypermetabolism in bilateral shoulders and in the soft
tissues around bilateral hips. Inflammatory process may show this
picture.</li>
<li>Mildly increased FDG accumulation in the colon and both kidneys.
Physiological FDG accumulation is more likely.</li>
</ul></li>
<li>2020-11-13 CT - abdomen, pelvis
<ul>
<li>No Abscess or lymphocele in right pelvic sidewall is noted.</li>
</ul></li>
<li>2020-09-18 CT - abdomen, pelvis
<ul>
<li>Abscess 3.5 x 2.8 cm in right pelvic sidewall is suspected.</li>
<li>The differential diagnosis include lymphocele.</li>
</ul></li>
<li>2020-09-08 CT - abdomen, pelvis
<ul>
<li>Post op. change of the rectum.</li>
<li>Cystic change at right pelvic side wall, stable.</li>
</ul></li>
<li>2020-05-25 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy.</li>
<li>Some LNs (up to 1.1cm) at bil. inguinal regions.</li>
<li>A cystic lesion (3.8cm) at right pelvic cavity.</li>
</ul></li>
<li>2019-12-24 CT - abdomen, pelvis
<ul>
<li>S/P pigtail catheter drainage, right lower abdomen.</li>
<li>S/P CAPD catheter in the pelvic cavity, with focal loculated fulid
in pericatheter region.</li>
<li>Cystic lesion, 3.8cm in right pelvic cavity, r/o lymphocele.</li>
<li>Post-op at the colon.</li>
<li>Bilateral pleural effusion with basal atelectasis.</li>
</ul></li>
<li>2019-07-25 Patho Level VI - sigmoid colon
<ul>
<li>pathologic diagnosis
<ul>
<li>Sigmoid colon, radical proctectomy?  Serous carcinoma,
metastatic<br />
</li>
<li>Faciform ligament, excision  Serous carcinoma, metastatic<br />
</li>
<li>Soft tissue over rectum, excision  Serous carcinoma,
metastatic<br />
</li>
<li>Lymph nodes, mesocolic, dissection  Metastatic serous carcinoma
(4/4)</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology: Serous carcinoma, metastatic<br />
</li>
<li>Histology Grade: High grade</li>
<li>Depth of invasion: Subserosal tumor with muscularis propria
invasion</li>
<li>Angiolymphatic invasion: Present<br />
</li>
<li>Perineural invasion: Not identified<br />
</li>
<li>Lymph node metastasis, mesocolic: Positive (4/4)</li>
<li>Faciform ligament: Serous carcinoma, metastatic<br />
</li>
<li>Soft tissue over rectum: Serous carcinoma, metastatic</li>
</ul></li>
</ul></li>
<li>2019-07-25 Patho Level VI - BSO, hysterectomy
<ul>
<li>pathologic diagnosis
<ul>
<li>Fallopian tube, right, BSO  Serous tubal intraepithelial carcinoma
and serous carcinoma, consistent with right fallopian tube is primary
site<br />
</li>
<li>Ovaries, bilateral, BSO  Involved by serous carcinoma<br />
</li>
<li>Fallopian tube, left, BSO  Involved by serous carcinoma<br />
</li>
<li>Uterus, corpus, total hysterectomy  Involved by serous
carcinoma<br />
</li>
<li>Uterus, cervix, total hysterectomy  Free of carcinoma<br />
</li>
<li>Omentume, omentectomy  Involved by serous carcinoma<br />
</li>
<li>Peritoneum, right, excision  Involved by serous carcinoma<br />
</li>
<li>Bladder, biopsy  Involved by serous carcinoma<br />
</li>
<li>Lymph nodes, external iliac, left, PLND  Metastatic serous
carcinoma<br />
</li>
<li>Pathologic Stage: pT3cN1aM1a; Stage IVA at least</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic type: Serous carcinoma<br />
</li>
<li>Histologic grade: High grade</li>
<li>Bilateral ovaries involvement: Present</li>
<li>Bilateral ovarian surface involvement: Present</li>
<li>Right tube involvement: Present</li>
<li>Left tube involvement: Present</li>
<li>Serous tubal intraepithelial carcinoma in right fallopian tube:
Present</li>
<li>Uterine serosa involvement: Present</li>
<li>Omentum involvement: Present</li>
<li>Uterine Cervix: Chronic cervicitis, Nabothain cyst and squamous
metaplasia</li>
<li>Endometrium involvement: Atrophy</li>
<li>Myometrium: Leiomyoma and adenomyopsis</li>
<li>Largest Extrapelvic Peritoneal Focus: 5.0 x 3.5 x 2.0 cm</li>
<li>Peritoneal/Ascitic Fluid: Malignant (positive for malignancy)</li>
<li>Pleural Fluid: Malignant (positive for malignancy)</li>
<li>Regional Lymph Nodes: Positive for metastasis</li>
<li>Other organs or specimens involvement: Present, specify: Bladder and
sigmoid colon (S2019-12175)</li>
<li>Additional Pathologic Findings: Brenner tumor in right ovary</li>
<li>IHC for tumor cells (S2019-12133FS): WT1(+), PAX8(+), p53(+ aberrant
expression), calretinin(-)</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2019-07-19
<ul>
<li>Debulking surgery (ATH + BSO + cytoreduction + infracolic
omentectomy + appendectomy)</li>
<li>CRS HIPES</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-03-02 ~ undergoing - docetaxel + carboplatin (plus bevacizumab
since 2022-03-28)</li>
<li>2019-08-20 ~ 2020-02-03 - paclitaxel + carboplatin, 6 times</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient was diagnosed with serous carcinoma of the right
fallopian tube with peritoneal and pleural invasion with recurrent
tumors, received [paclitaxel + carboplatin] 6 times in the period from
2019-08-20 to 2020-02-03 following debulking surgery on 2019-07-19, now
she is on [docetaxel + carboplatin] since 2022-03-02 (plus bevacizumab
since 2022-03-28).</li>
</ul>
</div>
</div>
<div id="section-167" class="section level1">
<h1>700560024</h1>
<div id="section-168" class="section level2">
<h2>220125</h2>
<p>{marginal zone lymphomas}</p>
<p>[objective]</p>
<ul>
<li>lab findings
<ul>
<li>2021-09-14 CT - Lung/Mediastinum/Pleura
<ul>
<li>Impression: lymphadenopathy in the axillary and abdominal regions,
involving both sides of diaphgrams.</li>
</ul></li>
<li>2021-09-07 Patho - lymphnode biopsy
<ul>
<li>Lymph node, axillary, left, biopsy - Small B-cell lymphoma,
compatible with marginal zone lymphoma.
<ul>
<li>Immunophenotyping: CK(-), CD3(-), CD20(+), CD5(-), CD23(+), CD43(-),
CD10(-/+), Cycline D1(-).</li>
</ul></li>
</ul></li>
<li>2020-11-20 Patho
<ul>
<li>Stomach, antrum, PW, biopsy - Suspicious lymphoid infiltrate,
probably extranodal marginal zone lymphoma of mucosa-associated lymphoid
tissue (MALT lymphoma) with Helicobacter pylori infection.
<ul>
<li>IHC, the small lymphoid cells: CD3(-), CD20(+), BCL2(+), CD5(-),
CD10(-), and CD43(-).</li>
</ul></li>
<li>Stomach, low body, GC side, biopsy - Suspicious lymphoid infiltrate,
probably extranodal marginal zone lymphoma of mucosa-associated lymphoid
tissue (MALT lymphoma) with Helicobacter pylori infection.
<ul>
<li>IHC, the small lymphoid cells: CD3(-), CD20(+), BCL2(+), CD5(-),
CD10(-), and CD43(-).</li>
</ul></li>
</ul></li>
</ul></li>
<li>treatment
<ul>
<li>2021-10 ~ ongoing - R-CHOP</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>first-line therapy regimens for marginal zone lymphomas could be:
<ul>
<li>CHOP(cyclophosphamide, doxorubicin, vincristine, prednisone) +
Rituximab</li>
<li>CVP(cyclophosphamide, vincristine, prednisone) + Rituximab</li>
<li>Bendamustine + Rituximab</li>
</ul></li>
<li>the patient is receiving R-CHOP without much intolerance.</li>
<li>no issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-169" class="section level1">
<h1>700598345</h1>
<div id="section-170" class="section level2">
<h2>220407</h2>
<p>{Acute myeloblastic leukemia, not having achieved remission}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-24 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, (AML, S/P induction C/T and consolidation C/T x
2), biopsy - Normal cellularity.</li>
<li>IHC: CD117: &lt;1 %; CD34: &lt;1 %; MPO: 20-30%, CD61: 5-10%; CD71:
70-75% (of the nucleated cells).</li>
<li>Section shows piece(s) of bone marrow with 40% cellularity and M:E
ratio of approximately 1:3. Three cell lineages are present with normal
maturation of leukocytes. Megakaryocytes are adequate in number. There
is no malignancy present.</li>
</ul></li>
<li>2022-03-09 CT - lung/mediastinum/pleura
<ul>
<li>pulmonary infection or leukemic infiltration in both lungs.</li>
</ul></li>
<li>2021-12-14 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac bone, biopsy - Hypocellularity and no increase of
blast</li>
<li>Hypocellularity for her age, 5-10%</li>
<li>Marked hypoplasia of all three lineages<br />
</li>
<li>No obviously increase of blast</li>
</ul></li>
<li>2021-11-29 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac bone, biopsy - Compatible with acute myeloid
leukemia</li>
<li>Microscopically, the sections show a picture of acute myeloid
leukemia, composed of hypercellular marrow (70-80%) with proliferative
blasts about 30% of nucleated cells, which immunohistochemistry shows
CD34(+), CD117(+) and MPO(+). Besides, hypoplasia of erythroid series
and megakaryocytes highlights by CD61(+, megakaryocytes) and CD71(+,
erythroid series) is also noted. Clinical and bone marrow smear
correlation is advised.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-03-18 P.jiroveci DNA-Sp undetectable</li>
<li>2021-12-09 FLT3-D835 mutation undetectable</li>
<li>2021-12-02 Aspiration
<ul>
<li>CD2 NA</li>
<li>CD3 0.39</li>
<li>CD4 NA</li>
<li>CD5 0.14</li>
<li>CD7 61.64</li>
<li>CD8 NA</li>
<li>CD10 1.15</li>
<li>CD11b 2.5</li>
<li>CD13 77.23</li>
<li>CD14 5.23</li>
<li>CD15 NA</li>
<li>CD16 2.28</li>
<li>CD19 1.14</li>
<li>CD19/kappa NA</li>
<li>CD19/Lambda NA</li>
<li>CD20 NA</li>
<li>CD23 NA</li>
<li>CD25 NA</li>
<li>CD33 99.86</li>
<li>CD34 92.71</li>
<li>CD38 NA</li>
<li>CD56 0.05</li>
<li>CD103 NA</li>
<li>CD117 83.82</li>
<li>CD138 NA</li>
<li>FMC7 NA</li>
<li>HLA-DR 95.7</li>
<li>MPO NA</li>
<li>TdT NA</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-07 ~ undergoing - cytarabine (high dose Ara-C, HiDAc,
300mg/m2 IVD 3h Q12H D1,3,5 total 5 doses or 200mg/m2 3h Q12H D1-4 total
8 doses) + daunorubicin (45mg/m2 IV D1-3)</li>
<li>2021-12-02 - idarubicin (45-80mg/m2 d1-3) + cytarabine (100-200mg/m2
d1-7)</li>
</ul></li>
<li>consultation
<ul>
<li>2021-12-02 Dr.YaoRen Xu
<ul>
<li>Q
<ul>
<li>This 40 year-old female patient who has history of childhood
epilepsy under medication was admitted via the OPD due to leukocytosis
with anemia and thrombocytopenia. The PB smear showed increase blast
cells (40-60%). Acute leukemia is considered. She was admitted for bone
marrow biopsy and AML was confirmed. We will start chemotherapy with
regimen of Idarubicin + Cytarabine - 3 + 7 days.</li>
<li>She is unmarried, G0P0 and no GYN history. For prevention of
excessive bleeding, we need to halt her menstrual cycle.</li>
</ul></li>
<li>A
<ul>
<li>consider to halt menstrual cycle due to thrombocytopenia</li>
<li>no active GYN problems</li>
<li>Danazol 200ml 1# BID PO may be considered, no more than 6 months,
can be administered during chemotherapy course.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient with AML (2021-11-29 bone marrow biopsy pathology)
without the FLT3-D835 mutation (2021-12-09 undetectable) was treated
with high dose cytarabine + daunorubicin starting on 2022-01-07,
following idarubicin + cytarabine (3+7) in December 2021.</li>
<li>The last two consecutive bone marrow biopsy pathology (2021-12-14
and 2022-03-24) showed no obviously increase of blast and normal
cellularity. So far, so good.</li>
<li>There were no other obvious abnormalities found except an elevated
level of uric acid of 7.6 mg/dL reported on 2022-04-06, which might be
controlled with febuxostat or benzbromarone.</li>
</ul>
</div>
<div id="section-171" class="section level2">
<h2>220311</h2>
<p>{compatibility}</p>
<p>The combination of calcium gluconate, magnesium sulfate, and
potassium chloride in 0.9% sodium chloride normal saline is
compatible.</p>
</div>
<div id="section-172" class="section level2">
<h2>220110</h2>
<p>Lab data reported on 2022-01-10 - RBC 3.44*10^6/uL - HGB 9.4g/dL</p>
<p>Danol (Danazol) androgen is prescribed to pause menses to maintain
RBC, HGB levels in the setting of chemotherapy.</p>
</div>
</div>
<div id="section-173" class="section level1">
<h1>700622927</h1>
<div id="section-174" class="section level2">
<h2>220504</h2>
<p>{Minutes of the Interprofessional Practice Meeting and Family
Meeting}</p>
<ul>
<li>This was the second meeting held on 2022-05-04 at 10:00 in the ward,
the first meeting being held on 2022-03-30. The patients son
participated in the meeting via a smart phone.</li>
<li>Dr.Kao explained the treatment schedule to the patient family, as
well as the prognosis and possible risks.</li>
<li>The patient asked questions about her small amount of bleeding from
the catheter needle wound and the soybean-based meals in the hospital.
These questions got immediate feedback, as she understood that willpower
is an indispensable element of treatment for the disease.</li>
</ul>
</div>
<div id="section-175" class="section level2">
<h2>220330</h2>
<p>{Interprofessional Practice Meeting and Family Meeting following
up}</p>
<ul>
<li>This meeting was held on 2022-03-30 at 9:00 in the ward, the patient
was present, as was her son.</li>
<li>Dr.Kao explained the treatment plan of the disease to the patient
family, as well as the prognosis and possible risks, and
interprofessional practice team members were present for inquiries.</li>
<li>For the transplant will need relatively rare used drugs, the
pharmacy should prepare in advance to ensure that the drugs are readily
available and Dr.Kao will provide an updated version of conditioning
agent schedule.</li>
</ul>
</div>
</div>
<div id="section-176" class="section level1">
<h1>700640254</h1>
<div id="section-177" class="section level2">
<h2>210907</h2>
<p>{ovary cancer s/p debulking surgery}</p>
<p>[history]</p>
<ul>
<li>laparoscopic myomectomy 10 years ago.</li>
</ul>
<p>[initial presentation]</p>
<ul>
<li>abdominal fullness with palpable mass over right side, poor
appetite, easily fullness and nausea sensation when eat a lot, less
urine output with voiding hesitation, back soreness and excertional
dyspnea since 2021-06.</li>
<li>constipation since 2021-07.</li>
</ul>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2021-07-27 abdominal ultrasound
<ul>
<li>cystic lesion, suspected cystic tumor, lower abdomen</li>
</ul></li>
<li>2021-07-28 CT - whole abdomen, pelvis
<ul>
<li>findings
<ul>
<li>a lobulated cystic mass with enhancing mural nodules and few septa
in the lower abodmen and pelvis, measuring 20.6 x 12.8 x 26 cm (width x
depth x cranial-caudal length). cystic adenocarcinoma of the right ovary
is highly suspected.</li>
<li>soft tissue nodules and fatty stranding in the omentum of right
middle abdomen that may be carcinomatosis. correlate with
peritoneoscopy.</li>
<li>poor enhancing lesions in the uterus that are compatible with
myomas. ill-defined enhancing lesions in the uterine myometrium that are
compatible with adenomyosis.</li>
</ul></li>
<li>image stage
<ul>
<li>T1aN0M0, stage IA</li>
</ul></li>
</ul></li>
<li>2021-08-16 patho - ovary tumor
<ul>
<li>histologic type: clear cell carcinoma</li>
<li>histologic grade: high grade</li>
<li>regional lymph nodes: left iliac: 0/1; left obturator: 0/3; right
iliac: 0/3; right obturator: 0/6; left paraaortic: 0/1; right
para-aortic: 0/1.</li>
<li>leiomyomas and endometriosis are seen in myometrium. endometrioma is
found in left ovary.</li>
<li>aggregation of histiocytes is present in the omentum.</li>
<li>IHC stains: PAX8(+), Napsin A(+), WT-1(-), PR(-), and p53(-).</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2021-08-16 debulking surgery (ATH + BSO + cytoreduction surgery +
omentectomy + LN dissection)</li>
</ul>
<p>[assessment]</p>
<ul>
<li>clear cell carcinoma of the ovary is a relatively less common
ovarian cancer, since the patient is just in her early fifties, her
liver and kidney functions showed no abnormality (lab data reported on
2021-08-13), IV platinum-based therapy might be applicable.
<ul>
<li>paclitaxel + carboplatin every 3 weeks for 3 to 6 cycles (hearing
test done 2021-09-07 morning)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-178" class="section level1">
<h1>700653751</h1>
<div id="section-179" class="section level2">
<h2>220419</h2>
<p>newly diagnosed with Endometrioid adenocarcinoma T1BN0M0 stage IB s/p
Laparoscopic gynecologic oncology staging surgery</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-16 Patho - uterus (with or without SO) neoplastic
<ul>
<li>pathologic diagnosis
<ul>
<li>Uterus, endometrium, laparoscopic staging surgery  Endometrioid
adenocarcinoma, grade 3<br />
</li>
<li>Uterus, myometrium, LSC staging surgery  Involved by adenocarcinoma
(more than half thickness)<br />
</li>
<li>Uterus, cervix, LSC staging surgery  Negative for malignancy</li>
<li>Ovaries and fallopian tubes, bilateral, LSC staging surgery 
Negative for malignancy</li>
<li>Lymph node, left iliac, dissection  Negative for malignancy
(0/4)<br />
</li>
<li>Lymph node, left obturator, dissection  Negative for malignancy
(0/6)</li>
<li>Lymph node, right iliac, dissection  Negative for malignancy (soft
tissue only)<br />
</li>
<li>Lymph node, right obturator, dissection  Negative for malignancy
(0/6)</li>
<li>AJCC 8th edition Pathology stage: pT1bN0(if cM0); FIGO IB; AJCC
stage IB</li>
</ul></li>
<li>IHC: p53(wild type), p16(-), ER: positive (moderate, 40%), PR:
positive (moderate, 40%)</li>
</ul></li>
<li>2022-02-11 MRI - pelvis
<ul>
<li>Soft tissue tumor in the uterine cavity, suspected endometrial
malignancy, cStage T1bN0M0.</li>
<li>Suspected right ovarian cyst.</li>
</ul></li>
<li>2022-02-10 Gynecologic ultrasonography
<ul>
<li>suspected endometrial hyperplasia</li>
<li>suspected rt ovarian cyst</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-16
<ul>
<li>Surgery
<ul>
<li>Laparoscopic gynecologic oncology staging surgery</li>
</ul></li>
<li>Finding
<ul>
<li>Uterus: normal size, smooth surface, papillary mass in uterus
cavity, myometrium invasion depth &lt;1/2</li>
<li>Bilateral adnexa: grossly normal</li>
<li>Bilateral pelvic lymph nodes: normal(-), enlarged(+),
indurated(+)</li>
<li>CDS: free</li>
<li>Adhesion between omentum and pelvic wall was noted</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-03-17 ~ undergoing - 3240cGy/18 fractions (15 MV photon) of the
pelvic area</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-23 - cisplatin (NCCN 20211104 Uterine Neoplasms p32 ENDO-D
1/4 - carboplatin + paclitaxel)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient has been recently diagnosed with endometrioid
adenocarcinoma stage IB s/p laparoscopic gynecologic oncology staging
surgery, and is receiving EBER since 2022-03-17 and cisplatin since
2022-03-23.</li>
<li>Lab data on 2022-04-19 and 2022-04-12 were grossly normal. Cardiac
conditions are managed with corresponding drugs. TPR readings are
normal. There is no information on blood sugar levels during this
hospital stay yet.</li>
</ul>
</div>
</div>
<div id="section-180" class="section level1">
<h1>700704174</h1>
<div id="section-181" class="section level2">
<h2>999999</h2>
<p>{colon cancer}</p>
<p>[objective]</p>
<ul>
<li>2019-09-20 screening for malignant neoplasm, colon: stool occult
blood test positive</li>
<li>2019-10-03 colonofiberoscopy: an ulcerative lesion with lumen
narrowing at 30 cm to 40 cm from anal verge and biopsy was done.
impression: suspicion of sigmoid colon tumor.</li>
<li>2019-10-03 CT, abdomen:
<ul>
<li>wall thickening of sigmoid colon, 4.4 cm in length, with perifocal
fat stranding.</li>
<li>sigmoid colon cancer T3N1MX.</li>
</ul></li>
<li>2019-10-14 laparoscopic anterior resection and
anastomosis-malignant, finding:
<ul>
<li>sigmoid cancer 5<em>3</em>3cm near D-S junction with nearly total
obstruction</li>
<li>splenic flexure was fully mobilized</li>
</ul></li>
<li>2019-10-16 patho:
<ul>
<li>sigmoid colon, laparoscopic sigmoid colectomy - adenocarcinoma</li>
<li>lymph node, mesocolic, dissection - positive for tumor metastasis
(8/18) with extracapsular extension (6/8)</li>
<li>AJCC pathologic stage - pT3N2bMx, stage IIIC at least B.</li>
</ul></li>
<li>2020-01-16 CT, abdomen:
<ul>
<li>colon cancer s/p operation. focal fat stranding at LUQ.</li>
<li>left adrenal nodule (1.3cm).</li>
</ul></li>
<li>2020-05-07 sigmoidoscopy: no evidence of recurrence</li>
<li>2020-05-07 CT, abdomen, pelvis:
<ul>
<li>colon cancer s/p operation. focal fat stranding at LUQ without
interval change.</li>
<li>left adrenal nodule (1.3cm) without interval change.</li>
</ul></li>
<li>2021-02-22 CT, abdomen:
<ul>
<li>tumor seeding in left paracolic gutter space is suspected. the
differential diagnosis include epiploic appendagitis or omentum
infarction.</li>
<li>metastatic nodes in para-aortic space and para-cava space are
suspected.</li>
</ul></li>
<li>2021-02-27 whole body PET scan:
<ul>
<li>a glucose hypermetabolic lesion in the rectal region, probably tumor
recurrence.<br />
</li>
<li>glucose hypermetabolic lesion at the C7 spine, probably tumor with
distant metastasis.</li>
<li>increased FDG uptake in bilateral pulmonary hilar regions and the
right shoulder, benign change is more likely.</li>
<li>s-colon cancer s/p treatment with tumor recurrence and C7 spine
metastasis, rcTxN0M1a, r-staging IVA (AJCC 8th edi.)</li>
</ul></li>
<li>2021-03-09 sigmoidoscopy:
<ul>
<li>negative finding up to D-colon.</li>
<li>no evidence of local recurrence.</li>
</ul></li>
<li>2021-03-17 MRI, C-spine:
<ul>
<li>bony spinal canal stenosis in the middle and lower C-spine.</li>
<li>degenerative change in the middle and lower C-spine disc spaces</li>
<li>a heterogeneous enhancing tumor at C7 vertebral body.<br />
</li>
<li>degerative change at lower C-spine facet joints.</li>
</ul></li>
<li>CEA
<ul>
<li>2021-04-20 3.43ng/mL</li>
<li>2021-03-09 8.40ng/mL</li>
<li>2021-02-05 6.04ng/mL</li>
<li>2020-11-06 1.31ng/mL</li>
<li>2020-08-07 0.76ng/mL</li>
<li>2020-04-15 1.28ng/mL</li>
<li>2019-12-31 1.97ng/mL</li>
<li>2019-10-04 2.38ng/mL</li>
</ul></li>
<li>CA199
<ul>
<li>2021-04-20 9.11U/mL</li>
<li>2021-03-09 5.89U/mL</li>
</ul></li>
<li>regimen
<ul>
<li>2019-11-04 ~ 2020-04-13: FOLFOX</li>
<li>2021-03-18 ~ up to now : FOLFIRI, plus avastin (bevacizumab) and
xgeva (denosumab) since 2021-04-02</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>no IHC stains (MSI, MMR) from patho report, no
KRAS/NRAS/BRAF/HER2/NTRK found.</li>
<li>adjuvant treatment with FOLFOX 6 months s/p laparoscopic anterior
resection.</li>
<li>the elevated CEA and CA199, together with PET and MRI imaging in
Feb~Mar 2021 showed spine metastasis. the startup FOLFOX might not work
anymore.</li>
<li>shift to FOLFIRI + bevacizumab + denosumab since Apr 2021. the
former two are 2nd-line treatment and the last one is for the bone mets.
<ul>
<li>prior to the use of denosumab, dentist has been consulted for
evaluating osteonecrosis of the jaw, ONJ.</li>
</ul></li>
<li>the treatments are followed the NCCN guidelines, no issue
found.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>patients with the UGT1A1 7/7 genotype may be at increased risk for
developing GI toxicity and myelosuppression. dose reduction should be
considered in this setting.</li>
</ul>
</div>
<div id="section-182" class="section level2">
<h2>210726</h2>
<p>[colon cancer]</p>
<ul>
<li>adjuvant treatment with FOLFOX 6 months s/p laparoscopic anterior
resection on 2019-10-14 inhibited the tumor for 1+ year.</li>
<li>the elevated CEA and CA199, together with PET and MRI imaging in
Feb~Mar 2021 showed spine metastasis, meaning the startup FOLFOX might
not work anymore.</li>
<li>shift to FOLFIRI + bevacizumab + denosumab since Apr 2021. the
former two are 2nd-line treatment and the last one is for the bone mets.
<ul>
<li>prior to the use of denosumab, dentist has been consulted for
evaluating osteonecrosis of the jaw, ONJ.</li>
<li>the slight elevated CEA and CA199 in 2021 July probably hinted a
decreasing response to the current treatment.</li>
</ul></li>
<li>MMR proficient, pembrolizumab or novolumab might not be
indicated.</li>
<li>EGFR(+), cetuximab or panitumumab might be indicated.</li>
<li>BRAF V600E lab data not found, vemurafenib, dabrafenib, encorafenib
might not be indicated.</li>
<li>regorafenib might be indicated for the next-line treatment (after
having 5-FU, OX, IRI based chemo regimen and anti-VEGF agent while KRAS
wild type, under the scope of benefits of NHI).</li>
</ul>
<p>[type 2 DM]</p>
<ul>
<li>lab data showed serum glucose (AC) ranging 142~191mg/dL, HbA1c
6.6~8.3% since May 2020.</li>
<li>prescribed anti-DM agents such as metformin, gliclazide,
vildagliptin were listed in PharmaCloud, could be set as self-carried
items if needed.</li>
</ul>
<p>[dyslipidemia]</p>
<ul>
<li>triglyceride, cholesterol total lab data were within normal range
these months, no special issue found.</li>
</ul>
</div>
<div id="section-183" class="section level2">
<h2>210315</h2>
<p>{felt fatigue in prior chemo}</p>
<p>visiting the patient at 09:47 on 2021-03-15, he is wide awake, this
patient has not been administrated chemo regimen yet since this
admission, in prior to the chemo course, consultations for C7 spinal
segment and ONJ are arranged (based on his PET scan outcome).</p>
<p>he says he felt fatigue after chemo been started 2-3 days in the
prior course.</p>
<p>HbA1c 8.3% and serum glucose (AC) 191mg/dL reported on 2021-01-14, no
newer data available, could be followed up if necessary.</p>
</div>
</div>
<div id="section-184" class="section level1">
<h1>700712820</h1>
<div id="section-185" class="section level2">
<h2>220112</h2>
<p>{hyponatremia, hypoosmolality}</p>
<p>[objective]</p>
<ul>
<li>lab data
<ul>
<li>2022-01-12 blood osmolality 254mOsm/Kg (normal 275~295)</li>
<li>2022-01-12 blood sodium 119mmol/L (normal 136-145)</li>
</ul></li>
<li>body weight
<ul>
<li>2022-01-11 54kgw</li>
<li>2022-01-04 58kgw</li>
</ul></li>
<li>medication
<ul>
<li>3% NaCl 300mL IVD QD</li>
<li>Saline 0.9% 500mL IVD QD</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>body weight decreased 4kgw within a week might hint some kind of
volume depletion.</li>
<li>solute repletion with administering 0.9% and 3% NaCl as of
2022-01-12.</li>
<li>reference: <a href="https://sci-hub.se/10.1016/S0889-8529(03)00004-5" class="uri">https://sci-hub.se/10.1016/S0889-8529(03)00004-5</a></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>no issue found in current medication.</li>
<li>recheck serum sodium as regular until problem solved.</li>
<li>might need to evaluate etiology of depletion hypoosmolality.</li>
</ul>
</div>
<div id="section-186" class="section level2">
<h2>220111</h2>
<ul>
<li>2022-01-11 CT: Brain
<ul>
<li>Imp: Brain atrophy with bilateral periventricular ischemic/aging
white matter change.</li>
</ul></li>
<li>2021-10-27 MRA: Brain
<ul>
<li>Imp: Brain metastases. General brain atrophy. Hydrocephalus.
Leukoaraiosis.</li>
</ul></li>
<li>2021-08-17 Tc-99m MDP whole body bone scan
<ul>
<li>The scintigraphic findings suggest multiple bone metastases.</li>
</ul></li>
<li>2021-08-16 PD-L1 (SP142)
<ul>
<li>Tumor type: formalin fixed paraffin embedded tissue block -
peritoneal and omental tumor (lung adenocarcinoma metastasis)<br />
</li>
<li>Adequate tumor cells present (&gt;=50 viable tumor cells): Yes</li>
<li>Result
<ul>
<li>Tumor cell (TC) staining assessment:
<ul>
<li>TC category: TC &lt; 1%<br />
</li>
<li>Percentage of PD-L1 expressing tumor cells (%TC): 0%<br />
</li>
</ul></li>
<li>Tumor-infiltrating immune cell (IC) staining assessment:
<ul>
<li>IC category: IC &lt; 1%<br />
</li>
<li>Proportion of tumor area occupied by PD-L1 expressing
tumor-infiltrating immune cells (% IC): 0%<br />
</li>
</ul></li>
<li>Note:
<ul>
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.<br />
</li>
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-08-11 Pathology - peritoneum biopsy
<ul>
<li>Labeled as diffuse seeding tumor over peritoneum and omentum,
biopsy  adenocarcinoma.</li>
<li>IHC stains:
<ul>
<li>CK7 (+), CK20 (-): disfavor gastrointestinal origin;</li>
<li>PAX-8 (-), WT-1 (-): disfavor ovarian origin;</li>
<li>TTF-1 (+): comaptible with pulmonanry origin.</li>
</ul></li>
</ul></li>
<li>2021-08-10 Cell block - 50 cc orange cloudy pleural effusion
<ul>
<li>The smears and cell block show lymphocytes, reactive mesothelial
cells and many hyperchromatic atypical epithelial cell clusters,
compatible with pulmonary adenocarcinoma.</li>
</ul></li>
<li>2021-08-09 Surgery - laparoscopic peritoneal tumor biopsy
<ul>
<li>Finding: multiple seeding tumors over liver surface, omentum,
peritoneum, and mesentary</li>
</ul></li>
</ul>
</div>
<div id="section-187" class="section level2">
<h2>210824</h2>
<p>[initial presentation]</p>
<ul>
<li>2021-01-22 left back pain for 1 year -&gt; congenital
spondylolisthesis</li>
<li>2021-07-09 left flank region pain in recent days, AZ covid-19
vaccination on 2021-06-21.</li>
<li>2021-07-16 remained abdominal pain, multiple, no obvious tenderness,
migratory abdominal pain, radiating to perineum region on left, tingling
sensation.</li>
</ul>
<p>[definite diagnosis &amp; disease extent]</p>
<ul>
<li>2021-07-16 CT - whole abdomen, pelvis:
<ul>
<li>carcinomatosis is suspected.</li>
<li>metastases on both hepatic lobes are suspected.</li>
<li>tumor seeding in left CP angle pleura is suspected.
<ul>
<li>lung cancer 1.7 cm in LLL of the lung is suspected.</li>
</ul></li>
</ul></li>
<li>2021-07-20 abdominal ultrasound:
<ul>
<li>hepatic tumor, multiple, probably metastatic tumor</li>
<li>dilated CBD, ascites, left pleural effusion</li>
</ul></li>
<li>2021-07-22 CT - lung/mediastinum/pleura
<ul>
<li>left upper lobe tumor, suspected lung cancer T2N2Mx</li>
<li>cancerous peritonitis and liver mets, suspected GI origin.</li>
</ul></li>
<li>2021-07-22 lab:
<ul>
<li>AFP 4.4 ng/mL WNL</li>
<li>CEA 107ng/mL &gt; ULN</li>
<li>CA125 474U/mL &gt; ULN</li>
<li>CA199 65U/mL &gt; ULN</li>
<li>CA153 114U/mL &gt; ULN</li>
<li>SCC 1.1ng/mL WNL</li>
</ul></li>
<li>2021-07-23 cytology - ascites:
<ul>
<li>abundant high-grade atypical cells with nuclear hyperchromasia,
pleomorphism and prominent nucleoli.</li>
</ul></li>
<li>2021-07-26 colonoscopy:
<ul>
<li>colon polyp, suspected adenoma, ascending colon, s/p cold snare
polypectomy.</li>
<li>diverticula, cecum and ascending colon.</li>
</ul></li>
</ul>
<p>[plan &amp; treatment]</p>
<p>[effect &amp; side effect]</p>
<p>[ongoing problem]</p>
</div>
</div>
<div id="section-188" class="section level1">
<h1>700713215</h1>
<div id="section-189" class="section level2">
<h2>220406</h2>
<p>{hepatic failure, cirrhosis of liver, hepatorenal syndrome,
esophageal varices, gastric varices, ascites, type 2 diabetes ellitus,
hyperlipidemia, anemia}</p>
<ul>
<li>All the oral drugs can be administered with nasogastric tube.</li>
<li>For the patient with hepatorenal syndrome, albumin (lower serum
reading 2.8 g/dL reported on 2022-04-06) might be an option to combine
with terlipressin (currently prescribed).</li>
</ul>
</div>
</div>
<div id="section-190" class="section level1">
<h1>700715400</h1>
<div id="section-191" class="section level2">
<h2>220401</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-22
<ul>
<li>Sigmoid colon cancer s/p stent placement and liver mets</li>
</ul></li>
<li>2022-01-20 Patho - colon biopsy
<ul>
<li>Colon, sigmoid, biopsy - Adenocarcinoma, moderately
differentiated</li>
<li>IHC: EGFR(+), PMS2(focal +), MLH1(+), MSH2(+), and MSH6(+).</li>
<li>Section shows pieces of colonic tissue with tumor necrosis,
tubulovillous glands and scant invasive irregular neoplastic
glands.</li>
</ul></li>
<li>2022-01-19 Colonoscopy
<ul>
<li>Colon cancer, sigmoid colon, with acute obstruction s/p self
expandable metal stent placement and biopsy</li>
<li>Mixed hemorrhoid</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-02-18
<ul>
<li>All-RAS mutation not detected (wild type)</li>
<li>BRAF mutation not detected (wild type)</li>
<li>EGFR G719X mutation not detected</li>
<li>EGFR Exon19 deletion not detected</li>
<li>EGFR S768I not detected</li>
<li>EGFR T790M not detected</li>
<li>EGFR Exon20 insertion not detected</li>
<li>EGFR L858R not detected</li>
<li>EGFR L861Q not detected</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-01-21 hematology and oncology
<ul>
<li>please check AntiHbc for chemotherapy HBV evaluation</li>
<li>if proven colon cancer, for advanced metastasis colon cancer,
systemic therapy is indicated. Ex: FOLFOX+/-avastin or
FOLFIRI+/-avastin, +ceftuximab if KRAS wide type, consider IO if
dMMR/MSI-H</li>
<li>pending pathology result and we wound like to follow up this
case</li>
</ul></li>
<li>2022-01-19 colon and rectal surgery
<ul>
<li>This is a case of sigmoid cancer with obstruction, multiple liver
metastasis. Ive discussed with the patient and her families, palliative
stent is indicated. After colonic stent, palliative chemotherapy and
target therapy will be arranged.</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-24 ~ undergoing - FOLFIRI (plus panitumumab since
2022-03-23)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>a patient diagnosed with sigmoid colon cancer s/p stent placement
and liver mets transferred from Cardinal Tien Hospital on 2022-01-19 and
start receiving FOLFIRI since 2021-01-24 (plus panitumumab since
2022-03-23).</li>
<li>lab data reported on 2022-02-18 revealed that RAS and BRAF were both
wild type and that no EGFR mutations were found. pathology results on
2022-01-20 indicated pMMR and EGFR(+). the patient is receiving
appropriate treatment with no issues currently.</li>
</ul>
</div>
</div>
<div id="section-192" class="section level1">
<h1>700728977</h1>
<div id="section-193" class="section level2">
<h2>220407</h2>
<p>{rectal cancer cT2N1bM0 stage IIIA}</p>
<p>[subjective]</p>
<ul>
<li>2021-07-12 having anal fresh bleeding on and off prior to visiting
OPD.</li>
<li>family history: two younger brothers died because of colon
cancer.</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2021-11-04 Patho - colon segmental resection for tumor
<ul>
<li>Large intestine, rectum, low anterior resection - No residual
viable tumor, s/p neoadjuvant CCRT<br />
</li>
<li>Resection margins: free<br />
</li>
<li>Lymph node, mesocolic, dissection - Negative for malignancy
(0/17)</li>
<li>Lymph node, IMA / SMA, dissection - Not received</li>
<li>AJCC 8th edition Pathology stage: ypT0N0(if cM0)</li>
</ul></li>
<li>2021-10-20 Patho - colon biopsy
<ul>
<li>Large intestine, rectum, biopsy - non-specific colitis with
fibrosis</li>
</ul></li>
<li>2021-10-19 CT - abdomen, pelvis
<ul>
<li>Compatible with rectal cancer s/p CCRT with swelling of the sigmoid
colon.</li>
</ul></li>
<li>2021-07-20 CT - lung/mediastinum/pleura
<ul>
<li>combined emphysema and pulmonary fibrosis.</li>
<li>old RUL TB change.</li>
</ul></li>
<li>2021-07-16 Patho - colorectal polyp
<ul>
<li>Rectum, 8 cm from anal verge, biopsy  Adenocarcinoma<br />
</li>
<li>IHC: EGFR(+), MLH1(+), PMS2(+), MSH2(+), and MSH6(+).<br />
</li>
</ul></li>
<li>2021-07-15 CT - abdomen, pelvis
<ul>
<li>for colorectal carcinoma T2N1bM0 IIIA</li>
</ul></li>
<li>2021-07-15 Colonoscopy
<ul>
<li>suspected rectal malignancy, 8cm from anal verge, s/p biopsy</li>
<li>diverticula, sigmoid colon, with lumen narrowing</li>
<li>mixed hemorrhoid</li>
</ul></li>
<li>2020-11-24 CT - brain
<ul>
<li>Brain atrophy</li>
<li>Atherosclerosis of vertebral arteries</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-11-03
<ul>
<li>Low anterior resection
<ul>
<li>Adenocarcinoma of rectum, cT2N1bM0, Stage IIIA s/p neoadjuvant
CCRT</li>
<li>Anastomosis by CDH 29#, TISSEL 4ml covered on anastomosis site</li>
<li>TA contour for low anterior resection</li>
<li>Protective ileostomy was created on RLQ area</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-07-28 ~ 2021-09-07 - 4500cGy/25 fractions (15 MV photon) of the
pelvic, and 5040cGy/28 fractions (15MV photon) of the rectal tumor area.
(pre-op CCRT)</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12-14 ~ undergoing - FOLFOX</li>
<li>2021-08-03 - 5-Fu + leucovorin (pre-op CCRT)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient was diagnosed with T2N1bM0 stage IIIA rectal cancer and
had LAR in Nov 2021 following pre-op CCRT during the 3rd quarter of that
year; he is currently undergoing adjuvant FOLFOX regimen since Dec
2021.</li>
<li>A colon segmental resection pathology on 2021-11-04 revealed no
residual viable tumor and evaluated the disease as ypT0N0 (if cM0).</li>
<li>As of 2022-03-29, the laboratory data showed normal liver and kidney
function as well as slightly lower blood cell counts, which should not
affect the chemotherapy course.</li>
<li>HBV is managed with Baraclude (entecavir) currently.</li>
</ul>
</div>
<div id="section-194" class="section level2">
<h2>210805</h2>
<p>{rectal cancer}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-07-12 having anal fresh bleeding on and off prior to visiting
OPD.</li>
<li>family history: two younger brothers died because of colon
cancer.</li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2021-07-15 colonoscopy:
<ul>
<li>suspected rectal malignancy, 8cm from anal verge.</li>
<li>diverticula, sigmoid colon, with lumen narrowing.</li>
<li>mixed hemorrhoid</li>
</ul></li>
<li>2021-07-16 patho - colorectal polyp
<ul>
<li>adenocarcinoma</li>
<li>IHC: EGFR(+), MLH1(+), PMS2(+), MSH2(+), and MSH6(+)</li>
</ul></li>
</ul>
<p>[disease extent]</p>
<ul>
<li>2021-07-15 CT - whole adbomen, pelvis:
<ul>
<li>imaging stage: cT2N1bM0, IIIA</li>
</ul></li>
</ul>
<p>[treatment &amp; plan]</p>
<ul>
<li>pre-Op CCRT then Op
<ul>
<li>radio
<ul>
<li>4500cGy/25frac for pelvic
<ul>
<li>900cGy/5frac from 2021-08-04 to 2021-08-06</li>
</ul></li>
<li>5040cGy/28frac for rectal tumor bed</li>
</ul></li>
<li>chemo
<ul>
<li>5-Fu + leucovorin from 2021-08-04</li>
</ul></li>
</ul></li>
</ul>
<p>[effect &amp; side effect]</p>
<ul>
<li>CCRT just started, to wait and see.</li>
<li>adjuvant chemo with cetuximab/panitumumab (EGFR+) might be indicated
after resection operation.
<ul>
<li>no RAS, BRAF, or other immune checkpoint biomarkers tested found in
charts yet.</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>HBV
<ul>
<li>2021-07-23 lab data
<ul>
<li>Anti-HBc Reactive</li>
<li>Anti-HBs 31.38mIU/mL</li>
</ul></li>
<li>medication
<ul>
<li>baraclude (entecavir 0.5mg) QDAC</li>
</ul></li>
</ul></li>
<li>combined pulmonary fibrosis and emphysema
<ul>
<li>2021-07-20 CT lung/mediastinum/pleura found</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>CCRT just kicked off and HBV is managed by entecavir, no medication
issue observed.</li>
</ul>
</div>
</div>
<div id="section-195" class="section level1">
<h1>700731496</h1>
<div id="section-196" class="section level2">
<h2>220128</h2>
<p>{possible drug interaction: Dasatinib / Histamine H2 Receptor
Antagonists}</p>
<p>[objective]</p>
<ul>
<li>current medication includes:
<ul>
<li>Sprycel (Dasatinib 50mg) 1# PO QD</li>
<li>Ulstop (Famotidine 20mg) 1# PO BID</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Histamine H2 Receptor Antagonists might decrease the absorption of
Dasatinib.</li>
<li>Coadministration of H2RAs and Dasatinib may reduce dasatinib
concentrations and efficacy.</li>
<li>Dasatinib prescribing information states histamine H2 receptor
antagonists (H2RAs) should not be coadministered with dasatinib due to
the risk of reduced dasatinib concentrations and efficacy. Given the
longer-term acid suppression achieved with H2-antagonist or proton pump
inhibitor therapy, the manufacturer suggests the use of antacids (with
2-hour dose separation) if acid-reducing therapy is required.</li>
<li>The likely mechanism for this apparent interaction is impaired
absorption of dasatinib, which does appear to display pH-sensitive
solubility, due to the increase in gastric pH caused by a H2-receptor
antagonist.</li>
<li>references:
<ul>
<li>Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor
antagonists and proton pump inhibitors on dasatinib pharmacokinetics in
Japanese leukemia patients. Cancer Chemother Pharmacol.
2012;69(4):999-1004.
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/22147077/" class="uri">https://pubmed.ncbi.nlm.nih.gov/22147077/</a></li>
</ul></li>
<li>Sprycel (dasatinib) [prescribing information]. Princeton, NJ:
Bristol-Myers Squibb Company; September 2016.</li>
<li>Eley T, Luo FR, Agrawal S, et al.Phase I study of the effect of
gastric acid pH modulators on the bioavailability of oral dasatinib in
healthy subjects. J Clin Pharmacol. 2009;49(6):700-709.
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/19395585/" class="uri">https://pubmed.ncbi.nlm.nih.gov/19395585/</a></li>
</ul></li>
<li>Matsuoka A, Takahashi N, Miura M, et al.H2-receptor antagonist
influences dasatinib pharmacokinetics in a patient with
Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother
Pharmacol. 2012;70(2):351-352.
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/22678358/" class="uri">https://pubmed.ncbi.nlm.nih.gov/22678358/</a></li>
</ul></li>
<li>Koutake Y, Taniguch J, Yasumori N, et al.Influence of proton pump
inhibitors and H2-receptor antagonists on the efficacy and safety of
dasatinib in chronic myeloid leukemia patients. Int J Hematol.
2020;111(6):826-832.
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/32152877/" class="uri">https://pubmed.ncbi.nlm.nih.gov/32152877/</a></li>
</ul></li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>Antacids should be taken 2 hours before or after dasatinib
administration if acid-reducing therapy is needed.</li>
</ul>
</div>
</div>
<div id="section-197" class="section level1">
<h1>700733699</h1>
<div id="section-198" class="section level2">
<h2>220406</h2>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>liver cell carcinoma</li>
<li>recurrence hepatocellular carcinoma with lung and bone metastasis,
stage IV</li>
<li>hepatitis B virus related liver cirrhosis, child A</li>
<li>essential (primary) hepertension</li>
<li>type 2 diabetes mellitus without complications</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-03-07 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>HCC s/p right hepatic lobectomy and RFA at S2, S3 and S4.</li>
<li>Bilateral Lung meta, stationary.</li>
<li>Bone meta. Suggest bone scan study.</li>
</ul></li>
<li>2021-11-24 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Cholangiocarcinoma at S3 liver is highly suspected.</li>
<li>The differential diagnosis include metastasis (colon cancer?) and
atypical HCC. Please correlate with tumor marker and MRI. Biopsy is
indicated.</li>
<li>Two metastases in S3 are suspected.</li>
</ul></li>
<li>2021-11-23 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>In comparison with the previous study on 20210720, some of the
previous bone lesions are a little more evident, suggesting multiple
bone metastases in a little more progression.</li>
<li>Suspected benign lesions in bilateral shoulders.</li>
</ul></li>
</ul></li>
<li>chemmoimmunotherapy
<ul>
<li>2020-03 ~ undergoing - lenvatinib</li>
<li>2020-01-17 ~ 2020-12-22 - nivolumab</li>
<li>2019-09 ~ 2019-12 - sorafenib</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient with advanced HCC (lung and bone mets) has been treated
with sorafenib (Sept to Dec in 2019), Nivolumab (in 2020) and Lenvatinib
(since March 2020), he refuses to be resuscitated and has been referred
to the hospice ward waiting list.</li>
</ul>
</div>
</div>
<div id="section-199" class="section level1">
<h1>700734842</h1>
<div id="section-200" class="section level2">
<h2>220427</h2>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-03-11 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20210723, the lesions in
the upper and middle T-spines are less evident. However, the lesion in
the left iliac bone is a little more evident.</li>
<li>The lesions in the right humeral head and L3 spine are new. Bone
metastases should be watched out. Please correlate with other clinical
findings for further evaluation.</li>
</ul></li>
<li>2022-03-10 CT - abdomen, pelvis
<ul>
<li>S/P prostate operation.</li>
<li>Some LNs (up to 1.6cm, mild regression) at retroperitoneum.</li>
<li>Suspected bony metastases at spine.</li>
<li>Gallbladder stone (0.9cm).</li>
</ul></li>
<li>2021-11-16 CT
<ul>
<li>S/P prostatectomy.</li>
<li>Progression of metastatic paraaortic lymph nodes and bone
metastasis.</li>
<li>GB stones.</li>
<li>Fatty content liver tumor, 2.6cm in S2 liver.</li>
</ul></li>
<li>2021-07-23 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20200715, the lesions in
the upper and middle T-spines and left iliac bone are new. Bone
metastases should be watched out.</li>
<li>No prominent change is noted in the previous two faint hot spots in
the left frontal region of the skull and posterior aspect of the left
11th rib, possibly more benign in nature.</li>
<li>Increased activity in the left aspect of maxilla. The nature is to
be determined (dental problem? other nature?).</li>
<li>Mildly increased activity in the lower L-spines. Degenerative change
is more likely.</li>
<li>Suspected benign jount lesions in the right sternoclavicular
junction, bilateral shoulders, hips, knees and boh feet.</li>
</ul></li>
<li>2021-07-22 MRI
<ul>
<li>S/P prostatectomy.</li>
<li>Regression of paraaortic lymph nodes in paraaortic lymph node.</li>
<li>Liver cyst.</li>
<li>Gallbladder stones.</li>
</ul></li>
<li>2021-07-13 CT
<ul>
<li>metastatic Lt supraclavicular fossa and left retroperitoneal
paraaortic lymphadenopathy.</li>
</ul></li>
<li>2021-03-24 MRI
<ul>
<li>S/P prostatectomy.</li>
<li>Suspected metastatic lymph nodes in paraaortic regions. Regression
as compare with MRI study on 2020-11-12.</li>
<li>Liver cyst.</li>
<li>Gallbladder stones.</li>
</ul></li>
<li>2021-07-15 Tc-99m MDP whole body bone scan
<ul>
<li>Two faint hot spots in the left frontal region of the skull and
post. aspect of the left 11th rib, probably post-traumatic change,
suggesting follow-up.</li>
<li>Suspected benign lesions in the maxilla, right sternoclavicular
junction, bilateral shoulders, and hips.</li>
</ul></li>
<li>2019-05-19 MRA - Brain
<ul>
<li>A frontal base meningioma. Left exophthalmus.</li>
</ul></li>
<li>2019-01-15 MRI
<ul>
<li>S/P prostatectomy.</li>
<li>Suspected metastatic lymph nodes in left common iliac and paraaortic
regions.</li>
<li>Liver cyst.</li>
</ul></li>
<li>2019-01-08 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20180207, the previous
lesions in the maxilla, left 11th rib and the left femoral neck are
stationary, indicating more benign in nature.</li>
<li>Other bone lesions are also stationary. Probably degenerative change
in the upper T-spine, bilateral sternoclavicular junctions and bilateral
sacroiliac joints, bilateral shoulders, and bilateral hips.</li>
</ul></li>
<li>2018-02-07 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20161103, the lesions in
the left 11th rib and the left femoral neck had become very faint,
indicating benignity in nature.</li>
<li>Probably degenerative change in the upper T-spine, sternoclavicular
junctions and sacroiliac joints.</li>
<li>Increased radiotracer uptake in the maxilla, local inflammatory
change such as sinusitis may show such a picture.</li>
</ul></li>
<li>2016-04 MRI
<ul>
<li>Prostate cancer with extracapsular extension and seminal vesicle
invasion, mainly in left aspect.</li>
<li>Metastatic left obturator lymph node. Stage T3N1Mx.</li>
</ul></li>
<li>2015-06-30 Patho (HuaLien TzuChi)
<ul>
<li>Prostate gland, radical prostatectomy, adenocarcinoma (Glason score:
5+4=9) (pT3bN1).</li>
<li>Urethra, prostatic, radical prostatectomy, squamous metaplasia.</li>
<li>Seminal vesicle, right, radical prostatectomy, adenocarcinoma,
invasion.</li>
<li>Seminal vesicle, left, radical prostatectomy, adenocarcinoma,
invasion.</li>
<li>Lymph node, right, lymphadenectomy, no lymph node retrived.</li>
<li>Lymph node, left, lymphadenectomy, adenocarcinoma, metastatic
(1/2).</li>
<li>Prostate gland, apex, resection, adenocarcinoma. Urinary bladder,
neck, resection, negative for malignancy.</li>
<li>Extraprostatic Extension: Present.</li>
<li>Seminal Vesicle Invasion (invasion of muscular wall required):
Present.</li>
<li>Lymph-Vascular Invasion: Present.</li>
<li>Perineural Invasion: Present.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-12-30 Psychiatry
<ul>
<li>A
<ul>
<li>This is a 65 y/o male patient with prostate cancer, admission for
palliative chemotherapy today. He has no psychiatric history.</li>
<li>Upon visit, the patient is sitting on his bed, with wife at
bedside.</li>
<li>The patient is in euthymic, smiley and inviting. Greeting and
appropriate speech. He deny depressed mood, deny suicide thought, able
to percieve fair night sleep under current medication, fair
appetite.</li>
<li>No extra medication is needed.</li>
</ul></li>
</ul></li>
<li>2021-11-15 Hemato-Oncology
<ul>
<li>Q
<ul>
<li>This is a 65 y/o male with underlying hypertension, hypothyroidism
and dyslipidemia. He was previous diagnosed prostate cancer, pT3bN1cM0
s/p radical prostatectomy + radiotherapy + hormone therapy with
refractory, s/p Zytiga 360# since 2020-02 with poor response, s/p
Zoladex and Androcur since 20210109, Pamorelin (Q3M) + Casodex on
20210206. However, follow-up lung CT still showed metastatic lymph nodes
in Lt supraclavicular fossa. Bony metastasis of upper, middle T spine
and left iliac bone was also noted in bone scan on 20210723. Serial PSA
level since 2021 April showed 8.74 -&gt; 12.47 -&gt; 14.19 -&gt; 17.40
-&gt; 28.39. He only complained about back pain in recent few months.
There was no decreased appetite or body weight loss. Due to progressed
disease, he was admitted for port-A insertion and further systemic
chemotherapy.</li>
<li>We need your expertise for further systemic chemotherapy regimen
suggest after port-A insertion.</li>
</ul></li>
<li>A
<ul>
<li>A case of castration-resistant prostate cancer is noted.</li>
<li>Based on the failure to LHRH + Andreocur and Casodex and further
abiraterone, palliative chemotherapy with docetaxel is indicated.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2015-06-30 at HuaLien TzuChi - radical prostatectomy
<ul>
<li>prostate adhesion to bladder wall, suspicious invasion to bladder
neck.</li>
<li>tumor invasion in seminal vesicle was also suspected. bilateral
neurovascular bundles (NVB) did not preserved.</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-07-28 ~ 2021-08-23: 4560cGy/19 fractions (6 MV photon) to left
SCF LAPs.</li>
<li>2020-12-10 ~ 2021-01-14: 5000cGy/25 fractions (15 MV photon) to
paraaortic LAPs.</li>
<li>2015-08-05 ~ 2015-09-25: 4500cGy/25 fractions of the pelvic,
5040cGy/28 fractions of the tumor bed and peripheral, and 6480cGy/36
fractions of the reduced tumor bed area.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-11-17 ~ undergoing: docetaxel</li>
<li>2021-02 ~ 2021-10 Pamorelin (triptorelin) Q3M</li>
<li>2020-02 ~ 2020-03 Zytiga (abiraterone) 1000mg QD poor response</li>
<li>2018-12 ~ 2019-12 Leuplin Depot (leuprorelin) Q3M</li>
<li>2018-05 ~ 2019-12 Casodex (bicalutamide)</li>
<li>2017-01 ~ 2021-01 Andreocur (cyproterone)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>After using hormone therapy from 2017-01 to 2021-10 and proving the
disease castration-resistant (2021-11-16 CT showed progression), the
patient has begun taking docetaxel since 2021-11-17.</li>
<li>Bone scans on 2022-03-11 revealed new lesions in the right humeral
head and L3 spine, and CTs on 2022-03-10 showed LNs up to 1.6 cm in the
retroperitoneum.</li>
<li>Lab results on 2022-04-26 showed that blood cell counts, liver and
kidney function, serum electrolytes were grossly normal, however PSA 27
ng/mL remained high.</li>
<li>Underlying health condition are managed with corresponding drugs
<ul>
<li>postprocedural hypothyroidism - Eltroxin (levothyroxine)</li>
<li>chronic viral hepatitis B without delta-agent - Baraclude
(entecavir)</li>
<li>hyperlipidemia - Zulitor (pitavastatin)</li>
<li>duodenal ulcer - Nexium (esomeprazole)</li>
<li>insomnia - Anxiedin (lorazepam)</li>
</ul></li>
</ul>
</div>
<div id="section-201" class="section level2">
<h2>220407</h2>
<p>[assessment]</p>
<ul>
<li>Novel hormone therapies include abiraterone, enzalutamide,
darolutamide, or apalutamide received for metastatic castration-nave
disease, M0 CRPC, or previous lines of therapy for M1 CRPC.</li>
<li>After using hormone therapy from 2017-01 to 2021-10 and proving the
disease castration-resistant (2021-11-16 CT showed progression), the
patient has begun taking docetaxel since 2021-11-17.</li>
<li>The bone scan on 2022-03-11 revealed new lesions in the right
humeral head and L3 spine, however, the PSA level decreased slightly
(26.9ng/mL 2022-03-23 &lt;- 43.2ng/mL 2022-02-15).</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>Tumor testing for microsatellite instability-high (MSI-H) or
deficient mismatch repair (dMMR) is recommended in patients with
metastatic castration-resistant prostate cancer and may be considered in
patients with regional or castration-nave metastatic prostate
cancer.</li>
<li>Tumor mutational burden (TMB) testing may be considered in patients
with metastatic castration-resistant prostate cancer.</li>
<li>Cabazitaxel 20 mg/m2 plus carboplatin AUC 4 mg/mL per min with
growth factor support can be considered for fit patients with aggressive
variant prostate cancer (visceral metastases, low PSA and bulky disease,
high LDH, high CEA, lytic bone metastases, neuroendocrine prostate
cancer histology) or unfavorable genomics (defects in at least 2 of
PTEN, TP53, and RB1). source: Cabazitaxel plus carboplatin for the
treatment of men with metastatic castration-resistant prostate cancers:
a randomised, open-label, phase 1-2 trial <a href="https://pubmed.ncbi.nlm.nih.gov/31515154/" class="uri">https://pubmed.ncbi.nlm.nih.gov/31515154/</a></li>
</ul>
</div>
<div id="section-202" class="section level2">
<h2>220216</h2>
<p>[assessment]</p>
<ul>
<li>image findings showed the disease progresive and lab data PSA
readings keep elevating from 8.7ng/mL (2021-04-05) to 43.2ng/mL
(2022-02-15)</li>
<li>the patient is undergoing hormone therapy triptorelin since 2021-02
(last dose 2021-10) and receiving chemotherapy docetaxel since
2021-11.</li>
<li>systemic therapies for metastatic castration-resistant prostate
cancer such as abiraterone/prednisone, enzalutamide, Ra-223, docetaxel,
cabazitaxel, and mitoxantrone have all been shown to reduce
skeletal-related events and improve bone pain.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>triptorelin could be continued with another dose if there is no
contraindication. -tumor testing for microsatellite instability-high
(MSI-H) or deficient mismatch repair (dMMR) is recommended in patients
with metastatic castration-resistant prostate cancer and may be
considered in patients with regional or castration-nave metastatic
prostate cancer. -tumor mutational burden (TMB) testing may be
considered in patients with metastatic castration-resistant prostate
cancer.</li>
</ul>
</div>
</div>
<div id="section-203" class="section level1">
<h1>700753433</h1>
<div id="section-204" class="section level2">
<h2>211019</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 7 items.</p>
<p>the 3 identified items has been shown as following while the other 4
items still remain unknown:</p>
<ul>
<li><p>Utapine F.C. Tablet (quetiapine fumarate 25mg) - bipolar
disorder, schizophrenia</p></li>
<li><p>Zoloft F.C. Tablet (sertraline hydrochloride 50mg) - major
depressive disorder (unipolar), obsessive-compulsive disorder, panic
disorder, posttraumatic stress disorder, premenstrual dysphoric
disorder, social anxiety disorder</p></li>
<li><p>Anxiedin Tablet (lorazepam 0.5mg) - anxiety</p></li>
</ul>
<p>these drugs will be sent back to ward by the in-hospital porter.</p>
</div>
</div>
<div id="section-205" class="section level1">
<h1>700766397</h1>
<div id="section-206" class="section level2">
<h2>220111</h2>
<p>CT and MRI on 2022-01-05 suggested possible malignant tumor in the
right adrenal gland measuring 8.2 x 10 x 9 cm.</p>
<p>Chromogranin A 918ng/mL, ACTH &lt; 5g/mL</p>
<p>lab data in early Jan 2022 did not backup hyperaldosteronism,
hypercortisonlemia (i.e.both in normal range).</p>
<p>hypertenstion and/or tachycardia might have been mitigated by Concor
(bisoprolol), higher readings of blood sugar (since mid Dec 2021) might
have been reduced by Galvus Met (vildagliptin + metformin), these
symptoms could be caused by neuroendocrine tumors.</p>
</div>
</div>
<div id="section-207" class="section level1">
<h1>700769250</h1>
<div id="section-208" class="section level2">
<h2>220331</h2>
<p>{ovary cancer s/p oophrocystectomy}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-15 Patho - uterus
<ul>
<li>pathologic diagnosis
<ul>
<li>Ovary, right, debulking surgery (s/p oophorcystectomy) - No residual
tumor</li>
<li>Ovary, left, debulking surgery - Negative for malignancy</li>
<li>Fallopian tube, bilateral, debulking surgery - Negative for
malignancy</li>
<li>Uterus, corpus,debulking surgery - Adenocarcinoma, seeding</li>
<li>Uterus, cervix, debulking surgery - Negative for malignancy</li>
<li>Omentume, debulking surgery- - Peritonitis</li>
<li>Labeled utreosaroligment - Negative for malignancy</li>
<li>Labeled rectum - Negative for malignancy</li>
<li>Labeled right abdominal wall - Negative for malignancy</li>
<li>AJCC 8th edition Pathology stage: pT2aNO(if cM0); FIGO IIA; AJCC
stage IIA</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic type: Adenocarcinoma, mixed endometrioid type and
mucinous type</li>
<li>Histologic grade: grade 1<br />
</li>
<li>IHC: CK(+), Calretinin(focal+), CD68(+), PAX8(-); Reference:
S2022-01793</li>
</ul></li>
</ul></li>
<li>2022-02-11 CT - pelvis
<ul>
<li>An enlarged nodes in left pelvic side wall measuring 2.3 cm in size
is noted.</li>
</ul></li>
<li>2022-02-04 Patho - ovary biopsy, wedge resection
<ul>
<li>Diagnosis:
<ul>
<li>Ovary, right, laparoscopic oophorocystectomy - Adenocarcinoma,
mixed endometrioid type and mucinous type, grade 1
<ul>
<li>IHC stains: WT( focal +), PAX-8 (-), p53 (wild type), Napsin-A (-),
ER (-), PR (-).</li>
<li>pT1c2 pNx (if cM0); FIGO stage: IC2, at least.</li>
</ul></li>
</ul></li>
<li>Gross description:
<ul>
<li>Tumor Site: Right ovary</li>
<li>Ovarian Surface Involvement - Absent</li>
<li>Fallopian Tube Surface Involvement - no tissue submitted.</li>
</ul></li>
<li>Microscopic Description:
<ul>
<li>Histologic Type: Mixed epithelial carcinoma: endometrioid grade 1
(60%) and mucinous grade 1 (40%).</li>
<li>Histologic Grade - WHO Grading System-G1: Well differentiated</li>
<li>IHC: WT( focal +), PAX-8 (-), p53 (wild type), Napsin-A (-), ER (-),
PR (-).</li>
</ul></li>
</ul></li>
<li>2022-01-31 CT - abdomen, pelvis
<ul>
<li>A lobulated right adnexal mass (9.0x6.8x10.2cm). Suspect TOA,
ovarian torsion, or ovarian cystic tumor.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-14
<ul>
<li>Excision of abdominal wall tumor</li>
<li>Excision of greater omentum and rectal serosa tumor</li>
<li>IOUS (intraoperative ultrasound)</li>
</ul></li>
<li>2022-01-31
<ul>
<li>ROV teratoma with rupture</li>
<li>pelvic adhesion</li>
<li>Laparoscopic oophorocystectomy + pelvic adhesionlysis</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-09, -03-30 - paclitaxel + carboplatin</li>
</ul></li>
<li>underlying disease
<ul>
<li>chronic viral hepatitis B without delta-agent</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient was diagnosed with ovarian adenocarcinoma, mixed
endometrioid and mucinous type in early 2022 s/p oophrcystectomy
(2022-01-31) and excision of abdominal wall tumor and greater omentum
and rectal serosa tumor (2022-02-14).</li>
<li>paclitaxel + carboplatin is a preferred regimen for both
endometrioid and mucinous ovarian cancers, and the patient has been
receiving this regimen since 2022-03-09.</li>
<li>According to CBC results on 2022-03-29, there was a slight decrease
in readings, not expected to affect chemotherapy.</li>
<li>HBV is managed with Baraclude (entecavir). No issue with current
medication.</li>
</ul>
</div>
</div>
<div id="section-209" class="section level1">
<h1>700770648</h1>
<div id="section-210" class="section level2">
<h2>210824</h2>
<p>{preparation and precaution - mephalan, post-IPP meeting following
up}</p>
<p>patient family meeting and IPP meeting was held at 10:00 on
2021-08-24.</p>
<ul>
<li><p>the schedule with regimen for PBSCT for the patient has been
disclosed in the meeting.</p></li>
<li><p>melphalan dosing as a conditioning agent, 140mg/m2 or 200mg/m2
are more commonly seen. source:</p>
<ul>
<li><a href="https://www.uptodate.com/contents/melphalan-drug-information" class="uri">https://www.uptodate.com/contents/melphalan-drug-information</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830386/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830386/</a></li>
<li><a href="https://www.astctjournal.org/article/S1083-8791(17)30965-5/fulltext" class="uri">https://www.astctjournal.org/article/S1083-8791(17)30965-5/fulltext</a></li>
</ul></li>
<li><p>the estimated total amount of melphalan used prior to the
scheduled transplantation would be 8 vials.</p>
<ul>
<li>based on melphalan 50mg/vial, dose 100mg/m2 (according to the time
table), body surface area 1.64m2.</li>
<li>4 vials per day for 2 days (2021-08-29, 2021-08-30).</li>
<li>8 vials in stock has been confirmed by the medicine storeroom.</li>
</ul></li>
<li><p>preparation and administration precautions of mephalan:</p>
<ul>
<li>expiration time is 60 minutes after preparation (the duration
including infusion time) according to package insert.
<ul>
<li>staff in chemo preparation room will inform the ward when the
melphalan preparation is done.</li>
</ul></li>
<li>based on lab data reported on 2021-07-09 and 2021-07-30, liver and
kidney have no abnormality, no dose adjustment is needed.</li>
</ul></li>
<li><p>damage of the oral mucosa together with profound myelo- and
immunosuppression after transplantation may lead to local and systemic
infections.</p>
<ul>
<li>other side effects in the early period may include bleeding due to
thrombocytopenia as well as pain, nutrition, and articulation impairment
caused by mucositis.</li>
<li>in the first year after transplantation, oral cavity is affected by
delayed complications like hyposalivation, taste disorders, and dentin
hypersensitivity, which often importantly decrease the patients quality
of life.</li>
<li>oral and maxillofacial surgery department has been consulted for
this.</li>
<li>if oral mucosa damage happens, some triamcinolone acetonide oral
ointment (nincort or oralog, the former is available now) for local
treatment might be of help.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-211" class="section level1">
<h1>700790807</h1>
<div id="section-212" class="section level2">
<h2>220323</h2>
<p>{gastric cancer pT4aN2M1, stage IV s/p gastrectomy}</p>
<p>[objective]</p>
<ul>
<li>lab findings
<ul>
<li>2021-10-05 Patho - Stomach
<ul>
<li>Stomach, total gastrectomy - Poorly cohesive carcinoma, signet-ring
cell type<br />
</li>
<li>Margins, total gastrectomy - Radial margin is involved by
tumor<br />
</li>
<li>Lymph nodes, D2 LN dissection - Metastatic carcinoma (3/55)<br />
</li>
<li>AJCC Pathologic staging - pT4aN2M1, stage IV</li>
</ul></li>
<li>2021-09-27 Patho - Stomach, low body, biopsy
<ul>
<li>Adenocarcinoma, poorly differentiated<br />
</li>
<li>IHC: CK(+), CDX2(+), and Her-2/neu(Ab): Negative(0).</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-11-05 ~ 2021-12-09) - 4500cGy/25 fractions (15MV photon) of the
gastric tumor bed, peripheral, and regional lymphatic area.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01 ~ ongoing FOLFOX</li>
<li>2021-10 ~ 2021-12 5-FU</li>
<li>2021-10 Mitomycin-C</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>According to lab data reported on 2022-03-22, serum potassium,
magnesium and HGB were low (2.6 mmol/L, 1.4 mg/dL, 6.7 g/dL
respectively).</li>
<li>KCl (IV), potassium gluconate (PO), MgSO4 (IV), MgO (PO) are
prescribed and blood products are ordered.</li>
</ul>
</div>
<div id="section-213" class="section level2">
<h2>220208</h2>
<p>[objective]</p>
<ul>
<li>lab findings
<ul>
<li>2021-10-05 Patho - Stomach
<ul>
<li>Stomach, total gastrectomy - Poorly cohesive carcinoma, signet-ring
cell type<br />
</li>
<li>Margins, total gastrectomy - Radial margin is involved by
tumor<br />
</li>
<li>Lymph nodes, D2 LN dissection - Metastatic carcinoma (3/55)<br />
</li>
<li>AJCC Pathologic staging - pT4aN2M1, stage IV</li>
</ul></li>
<li>2021-09-27 Patho - Stomach, low body, biopsy
<ul>
<li>Adenocarcinoma, poorly differentiated<br />
</li>
<li>IHC: CK(+), CDX2(+), and Her-2/neu(Ab): Negative(0).</li>
</ul></li>
</ul></li>
<li>medication
<ul>
<li>2022-01 ~ ongoing FOLFOX</li>
<li>2021-10 ~ 2021-12 5-FU</li>
<li>2021-10 Mitomycin-C</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>HER2 tested negative, trastuzumab might not be indicated.</li>
<li>PD-L1, microsatellite testing outcome not found, not sure nivolumab
should be applicable.</li>
<li>Over 95% of gastric cancers are adenocarcinomas, which are typically
classified based on anatomic location (cardia/proximal or
noncardia/distal) and histologic type (diffuse or intestinal). The
diffuse type, which is characterized by poorly differentiated and
discohesive tumor cells with a signet-ring or non-signet-ring morphology
diffusely infiltrating the gastric wall in a desmoplastic stroma, is
more prevalent in low-risk areas and is mostly associated with heritable
genetic abnormalities.
<ul>
<li>according the patients pedigree chart, he has 3 direct descendants
alive, who should be aware of suspected higher risk of gastric
cancer.</li>
</ul></li>
<li>no drug allergy recorded in database, no issue found in active
medication.</li>
</ul>
</div>
</div>
<div id="section-214" class="section level1">
<h1>700799013</h1>
<div id="section-215" class="section level2">
<h2>220329</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-25 CT - lung/mediastinum/pleura
<ul>
<li>Consolidation over both lungs. Pneumonia is favored.</li>
<li>Bilateral pleural effusion</li>
</ul></li>
<li>2022-01-11 Patho - omentum biopsy
<ul>
<li>Tissue, labeled LUQ omentum, CT-guide biopsy - adenocarcinoma,
seeding<br />
</li>
<li>IHC: CDX-2(+), CK7(-), CK20(-). The tumor is compatible with GI
tract origin.<br />
</li>
<li>Microscopically, it shows adenocarcinoma composed of irregular
neoplastic glands with infiltrative growth pattern, tumor necrosis and
stromal fibrosis. The tumor cells display hyperchromatic nuclei with
pleomorphism, prominent nucleoli, high N/C ratio and mitotic
figures.<br />
</li>
</ul></li>
<li>2021-11-24 CT - abdomen, pelvis
<ul>
<li>One Metastasis in LUQ omentum S/P C/T show partial response.</li>
<li>Two metastases in RLQ mesentery, and left lower pelvis (with urinary
bladder invasion) S/P C/T show stable disease.</li>
</ul></li>
<li>2021-08-13 CT - abdomen, pelvis
<ul>
<li>Three Metastases 3.6 x 2.6 cm in the LUQ omentum area, 1.3 x 0.7 cm
in RLQ mesentery, and 3.2 cm in left lower pelvis (with urinary bladder
invasion) are noted.</li>
<li>Intrapulmonary lymph node in LLL of the lung is suspected and it
shows stable in size and feature as compared with prior CT.</li>
</ul></li>
<li>2021-04-28 Whole body PET scan
<ul>
<li>Glucose-hypermetabolism in the soft tissue in the LUQ of abdomen,
lower pelvis, and RLQ of abdomen, probably tumor recurrence.<br />
</li>
<li>Glucose-hypermetabolic lesions in the right shoulder and right
elbow, probably post-traumatic change.<br />
</li>
<li>Increased FDG uptake in bilateral pulmonary hilar region, probably
reactive nodes or physiological uptake of FDG.</li>
<li>Colon cancer s/p treatment with tumor recurrence, rcTxNxM1c, stage
IVC (AJCC 8th ed.), by this F-18 FDG PET scan.</li>
</ul></li>
<li>2021-04-20 CT - abdomen, pelvis
<ul>
<li>Some infiltration at right anterior abdominal wall is found,
regional inflammation is considered</li>
<li>No evidence of soft tissue mass at pancreas.</li>
</ul></li>
<li>2021-01-18 CT - abdomen, pelvis
<ul>
<li>R-S colon cancer s/p operation. Some LNs at mediastinum and bil.
inguinal regions.</li>
<li>Stationary condition and lung nodules.</li>
</ul></li>
<li>2021-11-19 Patho - colon segmental resection for tumor
<ul>
<li>diagnosis
<ul>
<li>Tumor, rectosigmoid, left hemicolectomy  Residual mucinous
adenocarcinoma<br />
</li>
<li>Bilateral cutting ends, ditto  Free of tumor invasion<br />
</li>
<li>Lymph node, mesocolic, dissection  Free of tumor metastasis (0/18)
with acellular mucin deposit (7/18)<br />
</li>
<li>Pelvic lesion, frozen section  Acellular mucin, compatible with
tumor regression<br />
</li>
<li>AJCC pathologic stage  ypT3N0 (if cM0), stage IIA</li>
</ul></li>
</ul></li>
<li>2020-10-05 CT - abdomen, pelvis
<ul>
<li>S-colon cancer as described (mild regression). T4bN2bM1a (IVa).</li>
</ul></li>
<li>2020-07-02 CT - abdomen, pelvis
<ul>
<li>S-colon cancer T4bN2bM1a (IVa).</li>
</ul></li>
<li>2020-06-30 Patho - colon biopsy
<ul>
<li>Sigmoid colon, 20 cm from anal verge, biopsy  Adenocarcinoma</li>
<li>IHC: EGFR(+), MLH1(-), PMS2(-), MSH2(+), and MSH6(+).<br />
</li>
<li>Comment: The tumor cells show loss of expression of the mismatch
repair proteins MLH1 and PMS2. This pattern is likely to be sporadic
(MLH1 promoter hypermethylation), although it is possible due to Lynch
or related syndromes.</li>
</ul></li>
<li>2020-06-30 Patho - colorectal polyp
<ul>
<li>Rectum, 10 cm from anal verge, polypectomy  Adenocarcinoma in
high-grade tubulovillous adenoma<br />
</li>
<li>The sections show adeocarcinoma in tubulovillous adenoma, composed
of rectal mucosal tissue with atypical glands lined by pseudostratified,
high-grade dysplastic columnar cells, in tubular, cribriform and villous
arrangement. Focal desmoplastic stromal reaction is present.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-03-11 Closure of T-loop colostomy</li>
<li>2020-11-18 Exp. Lap with sigmoidectomy</li>
<li>2020-07-06 T-loop colostomy</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2020-07-22 ~ 2020-08-31 - 4500cGy/25 fractions of the pelvic, and
5040cGy/28 fractions of the tumor bed area.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-06-11 ~ 2022-02-23 - FOLFOX + bevacizumab</li>
<li>2020-07-16 ~ 2021-05-24 - FOLFIRI</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-216" class="section level1">
<h1>700803304</h1>
<div id="section-217" class="section level2">
<h2>220420</h2>
<p>{ovarian cancer}</p>
<ul>
<li>history
<ul>
<li>Right ovarian cancer status post suboptimal debulking surgery (right
salpingo-oophorectomy (RSO) + bilateral pelvic lymphadenectomy +
cytoreductive surgery + infracolic omentectomy + Appendectomy) and
hyperthermic intra-peritoneal chemotherapy on 2021-11-01.</li>
<li>Uterine myoma and left ovarian cyst s/p ATH + LSO</li>
<li>Type 2 diabetes mellitus with unspecified complications</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-01-21 SONO - abdomen
<ul>
<li>Fatty liver, moderate</li>
<li>GB adenomatosis</li>
</ul></li>
<li>2021-11-21 CT
<ul>
<li>Focal small bowel ileus.</li>
<li>Colonic diverticula.</li>
</ul></li>
<li>2021-11-02 Patho - ovary (tumor)
<ul>
<li>Pathologic diagnosis
<ul>
<li>Ovarian tumor, right, frozen + debulking surgery - Carcinosarcoma
and endometriosis</li>
<li>Pelvic tumor, debulking surgery - Tumor present</li>
<li>AJCC Pathologic staging: pT2bN0, if cM0, stage IIB</li>
<li>IHC
<ul>
<li>Carcinoma component: CK(+)<br />
</li>
<li>Sarcoma component: vimentin(+), CK(-), WT-1(-), ER(-), SMA(-),
myogenin(-), CDK4(-), beta-HCG(-), CD10(+) and cyclin-D1(+, focal),
CD31(+, focal)<br />
</li>
<li>Lymphovascular space invasion: present<br />
</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-10-27 CT - whole abdomen, pelvis
<ul>
<li>Right ovarian malignant tumor with carcinomatosis is highly
suspected. Please correlate with CA125 and ascites cytology.</li>
<li>Right side obstructive uropathy is noted.</li>
<li>Several small lymph nodes in para-aortic and para-cava space.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-11-01
<ul>
<li>HIPEC</li>
<li>Excision of intraabdominal tumor</li>
<li>Omentectomy</li>
<li>Appendectomy</li>
<li>Tenckhoff tube insertion<br />
</li>
<li>Right ovarian tumor, Frozen section: malignancy, type to be
determined</li>
<li>status post Laparoscopic Assisted Vaginal Hysterectomy(LAVH) + Left
Salpingo-oophorectomy (LSO)</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12 ~ ongoing: paclitaxel + carboplatin</li>
<li>2021-10-30: Liposome doxorubicin + carboplatin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient was diagnosed with ovarian cancer following suboptimal
debulking surgery on 2021-11-01, and has been treated with paclitaxel +
carboplatin since December 2021.</li>
<li>The findings in the lab on 2022-04-20 were generally typical.</li>
<li>Readings of blood sugar in the ward fluctuated up to 430 mg/dL at
06:12 on 2022-04-21, which should be addressed (self-carried metformin
has been prescribed on the active medication list). Additional insulin
might be considered if blood sugar levels remain unruly.</li>
</ul>
</div>
<div id="section-218" class="section level2">
<h2>220323</h2>
<p>[comment]</p>
<ul>
<li>At present, the patient is receiving platin-based chemotherapy
without intolerance during this hospital stay; no apparent abnormalities
were found in laboratory results reported on 2022-03-22.</li>
<li>Blood sugar readings tested in the ward fluctuated up to 211 mg/dL
at 06:30 on 2022-03-23, which should be addressed (self-carried
metformin has been prescribed in active medication list).</li>
</ul>
</div>
<div id="section-219" class="section level2">
<h2>220302</h2>
<p>[comment]</p>
<ul>
<li>the patient is currently receiving platin-based chemotherapy without
intolerance.</li>
<li>most recent HbA1c recorded 7.3% on 2021-10-27, blood sugar tested
328mg/dL at 06:48 on 2022-03-02, metformin prescribed at Metab &amp;
Endoc OPD might be considered if needed.</li>
</ul>
</div>
</div>
<div id="section-220" class="section level1">
<h1>700814298</h1>
<div id="section-221" class="section level2">
<h2>220330</h2>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>Pancreatic cancer, T3N1M1 (M1 diagnosed by CT), stage IV, tail,
status post endoscopic ultrasound-guided fine-needle biopsy on
2021-10-07</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-03-21 CT - abdomen, pelvis
<ul>
<li>Pancreatic cancer with liver mets and adrenal mets. In
progression.</li>
<li>Paraaortic lymphadenopathy, stable</li>
<li>Diffuse lung consoliations. Nature to be determined.</li>
<li>Air pockets inside the urinary bladder, suspected emphysematous
cystitis.</li>
</ul></li>
<li>2022-01-07 CT - brain
<ul>
<li>Old lacunar infarcts.</li>
<li>Encephalomalacic change in left temporal lobe.</li>
<li>Brain atrophy.</li>
</ul></li>
<li>2021-12-07 CT - abdomen, pelvis
<ul>
<li>Pancreatic tail cancer with liver mets. The primary tumor is
decreased in size but the liver mets progressed.</li>
<li>Paraaortic lymphadenopathy, in regression.</li>
<li>LEFT LOWER LOBE consolidation.</li>
</ul></li>
<li>2021-10-07 Patho - pancreas biopsy
<ul>
<li>Pancreas, EUS-FNB - adenocarcinoma, moderately differentiated<br />
</li>
<li>Sections show pancreas with neoplastic glandular cells infiltrating
in fibrous stroma.</li>
</ul></li>
<li>2021-10-07 Needle aspiration cytology
<ul>
<li>Smears show necrotic debris and clusters of atypical, hyperchromatic
cells. Malignancy is favored.</li>
</ul></li>
<li>2021-10-04 CT - abdomen, pelvis
<ul>
<li>suspected pancreas CA with splenic vessels and stomach
invasions</li>
<li>Liver and para-aortic lymph node metastases</li>
</ul></li>
<li>2018-07-23 MRA - brain
<ul>
<li>recent ischemic of left MCA territory due to severe stenosis in
distal M1 an M2 of left MCA.</li>
<li>Brain atrophy. Multiple lacunar infarcts, deep cerebral hemisphere
and cerebellum.</li>
<li>Bilateral subcortical and periventricular white matter change
(leukoaraiosis).</li>
</ul></li>
<li>2018-07-20 CT - brain
<ul>
<li>Brain atrophy and lacunar infarcts.</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-10-26 ~ undergoing - gemcitabine + nab-paclitaxel</li>
</ul></li>
<li>past history
<ul>
<li>Gout arthritis for 40+ years</li>
<li>CVA with right side hemiparesis and motor aphasia since 2018-07</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Patient presents with stage IV T3N1M1 pancreatic cancer with
paraaortic LAP, liver mets, and adrenal mets.</li>
<li>Fusions (ALK, NRG1, NTRK, ROS1), mutations (BRAF, BRCA1/2, HER2,
KRAS, PALB2), and MMR status were not found in HIS5.</li>
<li>FOLFIRINOX or gemcitabine + nab-paclitaxel would be preferred
regimens. The patient has been receiving the latter since late October
2021.</li>
<li>This patient has just been arranged for hospice combined care on
2022-03-29.</li>
<li>No issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-222" class="section level1">
<h1>700815802</h1>
<div id="section-223" class="section level2">
<h2>220411</h2>
<p>{Recurrence nasopharyngeal carcinoma with skull base destruction and
cranial nerve (V2, VI) invasion , liver metastasis and multiple lung
metastases in progression.yT4N2M1,stageIVB}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-24 Chest
<ul>
<li>Borderline cardiomegaly</li>
<li>Increased lung markings on both lower lung are noted.</li>
<li>Hypoinflation of both lung is noted.</li>
</ul></li>
<li>2022-02-19 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Progression of liver metastases.</li>
<li>Multiple lung metastases.</li>
</ul></li>
<li>2021-10-19 MRI - nasopharynx
<ul>
<li>NPC, s/p R/T with abnormal residual enhancing soft-tissue at Rt
skull base, pterygopalatine fissure and clivus, stationary.</li>
<li>Chronic bilateral mastoiditis and paranasal sinusitis,
stationary.</li>
</ul></li>
<li>2021-09-25 CT - abdomen, pelvis
<ul>
<li>Liver metastasis with tumors regression (partial remission)</li>
</ul></li>
<li>2021-06-16 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Multiple metastases on both hepatic lobes show stable disease or
progressive disease.</li>
</ul></li>
<li>2021-04-28 Nasopharyngoscopy
<ul>
<li>bulging tumor over NP, subside</li>
<li>NPC s/p CCRT with recur</li>
</ul></li>
<li>2021-04-22 SONO - abdomen
<ul>
<li>liver tumors, bil. propable metastases</li>
<li>suspected liver cyst, right</li>
<li>suspected right renal cyst</li>
</ul></li>
<li>2021-02-26 CT - abdomen, pelvis
<ul>
<li>Multiple metastases on both hepatic lobes show stable disease.</li>
</ul></li>
<li>2021-02-08 MRI - nasopharynx
<ul>
<li>C/W NPC s/p treatment with residual abnormal signal intensity at
skull base, stationary as compared with MRI on 2020817.</li>
</ul></li>
<li>2021-02-01 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20200213, increased
radiotracer uptake in skull base had been slightly less evident,
probably indicating post-treatment inflammatory change. Please correlate
with other imaging modalities to exclude the possibility of malignant
local bone invasion.</li>
<li>Mildly and non-focally increased radiotracer uptake in lower L-spine
and sacrum, degenerative spine diseases may show such a picture.</li>
<li>Some faint hot areas in maxilla and mandible, dental lesions may
show such a picture.</li>
<li>Probably degenerative joint lesions in shoulders, sternoclavicular
junctions, manubriosternal joint, sacroiliac joints, and hips.</li>
<li>No definite evidence of distant osteoblastic skeletal metastasis by
this bone scan.</li>
</ul></li>
<li>2021-01-05 GI bleeding embolization
<ul>
<li>Duodenal hemorrhage s/p TAE.</li>
</ul></li>
<li>2021-01-04 Esophagogastroduodenoscopy
<ul>
<li>Diagnosis
<ul>
<li>Reflux esophagitis LA classification grade A</li>
<li>Incomplete study of stomach and doudenum</li>
<li>Duodenal ulcers, 2nd portion, s/p hemostasis with injection, APC
&amp; hemoclipping</li>
</ul></li>
<li>Suggestion
<ul>
<li>Transfer to ICU for intensive care and monitor</li>
<li>NPO with high dose PPI for at least 3 days</li>
<li>Angiography is suggested if active bleeding develops</li>
</ul></li>
</ul></li>
<li>2020-11-17 CT - abdomen, pelvis
<ul>
<li>Liver metastsis, regression.</li>
<li>Liver cysts.</li>
<li>Right renal cyst.</li>
</ul></li>
<li>2020-10-12 Nasopharyngoscopy
<ul>
<li>bulging tumor over NP, subside</li>
<li>npc s/p ccrt with mets</li>
</ul></li>
<li>2020-09-22 Patho - colon biopsy
<ul>
<li>Rectum, biopsy - Nonspecific proctitis with superficial ulcer</li>
</ul></li>
<li>2020-09-18 Patho - stomach biopsy
<ul>
<li>Stomach, antrum, PW &amp; LC side, biopsy - ulcer. No H.pylori
present</li>
</ul></li>
<li>2020-08-17 MRI - nasopharynx
<ul>
<li>NPC, s/p R/T with abnormal residual enhancing soft-tissue at Rt
skull base, pterygopalatine fissure and clivus, stationary.</li>
<li>Chronic bilateral mastoiditis and paranasal sinusitis.</li>
</ul></li>
<li>2020-08-12 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Multiple metastases on both hepatic lobes.</li>
</ul></li>
<li>2020-08-04 Patho - liver biopsy needle/wedge
<ul>
<li>Liver, CT-guided biopsy  Metastatic non-keratinizing squamous
carcinoma, consistent with nasopharynx primary</li>
<li>The secvtions show non-keratinizing squamous cell carcinoma,
composed of nests of poorly differentiated neoplastic cells in fibrous
stroma.</li>
<li>IHC, tumor cells reveal: CK7(-), CK20(-), p40 (+) and Hepa-1(weakly
+). The finding is consistent with metastatic nasopharyngeal
carcinoma.</li>
</ul></li>
<li>2020-07-29 CT - CTA, chest
<ul>
<li>no acute pulmonary embolism.</li>
<li>multiple HCC in both lobes.</li>
</ul></li>
<li>2020-05-07 SONO - abdomen
<ul>
<li>fatty liver, mild</li>
<li>liver tumors, bil. propable metastases</li>
<li>suspected liver cyst, left</li>
<li>suspected fatty infiltration of pancreas</li>
<li>suspected right renal cyst</li>
<li>s/p cholecystectomy</li>
</ul></li>
<li>2020-03-26 MRI - nasopharynx
<ul>
<li>NPC, s/p R/T with abnormal enhancing soft-tissue at Rt skull base,
pterygopalatine fissure, and clivus still visible, stationaryas compared
with MRI 2019/11/26</li>
<li>Chronic mastoiditis and otitis media.</li>
<li>Thyroid goiter.</li>
</ul></li>
<li>2020-02-24 Nasopharyngoscopy
<ul>
<li>npc s/p ccrt with recur</li>
</ul></li>
<li>2020-02-13 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20180613, the hot spot in
the skull base is less evident. Please correlate with other imaging
modalities for further evaluation.</li>
<li>The previous hot spot in the suerolateral aspect of the left orbital
area of the skull is less evident and the previous rib lesions
disappeared, probably more benign in nature.</li>
<li>Suspected benign lesions in bilateral sternoclavicular junctions,
shoulders, knees, and feet.</li>
</ul></li>
<li>2020-02-10 CT - abdomen
<ul>
<li>No interval change of liver lesions.</li>
<li>Right renal cyst (2.4cm).</li>
</ul></li>
<li>2019-11-26 MRI - Nasopharynx
<ul>
<li>NPC, s/p R/T with abnormal enhancing soft-tissue at Rt skull base,
pterygopalatine fissure and clivus, stationary.</li>
<li>Chronic bilateral mastoiditis.</li>
</ul></li>
<li>2019-10-18 CT - abdomen
<ul>
<li>Indication: NPC with liver Metastasis in S5 s/p RFA, for follow
up</li>
<li>Impression: Prior CT identified metastasis in S5 S/P RFA shows
complete response.</li>
</ul></li>
<li>2019-07-23 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>Hepatic tumor, probably metastatic tumor (S5-6)</li>
<li>Hepatic tumor, probably post RFA change (S8, according hx and
CT)</li>
<li>Hepatic cyst</li>
<li>Postcholecystectomy</li>
</ul></li>
<li>2019-07-15 CT - abdomen
<ul>
<li>Liver tumors s/p RFA. suspected residual tumor in S6 of liver.</li>
</ul></li>
<li>2019-06-03 MRI - nasopharynx
<ul>
<li>Indication:
<ul>
<li>NPC, with skull base destruction and cranial nerve (V2, VI)
invasion, cT4N2M0. s/p CCRT and adjuvant RT.</li>
</ul></li>
<li>Impression:
<ul>
<li>NPC, s/p R/T with abnormal enhancing soft-tissue at Rt skull base,
pterygopalatine fissure and clivus, stationary.</li>
<li>Chronic Right mastoiditis.</li>
</ul></li>
</ul></li>
<li>2019-05-21 Surgical pathology Level V
<ul>
<li>Liver, needle biopsy  Metastatic undifferentiated carcinoma.</li>
</ul></li>
<li>2019-05-21 SONO guide biopsy
<ul>
<li>Metastasis in S5 of the liver is suspected.</li>
</ul></li>
<li>2019-04-23 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>Diagnosis
<ul>
<li>Hepatic tumor, probably metastaic tumor</li>
<li>GB stone, multiple</li>
<li>Splenomegaly, mild</li>
</ul></li>
<li>Suggestion
<ul>
<li>refer to medical ONC for further evaluation and treatment</li>
</ul></li>
</ul></li>
<li>2019-04-11 CT - abdomen
<ul>
<li>A faint enhancing lesion (2.1cm, srs501, img19) in S5 of liver.</li>
</ul></li>
<li>2019-02-27 Whole body PET scan
<ul>
<li>No significantly increased FDG uptake in bilateral N-P regions and
skull base was noted, indicating response to current therapy.</li>
<li>Glucose hypermetabolism in the left lobe of the thyroid gland, the
nature is to be determined (functioning nodule, benign or malignant
neoplasm, or others ?), suggesting biopsy for further
investigation.</li>
<li>Glucose hypermetabolism in the right lobe of the liver and in a
nodular lesion in the RLQ of abdomen, the nature is also to be
determined (benign or malignancy/metastasis ?).</li>
</ul></li>
<li>2019-02-19 MRI - nasopharynx
<ul>
<li>NPC, s/p R/T with post R/T change abnormal enhancing soft-tissue at
Rt skull base, pterygopalatine fissure and clivus, stationary.<br />
</li>
<li>Chronic Right mastoiditis.</li>
</ul></li>
<li>2018-12-11 SONO - abdomen
<ul>
<li>Fatty liver, mild</li>
<li>Liver cyst, left lobe</li>
<li>Gall stone</li>
<li>Renal cyst, left kidney</li>
<li>Splenomegaly</li>
</ul></li>
<li>2018-11-13 MRI - nasopharynx
<ul>
<li>NPC, s/p R/T with post R/T change abnormal enhancing soft-tissue at
Rt pterygopalatine fissure and clivus, suggest F/U.</li>
<li>Right mastoiditis.</li>
</ul></li>
<li>2018-06-13 Tc-99m MDP whole body bone scan
<ul>
<li>A hot spot at the skull base, NPC with local bone involvement should
be considered, suggesting F-18 FDG PET/CT scan for further
investigation.</li>
<li>Three hot spots in the right 8th to 10th ribs, respectively, the
nature is to be determined (post-traumatic change or other nature?).
Please follow up bone scan in 3 months.</li>
<li>Suspected benign lesions in the left rib cage, bilateral
sternoclavicular junctions, shoulders, knees, and feet.</li>
</ul></li>
<li>2018-06-12 MRI - nasopharynx
<ul>
<li>NPC T4N2Mx</li>
<li>Right mastoiditis.</li>
</ul></li>
<li>2018-05-28 Surgical pathology Level IV
<ul>
<li>Nasopahrynx, biopsy  Non-keratinizing carcinoma, undifferentiated
(lymphoepithelialcarcinoma) (WHO-2B).</li>
<li>IHC stain: CK (+).</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>EBV
<ul>
<li>2021-03-01 1236copies/mL (normal &lt; 120)</li>
<li>2019-11-11 &lt;120</li>
<li>2019-02-02 252</li>
<li>2018-09-17 &lt;120</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-01-07
<ul>
<li>Surgery
<ul>
<li>duodenal ulcer suture ligation</li>
<li>trucal vagotomy wth pyloroplasty</li>
</ul></li>
<li>Finding
<ul>
<li>active duodenal 2nd portion ulcer bleeding</li>
<li>chronic DU with bulb deformity</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2018-07-13 ~ 2018-08-23 - completed RT to the bil. neck lymphatic
drainage area: 50 Gy/ 25 fx. The NP tumor and LAPs: 70 Gy/ 35 fx.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-04 ~ undergoing - 5-Fu + Leucovorin</li>
<li>2021-07-09 ~ 2021-12-03 - Doxorubicin</li>
<li>2021-05-11 ~ 2021-06-07 - 5-Fu + Leucovorin</li>
<li>2020-08-27 ~ 2020-12-22 - 5-Fu + Leucovorin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This is a patient with non-keratinizing nasopharyngeal carcinoma
(2018-05-28 pathology).</li>
<li>According to medical images during the last 12 months (2021-04 and
2022-04), the primary lesions (s/p CCRT, now on FL) are generally
stable, however, liver metastases (s/p RFA) appear to have
developed.</li>
<li>Nivolumab might be an optional alternative for nonkeratinizing NPC
that has previously been treated.</li>
</ul>
</div>
</div>
<div id="section-224" class="section level1">
<h1>700825772</h1>
<div id="section-225" class="section level2">
<h2>210721</h2>
<p>{Rectal Cancer with UTI}</p>
<p>[objective]</p>
<ul>
<li>exams
<ul>
<li>2021-07-20 urine culture: Escherichia coli.</li>
<li>2021-05-18 patho - vaginal biopsy:
<ul>
<li>adenocarcinoma characterized by solid, villous or tubular pattern of
tumor cells with necrosis.</li>
<li>immunohistochemistry shows CDX-2(+); MLH1(+), MSH2(+), MSH6(+),
PMS2(+) and GATA-3(-) for tumor cells, compatible with recurrent rectal
adenocarcinoma.</li>
</ul></li>
<li>2021-05-17 CT - ABD:
<ul>
<li>rectal cancer s/p operation. a soft tissue lesion (3.0x4.1cm) at
right presacral region. some nodules (up to 1.1cm) in bil. lungs.</li>
</ul></li>
<li>2021-01-26 CT - ABD:
<ul>
<li>post-op at the rectum with recurrence in presacral region,
involvement of distal ureter and sigmoid colon.</li>
<li>progression of right hydronephrosis and hydroureter.</li>
<li>left lower lung nodule, suspected lung metastasis.</li>
</ul></li>
<li>2020-08-27 whole body PET:
<ul>
<li>in comparison with the previous study on 2019/12/23, a new glucose
hypermetabolic lesion in the midline pre-sacral region. malignancy with
local recurrence should be watched out.</li>
<li>another new glucose hypermetabolic lesion in the upper lobe of left
lung. the nature is to be determined (a metastatic lesion? other
nature?).</li>
<li>no prominent change was noted in the previous lesion in right
pre-sacral region.</li>
</ul></li>
<li>2020-04-02 CT - lung/mediastinum/pleura
<ul>
<li>left upper lobe and right upper lobe dense nodules, old insult is
more favored.</li>
</ul></li>
</ul></li>
<li>tests
<ul>
<li>Fecal Occult Blood 4+ (2021-07-17)</li>
<li>CEA 46ng/mL (2021-05-24), 48ng/mL (2021-04-27), 63ng/mL
(2021-03-30), 31ng/mL (2021-02-26), 0.8ng/mL (2020-07-17)</li>
<li>CA199 172U/mL (2021-05-24), 221U/mL (2021-04-27), 299U/mL
(2021-03-30), 228U/mL (2021-02-26), 16U/mL (2020-03-24)</li>
<li>hs-Troponin I 109pg/mL (2021-07-17)</li>
<li>CRP 42mg/dL (2021-07-17)</li>
<li>Lactic Acid 3.5mmol/L (2021-07-17)</li>
</ul></li>
<li>medication
<ul>
<li>UFT (tegafur 100mg, uracil 224mg) BID PO with Folina (folinate 15mg)
BID PO since 2021-03-02.
<ul>
<li>the same drugs have been prescirbed shortly in Feb and May each for
28-day in 2017.</li>
</ul></li>
<li>Flumarin (flomoxef sodium 1000mg) IVD Q12H</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>rectal cancer was first diagnosed in 2016, shortly thereafter
followed with RT 5040cGy/28 and the disease has been controlled for not
long years.</li>
<li>patients family have lost several relative elders these consecutive
years, care burdens let the lineal descendent caregivers exhausted.
hospice care is arranged.</li>
<li>oral prodrug of 5-FU for rectal cancer, lactulose for ileus,
tramadol for pain control, ABX for UTI, no issue with the
medication.</li>
<li>according to the time serial tumor markers level, the disease
somewhat responded to 5-FU prodrug since 2021 March.</li>
<li>hs-Troponin I has played an important role in the risk
stratification of patients during the in-hospital phase of acute
coronary syndrome, the elevated level should be concerned.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep monitoring progresstion of the infection and signs of acute
heart attack.</li>
<li>no adjustment for medication is needed.</li>
</ul>
</div>
</div>
<div id="section-226" class="section level1">
<h1>700826905</h1>
<div id="section-227" class="section level2">
<h2>210927</h2>
<p>{dedifferentiated liposarcoma}</p>
<p>[tube feeding]</p>
<ul>
<li>most oral drugs in active medication are patient-carried for her
underlying diseses, all the oral drugs can be administered via NG
tube.</li>
</ul>
<p>[objective]</p>
<ul>
<li>2021-04-22 patho - peritoneum biopsy
<ul>
<li>pathologic diagnosis: compatible with dedifferentiated
liposarcoma</li>
<li>composed of fascicles of markedly pleomorphic spindle tumor cells
embedded in myxoid stroma. subtle lipogenic tumor cells are found. foci
of tumor necrosis are present.</li>
<li>IHC: CK(-), S100(focal +), CD34(-), smooth muscle actin(-), MDM2
(+), and CDK4(+).</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>palbociclib might be considered for the treatment of unresectable
dedifferentiated liposarcoma
<ul>
<li>palbociclib, an inhibitor of cyclin-dependent kinases (CDKs) 4 and
6, induced objective tumor response and a favorable PFS of 56% to 66% in
patients with CDK-4-amplified, well-differentiated or dedifferentiated
liposarcoma in a phase II study.</li>
<li>reference: <a href="https://pubmed.ncbi.nlm.nih.gov/23569312/" class="uri">https://pubmed.ncbi.nlm.nih.gov/23569312/</a></li>
</ul></li>
<li>pembrolizumab demostrated clinical activity in resectable
dedifferentiated liposarcoma with a 20% overall response rate in a phase
II study.
<ul>
<li>reference: <a href="https://pubmed.ncbi.nlm.nih.gov/30249211/" class="uri">https://pubmed.ncbi.nlm.nih.gov/30249211/</a></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-228" class="section level1">
<h1>700834580</h1>
<div id="section-229" class="section level2">
<h2>210806</h2>
<p>{cancer workup}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-06-30 left leg knee and thigh pain for more than one month,
progresson</li>
<li>2021-07-14 limping gait, severe pain lower back radiating to left
hip and lower leg</li>
</ul>
<p>[objective]</p>
<ul>
<li>lab data (2021-07-28)
<ul>
<li>CA125 645U/mL</li>
<li>CA199 &gt;19610U/mL</li>
<li>CEA 613ng/mL</li>
<li>CA153 WNL</li>
<li>AFP WNL</li>
<li>SCC WNL</li>
</ul></li>
</ul>
<p>[definite diagnosis &amp; staging workup]</p>
<ul>
<li>still in workup, could be lung to bone mets, evidences observed
including:
<ul>
<li>2021-07-15 MRI L-spine:
<ul>
<li>tumors in the left iliac bone and right sacrum. origin?</li>
</ul></li>
<li>2021-08-04 Tc-99m MDP bone scan:
<ul>
<li>lung cancer with multiple bone metastases in the lower part of the
sternum, posterolateral aspect of the left 10th rib, and left iliac bone
is highly suspected.</li>
</ul></li>
<li>2021-08-05 bronchoscopy:
<ul>
<li>right intermediate bronchus submucosal tumor.</li>
<li>RLL orifice submucosal tumor, some protuding to the mucosa layer,
with RLL bonchus narrowing.</li>
</ul></li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>pain
<ul>
<li>morphine 15mg PO Q6H</li>
<li>morphine 5mg IVD PRNQ6H</li>
</ul></li>
<li>constipation
<ul>
<li>through (sennoside) 24mg PO HS</li>
<li>bisacodyl 10mg RECT PRNQD</li>
<li>MgO 500mg PO Q6H</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>post nasal dripping
<ul>
<li>actein (acetylcysteine) 200mg PO BID</li>
<li>sindecon nasal spray 1 puff NA BID</li>
</ul></li>
<li>hyperlipidemia
<ul>
<li>crestor (rosuvastatin) 10mg PO QD</li>
</ul></li>
<li>insomnia
<ul>
<li>anxiedin (lorazepam) 0.5mg PO HS</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>main activity is to control (pain) symptoms for now</li>
<li>constipation which could be an adverse reaction of morphine has been
mitigated with stimulant laxatives.</li>
</ul>
</div>
</div>
<div id="section-230" class="section level1">
<h1>700835850</h1>
<div id="section-231" class="section level2">
<h2>220304</h2>
<p>[subjective]</p>
<ul>
<li>2021-12 the patient noted vaginal bleeding and coital pain after
sexual intercourse, and post-voiding vaginal bleeding developed
afterwards.</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-25 Patho - uterus neoplastic
<ul>
<li>pathologic diagnosis
<ul>
<li>Tumor, uterine endocervix, radical hysterectomy -
Carcinosarcoma</li>
<li>Tumor, uterine fundus, ditto - Serous carcinoma, high grade</li>
<li>Myometrium, ditto - Tumor invasion, less than half thickness</li>
<li>Parametria, bilateral, ditto - Free from tumor, two reactive lymph
nodes at Rt parametrium</li>
</ul></li>
<li>AJCC pathological stage
<ul>
<li>endometrial cancer - pT1aN0, if cM0, stage IA</li>
<li>cervical cancer - pT1b1N0, if cM0, stage IB1 / FIGO stage IA1</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Tumor 1
<ul>
<li>Tumor location: Fundus</li>
<li>Myometrium involvement: involved, less than 0.2 cm in depth</li>
<li>Tumor type: high grade serous carcinoma</li>
<li>Histologic grade: high grade</li>
<li>Immunohistochemistry: P16(+), P53(+), WT-1(+, focal), ER(+, focal)
and PR(+, focal)</li>
</ul></li>
<li>Tumor 2
<ul>
<li>Tumor location: Between low body and endocervix</li>
<li>Corpus involvement: involved, focal</li>
<li>Tumor type: homologous type carcinosarcoma</li>
<li>Histologic grade: high grade</li>
<li>Depth of invasion: less than 0.1 cm, &lt;1/2 cervical wall</li>
<li>Immunohistochemistry:
<ul>
<li>carcinoma component: P16(+), P53(+), WT-1(+, focal), CK(+),
vimentin(-), CD10(-)</li>
<li>Sarcoma component: vimentin(+), CD10(+, focal), WT-1(+, focal),
P16(+), P53(+), CK(-)</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-01-11 MRI - pelvis
<ul>
<li>Clinical cervical polypectomy, carcinosarcoma. No evidence of
advanced lesion.</li>
<li>Soft tissue in the uterine cavity (fundus and lower body), suspected
polyps or endometrial tumors, suggest further study.</li>
</ul></li>
<li>2022-01-03 Patho - cervix/endometrial polyp
<ul>
<li>pathologic diagnosis
<ul>
<li>Uterus, cervix, polypectomy - Carcinosarcoma</li>
</ul></li>
<li>microscopic examination
<ul>
<li>The sections show carcinosarcoma, composed of a adenocarcinomatous
component admixed with a high-grade sarcomatous component.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-24 radical hysterectomy</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02-18 ~ 4500cGy/25 fractions of the pelvis, and 1200cGy/3
fractions by IVRT to vaginal cuff mucosa surface.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-03 ~ ongoing: cisplatin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Surgical findings without nodes, margins and parametrium
infiltrations, s/p radical hysterectomy (2022-01-24), pelvic EBRT and
concurrent platinum-containing chemotherapy were recommended for stage
IB1 cervical cancer.</li>
<li>concurrent platinum-containing chemotherapy with EBRT utilizes
cisplatin as a single agent. currently, the patient is being
hospitalized to receive her first chemotherapy dose. in case of
cisplatin intolerance, carboplatin may be used instead.</li>
<li>regular cytology can be considered for detection of lower genital
tract dysplasia and for immunocompromised patients, although its value
in detection of recurrent cervical cancer is limited.</li>
</ul>
</div>
</div>
<div id="section-232" class="section level1">
<h1>700841543</h1>
<div id="section-233" class="section level2">
<h2>210827</h2>
<p>{gastric cancer with colon mets s/p subtotal gastrectomy and partial
T-colectomy}</p>
<p>[initial presentation]</p>
<ul>
<li>2020-08-03
<ul>
<li>fasting epigastric discomfort for 1-2 weeks</li>
<li>fullness(-), nausea(-)</li>
</ul></li>
<li>2021-04-14
<ul>
<li>epigasrtalgia for for 2-3 months</li>
<li>mild response to strocain and h2 blocker from other hopsital but
still discomfort</li>
<li>hunger pain (+) improving after intake</li>
</ul></li>
</ul>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2021-04-20 patho - stomach biopsy
<ul>
<li>greater curvature side of lower body - adenocarcinoma.</li>
<li>IHC stains: CK highlights neoplastic cells. Her2/neu: negative
(score=0).</li>
</ul></li>
<li>2021-04-29 CT - whole abdomen, pelvis
<ul>
<li>imaging stage: T1aN0M0, stage I.</li>
</ul></li>
<li>2021-05-07 patho - stomach subtotal/total (tumor)
<ul>
<li>poorly cohesive carcinoma (signet-ring cell carcinoma)</li>
<li>margins, bilateral cutting ends, ditto - Free of tumor
invasion<br />
</li>
<li>lymph nodes, LN dissection - metastatic carcinoma (3/32)<br />
</li>
<li>omentum, omentectomy - free of tumor invasion</li>
<li>AJCC pathologic staging - pT4aN2M1, stage IV<br />
</li>
</ul></li>
<li>2021-05-07 patho - colon segmental resection for tumor
<ul>
<li>gastric ca with mescolon implantation<br />
</li>
<li>transverse colon, partial resection, poorly cohesive carcinoma
(signet-ring cell carcinoma), metastatic</li>
<li>histology grade: poorly differentiated</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2021-05-06 surgery
<ul>
<li>subtotal gastrectomy with LN 1,3,4,5,6,7,8,9,110,12a and 14v
dissection</li>
<li>partial T-colectomy</li>
<li>IPCT with Mitomycin C 25mg/m2(42mg) for 2 hrs</li>
</ul></li>
<li>2021-05-07: 5-Fu 500mg/m2(839mg) day 1~5, leucovorin 34mg day 1</li>
<li>2021-06-16, -07-16, -07-29, -08-12, -08-27: FOLFOX</li>
</ul>
<p>[assessment/suggestion]</p>
<ul>
<li>recent lab data unremarkable, liver and kidney functions no
abnormality, overall not bad.</li>
<li>2021-08-27 around 10:30 visiting the patient (accompanied by his
wife)
<ul>
<li>he felt soreness/ache (not pain) in his left arm during the first
30min when premedication being administrated in last three
hospitalization. rule out left arm compression or cruch caused symptom.
cause remains unknown.</li>
<li>mild oral mucosa damage, some triamcinolone acetonide oral ointment
(nincort or oralog, the former is available now) for local treatment
might be of help.</li>
<li>mild diarrhea, not often, could be monitored with PRN antidiarrheal
agent e.g.loperamide (2mg/cap is available now)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-234" class="section level1">
<h1>700842151</h1>
<div id="section-235" class="section level2">
<h2>220425</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-10 KUB
<ul>
<li>Degeneration of bony structures.</li>
<li>Stool retention in bowl.</li>
</ul></li>
<li>2022-04-08 CT - abdomen, pelvis
<ul>
<li>S/P LAR with autosuture retention over the rectosigmoid junction.
There is no evidence of tumor recurrence.</li>
<li>There are several enlarged nodes in the paratracheal space, right
hilum, and subcarina space. Metastatic nodes are suspected.</li>
</ul></li>
<li>2021-12-03 Patho - colon segmental resection for tumor
<ul>
<li>pathologic diagnosis
<ul>
<li>Large intestine, colon, rectosigmoid junction, laparoscopic LAR 
Adenocarcinoma, moderately differentiated<br />
</li>
<li>Resection margins, proximal and distal: free<br />
</li>
<li>Lymph node, mesocolic, dissection Positive for adenocarcinoma
(4/20)<br />
</li>
<li>Pathology stage: pT3N2a(if cM0); AJCC stage IIIB<br />
</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology: Adenocarcinoma<br />
</li>
<li>Histology Grade: moderately differentiated</li>
<li>Depth of invasion: pericolorectal tissue</li>
<li>Angiolymphatic invasion: Present.</li>
<li>Perineural invasion: Not identified.</li>
<li>Discontinuous extramural tumor extension: Not identified<br />
</li>
<li>Circumferential (radial) margin of rectum: Uninvolved<br />
</li>
<li>Lymph node metastasis, mesocolic: Positive (4/ 20)<br />
</li>
</ul></li>
</ul></li>
<li>2021-12-01 Sigmoidoscopy
<ul>
<li>advanced colorectal cancer, RS junction (25-28cm from AAV), s/p
Tattoo injection</li>
<li>mixed hemorrhoid.</li>
</ul></li>
<li>2021-11-13 CT - chest
<ul>
<li>s/p esophagectomy with gastric tube reoncstruction.</li>
<li>Bilateral lung focal opacity, stationary. Previous inflammation is
considered.</li>
<li>Intusussception of the sigmoid colon into rectum is found.
Compatible with rectal cancer.</li>
</ul></li>
<li>2021-11-11 CT - abdomen, pelvis
<ul>
<li>Imaging stage: T3N2M0, stage IIIB</li>
</ul></li>
<li>2021-11-11 Patho - colon biopsy
<ul>
<li>RS junction, 25 cm to 28 cm AAV, biopsy  Adenocarcinoma, moderately
differentiated<br />
</li>
<li>The sections show a picture of adenocarcinoma, moderately
differentiated, composed of columnar neoplastic cells, arranged in
glandular and cribriform patterns with desmoplastic stromal reaction.
Mucosal ulcer is present.</li>
<li>IHC, tumor cells reveal: EGFR(+), MLH1(+), PMS2(+), MSH2(+), and
MSH6(+).</li>
</ul></li>
<li>2021-11-09 Sigmoidoscopy
<ul>
<li>Advanced colorectal cancer, RS junction(25cm to 28cm AAV), s/p
biopsy</li>
<li>Mixed hemorrhoid.</li>
</ul></li>
<li>2021-06-08 CT - chest
<ul>
<li>No recurrent esophageal tumor. post treatment related change and
inflammatory process RUL and LLL, stationary.</li>
</ul></li>
<li>2020-12-22 CT - chest
<ul>
<li>No recurrent esophageal tumor. post treatment related change and
inflammatory process (infectious bronchiolitis) RUL and LLL (new
lesion).</li>
</ul></li>
<li>2020-05-12 CT - chest
<ul>
<li>No recurrent esophageal tumor; post treatment related change and
inflammatory process (infectious bronchiolitis) in lungs,
stationary.</li>
<li>2-vessels CAD.</li>
</ul></li>
<li>2019-11-03 CT - chest
<ul>
<li>No recurrent esophageal tumor; post treatment related change and
inflammatory process (infectious bronchiolitis) in both lungs, slightly
in progression.</li>
<li>2-vessels CAD.</li>
</ul></li>
<li>2019-06-11 CT - chest
<ul>
<li>No recurrent esophageal tumor; post treatment related change and
inflammatory process in lungs, slightly in regression.</li>
<li>2-vessels CAD.</li>
</ul></li>
<li>2018-11-29 CT - chest
<ul>
<li>No recurrent esophageal tumor; post treatment related change and
inflammatory process in lungs, stationary.</li>
</ul></li>
<li>2018-06-05 CT - chest
<ul>
<li>No recurrent esophageal tumor; post treatment related change and
inflammatory process in lungs, stationary.</li>
</ul></li>
<li>2017-12-13 CT - chest
<ul>
<li>No recurrent esophageal tumor; post treatment related change and
inflammatory process in lungs, in regression.</li>
<li>pneumonia in LLL?</li>
</ul></li>
<li>2017-06-14 CT - chest
<ul>
<li>No recurrent esophageal tumor; post treatment related change and
inflammatory process in lungs.</li>
<li>pneumonia in LLL?</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-02 Laparoscopic LAR
<ul>
<li>A large locally advanced tumor at RS-colon with intussusception and
partial obstruction. Some turbid (30ml) ascites was found at pelvic
floor. Marked edema of the colon wall and dilatation with much
soft0liquid stool retention.</li>
<li>The whole procedure was smooth. Blood loss was less than
30ml.</li>
<li>Adhesion of two segment of small bowel with anterior abdomen wall
was seen.</li>
<li>Anastomosis was achieved using endo-GIA/black*2 + CDH-33 + TISSEEL.
Air test is ok.</li>
<li>A drain in pelvis near anastomosis.</li>
</ul></li>
<li>2018-03-21
<ul>
<li>Diagnosis
<ul>
<li>Paralysis of vocal cords or larynx, unilateral , complete</li>
</ul></li>
<li>PCS code
<ul>
<li>66008A</li>
</ul></li>
<li>Finding
<ul>
<li>Complete paralysis of left vocal cord.</li>
<li>Sculptured silicon mass was inserted to left paraglottic space for
adduct left vocal cord</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-01-03 ~ undergoing - FOLFOX</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patients stage IIIB R-S colon cancer was treated with FOLFOX
since 2022-01-03 following laparoscopic LAR on 2021-12-02.</li>
<li>On the CT images obtained on 2022-04-08, there were enlarged nodes
in paratracheal space, right hilum, and subcarina space, which are
suspected to be metastatic.</li>
<li>Lab results on 2022-04-22 showed liver and kidney functions, serum
electrolytes, and blood cell counts were generally normal. However, the
CRP level of 3.99 mg/dL and body temperature of 38.9 degrees were
observed on 2022-04-23, which is currently being treated with tapimycin
(piperacillin, tazobactam) 4.5gm IVD Q6H.</li>
</ul>
</div>
</div>
<div id="section-236" class="section level1">
<h1>700842358</h1>
<div id="section-237" class="section level2">
<h2>210913</h2>
<p>[drug interaction]</p>
<ul>
<li>total 22 items in active medication (indlucing 3 in-hospital
prescribed and 19 patient-carried drugs) have been reviewed without
combinations to be avoided.</li>
</ul>
<p>[objective]</p>
<ul>
<li>CKD stage 3 management at Shuang Ho Hospital</li>
<li>patient-carried drug Furide (furosemide) 40mg QD listed in active
medication.</li>
<li>lab data reported on 2021-09-13 showed readings above normal limits
<ul>
<li>creatinine 4.83mg/dL</li>
<li>eGFR 12.58</li>
<li>BUN 78mg/dL</li>
<li>Bil T 15.42mg/dL</li>
<li>Bil D 8.89mg/dL</li>
<li>Alkaline phosphatase 243IU/L</li>
</ul></li>
<li>serum electrolytes Na, K reported on 2021-09-13 showed normal.</li>
<li>relatively low blood pressure recorded on 2021-09-11, -09-12</li>
</ul>
<p>[assessment]</p>
<ul>
<li>this patients liver and kidney functions are somewhat
impaired.</li>
<li>furosemide
<ul>
<li>for a patient with eGFR &lt;= 30 mL/minute/1.73m2, higher doses may
be required to achieve desired diuretic response due to decreased
secretion into the tubular fluid. however, single doses &gt;160 to 200
mg are unlikely to result in additional diuretic effect.</li>
<li>diminished natriuretic effect with increased sensitivity to
hypokalemia and volume depletion in cirrhosis.</li>
</ul></li>
<li>diuretics
<ul>
<li>dosing is empiric and frequently determined by the elimination of
edema for CKD stage 4 to 5.</li>
<li>spironolactone leads to natriuretic response in patients with
cirrhosis and ascites or heart failure, particularly used with a loop or
a thiazide-type diuretic or both.</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor furosemide effect to see if dose increasing or
considering spironolactone is needed.</li>
</ul>
</div>
</div>
<div id="section-238" class="section level1">
<h1>700867682</h1>
<div id="section-239" class="section level2">
<h2>220301</h2>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>2022-01-26 dischargenote
<ul>
<li>Recurrent hepatocellular carcinoma, rypT3N0(cM0), Stage IIIA; status
post 3rd Transarterial chemoembolization on 2022-01-25, BCLC: B,
ECOG:1</li>
<li>Liver cirrhosis with moderate splenomegaly, child score: A</li>
<li>Hypertension</li>
<li>Type 2 diabetes mellitus without complications</li>
<li>Enlarged prostate without lower urinary tract symptoms</li>
</ul></li>
</ul></li>
<li>exam finding
<ul>
<li>2022-02-25 MRI - L-spine
<ul>
<li>multiple bone tumors</li>
<li>herniated discs in the L2/3, L3/4 and L4/5 discs</li>
<li>mild spondylolisthesis at L4-5</li>
</ul></li>
<li>2022-01-17 MRI - Liver, Spleen
<ul>
<li>HCC s/p operation. Liver cirrhosis with splenomegaly. Multiple
recurrent HCCs (up to 2.0cm) in liver.</li>
</ul></li>
<li>2021-11-19 CT - ABD
<ul>
<li>Four newly-developed HCCs or pseudolesions in S8 and S2 are
suspected? Please correlate with MRI.</li>
<li>Viable HCC in S7 of the liver is suspected. Please correlate with
MRI.</li>
</ul></li>
<li>2021-09-09 MRI
<ul>
<li>HCC at right lobe liver up to 6.6cm with several satellite smaller
lesions at right lobe.</li>
<li>Lymphadenopathy at retroperitonum, paraaoritc and hepatic hilar
region.</li>
</ul></li>
<li>2021-08-25 CT - ABD
<ul>
<li>HCC 6.8 x 4.6 cm in S7 of the liver is suspected. Please correlate
with AFP and MRI to evaluate the tumor margin.</li>
<li>Two Recurrent HCCs 1.4 cm in S7 and 1.1 cm in S6 of the liver are
suspected. The differential diagnosis include dysplastic nodules. Please
correlate with MRI.</li>
<li>HCC or flow artifact 1.6 cm in S5 liver is suspected.</li>
</ul></li>
<li>2021-08-16 SONO - ABD
<ul>
<li>HCC status post S5 segmenectomy and cholecystectomy</li>
<li>Fatty liver, moderate</li>
<li>Liver cirrhosis with moderate splenomegaly</li>
<li>Fatty pancreas</li>
<li>Left renal stone</li>
</ul></li>
<li>2021-07-28 SONO - Kidney
<ul>
<li>Bilateral chronic change with large sized kidney suspect diabetic
nephropahty</li>
<li>Left renal stone</li>
</ul></li>
<li>2020-04-17 SONO = Kidney
<ul>
<li>Left moderate hydronephrosis</li>
</ul></li>
<li>2019-03-11 Surgical pathology Level V
<ul>
<li>Pathologic diagnosis
<ul>
<li>Liver, S5, partial hepatectomy - Hepatocellular carcinoma<br />
</li>
<li>Pathologic Staging: pT1bNx(cMx); Stage IB at least</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic type: Hepatocellular carcinoma, predominantly clear
cell<br />
</li>
<li>Histologic Grade: G3 (Poorly differentiated)<br />
</li>
<li>Cytological grade: Grade III<br />
</li>
<li>Tumor necrosis: Present (10%)<br />
</li>
<li>Inflammatory cell infiltration: Moderate<br />
</li>
<li>Tumor capsule: Partially ncapsulated with infiltrative border<br />
</li>
<li>Satellite nodule: Absent<br />
</li>
<li>Bile duct Invasion: Absent<br />
</li>
<li>Hepatitis: Non-B, non-C<br />
</li>
<li>Ishak Modified HAI Grading: Score=3 (interphase hepatitis=0/4,
confluent necrosis=0/6, focal necrosis=1/4, portal inflammation=2/4)
(Corresponding Metavir A1, mild activity)<br />
</li>
<li>Ishak Staging: F6 (Corresponding Metavir F4, cirrhosis)<br />
</li>
<li>Fatty Change: Marked (70%)</li>
</ul></li>
</ul></li>
<li>2019-02-26 Visceral Angiography 2 vessels
<ul>
<li>Right hepatic tumor suspected HCC</li>
</ul></li>
<li>2019-02-26 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>Fatty liver , severe</li>
<li>Liver tumor, S5, suspicious HCC</li>
<li>Renal stone, left</li>
<li>Accessory spleen</li>
</ul></li>
<li>2019-01-30 SONO - ABD
<ul>
<li>Bilateral parenchymal renal disease.</li>
<li>Left mild hydronephrosis.</li>
<li>Left renal stones.</li>
<li>Liver tumor.</li>
</ul></li>
</ul></li>
<li>Lab data
<ul>
<li>AFP
<ul>
<li>2022-01-17 103 ng/mL</li>
<li>2021-10-26 19</li>
<li>2021-08-16 20</li>
<li>2019-02-26 2</li>
</ul></li>
<li>S-GPT/ALT
<ul>
<li>2022-01-26 92 U/L</li>
<li>2022-01-17 35</li>
<li>2021-12-07 28</li>
<li>2021-12-01 62</li>
<li>2021-10-26 22</li>
<li>2021-09-24 43</li>
</ul></li>
<li>S-GOT/AST
<ul>
<li>2022-02-27 97 U/L</li>
<li>2022-01-26 279</li>
<li>2022-01-17 112</li>
<li>2021-12-01 87</li>
<li>2021-10-26 26</li>
<li>2021-09-24 53</li>
<li>2021-09-22 36</li>
</ul></li>
</ul></li>
<li>Embolization
<ul>
<li>2022-01-25 Embolization (TAE) - ABD for tumor
<ul>
<li>HCCs at both hepatic lobes s/p TACE.</li>
</ul></li>
<li>2021-11-30 Embolization (TAE) - ABD for tumor
<ul>
<li>HCCs at RIGHT hepatic lobe s/p TACE.</li>
</ul></li>
<li>2021-09-23 Embolization (TAE) - ABD for tumor
<ul>
<li>HCCs at RIGHT hepatic lobe s/p TACE.</li>
</ul></li>
</ul></li>
<li>Radiotherapy
<ul>
<li>2021-10-05 ~ 2021-11-08: 5000cGy/25 fractions (15 MV photon) to
hepatic hilum &amp; paraaortic LAPs.</li>
</ul></li>
<li>Medication
<ul>
<li>2021-01 ~ ongoing: lenvatinib 10mg QD</li>
<li>2021-10-12, -10-26, -11-30: nivolumab 100, 100, 40mg,
respectively<br />
</li>
<li>2021-09 ~ 2022-01: sorafenib 200mg BIDAC</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Recurrent HCC progressed, bone mets observed by MRI on 2022-02-25
s/p 3 times of TAE in 2021-09, 2021-11, 2022-01, s/p nivolumab (Oct, Nov
2021), sorafenib (Sep 2021 ~ Jan 2022) and lenvatinib (since Jan
2022).</li>
<li>Neither pembrolizumab nor atezolizumab used in advanced HCC setting
are covered by the most updated NHI policy (2022-02-23 version). However
atezolizumab/bevacizumab for Child-Pugh Class A patients is recommended
as a preferred regimen by NCCN (2021 version 5).</li>
<li>First-line nivolumab treatment did not significantly improve overall
survival compared with sorafenib, but clinical activity and a favourable
safety profile were observed in patients with advanced hepatocellular
carcinoma. Thus, nivolumab might be considered a therapeutic option for
patients in whom tyrosine kinase inhibitors and antiangiogenic drugs are
contraindicated or have substantial risks.
<ul>
<li>source: <a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00604-5/fulltext" class="uri">https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00604-5/fulltext</a></li>
</ul></li>
<li>There are limited data supporting the use of FOLFOX, and use of
chemotherapy in the context of a clinical trial is preferred.
<ul>
<li>source: <a href="https://pubmed.ncbi.nlm.nih.gov/23980077/" class="uri">https://pubmed.ncbi.nlm.nih.gov/23980077/</a></li>
</ul></li>
<li>If NTRK gene fusion is positive, then larotrectinib or entrectinib
might be opt-in as subsequent line use.</li>
<li>Lenvatinib was non-inferior to sorafenib in overall survival in
advanced hepatocellular carcinoma. This drug is prescirbed as part of
current medication.
<ul>
<li>source: <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext" class="uri">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30207-1/fulltext</a></li>
<li>source: <a href="https://pubmed.ncbi.nlm.nih.gov/30993651/" class="uri">https://pubmed.ncbi.nlm.nih.gov/30993651/</a></li>
</ul></li>
<li>In addition to dermatologic adverse effects, since lenvatinib could
increase the possibility of hypertension (45% to 73%; severe
hypertension 3%; UpToDate) which is a underlying disease the patient
has, a closer blood pressure monitoring might be needed.</li>
</ul>
</div>
</div>
<div id="section-240" class="section level1">
<h1>700876297</h1>
<div id="section-241" class="section level2">
<h2>220323</h2>
<p>{Rt breast cancer with Rt axillary LNs, lungs, and liver
metastases}</p>
<p>[objective]</p>
<ul>
<li>Lab findings
<ul>
<li>2022-01-17 CT - lung/mediastinum/pleura
<ul>
<li>Rt breast cancer with Rt axillary LNs, lungs, and liver metastases,
in regression compared with CT on 20211104.</li>
</ul></li>
<li>2021-11-04 CT - lung/mediastinum/pleura -Right huge breast cancer
with lung meta. Sacrum invasion and liver mets. Stationary.</li>
<li>2021-10-15 CT - abdomen - liver, spleen, biliary duct, pancreas
<ul>
<li>Right breast cancer with right axillary lymph nodes and lung
metastases.</li>
<li>One metastasis or primary lung cancer in LUL of the lung is
suspected.</li>
<li>One liver metastasis is highly suspected.</li>
</ul></li>
<li>2021-10-15 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>Increased activity in the lower L-spines and bilateral S-I joints.
Degenerative change may show this picture.</li>
<li>Increased activity in the maxilla. Dental problem may show this
picture.</li>
<li>Some faint hot spots in the anterior aspect of bilateral rib cages.
The nature is to be determined (post-traumatic change? other
nature?).</li>
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions, elbows, wrists, hips and knees, compatible
with benign joint lesions.</li>
</ul></li>
<li>2021-10-11 Patho - breast, right, core biopsy; lymph node, right
axillary, core biopsy
<ul>
<li>Invasive carcinoma, no special type, NST.</li>
<li>IHC stains (using lymph node tissue block S2021-14022):
<ul>
<li>ER (+, 90%, strong intensity),</li>
<li>PR (+, 90%, strong intensity, breast mass; +, 50%, strong intensity,
lymphonode biopsy),</li>
<li>Her2/neu: positive(score=3+),</li>
<li>Ki-67 (90%),</li>
<li>E-cadherin (+).</li>
</ul></li>
</ul></li>
<li>2021-10-11 SONO - breast
<ul>
<li>Right breast tumor with enlarged axillary lymph nodes, suspected
right breast malignancy, suggest follow up.</li>
<li>BI-RADS: Category 5: highly suggestive of malignancy - appropriate
action should be taken.</li>
</ul></li>
</ul></li>
<li>Medication
<ul>
<li>2022-03-02 ~ ongoing - docetaxel + trastuzumab + pertuzumab</li>
<li>2022-02-07 - docetaxel</li>
<li>2021-11-05 ~ 2022-01-07 - AC (doxorubicin/cyclophosphamide)</li>
</ul></li>
<li>THP (docetaxel + trastuzumab + pertuzumab) regimen for HER2-positive
metastatic breast cancer (source: UpToDate)
<ul>
<li>Cycle length: Every 21 days.</li>
<li>Duration of therapy: Until disease progression or unacceptable
toxicity.</li>
<li>Drugs
<ul>
<li>Pertuzumab - loading dose
<ul>
<li>840 mg IV</li>
<li>Dilute in 250 mL NS and administer over 60 minutes. DO NOT mix with
D5W and DO NOT infuse as an IV push or bolus.</li>
<li>Cycle 1: Day 1</li>
</ul></li>
<li>Pertuzumab
<ul>
<li>420 mg IV</li>
<li>Dilute in 250 mL NS and administer over 30 to 60 minutes. DO NOT mix
with D5W and DO NOT infuse as an IV push or bolus.</li>
<li>Cycle 2 and after: Day 1</li>
</ul></li>
<li>Trastuzumab - loading dose
<ul>
<li>8 mg/kg IV</li>
<li>Dilute in 250 mL NS and administer over 90 minutes for the loading
dose. DO NOT mix with D5W and DO NOT infuse as an IV push or bolus.</li>
<li>Cycle 1: Day 1</li>
</ul></li>
<li>Trastuzumab
<ul>
<li>6 mg/kg IV</li>
<li>Dilute in 250 mL NS and administer over 30 to 90 minutes. DO NOT mix
with D5W and DO NOT infuse as an IV push or bolus.</li>
<li>Cycle 2 and after: Day 1</li>
</ul></li>
<li>Docetaxel
<ul>
<li>75 mg/m2 IV</li>
<li>Dilute in 250 mL NS to a final concentration of 0.3 to 0.74 mg/mL
and administer over 60 minutes.</li>
<li>Day 1</li>
</ul></li>
</ul></li>
<li>Pretreatment considerations:
<ul>
<li>Emesis risk
<ul>
<li>LOW (10 to 30% risk of emesis).</li>
</ul></li>
<li>Prophylaxis for infusion reactions
<ul>
<li>Premedicate with dexamethasone prior to docetaxel administration.
Premedication is not routinely indicated for pertuzumab. Most clinicians
do not routinely premedicate prior to the first trastuzumab dose.
However, patients may be instructed to self-administer acetaminophen or
an NSAID if flu-like symptoms develop within 24 hours of drug
administration.</li>
</ul></li>
<li>Vesicant/irritant properties
<ul>
<li>Docetaxel is an irritant but can cause significant tissue damage;
avoid extravasation.</li>
</ul></li>
<li>Infection prophylaxis
<ul>
<li>In the original study, the risk of febrile neutropenia was 14%. The
decision to use primary prophylaxis with hematopoietic growth factors
should be individualized, and considered for patients who may be at risk
for increased complications from prolonged neutropenia.</li>
</ul></li>
<li>Dose adjustment for baseline liver or renal dysfunction
<ul>
<li>Docetaxel should not be administered to patients with a serum
bilirubin above the ULN or to patients with transaminase elevations
&gt;1.5 times the ULN in conjunction with alkaline phosphatase &gt;2.5
times the ULN.</li>
</ul></li>
<li>Cardiopulmonary issues
<ul>
<li>Trastuzumab and pertuzumab are associated with cardiotoxicity;
assess baseline LVEF prior to therapy and then as clinically indicated.
Patients with a baseline LVEF &lt;50% were excluded from the study.
Trastuzumab may cause serious pulmonary toxicity and should be used with
caution in patients with preexisting pulmonary disease.</li>
</ul></li>
<li>Dose adjustment for known drug interactions
<ul>
<li>Caution is needed when administering docetaxel with strong CYP3A4
inhibitors. Although specific dose recommendations are not available,
the United States Prescribing Information suggests close monitoring for
toxicity and consideration of docetaxel dose reduction if
coadministration with a strong CYP3A4 inhibitor cannot be avoided.</li>
</ul></li>
</ul></li>
<li>Monitoring parameters:
<ul>
<li>Obtain CBC with differential and platelet count prior to each
treatment cycle.</li>
<li>Assess electrolytes and liver and renal function prior to each
treatment cycle.</li>
<li>It is recommended to observe the patient for one hour after the
initial dose of pertuzumab and for 30 minutes after all subsequent doses
for signs of infusion reactions.</li>
<li>Assess cardiac function at baseline and then as clinically
indicated. In the clinical trial, LVEF was measured at screening and
then every nine weeks.</li>
<li>Assess changes in neurologic function prior to each cycle of
docetaxel.</li>
<li>Patients with renal impairment, hyperuricemia, and bulky tumors are
at risk for TLS and should undergo correction of dehydration and
lowering of high serum uric acid levels prior to treatment initiation,
and be closely monitored for TLS during and after treatment.</li>
</ul></li>
<li>Suggested dose modifications for toxicity:
<ul>
<li>Myelotoxicity
<ul>
<li>Reduce docetaxel dose by 25% for subsequent cycles in patients who
develop severe prolonged neutropenia (&lt;500/microL lasting seven days
or more), febrile neutropenia, or a grade 4 infection (ie, an infection
with life-threatening consequences).</li>
</ul></li>
<li>Hepatotoxicity
<ul>
<li>A 20% dose reduction in the dose of docetaxel may be needed for
patients who develop significant alterations in transaminases and
alkaline phosphatase during therapy.</li>
</ul></li>
<li>Cardiotoxicity
<ul>
<li>Hold both trastuzumab and pertuzumab if the LVEF drops to &lt;40% or
if the LVEF is 40-45% with a 10% or greater absolute decrease below
baseline.[4] Guidelines for managing cardiac dysfunction during therapy
with HER2-targeted agents are available.</li>
</ul></li>
<li>Pulmonary toxicity
<ul>
<li>Discontinue trastuzumab for serious pulmonary toxicity.</li>
</ul></li>
<li>Infusion reactions
<ul>
<li>Respond as clinically indicated with supportive care and possible
discontinuation of therapy for severe reactions.</li>
</ul></li>
<li>Cutaneous, mucosal, and neurologic toxicity
<ul>
<li>For severe or cumulative cutaneous reactions (erythema and
desquamation), grade 3 or 4 stomatitis, or moderate neurosensory signs
and/or symptoms, reduce docetaxel dose by 25%. Discontinue if toxicity
persists.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>As compared to the CT images taken on 2021-11-04, the CT images
taken on 2022-01-17 have revealed a partial response to the disease
under AC (doxorubicin + cyclophosphamide) regimen administrated during
early November 2021 to early January 2022</li>
<li>Currently, the patient receives THP (docetaxel + trastuzumab +
pertuzumab) since early March 2022.</li>
<li>Before the administration of the THP regimen, studies of the heart
(echocardiography, 2021-11-05) and lung (CT, 2022-01-17) have been
performed to obtain baseline information. Estimated LVEF 61% (based on
the echocardiography) and no obvious abnormal laboratory readings were
reported on 2022-03-23.</li>
</ul>
</div>
<div id="section-242" class="section level2">
<h2>220208</h2>
<p>[objective]</p>
<ul>
<li>Lab findings
<ul>
<li>2021-10 Patho - breast, right, core biopsy; lymph node, right
axillary, core biopsy
<ul>
<li>Invasive carcinoma, no special type, NST.</li>
<li>IHC stains (using lymph node tissue block S2021-14022):
<ul>
<li>ER (+, 90%, strong intensity),</li>
<li>PR (+, 90%, strong intensity, breast mass; +, 50%, strong intensity,
lymphonode biopsy),</li>
<li>Her2/neu: positive(score=3+),</li>
<li>Ki-67 (90%),</li>
<li>E-cadherin (+).</li>
</ul></li>
</ul></li>
</ul></li>
<li>Medication
<ul>
<li>2022-02 ~ ongoing docetaxel</li>
<li>2021-11 ~ 2022-01 AC (doxorubicin/cyclophosphamide)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>endocrine therapy e.g.tamoxifen might be preferred to aromatase
inhibitors</li>
<li>trastuzumab, pertuzumab might also be considered if no
contraindications</li>
</ul>
</div>
</div>
<div id="section-243" class="section level1">
<h1>700883303</h1>
<div id="section-244" class="section level2">
<h2>220415</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-07 CT - abdomen, pelvis
<ul>
<li>finding
<ul>
<li>Prior CT idenified multiple metastases on both hepatic lobe are
noted again, mild decreasing in size (the largest one measuring 13 cm
(the largest dimension) at S4 and residual right lobe at prior CT and
12.6 cm in current CT).</li>
<li>Prior CT identified multiple metastatic nodes in the celiac trunk,
hepatoduodenal ligament, mesentery and para-aortic space are noted
again, mild decreasing in size.</li>
</ul></li>
<li>impression
<ul>
<li>Multiple metastases on both hepatic lobes and multiple metastatic
nodes in the celiac trunk, hepatoduodenal ligament, mesentery and
para-aortic space S/P C/T show partial response.</li>
</ul></li>
</ul></li>
<li>2021-08-25 CT - abdomen, pelvis
<ul>
<li>finding
<ul>
<li>Prior CT idenified multiple metastases on both hepatic lobe are
noted again, mild decreasing in size (the largest one measuring 16.6 cm
in the largest dimension at S4 and residual right lobe at prior CT and
13 cm in current CT).</li>
<li>Prior CT identified multiple metastatic nodes in the celiac trunk,
hepatoduodenal ligament, mesentery and para-aortic space are noted
again, mild decreasing in size.</li>
</ul></li>
<li>impression
<ul>
<li>Multiple metastases on both hepatic lobes and Multiple metastatic
nodes in the celiac trunk, hepatoduodenal ligament, mesentery and
para-aortic space S/P C/T show partial response.</li>
</ul></li>
</ul></li>
<li>2021-05-21 MRA - brain
<ul>
<li>IMP: No evidence of brain metastasis. Old ischemic insults as
descibed. Intracranial artherosclerosis. General brain atrophy.</li>
</ul></li>
<li>2021-05-20 CT - abdomen, pelvis
<ul>
<li>IMP: Rectal cancer s/p operation. Right abdominal wall hernia. Mild
decreased size of liver and LNs metastases.</li>
</ul></li>
<li>2021-02-17 CT - abdomen, pelvis
<ul>
<li>Multiple metastases on both hepatic lobes and the largest one
measuring 16.6 cm at S4 and residual right lobe.</li>
<li>Multiple metastatic nodes in the celiac trunk, hepatoduodenal
ligament, mesentery and para-aortic space.</li>
</ul></li>
<li>2019-10-28 M-mode Echo
<ul>
<li>Dilated LA and LV; Mildly abnormal LV sytstolic function with global
hypokinesia</li>
<li>Septal hypertrophy</li>
<li>Trivial MR, mild AR, trivial TR and trivial PR</li>
<li>Preserved RV systolic function</li>
</ul></li>
<li>2019-10-24 CT - brain
<ul>
<li>Impression: Brain atrophy with old left basal ganalia lacunar brain
infarcts. Arteriosclerosis.</li>
</ul></li>
<li>2018-07-02 Whole body PET scan
<ul>
<li>At least five glucose hypermetablic lesions in both lobes of the
liver, rectal cancer with liver mets should be considered.<br />
</li>
<li>At least two glucose hypermetablic lesions in the LLQ and RLQ of
abdomen, rectal cancer with tumor seeding should be considered,
suggesting further investigation.</li>
<li>Mild glucose hypermetabolism in the mediastinal lymph node and left
SCF lymph node, reactive change may show such a picture.</li>
<li>Rectal cancer s/p treatment, cTxNxM1b-1c, stage IVB-IVC (AJCC, 8th
ed.), by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2018-06-28 CT - abdomen
<ul>
<li>S/P operation with liver metastases.</li>
<li>Gall stones (3-10mm).</li>
<li>Small bowel ileus.</li>
</ul></li>
<li>2018-06-15 CT - abdomen
<ul>
<li>Post-op at the colon and liver.</li>
<li>Liver metastasis.</li>
<li>Prominent soft tissue density in RLQ around the terminal ileum,
suspected tumor seeding. Suggest follow up.</li>
</ul></li>
<li>2018-02-20 CT - abdomen
<ul>
<li>Compatible with rectal cancer with liver meta s/p op. over liver and
rectum. No focal tumor is found.</li>
</ul></li>
<li>2017-11-15 Abdominal Ultrasonography
<ul>
<li>Diagnosis
<ul>
<li>Parenchymal liver disease</li>
<li>Possible liver cyst with calcification</li>
<li>Possible surgical artefact in liver dome</li>
<li>GB sludge ball with marked distention of GB</li>
<li>Poor postprandial contraction of GB, suggestive of obstruction of
GB</li>
</ul></li>
<li>Suggestion
<ul>
<li>Refer to GS for evaluation of cholecystectomy</li>
</ul></li>
</ul></li>
<li>2017-10-30 Abdominal Ultrasonography
<ul>
<li>GB stones with distended GB, with cholecystopathy; equivocal
echo</li>
<li>Murphy sign</li>
<li>Possible cystic duct stone</li>
<li>Dilated bilateral IHD</li>
<li>Suboptimal examination of liver and CBD</li>
<li>Parenchymal renal disease</li>
</ul></li>
<li>2017-10-29 CT - abdomen
<ul>
<li>Distal CBD stone (6mm) with biliary obstruction. Gall stones
(7-11mm).</li>
</ul></li>
<li>2017-07-28 CT - abdomen
<ul>
<li>Rectal CA wtih liver metastasis, s/p operation</li>
<li>Increased perirectal soft tissue.</li>
</ul></li>
<li>2017-07-06 CT - lung/pleura
<ul>
<li>Fracture of right clavicle, 4th-9th ribs with pneumothorax and
subcutaneous emphysema. Right hemothorax.</li>
<li>Gall stones (8-10mm).</li>
</ul></li>
<li>2017-04-21 Surgical pathology Level VI
<ul>
<li>pathological diagnosis
<ul>
<li>Large intestine, rectum, LAR  Adenocarcinoma, moderately
differentiated<br />
</li>
<li>Resection margins: Free of tumor</li>
<li>Lymph nodes, mesorectal, LAR  Metastatic adenocarcinoma
(4/34)<br />
</li>
<li>Liver, S7, S5 and S3, partial hepatectomy  Metastatic
adenocarcinoma (see path: S2017-05994)</li>
<li>Pathology stage: Stage IV (pT3N2aM1)</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology: Adenocarcinoma<br />
</li>
<li>Histology Grade: Moderately differentiated</li>
<li>Depth of invasion: Perirectal soft tissue</li>
<li>Angiolymphatic invasion: Present; Extramural venous invasion:
Present<br />
</li>
<li>Perineural invasion: Not identified<br />
</li>
<li>Discontinuous extramural tumor extension: Not identified<br />
</li>
<li>Circumferential (radial) margin of rectum: Uninvolved, 1.5 mm from
the margin</li>
<li>Lymph node metastasis, mesorectal: Metastatic adenocarcinoma
(4/34)</li>
<li>Extranodal involvement: Present<br />
</li>
</ul></li>
</ul></li>
<li>2017-04-21 Surgical pathology Level V
<ul>
<li>Liver, S7, S5, S3 &amp; S3, segmental hepatectomy + partial
hepatectomy  Metastatic adenocarcinoma, colorectal origin</li>
</ul></li>
<li>2017-04-18 M-mode Echo
<ul>
<li>Dilated LA and LV</li>
<li>Thick IVS and LVPW</li>
<li>Normal LV and RV contractility</li>
<li>LV Grade 1 diastolic dysfunction</li>
<li>Mild AR, mild MR</li>
</ul></li>
<li>2017-04-13 CT - abdomen
<ul>
<li>Rectal cancer with LNs and liver metastases</li>
<li>Cstage T3N2aM1a</li>
</ul></li>
<li>2017-04-06 Surgical pathology Level IV
<ul>
<li>Rectum, biopsy  Adenocarcinoma. IHC stain of EGFR (+).</li>
<li>IHC stains: PMS2 (+), MSH6 (+), using tissue block
(S2017-5995T1)</li>
</ul></li>
<li>2017-04-05 Colonoscopic polypectomy
<ul>
<li>Endoscopic examination of rectum and colon was done and the scope
has been inserted up to the level of cecum. One 8 mm Is polyp is noted
at A-colon 70 cm from anal verge, polypectomy done (A), another similar
lesion is seen at the 30 cm, polypectomy (B) done. An annular uclerative
tumor mass nearly occupying the whole circumferential lumen is noticed
at the rectum 7 cm to the anus, Bx done.</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2021-05-20 Neurology
<ul>
<li>The patient presented with acute left limbs weakness with right side
deviation of gait since 3 days ago. He denied limbs numbness, slurred
speech, facial asymmetry.</li>
<li>Impression
<ul>
<li>recurrent right subcortical stroke or left cerebellar stroke</li>
</ul></li>
<li>Suggestion
<ul>
<li>Arrange MRA brain with/without contrast, EKG</li>
<li>Keep bokey</li>
<li>Normal saline Hydration</li>
<li>Keep SBP&lt;220 or DBP&lt;120 mmHg in acute stroke</li>
<li>Check D-dimer for rule out Trousseaus syndrome.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemoimuunotherapy
<ul>
<li>2021-03-04 ~ undergoing - FOLFIRI + bevacizumab</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Recent CT images (2021-08-25, 2022-01-07) showed partial resonses,
however lab data showed elevated biomarker levels (CEA 1470ng/mL
2022-04-06 from 525 2021-09-29, CA199 1087U/mL 2022-04-07 from 465
2021-08-19).</li>
<li>Current chemotherapy regimen, FOLFIRI plus bevacizumab, has been in
use since 2021-03-04 and it should be still effective according to above
mentioned exam results.</li>
<li>Lab results on 2022-04-06 concerning liver function, renal function,
serum electrolytes, and blood cell counts were grossly normal.</li>
<li>Hypertension is one of the underlying health conditions that is well
managed based on the TPR records during this hospital stay with the
prescribed Sevikar (amlodipine + olmesartan).</li>
<li>Hyperlipidemia is also listed as a diagnosis and treated with
Crestor (rosuvastatin) currently, however, there is no follow up lab
data for more than six months. It is recommended that a blood lipid test
be performed.</li>
</ul>
</div>
<div id="section-245" class="section level2">
<h2>210621</h2>
<p>{Rectal Cancer}</p>
<p>[initial presentation]</p>
<ul>
<li>2017-04-07 tenesmus with bloody stool for more than 1 year.</li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2017-04-07 diagnosed with rectal cancer.</li>
</ul>
<p>[disease extent]</p>
<ul>
<li>2017-04-14 proved adenocarcinoma of low rectum with right liver
metastasis, cT3N2M1a, stage IVa, suggest LAR with protective ileostomy
and partial hepatectomy.</li>
<li>2017-04-21 pT3N2aM1(4/34), stage IVa, with rectal anastomotic leak
s/p debridement. RAS WT.</li>
<li>2018-07-05 PET showed liver metastases and may peritoneal seeding,
stage IVb-c</li>
</ul>
<p>[treatment]</p>
<ul>
<li>2017-06-23 mFOLFOX6 started</li>
<li>2017-08-18 hold chemotherapy due to chest contusion injury and
cholecystitis</li>
<li>2017-11-07 closure of colostomy on 2017-10-19</li>
<li>2018-02-27 refused adjuvant therapy</li>
<li>2021-03-04 Avastin with FOLFIRI Q2WK started</li>
</ul>
<p>[effect and side effect]</p>
<ul>
<li>2018-06-26 CT showed suspected liver metastases</li>
<li>2018-06-28 small bowel obstruction to ER</li>
<li>2021-02-17 CT, ABD:
<ul>
<li>Multiple metastases on both hepatic lobes and the largest one
measuring 16.6 cm at S4 and residual right lobe.</li>
<li>Multiple metastatic nodes in the celiac trunk, hepatoduodenal
ligament, mesentery and para-aortic space.</li>
</ul></li>
<li>2021-05-20 CT, ABD:
<ul>
<li>Rectal cancer s/p operation. Right abdominal wall hernia. Mild
decreased size of liver and LNs metastases.</li>
</ul></li>
<li>CEA (ng/mL)
<ul>
<li>2021-05-19 2259</li>
<li>2021-04-26 1870</li>
<li>2021-03-29 3623</li>
<li>2021-01-29 3951</li>
</ul></li>
<li>CBC 2021-05-21 WBC, RBC, PLT all in acceptable range.</li>
</ul>
<p>[ongoing problem]</p>
<p><thrombosis></p>
<p>Objective:</p>
<ul>
<li>2019-10-24 CT, Brain: Brain atrophy with old left basal ganalia
lacunar brain infarcts. Arteriosclerosis.</li>
<li>2021-05-21 MRA, Brain:
<ul>
<li>No evidence of brain metastasis. Old ischemic insults. Intracranial
artherosclerosis. General brain atrophy.</li>
</ul></li>
<li>2021-05-20 D-dimer 1291ng/mL(FEU)</li>
<li>bokey (aspirin, 100mg QD) in active medication.</li>
</ul>
<p>Assessment:</p>
<ul>
<li>biomarker hint increased probability of inappropriate blood
clots.</li>
<li>no related clinical symptom recorded.</li>
<li>Trousseaus syndrome not been concluded yet.</li>
</ul>
<p>Suggestion:</p>
<ul>
<li>keep following up clinical signs indicating the syndrome.</li>
</ul>
<p><hypertension></p>
<p>Objective:</p>
<ul>
<li>BP 141/93 at 10:55 on 06-21 (this is the only record for now during
this hospitalization)</li>
<li>sevikar (amlodipine 20mg, olmesartan 5mg) 0.5 tab QD in active
medication.</li>
</ul>
<p>Assessment:</p>
<ul>
<li>too few data points to tell the trend.</li>
<li>preliminary interpretation: BP still in acceptable range.</li>
</ul>
<p>Suggestion:</p>
<ul>
<li>keep monitor BP and collect more data points</li>
</ul>
<p><hyperlipdemia></p>
<p>Objective:</p>
<ul>
<li>Cholesterol total 110mg/dL (2020-07-08)</li>
<li>Triglyceride 51mg/dL (2020-07-08), 91mg/dL (2019-10-25)</li>
<li>crestor (rosuvastatin 10mg) QD in active medication.</li>
</ul>
<p>Assessment:</p>
<ul>
<li>gathered data showed the stable condition.</li>
<li>no new lab data since 2020 Aug.</li>
</ul>
<p>Suggestion:</p>
<ul>
<li>update lab data.</li>
</ul>
</div>
</div>
<div id="section-246" class="section level1">
<h1>700886156</h1>
<div id="section-247" class="section level2">
<h2>220425</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-02 ECG
<ul>
<li>Atrial fibrillation with rapid ventricular response</li>
<li>ST &amp; T wave abnormality, consider lateral ischemia</li>
</ul></li>
<li>2022-03-30 CT - lung/mediastinum/pleura
<ul>
<li>recurrent esophageal cancer with spinal metastasis, in
progresion.</li>
<li>post op change in RML and RUL.</li>
<li>small amount of pleural effusion, exudative, in regression.</li>
<li>dendritic change or old fibrosis at LLL and lingula</li>
</ul></li>
<li>2021-12-23 Chest PA erect view
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Pleura effusion of right and left costal-phrenic angle</li>
<li>S/P posterior instrumentation fixation at T-spine</li>
</ul></li>
<li>2021-12-22 SONO - chest
<ul>
<li>Pleural effusion, moderate, left</li>
<li>Atelectasis, RML, RLL and RUL</li>
</ul></li>
<li>2021-12-15 CT
<ul>
<li>Hemangioma or Metastasis 1.1 cm in S2/4 is highly suspected.</li>
</ul></li>
<li>2021-10-29 Patho - Interveterbral disc
<ul>
<li>T6 pathologic fx</li>
<li>Bone and joint, vertebra, T6 body, corpectomy - Neuroendocrine
carcinoma.</li>
<li>IHC: CK (+, intermediate intensity), S-100 protein (+), CK7 (-),
CK20 (-), CD117 (-), CD56 (+, intermediate intensity), p40 (-), TTF-1
(-). Ki-67: 20%.</li>
</ul></li>
<li>2021-10-23 MRI - T-spine
<ul>
<li>T5-6-7 metastases with thecal sac and spinal cord compression.</li>
</ul></li>
<li>2021-10-19 CT
<ul>
<li>recurrent esophageal cancer with spinal metastasis.</li>
<li>post op change in RML and RUL.</li>
<li>small amount of pleural effusion, exudative, in progression, and
nonspecific inflammation or fibrosis in left lower lung,
stationary.</li>
</ul></li>
<li>2021-04-20 CT
<ul>
<li>post op change in RML and RUL.</li>
<li>small amount of Rt pleura, exudative, post op change? and
nonspecific inflammation or fibrosis in left lower lung,
stationary.</li>
</ul></li>
<li>2021-01-19 CT
<ul>
<li>post op change in RML and RUL.</li>
<li>small amount of Rt pleura, exudative, post op change? and
nonspecific inflammation or fibrosis in left lower lung.</li>
</ul></li>
<li>2020-09-29 Patho - Lung wedge biopsy
<ul>
<li>Lung, RML, VATS pneumolysis+ RML wedge - necrotizing granuloma</li>
<li>IHC: CK7(-), TTF-1(+ at pneumocytes), Ki-67: &lt;10%.</li>
</ul></li>
<li>2020-09-28 Frozen section
<ul>
<li>Lung, RML, frozen section - Necrosis with focal atypia (reactive
change or AAH?)</li>
</ul></li>
<li>2020-09-03 CT
<ul>
<li>s/p esophagectomy with gastric tube reconstruction.</li>
<li>Tiny nodular lesion at right middle lobe, suspected lung meta.</li>
</ul></li>
<li>2020-06-02 CT
<ul>
<li>new RML nodules, favor metastatic lesions.</li>
<li>residual small amount of Rt pleura and nonspecific inflammation in
left lower lung.</li>
</ul></li>
<li>2019-07-09 CT
<ul>
<li>Pleura effusion, stationary and increased volume of pericardial
effusion.</li>
<li>post op change in RLL and nonspecific inflammation in left lower
lung, stationary.</li>
<li>No abnormal soft-tissue mass or LAP in the mediastinum.</li>
</ul></li>
<li>2018-03-29 Whole body PET scan
<ul>
<li>In comparison with the previous study on 2017-04-17, the glucose
hypermetabolic lesion between the descending aorta and the thoracic
spine is more prominent. Recurrent malignancy should be considered.</li>
<li>Glucose hypermetabolism in the right supraclavicular fossa. The
nature is to be determined (metastatic lesion? other nature?).</li>
<li>Glucose hypermetabolism in both lobes of the thyroid gland and left
cricoarytenoid area. The nature is to be determined (inflammation? other
nature?).</li>
</ul></li>
<li>2017-03-27 Surgical pathology Level V
<ul>
<li>Lung, RLL, wedge resection - Squamous cell carcinoma x 3, poorly
differentiate (G3), metastatic<br />
</li>
<li>IHC:
<ul>
<li>the large tumor reveal CK5/6(+), p40(weak +), p63(+), and
TTF-1(-).<br />
</li>
<li>the 2 small tumors reveal p40(+), CD56(-), and TTF-1(-).</li>
</ul></li>
</ul></li>
<li>2017-03-15 CT
<ul>
<li>Indication: Esophageal cancer, M/3, squamous cell carcinoma,
cT2N2M0, with Rt paratracheal and subcarinal LAP metastasis, Rt vocal
cord paralysis, s/p PortA on 2016-01-15, s/p CCRT since 2016-01-21 to
2016-03-03 s/p esophagectomy &amp; LN dissection on 2016-04-23, ypT3N0
(cM0) with involved circumferential (adventitial) margin s/p
fistulectomy on 2016-06-17.</li>
<li>s/p esophagectomy and gastric tube reconstruction.</li>
<li>A RLL nodule, recurrent tumor in lung?</li>
<li>Inflammation in LLL-basal segments.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-28
<ul>
<li>Surgery
<ul>
<li>Esophagal cancer with T5-6-7 spinal metastasis; tumor excision and
ant/ post fixation; Modified LECA approach</li>
</ul></li>
<li>Finding
<ul>
<li>Esophageal tumor s/p previous op.</li>
<li>T5-6-7 metastastic tumor with T6 pathologic fracture/ epidural
circumferential cord compression, more at anterolateral area;</li>
<li>Circumferential epidural tumor 3x3x3cm caused severe cord
compression;</li>
</ul></li>
</ul></li>
<li>2020-09-28
<ul>
<li>Surgery
<ul>
<li>VATS pneumolysis + RML wedge</li>
</ul></li>
<li>Finding
<ul>
<li>severe intra-pleura cavity adhesion due to previous RLL wedge for
esophagus SCC metastasis</li>
<li>one nodule about 1cm with caseating granuloma and calcification was
found in RML</li>
<li>Estimated blood loss: 150mL.</li>
<li>one 20 Fr.straight chest tubes were inserted via right 7th
ICS.</li>
</ul></li>
</ul></li>
<li>2019-07-29
<ul>
<li>Diagnosis
<ul>
<li>Pericardial effusion</li>
</ul></li>
<li>PCS code
<ul>
<li>68049B</li>
</ul></li>
<li>Finding
<ul>
<li>Moderate serosangious pericardial effusion was noted about
300mL.</li>
<li>One 14 Fr.pig-tail was inserted via left 7th ICS.</li>
</ul></li>
</ul></li>
<li>2017-03-27
<ul>
<li>Diagnosis
<ul>
<li>RLL lung nodule</li>
</ul></li>
<li>PCS code
<ul>
<li>67051B</li>
</ul></li>
<li>Finding
<ul>
<li>One firm nodular lesion was noted over RLL, size about 1.5cm in
diameter.</li>
<li>One 28 Fr.straight chest tube was inserted via right 8th ICS.</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2018-04-12 ~ 2018-05-07: 4500cGy/18 fractions (15 MV photon) to
para-T6 tumor (part of CCRT)</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-04-22 - PFL (cisplatin + 5-Fu + leucovorin)</li>
<li>2021-12-16 ~ 2022-03-29 - cisplatin + etoposide</li>
</ul></li>
<li>consultation
<ul>
<li>2021-12-21 Thoracic Medicine
<ul>
<li>Q
<ul>
<li>This 74-yrear-old man patient is a case of Esophageal cancer, M/3,
squamous cell carcinoma, cT2N2M0, with Rt paratracheal and subcarinal
LAP metastasis, Rt vocal cord paralysis, s/p PortA on 20160115, s/p CCRT
since 20160121 to 20160303 s/p esophagectomy &amp; LN dissection on
20160423, ypT3N0 (cM0) with involved circumferential (adventitial)
margin s/p fistulectomy on 20160621 with lung metastasis s/p resection
on 201703 s/p adjuvant C/T, last on 20180108 with 2nd mediastinum
relapse in 201803 s/p salvage RT on 20180507.</li>
<li>Pericardial effusion s/p Thoracoscopic Pericardial Window and
Pneumonolysis, extrapleural.</li>
</ul></li>
<li>A
<ul>
<li>I was consulted wheezing and suspected COPD of the patient</li>
<li>objective
<ul>
<li>PFT in 2017: normal screening, no further data</li>
<li>CXR cardiomegaly and left PE</li>
<li>Fibroreticular infiltration in right lung field</li>
<li>Mediastinum widening</li>
<li>Diffuse pleural thickening was found bilaterally, especially on
right</li>
</ul></li>
<li>assessment
<ul>
<li>recurrent esophageal ca with multiple mets</li>
<li>suspected COPD</li>
<li>restrictive lung ventilatory defect was suspected for bilateral
irregularly thickened pleurae</li>
</ul></li>
<li>plan
<ul>
<li>keep current bronchodilator nebulization</li>
<li>inform high risk of acute respiratory failure, plan of further
tx?</li>
<li>sputum AFS/TB cultures x 3 days</li>
<li>chest echo for left pleural effusion if dyspnea</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-11-03 ENT
<ul>
<li>Q: Current problem:
<ul>
<li>Tinnitus since 2021-10-29.</li>
<li>Post-op wound suspected CSF leakage. Remove drain on
2021-10-30.<br />
</li>
<li>We will give AcetaZOLAMAX 250 mg/tab (AcetaZOLAMIDE) and Diphenidol
S.C 25mg/tab use.</li>
<li>We need your expertise for further management.</li>
</ul></li>
<li>A
<ul>
<li>L&gt;R pulsatile tinnitus for 3 days.</li>
<li>PE:
<ul>
<li>Ear drum: bil intact, L ear drum atrophic scar</li>
<li>EAC: clean</li>
<li>Bedside scope: smooth NPx, OPx, HPx</li>
</ul></li>
<li>Tymp:
<ul>
<li>Rt type A; Lt type A with round peak.</li>
</ul></li>
<li>ART: Bil absent.</li>
<li>PTA:
<ul>
<li>Average RE 49 dB HL; LE 79 dB HL.</li>
<li>Rt normal to severe SNHL.</li>
<li>Lt moderately severe to profound mixed type HL.</li>
</ul></li>
<li>Suggestion:
<ul>
<li>keep current Betahistine 1# BID</li>
<li>ENT OPD follow up for PTA and hearing aid evaluation</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-11-01 Rehabilitation
<ul>
<li>Q
<ul>
<li>This 73-year-old patient has past history of
<ul>
<li><ol style="list-style-type: decimal">
<li>Coronary artery disease,</li>
</ol></li>
<li><ol start="2" style="list-style-type: decimal">
<li>Hypertension,</li>
</ol></li>
<li><ol start="3" style="list-style-type: decimal">
<li>Enlarged prostate with lower urinary tract symptoms,</li>
</ol></li>
<li><ol start="4" style="list-style-type: decimal">
<li>Gout,</li>
</ol></li>
<li><ol start="5" style="list-style-type: decimal">
<li>Middle third esophageal squamous cell carcinoma with lung metastasis
pathology stage: Stage IV, pT3N0M1 s/p CCRT,</li>
</ol></li>
<li><ol start="6" style="list-style-type: decimal">
<li>Hypothyroidism,</li>
</ol></li>
<li><ol start="7" style="list-style-type: decimal">
<li>AF,</li>
</ol></li>
<li><ol start="8" style="list-style-type: decimal">
<li>Hyperlipidemia,</li>
</ol></li>
<li><ol start="9" style="list-style-type: decimal">
<li>Right middle lobe lung nodule status post-video-assisted thoracic
surgery pneumolysin and right middle lung wedge resection on
2020-09-28.<br />
</li>
</ol></li>
</ul></li>
<li>He was a regular follow-up at our OPD. This time, he suffered from
left leg clumsiness and weakness for two weeks. Mild lower chest pain.
He was being referred from Oncology OPD. T-spine MRI with/without
contrast showed T5-6-7 metastases with thecal sac and spinal cord
compression. After discussing with the patient and his family surgical
risk. He was admitted for surgical intervention. Esophagal cancer with
T5-6-7 spinal metastasis post tumor excision and posterior fixation on
20211028. Post-operative course was uneventful. His discomfort was
relieved a lot.</li>
<li>Current problem:
<ul>
<li>Chest pain improve.</li>
<li>He complaint still left leg clumsiness and weakness.</li>
<li>Muscle power: Upper limbs: Rt 5 Lt 5; Lower limbs: Rt 5 Lt 4-5</li>
<li>Gait: unstable gait. Need use a walker to walk.</li>
</ul></li>
<li>We need your expertise for physical therapy.</li>
</ul></li>
<li>A
<ul>
<li>MP:
<ul>
<li>upper limbs 5/5</li>
<li>lower limbs</li>
<li>Quadriceps R/L 5/4</li>
<li>Knee extensors R/L 5/4</li>
<li>Ankle dorsiflexors R/L 4/4</li>
<li>Ankle plantar flexors R/L 4/4</li>
<li>toe extensors 4/4</li>
<li>BADL: max A</li>
<li>ambulation: now walker with min A</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: GYM PT + OT rehabilitation programs</li>
<li>Goal: recondition, improve endurance and muscle strength</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>After receiving etoposide + cisplatin since December 2021, the
patients chemotherapy regimen has been changed to 5-FU + cisplatin
since this hospitalization following 2022-03-30 CT evidence of
progression. The new regimen is generally tolerated by the patient.</li>
<li>A variety of underlying diseases such as coronary artery disease,
hypertension, enlarged prostate, lower urinary tract symptoms, gout,
hypothyroidism, AF, and hyperlipidemia are currently treated with
appropriate medications.</li>
<li>Lab data on 2022-04-20, liver and kidney functions, serum
electrolytes and blood cell counts were grossly normal, except decreased
WBC level of 2780/uL (neutrophil 58%) which should be noted.</li>
</ul>
</div>
<div id="section-248" class="section level2">
<h2>220330</h2>
<p>[assessment]</p>
<ul>
<li>No updated images for this patient since last hospital stay. Lab
data reported on 2022-03-29 indicated that the CBC readings were below
normal ranges and CEA (6.02 ng/mL), SCC (1.7 ng/mL) were above normal
ranges.</li>
<li>EP (etoposide + cisplatin) has been administered since December 2021
for his neuroendocrine carcinoma, and the patient has no intolerance
during this hospitalization according to nursing note.</li>
<li>Pembrolizumab can be considered for patients with dMMR/MSI-H or
advanced tumor mutational burdenhigh (TMB-H) tumors that have progressed
following prior treatment and have no satisfactory alternative treatment
options.</li>
<li>In the event hypothyroidism remains a diagnosis (no updated lab data
found since 2022), then levothyroxine (Eltroxin) might be
considered.</li>
</ul>
</div>
<div id="section-249" class="section level2">
<h2>220302</h2>
<p>[assessment]</p>
<ul>
<li>EP (etoposide + cisplatin) is applied since Dec 2021 and the patient
tolerates the treatment during this hospitalization.</li>
<li>if somatostatin receptor (SSR) is proved positive, then octreotide
or lanreotide might be an optional add-on.</li>
</ul>
</div>
</div>
<div id="section-250" class="section level1">
<h1>700890235</h1>
<div id="section-251" class="section level2">
<h2>210727</h2>
<p>{coadministration of Decan and Juluca}</p>
<p>[objective]</p>
<ul>
<li>active medication include
<ul>
<li>Decan (dexamethasone) 6mg IVD QD</li>
<li>Juluca (dolutegravir 50mg, rilpivirine 25mg) 1 tab PO QNCC</li>
</ul></li>
<li>lab data on 2021-07-22 showed lower lymphocyte percentage, however
other items were within normal range:
<ul>
<li>WBC 9.20*10^3/uL</li>
<li>Lymphocyte 14.3%</li>
<li>Lymphocyte count 1320/uL</li>
<li>CD3+/CD4+ Helper T 31.7%</li>
<li>CD3+/CD4+ Helper T C 418/uL</li>
<li>CD3+/CD8+ Suppre T 31.8%</li>
<li>CD3+/CD8+ Suppre T C 419/uL</li>
<li>CD4/CD8 Ratio 1.0</li>
<li>T Cells (CD3) 61.9%</li>
<li>B Cells (CD19) 9.7%</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>rilpivirine prescribing information lists coadministration with
multiple-dose dexamethasone as contraindicated due to a risk of
decreased rilpivirine concentrations and loss of virologic
response.</li>
<li>the presumed primary mechanism of interaction between these agents
is dexamethasone induction of CYP3A4 mediated rilpivirine
metabolism.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please keep monitoring virologic responses.</li>
</ul>
</div>
</div>
<div id="section-252" class="section level1">
<h1>700906364</h1>
<div id="section-253" class="section level2">
<h2>220420</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-15 CT - chest
<ul>
<li>recurrent left lung and pleural metastases.</li>
</ul></li>
<li>2021-09-01 CT - chest
<ul>
<li>no new lung nodule.</li>
</ul></li>
<li>2021-05-06 CT - chest
<ul>
<li>s/p left upper lobe and left lower lobe op.</li>
<li>no evidence of recurrent tumor in the study.</li>
</ul></li>
<li>2020-12-30 Patho - lung wedge biopsy
<ul>
<li>pathologic diagnosis
<ul>
<li>Lung, left upper lobe (frozen section specimen), wedge  Metastatic
colorectal adenocarcinoma<br />
</li>
<li>Lung, left lower lobe, wedge  Metastatic colorectal
adenocarcinoma<br />
</li>
<li>Lymph nodes, LN 9, dissection  Negative for malignancy (0/3)<br />
</li>
<li>Parietal pleura, biopsy  Metastatic colorectal adenocarcinoma</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Tumor Focality: Multiple tumors over LUL, LLL, and parietal
pleura<br />
</li>
<li>Histologic Type: Metastatic colorectal adenocarcinoma<br />
</li>
<li>Spread Through Air Spaces (STAS): Not identified<br />
</li>
<li>Visceral Pleura Invasion: Present<br />
</li>
<li>Lymphovascular Invasion: Present<br />
</li>
<li>Lymph nodes, LN 9: Negative for metastatic carcinoma (0/3)<br />
</li>
<li>IHC for tumor cells: CK7(-), CK20(+), and CDX2(+)</li>
</ul></li>
</ul></li>
<li>2020-12-29 Frozen resection
<ul>
<li>Lung, LUL, frozen section  Adenocarcinoma, compatible with
metastatic colorectal carcinoma</li>
</ul></li>
<li>2020-12-11 CT - chest
<ul>
<li>Left upper lobe and left lower lobe nodules. suspected lung
mets.</li>
<li>Focal Pleural thickening. suspected pleural seeding.</li>
</ul></li>
<li>2020-12-01 CT - abdomen
<ul>
<li>Left basal lung nodules. Nature? Suggest chest CT</li>
</ul></li>
<li>2020-09-01 CT - abdomen
<ul>
<li>Post-op at the colon.</li>
<li>Right adrenal tumor, suggest follow up.</li>
<li>Uterine tumor, suspected myoma.</li>
</ul></li>
<li>2019-12-30 CT - abdomen
<ul>
<li>Rectal cancer s/p operation. No evidence of tumor recurrence.</li>
</ul></li>
<li>2018-08-13 CT - abdomen
<ul>
<li>Status post LAR with stable condition.</li>
</ul></li>
<li>2017-08-31 CT - abdomen
<ul>
<li>Rectal cancer s/p operation. No evidence of tumor recurrence.</li>
</ul></li>
<li>2017-03-18 CT - abdomen
<ul>
<li>Rectal CA, s/p operation. No evidence of tumor recurrence</li>
</ul></li>
<li>2013-end pathology
<ul>
<li>adenocarcinoma, metastatic (7/34)</li>
<li>pathology stage: pStage IIIC, pT3N2b(cMx),</li>
<li>IHC stain of EGFR: weak positive on 30% to 40% of the neoplastic
glands.</li>
</ul></li>
<li>2013-11-29 CT - abdomen
<ul>
<li>rectal cancer with LNs &amp; lung mets (T2N1M1a)</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-12-29 VATS, LUL and LLL wedge + lymph node sampling
<ul>
<li>multiple scattered whitish to translucent nodules about 5mm~10mm on
visceral and parietal pleura suspected rectal metastasis parietal
biopsy, LLL wedge biopsy and lymph node sampling</li>
<li>a volcano like solid nodule about 1.5cm in diameter in LUL S1
segment after wedge biopasy</li>
</ul></li>
<li>2013-12-24 Laparoscopic LAR + Thoracoscopic wedge or Partial
resection of the Lung</li>
</ul></li>
<li>radiotherapy
<ul>
<li>early 2014</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-03-08 ~ undergoing - FOLFOX</li>
<li>2021-02-01 ~ 2021-07-27 - FOLFIRI plus bevacizumab</li>
<li>2021-01-18 - FOLFIRI</li>
<li>2014-04-03 ~ 2014-10-07 - PF, post CCRT adjuvant, 12 cycles</li>
<li>2014-02-10 ~ 2014-03-13 - 5-Fu based</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient diagnosed with rectal cancer with LNs and lung mets in
late 2013, recurrence monitored in late 2020, patient receives FOLFIRI
(plus bevacizumab) from 2021-02-01 to 2021-07-27, following VATS, LUL
and LLL on 2020-12-29, and recurrence detected again in early 2022. She
is currently treated with FOLFOX since 2022-03-08.</li>
<li>Lab data reported on 2022-04-19 revealed that liver and kidney
function, serum electrolytes, and blood cell counts were generally
normal. The nursing note does not indicate any intolerances so far since
this hospitalization.</li>
<li>Depending on the patients financial situation and there are no
contraindications, targeted and/or immunotherapy treatments might also
be considered.</li>
</ul>
</div>
</div>
<div id="section-254" class="section level1">
<h1>700909334</h1>
<div id="section-255" class="section level2">
<h2>220415</h2>
<p>{tube feeding}</p>
<ul>
<li>All the oral drugs can be administered with a nasogastric tube.</li>
<li>The coadministration of fentanyl, diphenhydramine, and estazolam may
enhance the CNS depressant effect, please observe for signs of slowed or
difficult breathing, and/or sedation.</li>
</ul>
</div>
</div>
<div id="section-256" class="section level1">
<h1>700926086</h1>
<div id="section-257" class="section level2">
<h2>220215</h2>
<p>[objective]</p>
<ul>
<li>Exam findings
<ul>
<li>2022-02-11 CT
<ul>
<li>Prior CT identified few small LNs at para-aortic space and bil.
inguinal regions show stationary.</li>
</ul></li>
<li>2021-11-08 MRI
<ul>
<li>Cervical spondylosis with diffuse spinal canal stenosis, cord
compression and neuroforaminal narrowing, esp C3-4 with compressive
myelopathy.</li>
</ul></li>
<li>2021-10-29 PET
<ul>
<li>Lymphoma of low FDG uptake involving multiple lymph nodes on both
sides of the diaphragm and bone marrow may show this picture (stage
IV).</li>
<li>Increased FDG uptake in the soft tissues around bilateral hips.
Inflammation is more likely.</li>
</ul></li>
<li>2021-10-20 Patho - bone marrow biopsy
<ul>
<li>Diagnosis
<ul>
<li>Bone marrow, iliac, biopsy  Lymphoma, B cell type</li>
<li>IHC:
<ul>
<li>CD3 and CD20: a predominant small sized B lymphoid cells
subpopulation;</li>
<li>CD138: 50%;</li>
<li>kappa and lambda: approximately 2:1.</li>
<li>bcl-2 (+, 90%) bcl-6 (-) (of the nucleated cells).</li>
<li>Serum immunoglobin levels show evelated both IgG and IgM
levels.</li>
<li>KI-67: marked variation from areas to areas ranging 5% to 60% and
averaing 20% to 25%.</li>
</ul></li>
</ul></li>
<li>Microscopic
<ul>
<li>Section shows piece(s) of bone marrow with 100 % cellularity a mixed
small lymphocytes subpopulation and plasmacytoid cell
subpupulation.</li>
<li>The bone marrow findings in conjunction with serum immunoglbulin
levels is suggestive of B cell lymphoma, small B cell type, or
lymphoplasmacytoid cell type. Probably a polyclonal Waldemstrom-like
lymphoma.</li>
</ul></li>
</ul></li>
<li>2021-07-24 CT
<ul>
<li>Minimal opacity over B6 (superior segment) of right lower lobe,
right middle lobe, and left upper lobe is found.</li>
<li>Small lymph nodes at bilateral axillary, supraclavicular and
abdominal paraaortic region.</li>
</ul></li>
<li>2020-10-23 MRA - Brain
<ul>
<li>Mild general brain atrophy. Subcortiacl arteriosclerotic
encephalopathy.</li>
</ul></li>
<li>2020-10-05 Clinical Dementia Rating (CDR)
<ul>
<li>Score 1</li>
</ul></li>
<li>2020-09-19 CT
<ul>
<li>Small LNs at retroperitoneum, bil. axillary and bil. inguinal
regions.</li>
</ul></li>
<li>2020-09-01 Patho - bone marrow biopsy
<ul>
<li>Diagnosis
<ul>
<li>Bone marrow, iliac, biopsy - Proliferation of lymphoplasmacytic
cells.</li>
<li>IHC:
<ul>
<li>CD20 (80-90%);</li>
<li>CD138 (weak intensity, approximately 50%);</li>
<li>kappa and lambda: no predominant subpopulation.</li>
<li>CD3: &lt;10%. (of the nucleated cells).</li>
</ul></li>
<li>The possibility of lymphoplasmycitc lymphoma/ Waldenstrm
macroglobulinemia (WM) cannot be excluded.</li>
</ul></li>
<li>Microscopic
<ul>
<li>Section shows one piece of bone marrow with 90% cellularity and M:E
ratio of approximately 5:1.</li>
<li>Three cell lineages are present with a predominant of
leukocytes.</li>
</ul></li>
</ul></li>
</ul></li>
<li>Chemotherapy
<ul>
<li>2021-11-16 ~ up to now: R-CVP (rituximab, cyclophosphamide,
vincristine, prednisone)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>the most updated NCCN clinical practice guidelines for B-Cell
Lymphomas (evidence blocks, version 5.2021 - Sep 22, 2021) suggests
small cell testing panel: CD5, CD10, CD21, CD23, cyclin D1, BCL2, BCL6,
Ki-67, CD11c, CD25, CD103 for differential diagnosis. not all items
found in patho records.</li>
<li>lab data reported on 2022-02-14 revealed no abnormality of liver and
kidney functions.</li>
<li>CT on 2022-02-11 showed stable LNs at para-aortic space and bil.
inguinal regions.</li>
<li>involved-site RT (ISRT) might not be indicated for the stage IV
disease.</li>
<li>the patient is on R-CVP regimen which is recommend in the
guidelines. R-CHOP (rituximab, cyclophosphamide, doxorubicin,
vincristine, prednisone) might be an alternative.</li>
<li>no drug allergy recorded in database. no issue with current
medication.</li>
</ul>
</div>
</div>
<div id="section-258" class="section level1">
<h1>700935936</h1>
<div id="section-259" class="section level2">
<h2>999999</h2>
<p>{rectal cancer}</p>
<ul>
<li>rectal cancer s/p LAR, pT3N0M0, stage IIA</li>
</ul>
<p>[initial presentation]</p>
<ul>
<li>2019/2020 bowel habit change, bloody stool, mucus stool,
tenesmus</li>
<li>2020 2nd half iFOBT(+)</li>
<li>2020-10-29 colonscopy showed one mass in the rectum 10cm from anal
verge</li>
</ul>
<p>[definite diagnosis]</p>
<ul>
<li>2020-11-04 patho outcome
<ul>
<li>adenocarcinoma: section shows pieces of colonic tissue with invasive
irregular neoplastic glands.</li>
<li>IHC stains: EGFR (+); PMS2 (+), MSH6 (+), MSH2(+), MLH1 (+).</li>
</ul></li>
<li>2020-12-17 NRAS/KRAS not detected.</li>
</ul>
<p>[disease extent &amp; staging]</p>
<ul>
<li>2020-11-04 CT, ABD: cT3N2aM1a, IVA
<ul>
<li>there is soft tissue nodule in LLL of the lung.</li>
<li>there is a suspicious soft tissue nodule in RLL of the lung.</li>
</ul></li>
<li>2020-11-23 patho: pT3N0, stage IIA (if cM0)
<ul>
<li>Histology: Adenocarcinoma</li>
<li>Histology Grade: G2: moderately differentiated</li>
<li>Angiolymphatic invasion: present</li>
<li>Perineural invasion: present</li>
<li>LLL nodule, frozen section: intrapulmonary lymph node (0/1) with
anthracosis</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2020-11-18 3D VATS wedge resection
<ul>
<li>one nodular lesion was noted over LLL, size about 0.5cm in
diameter.</li>
<li>frozen section showed benign lesion.</li>
</ul></li>
<li>2020-11-18 Robotic-assist low anterior resection</li>
<li>2020 Dec CCRT 4320cGy/24 with 5FU(400mg/m2)/LV(20mg/m2)</li>
<li>2021 Jan CCRT 5400cGy/30 with 5FU(400mg/m2)/LV(20mg/m2)</li>
<li>2021 Feb thereafter biweekly FOLFOX</li>
<li>2021-06-01 CT: no evidence of recurrent/residual tumor in the
study.</li>
</ul>
<p>[effect &amp; side effect]</p>
<ul>
<li>updated CT on 2021-06-01 shows current treatment still works</li>
<li>no side effect graded more than CTCAE grade 1 is found</li>
<li>active medication reviewed without issue:
<ul>
<li>metoclopramide, prophylaxis or treatment of nausea and vomiting
associated with emetogenic cancer chemotherapy</li>
<li>clonazepam, for anxiety disorder or rapid eye movement sleep
behavior disorder</li>
<li>sennoside, laxative/stimulant for constipation</li>
<li>acetylcysteine, mucolytic agent</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>suspected covid-19 resolved
<ul>
<li>2021-05-25 rapid test positive</li>
<li>2021-05-26 real-time pcr negative</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-260" class="section level1">
<h1>700936681</h1>
<div id="section-261" class="section level2">
<h2>220425</h2>
<ul>
<li>exam finding
<ul>
<li>2022-03-18 ENT Hearing Test
<ul>
<li>PTA</li>
<li>Reliability FAIR</li>
<li>Average RE &gt;120 dB HL; LE 55 dB HL.</li>
<li>RE profound SNHL</li>
<li>LE mild to profound SNHL</li>
</ul></li>
<li>2022-03-17 MRI - nasopharnyx
<ul>
<li>Right IAC and CPA tumor, stationary as compared with MRI on
20223015. Metastatic LAP with ENE at right neck.</li>
</ul></li>
<li>2022-03-15 MRI - brain
<ul>
<li>Right CP angle and IAC mass, regressed size and perifocal edema,
when compared with 20220108 MRI.</li>
<li>Mild Brain atrophy with bilateral periventricular ischemic/aging
white matter change.</li>
</ul></li>
<li>2022-01-08 MRI - posterior fossa, brain stem
<ul>
<li>A multi-lobuled lesion in the right IAC and right CPA with severe
mass effect on the right brain stem, marked increase in size.</li>
</ul></li>
<li>2022-01-03 Tc-99m MDP whole body bone scan
<ul>
<li>A hot spot in the left aspect of the maxilla, the nature is to be
determined (dental problem or other nature?), suggesting follow-up with
bone scan in 3-6 months for investigation.</li>
<li>Suspected benign lesions in the mandible, some C-, T- and L-spine,
right sternoclavicular junction, bilateral shoulders, S-I joints, and
hips.</li>
</ul></li>
<li>2021-10-06 SONO - abdomen
<ul>
<li>There are several hepatic cysts in right lobe and the largest one
measuring 1 cm in size at segment 8.<br />
</li>
<li>A renal cyst 1.35 cm on right kidney middle pole is noted.</li>
</ul></li>
<li>2021-06-30 MRI - posterior fossa, brain stem
<ul>
<li>Right CP angle and IAC mass, slightly regressed size DDx: Neuroma,
meningioma or metastasis.</li>
<li>Mild Brain atrophy with bilateral periventricular ischemic/aging
white matter change.</li>
</ul></li>
<li>2020-12-30 MRI - brain
<ul>
<li>Tumor at right CPA and IAC. Mild enlargement as compared with MRI on
20201126. Suspected metastasis. Meningioma or Schwannoma is less
likely.</li>
</ul></li>
<li>2020-11-26 SONO - abdomen
<ul>
<li>Right liver cysts and calcification. Left renal cyst and bil. renal
stones.</li>
</ul></li>
<li>2020-11-26 MRI - nasopharynx
<ul>
<li>C/W NPC s/p treatment without local recurrence, but with a
metastatic lesion involving right IAC and CPA</li>
</ul></li>
<li>2020-04-15 SONO - abdomen
<ul>
<li>There are several hepatic cysts in right lobe and the largest one
measuring 1.08 cm in size at segment 8.</li>
<li>A renal cyst 1.27 cm on right kidney middle pole is noted.</li>
</ul></li>
<li>2020-04-15 MRI - nasopharynx
<ul>
<li>C/W NPC s/p treatment without evidence of recurrence. An enhancing
lesion in right IAC and cochlea. Suspected post-RT neuropathy.
Metastasis is unlikely. Stationary as compared with previous MRIs.</li>
</ul></li>
<li>2019-09-26 MRI - liver, spleen
<ul>
<li>Post RT change of right lobe liver.</li>
<li>Hepatic simple cysts.</li>
</ul></li>
<li>2019-05-20 MRI - nasopharynx
<ul>
<li>C/W NPC s/p treatment with complete remission and no evidence of
recurrence. Stationary as compared with MRI on 20190108.</li>
</ul></li>
<li>2019-05-20 SONO - abdomen
<ul>
<li>Liver cysts.</li>
<li>Right renal stone.</li>
<li>Right renal cyst.</li>
</ul></li>
<li>2019-01-08 MRI - nasopharynx
<ul>
<li>Right NPC, post CCRT. No evidence local recurrent tumor. No neck
LAP.</li>
</ul></li>
<li>2019-01-08 SONO - hepatobiliary
<ul>
<li>There are several hepatic cysts in right lobe and the largest one is
measured about 0.91 cm in size at segment 8.<br />
</li>
<li>A renal cyst 1.33 cm on right kidney middle pole is noted.</li>
</ul></li>
<li>2018-09-05 Whole body PET scan
<ul>
<li>In comparison with the previous study on 20180118, the glucose
hypermetabolic tumor in the liver dome had disappeared in this study,
suggesting response to current treatment.</li>
<li>Glucose hypermetabolism in the right alveolar process of the maxilla
had been stationary since the previous study, suggesting benign
conditions such as dental inflammatory lesion.</li>
<li>Moderate glucose hypermetabolism in bilateral pulmonary hilar lymph
nodes, reactive change in response to locoregional inflammation may show
such a picture. Please correlate with clinical findings and keep
follow-up, however, to exclude the possibility of more significant
clinical problems.</li>
</ul></li>
<li>2018-08-21 MRI - upper abdomen
<ul>
<li>Liver metastasis in segment 4/8 dome Status post R/T with
inflammatory fibrosis is highly suspected.</li>
</ul></li>
<li>2018-05-21 CT - abdomen
<ul>
<li>Much regression of liver dome lesion.</li>
</ul></li>
<li>2018-01-24 CT - abdomen
<ul>
<li>A poor enhancing nodule (1.7cm) at liver dome c/w metastases.</li>
</ul></li>
<li>2012-07-12 Pathology
<ul>
<li>Nasopharynx, right: Non-keratinizing carcinoma, undifferentiated
(WHO-2B).</li>
</ul></li>
</ul></li>
<li>history
<ul>
<li>Hepatitis B carrier</li>
<li>Acoustic neuroma</li>
<li>NPC</li>
<li>Liver metastasis s/p SBRT on 20180209</li>
<li>R/I recurrence of NPC by surgical excision at TuCheng ChangGung
Hospital on 2022-01-21 by vice president Dr.Wei FuQuan.
<ul>
<li>Pathology: Brain, CP angle, Rt, carcinoma, metastatic.</li>
<li>Positive: AE1/AE3, EMA, p40; negative EBV, Hep-par-1, PR, S100; Ki67
100%.</li>
<li>Plan: Refer to LK-CGMH for evaluation of proton therapy.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>TuCheng ChangGung Hospital</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2018-01-30 ~ 2018-02-09 5000cGy/5 fractions (6 MV photon) to
metastatic tumor at liver dome</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-18 ~ undergoing - 5-Fu + cisplatin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>For nonkeratinizing and/or undifferentiated histology, consider
testing for EBV in tumor and blood. The EBV DNA load may reflect
prognosis and change in response to therapy.</li>
<li>Stereotactic proton radiosurgery might be effective in treating
brain metastases. reference: Proton Stereotactic Radiosurgery for Brain
Metastases. <a href="https://pubmed.ncbi.nlm.nih.gov/29976494/" class="uri">https://pubmed.ncbi.nlm.nih.gov/29976494/</a></li>
<li>5-Fu plus cisplatin has been the current regimen since 2022-03-18.
PD-1 inhibitors (e.g.pembrolizumab or nivolumab) might be an additional
treatment option for cancers that are recurrent, unresectable, or
metastatic (without surgery or radiation therapy).</li>
<li>Chronic viral hepatitis B is managed with Baraclude (entecavir)
currently.</li>
</ul>
</div>
</div>
<div id="section-262" class="section level1">
<h1>700948740</h1>
<div id="section-263" class="section level2">
<h2>210716</h2>
<p>{potential interactions among lorazepam, olanzapine, morphine and
labetalol}</p>
<p>[objective]</p>
<ul>
<li>concurrent medication:
<ul>
<li>lorazepam 2mg IVD PRNQ4H</li>
<li>olanzapine 5mg PO HS</li>
<li>morpine 5mg IVD PRNQ4H</li>
<li>labetalol 25mg IVD PRNQ8H</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>coadministered lorazepam, olanzapine, morphine might enhance the CNS
depressant effect.</li>
<li>olanzapine might enhance the adverse effect of lorazepam
(benzodiazepine).
<ul>
<li>reference:
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/15889948/" class="uri">https://pubmed.ncbi.nlm.nih.gov/15889948/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/20156413/" class="uri">https://pubmed.ncbi.nlm.nih.gov/20156413/</a></li>
</ul></li>
</ul></li>
<li>labetalol might enhance the hypotensive effect of olanzapine and
morphine.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor any sign such as anterograde amnesia, drowsiness,
sedated stated, hypotension to see if change is needed.</li>
</ul>
</div>
</div>
<div id="section-264" class="section level1">
<h1>700962042</h1>
<div id="section-265" class="section level2">
<h2>220302</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-09 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy. There is no evidence of tumor recurrence.</li>
</ul></li>
<li>2021-10-08 Patho - peritoneum biopsy
<ul>
<li>diagnosis
<ul>
<li>Peritoneum, left lower, cytoreductive surgery - Serous carcinoma,
seeding<br />
</li>
<li>Appendix, cytoreductive surgery - Serous carcinoma, seeding</li>
<li>Peritoneum, right flank, cytoreductive surgery - Serous carcinoma,
seeding<br />
</li>
<li>Omenum, cytoreductive surgery - Serous carcinoma, seeding</li>
<li>Peritoneum, right upper, cytoreductive surgery - Serous carcinoma,
seeding<br />
</li>
<li>Gallbladder, cytoreductive surgery - Serous carcinoma, seeding</li>
</ul></li>
<li>IHC: WT-1(+), CK7(+), CK20(-), PAX-8(+)</li>
</ul></li>
<li>2021-10-08 Patho - uterus neoplastic
<ul>
<li>diagnosis
<ul>
<li>Ovary, bilateral, salpingo-oophorectomy (s/p chemotherapy) - Serous
carcinoma, high-grade<br />
</li>
<li>Fallopian tube, bilateral, salpingo-oophorectomy - Serous carcinoma,
seeding<br />
</li>
<li>Uterus, serosa, abdominal total hysterectomy - Serous carcinoma,
seeding</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-07 total hysterectomy + bilateral salpingo-oophorectomy</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-11 ~ ongoing: paclitaxel + carboplatin + bevacizumab</li>
<li>2021-10-07: cisplatin + gentamicin (the surgical operation day)</li>
<li>2021-09-02: paclitaxel + carboplatin</li>
<li>2021-05 ~ 2021-07: paclitaxel + docetaxel + carboplatin +
gentamicin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>platin-based regimen has been introduced since May 2021, bevacizumab
added since Nov 2021 s/p total hysterectomy + bilateral
salpingo-oophorectomy, most recent CT on 2022-02-09 showed no evidence
of tumor recurrence. no issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-266" class="section level1">
<h1>700962200</h1>
<div id="section-267" class="section level2">
<h2>220301</h2>
<p>{myelodysplastic syndrome}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-16 Patho - bone marrow biopsy
<ul>
<li>Diagnosis - Bone marrow, biopsy - Compatible with myelodysplastic
syndrome</li>
<li>IHC:
<ul>
<li>MPO: positive for myeloid series</li>
<li>CD71: positive for erythroid series</li>
<li>CD61: positive for megakaryocytes</li>
<li>CD117: positive for blast</li>
<li>CD34: positive for blast</li>
</ul></li>
<li>Microscopically, the sections show pictures as follows:
<ul>
<li>Cellularity 30-40%</li>
<li>M/E ratio about 1/2, left shift maturation of both myeloid and
erythroid series</li>
<li>Megakaryocyte proliferation, 30% with dysplastic change.
Immunohistochemistry of CD34(+) and CD61(+)</li>
<li>Blast cells about 5%</li>
<li>According to all above histopathologic findings and clinical
presentation, it is compatible with myelodysplastic syndrome.</li>
</ul></li>
</ul></li>
<li>2021-09-27 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, buttock, biopsy - Hypocellularity</li>
<li>IHC:
<ul>
<li>MPO: positive for myeloid series<br />
</li>
<li>CD71: positive for erythroid series<br />
</li>
<li>CD61: positive for megakaryocytes<br />
</li>
<li>CD117: positive for blast<br />
</li>
<li>CD34: positive for blast<br />
</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Hypocellularity for her age, 5-10%</li>
<li>M/E ratio about 1/3, hypoplasia of myeloid series and hyperplasia of
erythroid series</li>
<li>Megakaryocyte proliferation, 20-30% with interstitial or
paratrabecular distribution</li>
<li>No obviously increase of blast (5%)<br />
</li>
<li>According to all above histopathologic findings and clinical
history, the differential diagnosis includes myelodysplastic syndrome
(MDS) or therapy-associated reactive change.</li>
</ul></li>
</ul></li>
<li>2020-09-04, -08-14 CT
<ul>
<li>S/P hysterectomy.</li>
<li>Hepatosplenomegaly, nature?</li>
</ul></li>
<li>2019-10-17 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the middle T-spines and L4-5 spines.
Degenerative change may show this picture.</li>
<li>Increased activity in the maxilla. The nature is to be determined
(dental problem? other nature?).</li>
<li>Some faint hot spots in bilateral rib cages. The nature is to be
determined (post-traumatic change? other nature?).</li>
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions, elbows, knees and right ankle. Benign joint
lesion is more likely.</li>
</ul></li>
<li>2016-05-17 Pathology
<ul>
<li>Uterus, endometrium, staging surgery - carcinosarcoma, Grade 3</li>
<li>pTNM: pT1bNO(cM0) , FIGO stage: IB.</li>
<li>Uterus, myometrium, staging surgery - involved by carcinosarcoma
(&gt; 1/2 thickness) - adenomyosis.</li>
</ul></li>
<li>2016-05-06 MRI
<ul>
<li>Endometrial tumor, suspected malignancy, cstage T1aN0Mx.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2016-05-10 laparoscopic gynecology staging surgery (LAVH + BSO +
BPLND + omentectomy); laparoscopic adhesionolysis.</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2016-06-16 ~ 2016-08-01: 4500cGy/25fx (15MV photon) of the pelvic,
and 900cGy/3fx via IVRT to vaginal cuff mucosa surface area.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2016-06-01, -06-23, -08-10, -09-06, -11-14.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Allogeneic hematopoietic cell transplantation (HCT) is the treatment
with the highest potential to cure MDS. However, because of advanced
age, comorbid conditions, lack of adequately matched donors, and/or
patient preferences, only a small subset of patients with MDS are
candidates for allogeneic HCT. HLA typing should be performed if
hematopoietic cell transplant (HCT) approach is not ruled out.</li>
<li>For most patients with MDS, the goals of care are to lessen
symptoms, improve the quality of life, and prolong survival, while
minimizing treatment-related toxicity. IPSS/IPSS-R could be applied to
categorize prognostic risk group.</li>
<li>If del(5q) is confirmed, then lenalidomide might be considered for
IPSS low/intermediate MDS.</li>
<li>lab data uric acid 11.8, eGFR 30.11 reported on 2022-02-28,
allopurinol (50 mg daily) or febuxostat (no dosage adjustment necessary)
might be considered if no contraindication.</li>
</ul>
</div>
</div>
<div id="section-268" class="section level1">
<h1>700965860</h1>
<div id="section-269" class="section level2">
<h2>210906</h2>
<p>{colon cancer with suspected liver mets and peritoneal seeding}</p>
<p>[initial presentation]</p>
<ul>
<li>2020-11 underwent a health examination arranged by the company and
found multiple liver nodules (2.7 cm).</li>
<li>2021-05 began to suffer from abdominal cramps after eating (below
umbilicus) and the symptom can be relieved after defecation.
<ul>
<li>no radiation pain, abdominal distension, burning sensation, nausea,
vomiting, diarrhea, constipation, appetite change.</li>
</ul></li>
<li>2021-08 LMD abdomenal echo found multiple liver tumors.</li>
</ul>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2021-08-18 abdominal ultrasound
<ul>
<li>liver tumors, multiple, suspect metastasis</li>
<li>several mixed echoic tumors with peripheral low echogenicity, and
the largest one 8 cm x 3.9 cm was at S4/8</li>
</ul></li>
<li>2021-08-19 CT, ABD - liver, spleen, biliary duct, pancreas
<ul>
<li>multiple liver tumors suspected metastases.</li>
<li>wall thickening of cecum and S-colon.</li>
<li>a soft tissue nodule (1.3cm) in pelvic cavity suspected tumor
seeding.</li>
<li>some LNs at paraaortic region suspected metastases.</li>
</ul></li>
<li>2021-08-20 coloscopy
<ul>
<li>suspect colon cancer with impending obstruction, sigmoid colon, 30cm
above AV, s/p biopsy</li>
<li>a large ulcerative tumor involving the whole circumference with
lumen narrowing and the scope can not pass through it, s/p biopsy</li>
</ul></li>
<li>2021-08-23 patho - colon biopsy
<ul>
<li>adenocarcinoma - pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
<li>IHC stains: EGFR(+), PMS2(+), MSH6(+), MSH2(+), MLH1(+).</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>staging workup is ongoing.
<ul>
<li>liver mets and peritoneal seeding are suspected, should be stage IVC
if both confirmed positive.</li>
</ul></li>
<li>diverting ostomy or bypass or stenting might be indicated for
imminent obstruction at colon lesion.</li>
<li>liver and kidney functions showed no abnormality (lab data on
2021-09-06, 2021-08-16); neither HBV nor HCV was active; systemic
therapy would be indicated for this chemo-naive patient.
<ul>
<li>FOLFOX or CAPEOX could be an option, bevacizumab could also be
added.</li>
<li>pembrolizumab, nivolumab might not be indicated for pMMR (PMS2(+),
MSH6(+), MSH2(+), MLH1(+)).</li>
</ul></li>
<li>KRAS/NRAS/BRAF lab data not found in chart yet.</li>
</ul>
</div>
</div>
<div id="section-270" class="section level1">
<h1>700972259</h1>
<div id="section-271" class="section level2">
<h2>220106</h2>
<p>combination use of H2 antagonist (Famotidine) and PPI (Rabeprazole)
might enhance gastric acid suppression, might also increase the
potential risk of Clostridioides difficile infection.</p>
<p>references: - <a href="https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/phar.1665" class="uri">https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/phar.1665</a>
- <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246810/pdf/ciaa545.pdf" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246810/pdf/ciaa545.pdf</a></p>
</div>
</div>
<div id="section-272" class="section level1">
<h1>700973989</h1>
<div id="section-273" class="section level2">
<h2>220422</h2>
<p>{esophageal squamous cell carcinoma with liver and lung mets}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-20 SONO - chest
<ul>
<li>left side moderate hemothroax, s/p chest tapping 600 ml bloody
effusion for study and s/s relief</li>
<li>right side moderate pleural effusion, s/p chest tapping 350 ml for
study</li>
</ul></li>
<li>2022-04-13 Chest PA (erect) view
<ul>
<li>A poorly defined huge mass over over medial RUL and midlung zone
with multiple nodular opacities in both lungs, due to metastases</li>
<li>Bilateral pleural effusions</li>
<li>Superior mediastinal widening due to lymph node enlargement,</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Otherwise, there is no significant abnormality of the chest. (Note
that ground-glass lesion, small nodule or retrocardiac lesion might be
missed on plain chest radiography.)</li>
</ul></li>
<li>2022-04-11 Tc-99m MDP whole body bone scan
<ul>
<li>No strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in both rib cages, some T-and L-spine,
bilateral sternoclavicular junctions, shoulders, S-I joints, right
femoral trochanters, and right knee.</li>
</ul></li>
<li>2022-04-08 Patho - lung transbronchial biopsy
<ul>
<li>Lung, right, CT-guide biopsy  squamous cell carcinoma, please
correlate with the clinical presentation and image study to
differentiate primary or metastatic tumor</li>
<li>Sections show solid sheets of hyperchromatic tumor cells
infiltrating in a fibrotic stroma. Focal keratinization is seen.</li>
<li>The immunohistochemical stains reveal p40(+), and TTF-1(-). Please
correlate with the clinical presentation and image study to
differentiate primary or metastatic tumor.</li>
</ul></li>
<li>2022-04-07 MRI - brain
<ul>
<li>No obvious intracranial lesion.</li>
<li>Large patchy area of encephalomalacia over left PCA territory.</li>
<li>Also small areas of old infarction over right frontal lobe, right
medial occipital lobe, bilateral cerebellar lobe.</li>
<li>Mild periventricular small vessel disease. NO acute ischemic
infarct.</li>
</ul></li>
<li>2022-04-06 Cell block
<ul>
<li>Suggestive of malignancy<br />
</li>
<li>The smears and cell block show lymphocytes, reactive mesothelial
cells and a few atypical cell nests, which immunocytochemistry shows
TTF-1(-), Napsin-A(-) and P40(+, scant) for atypical cells, suggestive
of malignancy. According to cytomorphologic finding, it is compatible
with metastatic squamous cell carcinoma. Please refer to S2022-05907 and
clinical correlation for tumor origin.</li>
</ul></li>
<li>2022-04-02 CT - chest
<ul>
<li>Imaging stage: T4aN3M1, stage IVB</li>
</ul></li>
<li>2022-04-01 Pathology - esophageal biopsy
<ul>
<li>Esophageal tumor, 27 and 40 cm below the incisors, biopsy  Squamous
cell carcinoma, moderately differentiated</li>
<li>Microscopically, the sections show a picture of squamous cell
carcinoma, moderately differentiated characterized by solid tumor nests
with enlarged, hyperchromatic and pleomorphic nuclei infiltratde in the
stroma with focal keratin formation and some necrotic debris.</li>
</ul></li>
<li>2022-03-31 Esophagogastroduodenoscopy, EGD
<ul>
<li>Reflux esophagitis LA A</li>
<li>Highly suspected esophageal cancer, 27-40cm, s/p biopsy</li>
<li>Superficial gastritis</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-21 family medicine
<ul>
<li>Q:
<ul>
<li>The 66-year-old male has history of Type II Diabetes mellitus and
Hypertension under Chang Gung OPD follow up and esophageal cancer with
lung and liver meta. He suffer from short of breath for one day. He came
to our ER for help on 20220402. Under the impression of esphogeal
cancer, jejunostomy performed on 20220414 and intubated ETT at the same
day. The patient prefer palliative care, so extubated on 20220418.
However, tachypnea with short of breath were noted, NIPPV
supportive.</li>
<li>Current problem: We need Hospice care and take over the patient for
palliative care.</li>
</ul></li>
<li>A:
<ul>
<li>66y/o gentleman just dx advanced esophageal cancer</li>
<li>Dyspnea s/p intubation now with BIPAP</li>
<li>DNR +</li>
<li>ECOG 4</li>
<li>Would put pt on Hospice ward list.</li>
<li>Our share care would follow up.</li>
</ul></li>
</ul></li>
<li>2022-04-20 Thoracic Medicine
<ul>
<li>Q:
<ul>
<li>The 66-year-old male has history of Type II Diabetes mellitus and
Hypertension under Chang Gung OPD follow up and esophageal cancer with
lung and liver meta. He suffer from short of breath for one day. He came
to our ER for help on 20220402. Under the impression of esphogeal
cancer, jejunostomy performed on 20220414 and intubated ETT at the same
day. The patient prefer palliative care, so extubated on 20220418.
However, tachypnea with short of breath were noted, NIPPV
supportive.</li>
<li>Current problem: We need your specialist to arrange pleural
drainage.</li>
</ul></li>
<li>A:
<ul>
<li>A case of heavy smoking with COPD, admitted due to esophageal cancer
s/p palliative feeding jejunostomy.</li>
<li>Bed-side chest echo had been done and showed right side serosanguous
exudative PE and left side hemothorax, s/p chest tapping with left side
350ml and right side 600ml.</li>
<li>Suggestion:
<ul>
<li>Left side chest tube drainage for hemothorax.</li>
<li>Add foster 2puff BID, spiriva 2puff HS.</li>
<li>F/U prn.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-04-18 Infectious Disease
<ul>
<li>Q:
<ul>
<li>Esophgeal Ca with lung metastasis s/p Feeding jejunostomy</li>
<li>Developed high fever suspected pneumonia</li>
</ul></li>
<li>A:
<ul>
<li>Antibiotic therapy should be adjusted according to the results of in
vitro sensitivity testing.</li>
<li>NO treatment for colonization. Do NOT use steroid.</li>
</ul></li>
</ul></li>
<li>2022-04-09 Hemato-Oncology
<ul>
<li>Impression:
<ul>
<li>Esophageal cancer with liver and lung metastasis</li>
<li>Type II Diabetes mellitus</li>
<li>Hypertension</li>
<li>Old CVA</li>
</ul></li>
<li>Suggestion:
<ul>
<li>We will discuss with patient about further treatment after complete
work up</li>
<li>Please check AntiHbc, SCC</li>
<li>May consult chest surgeon for port A insertion and involve in this
case.</li>
<li>Consult GI to involve in this case (esophagus stent? or
gastrostomy?)</li>
<li>Consult RT for CCRT</li>
</ul></li>
</ul></li>
<li>2022-04-06 Radiological Diagnosis
<ul>
<li>Q: for chest CT guiding biopsy of lung mass, sinecrely need your
professional evaluation</li>
<li>Q:
<ul>
<li>This 66-year-old patient is a case of bilateral lung nodules,
suspected metastasis or primary lung cancer.</li>
<li>CT-guided biopsy is indicated. Please chek platelet, PT, and aPTT
before this procedure. We will inform the risk of insufficient specimen,
pneumothorax, hemorrhage, infection, and air embolism to the patient and
the family.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient, who suffers from esophageal squamous cell carcinoma
with liver and lung metastases, has been placed on the hospice waiting
list on 2022-04-21.</li>
</ul>
</div>
</div>
<div id="section-274" class="section level1">
<h1>700974194</h1>
<div id="section-275" class="section level2">
<h2>220124</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 6 items.</p>
<p>the 4 identified items has been shown as following while the other 2
items still remain unknown: - Megajohn - megestrol 160mg - Kentamin -
thiamine 50mg, pyridoxine 50mg, cyanocobalamin 500mcg - Romicon-A -
lysozyme 20mg, dextromethorphan 20mg, cresolsulfonate 90mg - Olmetec -
olmesartan medoxomil 20mg</p>
<p>these drugs will be sent back to ward by an in-hospital porter.</p>
</div>
</div>
<div id="section-276" class="section level1">
<h1>700980179</h1>
<div id="section-277" class="section level2">
<h2>220318</h2>
<p>{Peripheral T-Cell Lymphoma, PTCL, relapsed}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-26 CT - neck
<ul>
<li>Necrotic tumor at right neck, much smaller in size and less
enhancement as compared with CT scan on 20211228.</li>
</ul></li>
<li>2021-12-28 CT - neck
<ul>
<li>Probably abscess with deep neck infection at right upper neck.
Differential diagnosis suspected necrotic tumor mass with
infection.</li>
</ul></li>
<li>2021-11-25 Whole body PET scan
<ul>
<li>Increased FDG uptake in bilateral tonsils and a right upper neck
lymph node, compatible with residual lymphoma. In comparison with the
previous study on 20210107, the FDG avid lesions in bilateral tonsils
and a right upper neck lymph node are less evident. Other previous
lesions in the nasopharynx and other bilateral neck lymph nodes
disappeared.<br />
</li>
<li>Increased FDG uptake in the stomach. Inflammation is more
likely.</li>
<li>No prominent change is noted in the mild FDG avid lesions in some
mediastinal lymph nodes, right pulmonary hilar lymph nodes and left
adrenal gland, possibly more benign in nature.</li>
<li>Increased FDG accumulation in both kidneys and bilateral ureters.
Physiological FDG accumulation may show this picture.</li>
</ul></li>
<li>2021-11-24 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy - No evidence of T-cell lymphoma
involvement</li>
<li>The sections show normocellular marrow (35%). M/E ratio = 4:1. The
erythroid precursors are not remarkable. The myeloid cells show good
maturation. The megakaryocytes are normal in number with few small
megakatyocytes. No lymphoid aggregates can be found. There is no
evidence of T-cell lymphoma involvement in CD20, CD3, CD4 and CD8
immunostains. Suggest further bone marrow smear evaluation and clinic
correlation.</li>
</ul></li>
<li>2021-11-10 Patho - tonsil biopsy
<ul>
<li>Diagnosis
<ul>
<li>Tonsil, left, tumor excision  Peripheral T-cell lymphoma<br />
</li>
<li>Tonsil, right, tumor excision  Peripheral T-cell lymphoma</li>
</ul></li>
<li>Histologic type: Peripheral T-cell lymphoma</li>
<li>Immunophenotyping: CD3(+), CD20(-), CD4(+), CD8(focal+), and
CD30(focal+)</li>
</ul></li>
<li>2021-11-09 Frozen section
<ul>
<li>Tonsil, left, frozen section  Atypical lymphoid cell infiltration,
compatible with lymphoma involvement.</li>
</ul></li>
<li>2021-11-03 CT - neck
<ul>
<li>C/W residual oropharyngeal lesions, mild regression as compared with
CT scna on 20210106.</li>
</ul></li>
<li>2021-01-07 Whole body PET scan
<ul>
<li>The FDG PET findings are compatible with lymphoma involving the
nasopharynx, bilateral tonsils and multiple bilateral neck lymph
nodes.</li>
<li>Milldy increased FDG uptake in some mediastinal lymph nodes and
right pulmonary hilar lymph nodes. Inflammation is more likely.</li>
<li>Milldy increased FDG uptake in the left adrenal gland. The nature is
to be determined (benign tumor? other nature?).</li>
<li>Increased FDG accumulation in both kidneys and right ureter.
Physiological FDG accumulation may show this picture.</li>
</ul></li>
<li>2021-01-06 CT - neck
<ul>
<li>Bilateral tonsillar lesions and bilateral neck LAPs. R/O lymphoma
(stage II).</li>
</ul></li>
<li>2020-12-28 Patho - tonsil biopsy
<ul>
<li>Tonsil, right, biopsy - Malignant T-cell lymphoma</li>
<li>Histology type: T-cell neoplasms, in favor of Peripheral T-cell
lymphoma<br />
</li>
<li>Immunohistochemical stain profiles: CD3(+), CD4(+), CD8(-), CD56(-),
Granzyme B(-), CD30(+), ALK(-), and CK(-).<br />
</li>
<li>Fungal hyphe is seen in necrotic debris. The PAS special stain is
positive.</li>
</ul></li>
<li>2020-12-26 Nasopharyngoscopy
<ul>
<li>Ulcerative lesion over right tonsil upper pole and right
palatopharyngeal arch</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12-10 ~ ongoing Folotyn (pralatrexate)</li>
<li>2021-01-11 ~ 2021-05-13 CHOP (cyclophosphamide, doxorubicin
hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and
prednisone)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Pralatrexate is indicated to treat relapsed PTCL. The patient is
taking pralatrexate currently since early December 2021, and CT scans
(2022-01-26 versus 2021-12-28) demonstrated improvements.</li>
<li>Hepatotoxicity and LFT abnormalities have been observed with
pralatrexate use. Persistent abnormalities may indicate hepatotoxicity.
In the period 2021-12-01 to now, S-GPT/ALT readings have ranged from
15U/L to 403U/L, with 77U/L being reported on 2022-03-17.</li>
<li>Package insert revealed 30% of patients treated with pralatrexate
experienced edema, which should be addressed.</li>
</ul>
</div>
</div>
<div id="section-278" class="section level1">
<h1>700990347</h1>
<div id="section-279" class="section level2">
<h2>210513</h2>
<p>{Tube Feeding}</p>
<p>all the oral drugs in current medication can be administrated via NG
tube.</p>
<p>actein effervescent (acetylcysteine) should not be grinded, please
dissolve the drug in adequate amount of drinking water prior to tube
feeding.</p>
</div>
</div>
<div id="section-280" class="section level1">
<h1>700990402</h1>
<div id="section-281" class="section level2">
<h2>210831</h2>
<p>{UTI, hypoalbuminemia}</p>
<p>[objective]</p>
<ul>
<li>2018-04-03 robotic assisted laparoscopic radical cystectomy + pelvic
lymph nodedissection + ileal pouch (ShuangHo hospital)
<ul>
<li>cystectomy and ileal conduit for bladder cancer s/p adjuvant
radiotherapy, bilateral PCN insertion, and T-colostomy.</li>
</ul></li>
<li>2020-05 right femoral neck fracture s/p bipolar hemiarthroplasty
(ShuangHo hospital)</li>
<li>2021-05-24 CT - abnominal
<ul>
<li>a 9cm pelvic mass, suspected to be recurrent tumor.</li>
</ul></li>
<li>2021 early Jane bilateral PCN placing and colostomy done for
obstructive ileus, followed with adjuvant radiotherapy in Cardinal Tien
hospital.</li>
<li>2021-06-25 Gyn ultrasound: uterine mass of 5x5cm at the posterior
wall of myometrium without clear margin. D&amp;C and ECC showed
inflammation and scanty gland cells with squamous metaplasia.</li>
<li>2021-07-13 LAVH, BSO, excision. adhesiolysis for severe adhesion of
small intestine.</li>
<li>2021-07-21 chest AP
<ul>
<li>bilateral lung tumors, suspected lung metastasis.</li>
</ul></li>
<li>2021-08-04 CT - brain
<ul>
<li>a right frontal lobe. suspected abscess or tumor.</li>
</ul></li>
<li>2021-08-04 MRI - brain
<ul>
<li>right frontal tumor (19 mm) with mass effect. metastasis is first
considered. D/D: abscess.</li>
<li>a suspected aneurysm (2.6 mm x 2.7 mm) near right M1
bifurcation.</li>
</ul></li>
<li>2021-08-30 urine lab data
<ul>
<li>sediment RBC 6-9</li>
<li>sediment WBC 10-19</li>
<li>leucocyte ester 2+</li>
<li>OB 1+</li>
</ul></li>
<li>2021-08-22, 23 urine culture - catheterized and patient urinated
midstream
<ul>
<li>Klebsiella pneumoniae, Escherichia coli</li>
</ul></li>
<li>bilirubin direct 0.32mg/dL (2021-08-23)</li>
<li>albumin
<ul>
<li>2021-08-23 2.7g/dL</li>
<li>2021-07-26 3.1g/dL</li>
<li>2021-07-22 3.0g/dL</li>
<li>2021-07-19 2.8g/dL</li>
<li>2021-07-01 2.9g/dL</li>
<li>2021-06-24 2.8g/dL</li>
</ul></li>
<li>prealbumin
<ul>
<li>2021-07-26 10.04mg/dL</li>
<li>2021-07-14 10.64mg/dL</li>
</ul></li>
</ul>
<p>[assessment, suggestion]</p>
<ul>
<li>UTI still ongoing (8/30 urine lab data), 1 week tapimycin
administrated until 9/1 morning, imipenem might be an alternative
successor for both cultured Klebsiella pneumoniae and Escherichia coli
are imipenem-sensitive (MIC&lt;=0.25, low creatinine reading) if no
other considerations.</li>
<li>S-GPT/ALT and S-GOT/AST (8/23) showed no abnormality, however,
bilirubin flucturated above normal range for at least 3 months. both
albumin and prealbumin remain low, if no evidence supports
liver-dysfunction-caused hypoalbuminemia for now, to improve patients
nutritional status could be tried. HBV and HCV might also be tested (no
in-hospital records seen yet).</li>
<li>underlying diseases or symptoms are managed with drugs in active
prescription, no issue found.
<ul>
<li>type 2 DM
<ul>
<li>metformin 500mg PO BID</li>
<li>linagliptin 5mg PO QD</li>
</ul></li>
<li>hypertension
<ul>
<li>amlodipine 5mg PO QD</li>
</ul></li>
<li>parkinsons disease
<ul>
<li>bendopar (levodopa 100mg, benserazide 25mg) PO BID+HS</li>
<li>amentadine 100mg PO BID</li>
</ul></li>
<li>flatulence
<ul>
<li>dimethylpolysiloxane 40mg PO BID</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-282" class="section level1">
<h1>701000332</h1>
<div id="section-283" class="section level2">
<h2>220317</h2>
<ul>
<li>In contrast to previous CT images on 2021-11-06, CT images updated
on 2022-02-23 showed stationary metastatic lung, liver, bones, and LAPs
in the mediastinum and hilar region.</li>
<li>Lab tests reported on 2022-03-16 indicated no abnormalities in liver
and kidney function, but low WBC, RBC, and HGB levels were observed,
which should be monitored as usual in patients undergoing
chemotherapy</li>
<li>According to the blood sugar level as of 2022-03-17, the level is
slightly low, which should be noted and monitored if anti-DM drugs need
to be adjusted.</li>
</ul>
</div>
<div id="section-284" class="section level2">
<h2>220125</h2>
<p>{Vulvar Cancer}</p>
<p>[objective]</p>
<ul>
<li>lab finding
<ul>
<li>2021-04-09 Patho
<ul>
<li>Skin, left post-auricular, excision - poorly differentiated
carcinoma, metastatic.</li>
<li>IHC: ER positive (strong, &gt;95%), PR: positive (moderate, 90%),
CK20(-), P40(-), CEA(+).</li>
</ul></li>
<li>2021-02-25 Patho
<ul>
<li>scalp metastatic cancer nodule</li>
<li>IHC: CD56(-), GATA-3(+), mamoglobin(focal +). The pattern is the
same as those of S2019-15699/S2019-15746.</li>
</ul></li>
<li>2021-01-29 MRA - Brain
<ul>
<li>A newly developed left cerebellar metastasis.</li>
<li>Marked regression of the left parietal skull and scalp
metastasis.</li>
<li>Brain atrophy and leukoaraiosis.</li>
</ul></li>
<li>2021-01-13 CT
<ul>
<li>metastasis 1.2cm in S2 liver is suspected.</li>
<li>there are three soft tissue nodules in left diaphragm.</li>
</ul></li>
<li>2020-10-28 Tc-99m MDP whole body bone scan
<ul>
<li>Suspected Ca with multiple bone mets in the left parietal region of
the skull, both rib cages, some T- and L-spine, and left femoral shaft,
M/3.</li>
<li>Suspected benign lesions in C-spine, maxilla, mandible, bilateral
sternocalvicular nctions, shoulders, elbows, knees, and right foot.</li>
</ul></li>
<li>2020-10-21 CT
<ul>
<li>newly developed T3 vertebral metastasis.</li>
</ul></li>
<li>2020-07-06 MRI - Brain
<ul>
<li>Left parietal scalp, skull metastasis with intracranial
extension.</li>
</ul></li>
<li>2020-07-03 CT
<ul>
<li>post operative change at right upper lobe with pleural thickening,
in progression.</li>
<li>recurrent pleural meta is favored.</li>
</ul></li>
<li>2019-09-18 Patho
<ul>
<li>Lung, right, upper, middle, lower lobe, wedge resection - poorly
differentiated carcinoma, metastatic.</li>
<li>Histologic Type: carcinoma, The morphology is consistent with
S2017-19644.</li>
<li>IHC: GATA3(+), Mammaglobin A(focal +), ER(+, 100%), PR(+, 20%),
HER-2/Neu(Ab): Negative (1+), PAX8(-), p63(-), Uroplakin II(-),
CK5/6(-), Chromogranin A(-), CD56(-), and TTF-1(-). The Ki-67 is about
40%. The results are most compatible with breast origin.</li>
</ul></li>
<li>2019-09-05 CT: multiple lung nodules, favor metastatic lesions.</li>
<li>2019-06-03 CT: uterine myoma is suspected.</li>
<li>2017-12-13 CT: a 3.0cm tumor at uterus.</li>
<li>2017-11-28 Patho
<ul>
<li>Right vulva, excision biopsy - Carcinoma, margin positive.</li>
<li>IHC: GATA-3(+), GCDFP-15(-), CK7(+), CK20(-), p40(-), p16(focal +),
HMB-45(-).</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-04-08 Excision of left post-auricular tumor</li>
<li>2021-02-25 Excision of scalp tumor</li>
<li>2018-01-15 Vulvectomy</li>
<li>2017-11-28 Excision of right upper vulvar major</li>
</ul></li>
<li>medication
<ul>
<li>2021-12 ~ ongoing - Onivyde (irinotecan liposome) + FL</li>
<li>2021-04 ~ 2021-07 - FOLFOX + Bevacizumab</li>
<li>2020-11 ~ 2021-04 - Nivolumab</li>
<li>2020-07 ~ 2020-09 - Cisplatin + Vinorelbine, Vinorelbine</li>
<li>2019-10 ~ 2019-12 - Cisplatin + Paclitaxel</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-285" class="section level1">
<h1>701008526</h1>
<div id="section-286" class="section level2">
<h2>220309</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-04 CT - whole abdomen, pelvis
<ul>
<li>S/P RFA for liver tumor.</li>
<li>Duodenal diverticulum.</li>
<li>Stationary of right upper pole kidney low density lesion, 1.4cm,
suggest follow up.</li>
<li>Fibrotic infiltrate in bilateral upper lungs.</li>
</ul></li>
<li>2021-10-01 Sigmoidoscopy
<ul>
<li>Diagnosis: local recurrent cancer at low rectum</li>
<li>Suggestion: possible R/T or transanal debulking excision</li>
</ul></li>
<li>2021-09-23 CT - whole abdomen, pelvis
<ul>
<li>Rectal cancer s/p operation without interval change.</li>
<li>Liver tumor s/p RFA without viable tumor.</li>
</ul></li>
<li>2021-04-20 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20190725, the lesions in
the upper L-spines are a little less evident. Compression fracture or
severe degenerative change with some resolution may show this
picture.</li>
<li>The previous hot spots in some right costovertebral junctions are
also a litlte less evident. However, please correlate with other imaging
modalities for further evaluation.</li>
<li>No prominent change is noted in the lesions in the lower L-spines.
Post-operative change may show this picture.</li>
<li>Increased activity in the maxilla and mandible. Dental problem may
show this picture.</li>
<li>Increased activity in bilateral shoulders, bilateral
sternoclavicular junctions and wrists, compatible with benign joint
lesions.</li>
</ul></li>
<li>2021-04-06 CT - whole abdomen, pelvis
<ul>
<li>Post-op at the colon with preirectal fatty infiltrates,
stationary.</li>
<li>S/P RFA for liver tumor.</li>
<li>Suspected complicated right renal cyst.</li>
<li>Fibrotic infiltrates in bilateral lung apex and RML.</li>
<li>Osteoblastic lesions in the ribs, spine and pelvis, suspected bone
metastasis.</li>
</ul></li>
<li>2021-02-26 Colonoscopy
<ul>
<li>Recurrent rectal tumor found 6cm AAV.</li>
</ul></li>
<li>2021-01-07 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Rectal cancer s/p operation without interval change.</li>
<li>Liver tumor s/p RFA without viable tumor.</li>
</ul></li>
<li>2020-11-10 PET scan
<ul>
<li>In comparison with the previous study on 20200622, the previous
glucose hypermetabolic lesion in the segment 5 of the liver is less
evident. However, the previous glucose hypermetabolic lesion on the
rectal wall disappeared and no prominent FDG uptake was noted in the
previous glucose hypermetabolic lesion in the segment 4 of the
liver.</li>
<li>Two mild and small glucose hypermetabolic lesions in the right lower
lung field. The nature is to be determined (inflammation? early
metastases? other nature?).</li>
<li>Glucose hypermetabolism in bilateral pulmonary hilar regions and
some mediastinal lymph nodes. Inflammation may show this picture.</li>
<li>Increased FDG accumulation in the colon. Physiological FDG
accumulation is more likely.</li>
</ul></li>
<li>2020-10-30 Sigmoidoscopy
<ul>
<li>Previous anastomosis site was no evidence disease (NED).</li>
</ul></li>
<li>2020-10-07 CT - abdomen, pelvis
<ul>
<li>Metastasis 1.6 x 1.1 cm in S5 of the liver is suspected and it shows
stable in size. Please correlate with MRI.</li>
<li>Renal cyst with hemorrhage 2 cm at right upper pole shows stable in
size.</li>
</ul></li>
<li>2020-07-03 Patho - colorectal polyp
<ul>
<li>Rectum, transanal excision - Adenocarcinoma, recurrent</li>
</ul></li>
<li>2020-06-22 PET scan
<ul>
<li>A glucose-hypermetabolic lesion on rectal wall, compatible with the
lesion of recurrent rectal cancer as diagnosed histopathologically.</li>
<li>Glucose hypermetabolism in the lesion in segment 5 of liver revealed
in the previous CT scan, hepatic metastasis may show such a
picture.</li>
<li>Another glucose-hypermetabolic lesion in segment 4 of liver, nature
to be determined (inflammatory lesion, malignancy, or other
nature).</li>
<li>Mild glucose hypermetabolism in bilateral pulmonary hilar lymph
nodes, reactive change resulting from locoregional inflammation may show
such a picture.</li>
<li>Rectal cancer with recurrence, rcTxN0M1a, stage IVA (AJCC 8th ed.),
by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2020-06-17 CT - abdomen, pelvis
<ul>
<li>Metastasis 1.6 x 1.1 cm in S5 of the liver is suspected.</li>
<li>Renal cyst with old hemorrhage 2 cm at right upper pole is
suspected.</li>
</ul></li>
<li>2020-06-15 Patho - colon biopsy
<ul>
<li>Large intestine, rectum, biopsy - Adenocarcinoma, moderately
differentiated</li>
</ul></li>
<li>2020-06-12 Sigmoidoscopy
<ul>
<li>one 2.5cm tumor mass was noted in the low rectum (previous
anastomosis, posterior site)</li>
</ul></li>
<li>2020-01-03 Patho - colon segmental resction for tumor
<ul>
<li>Recto-Sigmoid colon, LAR - Adenocarcinoma</li>
<li>Bilateral cutting ends, ditto - Free of tumor invasion</li>
<li>Lymph node, dissection - Positive for tumor metastasis (2/12)
without extracapsular extension (0/2)</li>
<li>AJCC pathologic stage - ypT3N1b(if cM0), stage IIIB</li>
<li>IHC: CDX-2(+), MLH1(+), PMS2(+), MSH2(+) and MSH6(+)</li>
</ul></li>
<li>2019-07-01 CT - liver, spleen, biliary duct
<ul>
<li>Rectal cancer s/p CCRT with regional LAP (T3N2Mx).</li>
<li>Segmental wall edema of terminal ileum with adjacent fat stranding
and ascites. A poor enhancing lesion (2.4cm) in right kidney.</li>
</ul></li>
<li>2019-06-08 CT - abdomen
<ul>
<li>Imaging Report Form for Colorectal Carcinoma: T3N2Mx</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-12-11 Colon cancer with single liver metastasis s/p RFA (2
sessions) using RVS</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2019-04-18 ~ 2019-05-31: 4500cGy/25fx of the pelvic and 5040cGy/28fx
of the rectal tumor area</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-09 ~ ongoing: FOLFOX</li>
<li>2021-10-19 ~ 2021-12-15: FOLFOX</li>
<li>2020-07-20 ~ 2021-09-24: FOLFIRI</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-287" class="section level1">
<h1>701011322</h1>
<div id="section-288" class="section level2">
<h2>220119</h2>
<ul>
<li><p>CBC reported on 2022-01-18 showed items below normal ranges:</p>
<ul>
<li>WBC 3.17*10^3/uL (Neutrophil 65%)</li>
<li>RBC 3.27*10^6/uL</li>
<li>HGB 8.6g/dL</li>
<li>PLT 73*10^3/uL</li>
</ul></li>
<li><p>no drug allergy recorded in database.</p></li>
<li><p>no liver or kidney dysfuncion shown in recent lab data based on
AST, ALT, BUN, Creatinine, eGFR.</p></li>
<li><p>no issue found in active medication.</p></li>
</ul>
</div>
</div>
<div id="section-289" class="section level1">
<h1>701023219</h1>
<div id="section-290" class="section level2">
<h2>220208</h2>
<ul>
<li>Lab findings
<ul>
<li>MRI - nasopharynx
<ul>
<li>Right NPC with neck LAPs. T2N3M0 stage IVA.</li>
</ul></li>
<li>2021-08-04 Patho - nasopharyngeal/oropharyngeal biopsy
<ul>
<li>Nasopharyngeal carcinoma, non-keratinizing and poorly
differentiated</li>
<li>IHC: CK(+).</li>
</ul></li>
<li>2021-08-04 Nasopharyngoscopy
<ul>
<li>rt np tumor.</li>
</ul></li>
<li>2021-07-29 Patho - lymphnode biopsy
<ul>
<li>Labeled as right neck, biopsy - Lymph node with round blue cell
tumor, metastatic.</li>
<li>IHC: CK(+), poorly differentiated carcinoma. EBV(-), p16(-).</li>
<li>Please check nasopharynx, oropharynx, supra- and sub-glottis
first.</li>
</ul></li>
</ul></li>
<li>Surgical operation
<ul>
<li>2021-08-17 removing an enlarged lymph node over right posterior
neck.</li>
</ul></li>
<li>Regimen
<ul>
<li>2021-11 ~ ongoing Cisplatin + Fluorouracil</li>
<li>2021-08 ~ 2021-10 Cetuximab</li>
</ul></li>
<li>Radiotherapy
<ul>
<li>2021-08-20 ~ 2021-10-11
<ul>
<li>5000cGy/25 fractions of the nasopharyngeal to bilateral neck,</li>
<li>6000cGy/30 fractions of the nasopharyngeal tumor and involved
nodal,</li>
<li>7000cGy/35 fractions of the reduced nasopharyngeal tumor and
involved nodal lesions.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-291" class="section level1">
<h1>701032519</h1>
<div id="section-292" class="section level2">
<h2>220127</h2>
<p>{marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
(MALT lymphoma)}</p>
<p>[objective]</p>
<ul>
<li>Exams
<ul>
<li>2022-01-11 Whole body PET scan
<ul>
<li>Mild glucose hypermetabolism in some focal areas in bilateral lung
fields. Residual lymphoma should be considered. However, in comparison
with the previous study on 2021/08/19, the previous glucose
hypermetabolic lesions in bilateral lung fields are either less evident
or disappeared.<br />
</li>
<li>Glucose hypermetabolism in some mediastinal and bilateral pulmonary
hilar lymph nodes. Inflammation is more likely.</li>
<li>Increased FDG accumulation in the colon, both kidneys and bilateral
ureters. Physiological FDG accumulation is more likely.</li>
<li>No prominent abnormal focal FDG uptake was noted elsewhere.</li>
</ul></li>
<li>2022-01-04 CT - Lung/Mediastinum/Pleura
<ul>
<li>post op change in LUL</li>
<li>regression nodular lesions of both lungs as compared with CT on
2021/8/18.</li>
</ul></li>
<li>2021-08-20 Patho
<ul>
<li>Bone marrow, iliac, biopsy - Negative for malignancy<br />
</li>
<li>Microscopically, it shows 15% of cellularity, prsence of trilineage
cellular component and some megakaryocytes.</li>
<li>IHC: CD20(-), CD34(-), CD117(-), CD3(-), CD138(-), MPO(+),
CD71(+).</li>
</ul></li>
<li>2021-08-19 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in multiple focal areas in bilateral lung
fields, compatible with lymphoma.</li>
<li>Glucose hypermetabolism in some mediastinal lymph nodes. The nature
is to be determined (inflammation? other nature?).</li>
<li>Increased FDG accumulation in the left neck muscle, both kidneys and
bilateral ureters. Physiological FDG accumulation is more likely.</li>
<li>No prominent abnormal focal FDG uptake was noted elsewhere.</li>
</ul></li>
<li>2021-08-18 CT - ABD - whole abdomen, pelvis
<ul>
<li>Lymphoma s/p treatment show partial response.</li>
</ul></li>
<li>2021-07-26 Patho
<ul>
<li>Lung, right upper lobe, CT-guide biopsy - Extranodal marginal zone
lymphoma of MALT type with amyloidosis</li>
<li>The immunohistochemical analysis shows that these cells are positive
for CD20, bcl-2, and CD43, and negative for CD3, BCL6, and CD23. CD138
highlights increased plasma cells, but kappa and lambda are
inconclusive. CD68 is positive for the foreign-body giant cells. CK
highlights lymphoepithelial lesions.<br />
</li>
<li>Taken together, extranodal marginal zone lymphoma of MALT type with
amyloidosis is considered.<br />
</li>
</ul></li>
<li>2020-10-13 Patho
<ul>
<li>Lung, RUL, CT-guide biopsy - interstitial fibrosis and lymphoplasma
cells infiltration<br />
</li>
<li>The immunohistochemical stains of CD3, CD20, CD138, and Ki-67 show
mixed lymphoid and plasma cells population with lymphoid follicles.</li>
<li>The immunohistochemical stain of CK reveals no invasive tumor. No
amyloid deposition is seen.</li>
</ul></li>
</ul></li>
<li>Surgery
<ul>
<li>2019-12-30
<ul>
<li>One nodular lesion was noted over left apex of LUL, another one
nodule was noted over LUL, size about 0.8cm and 1.5 cm.</li>
<li>Frozen section: benign lesion.</li>
</ul></li>
</ul></li>
<li>Regimen
<ul>
<li>2021-08 ~ ongoing R-CVP (R-COP)
<ul>
<li>Rituximab 375mg/m2 IV D1</li>
<li>Cyclophosphamide 750mg/m2 IV D1</li>
<li>Vincristine 1.4mg/m2 IV D1</li>
<li>Prednisone 40mg/m2 PO D1-5</li>
<li>repeat every 21 days for a max of 8 cycles</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This 80-year-old male patient was diagosed with extranodal marginal
zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 2021
summer, being receiving R-CVP since 2021-08 and partial response was
seen in early Jan 2022 based on CT and PET images.</li>
<li>R-CHOP, R-CVP (which is being usd now), Bendamustine + Rituximab,
are candidate regimen as first-line therapy. no issue with current
regimen.</li>
<li>Consolidation with rituximab 375mg/m2 one dose every 8~12wk for up
to 24 mo could be an optional extended therapy for future
consideration.</li>
</ul>
</div>
<div id="section-293" class="section level2">
<h2>220110</h2>
<p>COPD is listed as one of the diagnoses (but not in current problem
list) in this hospitalization, however no corresponding medication
prescribed yet.</p>
<p>Some bronchodilators such as beta agonists, antimuscarinic agents, or
methylxanthines might be considered later after other acute symptoms
mitigated.</p>
</div>
</div>
<div id="section-294" class="section level1">
<h1>701034857</h1>
<div id="section-295" class="section level2">
<h2>210816</h2>
<p>{liver cancer with bone mets}</p>
<p>[initial presentation]</p>
<ul>
<li>2017~ abdominal fullness</li>
</ul>
<p>[definite diagnosis, disease extent, effect &amp; side effect]</p>
<ul>
<li>2017-09-20 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>parenchymal liver disease; postcholecystectomy; liver cyst; hepatic
tumors, three suspected HCC</li>
</ul></li>
<li>2018-04-03 CT, ABD - liver, spleen, biliary duct
<ul>
<li>HCCs s/p operation and TACE without viable tumor.</li>
</ul></li>
<li>2018-07-25 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>parenchymal liver disease; postcholecystectomy; liver cyst; probable
hepatic tumor; renal stone, left</li>
</ul></li>
<li>2018-12-26 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>liver cirrhosis; postcholecystectomy; hepatic tumor, nature?</li>
</ul></li>
<li>2019-03-03 CT, ABD - liver, spleen, biliary duct
<ul>
<li>HCC s/p TACE with recurrent HCC at S3 and S7.</li>
</ul></li>
<li>2019-05-08 Echo for liver, gall bladder, pancreas, spleen
<ul>
<li>parenchymal liver disease; hepatic tumors, two c/w HCC; increased
risk of RFA due to near diaphargm</li>
</ul></li>
<li>2019-06-29 CT, ABD - liver, spleen, biliary duct
<ul>
<li>HCC s/p op. and TACE with viable tumor at S7.; liver cirrhosis.</li>
</ul></li>
<li>2019-09-23 MRI, liver, spleen
<ul>
<li>a recurrent HCC (2.0cm) in S7 of liver.</li>
</ul></li>
<li>2020-02-03 CT, ABD - liver, spleen, biliary duct
<ul>
<li>HCCs s/p operation and TACE. a recurrent HCC (2.9cm) in S7 of
liver.</li>
</ul></li>
<li>2020-05-13 Abdominal Ultrasonography
<ul>
<li>liver cirrhosis; hepatic tumors, two probable hcc</li>
</ul></li>
<li>2020-12-30 Abdominal Ultrasonography
<ul>
<li>liver cirrhosis; hepatic tumors, three c/w hcc</li>
</ul></li>
<li>2021-05-24 CT, ABD - liver, spleen, biliary duct
<ul>
<li>HCCs s/p operation and TACE. recurrent HCCs (up to 4.3cm) in S7-8 of
liver. some lucent lesions in left pelvic bone probable metastases.</li>
</ul></li>
<li>2021-05-26 Abdominal Ultrasonography
<ul>
<li>liver cirrhosis; hepatic tumors, five c/w HCC (two s/p TACE with
viable tumors, three recurrent).</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>HCC op and TACE done at other hospital in late 2017.</li>
<li>entecavir been used years ago, restarted from 2021-07-03
(self-paid).</li>
<li>nexavar (sorafenib) 200mg BIDAC tappered to QDAC because of poor
appetite, dizziness, malaise.</li>
<li>palliative RT to the Lt shoulder to deliver at least 30 Gy/ 10 fx
started in the middle third of 2021-08.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>medication
<ul>
<li>no issues with the following indications
<ul>
<li>HCC
<ul>
<li>nexavar (sorafenib 200mg) PO QDAC (Child-Pugh Class A)</li>
</ul></li>
<li>HBV, cirrhosis
<ul>
<li>baraclude (entecavir 0.5mg) PO QDAC</li>
<li>baogan (silymarin 150mg) PO BID</li>
</ul></li>
</ul></li>
<li>potential interaction
<ul>
<li>the antitumor activity of sorafenib might be potentially reduced by
neomycin for the later may decrease the serum concentration of the
former.</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>palliative RT is appropriate for symptom control and/or prevention
of complications from metastatic lesions, such as bone (like this
patient) or brain.</li>
</ul></li>
<li>patient wants to take herbal medicine.
<ul>
<li>not being followed up with chinese medicine department since late
2017</li>
<li>no herbal medicine items disclosed in PharmaCloud.</li>
</ul></li>
<li>dMMR/MSI-H, NTRK, BRCA1/2 gene tests not found in the charts</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>introduce the patient to visit our chinese medicine OPD to get
scientfic chinese medicine rather than using unknnow herbal
medicine.</li>
<li>shorten the use time of meomycin to avoid potential drug interaction
with sorafenib.</li>
<li>dMMR/MSI-H, NTRK, BRCA1/2 gene tests might be ordered if
needed.</li>
<li>the patient seemed being hesitating to have curative care for a not
short while and hopping from and to WanFang hospital for medical demand,
having him to meet with social-work staff might be of help to get his
considerations behind.</li>
</ul>
</div>
</div>
<div id="section-296" class="section level1">
<h1>701049704</h1>
<div id="section-297" class="section level2">
<h2>220301</h2>
<p>[objective]</p>
<ul>
<li>underlying disease
<ul>
<li>ESRD and dependence on renal dialysis (QW135)</li>
</ul></li>
<li>exam finding
<ul>
<li>2021-12-23 CT
<ul>
<li>Right hilar lung meta, in regression.</li>
<li>Mediasitnal lymphadenopathy, regressed.</li>
<li>s/p left nephrectomy.</li>
</ul></li>
<li>2021-09-24 CT
<ul>
<li>Bladder ca. with right pulmonary hilar meta, causing right lung
partial collapse and bilatral pleural effusion. The tumor is stationary
in size and extension.</li>
</ul></li>
<li>2021-08-13 CT
<ul>
<li>Lung metastases show decreasing in size.</li>
</ul></li>
<li>2021-04-21 bronchoscopy
<ul>
<li>right main residual endobronchial tumors s/p electrocautery.</li>
<li>RUL and right intermediate bronchus endobronchial tumors, cannot be
approached.</li>
</ul></li>
<li>2021-04-21 patho - bronchus biopsy
<ul>
<li>sections show solid sheets of hyperchromatic tumor cells in a
fibrotic stroma. keratinization is focally seen.</li>
<li>IHC: CK5/6(+), p63(+), GATA3(+), TTF-1(-), and CD56(-). the results
are consistent with metastatic urothelial carcinoma.</li>
</ul></li>
<li>2021-04-16 bronchoscopy
<ul>
<li>autofluorescence: abnormal mucosa over right main bronchus</li>
<li>right main bronchus: total occlusion by tomor s/p biopsy for 1
specimen with mild bloody oozing s/p epinephrin 0.5 amp local spray</li>
<li>EBUS: endobronchial tumor over right main bronchus.</li>
</ul></li>
<li>2021-03-25 chest PA (erect) view
<ul>
<li>extensive opacification and volume reduce and nodular opacities over
Rt lung, in progression associated Rt pleural effusion as compared with
previous image</li>
<li>obliteration of Rt main bronchus</li>
<li>small nodular opacities over left lung</li>
</ul></li>
<li>2021-02-19 CT - lung/mediastinum/pleura
<ul>
<li>right middle lobe lung cancer with right lower lobe lung mets is
suspected.</li>
</ul></li>
<li>2020-10-29 chest AP
<ul>
<li>extensive consolidation in Rt upper lobe and extensive ground glass
opacity over Rt mid and lower lung zones</li>
</ul></li>
<li>2020-10-16 patho - urinary bladder TUR
<ul>
<li>histologic type: papillary urothelial carcinoma, invasive, with
marked squamous differentiation</li>
<li>histologic grade: high-grade</li>
<li>tumor configuration: papillary</li>
<li>mascularis propria: present</li>
<li>microscopic tumor extension: tumor invades subepithelial connective
tissue</li>
<li>VENTANA PD-L1 (SP142) assay for urothelial carcinoma: PD-L1
expression &lt;5% IC</li>
</ul></li>
<li>2020-08-17 patho - urethra biopsy
<ul>
<li>urothelial carcinoma, low-grade.</li>
<li>muscularis propria not present.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-01-16 Transurethral Resection of Bladder Tumor, TURBT</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-10: 60Gy/30fx to the Rt hilar mets.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-11: VAC(vinblastin 3mg/m2, doxorubicin 22.5mg/m2, carboplatin
50mg)</li>
<li>2021-05 ~ 2021-09: gemcitabine + carboplatin</li>
<li>2020-11 ~ 2020-12: doxorubicin (intravesical)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>hypotenstion 80/40 around 2022-03-01 01:00 ~ 02:00 was mitigated to
110/55 at 08:20 later the same day.</li>
<li>HGB 8.2 g/dL reported on 2022-02-28, EPO 5000U weekly could be
considered if no contraindiction, until the reading backs to 11
g/dL.</li>
</ul>
</div>
<div id="section-298" class="section level2">
<h2>210831</h2>
<p>{lowering BP gently}</p>
<p>visiting the patient at around 16:45 on 2021-08-30, he did not
complain of discomfort or unwellness these days, however he shared his
experience of dizziness and fainting when SBP below 160mmHg since years
ago. lowering blood pressure should be in a gentle way.</p>
</div>
<div id="section-299" class="section level2">
<h2>210830</h2>
<p>{Low HGB, HTN, ESRD}</p>
<p>[objective]</p>
<ul>
<li>2021-08-25
<ul>
<li>epoetin beta 5000 unit SC administered (QW3)</li>
</ul></li>
<li>lab data
<ul>
<li>RBC 2.84(8/30), 2.51(8/26), 2.28(8/24)</li>
<li>HGB 8.6 (8/30), 7.8 (8/26), 7.0 (8/24)</li>
<li>Na 135mmol/L(8/24)</li>
</ul></li>
<li>blood pressure around 200/90 for half week</li>
<li>current medication including:
<ul>
<li>captopril 25mg PO BID</li>
<li>nicorandil 5mg PO HS</li>
<li>amlodipine 5mg PO QW2467</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Low HGB
<ul>
<li>EPO worked, RBC and HGB increased gradually, still some gap to
normal range.</li>
</ul></li>
<li>hypertenstion
<ul>
<li>drugs act as antihypertensive agents:
<ul>
<li>captopril (angiotensin converting enzyme inhibitor)</li>
<li>nicorandil (guanylyl cyclase stimulator; K channel activator)</li>
<li>amlodipine (Ca channel blocker)</li>
</ul></li>
<li>for an ESRD patient, diurectics might not be indicated</li>
<li>sodium had fallen to the lower margin of normal range, no need to
restrict Na intake.</li>
<li>interdialytic BP of &lt;140/80 mmHg could be set an the target
<ul>
<li>there were argues on beta-blockers application to NSTEMI patient,
source: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721004/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721004/</a></li>
<li>increase dialysis time: the length or frequency of sessions is often
effective in reducing target dry weight.</li>
</ul></li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep routine CBC monitoring as usual.</li>
<li>increase dialysis time might be considered if blood pressure remains
high too long.</li>
</ul>
</div>
<div id="section-300" class="section level2">
<h2>210826</h2>
<p>{bladder cancer with lung mets}</p>
<p>[definite diagnosis]</p>
<ul>
<li>2020-08-17 patho - urethra biopsy
<ul>
<li>urothelial carcinoma, low-grade.<br />
</li>
<li>muscularis propria not present.<br />
</li>
</ul></li>
<li>2020-10-16 patho - urinary bladder TUR
<ul>
<li>histologic type: papillary urothelial carcinoma, invasive, with
marked squamous differentiation<br />
</li>
<li>histologic grade: high-grade</li>
<li>tumor configuration: papillary<br />
</li>
<li>mascularis propria: present<br />
</li>
<li>lymphovascular invasion: not identified<br />
</li>
<li>microscopic tumor extension: tumor invades subepithelial connective
tissue<br />
</li>
<li>VENTANA PD-L1 (SP142) assay for urothelial carcinoma: PD-L1
expression &lt;5% IC<br />
</li>
</ul></li>
<li>2020-10-29 chest AP
<ul>
<li>extensive consolidation in Rt upper lobe and extensive ground glass
opacity over Rt mid and lower lung zones</li>
</ul></li>
<li>2021-02-19 CT - lung/mediastinum/pleura
<ul>
<li>imp: right middle lobe lung cancer with right lower lobe lung mets
is suspected.</li>
</ul></li>
<li>2021-03-25 chest PA (erect) view
<ul>
<li>extensive opacification and volume reduce and nodular opacities over
Rt lung, in progression associated Rt pleural effusion as compared with
previous image</li>
<li>obliteration of Rt main bronchus</li>
<li>small nodular opacities over left lung</li>
</ul></li>
<li>2021-04-16 bronchoscopy
<ul>
<li>autofluorescence: abnormal mucosa over right main bronchus</li>
<li>right main bronchus: total occlusion by tomor s/p biopsy for 1
specimen with mild bloody oozing s/p epinephrin 0.5 amp local spray</li>
<li>EBUS: endobronchial tumor over right main bronchus.</li>
</ul></li>
<li>2021-04-21 patho - bronchus biopsy
<ul>
<li>sections show solid sheets of hyperchromatic tumor cells in a
fibrotic stroma. keratinization is focally seen.</li>
<li>IHC stains CK5/6(+), p63(+), GATA3(+), TTF-1(-), and CD56(-). the
results are consistent with metastatic urothelial carcinoma.</li>
</ul></li>
<li>2021-04-22 bronchoscopy
<ul>
<li>right main residual endobronchial tumors s/p electrocautery.</li>
<li>RUL and right intermediate bronchus endobronchial tumors, cannot be
approached.</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2020-11-24, -12-01, -12-08: doxorubicin</li>
<li>2020-12-15: cisplatin</li>
<li>2020-12-22, -12-29: doxorubicin</li>
<li>2021-05-11 up to now: doxorubicin + carboplatin, palliative</li>
</ul>
<p>[assessment]</p>
<ul>
<li>this is an ESRD patient on hemodialysis with multiple
comorbidities.</li>
<li>chemo drug dosing - source: <a href="https://pubmed.ncbi.nlm.nih.gov/30942181/" class="uri">https://pubmed.ncbi.nlm.nih.gov/30942181/</a>
<ul>
<li>doxorubicin:
<ul>
<li>hemodialysis: consider administering 75% of the original dose.</li>
</ul></li>
<li>carboplatin:
<ul>
<li>hemodialysis: carboplatin dose (mg) = target AUC x 25; administer on
a nondialysis day, hemodialysis should occur between 12 to 24 hours
after carboplatin dose.</li>
</ul></li>
</ul></li>
<li>hypochromemia
<ul>
<li>HGB 7.8g/dL reported on 2021-08-26 remains low for now.</li>
<li>epoetin beta 5000 unit SC QW3 prescribed since 2021-08-24.</li>
</ul></li>
<li>not received chemo yet since this hospitalization.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>drugs prescribed for NSTEMI found in PharmCloud, refilled items
listed as following, might be set as patient-carried ones into active
medication if no contraindication
<ul>
<li>famotidine 20mg QD</li>
<li>clopidogrel 75mg QD</li>
<li>aspirin 100mg QD</li>
<li>amiodarone QD</li>
<li>nitroglycerin ASORDER</li>
<li>nicorandil 5mg HS</li>
<li>amlodipine 5mg ASORDER</li>
<li>atorvastatin 20mg QD</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-301" class="section level1">
<h1>701057711</h1>
<div id="section-302" class="section level2">
<h2>999999</h2>
<ul>
<li>D-colon cancer obstruction s/p self expandable metalic stent placed
on 2020-07-16, and single-incision laparoscopic surgery (SILS) with left
hemicolectomy on 2020-07-22</li>
<li>patho colon segmental resection for tumor reported on 2020-07-28:
<ul>
<li>tumor, descending colon, laparoscopic low anterior resection (LAR) -
adenocarcinoma</li>
<li>lymph node, mesocolic, dissection - Tumor metastasis (2/16) without
extracapsular extension (0/2).</li>
<li>AJCC pathologic staging pT4aN1b (if cM0), stage IIIB.</li>
<li>histology grade G2: moderately differentiated with focal tumor
necrosis, abscess and mucin production.</li>
<li>ImmunoHistoChemistry for tumor cells: EGFR(+, 100%), PMS2(+),
MLH1(+), MSH2(+) and MSH6(+).</li>
</ul></li>
<li>mFOLFOX6 adjuvant chemotherapy 12 cycles from 2020-08-14 to
2021-01-22.</li>
<li>metastatic adenocarcinoma over left lower lung status post
video-assisted thoracic surgery left lower lung wedge resection on
2021-02-26.</li>
<li>shift chemo regimen to FOLFIRI since 2021-03-26.</li>
</ul>
<p>Decreased chemotherapy dose to 67 % for grade 3 diarrhea with blody
weight loss. Decreased chemotherapy dose to 75 % for grade 2 diarrhea
with blody weight loss.</p>
</div>
</div>
<div id="section-303" class="section level1">
<h1>701072376</h1>
<div id="section-304" class="section level2">
<h2>220408</h2>
<p>{cholangiocarcinoma, recurrenct, liver and lung mets, s/p colon
cancer}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2021-12-21 CT
<ul>
<li>S/P right lobectomy and cholecystectomy. S/P colostomy.</li>
<li>Multiple recurrent tumors in the liver and peritoneal seeding, lymph
nodes metastasis, bilateral lung metastasis. (recurrent
cholangiocarcinoma or colon malignancy?)</li>
</ul></li>
<li>2021-11-16 CT
<ul>
<li>recurrent cholangiocarcinoma in left hepatic lobe with lung and Rt
cardiophenic angle LNs metastases. small airways disease in lungs
too.</li>
</ul></li>
<li>2021-09-01 Myocrdial perfusion SPECT with persantin
<ul>
<li>Mildly improved myocardial perfusion to LV compared with the
previous study on 2020-06-02, indicating resposne to current
therapy.</li>
<li>There is still mild myocardial ischemia at the basal inferolateral
wall and apical inferolateral wall (LCx territory) of LV. 3. No
dilatation of LV is noted.</li>
</ul></li>
<li>2021-06-02 Myocrdial perfusion SPECT with persantin
<ul>
<li>Probably mild to moderate myocardial ischemia with possible a small
portion of severe ischemia at the inferoapical wall and inferolateral
wall and mild myocardial ischemia at the inferoseptal wall and posterior
wall.</li>
</ul></li>
<li>2021-03-25 MRI - L-spine
<ul>
<li>mild spondylolisthesis at L5-S1</li>
<li>herniated discs in the L2/3, L3/4, and L4/5 discs.</li>
</ul></li>
<li>2019-05-21 CT
<ul>
<li>Recurrent cholangiocarcinoma or artifact 1.8 cm in S4 of the liver
is suspected. Please correlate with AFP, CEA, and MRI.</li>
</ul></li>
<li>2018-08-07 SONO - Hepatobiliary
<ul>
<li>Post right hepatectomy. Poor defined gallbladder.</li>
</ul></li>
<li>2018-03-23 Surgical pathology Level V
<ul>
<li>Diagnosis: Liver, intrahepatic bile ducts, S5, right lobectomy -
Cholangiocarcinoma
<ul>
<li>Pathologic Staging (AJCC): pT2N0(cMx); Stage II if cM0</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic Type: Cholangiocarcinoma<br />
</li>
<li>Histologic Grade: GIII (Poorly differentiated)<br />
</li>
<li>Tumor Growth Pattern: Mass-forming<br />
</li>
<li>Microscopic Tumor Extension: Tumor confined to hepatic
parenchyma<br />
</li>
<li>Small Vessel Invasion (L): Present<br />
</li>
<li>Additional Pathologic Findings: Cirrhosis<br />
</li>
<li>Hepatitis: Chronic hepatitis B<br />
</li>
<li>Ishak Modified HAI Grading: Score = 4 (interphase hepatitis = 1/4,
confluent necrosis = 0/6, focal necrosis = 1/4, portal inflammation =
2/4) (Corresponding Metavir A1, mild activity)<br />
</li>
<li>Ishak Staging: F6 (Corresponding Metavir F4, cirrhosis)</li>
<li>Fatty Change: Present (5%)</li>
<li>IHC for tumor cells: CK7(+), Hepa-1(-), Arginase(-)</li>
</ul></li>
</ul></li>
<li>2018-02-23 Surgical pathology Level V
<ul>
<li>Diagnosis: Liver, c;inical histroy of colorectal adenocarcinoma,
neele biopsy - Adenocarcinoma.</li>
<li>IHC:
<ul>
<li>CK7(+), CK20(-), CDX-2(-): dis-favor colorectal origin;</li>
<li>Hepatocyte(-), Arginase(-): dis-favor hepatocellular carcinoma.</li>
<li>CK19(+): favor cholangiocarcinoma.</li>
</ul></li>
</ul></li>
<li>2018-01-19 CT
<ul>
<li>Irregular low density(around 2.4cm) in right lobe liver, suspected
liver metastasis.</li>
<li>Post-op with colostomy in left abdomen.</li>
</ul></li>
<li>2017-07-12 Tc-99m MDP whole body bone scan
<ul>
<li>A new lesion in a middle C-spine in comparison with the previous
study on 2013-07-17, the nature is to be determined (DJD, post-traumatic
change or other nature ?), suggesting follow-up.</li>
<li>Significantly increased radioactivity in the mandilbe, dental
problems may show this picture.</li>
<li>Suspected benign lesions in the maxilla, bilateral sternoclavicular
junctions, L-S junction, bilateral shoulders, bilateral knees, and
bones/joints of right foot.</li>
</ul></li>
<li>2017-07-12 CT
<ul>
<li>Suspect small airway disease in lower lobes of lung.</li>
<li>Gallstones.</li>
</ul></li>
<li>2007-10-26 Patho
<ul>
<li>rectal adenocarcinoma pT2N1M0 s/p abdominal perineal resection.</li>
</ul></li>
</ul></li>
<li>surgical operations
<ul>
<li>2021-03-23
<ul>
<li>Surgery: tumors excision</li>
<li>Finding: multiple granulomatous polyps formation around the
colostomy</li>
</ul></li>
</ul></li>
<li>chemotherapy regimen
<ul>
<li>2022-04-07 - 5-FU + carbosplatin + gemcitabine</li>
<li>2022-02-23 ~ 2022-03-22 - 5-FU + cisplatin + gemcitabine</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The serum creatinine level rises from 1.04mg/dL (2022-01-04) to
1.62mg/dL (2022-04-07), which should be addressed.</li>
<li>In the new regimen used during this hospital stay, cisplatin was
substituted for carboplatin, which might mitigate renal toxicity.</li>
</ul>
</div>
<div id="section-305" class="section level2">
<h2>220323</h2>
<p>{cholangiocarcinoma s/p colon cancer}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2021-12-21 CT
<ul>
<li>S/P right lobectomy and cholecystectomy. S/P colostomy.</li>
<li>Multiple recurrent tumors in the liver and peritoneal seeding, lymph
nodes metastasis, bilateral lung metastasis. (recurrent
cholangiocarcinoma or colon malignancy?)</li>
</ul></li>
<li>2021-11-16 CT
<ul>
<li>recurrent cholangiocarcinoma in left hepatic lobe with lung and Rt
cardiophenic angle LNs metastases. small airways disease in lungs
too.</li>
</ul></li>
<li>2021-09-01 Myocrdial perfusion SPECT with persantin
<ul>
<li>Mildly improved myocardial perfusion to LV compared with the
previous study on 2020-06-02, indicating resposne to current
therapy.</li>
<li>There is still mild myocardial ischemia at the basal inferolateral
wall and apical inferolateral wall (LCx territory) of LV. 3. No
dilatation of LV is noted.</li>
</ul></li>
<li>2021-06-02 Myocrdial perfusion SPECT with persantin
<ul>
<li>Probably mild to moderate myocardial ischemia with possible a small
portion of severe ischemia at the inferoapical wall and inferolateral
wall and mild myocardial ischemia at the inferoseptal wall and posterior
wall.</li>
</ul></li>
<li>2021-03-25 MRI - L-spine
<ul>
<li>mild spondylolisthesis at L5-S1</li>
<li>herniated discs in the L2/3, L3/4, and L4/5 discs.</li>
</ul></li>
<li>2019-05-21 CT
<ul>
<li>Recurrent cholangiocarcinoma or artifact 1.8 cm in S4 of the liver
is suspected. Please correlate with AFP, CEA, and MRI.</li>
</ul></li>
<li>2018-08-07 SONO - Hepatobiliary
<ul>
<li>Post right hepatectomy. Poor defined gallbladder.</li>
</ul></li>
<li>2018-03-23 Surgical pathology Level V
<ul>
<li>Diagnosis: Liver, intrahepatic bile ducts, S5, right lobectomy -
Cholangiocarcinoma
<ul>
<li>Pathologic Staging (AJCC): pT2N0(cMx); Stage II if cM0</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic Type: Cholangiocarcinoma<br />
</li>
<li>Histologic Grade: GIII (Poorly differentiated)<br />
</li>
<li>Tumor Growth Pattern: Mass-forming<br />
</li>
<li>Microscopic Tumor Extension: Tumor confined to hepatic
parenchyma<br />
</li>
<li>Small Vessel Invasion (L): Present<br />
</li>
<li>Additional Pathologic Findings: Cirrhosis<br />
</li>
<li>Hepatitis: Chronic hepatitis B<br />
</li>
<li>Ishak Modified HAI Grading: Score = 4 (interphase hepatitis = 1/4,
confluent necrosis = 0/6, focal necrosis = 1/4, portal inflammation =
2/4) (Corresponding Metavir A1, mild activity)<br />
</li>
<li>Ishak Staging: F6 (Corresponding Metavir F4, cirrhosis)</li>
<li>Fatty Change: Present (5%)</li>
<li>IHC for tumor cells: CK7(+), Hepa-1(-), Arginase(-)</li>
</ul></li>
</ul></li>
<li>2018-02-23 Surgical pathology Level V
<ul>
<li>Diagnosis: Liver, c;inical histroy of colorectal adenocarcinoma,
neele biopsy - Adenocarcinoma.</li>
<li>IHC:
<ul>
<li>CK7(+), CK20(-), CDX-2(-): dis-favor colorectal origin;</li>
<li>Hepatocyte(-), Arginase(-): dis-favor hepatocellular carcinoma.</li>
<li>CK19(+): favor cholangiocarcinoma.</li>
</ul></li>
</ul></li>
<li>2018-01-19 CT
<ul>
<li>Irregular low density(around 2.4cm) in right lobe liver, suspected
liver metastasis.</li>
<li>Post-op with colostomy in left abdomen.</li>
</ul></li>
<li>2017-07-12 Tc-99m MDP whole body bone scan
<ul>
<li>A new lesion in a middle C-spine in comparison with the previous
study on 2013-07-17, the nature is to be determined (DJD, post-traumatic
change or other nature ?), suggesting follow-up.</li>
<li>Significantly increased radioactivity in the mandilbe, dental
problems may show this picture.</li>
<li>Suspected benign lesions in the maxilla, bilateral sternoclavicular
junctions, L-S junction, bilateral shoulders, bilateral knees, and
bones/joints of right foot.</li>
</ul></li>
<li>2017-07-12 CT
<ul>
<li>Suspect small airway disease in lower lobes of lung.</li>
<li>Gallstones.</li>
</ul></li>
<li>2007-10-26 Patho
<ul>
<li>rectal adenocarcinoma pT2N1M0 s/p abdominal perineal resection.</li>
</ul></li>
</ul></li>
<li>surgical operations
<ul>
<li>2021-03-23
<ul>
<li>Surgery: tumors excision</li>
<li>Finding: multiple granulomatous polyps formation around the
colostomy</li>
</ul></li>
</ul></li>
<li>chemotherapy regimen
<ul>
<li>2022-02-23 ~ ongoing - 5-FU + cisplatin + gemcitabine</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Since late February 2022, the patient has been receiving 5-FU +
cisplatin + gemcitabine. No issue with current medication.</li>
<li>If a patient is not a candidate for a clinical trial or one is not
available, and if S-1 is not available, gemcitabine plus cisplatin is
recommended as a first-line regimen for patients with a good performance
status. Another reasonable, possibly better tolerated option is
gemcitabine plus oxaliplatin (GEMOX). Gemcitabine plus nanoparticle
albumin-bound paclitaxel (nabpaclitaxel) might also be considered.
<ul>
<li>reference: <a href="https://www.uptodate.com/contents/systemic-therapy-for-advanced-cholangiocarcinoma" class="uri">https://www.uptodate.com/contents/systemic-therapy-for-advanced-cholangiocarcinoma</a></li>
</ul></li>
</ul>
</div>
<div id="section-306" class="section level2">
<h2>220224</h2>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2021-12-21 CT
<ul>
<li>S/P right lobectomy and cholecystectomy. S/P colostomy.</li>
<li>Multiple recurrent tumors in the liver and peritoneal seeding, lymph
nodes metastasis, bilateral lung metastasis. (recurrent
cholangiocarcinoma or colon malignancy?)</li>
</ul></li>
<li>2021-11-16 CT
<ul>
<li>recurrent cholangiocarcinoma in left hepatic lobe with lung and Rt
cardiophenic angle LNs metastases. small airways disease in lungs
too.</li>
</ul></li>
<li>2021-09-01 Myocrdial perfusion SPECT with persantin
<ul>
<li>Mildly improved myocardial perfusion to LV compared with the
previous study on 2020-06-02, indicating resposne to current
therapy.</li>
<li>There is still mild myocardial ischemia at the basal inferolateral
wall and apical inferolateral wall (LCx territory) of LV. 3. No
dilatation of LV is noted.</li>
</ul></li>
<li>2021-06-02 Myocrdial perfusion SPECT with persantin
<ul>
<li>Probably mild to moderate myocardial ischemia with possible a small
portion of severe ischemia at the inferoapical wall and inferolateral
wall and mild myocardial ischemia at the inferoseptal wall and posterior
wall.</li>
</ul></li>
<li>2021-03-25 MRI - L-spine
<ul>
<li>mild spondylolisthesis at L5-S1</li>
<li>herniated discs in the L2/3, L3/4, and L4/5 discs.</li>
</ul></li>
<li>2019-05-21 CT
<ul>
<li>Recurrent cholangiocarcinoma or artifact 1.8 cm in S4 of the liver
is suspected. Please correlate with AFP, CEA, and MRI.</li>
</ul></li>
<li>2018-08-07 SONO - Hepatobiliary
<ul>
<li>Post right hepadectomy. Poor defined gallbladder.</li>
</ul></li>
<li>2018-03-23 Surgical pathology Level V
<ul>
<li>Diagnosis: Liver, intrahepatic bile ducts, S5, right lobectomy -
Cholangiocarcinoma
<ul>
<li>Pathologic Staging (AJCC): pT2N0(cMx); Stage II if cM0</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic Type: Cholangiocarcinoma<br />
</li>
<li>Histologic Grade: GIII (Poorly differentiated)<br />
</li>
<li>Tumor Growth Pattern: Mass-forming<br />
</li>
<li>Microscopic Tumor Extension: Tumor confined to hepatic
parenchyma<br />
</li>
<li>Small Vessel Invasion (L): Present<br />
</li>
<li>Additional Pathologic Findings: Cirrhosis<br />
</li>
<li>Hepatitis: Chronic hepatitis B<br />
</li>
<li>Ishak Modified HAI Grading: Score=4 (interphase hepatitis=1/4,
confluent necrosis=0/6, focal necrosis=1/4, portal inflammation=2/4)
(Corresponding Metavir A1, mild activity)<br />
</li>
<li>Ishak Staging: F6 (Corresponding Metavir F4, cirrhosis)</li>
<li>Fatty Change: Present (5%)</li>
<li>IHC for tumor cells: CK7(+), Hepa-1(-), Arginase(-)</li>
</ul></li>
</ul></li>
<li>2018-02-23 Surgical pathology Level V
<ul>
<li>Diagnosis: Liver, c;inical histroy of colorectal adenocarcinoma,
neele biopsy - Adenocarcinoma.</li>
<li>IHC:
<ul>
<li>CK7(+), CK20(-), CDX-2(-): dis-favor colorectal origin;</li>
<li>Hepatocyte(-), Arginase(-): dis-favor hepatocellular carcinoma.</li>
<li>CK19(+): favor cholangiocarcinoma.</li>
</ul></li>
</ul></li>
<li>2018-01-19 CT
<ul>
<li>Irregular low density(around 2.4cm) in right lobe liver, suspected
liver metastasis.</li>
<li>Post-op with colostomy in left abdomen.</li>
</ul></li>
<li>2017-07-12 Tc-99m MDP whole body bone scan
<ul>
<li>A new lesion in a middle C-spine in comparison with the previous
study on 2013-07-17, the nature is to be determined (DJD, post-traumatic
change or other nature ?), suggesting follow-up.</li>
<li>Significantly increased radioactivity in the mandilbe, dental
problems may show this picture.</li>
<li>Suspected benign lesions in the maxilla, bilateral sternoclavicular
junctions, L-S junction, bilateral shoulders, bilateral knees, and
bones/joints of right foot.</li>
</ul></li>
<li>2017-07-12 CT
<ul>
<li>Suspect small airway disease in lower lobes of lung.</li>
<li>Gallstones.</li>
</ul></li>
<li>2007-10-26 Patho
<ul>
<li>rectal adenocarcinoma pT2N1M0 s/p abdominal perineal resection.</li>
</ul></li>
</ul></li>
<li>surgical operations
<ul>
<li>2021-03-23
<ul>
<li>Surgery: tumors excision</li>
<li>Finding: multiple granulomatous polyps formation around the
colostomy</li>
</ul></li>
</ul></li>
<li>chemotherapy regimen
<ul>
<li>2022-02-23</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-307" class="section level1">
<h1>701084563</h1>
<div id="section-308" class="section level2">
<h2>220322</h2>
<p>{Small Lymphocytic Lymphoma}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-08 Patho - lymph node region resection
<ul>
<li>Lymph node, right neck, excision - Small lymphocytic lymphoma</li>
<li>IHC: CD20(+), CD23(+), CD3(-), CD5(+) and CD10(-).</li>
<li>According to above histopathologic findings and past history, it is
consistent with small lymphocytic lymphoma.</li>
</ul></li>
<li>2022-03-04 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in bilateral axillary lymph nodes, bilateral
supra and infraclavicular lymph nodes, bilateral neck lymph nodes and
abdominal lymph nodes, suggesting recurrent lymphoma involving multiple
lymph node regions on the both sides of the diaphragm (stage III).</li>
<li>Increased FDG accumulation in both kidneys, bilateral ureters and
colon. Physiological FDG accumulation is more likely.</li>
</ul></li>
<li>2022-03-03 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac bone, biopsy - Small lymphocytic lymphoma /
chronic lymphocytic leukemia<br />
</li>
<li>IHC: CD20(+), CD3(-), CD23(+), CD34(-), CD117(-), CD61 showed
adequate megakaryocyte with focal mononucleation and hyposegmentation,
MPO and CD71 showed marked hypoplasia of both myeloid and erythroid
series.</li>
</ul></li>
<li>2021-12-21 SONO - abdomen
<ul>
<li>Two gallbladder polyp or sludge (2.2 mm).<br />
</li>
<li>A renal cyst measuring 1 cm in left lower pole is noted.</li>
</ul></li>
<li>2021-09-28 MRI - larynx
<ul>
<li>Small residual bil. supraclavicular LNs, seems stationary.</li>
<li>Markedly regression in other neck LNs found, stationary.</li>
</ul></li>
<li>2021-07-06 SONO - abdomen
<ul>
<li>Two gallbladder polyp or sludge (&lt; 2 mm).<br />
</li>
<li>A renal cyst measuring 0.89 cm in left lower pole is noted.</li>
</ul></li>
<li>2021-03-23 MRI - larynx
<ul>
<li>Small residual bil. supraclavicular LNs, stationary.</li>
<li>Markedly regression in other neck LNs found, stationary.</li>
</ul></li>
<li>2020-12-29 SONO - abdomen
<ul>
<li>A gallbladder polyp 2.5 mm.<br />
</li>
<li>A renal cyst measuring 0.93 cm in left lower pole is noted.</li>
</ul></li>
<li>2020-10-06 MRI - larynx
<ul>
<li>Small residual bil. supraclavicular LNs.</li>
<li>Markedly regression in other neck found.</li>
<li>Chronic bil. paranasal sinusitis.</li>
</ul></li>
<li>2020-05-11 MRI - brain
<ul>
<li>Subacute ICH at left anterior frontal base. No evidence of brain
metastasis.</li>
</ul></li>
<li>2020-05-06 CT -brain
<ul>
<li>localized SAH in the bilateral inferior frontal regions.</li>
</ul></li>
<li>2020-04-16 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy - Compatible with B-cell lymphocytosis</li>
<li>B-cell proliferation in focal area, arranged in interstitial
pattern, which immunohistochemistry shows CD3 and CD5: similar pattern,
CD23: almost (-), CD20(+), Cyclin-D1(-), MPO(+) for myeloid series,
CD71(+) for erythroid series, CD61(+) for megakaryocytes and CD117(+)
for blast.. According to all above histopathologic findings, it is
compatible with B-cell lymphocytosis due to lack aberrant
expression.</li>
</ul></li>
<li>2020-04-08 Whole body PET scan
<ul>
<li>Glucose hypermetabolism in bilateral axillary lymph nodes,
supraclavicular lymph nodes, and cervical lymph nodes, suggesting
lymphoma with tumor recurrence in multiple lymph node regions.<br />
</li>
<li>Glucose hypermetabolism in the spleen and bilateral inguinal lymph
nodes, the nature is to be determined. Please correlate with clinical
findings and keep follow up to exclude the possibility of tumor
recurrence in these regions.</li>
<li>B-cell lymphoma s/p treatment with tumor recurrence, rc-stage II, at
least (AJCC 8th ed.), by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2020-03-27 Patho - lymphnode biopsy
<ul>
<li>Lymph node, right neck, excision - Small lymphocytic lymphoma<br />
</li>
<li>IHC: CD20(+), CD23(+, focal), CD3(-), CD5(+, focal), Bcl-2(+).</li>
<li>According to above histopathologic findings and past history, it is
consistent with small lymphocytic lymphoma.<br />
</li>
<li>Reference: S2014-05750 Lymph node, neck, excisional biopsy - Chronic
lymphocytic leukaemia / small lymphocytic lymphoma</li>
</ul></li>
<li>2020-03-19 MRI - larynx
<ul>
<li>lymphoma with extensive neck lymphadenopathy.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-03-08 Excision of rt neck tumor</li>
<li>2020-03-27 Excisional biopsy, right neck enlarged LAP</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-03-21 ~ now - bendamustine + rituximab</li>
<li>2022-03-18 ~ 2022-03-23 - hydroxyurea</li>
<li>2022-03-11 ~ 2022-03-18 - cyclophosphamide</li>
<li>2020-05-05 ~ 2020-08-03 - bendamustine + rituximab</li>
</ul></li>
<li>lab data
<ul>
<li>2022-03-22 BCR-abl mutation undetectable</li>
<li>2022-03-16 bone marrow
<ul>
<li>FLT3-D835 mutation undetectable</li>
<li>FLT3/ITD mutation undetectable</li>
<li>NPM1 mutation undetectable</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>For this patient with recurrent SLL, the rt neck tumor was excised
on 2022-03-08.</li>
<li>The patient is receiving bendamustine and rituximab, the same
regimen used from May to August of 2020.</li>
<li>There were no detectable mutations in any of the following genes:
BCR-abl (2022-03-22), FLT3-D835, FLT3/ITD, and NPM1 (2022-03-16).</li>
<li>There is no del(17p), TP53 mutation status, CpG-stimulated karyotype
or IGHV mutation status found in lab data.</li>
</ul>
</div>
</div>
<div id="section-309" class="section level1">
<h1>701096428</h1>
<div id="section-310" class="section level2">
<h2>220505</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-11 CT - abdomen, pelvis
<ul>
<li>Indication: Right ovarian cancer, pT2bN0; stage IIB; FIGO stage IIB
post Debulking surgery s/p C/T with BEP recurrence s/p Debulking surgery
on 2021/10/25</li>
<li>Abdominal CT with and without enhancement revealed:
<ul>
<li>s/p ATH and BSO.</li>
<li>Soft tissue mass at right pelvic floor up to 3.44*1.65cm in largest
dimension. In comparison with CT dated on 2021-10-04, the lesion
regressed.</li>
<li>s/p drainage tube placement at pelvis is found.</li>
<li>Wall thickening of the urinary bladder is found.</li>
<li>One cystic change at splenic tip up to 0.6cm in largest dimension is
found. Stable. Simple cyst is considered.</li>
<li>Calcified coronary arteries is found.</li>
<li>S/p port-A placement with its tip at SUPERIOR VENA CAVA.</li>
<li>Suggest clinical correlation</li>
</ul></li>
<li>IMp:
<ul>
<li>Right ovarian cancer s/p BSO and ATH with recurrence s/p dubulking
surgery. Residual soft tissue mass at right pelvis side wall. In
regression.</li>
<li>Wall thickening of the urinary bladder, post op. change? Ovarian
seeding at bladder out-layer? Suggest closely follow up.</li>
</ul></li>
</ul></li>
<li>2022-02-18 Chest PA erect view
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Right hemi-diaphragm elevation is noted, which may be due to
eventration.</li>
</ul></li>
<li>2021-10-26 Patho - soft tissue tumor, extenstive resection
<ul>
<li>S2021-14976:
<ul>
<li>Soft tissue, pelvic, excision  consistent with recurrent malignant
ovarian sex cord tumor<br />
</li>
</ul></li>
<li>F2021-420:
<ul>
<li>Soft tissue, pelvic, excision  consistent with recurrent malignant
ovarian sex cord tumor<br />
</li>
</ul></li>
</ul></li>
<li>2021-10-25 Frozen section
<ul>
<li>Preliminary diagnosis:
<ul>
<li>Soft tissue, pelvic, biopsy  consistent with recurrent malignant
tumor<br />
</li>
</ul></li>
</ul></li>
<li>2021-10-12 Whole body PET scan
<ul>
<li>An inhomogenous glucose hypermetabolic lesion in the right posterior
lower pelvic cavity. A recurrent tumor should be considered.</li>
<li>Mild glucose hypermetabolism in bilateral pulmonary hilar regions.
Inflammatory process may show this picture.</li>
<li>Increased FDG uptake in bilateral masseter muslces and increased FDG
accumulation in the colon, rectum, both kidneys and bilateral ureters.
Physiological FDG uptake/accumulation is more likely.</li>
</ul></li>
<li>2021-10-04 CT - abdomen, pelvis
<ul>
<li>S/P hysterectomy. A soft tissue lesion (3.6x5.4cm) at right pelvic
cavity with some cystic component suspected tumor recurrence.</li>
</ul></li>
<li>2021-08-16 Patho - soft tissue debridment
<ul>
<li>Skin and soft tissue, left anterior thigh., fasciectomy  Necrosis
and acute inflammation.</li>
</ul></li>
<li>2021-08-13 CT - left femur
<ul>
<li>Abscess formation at left anterior thigh (vastus medialis muscle)and
iliopsoas muscle</li>
<li>Cellulitis of left thigh</li>
<li>Post-OP change of pelvis with a mass lesion in right perirectal
region.</li>
</ul></li>
<li>2021-05-20 Patho - soft tissue tumor, extensive resection
<ul>
<li>pathologic diagnosis
<ul>
<li>Ovary right, debulking surgery  Compatible with malignant ovarian
sex cord tumor</li>
<li>Lymph nodes, pelvic, bilateral, BPLND  Negative for malignancy</li>
<li>Soft tissue, pelvic, debulking surgery  Metastatic tumor</li>
<li>AJCC 8 th edition, Pathology stage: pT2bN0; stage IIB; FIGO stage
IIB</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histologic Type: Compatible with malignant ovarian sex cord
tumor<br />
</li>
<li>Histologic grade: High grade<br />
</li>
<li>Regional Lymph Nodes: All lymph nodes negative for tumor cells
<ul>
<li>number of lymph node examined: 4 (left iliac), 1 (left obturator), 4
(right iliac), 1 (right obturator)<br />
</li>
</ul></li>
<li>Pathologic Stage
<ul>
<li>Primary Tumor: pT2b (tumor extension and/or implants on other pelvic
tissues)</li>
<li>Regional Lymph Nodes: pN0 (no regional lymph node metastasis)</li>
<li>Distant Metastasis: Not applicable</li>
</ul></li>
<li>Specimen labled pelvic tumor: Compatible with malignant ovarian
sex cord tumor with pelvic seeding</li>
<li>IHC: WT1(+), CAM 5.2(+), CK(-), Inhibin(-), CD117(focally weakly+),
DOG1(-), Desmin(-), Smooth mucle actin(-), CD34(-), S100(-), MDM2(-),
STAT6(-)<br />
</li>
</ul></li>
</ul></li>
<li>2021-05-19 Frozen section
<ul>
<li>Ovary right, frozen section  Favor malignant (pleomorphic
epitheloid tumor cells with necrosis), tumor nature wait for paraffin
section</li>
</ul></li>
<li>2021-05-13 Gynecologic ultrasonography
<ul>
<li>suspected pelvis mass &gt; 25cm, malignancy can not be ruled
out</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-25
<ul>
<li>operation
<ul>
<li>Excision of pelvic cancer</li>
<li>HIPEC</li>
<li>IOUS</li>
<li>Tenckhoff insertion - finding</li>
<li>s/p midline incision</li>
<li>Adhesion of small bowel was encountered.</li>
<li>IOUS: a recurrent ovarian cancer in the pelvic cavity adjacent to
rectum</li>
<li>Pathologic report of frozen section: malignancy</li>
<li>HIPEC regimen: Lipodox 30mg/m^2 + Carboplatin AUC 5</li>
<li>Drain: 15 Fr Blake drain x 1 in the pelvic cavity</li>
<li>Tenckhoff catheter from RLQ</li>
</ul></li>
</ul></li>
<li>2021-10-25
<ul>
<li>surgery
<ul>
<li>Debulking surgery + adhesiolysis - finding</li>
<li>Supraumbilical midline vertical skin incision</li>
<li>Uterus: s/p hysterectomy</li>
<li>Adnexa: s/p Bilateral Salpingo-oophorectomy</li>
<li>CDS: adhesion with intestines</li>
<li>Moderate adhesion between omentum, small &amp; large intestines and
CDS</li>
<li>A 5x4 cm mass at right pelvic cavity with cystic component, beside
the rectum.</li>
<li>s/p bilateral cystoscopic catheterization insertion before the
operation</li>
</ul></li>
</ul></li>
<li>2021-08-13
<ul>
<li>surgery
<ul>
<li>Deep debridement + fasciectomy + primary closure</li>
</ul></li>
<li>finding
<ul>
<li>An abscess with necrotizing fasciitis and gas gangrene is found
about 10*20cm in size over the left anterior thigh.</li>
</ul></li>
</ul></li>
<li>2021-05-19
<ul>
<li>operation
<ul>
<li>enterolysis</li>
<li>excision of intraabdominal tumor</li>
</ul></li>
<li>finding
<ul>
<li>s/p hystectomy</li>
<li>a bulky tumor mass in pelvic cavity with adhesion to small bowel and
rectum</li>
<li>several bleeders in pelvic wall</li>
</ul></li>
</ul></li>
<li>2021-05-19
<ul>
<li>surgery
<ul>
<li>Pelvic tumor, suspect malignancy</li>
<li>Frozen: sarcoma</li>
<li>Debulking surgery (tumor excision + pelvic lymph nodes dissection+
Cytoreduction surgery + infracolic omentectomy )</li>
</ul></li>
<li>finding
<ul>
<li>Supraumbilical midline vertical skin incision</li>
<li>Uterus: s/p hysterectomy</li>
<li>Adnexa: pelvic tumor 10*10 cm, invasion to posterior pelvic wall,
intra-op rupture(+)</li>
<li>CDS: invisible due to tumor mass occupied</li>
<li>Ascites: bloody , about 500 ml</li>
<li>Bilateral pelvic lymph nodes: normal(+), enlarged(-),
indurated(-)</li>
<li>Omentum: normal appearance, infracolic omentectomy was done.</li>
<li>Liver: grossly normal &amp; smooth</li>
<li>Appendix: grossly normal.</li>
<li>After the operation, suboptimal debulking surgery was achieved.</li>
<li>Residue tumor: multiple tumors, maximal diameter more than 1 cm,
over rectum and peritonealwall and bladder base</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-05-05 - paclitaxel + cisplatin</li>
<li>2022-04-19 - paclitaxel</li>
<li>2022-04-12 - paclitaxel + cisplatin</li>
<li>2022-03-16 - paclitaxel</li>
<li>2022-03-09 - paclitaxel + cisplatin</li>
<li>2022-02-16 - paclitaxel</li>
<li>2022-02-08 - paclitaxel + cisplatin</li>
<li>2022-01-13 - paclitaxel</li>
<li>2022-01-05 - paclitaxel + cisplatin</li>
<li>2021-12-24 - paclitaxel</li>
<li>2021-12-16 - paclitaxel + cisplatin</li>
<li>2021-11-22 - paclitaxel + cisplatin</li>
<li>2021-10-23 - liposome doxorubicin + carboplatin</li>
<li>2021-09-22 - bleomycin</li>
<li>2021-09-13 - bleomycin + etoposide + cisplatin</li>
<li>2021-07-14 - bleomycin + etoposide + cisplatin</li>
<li>2021-07-01 - bleomycin</li>
<li>2021-06-24 - bleomycin</li>
<li>2021-06-17 - bleomycin + etoposide + cisplatin (BEP)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The CT (2022-04-11) showed a residual soft tissue mass over the
right pelvis side wall in regression, as well as a thickening of the
bladder wall. At least a partial response was achieved by the current
regimen [paclitaxel + cisplatin] so far.</li>
<li>The blood concentrations of cations have remained relatively low in
recent months. Mg 1.4 mg/dL, K 3.8 mmol/L, Na 134 mmol/L (2022-05-03),
Ca 2.01 mmol/L (2022-04-18). Following administration of magnesium
sulfate injections, Mg rebounded to 2.0 mg/dL on 2022-05-05.</li>
<li>Poor control of blood sugar levels. A record of 422 mg/dL was
obtained 2022-05-05 07:33, one hour after 8 units of insulin actrapid
were administered. No HbA1c data found in recent 3 months.</li>
<li>The last acute embolism and thrombosis of unspecified deep veins of
lower extremity was diagnosed in cardiology OPD on 2021-11-19. There is
no cardiology follow-up record since then, so it is unclear if the
thrombosis risk remains for the purpose of determining the need for
edoxaban.</li>
</ul>
</div>
<div id="section-311" class="section level2">
<h2>220408</h2>
<p>[assessment]</p>
<ul>
<li>Systemic therapy regimens for patients with recurrent advanced sex
cord stromal tumors might include paclitaxel + carboplatin, EP
(etoposide + cisplatin), or BEP (bleomycin + etoposide + cisplatin). The
patient had received BEP from June to September 2021 and has been
receiving paclitaxel + cisplatin since November 2021.</li>
<li>The last three consecutive analyses of body fluid cytology (ascites,
on 2022-02-18, 2022-03-14, 2022-03-18) after debulking surgery with
HIPEC (2021-10-25) did not reveal granuloma or malignancy. Regarding the
cancer, so far, not bad.</li>
<li>Low serum magnesium level (1.6mg/dL on 2022-04-06) has been managed
with prescribed magesium sulfate injection, however, high blood sugar
reading (359mg/dL at 17:23 on 2022-04-07) should be monitored closely to
determine whether a hypoglycemic agent is needed.</li>
</ul>
</div>
</div>
<div id="section-312" class="section level1">
<h1>701113992</h1>
<div id="section-313" class="section level2">
<h2>220504</h2>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>Esophagus cancer (Squamous cell carcinoma) with right middle lobe
lung metastasis, cT4bN2M1, stage IVB, s/p Tr and jejunostomy on
2022-02-18</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-05-03 Chest PA/AP view
<ul>
<li>Ground glass opacity in RUL.</li>
</ul></li>
<li>2022-04-18 Abdominal Ultrasonography
<ul>
<li>liver parenchyma disease (incomplete exam of liver)</li>
<li>bilateral renal cysts</li>
<li>pancreas obscured</li>
<li>left pleural effusion</li>
</ul></li>
<li>2022-04-06 Chest PA/AP view
<ul>
<li>S/P tracheostomy</li>
<li>S/P port-A implantation.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Spondylosis of the T-spine</li>
<li>Blunting of bilateral costal-phrenic angle is noted, which may be
due to pleura effusion?</li>
<li>Increased lung markings on both lower lung are noted. Please
correlate with clinical condition.</li>
<li>Otherwise, there is no significant abnormality of the chest. (Note
that ground-glass lesion, small nodule or retrocardiac lesion might be
missed on plain chest radiography.)</li>
</ul></li>
<li>2022-03-26 MRI - brain
<ul>
<li>Without- and with-contrast multiplanar cerebral MRI (including axial
and coronal T1W FLAIR, axial and sagittal T2WI, axial T2W FLAIR, and
axial DW images; using 4 mm thickness for sagittal section and 5 mm
thickness for the others) and cerebral TOF MRA reveal:
<ul>
<li>General enlargement of cistern spaces and cortical sulci, indicating
general brain atrophy.</li>
<li>Dilatation of ventricles, periventricular T2-hyperintense caps and
flattening corpus callosum, indicating hydrocephalus.</li>
<li>Diffuse T2-hyperintensities in periventricular deep white matters,
indicating leukoaraiosis.</li>
<li>No evidence of intracranial hemorrhage, nor acute/subacute
infarct.</li>
<li>No midline shift, nor space-occupying lesion.</li>
<li>No remarkable finding of skull base and bony structures.</li>
<li>No remarkable finding of bilateral orbital contents and optic
nerves.</li>
<li>No remarkable finding of nasopharynx visible in these images.</li>
<li>Diffuse luminal irregularity with mild segmental stenosis of major
intracranial arteries in MRA study (including bilateral ICAs, MCAs,
ACAs, PCAs and VAs and BA).</li>
</ul></li>
<li>IMP:
<ul>
<li>General brain atrophy.</li>
<li>Hydrocephalus.</li>
<li>Leukoaraiosis.</li>
<li>Intracranial artherosclerosis.</li>
</ul></li>
</ul></li>
<li>2022-03-24 ENT hearing test
<ul>
<li>Tymp:
<ul>
<li>Rt type A; Lt type Ad.</li>
</ul></li>
<li>ART:
<ul>
<li>Bil absent.</li>
</ul></li>
<li>PTA
<ul>
<li>Reliability FAIR TO POOR</li>
<li>Average RE 63 dB HL; LE 65 dB HL.</li>
<li>Bil moderate to profound mixed type HL.</li>
</ul></li>
</ul></li>
<li>2022-03-23 Nasopharyngoscopy
<ul>
<li>Rt. side tympanic membrane was in pattern of post tympanoplasty</li>
<li>Lt. side atrophic scar</li>
</ul></li>
<li>2022-03-16 Tc-99m MDP whole body bone scan
<ul>
<li>Increased radioactivity in the sternum, the nature is to be
determined (post-traumatic change or other nature?), suggesting
follow-up with bone scan in 3 months for investigation.</li>
<li>Suspected benign lesions in the right rib cage, some lower C-, upper
T- and L2-5 spines, bilateral sternoclavicular junctions, shoulders,
right S-I joint, and knees.</li>
</ul></li>
<li>2022-02-16 Patho - esophageal biopsy
<ul>
<li>Esophageal tumor, 20-25 cm below incisors, biopsy  Squamous cell
carcinoma</li>
<li>Microscopically, the sections show a picture of squamous cell
carcinoma, poorly differentiated of the esophageal tumor tissue
characterized by solid tumor cell nests show enlarged, hyperchromatic
and pleomorphic nuclei infiltrate in the stroma with focal
necrosis.</li>
<li>Immunohistochemical stains of CK(+); P16(-), P63(+) and P53 (+,
scant) for tumor.</li>
</ul></li>
<li>2022-02-15 CT - lung/mediastinum/pleura
<ul>
<li>advanced lower cervical esophageal cancer or Cervithorocic junction
esophageal cancer with extensive adjacent structures involvement and
regional LNs metastases d/d includes large conglomerated metastatic
LAP.</li>
<li>LLL pneumonia and RML metatasis of lung.</li>
</ul></li>
<li>2022-02-15 Esophagogastroduodenoscopy
<ul>
<li>Diagnosis
<ul>
<li>Highly suspect esophageal cancer, 20-25cm below the incisor, s/p
biopsy</li>
<li>Esophageal stenosis, 20cm below the incisor</li>
<li>Gastric subepithelial lesion, fundus</li>
<li>Superficial gastritis</li>
</ul></li>
<li>Suggestion
<ul>
<li>Pursue pathology result</li>
</ul></li>
</ul></li>
<li>2022-02-15 Bronchoscopy
<ul>
<li>Bronchoscopic diagnosis:
<ul>
<li>Upper airway external compression over upper trachea</li>
<li>left lower lobe bronchus: sputum impaction s/p bronchoscopic
sunction</li>
</ul></li>
</ul></li>
<li>2022-02-14 Esophagogastroduodenoscopy
<ul>
<li>Esophagus
<ul>
<li>Luminal stenosis with acute angle was noted at 20cm below the
incisor, suspect external compression. The endoscopy could not pass
through it.</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Esophageal stenosis, 20cm below the incisor, suspect external
compression by left neck mass</li>
</ul></li>
<li>Suggestion
<ul>
<li>arrange CT: neck ~ chest</li>
<li>If EGD was indicated, slim-caliber scope is needed</li>
</ul></li>
</ul></li>
<li>2017-05-25 Pelvis - THR
<ul>
<li>Marked disk space narrowing with spurs formation at L3-L4, L4-L5
levels due to spondylosis</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-14 Rehabilitation
<ul>
<li>Dx: Cervithorocic junction esophageal cancer with extensive adjacent
structures involvement and regional LNs metastases d/d includes large
conglomerated metastatic LAP. LLL pneumonia and RML metatasis of
lung</li>
<li>swallowign evaluation
<ul>
<li>no drooling</li>
<li>no choking with 3cc water</li>
<li>tongue ROM: intact</li>
<li>tongue muscle power : fair</li>
<li>delayed reflex (prolonged oral holding)</li>
<li>hyoid bone elevation: fair.</li>
<li>foreign body sensation during swallowing</li>
<li>no dyspnea upon examination</li>
</ul></li>
<li>Plan
<ul>
<li>arrange swallowing training</li>
<li>consider arrnage PMR Dr.Wus OPD follow up for further OPD
swallowing trainign program. Maybe arrange VFSS in the future</li>
</ul></li>
</ul></li>
<li>2022-03-28 Dermatology
<ul>
<li>Q
<ul>
<li>For skin rash &amp; icthing at back</li>
</ul></li>
<li>A
<ul>
<li>This patient suffered frpm erythematous papules-patches on trunk for
days.</li>
<li>Imp: Subacute dermatities</li>
<li>Suggestion:
<ul>
<li>Sinphardema 1 tubes, bid</li>
<li>Topsym cream 5 tubes, bid</li>
<li>Zaditen 1, bid</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-03-23 ENT
<ul>
<li>Q
<ul>
<li>For right ear tinnitus</li>
<li>This 85-year-old man, a patient of Eso cancer with Lns mets S/P Tr
&amp; J-tube inserted. He was admitted for CCRT. He complained of right
ear tinnitus for 2 days. We need expertise to evaluate his condition
thanks!</li>
</ul></li>
<li>A
<ul>
<li>Local finding via scope:
<ul>
<li>Rt. side tympanic membrane was in pattern of post tympanoplasty</li>
<li>Lt. side atrophic scar</li>
</ul></li>
<li>The tinnitus may be due to chemotherapy</li>
<li>Well arrange PTA exam this afternoon, thanks for your
consultation.</li>
</ul></li>
</ul></li>
<li>2022-03-09 Rehabilitation
<ul>
<li>Assessment
<ul>
<li>respiratory failure s/p intubation</li>
<li>advanced lower cervical esophageal cancer or Cervithorocic junction
esophageal cancer with extensive adjacent structures involvement and
regional LNs metastases<br />
</li>
</ul></li>
<li>Plan
<ul>
<li>Rehabilitation programs: Bedside PT rehabilitation programs</li>
<li>W5 starts with standing balance training. caregiver transfer skills
training. next W1 ambulation trianing.</li>
</ul></li>
<li>Goal
<ul>
<li>Recondition, improve endurance and muscle strength</li>
</ul></li>
</ul></li>
<li>2022-02-17 General and Gastroenterological Surgery.
<ul>
<li>Q
<ul>
<li>This time, he was admitted to MICU for treatment of hypercapnea
respiratory failure post intubation with ventilator since 20220214.
After admission, NG tube insert was done but failure. Dut to long term
NPO status, so we need your help for TPN nutrition supply, thanks !</li>
</ul></li>
<li>A
<ul>
<li>obj?
<ul>
<li>A case of esophageal cancer with obstruction who request nutrition
support.</li>
<li>General appearance: ill looking</li>
<li>GI tract: Dysphagia (+), Abd pain (-), Abd distension (-), Nausea
(-), Vomiting (-), Diarrhea (-), Poor appetite (+), Poor digestion (-),
BW loss (-) , stool (+), Bowel sound (+)<br />
</li>
<li>Feeding: NPO (NG tube insert failure)</li>
<li>Allergy: NKA</li>
<li>Nutrition assessment: BH 172cm, BW 57.8kg, IBW 65kg, 89% IBW, BMI
19.5, BEE (calculated based on IBW) 1246kcal, TEE 1943kcal</li>
<li>Lab data: Alb 2.9, BUN 26, Cr 0.58, Na 133, K 3.6, BS 100</li>
<li>According to the patients present conditions, parenteral nutrition
will be suitable for nutrition supply. We will follow this case for
adjustment of optimal nutrition support.</li>
</ul></li>
<li>PN suggestion:
<ul>
<li>F/U preAlb. ALP. rGT. T/D Bil GOT GPT TG</li>
<li>DC Bfluid 1000ml QD</li>
<li>SMOFkabiven central 1477ml QD, 61.5ml/hr</li>
<li>Lyo-Povigent 4ml/QD (add in TPN) (if out of stock, then use
B-complex 1ml/QD and Vitacicol 2ml/QD in TPN)</li>
<li>Addaven 10ml/QD (add in TPN)</li>
<li>Total fluid 30-40ml/kg/day (2000-2500ml/day)</li>
<li>Feeding gastrostomy or feeding jejunostomy ASAP</li>
</ul></li>
<li>PN monitor items
<ul>
<li>Check BW QW5 and record I/O Q8H</li>
<li>Check one touch Q6H for 2days, if stable QD check</li>
<li>Please control BS &lt; 200 mg/dl with RI sliding scale</li>
<li>QW1 check CBC/DC</li>
<li>QW1 check BUN. Cr. AST. ALT. T/D Bil. TG. ALP. rGT. Na. K. Cl. Ca.
P. Mg. Zinc. Alb. Prealbumin or Transferrin</li>
<li>if TPN not sufficient, use YF5 or D10W instead.</li>
</ul></li>
<li>postscript
<ul>
<li>20220218 op, on feeding gastrostomy or feeding jejunostomy</li>
<li>20220218 Sent to OR DC TPN, post-op PPN supply and try EN as soon as
possible.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-16 Radiation Oncology
<ul>
<li>Assessment
<ul>
<li>Suspicious advanced lower cervical esophageal cancer or
cervithorocic junction esophageal cancer with extensive adjacent
structures involvement and regional LNs metastases.</li>
</ul></li>
<li>Plan
<ul>
<li>Radiotherapy can be considered for this patient if positive
pathology report available and his condition stable (including
respiration such as if s/p tracheostomy). Further discussion in tumor
board (20220218).</li>
</ul></li>
</ul></li>
<li>2022-02-16 Thoracic Surgery
<ul>
<li>Q
<ul>
<li>For tumor excision and tracheostomy</li>
<li>This 85-year-old male who had past history of: 1) BPH; 2) Thyroid
cancer with squsamous cell carcinoma (Cheng Hsin general hospital in
20211126 report).</li>
<li>According to the description of the patients family and medical
record. He suffered from poor appetite and general weakness since
2021-12, he went to VGHTPE and left neck neoplasm was noted by CT.
Panendoscopy showed one protruding ulcerative lesion with luminal
narrowing and easily contact bleeding was noted at 20 to 21 cm of
incisor. The ordinary scope could not pass through the stenosis and we
then shifted to nasoendoscope. Biopsy was done on 20220110 and pending
biopsy result.</li>
<li>This time, progressive shortness of breath and fever intermittently
since 20220210, he was sent to our ER for help. At ER, his consciousness
clear, marked dyspnea with desaturation, stridor and left decreased
breath sound were noted. ABG analysis showed CO2 retension (PaCO2: 61.8
-&gt; 85.8 mmHg). Emergency intubation with ventilator was done. He was
admitted to MICU for treatment of 1) hypercapnea post intubation with
ventilator; 2) Suspect esophageal cancer survey.</li>
<li>After admission, keep on ventilator support. EGD was done which
showed Esophageal stenosis, 20cm below the incisor, suspect external
compression by left neck mass. Chest CT showed advanced lower cervical
esophageal cancer or Cervithorocic junction esophageal cancer with
extensive adjacent structures involvement and regional LNs metastases
d/d includes large conglomerated metastatic LAP. LLL pneumonia and RML
metatasis of lung. So we need your help for tumor excision and
tracheostomy evaluation, thanks!</li>
</ul></li>
<li>A
<ul>
<li>I have visited the patient and reviwed the images. If his family
agree treatment, I will arrange tracheostomy, port-A and feeding
jejunostomy. Thanks for your consultation!!</li>
</ul></li>
</ul></li>
<li>2022-02-14 Anesthesiology
<ul>
<li>Q
<ul>
<li>For difficult intubation
<ul>
<li>This 85 y/o male patient had history of suspect esophageal
cancer.</li>
<li>This time, he was admitted to MICU for hypercapnea with respiratory
failure post intubation with ventilator. After admisison to MICU,
irritable and dyspnea, stridor were noted. so we change endotracheal
tube but difficult intubation, so we need your help, thanks!</li>
</ul></li>
</ul></li>
<li>A
<ul>
<li>We were consulted for emergent intubation.</li>
<li>A #6.5 ETT was placed via McGrath and fiber-scope fixed at
25cm.</li>
<li>Bil. breathing sounds were noticed equally.</li>
<li>SpO2 was 99-100% after the procedure.</li>
<li>Please f/u CXR.</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-18 tracheostomy + port-A + jejunostomy
<ul>
<li>7.0mm ID, 120mm length bivona tracheal tube in place</li>
<li>8Fr. polysite port-A via right cephalic vein</li>
<li>18 Fr.jejunosotmy tube</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient is an elderly male suffering from esophageal cancer
(squamous cell carcinoma) with RML lung mets following tracheostomy and
jejunostomy (Op on 2022-02-18).</li>
<li>The advanced age could necessitate shared decision-making prior to
cancer-specific treatment, taking into account the patients overall
life expectancy. Alternatively, the following regimen in combination
with RT might also be considered:
<ul>
<li>Paclitaxel + carboplatin</li>
<li>Fluorouracil + oxaliplatin</li>
<li>Fluorouracil + cisplatin</li>
</ul></li>
<li>The S-GPT/ALT level was normal in early 2022-04, rose above 50 U/L
on 2022-04-11 and reached 113 U/L on 2022-05-03. No hepatitis virus lab
data were found. During that period, no medications other than herbal
medicine were prescribed according to in-hospital records. Access to
NHI-PharmaCloud is not authorized. Further study might be needed.</li>
<li>There could be a decrease in ventilation efficiency due to lung
mets, making oxygenation more important. Lab data showed RBC
3.62*10^3/uL and HGB 10.8g/dL on 2022-05-03, both below normal limits.
There might be a need for monitoring.</li>
<li>Pneumonia at RUL is treated with Tapimycin 4.5g IVD Q6H
currently.</li>
</ul>
</div>
</div>
<div id="section-314" class="section level1">
<h1>701118237</h1>
<div id="section-315" class="section level2">
<h2>210820</h2>
<p>{sepsis and pancytopenia with underlying DLBCL}</p>
<p>[subjective]</p>
<ul>
<li>this 64 y/o female patient sent by her family to our ER on
2021-08-11 for her dizziness and hypotension after having
chemotherapy.</li>
<li>underlying history of (neck) diffuse large B cell lymphoma</li>
</ul>
<p>[objective]</p>
<ul>
<li>2021-08-11 ER Imp: sepsis, unspecified organism</li>
<li>DLBCL
<ul>
<li>2019-09-24 CT, neck-hypopharynx:
<ul>
<li>diffuse enlarged lymph nodes on both sides of neck, more prominent
on right side.</li>
<li>D/D: lymphoproliferative disease, metastases.</li>
</ul></li>
<li>2019-09-27 surgical pathology level IV:
<ul>
<li>pathologic diagnosis
<ul>
<li>Lymph node, level IV, right neck, dissection B- cell lymphoma</li>
<li>Lymph node, level III, right neck, dissection B- cell lymphoma</li>
</ul></li>
<li>Histology type:
<ul>
<li>B-cell lymphoma (favor diffuse large B-cell lymphoma)</li>
</ul></li>
<li>Immunohistochemical stain profiles:
<ul>
<li>CD20(+), Bcl-2(+), CD3(focal positive at the background T-cells),
Bcl-6(+), Sox11(-), cyclin-D(-), CD10(-), Ki-67 index:70%, CD5 (focal+),
c-myc(-), CD23(-).</li>
</ul></li>
</ul></li>
<li>2020-11 bone marrow transplant, followed up at NTUH</li>
<li>2021-05 recurrence, neck mass noted</li>
<li>2021-07 PET showed progressing</li>
<li>2021-08-06 chemotherapy endoxan (cyclophosphamide) prescirbed
(according to PharmaCloud), pre-chemotherapy WBC 1600</li>
</ul></li>
<li>Lab data
<ul>
<li>RBC 2021-08-20 3.45*10^6/uL</li>
<li>HGB 2021-08-20 10.1g/dL</li>
<li>PLT 2021-08-20 52*10^3/uL</li>
<li>WBC
<ul>
<li>2021-08-20 3.65*10^3/uL</li>
<li>2021-08-18 1.69</li>
<li>2021-08-17 1.02</li>
<li>2021-08-16 0.43</li>
<li>2021-08-14 0.10</li>
<li>2021-08-13 0.08</li>
<li>2021-08-11 0.10</li>
</ul></li>
<li>CRP
<ul>
<li>2021-08-16 15mg/dL</li>
<li>2021-08-11 12</li>
</ul></li>
<li>urine culture on 2021-08-17: after 48 hours, &lt;1000 CFU/ml</li>
<li>blood culture on 2021-08-12: no growth for 5 days aerobically &amp;
anaerobically</li>
</ul></li>
<li>medication
<ul>
<li>granocyte (lenograstim) 250mcg SC QD since 2021-08-12</li>
<li>cefim (cefepime) 2000mg IVD Q12H 2021-08-12 to 2021-08-18</li>
<li>eraxis (anidulafungin) 100mg IVD QD</li>
<li>targocid (teicoplanin) 600mg IVD Q12H~QD 2021-08-12 to
2021-08-16</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>sepsis
<ul>
<li>urine culture and blood culture found no obvious infection</li>
<li>body temp no higher than 36.8 since last week</li>
<li>CRP still showed elevated.</li>
<li>after days of ABX administration, the infection should has been
mitigated.</li>
</ul></li>
<li>pancytopenia
<ul>
<li>WBC has been boosted by lenograstim</li>
<li>RBC and PLT still below than LLN, but moved out of critical
range.</li>
<li>the condition has been improved.</li>
</ul></li>
<li>DLBCL
<ul>
<li>alkylating agent been paused (not listed in active medication)
because of pancytopenia.</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>ABX might be deescalated when CRP goes down and no other infectious
sign shows up.</li>
<li>DLBCL treatment should be restarted as soon as possible when the
patient gets in stable condition.
<ul>
<li>no chemo or target drugs other than cyclophosphamide found in
PharmaCloud, based on the limited info, ISRT after RCHOP might be a
treatment option.</li>
<li>uric acid, beta-2 microglobulin could also be followed up when
having DLBCL treatment.</li>
</ul></li>
<li>HBV, HCV lab data not found in in-hospital database, could be
ordered.</li>
</ul>
</div>
</div>
<div id="section-316" class="section level1">
<h1>701118846</h1>
<div id="section-317" class="section level2">
<h2>999999</h2>
<p>{colon cancer}</p>
<ul>
<li>2020-08-24 CT, ABD:
<ul>
<li>RLL tumor with abdominal wall involvement, suspect appendix tumor or
appendicitis with tumor formation.</li>
<li>skin tumor, 1.3cm in right lower abdominal wall.</li>
<li>ill-defined hypodensities in S6 liver.</li>
</ul></li>
<li>2020-08-25 abdominal ultrasound:
<ul>
<li>hepatic cyst, multiple</li>
<li>abodminal wall lesoin and intraperitoneal lesion with
communication</li>
</ul></li>
<li>2020-08-26 operation - laparoscopic right hemicolectomy:
<ul>
<li>a tumor mass over appendix with severe adhesion to omentum and right
lower abdoinal wall; with localized abscess</li>
<li>several small liver cysts in right lobe</li>
</ul></li>
<li>2020-09-01 patho, appendix, rt hemicoloectomy:
<ul>
<li>mucinous adenocarcinoma with abscess</li>
<li>AJCC pathologic stage pT4aN0 (if cM0), IIB</li>
<li>IHC: CDX-2(+), MLH1(+), PMS2(+), MSH2(+) and MSH6(+) for tumor
cells</li>
</ul></li>
<li>2020-09-01 Tc-99m MDP bone scan:
<ul>
<li>mildly and non-focally increased radiotracer uptake in C-spine and
lower L-spine, degenerative spine diseases may show such a picture.</li>
<li>some areas of mildly increased radiotracer uptake in maxilla and
mandible, dental lesions may show such a picture.</li>
<li>probably degenerative joint lesions in shoulders, sternoclavicular
junctions, sacroiliac joints, and hips.</li>
<li>no definite evidence of osteoblastic skeletal metastasis by this
bone scan.</li>
</ul></li>
<li>2020-09-22 MRI, liver, spleen:
<ul>
<li>liver and renal cysts (up to 2.3cm).</li>
<li>prominent accessory pancreatic duct.</li>
</ul></li>
<li>2020-09-23 CT, ABD:
<ul>
<li>two metastases in S7/8 and S7 show stable disease.</li>
<li>a metastasis 5 mm in LUL of the lung is suspected.</li>
<li>left ureter stone causing hydroureteronephrosis and delayed contrast
excretion of left kidney.</li>
<li>metastasis -&gt; pT4aN0M1a, stage IVA, lymphovascular invasion (-),
perineural invasion (+)</li>
</ul></li>
<li>2021-01-26 ENT consultation:
<ul>
<li>bilateral vocal cord atrophy and bilateral vocal nodules.</li>
<li>the disease is needed to receive operation.</li>
</ul></li>
<li>2020-12-29 CT, ABD:
<ul>
<li>post-op at colon with mesentery nodules and lymph nodes, suspect
carcinomatosis.</li>
<li>gallbladder stone.</li>
<li>liver cysts.</li>
</ul></li>
<li>2021-03-27 CT, ABD:
<ul>
<li>s/p right hemicolectomy</li>
<li>peritoneal carcinomatosis, mild in regression.</li>
</ul></li>
<li>2021-04-21 operation - laparoscopy adhesionolysis, finding:
<ul>
<li>adhesion of greater omentum to abdominal wall.</li>
<li>no gross peritoneal seedings and minimal ascites.</li>
</ul></li>
<li>2021-05-03 KUB:
<ul>
<li>calcification in LUQ, suspect left renal stone.</li>
<li>lumbar spondylosis.</li>
</ul></li>
<li>2021-05-03 CT, brain:
<ul>
<li>brain atrophy</li>
<li>suspect chronic sinusitis</li>
</ul></li>
<li>CEA:
<ul>
<li>2021-03-17 _4.00ng/mL</li>
<li>2021-01-26 _3.47ng/mL</li>
<li>2020-12-29 _2.89ng/mL</li>
<li>2020-11-25 _2.98ng/mL</li>
<li>2020-10-27 _2.87ng/mL</li>
<li>2020-09-30 _3.44ng/mL</li>
<li>2020-08-28 30.09ng/mL</li>
</ul></li>
<li>CA199:
<ul>
<li>2021-03-17 29.29U/mL</li>
<li>2021-01-26 21.00U/mL</li>
<li>2020-12-29 30.73U/mL</li>
<li>2020-11-25 28.28U/mL</li>
<li>2020-10-27 27.41U/mL</li>
<li>2020-09-30 28.12U/mL</li>
</ul></li>
<li>regimen:
<ul>
<li>2020-09-23 ~ 2021-03-30: FOLFIRI (plus self-paid bevacizumab up to
2021-03-02)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-318" class="section level1">
<h1>701148578</h1>
<div id="section-319" class="section level2">
<h2>220318</h2>
<p>{Nasopharyngenl Carcinoma - NPC, non-keratinizing carcinoma}</p>
<p>[objective]</p>
<ul>
<li>radiotherapy
<ul>
<li>2022-02 ~ ?? CCRT?</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-14 ~ ongoing - 5-FU + carboplatin</li>
<li>2021-11-29 ~ 2022-01-10 - carboplatin (weekly)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Nivolumab could be added optionally to the treatment regimen for
patients suffering from recurrent or metastatic non-keratinizing
disease.
<ul>
<li>reference: <a href="https://pubmed.ncbi.nlm.nih.gov/29584545/" class="uri">https://pubmed.ncbi.nlm.nih.gov/29584545/</a></li>
</ul></li>
</ul>
</div>
<div id="section-320" class="section level2">
<h2>220215</h2>
<p>[objective]</p>
<ul>
<li>Exam findings
<ul>
<li>2021-11-24 PET
<ul>
<li>Glucose hypermetabolic lesions in the post. aspect of nasal septum,
nasal cavity, and part of left NP region, compatible with recurrent
tumor of NPC.<br />
</li>
<li>Glucose hypermetabolic lesions in bilateral mediastinal lymph nodes
and bilateral pulmonary hilar lymph nodes, probably reactive nodes.</li>
<li>Glucose hypermetabolic lesion in the right femoral shaft, the nature
is to be determined (post-traumatic change, benign or even another
primary malignant neoplasm of bone, or other nautre?), suggesting
further investigation.<br />
</li>
<li>NPC s/p treatment with tumor recurrence, rcTxN0M0, by this F-18 FDG
PET scan.</li>
</ul></li>
<li>2021-11-01 Patho - Larynx biopsy
<ul>
<li>Nasopahrynx, biopsy - Non-keratinizing carcinoma, undifferentiated
(lymphoepithelialcarcinoma) (WHO-2B).</li>
<li>IHC: CK(+), EBER(+).</li>
</ul></li>
<li>2021-11-01 MRI - Nasopharynx
<ul>
<li>A soft tissue tumor, about 27 mm x 22 mm x 24 mm, with relatively
homogeneous mild T1- and T2-hyperintensity and faint enhancement
involving posterior aspect of nasal septum, posterior nostril, florr of
sphenoid sinus and part of left nasopharyngeal wall.</li>
<li>Diffuse fluid accumulation in bilateral sphenoid sinuses.</li>
</ul></li>
<li>2020-11-02 MRI - Nasopharynx
<ul>
<li>Markedly regressed bil. neck LNs.</li>
</ul></li>
<li>2020-04-22 MRI - Nasopharynx
<ul>
<li>C/W NPC T4N2Mx, Stage IVA. Progressive change as compared with MRI
on 2019-12-04.</li>
</ul></li>
<li>2019-12-05 PET
<ul>
<li>The FDG PET findings are compatible with nasopharyngeal malignancy
with invasion to the skull base and possible intracranial
extension.</li>
<li>Glucose hypermetabolism in bilateral retropharyngeal lymph nodes and
multiple right neck level II to III and left neck level II lymph nodes,
compatible with metastatic lymph nodes.</li>
<li>Mild glucose hypermetabolism in the lesser trochanter of right
femur. The nature is to be determined (post-traumatic change? other
nature?).</li>
</ul></li>
<li>2019-12-04 MRI - Nasopharynx
<ul>
<li>Bilateral NPC, at least T4N2Mx, stage IVA.</li>
</ul></li>
</ul></li>
<li>Radiotherapy
<ul>
<li>2020-05 ~ 2020-06:
<ul>
<li>6090cGy/29 fractions (6 MV photon) to NPX tumor and bilateral neck
LAPs (incomplete).</li>
<li>2020-06-22 RT side effect evaluation: radiation mucositis, grade 2;
pharyngitis, grade 2; dermatitis, grade 2; N/V, grade 1; esophagitis,
grade 1; xerostomia, grade 2.</li>
</ul></li>
</ul></li>
<li>Chemotherapy
<ul>
<li>2020-11 ~ ongoing: carboplatin + fluorouracil</li>
<li>2019-12 ~ 2020-06: cisplatin, 2020-04-21 + UFT</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-321" class="section level1">
<h1>701150775</h1>
<div id="section-322" class="section level2">
<h2>220420</h2>
<p>{pancreatic neck adenocarcinoma,cT1cNXM1, stageIV, with
retroperitoneal spread status post Roux-en-Y hepatico-jejunostomy and
cholecystectomy}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-03-30 CT - abdomen, pelvis
<ul>
<li>pancreatic neck cancer with vessel encasement and lymph nodes
metastases show mild decreasing in size.</li>
</ul></li>
<li>2022-01-26 CT - abdomen, pelvis
<ul>
<li>pancreatic neck cancer with vessel encasement, lymph nodes
metastases, and lung metastases.</li>
</ul></li>
<li>2022-01-06 Patho - F2022-00006
<ul>
<li>soft tissue, retroperitoneal, biopsy - metastatic adenocarcinoma,
consistent with pancreas origin</li>
<li>section shows fibroadipose tissue and nerve bundles with metastatic
adenocarcinoma. perineural invasion is seen.</li>
<li>IHC: CK7(+), CK20(-), and CK19(+).</li>
<li>the morphology and immunohistochemical stains are consistent with
pancreas origin.</li>
</ul></li>
<li>2021-12-14 Patho -</li>
<li>2021-12-03 Endoscopic Ultrasonography, EUS
<ul>
<li>pancreatic genu tumor s/p CH-EUS &amp; EUS/FNB</li>
<li>lymphadenopathy, beside hepatic hilum</li>
<li>reflux esophagitis LA classification grade A</li>
</ul></li>
<li>2021-12-02 Ultrasound - abdomen
<ul>
<li>pancreastic head tumor with lymphadenopathy</li>
<li>GB sludge with distension</li>
<li>CBD dilatation</li>
<li>fatty liver, mild</li>
</ul></li>
<li>2021-11-30 MRI - pancreas
<ul>
<li>a faint enhancing tumor (1.2cm) at pancreatic body with distal
p-duct dilatation.</li>
<li>some LNs around celiac trunk and proximal SMA.</li>
<li>dilatation of biliary tree suspected distal CBD lesion.</li>
<li>inhomogeneous intensity of pancreatic head.</li>
</ul></li>
<li>2021-11-25 CT - abdomen, pelvis
<ul>
<li>suspected pancreatic body cancer with distal pancreatic duct
dilatation.</li>
<li>T4N1M0</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01 ~ ongoing: FOLFIRINOX
<ul>
<li>FOL: folinic acid (leucovorin), a vitamin B derivative that enhances
the effects of 5-fluorouracil (5-FU);</li>
<li>F: fluorouracil, a pyrimidine analog and antimetabolite which
incorporates into the DNA molecule and stops DNA synthesis;</li>
<li>IRIN: irinotecan, a topoisomerase inhibitor, which prevents DNA from
uncoiling and duplicating; and</li>
<li>OX: oxaliplatin, a platinum-based antineoplastic agent, which
inhibits DNA repair and/or DNA synthesis.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>FOLFIRINOX is a chemotherapy regimen that is used to treat advanced
pancreatic cancer. The patient is undergoing the regimen since Jan
2022.</li>
<li>2022-03-30 updated CT images showed a mild decrease in the size of
the tumor, indicating that current treatment is working. However, CA-199
(137U/mL 2022-04-06) remained above the upper limit of normal, and
should be noted.</li>
<li>S-GPT/ALT elevated since late March (126U/L 2022-04-19), if
bilirubin also elevates up to 1.5mg/dL, then the dosage of irinotecan
should be lowered.</li>
<li>Some targeted therapeutic agents might be an option if no
contraindication
<ul>
<li>pembrolizumab for MSI-H or dMMR cases.</li>
<li>larotrectinib/entrectinib for NTRK gene fusion positive cases.</li>
</ul></li>
</ul>
</div>
<div id="section-323" class="section level2">
<h2>220215</h2>
<p>[assessment]</p>
<ul>
<li>FOLFIRINOX is a chemotherapy regimen for treatment of advanced
pancreatic cancer. the patient is on this regemen, which is made up of
the following four drugs:
<ul>
<li>FOL: folinic acid (leucovorin), a vitamin B derivative that enhances
the effects of 5-fluorouracil (5-FU);</li>
<li>F: fluorouracil, a pyrimidine analog and antimetabolite which
incorporates into the DNA molecule and stops DNA synthesis;</li>
<li>IRIN: irinotecan, a topoisomerase inhibitor, which prevents DNA from
uncoiling and duplicating; and</li>
<li>OX: oxaliplatin, a platinum-based antineoplastic agent, which
inhibits DNA repair and/or DNA synthesis.</li>
</ul></li>
<li>some targeted therapeutic agents might be considered if no
contraindication
<ul>
<li>pembrolizumab for MSI-H or dMMR cases.</li>
<li>larotrectinib/entrectinib for NTRK gene fusion positive cases.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-324" class="section level1">
<h1>701164228</h1>
<div id="section-325" class="section level2">
<h2>220421</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-08 Patho - uterus (with or without SO) neoplastic
<ul>
<li>Pathologic Diagnosis
<ul>
<li>Uterus, endometrium, ATH  Endometroid carcinoma, FIGO grade 3</li>
<li>Fallopian tube, right, BSO  Involved by carcinoma</li>
<li>Lymph nodes, pelvic and para-aortic, bilateral, BPLND + PALND 
Negative for malignancy (0/39)</li>
<li>AJCC 8 th edition, Pathology stage: pT3aN0; stage IIIA; FIGO stage
IIIA; if cM0</li>
</ul></li>
<li>Macroscopic Examination
<ul>
<li>Procedure: ATH + BSO + omentectomy + BPLND + para-aortic LN
dissection</li>
</ul></li>
<li>Microscopic Examination
<ul>
<li>Histologic Type: Endometroid carcinoma</li>
<li>Histologic Grade: FIGO grade 3</li>
<li>Adenomyosis: Not identified</li>
<li>Depth of Tumor Invasion: Tumor invading more than half of
myometrium</li>
<li>Cervical Stromal Involvement: Not identified</li>
<li>Other Tissue/Organ Involvement: Tumor involving right fallopian
tube</li>
<li>Peritoneal/Ascitic Fluid: Not submitted</li>
<li>Margins: Uninvolved by carcinoma
<ul>
<li>Distance of invasive carcinoma from closest margin: 1.5 cm</li>
</ul></li>
<li>Lymphvascular Invasion: Present</li>
<li>Regional Lymph Nodes: All lymph nodes negative for tumor cells
(0/39)</li>
<li>AdditionalPathologic Findings
<ul>
<li>Cervix: Chronic cervicitis with squamous metaplasia</li>
<li>Myometrium: Leiomyoma</li>
<li>Ovary, right: No remarkable change</li>
<li>Ovary, left: No remarkable change</li>
<li>Fallopian tube, left: Chronic salpingitis</li>
<li>Omentum: No remarkable change</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-08 Cytology - ascites
<ul>
<li>ASCITES: suspicious for malignancy<br />
</li>
<li>Smears show lymphoid cells, and few suspicious cells with
elongated</li>
</ul></li>
<li>2022-01-17 MRI - pelvis
<ul>
<li>suspected endometrial malignancy with lymph nodes metastasis
(paraaortic region).
<ul>
<li>right parametrial soft tissue tumors, parametrial lymph nodes
metastasis or tumor seeding? cstage T3N2M0.</li>
</ul></li>
<li>uterine tumors, suspected myomas.</li>
<li>suspected liver cysts.</li>
</ul></li>
<li>2022-01-06 Patho - endometrium curretage/biopsy
<ul>
<li>Uterus, endometrium, TCR  Endometrioid adenocarcinoma<br />
</li>
<li>Microscopically, sections show endometrioid adenocarcinoma
characterized by proliferation of neoplastic ells arranged in
cribrinform to solid architecture and invasive growth pattern with tumor
necrosis. The tumor shows eosinophilic cytoplasm, nuclear
hyperchromasia, pleomoephism, loss of polarity, prominent nuleoli and
mitoses.<br />
</li>
<li>Immunohistochemical stain reveals p16(patchy positive), p53(wild
type), CK7(+), CK20(-) and vimentin(+).</li>
</ul></li>
<li>2021-12-31 Gynecologic ultrasonography
<ul>
<li>Uterine myoma</li>
<li>Uterine mass: 27x23mm, no blood flow</li>
</ul></li>
<li>2021-11-09 SONO - abdomen
<ul>
<li>Bil. liver cysts (up to 1.0cm).</li>
</ul></li>
<li>2021-11-09 SONO - breast
<ul>
<li>Right fibroadenomas</li>
<li>s/p right breast operation</li>
<li>benign</li>
</ul></li>
<li>2021-05-07 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20200316, no prominent
change is noted in the lesions in the lower L-spines. Degenerative spine
diseases may show such a picture.</li>
<li>Increased radiotracer uptake in maxilla and mandible, Dental lesions
may show this picture.</li>
<li>Probably degenerative change in bilateral shoulders,
sternoclavicular junctions, sacroiliac joints, knees, ankles and both
feet.</li>
<li>No prominent bone abnormality was noted elsewhere.</li>
</ul></li>
<li>2021-03-16 Mammography
<ul>
<li>Post-op with breast tissue reduction in right breast.</li>
<li>Benign calcifications in bilateral breasts.</li>
</ul></li>
<li>2021-03-16 SONO - breast
<ul>
<li>Operation scar at right UOQ breast.</li>
<li>Probably right breast fibroadenomas, stationary.</li>
</ul></li>
<li>2021-03-02 Gynecologic ultrasonography
<ul>
<li>uterine myoma</li>
</ul></li>
<li>2020-12-08 SONO - breast
<ul>
<li>Operation scar at right UOQ breast.</li>
<li>Probably right breast fibroadenomas.</li>
</ul></li>
<li>2020-03-18 SONO - breast
<ul>
<li>Breast tissue reduction in right breast, could be due to post-op
change.</li>
<li>Benign calcifications in bilateral breasts.</li>
</ul></li>
<li>2020-03-16 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20190114, the previously
noted faint hot spots in bilateral rib cages had disappeared, indicating
benign in nature.</li>
<li>Mildly and non-focally increased radiotracer uptake in lower
L-spine, degenerative spine diseases may show such a picture.</li>
<li>Increased radiotracer uptake in maxilla and mandible, suggesting
dental lesions.</li>
<li>Probably degenerative change in shoulders, sternoclavicular
junctions, sacroiliac joints, knees, and ankles.</li>
<li>No definite evidence of osteoblastic skeletal metastasis by this
bone scan.</li>
</ul></li>
<li>2019-02-12 Whole body PET scan
<ul>
<li>Mild glucose hypermetabolism in the right breast. The nature is to
be determined (post-operative inflammation? other nature?). Please
correlate with other clinical findings for further evaluation.</li>
<li>Mild glucose hypermetabolism in bilateral shoulder joints,
compatible with benign joint lesion such as arthritis.</li>
<li>Mildly increased FDG accumulation in the colon. Physiologic FDG
accumulation is more likely.</li>
</ul></li>
<li>2019-01-22 Pathology Level VI
<ul>
<li>Pathologic diagnosis
<ul>
<li>Breast, right, partial mastectomy  Invasive carcinoma of no special
type (90%) with focal mucinous carcinoma (10%)<br />
</li>
<li>Resection margin: Free of carcinoma<br />
</li>
<li>Lymph node, right axillary sentinel, lymphadenecomy  Metastatic
carcinoma (1/1)<br />
</li>
<li>Pathology stage: pT2N1a(sn)(cMx); Anatomic stage IIB, Prognostic
stage IB</li>
</ul></li>
<li>Microscopic examination
<ul>
<li>Histologic grade (Nottingham histologic score): Grade I (score=
5)<br />
</li>
<li>Tumor necrosis: Present<br />
</li>
<li>Nodal status (Sentinel): Positive (1/1)</li>
<li>Treatment Effect: No presurgical neoadjuvant therapy received<br />
</li>
<li>Lymphovascular invasion: Absent<br />
</li>
<li>Perineural invasion: Absent<br />
</li>
</ul></li>
<li>Immunohistochemical study (S2019-00163)
<ul>
<li>ER (Ab): Positive (90%)</li>
<li>PR (Ab): Positive (90%)</li>
<li>HER-2/Neu (Ab): Negative (score=0)</li>
<li>Ki-67: &lt;5%</li>
<li>p53: &lt;2%.</li>
</ul></li>
</ul></li>
<li>2019-01-04 Surgical pathology Level IV
<ul>
<li>Breast, right, 10 oclock/3cm, SONO guided core biopsy  Invasive
carcinoma.</li>
<li>IHC: ER (+, 90%), PR: (+, 90%), Her2/neu: negative (score=0); Ki-67:
&lt;5%, p53: &lt;2%.</li>
</ul></li>
<li>2019-01-03 SONO - breast
<ul>
<li>Highly suspicious of malignancy, with sonographic negative axillary
LNs, suspected carcinoma, cT2N0.</li>
<li>BI-RADS: 5-Highly Suggestive of Malignancy (&gt;95% malignant)
Appropriate Action Should Be Taken.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-07 Endometrial cancer - Staging surgery (ATH + BSO + lymph
node dissection + infracolic omentectomy)
<ul>
<li>Supraumbilical midline vertical skin incision</li>
<li>Uterus: normal size, tense contact with bladder, peritoneum due to
tumor mass accupied .</li>
<li>Adnexa:
<ul>
<li>LOV: 3x2x2cm, capsule intact, smooth surface.</li>
<li>ROV: 3x3x3cm, capsule intact, smooth surface.</li>
<li>Fallopian tube: bilateral grossly normal</li>
</ul></li>
<li>CDS: invisible due to tumor mass occupied</li>
</ul></li>
<li>2022-01-06 Transcervical resection polypectomy
<ul>
<li>One endometrial polyp from low segemtn of uterus, with stalk from
5oclock of direction</li>
</ul></li>
<li>2019-01-21 right breast cancer - BCT + SLND</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-03-09 ~ ?? 4140cGy/23 fractions of the pelvic area</li>
<li>2019-08-27 ~ 2019-10-17 - 5000cGy/25 fractions of the right breast
to right SCF, and 6000cGy/30 fractions of the right breast tumor bed
(scar) area</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-03-18 ~ undergoing - paclitaxel + carboplatin</li>
<li>2021-03-02 ~ 2021-06-XX - Medrone (medroxyprogesterone acetate)
5mg/tab 1# QD PO</li>
<li>2019-08-13 ~ undergoing - Femara (letrozole) 2.5mg/tab 1# QD PO</li>
<li>2019-02-25 ~ 2019-08-05 - (pegylated liposomal) doxorubicin +
cyclophosphamide</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient has been diagnosed with endometrial cancer s/p ATH +
BSO + lymph node dissection + infracolic omentectomy on 2022-02-07 and
is being treated with paclitaxel + carboplatin since 2022-03-18. Prior
to that, right breast invasive carcinoma was treated with partial
mastectomy on 2019-01-21, followed by doxorubicin + cyclophosphamide
from 2019-02-25 to 2019-08-05, then letrozole since 2019-08-13.</li>
<li>Lab data reported on 2022-04-20 showed that liver and kidney
function, serum electrolytes, and blood cell counts were grossly
normal.</li>
</ul>
</div>
</div>
<div id="section-326" class="section level1">
<h1>701164753</h1>
<div id="section-327" class="section level2">
<h2>220120</h2>
<ul>
<li><p>Diagnosis: Splenic flexure colon obstruction and massive ascites
suspected carcinomatosis status post T-loop colostomy on
2021-08-27.</p></li>
<li><p>2021-08-30 Patho - omentum tumor, extensive resection</p>
<ul>
<li>Omentum, frozen section + end transverse colostomy - Metastatic
adenocarcinoma.</li>
</ul></li>
<li><p>2021-08-25 Patho - colorectal polyp</p>
<ul>
<li>IHC: CK(+), CK7(-), CK20(-), CDX2(+), CD56(-), LCA(-), PSA(-), and
AMACR(-).
<ul>
<li>The morphology and immunohistochemical stains are not typical for
colonic adenocarcinoma.</li>
<li>The CDX2 is positive, in favor of GI tract, pancreas, and biliary
tract.</li>
<li>The PAS and AMACR are negative, so disfavor prostate origin.</li>
<li>The CD56 and LCA are negative, so disfavor neuroendocrine tumor and
lymphoma.</li>
<li>Please correlate with the clinical presentaion, and image study,
such as PET or gastroscope, for tumor origin.</li>
</ul></li>
</ul></li>
<li><p>Medication</p>
<ul>
<li>2021-09 ~ gogoing - FOLFIRI (plus bevacizumab since 2021-10)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-328" class="section level1">
<h1>701186882</h1>
<div id="section-329" class="section level2">
<h2>220503</h2>
<p>[objective]</p>
<ul>
<li><p>This 43 years old female patient has the history of: 1) Chronic
kidney disease for 10 years; 2) Ulcerative colitis with medical
treatment for 20 years; 3) Fourth degree hemorrhoids status post
hemorrhoidectomy on 20210623; 4) Left arteriovenous fistula on
20220124.</p></li>
<li><p>diagnosis</p>
<ul>
<li>chronic kidney disease, stage 5</li>
<li>anemia, unspecified</li>
<li>ulcerative colitis without complications</li>
<li>fever, unspecified</li>
</ul></li>
<li><p>exam finding</p>
<ul>
<li>2022-05-02 Abdominal Ultrasonography
<ul>
<li>Parenchymal renal disease</li>
<li>Renal cyst, right</li>
<li>Gallbladder sludge</li>
<li>Minimal ascites</li>
</ul></li>
<li>2022-03-08 Abdominal Ultrasonography
<ul>
<li>Parenchymal renal disease</li>
</ul></li>
<li>2021-11-19 Renal ultrasound
<ul>
<li>Chronic renal parenchymal disease, advanced degree</li>
</ul></li>
<li>2021-06-23 Patho - hemorrhoids
<ul>
<li>Anus, hemorrhoidectomy  hemorrhoid</li>
<li>Microscopically, it shows dilatation of venous plexus with
congestion.</li>
</ul></li>
</ul></li>
<li><p>lab data</p>
<ul>
<li>2022-03-11
<ul>
<li>HSV 1 IgG positive</li>
<li>HSV 1 IgG Value 53.6 RU/mL</li>
<li>HSV 2 IgG negative</li>
<li>HSV 2 IgG Value &lt; 0.50</li>
<li>HSV 1 IgM negative</li>
<li>HSV 1 IgM Value 0.05</li>
<li>HSV 2 IgM negative</li>
<li>HSV 2 IgM Value 0.08</li>
</ul></li>
<li>2022-03-10
<ul>
<li>EB VCA IgA positive</li>
<li>EB VCA IgA Value 1.9</li>
<li>EB VCA IgG positive</li>
<li>EB VCA IgG Value 8.6</li>
<li>Toxoplasma IgG negative IU/mL</li>
<li>Toxoplasma IgG Value 0.2 IU/mL<br />
</li>
<li>Toxoplasma IgM negative</li>
<li>Toxoplasma IgM-index 0.05</li>
<li>HLA A 11<br />
</li>
<li>HLA A 24<br />
</li>
<li>HLA B 60<br />
</li>
<li>HLA B 61<br />
</li>
<li>HLA C 9<br />
</li>
<li>HLA C 10<br />
</li>
</ul></li>
<li>2022-03-09
<ul>
<li>EB VCA IgM negative</li>
<li>EB VCA IgM Value 0.0<br />
</li>
<li>VZV IgM negative</li>
<li>VZV IgM Value 0.1</li>
<li>CMV_IgG Reactive<br />
</li>
<li>CMV_IgG Value 937.1 AU/mL<br />
</li>
<li>CMV IgM Nonreactive<br />
</li>
<li>CMV IgM Value 0.19 Index<br />
</li>
</ul></li>
<li>2022-03-08
<ul>
<li>VZV IgG positive</li>
<li>VZV-G Value 3.1</li>
</ul></li>
<li>2022-02-22
<ul>
<li>Thyroglobulin 12.95 ng/mL<br />
</li>
</ul></li>
<li>2022-02-21
<ul>
<li>RPR/VDRL Nonreactive<br />
</li>
<li>RH(D) Positive<br />
</li>
<li>Blood type ABO O<br />
</li>
<li>HBsAg Nonreactive<br />
</li>
<li>HBsAg (Value) 0.28 S/CO</li>
<li>Anti-HBc Nonreactive<br />
</li>
<li>Anti-HBc-Value 0.14 S/CO</li>
<li>Anti-HCV Nonreactive<br />
</li>
<li>Anti-HCV Value 0.08 S/CO<br />
</li>
<li>Anti HTLV I/II Nonreactive<br />
</li>
<li>Anti HTLV I/II Value 0.06 S/CO<br />
</li>
<li>HIV Ab-EIA Nonreactive<br />
</li>
<li>Anti-HIV Value 0.05 S/CO<br />
</li>
<li>Anti-HBe S/CO<br />
</li>
<li>Anti-HBe Nonreactive<br />
</li>
<li>Anti-HBe Ratio 1.56 S/CO<br />
</li>
<li>Anti-HBs 376.18 mIU/mL<br />
</li>
<li>HBeAg(EIA) S/CO<br />
</li>
<li>HBeAg Nonreactive<br />
</li>
<li>HBeAg(Value) 0.362 S/CO<br />
</li>
<li>RF &lt;10 IU/mL<br />
</li>
<li>CA125 14.8 U/mL<br />
</li>
<li>CA153 7.7 U/mL<br />
</li>
<li>CA199 34.20 U/mL<br />
</li>
<li>CEA 3.62 ng/mL<br />
</li>
<li>AFP 2.1 ng/mL<br />
</li>
</ul></li>
<li>2020-05-14
<ul>
<li>ANA Negative<br />
</li>
</ul></li>
<li>2020-05-13
<ul>
<li>Zinc,Zn 621 ug/L<br />
</li>
</ul></li>
<li>2020-05-11
<ul>
<li>Anti-ENA SS-A(Ro) 0.4 EliA U/ml<br />
</li>
<li>Anti-ENA SS-B(La) 0.4 EliA U/ml<br />
</li>
<li>TPHA &lt;1:80<br />
</li>
</ul></li>
<li>2020-05-08
<ul>
<li>RPR/VDRL Nonreactive<br />
</li>
<li>Ferritin 105.3 ng/mL<br />
</li>
<li>T3 0.88 ng/dL<br />
</li>
<li>TSH 1.373 uIU/mL<br />
</li>
<li>Free-T4 0.80 ng/dL<br />
</li>
<li>Ferritin 110.1 ng/mL</li>
</ul></li>
</ul></li>
<li><p>surgical operation</p>
<ul>
<li>2022-01-24 Creation of LT wrist AVF
<ul>
<li>Left Radial Artery: Calcification(-), Diameter(2.3)mm</li>
<li>Cephalic Vein: Stenosis(-),
Fibrosis(-),Transpostion(-),Diameter(3.0)mm</li>
<li>Anastomosis of Left Radial artery &amp; cephalic vein with 7-0
prolene.</li>
</ul></li>
<li>2021-06-23 Hemorrhoidectomy
<ul>
<li>Prolasped hemorrhoids at 3,7,11 oclock</li>
<li>Easy bleeding, Naldebain</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<p>This patient has CKD stage 5 adminitted on 2022-04-29</p>
<p>CKD stage 5, high Creatinine, high BUN, high phosphorus, low calcium,
low bicarbonate normal CRP and WBC AV shunt</p>
</div>
</div>
<div id="section-330" class="section level1">
<h1>701198481</h1>
<div id="section-331" class="section level2">
<h2>220422</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-01 Abdomen - Standing(Diaphragm)
<ul>
<li>Fecal material store in the colon.</li>
<li>Ascites is suspected. Please correlate with sonography.</li>
</ul></li>
<li>2022-03-22 Abdomen - Standing(Diaphragm)
<ul>
<li>Air-fluid level in the bowel at the upper abdomen is noted that may
be bowel obstruction? Please correlate with contrast enhanced CT.</li>
<li>Fecal material store in the colon.</li>
<li>Ascites is suspected.</li>
</ul></li>
<li>2022-03-09 Abdomen - Standing(Diaphragm)
<ul>
<li>Fecal material store in the colon.</li>
<li>Ascites is suspected. Please correlate with sonography.</li>
</ul></li>
<li>2022-03-07 Abdomen - Standing(Diaphragm)
<ul>
<li>Multiple segment of small intestine show air-fluid level that are
c/w bowel obstruction.</li>
<li>Ascites is suspected. Please correlate with sonography.</li>
</ul></li>
<li>2022-03-04 CT - abdomen, pelvis
<ul>
<li>Carcinomatosis induce mechanical bowel obstruction is
suspected.</li>
</ul></li>
<li>2022-03-04 KUB
<ul>
<li>Increased intestinal gas is found.</li>
<li>Stool impaction at the abdominal cavity is noted.</li>
</ul></li>
<li>2021-11-23 CT - abdomen, pelvis
<ul>
<li>Stationary of pancreatic tail low density lesion.</li>
<li>More prominent soft tissue density in RLQ, suspected
carcinomatosis.</li>
<li>Stationary of bilateral lung nodules, suspected lung
metastasis.</li>
</ul></li>
<li>2021-11-09 Tc-99m MDP bone scan
<ul>
<li>In comparison with the previous study on 20210120, no prominent
change is noted, suggesting no strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in the maxilla, middle T-spines, lower
L-spines, sacrum, bilateral sacroiliac joints, shoulders,
sternoclavicular junctions, hips, and knees,</li>
</ul></li>
<li>2021-09-21 CT - abdomen, pelvis
<ul>
<li>Small bowel ileus, suspected adhesion.</li>
<li>Relative increased density in RLQ, suspected carcinomatosis.</li>
<li>Stationary of pancreatic lesion.</li>
<li>Left lower lung nodule, suspected lung metastasis.</li>
</ul></li>
<li>2021-07-13 Abdomen - Standing(Diaphragm)
<ul>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2021-07-12 CT - abdomen, pelvis
<ul>
<li>Stationar condition of pancreatic cancer and peritoneal
carcinomatosis as compared with previous CT study on 20210511.</li>
</ul></li>
<li>2021-05-11 CT - abdomen, pelvis
<ul>
<li>Dilated pancreatic duct at tail portion. The pancreatic condition is
stationary.</li>
<li>No evidence of mestastatic lesion in the study.</li>
</ul></li>
<li>2021-04-18 Abdomen - Standing(Diaphragm)
<ul>
<li>Fecal material store in the colon.</li>
</ul></li>
<li>2021-03-02 CT - abdomen, pelvis
<ul>
<li>Suspected rupture appendicitis.</li>
<li>Suspected abscess in the pelvic cavity.</li>
</ul></li>
<li>2021-01-20 Tc-99m MDP bone scan
<ul>
<li>No strong evidence of bone metastasis.</li>
<li>Suspected benign lesions in middle T-spine, lower L-spine, sacrum,
sacroiliac joints, shoulders, sternoclavicular junctions, hips, and
knees.</li>
</ul></li>
<li>2021-01-19 CT - abdomen, pelvis
<ul>
<li>Non-visualization of the pancrreatic tumor. Either current therpay
is effective or the diagnostic method should be further
investigated.</li>
</ul></li>
<li>2020-12-14 Abdomen - Standing(Diaphragm)
<ul>
<li>Transitional vertebra of L5-S1, left side.</li>
</ul></li>
<li>2020-10-12 CT - abdomen, pelvis
<ul>
<li>Stationar condition of pancreatic cancer and peritoneal
carcinomatosis as compared with previous CT study on 20200706.</li>
</ul></li>
<li>2020-07-20 Tc-99m MDP bone scan
<ul>
<li>Mildly and non-focally increased radiotracer uptake in middle
T-spine, lower L-spine, and sacrum that had been less evident in
comparison with the previous study on 20200204, degenerative spine
diseases may show such a picture.</li>
<li>Probably degenerative joint lesions in shoulders, sternoclavicular
junctions, sacroiliac joints, hips, and knees.</li>
<li>No definite evidence of osteoblastic skeletal metastasis by this
bone scan.</li>
</ul></li>
<li>2020-07-06 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Much regression of pancreatic cancer and peritoneal
carcinomatosis.</li>
</ul></li>
<li>2020-04-07 CT - abdomen, pelvis
<ul>
<li>Pancreatic malignancy s/p treatment.</li>
<li>Regression of peritoneal carcinomatosis.</li>
</ul></li>
<li>2020-02-04 Tc-99m MDP bone scan with SPECT
<ul>
<li>Increased activity in the lower C-spine and lower L-spine.
Degenerative change may show this picture. However, please correlate
with other imaging modalities for further evaluation and to rule out
other possibilities.</li>
<li>Increased activity in the bilateral shoulders, bilateral
sternoclavicular junctions, hips, knees, ankles and both feet,
compatible with benign joint lesion.</li>
</ul></li>
<li>2020-01-02 CT - abdomen
<ul>
<li>Pancreatic carcinoma imaging stage: T1cN1M1, Stage IV</li>
<li>Other findings: mild repression of primary tumor and peritoneal
seeding</li>
</ul></li>
<li>2019-09 Pathology - omentum (at VGHTPE)
<ul>
<li>pancreatic adenocarcinoma, metastatic, cT4N1M1</li>
<li>CK7(+), CK20(-).</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>CEA
<ul>
<li>2022-04-19 8.36 ng/mL</li>
<li>2022-04-08 8.734</li>
<li>2022-04-06 8.86</li>
<li>2022-03-23 5.451</li>
<li>2022-02-22 10.47</li>
<li>2022-02-08 8.176</li>
<li>2022-01-19 5.384</li>
<li>2022-01-03 6.370</li>
<li>2021-12-21 5.508</li>
<li>2021-11-25 7.414</li>
<li>2021-04-28 2.419</li>
<li>2021-04-20 2.64</li>
<li>2021-03-04 1.607</li>
<li>2021-01-14 1.155</li>
<li>2020-12-09 1.343</li>
<li>2020-12-08 1.11</li>
<li>2020-11-06 1.757</li>
<li>2020-10-02 1.591</li>
<li>2020-08-28 1.875</li>
<li>2020-08-04 0.749</li>
<li>2020-04-13 1.86</li>
<li>2020-02-27 2.766</li>
<li>2019-12-31 3.478</li>
<li>2019-11-05 2.995</li>
<li>2019-10-16 2.789</li>
</ul></li>
<li>CA199
<ul>
<li>2022-04-19 10566.2 U/mL</li>
<li>2022-04-08 10638</li>
<li>2022-04-06 5603.49</li>
<li>2022-03-23 10346.6</li>
<li>2022-02-22 9232.6</li>
<li>2022-02-08 8534.6</li>
<li>2022-01-19 8673.8</li>
<li>2022-01-03 9546</li>
<li>2021-12-21 8695.7</li>
<li>2021-12-17 3930.36</li>
<li>2021-12-03 11539.95</li>
<li>2021-11-25 11030.5</li>
<li>2021-11-09 16219.4</li>
<li>2021-10-13 12661</li>
<li>2021-09-17 5472.1</li>
<li>2021-09-07 6671.4</li>
<li>2021-08-06 3643.3</li>
<li>2021-07-23 4275.3</li>
<li>2021-07-09 2841.0</li>
<li>2021-06-25 3306.2</li>
<li>2021-06-18 3287.4</li>
<li>2021-06-08 3073.35</li>
<li>2021-05-25 3015.7</li>
<li>2021-05-12 3141.6</li>
<li>2021-04-28 2667.2</li>
<li>2021-04-20 1630.65</li>
<li>2021-04-01 1143.5</li>
<li>2021-03-19 701.39</li>
<li>2021-03-04 354.060</li>
<li>2021-02-24 335.25</li>
<li>2021-01-15 177.130</li>
<li>2021-01-14 169.370</li>
<li>2020-12-16 110.182</li>
<li>2020-12-08 156.614</li>
<li>2020-11-06 71.735</li>
<li>2020-10-02 38.132</li>
<li>2020-08-28 23.155</li>
<li>2020-08-11 21.897</li>
<li>2020-07-31 20.589</li>
<li>2020-07-20 19.681</li>
<li>2020-06-24 23.338</li>
<li>2020-05-29 29.415</li>
<li>2020-04-30 64.378</li>
<li>2020-04-13 68.09</li>
<li>2020-04-08 145.41</li>
<li>2020-02-27 493.18</li>
<li>2020-02-04 678.54</li>
<li>2019-12-31 1127.2</li>
<li>2019-12-03 1981.5</li>
<li>2019-11-14 3700</li>
<li>2019-11-05 4329.2</li>
<li>2019-10-18 8888.3</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-15 - gemcitabine</li>
<li>2022-04-07 - carboplatin + gencitabine</li>
<li>2021-09-29 ~ 2022-03-21 - FOLFIRI?</li>
<li>2020-09-14 - FOLF (irinotecan to be plused)</li>
<li>2020-02-13 - 2021-09-07 - gemcitabine + nal-paclitaxel</li>
<li>2020-02-06 - gemcitabine</li>
<li>2019-10-21 ~ 2020-01-20 - FOLFIRINOX (experienced
oxaliplatin-allergic shock 2020-01)</li>
<li>2019-10-07 - oxalip 150 mg iv q2wk plus TS-1 60 mg 3tab bid and
folic acid 2tab bid</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Initially diagnosed with pancreatic carcinoma (T1cN1M1, Stage IV) in
September 2019, followed by FOLFIRINOX between 2019-10 and 2020-01;
following oxaliplatin allergy, the regimen changed to gemcitabine +
nal-paclitaxel until 2021-09; following lung metastases, the regimen
changed to 5-Fu + irinotecan until 2022-03; following
carcinomatosis-induced mechanical bowel obstruction, the regimen changed
to carboplatin + gencitabine since 2022-04.</li>
<li>The patient experienced severe back pain on 2022-04-20 night and was
taken to the Emergency Department. Morphine 5mg IVD PRNQ4H is prescribed
to treat the pain.</li>
<li>Lab readings on 2022-04-21 were CRP 7.53mg/dL, urine bacteria 3+,
urine OB 2+, urine sediment RBC 6-9/HPF, urine sediment WBC 50-99/HPF.
Body temperature did not exceed 37.5 degrees during this hospital stay
for now. The blood culture has been ordered, but the results are not yet
available. Empirical antibiotics ceftriaxone 2000mg IVD QD are being
used since 2022-04-22.</li>
<li>Vemlidy (tenofovir alafenamide) is used to treat underlying positive
HBsAg.</li>
</ul>
<p></p>
</div>
</div>
<div id="section-332" class="section level1">
<h1>701199326</h1>
<div id="section-333" class="section level2">
<h2>220420</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-14 CT - lung/mediastinum/pleura
<ul>
<li>Bilateral pulmonary metastasis with progression.</li>
<li>Consolidation over right lower lobe with right pleural
effusion.</li>
<li>Heterogeneous low density lesions are found at residual right lobe
liver is found. Liver hematoma is favored.<br />
</li>
</ul></li>
<li>2022-02-16 Abdominal Ultrasonography
<ul>
<li>chronic liver parenchymal disease</li>
<li>hepatic tumors, three c/w mets s/p MWA</li>
<li>ascites, mild</li>
<li>subcapsule hematoma</li>
<li>GB sludge</li>
</ul></li>
<li>2022-02-11 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Hematoma in S4-8 of the liver subcapsule is noted.</li>
<li>Hematoma or bloody ascites in subphrenic space, perisplenic space,
and bilateral paracolic gutter space.</li>
</ul></li>
<li>2022-01-20 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>Rectal cancer with liver/lung metastases s/p operation and RFA.
Segeral poor enhancing tumors (up to 5.4cm) in liver c/w
metastases.</li>
<li>Right pleural effusion with adjacent lung collapse. Some nodules at
bil. basal lungs c/w metastases.</li>
</ul></li>
<li>2022-01-13 CT- lung/mediastinum/pleura
<ul>
<li>Colon cancer with liver and lung meta s/p op. and RFA at both lungs.
Recurrent/residual tumor at both lungs and liver, suggest further
treatment.</li>
</ul></li>
<li>2021-09-28 Patho - pleura/pericardial biopsy
<ul>
<li>Lung and pleura, right, decortication
<ul>
<li>empyema<br />
</li>
<li>metastatic adenocarcinoma, moderately differentiated, consistent
with colonic origin<br />
</li>
</ul></li>
<li>IHC: CK7(-), CK20(-), CDX2(focal +), and TTF-1(-). The results are
consistent with metastatic colonic adenocarcinoma.</li>
</ul></li>
<li>2021-09-21 CT - lung/mediastinum/pleura
<ul>
<li>S/P right lung operation. Right pneumothorax with right lung
collapse. Right pleural effusion. Some patchy densities at left
lung.</li>
</ul></li>
<li>2021-07-27 CT - lung/mediastinum/pleura
<ul>
<li>bilateral pulmonary metastatic tumors, in progression compared with
CT on 20210311.</li>
</ul></li>
<li>2021-03-29 Patho - lung wedge biopsy
<ul>
<li>Pathologic Diagnosis
<ul>
<li>Lung, left, upper lobe, wedge resection - Adenocarcinoma,
moderately differentiated, consistent with metastatic colonic tumor</li>
<li>Lung, left, lower lobe, wedge resection - Adenocarcinoma,
moderately differentiated, consistent with metastatic colonic
tumor<br />
</li>
<li>Lymph node, group No.9, lymphadenectomy - Negative for malignancy
(0/1)<br />
</li>
</ul></li>
<li>Microscopic Description
<ul>
<li>Tumor Focality: Separate tumor nodules of same histopathologic type
in different lobe (S2021-4686)<br />
</li>
<li>Histologic Type (select all that apply): Adenocarcinoma; The
morphology is consistent with metastatic colonic tumor.<br />
</li>
<li>Histologic Grade: G2: Moderately differentiated<br />
</li>
<li>Spread Through Air Spaces (STAS): Not identified<br />
</li>
<li>Visceral Pleura Invasion: Not identified<br />
</li>
<li>Lymphovascular Invasion (select all that apply): present<br />
</li>
<li>Direct Invasion of Adjacent Structures: No adjacent structures
present<br />
</li>
<li>Margins (select all that apply): All margins are uninvolved by
carcinoma<br />
</li>
<li>Treatment Effect: No known presurgical therapy<br />
</li>
<li>Regional Lymph Nodes: group 9: 0/1<br />
</li>
<li>Extranodal Extension: Not identified<br />
</li>
<li>Additional Pathologic Findings: No tumor is seen in specimen A.</li>
</ul></li>
</ul></li>
<li>2021-03-11 CT - chest
<ul>
<li>Multiple spiculated nodules, in enlargement. Compatible with lung
mets.</li>
</ul></li>
<li>2021-03-04 CT - abdomen
<ul>
<li>Mild decreased size of liver metastases. Small nodules at bil. lower
lungs.</li>
<li>Left hydronephrosis and hydroureter. Bil. tiny renal stones.</li>
</ul></li>
<li>2020-12-30 CT - abdomen
<ul>
<li>Two metastases in S7/8 and S7 show stable disease.</li>
<li>Two lung metastases show stable disease.</li>
</ul></li>
<li>2020-09-23 CT - abdomen
<ul>
<li>Two metastases in S7/8 and S7 show stable disease.</li>
<li>A metastasis 5 mm in LUL of the lung is suspected.</li>
<li>Left L/3 ureter stone causing hydroureteronephrosis and delayed
contrast excretion of left kidney.</li>
</ul></li>
<li>2020-07-19 CT - chest
<ul>
<li>right pneumothorax</li>
<li>suspicious a nodular lesion, about 20mm, in the lower lobe of the
right lung.</li>
</ul></li>
<li>2020-07-02 Patho - lung wedge biopsy
<ul>
<li>Lung, right, middle lobe, wedge resection - Adenocarcinoma,
moderately differentiated, consistent with metastatic colorectal
origin</li>
<li>Lung, right, lower lobe, wedge resection - Adenocarcinoma,
moderately differentiated, consistent with metastatic colorectal
origin</li>
</ul></li>
<li>2020-07-01 Patho - lung wedge biopsy
<ul>
<li>Lung, right, upper lobe, wedge resection - Adenocarcinoma,
moderately differentiated, consistent with metastatic colorectal
origin</li>
<li>Tumor Focality: Separate tumor nodules of same histopathologic type
in different lobes (S2020-8766 and S2020-8767)</li>
<li>IHC: MSH2(+), MSH6(+), MLH1(+), and PMS2(+).</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-11 MWA, Microwave ablation
<ul>
<li>Procedure
<ul>
<li>Liver metastatic tumors, three (5.5 cm, 2.5 cm and 1.9 cm) s/p MWA x
(total 11 sessions)</li>
</ul></li>
<li>Course
<ul>
<li>By sono-guided, MWA probe was inserted to the 1st tumor (total 9
sessions; 100 W, 5 mins). MWA probe were inserted to the other two
tumors (total 2 sessions; 70 W, 3 mins). The patient tolerated the
procedure. IV anesthesia was performed during the procedure.</li>
</ul></li>
<li>Findings
<ul>
<li>A 5.5 cm tumor was noted at S7 near diaphragm. A 2.5 cm mass at rt
post seg near liver surface. A 1.9 cm mass at rt ant seg near liver
surface.</li>
</ul></li>
</ul></li>
<li>2021-09-27 VATS, decortication
<ul>
<li>Loculated serosanguenous pleural effusion with fibrotic debris over
visceral and parietal pleura</li>
<li>Necrotic RLL parenchyma were bleeding during debridement s/p 4D
field hemostatic powder treatment</li>
</ul></li>
<li>2021-03-29 VATS, LUL and LLL wedges resection for metastasectomy +
pneumolysis
<ul>
<li>multiple solid nodules over LUL and LLL r/o rectal cancer
metastasis</li>
<li>LUL nodules x7 and LLL nodules x3 were resected with one of the
maximum about 1cm in diameter</li>
<li>no noted pleural effusion. Intrapleural cavity adhesion s/p
pneumolysis</li>
</ul></li>
<li>2021-09-16 RFA, Radiofrequency Ablation</li>
<li>2021-08-19 RFA, Radiofrequency Ablation</li>
<li>2020-07-01 3D VATS RUL, RML and RLL wedge resections + LND.
decortication
<ul>
<li>Multiple lung nodules were noted over right lung field.</li>
</ul></li>
<li>2018-03-29 laparoscopic lower anterior resection w/ TaTME and S3, S8
subsegmentectomy + S5 cyst unroofing (Taipei Veterans General
Hospital)</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2018-002-01 ~ 2018-02-06 - neoadjuvant short radiotherapy of
25Gy/5fx for adenocarcinoma of lower rectum with liver mets, at Taipei
Veterans General Hospital</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-19 ~ undergoing - FOLFOXIRI plus bevacizumab and
pembrolizumab (last two items are self-paid)</li>
<li>2021-05-04 ~ 2021-07-14 - FOLFOXIRI plus bevacizumab and
pembrolizumab, 4 times</li>
<li>2020-08-18 ~ 2021-02-17 - FOLFOXIRI plus bevacizumab, 13 times</li>
<li>2020-08-03 - FOLFOXIRI</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient has MMR-proficient lower rectal cancer with liver and
lung metastases (2020-07-01 pathology). The lung mets were confirmed to
be in progress (2022-04-14 CT) followed by the MWA (2022-02-11) for the
liver mets.</li>
<li>During this hospital stay, the patient resumed using FOLFOXIRI plus
self-paid bevacizumab and pembrolizumab as a palliative treatment, the
same regimen was used during 2021-05-04 to 2021-07-14. Before that,
FOLFOXIRI plus bevacizumab were also used from August 2020 to February
2021.</li>
<li>Lab data reported on 2022-04-19 revealed that liver and kidney
function, serum electrolytes, and blood cell counts were generally
normal.</li>
<li>The nursing note does not indicate any intolerances so far since
this hospitalization. No issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-334" class="section level1">
<h1>701204933</h1>
<div id="section-335" class="section level2">
<h2>220322</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-14 CT - whole abdomen, pelvis
<ul>
<li>S/P right hemicolectomy. There is no evidence of tumor
recurrence.</li>
</ul></li>
<li>2021-12-31 Abdomen Ultrasound
<ul>
<li>chronic liver parenchymal disease</li>
<li>suspect GB polyp</li>
<li>cholecystopathy</li>
<li>suspect tiny stones, left kidney</li>
</ul></li>
<li>2021-08-26 Patho - colon segmental resection for tumor
<ul>
<li>Large intestine, ascending colon, laparoscopic right hemicolectomy -
Adenocarcinoma, moderately differentiated</li>
<li>Lymph node, mesocolic, dissection - metastatic carcinoma<br />
</li>
<li>pT3 pN2a (if cM0) Pathology stage: IIIB.<br />
</li>
<li>Histologic Type - Adenocarcinoma<br />
</li>
<li>Histologic Grade - G2 Moderately differentiated<br />
</li>
<li>Tumor Extension-Tumor invades through the muscularis propria into
pericolorectal tissue with no involvement of visceral peritoneum serosal
surface.<br />
</li>
<li>Lymphovascular Invasion: Present<br />
</li>
<li>Regional Lymph Nodes - Number of Lymph Nodes Involved/Examined: 4/15
with extranodal extension.<br />
</li>
<li>Ancillary Studies - The result of biopsy specimen: S2021-09938<br />
</li>
<li>IHC: EGFR(+), PMS2(+), MLH-1(+), MSH-2(+), MSH-6(+)</li>
</ul></li>
<li>2021-08-16 CT - whole abdomen, pelvis
<ul>
<li>Imaging stage: T3N1bM0, stage IIIB</li>
</ul></li>
<li>2021-08-03 Patho - colon biopsy
<ul>
<li>Intestine, large, hepatic flexure colon, biopsy -
adenocarcinoma<br />
</li>
<li>Microscopically, it shows adenocarcinoma composed of a proliferation
of irregular neoplastic glands with areas of cribriform architecture,
and infiltrative growth pattern. The tumor cells display hyperchromatic
nuclei with pleomorphism, prominent nucleoli, high N/C ratio and mitotic
figures.</li>
</ul></li>
<li>2021-08-03 Colonoscopy
<ul>
<li>suspect colon cancer, hepatic flexure, s/p biopsy</li>
<li>internal hemorrhoid</li>
</ul></li>
<li>2021-01-31 CT - whole abdomen, pelvis
<ul>
<li>suspected acute pancreatitis, suggest clinical lab data
correlation.</li>
<li>small gallbladder stone. collapsed gallbladder with wall thickening,
suspected chronic cholecystitis.</li>
<li>left renal stone without obstruction.</li>
<li>relative thickening renal pelvis wall, right side.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-08-25 SILS Right-hemicolectomy- Proximal T-colon tumor</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-10-12 ~ ongoing - FOLFOX</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The survival benefit of adding oxaliplatin to adjuvant
fluoropyrimidines in patients with resected stage III colon cancer has
been shown in multiple randomized trials, and benefit appears to be
evident across diverse practice settings and patient subgroups.
<ul>
<li>reference: <a href="https://www.uptodate.com/contents/adjuvant-therapy-for-resected-stage-iii-node-positive-colon-cancer" class="uri">https://www.uptodate.com/contents/adjuvant-therapy-for-resected-stage-iii-node-positive-colon-cancer</a></li>
</ul></li>
<li>After undergoing right hemicolectomy on 2021-08-25, the patient has
been treated with FOLFOX regimen since mid-October 2021. There is no
evidence of peripheral neuropathy mentioned in nursing notes or medical
records in 2022.</li>
</ul>
</div>
</div>
<div id="section-336" class="section level1">
<h1>701205775</h1>
<div id="section-337" class="section level2">
<h2>210907</h2>
<p>{unresectable liver tumor}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-08-26 coffee ground vomiting, gastrointestinal hemorrhage,
hypovolemic shock.</li>
</ul>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2021-08-27 abdominal ultrasound
<ul>
<li>liver tumors, both lobe</li>
<li>parenchymal liver disease</li>
<li>cholecystopathy</li>
<li>minimal ascites</li>
</ul></li>
<li>2021-08-27 CT - whole abdomen, pelvis
<ul>
<li>findings:
<ul>
<li>lobulated patchy geographic poor enhancing cystic-like lesions in
right lobe and S4 of the liver, the largest one measuring 14.3 cm in the
largest dimension, with patent flow of both lobe portal vein and hepatic
vein.</li>
<li>several enlarged nodes in the hepatoduodenal ligament are noted and
the largest one measuring 2.5 cm that may be metastatic nodes?</li>
<li>liver infarction is highly suspected?</li>
<li>the differential diagnosis include angiosarcoma,
poorly-differentiated HCCs, and metastases.</li>
<li>the liver shows irregular contour that may be cirrhosis. enlarged of
the spleen (long axis: 12 cm) and minimal ascites in right subphrenic
and right perihepatic space that may be portal hypertension.</li>
</ul></li>
<li>imaging stage:
<ul>
<li>T3N1M0, stage IVA.</li>
</ul></li>
</ul></li>
<li>2021-08-30 patho - liver biopsy needle/wedge, sono-guided aspiration
<ul>
<li>hepatocellular carcinoma, composed of nests of well differentiated
neoplastic hepatocytes, arranged in pseudoglandular and trabecular
patterns. extensive coagulative necrosis and hemorrhage are
present.</li>
</ul></li>
<li>2021-08-30 MRI - liver, spleen
<ul>
<li>bil. liver tumors, angiosarcoma is first considered.</li>
</ul></li>
</ul>
<p>[underlying disease]</p>
<ul>
<li>T2DM, GERD, HTN, hyperlipidemia</li>
</ul>
<p>[assessment]</p>
<ul>
<li>liver tumor
<ul>
<li>tumor too large to be resectable (low anticipated liver reserve and
remnant). this patient is in her early sixties with multiple
comorbidities (and probable portal hypertenstion), being a candidate for
transplant might be an option but not a highly realistic one.</li>
<li>limiting tumor growth or downsizing it to mitigate possible
encephalopathy, ascites, hypoalbuminemia, prolonged prothrombin time,
hyperbilirubinemia, would be on a general right track in a short-term to
medium-term time scale.</li>
<li>bevacizumab might not be applicable at the present time for its
possible cardiovascular (heart failure), GI (perforation), HTN,
hemorrhage adverse reactions.</li>
<li>patient-carried stivarga (regorafenib 40mg PO QD) has been listed in
active medication since 2021-09-01 during this hospitalization.</li>
</ul></li>
<li>current symptoms and most of underlying diseases are managed under
following drugs without issues:
<ul>
<li>encephalopathy
<ul>
<li>lactul (lactulose) 13.32g PO QD</li>
</ul></li>
<li>prolonged prothrombin time
<ul>
<li>katimin (phytomenadione) 10mg IVD QD</li>
</ul></li>
<li>cachexia
<ul>
<li>megest (megestrol) 160mg PO TID</li>
</ul></li>
<li>edema, ascite
<ul>
<li>plasbumin (human albumin) 50ml IVD BID</li>
<li>furosemide 20mg IVD BID</li>
<li>spironolactone 25mg PO BID</li>
</ul></li>
<li>GERD
<ul>
<li>takepron (lansoprazole) 30mg PO QDAC</li>
</ul></li>
<li>HTN
<ul>
<li>concor (bisoprolol) 1.25mg PO BID</li>
</ul></li>
<li>T2DM
<ul>
<li>actrapid hm insulin 4unit SC BIDAC</li>
<li>relinide (repaglinide) 1mg PO TIDAC15</li>
<li>trajenta (linagliptin) 5mg PO QDAC</li>
</ul></li>
</ul></li>
<li>pravafen (pravastatin 40mg, fenofibrate 160mg) QD for hyperlipidemia
(lab data on 2021-08-05 remained high readings) listed in PharmaCloud
could be considered to add to active medication as a patient-carried
item.</li>
</ul>
</div>
</div>
<div id="section-338" class="section level1">
<h1>701208485</h1>
<div id="section-339" class="section level2">
<h2>220331</h2>
<p>{pancreatic cancer T4N1M0 stage III}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-24 ERCP (Endoscopic Retrograde CholangioPancreatography)
<ul>
<li>biliary obstruction s/p SEMS</li>
<li>chronic cholangitis</li>
</ul></li>
<li>2022-01-14 CT - liver, spleen, biliary duct, pancreas
<ul>
<li>There is filling defects at left lobe portal vein that is c/w
thrombosis and the etiology may be thrombophlebitis.</li>
<li>Adenocarcinoma of the pancreatic head-body with portal vein, splenic
vein, and celiac trunk encasement is suspected.</li>
</ul></li>
<li>2022-01-12 Patho - pancreas biopsy
<ul>
<li>Pancreas, head, EUSFNB  adenocarcinoma, moderately
differentiated<br />
</li>
<li>Section shows pancreas tissue with infiltration of neoplastic glands
in fibrous stroma.</li>
<li>IHC: CK(+)</li>
</ul></li>
<li>2022-01-10 ERCP (Endoscopic Retrograde CholangioPancreatography)
<ul>
<li>biliary obstruction s/p brushing cytology &amp; plastic stent
placement</li>
<li>chronic cholangitis</li>
<li>reflux esophagitis</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-10 ~ undergoing - FOLFIRINOX + pembrolizumab</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Pancreatic adenocarcinoma with or without BRCA1/2 or PALB2
mutations, FOLFIRINOX is preferred; this patient has been receiving this
regimen since 2022-02-10.</li>
<li>Results of liver and kidney function tests reported on 2022-03-30
were normal, CBC readings were slightly lower, the latter should not be
likely to affect treatment in this hospital stay.</li>
<li>No issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-340" class="section level1">
<h1>701239654</h1>
<div id="section-341" class="section level2">
<h2>210706</h2>
<p>{post-IPP meeting following up}</p>
<p>patient family meeting and IPP meeting was held at 10:00 on
2021-07-06</p>
<ul>
<li><p>the schedule with regimen for PBSCT for the patient has been
disclosed in the meeting.</p></li>
<li><p>the estimated total amount of melphalan used in the time table is
6 vials.</p>
<ul>
<li>based on melphalan 50mg/vial, dose 100mg/m2, body surface area
1.425m2.</li>
<li>3 vials per day for 2 days (2021-07-07, 2021-07-08).</li>
<li>the amount has been secured by medicine storeroom.</li>
</ul></li>
<li><p>preparation and administration precautions of mephalan:</p>
<ul>
<li>expiration time 1.5hr after preparation (the duration including
infusion time) according to package insert.</li>
<li>based on lab data reported on 2021-07-05, liver and kidney have no
abnormality, no dose adjustment needed.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-342" class="section level1">
<h1>701240249</h1>
<div id="section-343" class="section level2">
<h2>220315</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-02 Patho - bone marrow biopsy
<ul>
<li>pathologic diagnosis
<ul>
<li>Bone marrow, biopsy - acute myeloid leukemia</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Microscopically, the sections show a picture of acute myeloid
leukemia, composed of hypercellular marrow (&gt;90%). The marrow space
is almost completely replaced by blasts.</li>
</ul></li>
<li>Immunohistochemistry: CD34(+, 60%), CD117(+, 60%), MPO(+, 10%),
CD61(+, megakaryocytes) and CD71(+, erythroid series).</li>
</ul></li>
<li>2022-02-25 CT - lung/mediastinum/pleura
<ul>
<li>Right middle lobe and right lower lobe subsegmental
consolidation.</li>
</ul></li>
<li>2022-01-12 Patho - bone marrow biopsy
<ul>
<li>pancytopenia<br />
</li>
<li>Bone marrow, iliac, biopsy - Normal cellular marrow.</li>
<li>IHC stains: CD117: &lt;2%; CD34: &lt;2 %; MPO: 10%, CD61: &lt;2 %;
CD71: 20%, CD138: 5% (of the nucleated cells). Kappa and lambda light
chains: no predominant monoclonal sub-population.<br />
</li>
<li>Section shows piece(s) of bone marrow with 50 % cellularity and M:E
ratio of approximately 3:1. Three cell lineages are present with normal
maturation of leukocytes. Megakaryocytes are adequate in number. There
is no metastatic malignancy present.</li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-344" class="section level1">
<h1>701243405</h1>
<div id="section-345" class="section level2">
<h2>999999</h2>
<p>[initial presentation]</p>
<ul>
<li>2021-05-07 intermittent lower abdominal pain for 3 weeks. pain was
relieved after taking acetaminophen and diclofenac but recurred since 4
days ago. associated symptoms: constipation for 2 days, hiccup, nausea,
poor appetite.</li>
</ul>
<p>[definite diagnosis]</p>
<p>2021-05-06 CT - abd - loculated fluid accumulation at uterus up to
9.7*7.1cm in largest dimension is found. - uterine abscess is considered
first. 2021-05-11 patho - ovary (tumor) - taiwan society of pathology
was consulted to diagnose: malignant spindle cell and epithelioid cell
neoplasm. - IHC: SALL4/BRG1/INI1(+), glypican/SATB2/cyclinD1( focal+);
SS18-SSX/OCT4/CD30/ETV4/MDM2/S100/NUT/MyoD1(-).<br />
- molecular pathology: SS18(-)(poor quality); chr12p/q FISH: failed. -
comment: - while the majority of it was composed of relatively uniform
spindle cells, gland-like components were also notable, in conjunction
with the strong TLE1 immunostaining, justifying your original
consideration of synovial sarcoma. - the degree of nuclear atypia would
be somewhat too high for synovial sarcoma, and TLE1 expression is not
specific. both SS18-SSX IHC and SS18 FISH performed to exclude this
possibility. - given the gland-like structures which reminded yolk sac
tumor, SALL4 (multifocally positive) and glypican (weakly positive,
mainly in the gland-like structures) staining were performed and
somewhat supported the speculation, albeit neither convincing nor
specific enough. - attempt to pursue some molecular evidence of
isochromosome 12p with chr12p, chr12q, and chr12 centromere FISH failed.
- other possibilities including myoepithelial carcinoma were not
supported by the current immunostaining results. - the case was reviewed
by one senior GYN pathologist, one GU pathologist, and another soft
tissue pathologist, and no conclusion could be drawn. - while a germ
cell tumor with a component of yolk sac tumor and sarcomatoid
transformation could not be excluded, the overall pathologic and
clinical features would be atypical. - perhaps a genomewide study aiming
at copy number variation/LOH might help in this regard. - note: some of
the original immunostaining showed CK weak+, TLE1+, SMA f+, GFAP-.
2021-07-13 patho - ovary (tumor) - diagnosis: pelvic tumor, debulking
surgery - compatible with recurrent malignant neoplasm. - the sections
show a picture of spindle and epithelioid cell tumor characterized by
spindle, ovoid or epithelioid tumor cells with congestion, hemorrhage,
extensive necrosis, active mitoses, arranged in solid, focal fascicular
or focal gland-like or rossette-like pattern, compatible with tumor
recurrence.</p>
<p>[treatment]</p>
<ul>
<li>2021-05-10 debulking surgery (BSO + cytoreduction surgery +
infracolic omentectomy + appendectomy) for malignant left ovarian
tumor.</li>
<li>2021-06-11 BEP (bleomycin + etoposide + cisplatin)</li>
<li>2021-08-13 doxorubicin</li>
</ul>
</div>
<div id="section-346" class="section level2">
<h2>210630</h2>
<p>{form virless (acyclovir) to famvir (famciclovir)}</p>
<p>[objective]</p>
<ul>
<li>being diagnosed with herpes virus infection.</li>
<li>virless 500mg IVD Q8H ends by 2021-06-30 and famvir (famciclovir)
250mg PO TID starts from 2021-07-01.</li>
<li>ALT elevated few days ago, newer lab data reported on 2021-06-30 and
2021-06-28 showd liver and kidney function normal.</li>
</ul>
<p>[assessment]</p>
<ul>
<li>oral famciclovir excretion is primarily renal, and dose reduction is
recommended in patients with impaired renal function.
<ul>
<li>no observed kidney problem, no adjustment need.</li>
</ul></li>
<li>hepatic impairment
<ul>
<li>a 44% decrease in the Cmax of penciclovir (active metabolite) was
noted in patients with mild-to-moderate impairment</li>
<li>impaired conversion of famciclovir to penciclovir may affect
efficacy becaused of declined first pass effect.</li>
<li>source <a href="https://clinicalinfo.hiv.gov/en/drugs/famciclovir/tablet-film-coated" class="uri">https://clinicalinfo.hiv.gov/en/drugs/famciclovir/tablet-film-coated</a></li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor the liver and kidney function as before, if liver
function deteriorates, then adjust agent to maintain effect might be
considered.</li>
</ul>
</div>
<div id="section-347" class="section level2">
<h2>210628</h2>
<p>{reported thrombotic microangiopathy with acyclovir}</p>
<p>[objective]</p>
<ul>
<li>thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic
syndrome (HUS), manifestations of thrombotic microangiopathy, have been
reported with acyclovir/valacyclovir
<ul>
<li>source:
<ul>
<li>Bell WR, Chulay JD, Feinberg JE. Manifestations resembling
thrombotic microangiopathy in patients with advanced human
immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis
trial (ACTG 204). Medicine (Baltimore). 1997;76(5):369-380. doi:
10.1097/00005792-199709000-00004.</li>
<li>Bukhari S, Aslam HM, Awwal TA, Christmas D, Wallach SL.
Valacyclovir-induced thrombotic thrombocytopenic purpura. Cureus.
2020;12(5):e8156. doi: 10.7759/cureus.8156.</li>
<li>Moake JL. Thrombotic microangiopathies. N Engl J Med.
2002;347(8):589-600. doi: 10.1056/NEJMra020528.</li>
<li>Trachtman H. HUS and TTP in children. Pediatr Clin North Am.
2013;60(6):1513-1526. doi: 10.1016/j.pcl.2013.08.007.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>Bilirubin direct 0.06(6/28)</li>
<li>Bilirubin total 0.45(6/28)</li>
<li>S-GPT/ALT 59(6/28), 117(6/25)</li>
<li>Creatinine 0.67(6/28), 0.41(6/25)</li>
</ul></li>
<li>acitve medication
<ul>
<li>virless (acyclovir) 500mg IVD Q8H</li>
<li>imperan (metoclopramide) 10mg IVD PRNQ6H</li>
<li>loperamide 2mg PO PRNQ6H</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>thrombotic microangiopathy mechanism:
<ul>
<li>idiosyncratic; leading to intravascular platelet-fibrin
microthrombi, vascular damage, hemolysis, and thrombocytopenia. in HUS,
this injury is believed to be initiated by uncontrolled activity of the
alternative complement pathway, while TTP features a reduction in
activity of ADAMTS13, the metalloprotease responsible for cleaving
ultra-large von Willebrand factor multimers.</li>
<li>source: Trachtman H. HUS and TTP in children. Pediatr Clin North Am.
2013;60(6):1513-1526. doi: 10.1016/j.pcl.2013.08.007.</li>
</ul></li>
<li>bilirubin within normal range, no sign of TTP and HUS in nursing
records.</li>
<li>urinary retention and constipation could caused by herpes viral
infection of the S2-S4 dermatome. accouding to active medication and
nursing record, these should not be an issue.
<ul>
<li>source:
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613994/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613994/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/19530489/" class="uri">https://pubmed.ncbi.nlm.nih.gov/19530489/</a></li>
</ul></li>
</ul></li>
<li>liver function improved based on lowered ALT data, creatinine
elevated but still in normal range.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>keep current medication, acyclovir prescription will be end on 6/30,
please continue to prescribe if the condition need.</li>
</ul>
</div>
<div id="section-348" class="section level2">
<h2>210624</h2>
<p>{acyclovir to treat herpes virus infection in HBV active carrier}</p>
<p>[objective]</p>
<ul>
<li>Lab
<ul>
<li>2021-06-23
<ul>
<li>S-GOT/AST 68U/L</li>
<li>S-GPT/ALT 103U/L</li>
<li>creatinine 0.47mg/dL</li>
<li>eGFR 151</li>
</ul></li>
<li>2021-05-17
<ul>
<li>Anti-HBc Reactive</li>
<li>Anti-HBs 41mIU/mL</li>
</ul></li>
</ul></li>
<li>Medication
<ul>
<li>baraclude (entecavir) 0.5mg PO QD</li>
<li>virless (acyclovir) 500mg IVD Q8H</li>
</ul></li>
</ul>
<p>[accessment]</p>
<ul>
<li>AST within 2x ULN, ALT within 3x ULN, liver function not so good but
far from failure.</li>
<li>renal function tests showed no abnormaility.</li>
<li>the major route of acyclovir elimination is the renal excretion of
unchanged drug (&gt; 85%). liver plays no major roles in metabolism.
<ul>
<li>source <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825963/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825963/</a></li>
</ul></li>
<li>acyclovir can inhibit hepatitis B viral replication especially using
higher dose.
<ul>
<li>source <a href="https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.1840080642" class="uri">https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.1840080642</a></li>
<li>source <a href="https://academic.oup.com/jac/article-abstract/11/3/223/784017" class="uri">https://academic.oup.com/jac/article-abstract/11/3/223/784017</a></li>
</ul></li>
<li>acyclovir and its alternatives, e.g.cidofovir, foscarnet,
ganciclovir, all need to be adjusted dose based on CrCl but not on liver
function.</li>
<li>possible adverse reactions
<ul>
<li>acyclovir: acute renal failure, neurologic toxicity.</li>
<li>entecavir: increased serum alanine aminotransferase. (&gt;5 x ULN:
11% to 12%; &gt;10 x ULN and &gt;2 x baseline: 2%), increased serum
creatinine (1% to 2%)</li>
</ul></li>
<li>there is no drug interaction of risk level A or greater identified
between acyclovir, entecavir and current chemo regimen.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>regularily monitor liver and kidney functions the same as before, no
adjustment needed.</li>
</ul>
</div>
</div>
<div id="section-349" class="section level1">
<h1>701243929</h1>
<div id="section-350" class="section level2">
<h2>220420</h2>
<p>{esophageal SCC moderately differentiated T3N2M1 with lung mets}</p>
<p>[objective]</p>
<ul>
<li>lab findings
<ul>
<li>2022-02-08 CT - Lung/Mediastinum/Pleura
<ul>
<li>Impression: bilateral lung metastases, sligthly in regression as
compared with previous CT study on 2021-12-08.</li>
</ul></li>
<li>2021-12-08 CT - Lung/Mediastinum/Pleura
<ul>
<li>Impression: bilateral lung metastases, in progression as compared
with previous CT study on 2021-08-20.</li>
</ul></li>
<li>2021-02-08 Patho - Lung wedge biopsy
<ul>
<li>Diagnosis: Lung, left, upper lobe, wedge resection - Squamous cell
carcinoma, moderately differentiated, consistent with metastatic
esophageal tumor</li>
<li>The HER2/NEU In-Situ Hybridization Test is NEGATIVE. There is NO
amplification of HER2 detected.</li>
<li>IHC: Her-2/neu (Ab) equivocal(2+).</li>
</ul></li>
<li>2020-09-25 Patho - Esophageal biopsy
<ul>
<li>Esophagus, middle, 32cm to 34cm below incisor - squamous cell
carcinoma, moderately differentiated</li>
<li>IHC: CK(+), p63(+)</li>
</ul></li>
<li>2020-07-09 Patho - Esophageal biopsy
<ul>
<li>Esophagus, middle, 25cm below incisor - squamous cell carcinoma,
moderately differentiated</li>
<li>IHC: p63(+), CD56(focal +)</li>
</ul></li>
</ul></li>
<li>systematic treatments
<ul>
<li>2021-12 ~ ongoing 5-FU Cisplatin Paclitaxel</li>
<li>2021-09 ~ 2021-11 HDFL Irinotecan</li>
<li>2021-05 ~ 2021-09 FOLFOX</li>
<li>2021-02 ~ 2021-04 5-FU Cisplatin Docetaxel</li>
<li>2020-08 ~ 2020-08 CCRT 5040cGy/28fx</li>
<li>2020-07 ~ 2020-08 5-FU Cisplatin</li>
</ul></li>
<li>lab data
<ul>
<li>WBC 1.23*10^3/uL (2022-02-23), 1.22 (2022-02-22)</li>
<li>Neutrophil 85% (2022-02-23), 56% (2022-02-22)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The progression was seen to have slowed in the most recent CT dated
2022-02-08, which implies that the present [5-FU + Cisplatin +
Paclitaxel] regimen, which begins in December 2021, has had an
effect.</li>
<li>As of 2022-04-19, lab data showed that liver and kidney functions,
serum electrolytes, and blood cell counts were grossly normal.</li>
<li>No PD-L1, NTRK, MSI/MMR, TMB results found. HER2 overexpression is
not evident, trastuzumab might not be applicable.</li>
<li>There has been a slight decline in blood magnesium levels
(&lt;1.9mg/dL) that might be asymptomatic for at least 12 months.
Magnesium depletion is more prevalent as a result of diarrhea than
vomiting in general. The causal relationship could be further clarified
if clinically needed.</li>
<li>No drug allergy recorded in database, no issue with current
medication.</li>
</ul>
</div>
<div id="section-351" class="section level2">
<h2>220223</h2>
<p>[assessment]</p>
<ul>
<li>the on going progression slightly slowed down according to CT
findings on 2022-02-08, it seems that the current 5-FU + Cisplatin +
Paclitaxel regimen since Dec 2021 showed certain effect.</li>
<li>ANC ~ 1.23 x 0.85 (based on 2022-02-23 lab data) is just above 1
with fluctuation which should be monitored.</li>
<li>HER2 overexpression is not evident, trastuzumab might not be
applicable.</li>
<li>PD-L1, NTRK, MSI/MMR, TMB test might be ordered optionally.</li>
<li>no drug allergy recorded in database, no issue with current
medication.</li>
</ul>
</div>
<div id="section-352" class="section level2">
<h2>220125</h2>
<p>[assessment]</p>
<ul>
<li>in progresstion, several subsequent therapies have been tried.</li>
<li>HER2 overexpression is not evident, trastuzumab might not be
applicable.</li>
<li>PD-L1, NTRK, MSI/MMR, TMB test might be ordered optionally.</li>
<li>no drug allergy recorded in database, no issue with current
medication.</li>
</ul>
</div>
</div>
<div id="section-353" class="section level1">
<h1>701252496</h1>
<div id="section-354" class="section level2">
<h2>220302</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-01 CT
<ul>
<li>bilateral lung, mediastinal and supraclavicular LNs, chest wall,
pleural, bony, and liver metastases, in progression as compared with CT
on 2022-01-19.</li>
<li>multiple numerous nodules of variable sizes throughout in both lungs
due to metastasis.</li>
</ul></li>
<li>2022-01-19 CT
<ul>
<li>bilateral lung, mediastinal and supraclavicular LNs, chest wall,
pleural, and liver metastases, in progression as compared with CT on
2021-11-09.</li>
<li>multiple numerous nodules of variable sizes throughout in both lungs
due to metastasis.</li>
</ul></li>
<li>2021-12-20 Pelvis &amp; Bilat. Hip Lat
<ul>
<li>osteolytic bony lesion in left lower sacrum and right pubic bone are
suspected.</li>
</ul></li>
<li>2021-12-01 Hearing test
<ul>
<li>bil. moderately severe to profound HL.</li>
</ul></li>
<li>2021-11-09 CT
<ul>
<li>bilateral lung, mediastinal LNs, chest wall, and liver metastases,
in progression as compared with CT on 2021-09-06.</li>
</ul></li>
<li>2021-09-06 CT
<ul>
<li>bilateral lung, mediastinal LNs, chest wall, and liver metastases,
in progression as compared with CT on 2021-07-02.</li>
</ul></li>
<li>2021-07-02 CT
<ul>
<li>esophageal cancer s/p esophagectomy and gastric tube reconstruction.
No regional recurrence is found.</li>
<li>bilateral lung meta with enlarged size is found.</li>
<li>s/p jejunal stomy.</li>
</ul></li>
<li>2021-03-24 Patho - soft tissue biopsy / simple excision (non lipoma)
<ul>
<li>skin, infra-gluteal fold, right, excision - metastatic adenosquamous
carcinoma, compatible with esophageal primary</li>
</ul></li>
<li>2021-03-16 CT
<ul>
<li>favor bilateral lung and mediastinal LNs metastases and
bronchiolitis or endobronchial spreadinf nodules, and residal posterior
wall thickening at M/3 of esophages</li>
</ul></li>
<li>2021-02-01 Patho - soft tissue biopsy / simple excision (non lipoma)
<ul>
<li>skin, scalp, incisional biopsy - compatible with metastatic
adenosquamous carcinoma from esophagus<br />
</li>
<li>IHC: CK7(+), CK5/6(+), and p63(focal +).</li>
</ul></li>
<li>2021-01-19 Patho - esophagus subtotal/total resection
<ul>
<li>Esophagus, middle third, VATS esophagectomy - Adenosquamous
carcinoima, poorly differentiated, s/p CCRT<br />
</li>
<li>Soft tissue, peri-gastric, specimen 1, dissection - Adenosquamous
carcinoima, metastatic (1/10)<br />
</li>
<li>Lymph node, group 5, dissection - Adenosquamous carcinoima,
metastatic (1/2)<br />
</li>
<li>Pathology stage:
<ul>
<li>ypStage IIIB, ypT3N1(if cM0)</li>
<li>if brain metastasis is proofed, ypStage IVB, ypT3N1(if cM1)</li>
</ul></li>
</ul></li>
<li>2021-01-06 Whole body PET scan
<ul>
<li>The glucose hypermetabolic lesions in the middle portion of the
esophagus, in mediastinal lymph nodes, and in bilateral pulmonary hilar
lymph nodes come to less evident compared with the previous study on
2020-10-16, compatible with esophageal malignancy s/p treatment.<br />
</li>
<li>However, glucose hypermetabolic lesions in the left lower lung and
right lower lung become more prominent, suggesting lung metastases.</li>
</ul></li>
<li>2021-01-05 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 2020-10-13, the lesion in
the region about left 3rd costovertebral junction is new. The nature is
to be determined (post-traumatic change? other nature?).</li>
<li>No prominent change is noted in other bone lesions, possibly more
benign in nature.</li>
</ul></li>
<li>2021-01-05 MRI - Brain
<ul>
<li>A small enhancing nodule in right caudate nucleus head. Seems
slightly increase in size (4.7 mm), suggest follow up.</li>
<li>Brain atrophy.</li>
</ul></li>
<li>2021-01-04 CT
<ul>
<li>M/3 thoracic esophageal cancer, significant regression of a sessile
like intralumal mass in posterior wall as compared with CT on
2020-09-30.</li>
<li>no regional LAP. inflammation or infection in RLL and LLL of
lungs.</li>
</ul></li>
<li>2020-10-23 MRI - Spectroscopy
<ul>
<li>An enhancing lesion (3 mm) in right caudate nucleus. Metastasis is
first considered until proved otherwise.</li>
</ul></li>
<li>2020-10-16 Whole body PET scan
<ul>
<li>A glucose hypermetabolic lesion involving the middle portion of the
esophagus, compatible with primary esophageal malignancy. Besides, there
were two small focal areas of glucose hypermetabolism in the lower
portion of the esophagus. Esophageal malignancy involving these two
small focal areas should be considered.</li>
<li>Glucose hypermetabolism in multiple bilateral supraclavicular lymph
nodes and multiple mediastinal lymph nodes (more than 7 lymph nodes), in
bilateral pulmonary hilar lymph nodes and in two upper abdominal lymph
nodes. Metastatic lymph nodes may show this picture.</li>
<li>Some small glucose hypermetabolic lesions in bilateral lung fields.
Lung metastases should be watched out.</li>
</ul></li>
<li>2020-10-15 Patho - Esophageal biopsy
<ul>
<li>Esophagus, 34, 37-38 cm below incisors, biopsy - Squamous cell
carcinoma, poorly differentiated<br />
</li>
</ul></li>
<li>2020-10-15 MRI - Brain
<ul>
<li>A metastatic lesion (3 mm) in right caudate nucleus. Left lateral
nasopharyngeal mucosal thickening.</li>
</ul></li>
<li>2020-09-30 CT
<ul>
<li>Esophageal Carcinoma</li>
<li>Imaging stage: T2N1M0, stage IIIA</li>
</ul></li>
<li>2020-09-28 Patho - Esophageal biopsy
<ul>
<li>Esophagus, middle third, 25-30 cm below incisor, biopsy - Squamous
cell carcinoma, poorly differentiated</li>
</ul></li>
<li>2020-09-28 Esophagogastroduodenoscopy, EGD
<ul>
<li>Suspect esophageal cancer, middle third, 25-30 cm below incisor s/p
biopsy x 3</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-01-18 VATS + esophagectomy + laparoscopy gastric tube
reconstruction</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-02-22 ~ 2021-03-05 18Gy/6fx to the whole brain The .
<ul>
<li>whole brain: 18Gy/6fx</li>
<li>rt caudate nucleus metastatic tumor: 30Gy/10fx</li>
<li>scalp boost: 9Gy/3fx (4MeV electron)</li>
</ul></li>
<li>2020-11-02 ~ 2020-12-11 50.4Gy/28fx to the esophagus, Rt hilar LAPs,
and adjacent lymphatic drainage area (part of preOp neoadjuvant
CCRT)</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12 ~ ongoing: 5-Fu + cisplatin + paclitaxel</li>
<li>2021-07 ~ 2021-11: FOLFIRI</li>
<li>2021-03 ~ 2021-07: 5-Fu + cisplatin + docetaxel</li>
<li>2020-11 ~ 2020-12: 5-Fu + cisplatin (PF, part of preOp neoadjuvant
CCRT)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>for recurrent, metastatic esophageal squamous cell carcinoma with
general weakness and fatigue, if ECOG score &lt;= 2 or Karnofsky score
&gt;= 60%, then microsatellite and PD-L1 testing might be performed for
those previously not done, to expand the subsequent choice like
nivolumab or pembrolizumab.</li>
<li>if NTRK gene fusion positive proved, entrectinib or larotrectinib
could also serve as an optional choice.</li>
</ul>
</div>
<div id="section-355" class="section level2">
<h2>210517</h2>
<p>{tube feeding}</p>
<p>the oral drugs in active medication including: - keto (ketorolac
10mg) - neurontin (gabapentin 100mg) - tramacet (tramadol 37.5mg,
acetaminophen 325mg)</p>
<p>all the above drugs can be grinded and administrated via NG tube</p>
</div>
</div>
<div id="section-356" class="section level1">
<h1>701253142</h1>
<div id="section-357" class="section level2">
<h2>210811</h2>
<p>{cecal cancer}</p>
<p>[initial presentation, definite diagnosis, disease extent]</p>
<ul>
<li>2019-12-15 CT at TMUH: cecal or appendiceal malignancy with adjacnet
infiltration, few prominent regional lymph nodes and liver metastasis.
<ul>
<li>no blood stool and no stool impaction could be noted prior to the CT
exam.</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2020-02-10 ~ 2020-11-xx: biweekly high dose 5-fluorouracil and
leucovorin (HDFL) at TMUH?
<ul>
<li>outcome: partial response</li>
</ul></li>
<li>2020-12-07 ~ up to now : continuing HDFL.
<ul>
<li>plus UFT (tegafur + uracil) from 2020-09 ~ 2020-12.</li>
<li>plus Xeloda (capecitabine) from 2021-05 ~ up to now.</li>
</ul></li>
</ul>
<p>[effect &amp; side effect]</p>
<ul>
<li>2020-11-07 CT, ABD:
<ul>
<li>regression of cecum tumor and liver metastasis.</li>
<li>right adrenal tumor, suspect adrenal mestasis, mild
progression.</li>
</ul></li>
<li>2021-02-22 CT, ABD:
<ul>
<li>stable condition of cecal tumor and liver metastases.</li>
<li>wall thickening of urinary bladder, right aspect.</li>
<li>mild regression of right adrenal tumor.</li>
</ul></li>
<li>2021-04-13 KUB:
<ul>
<li>S/P posterior instrumentation fixation from T10 To L5.</li>
<li>S/P laminectomy of L2, L3, and L4; partial laminectomy of L5</li>
<li>vacuum phenomenon of L4-5.</li>
<li>fecal material store in the colon.</li>
</ul></li>
<li>2021-04-15 KUB:
<ul>
<li>S/P posterior longitudinal transpedicular screws and rods
fixation.</li>
<li>stool retention in the bowel.</li>
</ul></li>
<li>2021-05-22 CT, ABD:
<ul>
<li>borderline heart size.</li>
<li>s/p posterior fixation of the lumbar spine</li>
<li>cecal tumor with liver meta, right adrenal meta(?), statinoary.</li>
</ul></li>
<li>2021-07-16 CT, ABD: left hydronephrosis and hydroureter. focal wall
thickening of urinary bladder. urinary bladder and left lower ureter
tumors should be ruled out.</li>
<li>2021-08-02 kidney ultrasound: right renal cyst.</li>
<li>2021-08-02 bladder sonography: post-void residual volume 297ml</li>
<li>CEA
<ul>
<li>2021-08-10 _9.55ng/mL</li>
<li>2021-07-06 11.17</li>
<li>2021-06-08 10.43</li>
<li>2021-05-11 _5.05</li>
<li>2021-04-13 _5.63</li>
<li>2021-03-17 _4.50</li>
<li>2021-02-03 _5.34</li>
<li>2021-01-06 10.98</li>
<li>2020-12-22 16.63</li>
<li>2020-12-03 32.41</li>
<li>2020-11-05 40.06</li>
<li>2020-09-25 21.92</li>
</ul></li>
<li>CA199
<ul>
<li>2021-08-10 _37.74U/mL</li>
<li>2021-07-06 _42.15</li>
<li>2021-06-08 _37.56</li>
<li>2021-05-11 _24.28</li>
<li>2021-04-13 _27.14</li>
<li>2021-03-17 _25.11</li>
<li>2021-02-03 _26.37</li>
<li>2021-01-06 _31.50</li>
<li>2020-12-22 _41.91</li>
<li>2020-12-03 _95.77</li>
<li>2020-11-05 119.26</li>
<li>2020-09-25 119.70</li>
</ul></li>
</ul>
<p>[ongoing problem]</p>
<ul>
<li>BPH
<ul>
<li>medication
<ul>
<li>Avodart (dutasteride) 0.5mg PO QD</li>
<li>Betmiga (mirabegron) 50mg PO QD</li>
<li>Urief (silodosin) 8mg PO QD</li>
</ul></li>
</ul></li>
<li>HTN
<ul>
<li>medication
<ul>
<li>Diovan (valsartan) 80mg PO QD</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>patient is relatively stable with slow tumor progression.</li>
<li>mirabegron is a CYP2D6 inhibitor which might increase the serum
concentration of metoclopramide (10mg IVD PRNQ6H).
<ul>
<li>CYP2D6 is an enzyme responsible for metoclopramide metabolism.</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-358" class="section level1">
<h1>701254197</h1>
<div id="section-359" class="section level2">
<h2>220506</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-04 SONO chest
<ul>
<li>right side minimal amount of pleural effusion, 600cc serosangious
fluid was drained out for symptom relief.</li>
</ul></li>
<li>2022-03-03 Chest PA erect view
<ul>
<li>Atherosclerotic change of aortic arch</li>
<li>Pleura effusion of right costal-phrenic angle</li>
<li>Few nodular opacity projecting in the both lung are suspected.
Please correlate with CT.</li>
</ul></li>
<li>2022-02-25 CT - abdomen, pelvis
<ul>
<li>FINDINGS:
<ul>
<li>Prior CT identified an ill-defined mild heterogeneous enhancing mass
in left hepatic lobe is noted again, increasing in size that is c/w
cholangiocarcinoma S/P C/T with progressive disease.</li>
<li>Prior CT identified several metastatic lymph nodes in gastrohepatic
ligament, hepatoduodenal ligament, para-aortic space and para-cava space
are noted again, mild increasing in size that is c/w progressive
disease.</li>
<li>Prior CT identified several small metastasis on both lung are noted
again, mild increasing in size.</li>
<li>Prior CT identified mild right side Pleura effusion is noted again,
increasing in volume.</li>
<li>Ascites in the abdomen and pelvis is noted.</li>
<li>Prior CT identified tumor seeding in bilateral ovary (more severe on
right side) are noted again, stable in size.</li>
<li>Segmental sigmoid colon shows enhancement and thickening that may be
tumor seeding in left ovary with sigmoid invasion? Please correlate with
colonoscopy.</li>
<li>S/P colostomy at left transverse colon.</li>
<li>S/P R/T device implantation in the vagina is suspected? please
correlate with clinical history.</li>
<li>Compression fracture of T12 vertebral body.</li>
</ul></li>
<li>IMP:
<ul>
<li>Cholangiocarcinoma at Lt lobe liver shows progressive disease.</li>
</ul></li>
</ul></li>
<li>2021-11-26 Patho - liver biopsy needle/wedge
<ul>
<li>pathologic diagnosis
<ul>
<li>Liver, CT-guided biopsy  Adenocarcinoma, moderately differentiated,
compatible with cholangiocarcinoma</li>
<li>IHC shows: CK7(+), CK20(few tumor cells+), and Hepatocyte(-).</li>
</ul></li>
</ul></li>
<li>2021-11-24 CT - abdomen, pelvis
<ul>
<li>Cholangiocarcinoma at left lobe liver shows mild increasing
size.</li>
</ul></li>
<li>2021-08-11 CT - abdomen, pelvis
<ul>
<li>Cholangiocarcinoma at left lobe liver shows mild increasing
size.</li>
<li>Lobulated metastatic tumor in right ovary shows mild increasing in
size. please correlate with clinical condition.</li>
</ul></li>
<li>2021-06-06 CT - abdomen, pelvis
<ul>
<li>Lobulated metastatic tumor in right ovary shows mild increasing in
size. please correlate with clinical condition.</li>
<li>Segmental sigmoid colon shows enhancement and thickening that may be
normal variation or tumor? Please correlate with colonoscopy.</li>
</ul></li>
<li>2021-04-13 CT - abdomen, pelvis
<ul>
<li>Stationary of left lobe cholangiocarcinoma and lymph nodes
metastasis.</li>
<li>Stationary peritoneal carcinomatosis.</li>
<li>Suspected right ovarian metastasis, stationary.</li>
<li>Colon diverticulosis.</li>
<li>Multiple lung nodules, suspected lung metastasis.</li>
</ul></li>
<li>2021-03-31 CT - abdomen, pelvis
<ul>
<li>Cholangiocarcinoma at left lobe liver with metastasis in right
ovary, metastatic lymph nodes in gastrohepatic ligament, hepatoduodenal
ligament, and para-aortic space, and lung metastases show stable
disease.</li>
</ul></li>
<li>2020-12-24 CT - abdomen, pelvis
<ul>
<li>Imaging Report Form for Cholangiocarcinoma: T2N2M1, stage IV</li>
</ul></li>
<li>2020-03-05 Pathology at TMUH
<ul>
<li>colonoscopy biopsy - showing adenocarcinoma (CK7+, CDX2-, P40-,
CD20-, ER-, PR-, PA8X-)</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2020-02-20 T-colostomy and intra-abdominal tumor excision</li>
</ul></li>
<li>lab data
<ul>
<li>CEA
<ul>
<li>2022-04-20 4.42 ng/mL<br />
</li>
<li>2022-03-29 5.37</li>
<li>2022-03-09 5.56</li>
<li>2022-02-11 6.65</li>
<li>2021-11-23 18.18</li>
<li>2021-10-26 19.05</li>
<li>2021-09-24 15.90</li>
<li>2021-08-17 14.77</li>
<li>2021-07-20 14.81</li>
<li>2021-06-22 14.92</li>
<li>2021-05-24 12.44</li>
<li>2021-04-13 9.68</li>
<li>2021-03-17 9.98</li>
<li>2021-02-17 9.07</li>
<li>2021-01-20 8.42</li>
<li>2020-12-23 8.64</li>
<li>2020-11-10 10.77</li>
<li>2020-10-14 9.25</li>
</ul></li>
<li>CA125
<ul>
<li>2022-04-20 350.9 U/mL<br />
</li>
<li>2022-03-29 386.6</li>
<li>2022-03-09 329.8</li>
<li>2020-12-23 26.8</li>
<li>2020-11-10 26.2</li>
<li>2020-10-14 26.7</li>
</ul></li>
<li>CA199
<ul>
<li>2022-04-20 120.56 U/mL<br />
</li>
<li>2022-03-29 113.47</li>
<li>2022-03-09 119.88</li>
<li>2022-02-11 130.83</li>
<li>2021-11-23 237.10</li>
<li>2021-10-26 195.89</li>
<li>2021-09-24 154.07</li>
<li>2021-08-17 125.27</li>
<li>2021-07-20 92.50</li>
<li>2021-06-22 89.58</li>
<li>2021-05-24 72.72</li>
<li>2021-04-13 73.86</li>
<li>2021-03-17 72.85</li>
<li>2021-02-17 56.65</li>
<li>2021-01-20 51.93</li>
<li>2020-12-23 46.93</li>
<li>2020-11-10 55.32</li>
<li>2020-10-14 51.87</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-12-01 ~ 2022-01-04 RT to the ovarian metastases: 50 Gy/ 25 fx
completed</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-03-03 ~ undergoing - gemcitabine + carboplatin</li>
<li>2021-08-23 ~ 2021-11-11 - FOLFOX (5-Fu + oxaliplatin)</li>
<li>2021-06-22 ~ 2021-08-17 - PXL-249145 (CAL056 mesylate 20mg/tab) 2#
QDAC PO</li>
<li>2021-05-25 ~ 2021-05-26 - PXL-249145 (CAL056 mesylate 20mg/tab) 2#
QDAC PO</li>
<li>2021-04-27 ~ 2021-05-11 - PXL-249145 (CAL056 mesylate 20mg/tab) 2#
QDAC PO</li>
<li>2020-08-28 ~ 2021-03-16 - Gemcitabine 1000 mg/m2 and Carboplatin AUC
2 on 2020-08-28, -09-11, -09-24, -10-08, -10-20, -11-03, -11-11, -11-30,
-12-09, -12-25, -12-31, 2021-01-13, -01-20, -02-03, -02-17, -02-24,
-03-09, -03-16.
<ul>
<li>The cisplatin was shifted to carboplatin due to elevated level of
creatinine upto 1.5 (eGFR down to 37 mL/min/1.73 m2) on 2020-08-27.</li>
<li>Best response: SD.</li>
<li>Discontinuation: PD in liver. (PD date:2020-12-24)</li>
</ul></li>
<li>2020-03-17 ~ 2020-08-13 - Gemcitabine 1000 mg/m2 and Cisplatin 30
mg/m2 on 2020-03-17, 03-24, 04-07, 04-14, 04-28, 05-05, 05-19, 05-26,
06-09, 06-17, 07-02, 07-09, 08-03, 08-13.
<ul>
<li>Best response: SD.</li>
<li>Discontinuation: The creatinine level was increased during regular
lab test. (PD date: nil)</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient diagnosed with cholangiocarcinoma (in early 2020) has
previously undergone T-colostomy and intra-abdominal tumor excision
(2020-02), [gemcitabine + cisplatin] (2020-03 ~ 2020-08), [gemcitabine +
carboplatin] (2020-08 ~ 2021-03), CAL056 (2021-04 ~ 2021-08), FOLLFOX
(2021-08 ~ 2021-11), RT (2021-12 ~ 2022-01), and is now on [gemcitabine
+ carboplatin] (2022-03 ~ undergoing).</li>
<li>Following consecutive CT scans conducted over the past 12 months,
the disease appeared to be mildly advancing unidirectionally.</li>
<li>Both RBC and HGB have rebounced (3.72 (2022-05-06) &lt;- 3.12
(2022-05-04), 10.3 (2022-05-06) &lt;- 8.6 (2022-05-04), respectively).
In the blood lab, sodium (134 mmol/L), potassium (3.2 mmol/L), and
magnesium (1.3 mg/dL) levels were low (2022-05-04). MgSO4 10% 20mL IVD
QD has been prescribed.</li>
</ul>
</div>
</div>
<div id="section-360" class="section level1">
<h1>701255029</h1>
<div id="section-361" class="section level2">
<h2>210826</h2>
<p>{potential drug interaction}</p>
<p>[objective]</p>
<ul>
<li>the following drugs are listed in active medication:
<ul>
<li>morphine, tramadol</li>
<li>cyproheptadine, quetiapine</li>
<li>atorvastatin</li>
<li>daptomycin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>atorvastatin is an HMG-CoA reductase inhibitors which might enhance
the adverse effect of daptomycin, the risk of skeletal muscle toxicity
might be increased.</li>
<li>cyproheptadine and quetiapine coadministered with opioid agonists
i.e.morphine and tramadol might enhance the CNS depressant effect.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor any sign of the potential adverse effects mentioned
above.</li>
</ul>
</div>
</div>
<div id="section-362" class="section level1">
<h1>701257485</h1>
<div id="section-363" class="section level2">
<h2>999999</h2>
<ul>
<li>Hx: chronic viral hepatitis B without delta-agent</li>
<li>2020-10-22 abdominal fullness without stool passage for days, lower
abd mass with ascites -&gt; CT: focal wall thickening at sigmoid colon
and descending colon junction with severely dilated proximal colon and
ileum is found. colon cancer with obstruction is considered.</li>
<li>2020-10-23 sigmoidoscopy: one mass was noted in the DS colon with
near total obstruction Size 3.6 cm. ( 50 cm from anal verge) s/p 9-cm
stent under fluoroscopy.</li>
<li>2020-11-10 patho: colon, descending-sigmoid, left hemicolectomy -
adenocarcinoma, moderately differentiated.
<ul>
<li>IHC stain: EGFR (+); PMS2 (+), MSH6 (+), MSH2(+), MLH1(+).</li>
<li>tissue labeled as gastric superficial lesion, biopsy - metastatic
carcinoma.</li>
<li>staging: pT3pN0pM1c, pStage IVC.</li>
</ul></li>
<li>regimen
<ul>
<li>2020-11-27 ~ 2020-12-15, _3 times: FOLFIRI</li>
<li>2020-12-29 ~ 2021-05-13, 11 times: FOLFIRI + Avastin
(bevacizumab)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-364" class="section level1">
<h1>701263241</h1>
<div id="section-365" class="section level2">
<h2>999999</h2>
<p>701263241__999999__MNote</p>
<p>{colon cancer}</p>
<p>[objective]</p>
<ul>
<li><p>2019-05-21 colonoscopy: one ulceative mass lesion with lumen
stenosis over 15 cm from anal verge, patho - adenocarcinoma.</p></li>
<li><p>2019-06-12 laparoscopic anterior resection and partial
cystectomy, findings:</p>
<ul>
<li>sigmoid cancer with direct invasion to urinary bladder, enlarged
LNs, and extraserosal surface invasion, but no peritoneal seedings, no
liver surface lesion.</li>
<li>poorly differentiated, signet ring cell (+), lymphovascular invasion
(+), perineural invasion (+), LN (+, 10/16), urinary bladder margin (+),
pericolorectal tissues (+), MSH-6 intact, PMS-2 intact</li>
<li>ATCC 8 pT4bN2bMx, stage IIIC (if M0).</li>
</ul></li>
<li><p>2019-09-10 CT: recurrence over left pelvis, and omentum of
LLQ.</p></li>
<li><p>stayed in USA for months, lost following up in Taiwan health care
provider.</p></li>
<li><p>2021-01-04 CT abdomen: colon cancer s/p operation with peritoneal
carcinomatosis with massive ascites, T0N0M1c, Stage IVC.</p></li>
<li><p>2021-04-06 CT abdomen, pelvis:</p>
<ul>
<li>massive ascites with suspected omental cake is found.</li>
<li>the severity of the ascites is stationary.</li>
<li>right pleural effusion, probably reactive pleural effusion.</li>
</ul></li>
<li><p>2021-04-16 ascites tapping: 3075cc clear yellowish ascites was
drained.</p></li>
<li><p>2021-04-20 cyto, ascites: smears show clusters of pleomorphic
tumor cells. the morphology is consistent with metastatic
adenocarcinoma.</p></li>
<li><p>CEA</p>
<ul>
<li>2021-05-04 46.48ng/mL</li>
<li>2021-04-13 36.13ng/mL</li>
<li>2021-03-22 26.25ng/mL</li>
<li>2021-02-02 27.45ng/mL</li>
<li>2020-12-15 22.34ng/mL</li>
</ul></li>
<li><p>CA199</p>
<ul>
<li>2021-05-04 8.51U/mL</li>
<li>2020-12-15 8.63U/mL</li>
</ul></li>
<li><p>CA125</p>
<ul>
<li>2021-04-13 115.4U/mL</li>
<li>2021-03-22 _56.6U/mL</li>
<li>2021-02-02 _48.0U/mL</li>
<li>2020-12-15 _30.8U/mL</li>
</ul></li>
<li><p>regimen</p>
<ul>
<li>2019-09-23 ~ 2020-01-22: FOLFIRI plus bevacizumab, 8 times</li>
<li>2021-01-13 ~ up to now : FOLFIRI plus bevacizumab</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>KRAS/NRAS/BRAF not found in sheets</li>
<li>2 (MSH-6, PMS-2) of 4 MMR proteins remain intact, pembrolizumab
might not be indicated.</li>
</ul>
</div>
</div>
<div id="section-366" class="section level1">
<h1>701264039</h1>
<div id="section-367" class="section level2">
<h2>220401</h2>
<p>{mediastinum small cell carcinoma with pericardial effusion with SVC
syndrome, stage IV}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-11 CT - lung/mediastinum/pleura
<ul>
<li>suspected IPF (idiopathic pulmonary fibrosis)</li>
<li>Extensive mediasitinal lymphadenopathy, in regression with mild
SUPERIOR VENA CAVA compression.</li>
</ul></li>
<li>2022-01-19 Chest PA/AP view
<ul>
<li>S/P median sternotomy with metalic wires fixation.</li>
<li>Patchy opacity projecting at right suprahilum and Diffuse miliary
lesions on both lung are notd.</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette</li>
</ul></li>
<li>2021-12-08 Patho - soft tissue biopsy
<ul>
<li>diagnosis
<ul>
<li>Mediastinum, biopsy - Small cell carcinoma</li>
<li>Thymus, thymectomy - Involution</li>
<li>Lymph node, regional, thymectomy - Negative for malignancy
(0/2)</li>
</ul></li>
<li>IHC: CD56(+), chromogranin(+), CK(+), LCA(-) and TTF-1(-).</li>
</ul></li>
<li>2021-12-07 Cell block
<ul>
<li>suspect small cell carcinoma</li>
<li>smears and cell block show small clusters of malignant tumor cells
with inconspicuous nuclei, high N/C ratio, scanty cytoplasm,
pleomorphism, hyperchromasia and nuclear molding.
<ul>
<li>reference: S2021-18038</li>
</ul></li>
</ul></li>
<li>2021-12-03 CT - chest
<ul>
<li>T4N3M0, stage IIIC
<ul>
<li>T4: Tumor &gt; 7cm or tumor of any size invading one or more of the
following: diaphragm , mediastinum, heart, great vessels, trachea,
recurrent laryngeal nerve, esophagus, vertebral body, carina, separate
tumor nodule(s) in a different lobe of the ipsilateral lung.</li>
<li>N3: Contralateral mediastinal, contralateral hilar, ipsilateral or
contralateral scalene, or supraclavicular lymph node(s).</li>
<li>M0: No distal metastasis (in this study)</li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-07
<ul>
<li>surgery
<ul>
<li>partial pericardiectomy</li>
<li>thymectomy</li>
<li>mediatinal tumor biopsy</li>
</ul></li>
<li>finding
<ul>
<li>Some masses at mediastinum with mass effect to SVC.</li>
<li>Pericardial effusion.</li>
<li>Bil. lung fibrosis.</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12-10 ~ undergoing: etoposide + cisplatin</li>
</ul></li>
<li>medication
<ul>
<li>2021-04-07 ~ undergoing: nintedanib</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This patient presented with stage IV mediastinum small cell
carcinoma, recent CT scan taken on 2022-03-11 showed extensive
mediastinal lymphadenopathy, in regression with mild superior vena cava
compression.</li>
<li>The goals of management for malignant SVC syndrome are to alleviate
symptoms and treat the underlying disease. Treatment of the underlying
cause depends on the type of cancer, the extent of disease, and the
overall prognosis, which is closely linked to histology and whether or
not prior therapy has been administered.</li>
<li>The patient has been receiving [nintedanib] since April 2021 then
[etoposide + cispaltin] have been added since mid December 2021 s/p
[partial pericardiectomy and thymectomy] early December 2021. According
to the aforementioned CT examination results, the current treatment
should still be effective.</li>
<li>Laboratory data indicate slight low serum magnesium levels for
months since the end of 2021. This might be related to the
administration of cisplatin. MgO tablets are currently being
administered.</li>
</ul>
</div>
<div id="section-368" class="section level2">
<h2>220311</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2021-12-08 Patho - soft tissue biopsy
<ul>
<li>diagnosis
<ul>
<li>Mediastinum, biopsy - Small cell carcinoma</li>
<li>Thymus, thymectomy - Involution</li>
<li>Lymph node, regional, thymectomy - Negative for malignancy
(0/2)</li>
</ul></li>
<li>IHC: CD56(+), chromogranin(+), CK(+), LCA(-) and TTF-1(-).</li>
</ul></li>
<li>2021-12-07 Cell block
<ul>
<li>suspect small cell carcinoma</li>
<li>smears and cell block show small clusters of malignant tumor cells
with inconspicuous nuclei, high N/C ratio, scanty cytoplasm,
pleomorphism, hyperchromasia and nuclear molding.
<ul>
<li>reference: S2021-18038</li>
</ul></li>
</ul></li>
<li>2021-12-03 CT - chest
<ul>
<li>T4N3M0, stage IIIC
<ul>
<li>T4: Tumor &gt; 7cm or tumor of any size invading one or more of the
following: diaphragm , mediastinum, heart, great vessels, trachea,
recurrent laryngeal nerve, esophagus, vertebral body, carina, separate
tumor nodule(s) in a different lobe of the ipsilateral lung.</li>
<li>N3: Contralateral mediastinal, contralateral hilar, ipsilateral or
contralateral scalene, or supraclavicular lymph node(s).</li>
<li>M0: No distal metastasis (in this study)</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-12-10 ~ ongoing: etoposide + cisplatin</li>
</ul></li>
<li>medication
<ul>
<li>2021-04-07 ~ ongoing: nintedanib</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>It is common for patients with SCLC to have extensive stage of the
disease. Unlike limited-stage cancers, extensive-stage cancers are not
recommended to be treated with high radiation doses intended to cure the
disease.</li>
<li>T4N3Mo, stage IIIC, was shown in the CT images of 2021-12-03, which
is classified as a limited but not extensive stage using VA system in
NCCN guidelines.</li>
<li>Using individual patient data from four randomized studies,
meta-analysis has been conducted to compare cisplatin-based versus
carboplatin-based regimens for patients with SCLC. Among the 663
patients included in this meta-analysis, 32% had a limited-stage disease
and 68% had an extensive-stage disease. As a result, no significant
difference was observed in response rate (67% vs.66%), progression-free
survival (PFS) (5.5 vs.5.3 months), or overall survival (9.6 vs.9.4
months) in patients treated with cisplatin-containing versus
carboplatin-containing regimens, indicating equivalent efficacy in
patients with SCLC.
<ul>
<li>reference: <a href="https://pubmed.ncbi.nlm.nih.gov/22473169/" class="uri">https://pubmed.ncbi.nlm.nih.gov/22473169/</a></li>
</ul></li>
<li>Trilaciclib or G-CSF may be used as prophylactic options to reduce
the incidence of chemotherapy-induced myelosuppression in patients
receiving platinum/etoposide (might plus immunocheckpoint inhibitor if
applicable) containing regimens or topotecan containing regimens.</li>
<li>Electrolyte disorders including hyponatremia, hypokalemia and
hypomagnesemia might be associated with administration of cisplatin or
carboplatin. Lab readings for Na, K, and Mg in the past few months have
been low. Monitoring is needed.
<ul>
<li>reference: <a href="https://www.frontiersin.org/articles/10.3389/fonc.2020.00779/full" class="uri">https://www.frontiersin.org/articles/10.3389/fonc.2020.00779/full</a></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-369" class="section level1">
<h1>701265877</h1>
<div id="section-370" class="section level2">
<h2>999999</h2>
<p>701265877</p>
<p>{Colon cancer}</p>
<p>[subj/obj]</p>
<ul>
<li><p>(transverse) colon cancer with liver metastases, cT4aN1aM1c,
stage IV s/p LPS right extended and hemicolectomy on 2020-03-26 and
seedings over omentum found.</p>
<ul>
<li>patho peritoneum metastases, pT4aN2aM1c, stage IVc s/p
radiofrequency ablation (RFA) with switch controller (SWC) x3 on
2020-08-25.</li>
<li>patho result: poorly differentiated, EGFR (+), wildtype RAS,
proficient MMR but B-Raf V600E mutation.</li>
</ul></li>
<li><p>chemo (palliative) from 2020-04-27 with FOLFOXIRI (ox: self-paid;
iri: insurance covered) with bevacizumab.</p></li>
<li><p>chest echography on 2021-02-23 showed right thorax pleural
effusion s/p drainage of 600 cc.</p></li>
<li><p>CXR on 2021-03-09 showed right thorax small pleural
effusion.</p></li>
<li><p>CEA:</p>
<ul>
<li>1.85ng/mL(2021-05-04)</li>
<li>1.35ng/mL(2021-04-20)</li>
<li>1.18ng/mL(2021-04-06)</li>
<li>1.59ng/mL(2021-03-23)</li>
<li>1.90ng/mL(2021-03-09)</li>
</ul></li>
<li><p>CA199:</p>
<ul>
<li>11764U/mL(2021-05-04)</li>
<li>4875U/mL(2021-04-20)</li>
<li>2068U/mL(2021-04-06)</li>
<li>1388U/mL(2021-03-23)</li>
<li>1557U/mL(2021-03-09)</li>
</ul></li>
</ul>
<p>for 3 consecutive weeks then 1 week off as a cycle</p>
<p>Oral target therapy with Cobimetinib 20mg 1# po QD (self-carried)
(for 3 consecutive weeks then 1 week off as a cycle) from
2021/02/24~2021/0314. Oral target therapy with Dabrafenib 75mg 2# po
Q12H (self-carried) (for 3 consecutive weeks then 1 week off as a cycle)
from 2021/02/24. Chemotherapy with biweekly Erbitux(500mg)/Campto(100mg)
(C1D1) on 2021/02/24, (C1D15) on 2021/03/10, (C2D1) on 2021/03/24,
(C2D15) on 2021/04/07. Oral target therapy with Mekinisc 2mg 1# po
QDAC(self-paid) from 2021/03/15 (for 3 consecutive weeks then 1 week off
as a cycle). Therefore, the treatment would be cetuximab plus
irinotecan(C1D15) and dabrafenib and MEK inhiitor, under the recognition
of T-colon cancer with metastases to liver, peritoneum and pleura, and
with B-Raf mutation. This time, she was admitted for Chemotherapy with
biweekly Erbitux(500mg)/Campto(100mg) (C3D1) on 2021/4/22.</p>
<p>Oral target therapy with Dabrafenib(Tafinlar) 75mg 1# po
BID(self-carried) from 2021/02/24 Oral target therapy with Mekinisc 2mg
1# po QDAC(self pay) from 2021/03/15. Chemotherapy with biweekly
Erbitux(500mg)/Campto(100mg) (C3D1) from on 2021/04/23</p>
</div>
</div>
<div id="section-371" class="section level1">
<h1>701272755</h1>
<div id="section-372" class="section level2">
<h2>220315</h2>
<p>[subjective]</p>
<ul>
<li>2021-03-04 cough for several months, CT scan at ShuangHo Hospital
showed a necrotic mass at anterosuperior mediastinum, suspected
malignant thymoma.</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-11 CT - brain
<ul>
<li>multiple brain metastases.</li>
</ul></li>
<li>2022-02-17 CT - lung/mediastinum/pleura
<ul>
<li>s/p thymectomy with recurrent soft tissue at anterior mediastinum
and lymph nodes at subcarina region. stationary as compred with previous
CT.</li>
</ul></li>
<li>2021-1-17 Patho - soft tissue nontumor/mass/lipoma/debridement
<ul>
<li>subcutanoeus nodule over right back</li>
<li>diagnosis - soft tissue, back, excisional biopsy - Metastatic
thymoma - Margin free</li>
<li>IHC: P40(+), CK5/6(+), CD5(focal+).</li>
</ul></li>
<li>2021-11-04 CT - lung/mediastinum/pleura
<ul>
<li>Residual low density lesion at anterior mediatinum, in
regression.</li>
<li>Some lymph nodes are found at paracaval region. Stable.</li>
<li>The pleural effusion is not visualized in the current study.</li>
</ul></li>
<li>2021-09-08 Patho - soft tissue nontumor/mass/lipoma/debridement
<ul>
<li>Diagnosis - Skin and soft tissue, previous right chest tube wound,
excisional biopsy - metastatic thymoma<br />
</li>
<li>IHC: CK5/6(+), p40(+), CD5(-), and CD117(-). The results are
consistent with metastatic thymoma. The deep resection margin is
involved by tumor.</li>
</ul></li>
<li>2021-08-03 CT - lung/mediastinum/pleura
<ul>
<li>recurrent or residual mediastinal invasive thymoma with mediastinal
LAP and bilateral pleural effusions suspected mediastinal abscess.</li>
</ul></li>
<li>2021-04-13 Patho - meiastinum mass
<ul>
<li>anterior mediastinal tumor with pericardial and LUL invasion</li>
<li>Thymus, excision - Invasive thymoma, poorly differentiated, AJCC 8th
edition: pStage IIIA, pT3N0 (if cM0), at least
<ul>
<li>The peripheral resection margin is involved<br />
</li>
</ul></li>
<li>Lung, LUL, wedge resection - Invasive thymoma, by direct invasion,
with negative resection margin.</li>
<li>IHC CK5/6(+), p63(+), CD117(-), CD5(-), TTF-1(-), GATA3(-) and
CD56(-).</li>
</ul></li>
<li>2021-03-18 Patho - thymus tumor
<ul>
<li>Mediastinal tumor</li>
<li>Diagnosis: Thymus, CT-guide needle biopsy - in favor of invasive
thymoma</li>
<li>IHC: CK5/6(+), p63(+), TTF-1(-), Naspin A(-), CD56(-),
Calretinin(-), PAX8(-), and CD117(-). The results are in favor of
invasive thymoma, but metastatic squamous cell carcinoma or urothelial
carcinoma can not be excluded.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-09-08
<ul>
<li>Surgery: Removal of granuloma</li>
<li>Finding: Erythematous granuloma over previous right chest tube
wound. suspected stitches-related and tumor seeding.</li>
</ul></li>
<li>2021-04-12
<ul>
<li>Surgery: Radical left side pericardiectomy with tumor mobilization
and excision.</li>
<li>Finding: A huge, stiff anterior mediastinal mass tightly adhered to
ASAo/MPA and extended to left anterior chest wall. We meticulously
divided the InV and LIJV and tumor debulking from surroundings.</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-05-14 ~ 2021-07-05: 4500cGy/25 fractions of the thymic tumor,
and 6480cGy/36 frcations of the reduced thymic tumor area.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-06 vincristine + cyclophosphamide</li>
<li>2022-01-05 cisplatin + doxorubicin</li>
<li>2021-12-01 vincristine + cyclophosphamide</li>
<li>2021-11-29 cisplatin + doxorubicin</li>
<li>2021-10-20 vincristine + cyclophosphamide</li>
<li>2021-10-18 cisplatin + doxorubicin</li>
<li>2021-09-20 vincristine + cyclophosphamide</li>
<li>2021-09-20 cisplatin + doxorubicin</li>
<li>2021-08-11 vincristine + cyclophosphamide</li>
<li>2021-08-09 cisplatin + doxorubicin</li>
<li>2021-07-13 vincristine + cyclophosphamide</li>
<li>2021-07-13 cisplatin + doxorubicin</li>
<li>2021-05-15 ~ 2021-06-29: cisplatin (part of CCRT)</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-373" class="section level1">
<h1>701273730</h1>
<div id="section-374" class="section level2">
<h2>220110</h2>
<p>{Cancer of Unknown Primary}</p>
<ul>
<li>Additional reference
<ul>
<li>Cancer of Unknown Primary: A Review on Clinical Guidelines in the
Development and Targeted Management of Patients with the Unknown Primary
Site
<ul>
<li>source: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820325/pdf/cureus-0011-00000005552.pdf" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820325/pdf/cureus-0011-00000005552.pdf</a></li>
</ul></li>
<li>NCCN Clinical Practice Guideline - Occult Primary (Cancer of Unknown
Primary [CUP])
<ul>
<li>source: <a href="https://www.nccn.org/professionals/physician_gls/pdf/occult_blocks.pdf" class="uri">https://www.nccn.org/professionals/physician_gls/pdf/occult_blocks.pdf</a></li>
</ul></li>
<li>Cancer of Unknown Primary Site: Real Entity or Misdiagnosed Disease?
<ul>
<li>source: <a href="https://sci-hub.se/10.7150/jca.42880" class="uri">https://sci-hub.se/10.7150/jca.42880</a></li>
</ul></li>
<li>Cancer of Unknown Primary Sites: What Radiologists Need to Know and
What Oncologists Want to Know
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603700/pdf/nihms449402.pdf" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603700/pdf/nihms449402.pdf</a></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-375" class="section level1">
<h1>701273749</h1>
<div id="section-376" class="section level2">
<h2>999999</h2>
<p>{colon cancer}</p>
<p>[objective]</p>
<ul>
<li>2021-03-06 CT, abdomen: A-colon tumor with pericolonic fat stranding
and enlarge lymphnode.</li>
<li>2021-03-07 laparoscopic right hemicolectomy for A-colon
adenocarcinoma with obstruction, patho:
<ul>
<li>AJCC 8 staging: pT4aN2b, G3, IIIC</li>
<li>adenocarcinoma, poorly differentiated, with neuroendocrine
feature.</li>
<li>tumor invades visceral peritoneum. bilateral resection margins are
free.</li>
<li>mesocolonic lymph node: positive for tumor metastasis (10/14) with
extranodal extension.</li>
</ul></li>
<li>CEA
<ul>
<li>2021-05-04: 1.35ng/mL</li>
<li>2021-04-02: 1.47ng/mL</li>
</ul></li>
<li>CA199
<ul>
<li>2021-05-04: _33.17U/mL</li>
<li>2021-04-02: 121.19U/mL</li>
</ul></li>
<li>regimen
<ul>
<li>FOLFOX since 2021-04-06</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>dMMR/MSI-H, KRAS/NRAS/BRAF lab data not found in sheets.</li>
<li>based on the short trend of CEA and CA199, we might consider the
condition is relatively stable.</li>
<li>for T4, N1-2 or T any, N2 (high-risk stage III) stage which
includes the patient, the preferred regimen as first-line adjuvant
treatment could be:
<ul>
<li>CAPEOX 3-6 months or</li>
<li>FOLFOX 6 months,</li>
<li>other treatment options for this stage include:
<ul>
<li>Capecitabine 6 months or</li>
<li>5-FU 6 months</li>
</ul></li>
</ul></li>
<li>current regimen is the standard startup treatment without
issue.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>have KRAS, NRAS, and BRAF mutation testing, microsatellite
instability or mismatch repair testing done, even HER2, NTRK testing if
possible.</li>
</ul>
</div>
</div>
<div id="section-377" class="section level1">
<h1>701275722</h1>
<div id="section-378" class="section level2">
<h2>210524</h2>
<p>{tube feeding}</p>
<p>all the oral drugs in active medication can be administrated via NG
tube except following items which should not be grinded:</p>
<ul>
<li>nexium (esomeprazole): please dissolve it with adequate drinking
water prior to tube feeding.</li>
<li>protase (pancrelipase): please open the capsule and mix the granules
with pH&lt;5.5 liquid food prior to tube feeding.</li>
<li>oxynorm (oxycodone): if injection is not preferred, then fentanyl
patch such as durogesic d-trans or fentanyl transdermal path PPCD
might be an alternative.</li>
</ul>
</div>
</div>
<div id="section-379" class="section level1">
<h1>701277089</h1>
<div id="section-380" class="section level2">
<h2>999999</h2>
<p>{}</p>
<p>[initial presentation]</p>
<p>[definite diagnosis]</p>
<ul>
<li>2021-04-20 patho, pleural/pericardial biopsy:
<ul>
<li>skeletal muscle fibers and fibroadipose tissue with mild fibrosis
and chronic inflammatory cell infiltration.</li>
<li>IHC scant atypical cells: CK(+), CK7(+), CK20(-), TTF-1(-),
Calretinin(-), p63(-), and CD56(-).</li>
<li>The PAS and AFB special stains are negative.<br />
</li>
</ul></li>
<li>2021-07-06 patho, bronchus biopsy:
<ul>
<li>alveolar lung tissue with interstitial fibrosis and infiltration of
mucinous glandular cells.</li>
<li>IHC stains: CK(+), CK7(+), CK20(+), CDX2(+), TTF-1(-), and Napsin
A(-).</li>
<li>should check pancreas, billiary tract, stomach and else for tumor
origin.</li>
</ul></li>
<li>2021-07-12 patho, stomach biopsy:
<ul>
<li>gastric tissue infiltrated by neoplastic mucinous glands and signet
ring cells.</li>
<li>IHC stains: CK(+) and Her-2/neu (Ab)(-).</li>
</ul></li>
</ul>
<p>[disease extent]</p>
<ul>
<li>still working out</li>
</ul>
<p>[Summary]</p>
<p>This 67-year-old woman has the history of 1: Solitary pulmonary
nodule, r/o malignancy 2: Type 2 DM Parapneumonic effusion, right This
time, she has suffered from dyspnea for weeks. Since the symptom
exacerbation recent days. She was then brought to our ER for further
help. At ER, rapid screeing of COVID19 revealed negative finding. CXR
showed bilateral consolidation and pleural effusions, cardiomegaly. Lab
exam revealed elevated CRP. Under the impression of suspect COVID19
pnuemonia, right lung mass and bilateral pleural effusion, the patient
was admitted for further care on 20210629.</p>
<p>Bilateral pneumonia Bilateral pleural effusion r/o COVID -19
infection</p>
<p>=&gt; Abx with Brosym =&gt; Oxygen supplement =&gt; Oral radi-K =&gt;
Diuretic for bilateral plerual effusion =&gt; Transfer to CM ward if PCR
negative</p>
<p>==============================</p>
<p>This 67-year-old woman has the history of 1: Solitary pulmonary
nodule, r/o malignancy 2: Type 2 DM 3: Parapneumonic effusion,
right.Under the impression of suspect COVID19 pnuemonia, right lung mass
and bilateral pleural effusion, the patient was admitted for further
care on 20210629.After admission. antiboitc with Brosym for pneumonia
and fiuretic for bilateral plerual effusion were given. RT-PCR of
COVID-19 revealed negative finding. The patient might transfer to chest
ward for further management on 2021/06/29.</p>
<p>After CM ward, she has been orthopnea and dyspnea was noted, well
explained present condition and treatment plan to the patient and her
husband, emergency arrange cardiac echo and chest echo for right lung
mass, pericardial effusion and bilateral pleural effusion for
evaluation. Cardiac echo and chest echo was done and smoothly on 06/30,
cardiac echo showed moderate amount pericardial effusion, No RV
compression sign, No tamponade, No pericardial constriction at present,
recommended to consult with cardiac surgery for P.P. window. Chest echo
report showed Left side massive amount of pleural effusion, s/p
thoracentesis, yield 1000cc, serosanguos fluid. Right side minimal
amount of pleural effusion. She was transferre to SICU for intensive
care on 6/30. We consult CVS for moderate amount pericardial effusion
and P.P window surgery(Pericardiac effusion:1350cc) on 7/01. All
operation procedure smoothly and return SICU for postoperation care.
Weaning ventilaotr with etubated on 7/01. Under hemodynamic stable and
she will be transfer to ward for care.</p>
<p>After transfered to Chest ward on 7/3, Tumor marker showed elevated
CA-125, CA199, 7/6 CT guide biopsy was done and patho showed
adenocarcinoma with TFF-1(-), abdomen CT showed ascites and multiple
soft tissue nodules in the omentum, pending cytology, and lobulated
pleura thickening at right anterior basl CP angle that may be tumor
seeding or primary pleura tumor. brain MRI showed No brain nodule or
metastasis, EGD+colonscopy was done on 7/12 showed gastric
adenocarcinoma, bone scan was done on 7/13, whole body PET was done on
7/15 revealed prominent glucose hypermetabolic lesion in the right
lateral aspect of the pharyngeal wall, we will consult ENT for
assessment, she was transfered to hema ward on 7/16 for further
assessment and management.</p>
</div>
</div>
<div id="section-381" class="section level1">
<h1>701277175</h1>
<div id="section-382" class="section level2">
<h2>220428</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-22 CT - lung/mediastinum/pleura
<ul>
<li>Chest CT with and without IV contrast ehnancement shows:
<ul>
<li>Chest:
<ul>
<li>S/P mastectomy at left side.</li>
<li>Spiculated nodule at right upper lobe up to 1.9cm in largest
dimension is found. Another fissural based lesion at right middle lobe
up to 1.4cm in largest dimension. In comparison with CT dated on
2021-12-17, the lesions are new. Suggest correlate with PET or other
exam.</li>
<li>No evidence of bilateral pleural effusion.</li>
<li>S/p port-A placement with its tip at Superior vena cava.</li>
</ul></li>
<li>Visible abdomen:
<ul>
<li>The liver, spleen, pancreas, both kidneys and adrenals are
intact.</li>
<li>There is no evidence of paraarotic LAPs.</li>
<li>Non-specific bowel gas at abdominal cavity is found.</li>
<li>Suggest clinical correlation</li>
</ul></li>
</ul></li>
<li>Imp:
<ul>
<li>S/P mastectomy at left side.</li>
<li>New spiculated nodule at right upper lobe and right middle lobe, the
nature of the lesions should be further characterized or closely follow
up. (mets is less likely but primary tumor or inflammation cannot be
excluded.)</li>
</ul></li>
</ul></li>
<li>2022-02-11 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20210924, no prominent
change is noted in the previous hot spots in the skull, anterior aspect
of bilateral rib cages, right S-I joint and bilateral iliac bones,
suggesting stable condition.</li>
<li>Increased activity in the maxilla. Dental problem and/or sinusitis
may show this picture.</li>
</ul></li>
<li>2022-01-20 Patho - breast simple/partial mastectomy
<ul>
<li>Breast, left, simple mastectomy (s/p chemotherapy)  No residual
tumor</li>
<li>Pathology stage: ypT0N0(if cM0)</li>
</ul></li>
<li>2022-01-19 Lymphoscintigraphy
<ul>
<li>No sentinel lymph node in the left axillary region or left ant.
chest wall is delineated throughout the whole study.</li>
</ul></li>
<li>2022-01-11 SONO - breast
<ul>
<li>Clinical left breast s/p C/T.</li>
<li>Right breast cysts and fibroadenomas. Suggest follow up.</li>
<li>BIRADS 6 - proven malignancy</li>
</ul></li>
<li>2021-12-17 CT - chest
<ul>
<li>No evidence of recurrent/residual tumor at both sides of the breast
and other region.</li>
</ul></li>
<li>2021-09-24 Tc-99m MDP whole body bone scan
<ul>
<li>In comparison with the previous study on 20210427, the previous hot
spots in the skull, anterior aspect of bilateral rib cages, right S-I
joint and bilateral iliac bones are less evident. Bone metastases with
some resolution may show this picture. Please correlate with other
clinical findings for further evaluation.</li>
<li>Increased activity in the maxilla in stationary status. Dental
problem and/or sinusitis may show this picture.</li>
</ul></li>
<li>2021-09-06 CT - chest
<ul>
<li>resolution of Lt breast tumor and metastatic axillary and
supraclavicular lymphadenopathy as compared with CT on 20210423.</li>
<li>minimal paraspinal fibrosis in RLL of lung.</li>
</ul></li>
<li>2021-04-30 CT - brain
<ul>
<li>No intracranial lesion based on this study.</li>
</ul></li>
<li>2021-04-27 Tc-99m MDP whole body bone scan
<ul>
<li>Multiple hot spots in the skull, anterior aspect of bilateral rib
cages and bilateral iliac bones. Bone metastases should be watched out
if no definite traumatic event is noted. Please correlate with other
clinical findings for further evaluation.</li>
<li>Increased activity in the maxilla. Dental problem and/or sinusitis
may show this picture.</li>
</ul></li>
<li>2021-04-26 Patho - lymphnode biopsy
<ul>
<li>Lymph node, left axilla, core biopsy  Invasive carcinoma, no
special type, NST.</li>
<li>IHC stains (using block S21-6478): ER (+, strong intensity, 70%),
PR(-), Her2/neu: positive(score=3+), Ki-67(50%), p53 (&lt;5%).<br />
</li>
<li>Section shows fragments of tissue with irregular neoplastic ducts
infiltration.</li>
</ul></li>
<li>2021-04-26 Patho - breast biopsy
<ul>
<li>Breast, left, core biopsy  Invasive carcinoma, no special type,
NST.</li>
<li>IHC stains (using block S21-6477): ER (+, strong intensity, 70%),
PR(+, weak intensity,5%), Her2/neu: positive(score=3+), Ki-67(80%), p53
(10%).<br />
</li>
<li>Section shows fragments of breast tissue with irregular neoplastic
ducts infiltration.</li>
</ul></li>
<li>2021-04-26 SONO - breast
<ul>
<li>Left breast tumors with axillary lymph nodes, suspected malignancy
with lymph nodes metastasis.</li>
<li>BI-RADS5</li>
</ul></li>
<li>2021-04-23 CT - nect
<ul>
<li>Suspect left breast tumor with left axillary lymphadenopathy.
Several small lymph nodes at left supraclavicular region.</li>
<li>Suggest further breast ultrasound correlation and tissue proof if
needed.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-19 Simple mastectomy and SLNB(Sentinel Lymph Node Biopsy)
<ul>
<li>No palpable and visible tumor over L`t breast UOQ.</li>
<li>Sentinel nodes biopsy was done</li>
<li>Simple mastectomy was done.</li>
<li>Lt big toe nail bed redness &amp; loosen wit hpus
discharge.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2021-07-02 ~ undergoing - docetaxel + trastuzumab + pertuzumab</li>
<li>2021-05-05 ~ 2021-06-01 - docetaxel</li>
<li>2021-12-02, 2022-01-06, 2022-02-25 - Xgeva (denosumab)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient was diagnosed with hormone receptor and Her2 positive
breast cancer with bone mets. Mastectomy with SLNB was performed on
2022-01-19. Her chemoimmunotherapy with docetaxel began in May 2021,
then trastuzumab and pertuzumab were added since July 2021.</li>
<li>She also received three denosumab injections for the bone mets on
2021-12-02, 2022-01-06, and 2022-02-25. Tc-99m MDP scan on 2022-04-22
showed that bone mets were stable.</li>
<li>The lab results of 2022-04-27 revealed no noticeable abnormalities.
No issue with current prescription.</li>
</ul>
</div>
</div>
<div id="section-383" class="section level1">
<h1>701277494</h1>
<div id="section-384" class="section level2">
<h2>220302</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-08 Patho - Liver biopsy needle/wedge
<ul>
<li>Liver, CT-guided biopsy - Consistent with metastatic endometroid
carcinoma, poorly differentiated<br />
</li>
<li>IHC: ER (+), PR (focal +), Vimentin (+), and PAX8 (+).</li>
</ul></li>
<li>2022-01-29 CT - Lung, mediastinum, pleura
<ul>
<li>Liver surface meta and lung meta. The liver meta progressed.</li>
<li>There is no previous chest CT for comparison. the lung meta might be
new.</li>
</ul></li>
<li>2022-01-11 CT - Liver, spleen, biliary duct, pancreas
<ul>
<li>S/P hysterectomy and oophorectomy.</li>
<li>Recurrent/peritoneal carcinomatosis in RUQ (subphrenic region with
indentation of liver surface).</li>
<li>Subpleural nodule, 0.5cm in LLL.</li>
</ul></li>
<li>2021-12-20 MRI - Pelvis
<ul>
<li>S/P hysterectomy and oophorectomy.</li>
<li>Irregularity at liver surface (srs11 img11 and 18), carcinomatosis
or artifact?</li>
</ul></li>
<li>2021-05-20 Patho - uterus neoplastic
<ul>
<li>pathologic diagnosis
<ul>
<li>Uterus, endometrium, staging surgery - Endometrioid carcinoma, grade
3<br />
</li>
<li>Uterus, myometrium, staging surgery - Involved by tumor ( &gt; 1/2
thickness)<br />
</li>
<li>AJCC 8th edition Pathology stage: pT1bN0 (If cM0), FIGO IB, pStage
IB</li>
</ul></li>
<li>IHC: ER: positive (90%), PR: positive (90%), CK(+), vimentine(+),
p63(+), Napsin A(-)</li>
</ul></li>
<li>2021-04-29 Patho - endometrium curretage/biopsy
<ul>
<li>Uterus, endometrium, D&amp;C - poorly differentiated carcinoma</li>
<li>ER(+), PR(+), p16(focal +), p63(focal +), and Vimentin(+).</li>
</ul></li>
<li>2021-04-23 MRI - Pelvis
<ul>
<li>suspected endometrial malignancy, if proven malignancy, cstage
T1bN0M0.</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-05-20 ATH + BSO
<ul>
<li>Staging surgery for endometrial cancer.</li>
<li>Pathology and cytology pending.</li>
<li>Residual tumor: not seen residual tumor.</li>
</ul></li>
<li>2021-04-29
<ul>
<li>D&amp;C, diagnostic and theraputic</li>
<li>Endometrial hyperplasia</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-06-18 ~ 2021-08-02: 4500cGy/25fx pelvic, 1200cGy/3fx vis IVRT
to vaginal cuff mucosa surface.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2021-03-01 ~ ongoing: paclitaxel + carboplatin</li>
<li>2021-06-22 ~ 2021-07-27: cisplatin 6 cycles as part of CCRT.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>disease progresses, liver mets has been proved s/p cisplatin-based
CCRT (Jun ~ Jul 2021) s/p ATH + BSO (Apr ~ May 2021).</li>
<li>the patient just starts receiving paclitaxel + carboplatin during
this hospitalization.</li>
<li>lenvatinib plus pembrolizumab showed promising antitumor activity in
patients with advanced endometrial carcinoma who have experienced
disease progression after prior systemic therapy, regardless of tumor
MSI status.
<ul>
<li>source: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479759/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479759/</a></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-385" class="section level1">
<h1>701280715</h1>
<div id="section-386" class="section level2">
<h2>220418</h2>
<p>{rectal cancer with LNs, lung, sacrum, sacroiliac joints mets, stage
IV}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-08 Chest PA erect view
<ul>
<li>There are few nodular opacity projecting in both lung that are c/w
metastases.</li>
</ul></li>
<li>2022-02-21 CT - abdomen, pelvis
<ul>
<li>Mild progression of rectal cancer with LNs and lung metastases.</li>
</ul></li>
<li>2021-12-21 Chest PA erect view
<ul>
<li>There are few nodular opacity projecting in both lung that are c/w
metastases.</li>
</ul></li>
<li>2021-11-18 CT - abdomen, pelvis
<ul>
<li>Mild regression of rectal cancer with LNs and lung metastases.</li>
</ul></li>
<li>2021-08-10 CT - abdomen, pelvis
<ul>
<li>Rectal malignancy with lymph nodes and lung metastasis,
regression.</li>
</ul></li>
<li>2021-05-06 Chest PA eract view
<ul>
<li>There are few nodular opacity projecting in both lung that may be
metastases. Please correlate with CT.</li>
</ul></li>
<li>2021-05-05 Tc-99m MDP whole body bone scan
<ul>
<li>Markedly increased tracer uptake in the sacrum and bilateral S-I
joints, the nature is to be determined, suggesting further investigation
and follow-up with bone scan in 3 months for further evaluation.</li>
<li>Probably benign lesions in both rib cages, bilateral
sternoclavicular junctions, shoulders, hips, and knees.</li>
</ul></li>
<li>2021-05-03 Patho - colon biopsy
<ul>
<li>Rectum, 5 cm above anal verge, biopsy  Adenocarcinoma.</li>
<li>IHC: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+).<br />
</li>
<li>Section shows pieces of colonic tissue with invasive irregular
neoplastic glands.</li>
</ul></li>
<li>2021-05-03 CT - abdomen, pelvis
<ul>
<li>Impression (Imaging stage): T4aN2bM1a, stage IVA</li>
</ul></li>
<li>2021-05-03 Chest PA erect view
<ul>
<li>Multiple nodules at bil. lungs.</li>
</ul></li>
<li>2021-05-03 Colonoscopy
<ul>
<li>Diagnosis: Rectal ulcerative lesion, s/p biopsy, suspected
malignancy.</li>
<li>Suggestion: F/U pathology report; suggest admission for more
evaluation and management.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2021-06-02
<ul>
<li>KRAS codon 12/13 mutation detected</li>
<li>NRAS/KRAS mutation not detected</li>
</ul></li>
<li>2021-05-14
<ul>
<li>HBsAg nonreactive, 0.34 S/CO</li>
<li>Anti-HBc Nonreactive, 0.44 S/CO</li>
<li>AntiHCV nonreactive, 0.06 S/CO</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-02-22 ~ undergoing - FOLFIRI + ramucirumab</li>
<li>2022-02-08 - FOLFIRI</li>
<li>2021-06-29 ~ 2022-01-18 - FOLFIRI + bevacizumab</li>
<li>2021-05-13 ~ 2021-06-11 - FOLFIRI</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>This is a patient with stage IV rectal cancer with a LN and lung
metastasis being treated with FOLFIRI since 2021-05-13.</li>
<li>Earlier tests indicated that EGFR(+), MMR-proficient, and mutated
KRAS codon 12/13.</li>
<li>CT images revealed first regression (2021-11-18) and then
progression (2022-02-21). Bevacizumab was added from 2021-06-29 to
2022-01-18, then ramucirumab was added from 20202-22-22.</li>
<li>Lab readings were generally normal (2022-04-15), however CEA
(2022-04-01) and CA199 (2022-04-08) remained elevated.</li>
<li>Current updated treatment is still being observed, and if the
results are not as expected, then [trifluridine + tipiracil] might be an
option (the drug is covered by national health insurance).</li>
<li>Besides analgesics, non-pharmacological interventions that can
control pain over a longer period of time might also be considered. The
following interventions are available to treat metastatic bone cancer
pain (not exhaustive, reference: <a href="https://pubmed.ncbi.nlm.nih.gov/31140913/" class="uri">https://pubmed.ncbi.nlm.nih.gov/31140913/</a>):
<ul>
<li>Epidural and selective nerve root block</li>
<li>Radiofrequency ablation and cryoablation</li>
<li>Vertebral augmentation</li>
<li>Intrathecal drug delivery</li>
<li>Spinal cord stimulation</li>
<li>Dorsal root ganglion stimulation</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-387" class="section level1">
<h1>701282961</h1>
<div id="section-388" class="section level2">
<h2>210722</h2>
<p>{suspected MDS}</p>
<p>[objective]</p>
<ul>
<li>2021-07-12 patho - bone marrow biopsy:
<ul>
<li>piece(s) of bone marrow with 70-80% cellularity and M:E ratio of
approximately 1:4.</li>
<li>three cell lineages are present with normal maturation of
leukocytes.</li>
<li>megakaryocytes are increased in number with nuclear atypia.
myelodysplastic syndrome with no excessive blasts cannot be
excluded.</li>
<li>IHC stains (of the nucleated cells):
<ul>
<li>CD117: &lt;1%</li>
<li>CD34: &lt;1%</li>
<li>MPO: 10-15%</li>
<li>CD61: 10-15%</li>
<li>CD71: 70-80%</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>driver mutations are detected in &gt;90 percent of cases of MDS.
most commonly mutated genes are DNMT3A, TET2, IDH genes, ASXL1, TP53,
RUNX1, SF3B1, U2AF1, SRSF2, ZRSR2.</li>
<li>chromosomal abnormalities are presumptive evidence of MDS in
patients with otherwise unexplained refractory cytopenia and no
morphologic evidence of dysplasia, including:
<ul>
<li>unbalanced chromosomal abnormalities:
<ul>
<li>loss of chromosome 7 or del(7q)</li>
<li>del(5q) or t(5q)</li>
<li>del 20(q)</li>
<li>isochromosome 17q or t(17p)</li>
<li>loss of chromosome 13 or del(13q)</li>
<li>del(11q)</li>
<li>del(12p) or t(12p)</li>
<li>del(9q)</li>
<li>idic(X)(q13)</li>
</ul></li>
<li>balanced chromosomal abnormalities:
<ul>
<li>t(11;16)(q23.3;p13.3)</li>
<li>t(3;21)(q26.2;q22.1)</li>
<li>t(1;3)(p36.3;q21.2)</li>
<li>t(2;11)(p21;q23.3)</li>
<li>inv(3)(q21q26.2) or t(3;3)(q21.2;q26.2)</li>
<li>t(6;9)(p23;q34.1)</li>
</ul></li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>no issue with current medication, chromosome tests has just been
ordered on 2021-07-22, treatment plan will be more clear after having
the outcome.</li>
</ul>
</div>
</div>
<div id="section-389" class="section level1">
<h1>701284346</h1>
<div id="section-390" class="section level2">
<h2>210512</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 6 items.</p>
<p>the 4 identified items has been shown as following while the other 2
items still remain unknown: - sinemet (carbidopa 25mg, levodopa 100mg) -
urief (silodosin 4mg) - rivotril (clonazepam 2mg) - through (sennoside
12mg)</p>
<p>these drugs will be sent back to ward by the in-hospital porter.</p>
</div>
</div>
<div id="section-391" class="section level1">
<h1>701300783</h1>
<div id="section-392" class="section level2">
<h2>210716</h2>
<p>{potential interactions among alprazolam, olanzapine and
zolpidem}</p>
<p>[objective]</p>
<ul>
<li>concurrent medication:
<ul>
<li>alprazolam 0.5mg PO HS</li>
<li>olanzapine 5mg PO HS</li>
<li>zolpidem 10mg PO HS</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>coadministered alprazolam, olanzapine and zolpidem might enhance the
CNS depressant effect.</li>
<li>olanzapine might enhance the adverse effect of alprazolam
(benzodiazepine).
<ul>
<li>reference:
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/15889948/" class="uri">https://pubmed.ncbi.nlm.nih.gov/15889948/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/20156413/" class="uri">https://pubmed.ncbi.nlm.nih.gov/20156413/</a></li>
</ul></li>
</ul></li>
<li>clinical significance of this interaction may be lower with oral
forms.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>please monitor any sign such as drowsiness, fatigue, sedation,
ataxia, memory impairment, irritability, cognitive dysfunction,
dysarthria, dizziness to see if change is needed.</li>
</ul>
</div>
<div id="section-393" class="section level2">
<h2>210708</h2>
<p>{potential interaction when coadministering alprazolam,
metoclopramide, olanzapine}</p>
<p>[objective]</p>
<p>the following items are listed in active medication: - alpraline
(alprazolam, 0.5mg/tab) 1 tab PO HS - promeran (metoclopramide,
3.84mg/tab) 1 tab PO TIDAC - zyprexa zydis (olanzapine, 5mg/tab) 1 tab
PO HS</p>
<p>[assessment]</p>
<ul>
<li>metoclopramide might enhance the adverse/toxic effect of olanzapine.
<ul>
<li>this could associate with development of extrapyramidal reactions or
neuroleptic malignant syndrome.</li>
</ul></li>
<li>olanzapine might enhance the adverse/toxic effect of alprazolam.
<ul>
<li>due to risks of additive adverse effects (e.g., cardiorespiratory
depression, excessive sedation).</li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>if any above suspected symptom is observed, please discontinue the
coadministration.</li>
</ul>
</div>
</div>
<div id="section-394" class="section level1">
<h1>701304862</h1>
<div id="section-395" class="section level2">
<h2>210625</h2>
<p>{potential abx absorption problem}</p>
<p>[objective]</p>
<ul>
<li>active medication including:
<ul>
<li>Cravit (levofloxacin 500mg/tab) 1.5tab PO QDAC</li>
<li>Smecta (dioctahedral smectite 3gm/k) 1pk PO TIDAC</li>
</ul></li>
<li>the above items used at the same time in the morning.</li>
</ul>
<p>[accessment]</p>
<ul>
<li>the adsorbent properties of smecta may interfere with the rates
and/or levels of absorption of other substances, e.g.cravit.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>it is recommended not to administer any other drugs at the same time
as smecta.</li>
<li>cravit could be shifted to HS to decouple administration time and
still keep the same daily dose.</li>
</ul>
</div>
</div>
<div id="section-396" class="section level1">
<h1>701307426</h1>
<div id="section-397" class="section level2">
<h2>220412</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-10 Patho - esophageal biopsy
<ul>
<li>Esophagus, 30cm below incisors, biopsy  squamous cell carcinoma,
moderately differentiated, at least.</li>
<li>The grade of tumor differentiation might be the same or might be
upgraded when the entire tumor is resected for further pathological
evaluation.</li>
</ul></li>
<li>2022-01-20 Patho - esophageal biopsy
<ul>
<li>Labeled as Esophagus, 30cm below incisors, biopsy  squamous cell
carcinoma.</li>
<li>IHC stain: p16(-).</li>
</ul></li>
<li>2022-01-20 CT - lung/mediastinum/pleura
<ul>
<li>Esophageal cancer with lung mets.</li>
<li>Previous tubercuosis at bilateral apical lungs.</li>
</ul></li>
<li>2022-01-20 Miniprobe endoscopic ultrasound
<ul>
<li>Advanced esophageal squamous cell carcinoma, at least T3N2Mx</li>
</ul></li>
<li>2022-01-19 Whole body PET scan
<ul>
<li>A glucose hypermetabolic lesion in the middle to lower third
esophagus, compatible with the primary esophageal cancer.<br />
</li>
<li>A glucose hypermetabolism in the gastrohepatic lymph node, reactive
node or cancer with regional lymph node metastasis may show this
picture, suggesting biopsy for further investigation.<br />
</li>
<li>Increased FDG uptake in the left pulmonary hilar region, left upper
lung, left lower lung, and right upper lung, TB or cancer with both
lungs metastases may show this picture.</li>
<li>Glucose hypermetabolic lesions in the right lower lung pleura,
cancer with pleura metastases should be considered, suggesting biopsy
for further investigation also.<br />
</li>
<li>Esophageal cancer, cT4aN0-1M0-1, c-stage III at least (AJCC 8th
ed.), by this F-18-FDG PET/CT scan.</li>
</ul></li>
<li>2022-01-18 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the lower C-spine. Degenerative change may
show this picture. However, please correlate with other imaging
modalities for further evaluation.</li>
<li>Some faint hot spots in bilateral rib cages. The nature is to be
determined (post-traumatic change? other nature?). Please follow up bone
scan for further evaluation.</li>
<li>Increased activity in bilateral shoulders, hips and knees,
compatible with benign joint lesions.7</li>
</ul></li>
<li>2022-01-07 Esophagogastroduodenoscopy, EGD
<ul>
<li>One lumen occupied mass lesion with friability was noted at 30cm
below incisors. The scope cannot advance over the lesion.</li>
<li>Highly suspected esophageal cancer.</li>
</ul></li>
<li>2021-08-27 CT - lung/mediastinum/pleura
<ul>
<li>Cavitatory lesion at left apical lung about 5.58cm and traction
fibrotic mass at right upper lobe are found. Smaller nodules mixed with
fibrotic change is found at bilateral upper lobes. Tuberculosis is more
favored.</li>
</ul></li>
</ul></li>
<li>history
<ul>
<li>2021-08-27 ~ 2022-03-10 - AKuriT-4 for TB</li>
</ul></li>
<li>consultation
<ul>
<li>2022-01-21 hematology &amp; oncology
<ul>
<li>advanced or metastasis disease, systemic therapy is indicated. Ex:
FLuorouracil (or capecitabine) with cisplatin (or oxaliplatin), or
clinical trial</li>
<li>please check anti Hbc for HBV evaluation</li>
</ul></li>
<li>2022-01-20 radiation oncology
<ul>
<li>Clinical trial may be considered if he fits the inclusion criteria.
RT to esophageal tumor &amp; LAPs for 5040cGy/28 fx is suggested for
tumor control.</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02-04 ~ 2022-03-16 - 5040cGy/28 fractions (15 MV photon) to
esophageal tumor &amp; LAPs</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-11 ~ undergoing - 5-Fu + cisplatin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>An economically not advantaged divorced man living with his
school-age daughters has recently learned that he has an advanced
esophageal squamous cell carcinoma and is undergoing 5-Fu + cisplatin
since early February 2022.</li>
<li>According to the most recent lab results reported on 2022-04-07,
liver and kidney function were normal and there were no obvious
abnormalities with CBC and WBC readings.</li>
<li>Trastuzumab might be added to first-line chemotherapy for HER2
overexpression positive adenocarcinoma (HER2 testing result not found
yet).</li>
<li>Oxaliplatin is generally preferred over cisplatin due to lower
toxicity.
<ul>
<li>Oxaliplatin-based regimen is superior to cisplatin-based regimen in
tumour remission as first-line chemotherapy for advanced GC, and is
associated with less toxicity and better tolerability.
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547983/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547983/</a></li>
</ul></li>
<li>A comparative analysis of the mutagenicity of platinum-containing
chemotherapeutic agents reveals direct and indirect mutagenic
mechanisms.
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/33502495/" class="uri">https://pubmed.ncbi.nlm.nih.gov/33502495/</a></li>
</ul></li>
</ul></li>
</ul>
</div>
<div id="section-398" class="section level2">
<h2>220411</h2>
<p>{tube feeding}</p>
<ul>
<li>Broen-C (bromelain, L-cysteine) enteric coated tablets should not be
ground for tube feeding, acetylcysteine is available to act as an
alternative.</li>
</ul>
</div>
</div>
<div id="section-399" class="section level1">
<h1>701312127</h1>
<div id="section-400" class="section level2">
<h2>220321</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-07 Chest PA/AP view
<ul>
<li>Normal heart size.</li>
<li>Tortous aorta with calcification is noted.</li>
<li>S/p port-A placement with its tip at Superior vena cava.</li>
<li>Faint aveolar opacity over RIGHT LOWER LOBE is found.</li>
<li>Right pleural effusion is found.</li>
</ul></li>
<li>2022-02-21 CT - abdomen, pelvis
<ul>
<li>Mild progression of lymphoma.</li>
<li>Right pleural effusion with adjacent lung collapse. Some nodules at
bil. lungs.</li>
</ul></li>
<li>2022-02-09 Chest PA (Erect) view
<ul>
<li>A nodular opacity projecting in the right lower lung is suspected.
Please correlate with CT.</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Blunting of bilateral costal-phrenic angle is noted, which may be
due to pleura effusion?</li>
</ul></li>
<li>2022-01-10 CT - abdomen, pelvis
<ul>
<li>Follicular lymphoma S/P C/T show partial response.</li>
</ul></li>
<li>2021-10-08 Chest AP
<ul>
<li>S/P port-A implantation.</li>
<li>Enlargement of cardiac silhouette.</li>
<li>Blunting of left costal-phrenic angle is noted, which may be due to
pleura effusion?</li>
</ul></li>
<li>2021-10-05 Ga-67 Whole body inflammation scan with SPECT
<ul>
<li>Increased radiotracer uptake in bilateral lungs, bilateral pulmonary
hilar regions, left mediastinum, stenum, spines, and S-I joints, the
nature is to be determined (lymphoma involving regions, inflammation or
other nature ?).</li>
<li>Increased radiotracer accumulation in the colon, probably
physiological radiotracer accumulation.</li>
<li>No prominent abnormal focal radiotracer uptake is noted
elsewhere.</li>
</ul></li>
<li>2021-10-01 CT - whole abdomen, pelvis
<ul>
<li>Follicular lymphoma S/P C/T show partial response.</li>
</ul></li>
<li>2021-07-19 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy - B-cell lymphoma involvement<br />
</li>
<li>Microscopically, it shows positive for B-cell lymphoma composed of
foci of lymphoid aggregation with follicular architecture.</li>
<li>IHC: CD20(+), Bcl-2(+), CD10(+), MPO(+), Bcl-6(+, at germinal
center), CD71(focal+), CD117(-), CD34(-).<br />
</li>
</ul></li>
<li>2021-07-16 Chest PA (Erect) view
<ul>
<li>S/P port-A implantation.</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion ?</li>
<li>Increased lung markings on both lower lung are noted.</li>
</ul></li>
<li>2021-07-16 Whole body PET scan
<ul>
<li>The FDG PET findings are compatible with lymphoma involving multiple
lymph nodes on both sides of the diaphragm, spleen and sacrum (stage
IV).</li>
<li>Mildly and diffusely increased FDG uptake in the bone marow of the
skeleton. The nature is to be determined (lymphoma? bone marrow
hyperplasia?).</li>
</ul></li>
<li>2021-07-12 Patho - lymphnode biopsy
<ul>
<li>Lymph node, right axillary, sono guide biopsy - Follicular lymphoma,
grade 2<br />
</li>
<li>Histology type: B-cell neoplasms, Follicular lymphoma, grade 2<br />
</li>
<li>IHC: CD3(-), CD20(+), CD10(+), BCL2(+), BCL6(+), Cyclin D1(-),
CD56(-), and CK(-).</li>
</ul></li>
<li>2021-07-09 CT - CTA, chest
<ul>
<li>Diffuse enlarged lymph nodes, suspected lymphoma.</li>
<li>Bilateral pleural effusion with lung collapse.</li>
<li>GB stone.</li>
<li>Ascites.</li>
</ul></li>
</ul></li>
<li>Chemotherapy
<ul>
<li>2022-03-18 - bendamustine + obinutuzumab</li>
<li>2022-02-09 - rituximab</li>
<li>2021-11-17 - R-CHOP (Rituximab, cyclophosphamide, doxorubicin,
vincristine, prednisone)</li>
<li>2021-10-27 - R-CHOP</li>
<li>2021-09-22 - R-CHOP</li>
<li>2021-09-01 - R-CHOP</li>
<li>2021-08-03 - R-CHOP</li>
<li>2021-07-19 - R-CHOP
<ul>
<li>R-CHOP Regimen - An immunochemotherapy regimen consisting of
rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride
(doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used
to treat both indolent and aggressive forms of non-Hodgkin lymphoma.
<ul>
<li>Regimen - cycle length 21 days.
<ul>
<li>Rituximab
<ul>
<li>375 mg/m2 IV</li>
<li>Dilute in NS or D5W to a final concentration of 1 to 4 mg/mL.
Initial infusion: Start at 50 mg/hour; escalate in 50 mg/hour increments
every 30 minutes to a maximum of 400 mg/hour, as tolerated. For
subsequent infusions, administer 20% of the total dose over the first 30
minutes and the remaining 80% over 60 minutes, as tolerated. The
90-minute infusion schedule should NOT be used in patients who have
clinically significant cardiovascular disease or have a circulating
lymphocyte count &gt;=5000/microL.</li>
<li>Day 1</li>
</ul></li>
<li>Cyclophosphamide
<ul>
<li>750 mg/m2 IV</li>
<li>Dilute in 250 mL NS or D5W and administer over 30 minutes.</li>
<li>Day 1</li>
</ul></li>
<li>Doxorubicin
<ul>
<li>50 mg/m2 IV</li>
<li>Dilute in 50 mL NS or D5W and administer over three to five
minutes.</li>
<li>Day 1</li>
</ul></li>
<li>Vincristine
<ul>
<li>1.4 mg/m2 IV (max dose 2 mg)</li>
<li>Dilute in 50 mL NS or D5W and administer over 15 to 20 minutes.</li>
<li>Day 1</li>
</ul></li>
<li>Prednisone
<ul>
<li>100 mg orally</li>
<li>Administer 30 minutes prior to chemotherapy on day 1, then every 24
hours on days 2 to 5.</li>
<li>Days 1 to 5</li>
</ul></li>
</ul></li>
<li>Pretreatment considerations:
<ul>
<li>Hydration
<ul>
<li>Patients receiving cyclophosphamide should maintain adequate oral
hydration (2 to 3 L/day) and void frequently to reduce risk of
hemorrhagic cystitis.</li>
</ul></li>
<li>Emesis risk
<ul>
<li>MODERATE (30 to 90% risk of emesis).</li>
</ul></li>
<li>Prophylaxis for infusion reactions
<ul>
<li>Premedicate with acetaminophen and diphenhydramine, with or without
an H2 blocker, 30 minutes prior to at least the first and second
infusions of rituximab.</li>
</ul></li>
<li>Vesicant/irritant properties
<ul>
<li>Doxorubicin and vincristine are vesicants; avoid extravasation.</li>
</ul></li>
<li>Infection prophylaxis
<ul>
<li>The risk of febrile neutropenia with this regimen is 10 to 20%;
primary prophylaxis with hematopoietic growth factors should be
considered on an individual basis, particularly for high-risk patients
such as those with preexisting neutropenia, advanced disease, poor
performance status, or patients age 65 years or older.</li>
</ul></li>
<li>Dose adjustment for baseline liver or renal dysfunction
<ul>
<li>Adjustment of initial cyclophosphamide, doxorubicin, and vincristine
doses may be needed for preexisting liver dysfunction. In addition, dose
adjustment of cyclophosphamide may be required for renal
dysfunction.</li>
</ul></li>
<li>Hepatitis screening
<ul>
<li>Patients should be screened for hepatitis B and C virus prior to
starting rituximab, and if positive, considered for antiviral
prophylaxis.</li>
</ul></li>
<li>Cardiac screening
<ul>
<li>LVEF should be evaluated prior to initiation of therapy. Dose
alterations should be considered for LVEF &lt;50%, and doxorubicin
therapy is contraindicated in patients with LVEF &lt;30% at initiation.
Infusion times and schedule may be adjusted to decrease the risk of
cardiotoxicity in individuals at high risk for its development.</li>
</ul></li>
<li>Neurotoxicity
<ul>
<li>Vincristine may cause constipation, and in severe cases, paralytic
ileus. A routine prophylactic regimen against constipation is
recommended in all patients receiving vincristine.</li>
</ul></li>
</ul></li>
<li>Monitoring parameters:
<ul>
<li>CBC with differential and platelet count weekly during
treatment.</li>
<li>Assess basic metabolic panel (creatinine and electrolytes) and liver
function prior to each subsequent treatment cycle.</li>
<li>LVEF should be evaluated periodically based on LVEF at initiation of
therapy and cumulative dose of doxorubicin.</li>
<li>Carriers of hepatitis B or C should be monitored for clinical and
laboratory signs of active infection during and following completion of
therapy. Rituximab should be discontinued if reactivation occurs.</li>
</ul></li>
<li>Suggested dose modifications for toxicity:
<ul>
<li>Myelotoxicity
<ul>
<li>Treatment should be delayed until ANC is &gt;1500/microL and
platelet count is &gt;100,000/microL. If a patient develops grade 4 (ANC
&lt;500/microL) neutropenia or febrile neutropenia with any cycle, G-CSF
support is added to the regimen for subsequent cycles. If grade 4
neutropenia or febrile neutropenia occurs despite G-CSF support, or if
the patient develops grade 3 (25,000 to 50,000/microL) or 4
(&lt;25,000/microL) thrombocytopenia with any cycle, the doses of
cyclophosphamide and doxorubicin should be decreased by 50% for
subsequent cycles.</li>
</ul></li>
<li>Neuropathy
<ul>
<li>Dose adjustment of vincristine may be necessary if the severity of
neuropathy persists or worsens. No specific guidelines are available for
dose adjustments.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>A patient with stage II, III, or IV FL is usually not cured by
conventional treatment. Remissions can be achieved, but relapses are not
uncommon. The treatment is intended to relieve symptoms, reverse
cytopenias, and improve the quality of life. Despite not being curative,
a modern therapy that incorporates anti-CD20 antibodies can prolong
survival. The goal of modern chemoimmunotherapy regimens is usually to
achieve a complete response, however, a significant minority of patients
treated with these regimens will only show a partial response.
Additional therapy (e.g., maintenance) may result in complete recovery
in some of these patients. As well, for this group as a whole, some
interventions, such as maintenance therapy and obinutuzumab, prolong
progression-free survival but do not improve overall survival.
<ul>
<li>reference: <a href="https://www.uptodate.com/contents/initial-treatment-of-stage-ii-to-iv-follicular-lymphoma" class="uri">https://www.uptodate.com/contents/initial-treatment-of-stage-ii-to-iv-follicular-lymphoma</a></li>
</ul></li>
<li>During the period of Mid-July 2021 through Mid-November 2021, this
patient received R-CHOP, then had rituximab prescribed on 2022-02-09. CT
images taken on 2021-10-01 and 2022-01-10 indicated partial response,
however CT images taken on 2022-02-21 showed mild progression.</li>
<li>During this hospitalization, the patient begins receiving his new
chemoimmunotherapy regimen of bendamustine plus obinutuzumab without
issue.</li>
<li>Underlying diseases include HTN and DM (admission diagnosis), drugs
for the latter have not been prescribed as active medication and no
updated blood sugar lab readings found within these 3 months.</li>
</ul>
</div>
</div>
<div id="section-401" class="section level1">
<h1>701313105</h1>
<div id="section-402" class="section level2">
<h2>220120</h2>
<ul>
<li>Lab
<ul>
<li>2021-08 Patho - overy tumor
<ul>
<li>IHC: CK7 (+), CK20 (-), p53 (-), Napsin-A(-), WT-1 (-).</li>
</ul></li>
</ul></li>
<li>Medication
<ul>
<li>20210823 ~ ongoing - Paclitaxel, Carboplatin</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-403" class="section level1">
<h1>701319969</h1>
<div id="section-404" class="section level2">
<h2>210812</h2>
<p>{metastatic breast cancer}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-07 right breast palpable mass with oozing and purulent
discharge were noted.
<ul>
<li>history:
<ul>
<li>left breast cancer, stage IV, with liver and right femoral bone
metastasis? s/p 8 cycles chemotherapy and herceptin for 2-3 cycles at
Taipei city hospital Fuyou branch, and hold since 2021-04.</li>
<li>hypertension.</li>
</ul></li>
</ul></li>
</ul>
<p>[definite diagnosis, disease extent]</p>
<ul>
<li>2021-08-10 SONO, breast:
<ul>
<li>left breast cancer, upper hemisphere.</li>
<li>suspicious right breast tumors at 4 and 10 (#2, #3), contralateral
cancer cannot be excluded. suggest biopsy.</li>
<li>BI-RADS category 6, known Biopsy-proven malignancy. surgical
excision should be considered when clinically appropriate.</li>
</ul></li>
<li>2021-08-10 CT, lung/mediastinum/pleura:
<ul>
<li>advanced Lt breast cancer with liver, lungs, and axillary LNs
metastases, in progression compared with CT on 6/24.</li>
<li>decreased size of Rt breast mass with axillary lymphadenopathy
compared with CT on 6/24.</li>
<li>uterine myomas.</li>
</ul></li>
</ul>
<p>[assessment, suggestion]</p>
<ul>
<li>stage workup is renewing, continuing HTN management for the moment
with patient-carried drugs
<ul>
<li>Adapine (nifedipine) 30mg PO QD</li>
<li>Diovan (valsartan) 80mg PO QD</li>
<li>Syntrend (carvedilol) 12.5mg PO QD</li>
</ul></li>
<li>brain and/or spine MRI with contrast should be indicated if CNS
symptoms, back pain or symptoms of spinal cord compression.
<ul>
<li>bone scan or sodium fluoride PET/CT, if needed.</li>
</ul></li>
<li>all or some of ER, PR, HER2, BRCA, PIK3CA, PD-L1, NTRK, MSI-H/dMMR,
TMB-H tests might have been done at Taipei city hospital Fuyou branch,
order the tests for new biopsy if needed.
<ul>
<li>since the patient received herceptin before, HER2 should be
positive.</li>
</ul></li>
<li>for preoperative/adjuvant therapy for HER2(+), options including:
<ul>
<li>paclitaxel/trastuzumab</li>
<li>docetaxel/carboplatin/trastuzumab</li>
<li>docetaxel/carboplatin/trastuzumab/pertuzumab</li>
<li>doxorubicin/cyclophosphamide followed by paclitaxel/trastuzumab</li>
<li>doxorubicin/cyclophosphamide followed by paclitaxel plus
trastuzumab/pertuzumab</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-405" class="section level1">
<h1>701320982</h1>
<div id="section-406" class="section level2">
<h2>210812</h2>
<p>{lung cancer with brain mets}</p>
<p>[initial presentation]</p>
<ul>
<li>2021-07-12 being diagnosed as hypnic headache at LMD.</li>
<li>2021-07-26 intermittent occipital headache accompanied with Rt limbs
weakness for 2 weeks, exacerbated since 2021-07-24.</li>
</ul>
<p>[definite diagnose, disease extent]</p>
<ul>
<li>2021-07-26 CT, brain:
<ul>
<li>masses in right cerebrum; DDx: metastasis, meningiomas.</li>
<li>midline shift (11mm) and impending uncal herniation.</li>
</ul></li>
<li>2021-07-26 MRI, brain:
<ul>
<li>bifrontal and right medial temporal tumors, favor metastases, with
brain herniation.</li>
</ul></li>
<li>2021-07-27 CT, lung/mediastinum/pleura:
<ul>
<li>LUL lung cancer, T4N3M1c, stage IVB.</li>
</ul></li>
<li>2021-07-28 whole body PET scan:
<ul>
<li>glucose hypermetabolism in the right cerebral cortex, probably the
primary or secondary (priority) brain malignancy.</li>
<li>glucose hypermetabolism in the left upper lung and left lower lung
pleura, probably lung cancer with lung to lung metastases.<br />
</li>
<li>glucose hypermetabolism in bilateral mediastinal lymph nodes and
bilateral SCF lymph nodes, probably lung cancer with regional lymph
nodes metastases.<br />
</li>
<li>left upper lung cancer (if proved), cT4N3M1c, stage IVB.</li>
</ul></li>
<li>2021-07-30 patho, lung transbronchial biopsy:
<ul>
<li>adenocarcinoma, moderately to poorly differentiated. solid nests and
glandular cells infiltrating in a fibrotic stroma.</li>
<li>ICH stains: TTF-1(+), Napsin A(+), p40(-), CD56(-) are supportive
for lung cancer diagnosis.</li>
</ul></li>
<li>2021-08-04 PD-L1:
<ul>
<li>tumor cell (TC) staining assessment: &lt;1%</li>
<li>tumor-infiltrating immune cell (IC) staining assessment: &lt;1%</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>Radiotherapy
<ul>
<li>palliative RT for brain metastases is indicated.</li>
<li>delivering 18 Gy/ 6 fx to the whole brain and then boost the
bi-frontal and Rt medial temporal tumors to 36 Gy/ 12 fx.</li>
</ul></li>
</ul>
<p>[assessment, suggestion]</p>
<ul>
<li>active medication without issues
<ul>
<li>brain mets:
<ul>
<li>Mannitol 20% 100mL IVD Q8H</li>
<li>Keppra (levetiracetam) 500mg PO BID</li>
</ul></li>
<li>insomnia:
<ul>
<li>Anxiedin (lorazapam) 0.5mg PO PRNHS</li>
</ul></li>
<li>constipation:
<ul>
<li>MgO 500mg PO TID</li>
</ul></li>
</ul></li>
<li>PD-L1 &lt;1% is known. EGFR, KRAS, ALK, POS1, BRAF V600E, NTRK,
METex14, RET might be tested</li>
<li>if CCRT is applicable, the chemo option could be:
<ul>
<li>carboplatin + pemetrexed</li>
<li>cisplatin + pemetrexed</li>
<li>paclitaxel + carboplatin</li>
<li>etooside + cisplatin</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-407" class="section level1">
<h1>701325918</h1>
<div id="section-408" class="section level2">
<h2>999999</h2>
<p>{metastatic renal cell carcinoma}</p>
<p>[history]</p>
<ul>
<li>left renal cancer with gastric and lung metastasis, status post
target therapy and immunotherapy at Taipei Veterans General
Hospital</li>
<li>nodular goiter s/p total thyroidectomy 10+ years ago</li>
<li>breast nodular s/p operation.</li>
</ul>
<p>[diagnosis]</p>
<ul>
<li>2021-08-12 CT - whole abdomen, pelvis
<ul>
<li>clinical history of left renal tumor (6.0cm) with solid/cystic
components and calcifications. probable abscess formation (6.7x12.9cm)
at left retroperitoneum with adjacent muscle invasion. some LNs at
retroperitoneum.</li>
</ul></li>
<li>2021-08-12 general and gastroenterological surgery
<ul>
<li>less likely cholecystitis related</li>
<li>favor left retroperitoneal abscess related</li>
</ul></li>
<li>2021-08-13 gastroenterology
<ul>
<li>upper gastrointestinal bleeding, gastric metastasis related?</li>
</ul></li>
</ul>
<p>[treatment]</p>
<ul>
<li>2020-10 erlotinib + bevacizumab followed with nivolumab +
carboplatin.</li>
<li>2021-09-08 pembrolizumab</li>
</ul>
</div>
</div>
<div id="section-409" class="section level1">
<h1>701326125</h1>
<div id="section-410" class="section level2">
<h2>210816</h2>
<p>{some preparation before tube feeding}</p>
<p>active medication is reviewed, all the oral drugs can be administered
via NG tube.</p>
<p>acetin (acetylcysteine) and nexium (esomeprazole) should be dissolved
in adequate drinking water prior to tube feeding.</p>
</div>
</div>
<div id="section-411" class="section level1">
<h1>701326360</h1>
<div id="section-412" class="section level2">
<h2>210816</h2>
<p>{switch drug for tube feeding}</p>
<p>active medication has been reviewed, all the oral drugs can be
administered via NG tube.</p>
<p>Harnalidge (tamsulosin) 0.4mg PO QDAC replaced by Urief (silodosin)
8mg PO QD is recommended.</p>
</div>
</div>
<div id="section-413" class="section level1">
<h1>701328847</h1>
<div id="section-414" class="section level2">
<h2>220413</h2>
<p>{Interprofessional Practice Meeting and Family Meeting}</p>
<ul>
<li>The postponed meeting rescheduled at 10:30 2022-04-13 in the ward,
the patient was present, as was her son.</li>
<li>Dr.Kao explained the treatment plan of the disease to the patient
family, as well as the prognosis and possible risks, and
interprofessional practice team members were present for inquiries.</li>
</ul>
</div>
<div id="section-415" class="section level2">
<h2>220412</h2>
<p>{mesna administration}</p>
<ul>
<li>mesna administration via ntravenous route
<ul>
<li>dilute with D5W, NS, LR, D5-0.2%NaCl, D5-0.33%NaCl, or D5-0.45%NaCl
to a final concentration of 20 mg/mL</li>
<li>following initial puncture of multidose vial, use within 8 days</li>
<li>following dilution, store at 25 degrees C and use within 24
hours</li>
<li>do not mix with epirubicin, cyclophosphamide, cisplatin,
carboplatin, or nitrogen mustard</li>
<li>if mixed with ifosfamide in the same IV bag, do not exceed a final
ifosfamide concentration of 50 mg/mL</li>
</ul></li>
<li>the patient is 50kgw, scheduled dose is 12mg/kg, 600mg should be
dissolved in at least 30mL aforementioned solvent, injection 30 min is
recommended.</li>
</ul>
</div>
<div id="section-416" class="section level2">
<h2>220411</h2>
<p>[objective]</p>
<ul>
<li>diagnosis
<ul>
<li>Mantle cell lymphoma involving in bilateral neck lymph nodes,
supraclavicular lymph nodes, mediastinal and bilateral pulmonary hilar
lymph nodes and some bilateral axillary lymph nodes and the soft tissue
in the right buttock, bone marrow(+), PS:0, Lugano stage IV, MIPI 6.7,
high risk, HCT-CI score:0 (low risk, non-relapse mortality 14% at
2years)</li>
</ul></li>
<li>exam finding
<ul>
<li>2022-03-18 CT - lung/mediastinum/pleura
<ul>
<li>Mild splenomegaly</li>
<li>No evidence of lymphadenopathy in the study.</li>
<li>Dilated aortic root.</li>
</ul></li>
<li>2022-02-08 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac, biopsy  Consistent with myelodysplastic
syndrome</li>
<li>Sections show 30-50 % cellularity with marked decreased erythroid
cells. Atypical small and hypolobated megakaryocytes are found about
3-8/HPF. Some megakaryocytes are positive for CD34. The CD34 and CD117
show no increased blasts. The immunohistochemical stain of Hemoglobin A
show scant residual erythroid cells. The immunohistochemical stains of
CD3 and CD20 show some CD3-positive lymphocytes without CD20-positive
lymphocytes.</li>
<li>The morphology is consistent with myelodysplastic syndrome.</li>
</ul></li>
<li>2022-01-13 MRA - brain
<ul>
<li>Cerebral white matter FLAIR-hyperintensitie. Suspected
demyelineation process due to ischemia or chemotherapy.</li>
</ul></li>
<li>2021-12-17 CT - lung/mediastinum/pleura
<ul>
<li>No evidence of lymphadenopathy in the study but borderline
splenomegaly is noted.</li>
</ul></li>
<li>2021-09-16 Patho - bone marrow biopsy
<ul>
<li>diagnosis
<ul>
<li>Bone marrow, iliac, clinically: newly diagnosed in China with first
time chemotherapy), biopsy  Mantle cell lymphoma.</li>
<li>IHC: CD3(-), CD20(+), bcl-2(+), bcl-6(-), Cyclin-D1(focal +).<br />
</li>
</ul></li>
<li>microscopic description
<ul>
<li>Section shows piece(s) of bone marrow with 50% cellularity and M:E
ratio of approximately 3:1. Three cell lineages are present with normal
maturation of leukocytes. Megakaryocytes are adequate in number. There
are multiple minute aggregates of small atypical lymphoid cells.</li>
</ul></li>
</ul></li>
<li>2021-09-07 Whole body PET scan
<ul>
<li>The FDG PET findings are compatible with lymphoma of low to median
FDG uptake involving multiple lymph nodes on the same side of the
diaphragm as mentioned above (stage II).</li>
<li>Mildly increased FDG uptake in a focal area in the soft tissue in
the right buttock. The nature is to be determined (inflammation? other
nature?).</li>
<li>Increased FDG accumulation in both kidneys and left ureter.
Physiological FDG accumulation is more likely.</li>
</ul></li>
<li>2021-09-07 CT - neck
<ul>
<li>Multiple enlarged bil. neck LNs, esp.at right posterior cervical
space, supraclavicular fossa and axilla.</li>
</ul></li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-02-15 - ESHAP (etoposide, methylprednisolone, cytarabine,
cisplatin)</li>
<li>2022-02-14 - rituximab</li>
<li>2021-12-28 - R-DHAP
<ul>
<li>R - rituximab (also called Mabthera), a type of targeted cancer drug
called a monoclonal antibody</li>
<li>DH - dexamethasone, which is a steroid</li>
<li>A - cytarabine (also known as Ara C), a chemotherapy drug</li>
<li>P - cisplatin, a chemotherapy drug</li>
</ul></li>
<li>2021-12-01 - R-CHOP, rituximab, cyclophosphamide,
hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride),
vincristine (Oncovin) and prednisone</li>
<li>2021-11-08 - R-DHAP</li>
<li>2021-09-16, -10-12 - R-CHOP</li>
<li>2021-08-04 - R-CHOP (in mainland China)</li>
</ul></li>
<li>consultation
<ul>
<li>2022-01-12 Neurology
<ul>
<li>Assessment
<ul>
<li>Peripheral vertigo, suspected platinum based chemotherapy
related</li>
</ul></li>
<li>Suggestion
<ul>
<li>Arrange BAEP, Intracranial and carotid doppler ultrasound, check BP
at lying, sitting and standing with 3 minutes interval each
position.</li>
<li>Use diphenidol and meclizine routinely.</li>
<li>MRA brain with/without contrast may be arranged if new neurological
deficit occured.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The arranged IPP meeting (TP1110411001) has been postponed until
further notice.</li>
<li>There is no TP53 mutation lab data found.</li>
<li>The patient has been treated with RCHOP, alternating RCHOP/RDHAP,
R-ESHAP during Aug 2021 to Feb 2022.</li>
<li>The results of two consecutive bone marrow biopsies revealed mantle
cell lymphoma (2021-09-16) and myelodysplastic syndrome (2022-02-08).
High-dose therapy (HDT) and autologous stem cell rescue (ASCR) might be
indicated. There will be a patient family meeting to discuss ASCR in the
near future.</li>
<li>During this hospital stay, phenytoin was prescribed to prevent
intravenous busulfan induced seizures in recipients of hematopoietic
cell transplantation. Phenytoin is primarily metabolized by the liver to
inactive metabolites with &lt;5% of active drug excreted unchanged in
the urine, making routine dose adjustments for kidney dysfunction
unnecessary. Lab results reported on 2022-04-11 indicated slight
elevations of ALT (44 U/L, normal &lt; 41) and creatinine (1.4 mg/dL,
normal &lt; 1.3), which did not require adjusting the pheytoin
dose.</li>
</ul>
</div>
<div id="section-417" class="section level2">
<h2>220111</h2>
<p>[objective]</p>
<p>Creatinine lab data: - 2022-01-10 1.25mg/dL - 2022-01-07 1.43mg/dL -
2022-01-03 0.93mg/dL</p>
<p>[assessment]</p>
<ul>
<li>serum creatinine elevates slightly above normal range during ABX
administration.</li>
</ul>
<p>[suggestion]</p>
<ul>
<li>no immediate dose adjustment needed for now, keep monitoring renal
function as regular to check the trend.</li>
</ul>
</div>
</div>
<div id="section-418" class="section level1">
<h1>701331484</h1>
<div id="section-419" class="section level2">
<h2>210914</h2>
<p>[tube feeding]</p>
<ul>
<li>all the oral drugs in active medication can be administered with NG
tube.</li>
</ul>
<p>[iron supplement]</p>
<ul>
<li>foliromin is prescribed.<br />
</li>
<li>coadministration ferrous suppement with vit. C would somewhat
increase iron intake.
<ul>
<li>source
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/2507689/" class="uri">https://pubmed.ncbi.nlm.nih.gov/2507689/</a></li>
<li><a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772395" class="uri">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772395</a></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-420" class="section level1">
<h1>701333841</h1>
<div id="section-421" class="section level2">
<h2>220304</h2>
<p>{drug identification}</p>
<p>requesting drug identification for 2 items.</p>
<p>all the 2 items are identified as following</p>
<ul>
<li>allegra (fexofenadine 60mg) - antiallergic agent, antihistamine,
second generation</li>
<li>orolisin (orotic acid 30mg + glycyrrhizinate extract 50mg +
chlorpheniramine maleate 5mg) - antiallergic agent, antihistamine,
second generation</li>
</ul>
<p>these drugs will be sent back to ward by an in-hospital porter.</p>
</div>
</div>
<div id="section-422" class="section level1">
<h1>701334097</h1>
<div id="section-423" class="section level2">
<h2>220408</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-06 Patho - colon segmental resection for tumor
<ul>
<li>pathology diagnosis
<ul>
<li>Rectum, Hartmanns operation  Adenocarcinoma, moderately
differentiated<br />
</li>
<li>Resection margins, Hartmanns operation  Free of carcinoma<br />
</li>
<li>Lymph nodes, mesocolorectal, Hartmanns operation  Metastatic
adenocarcinoma (1/12)<br />
</li>
<li>Specime labeled pelvic tumor margin, biopsy  Necrosis and
granulation tissue and free of carcinoma<br />
</li>
<li>T-colon colostomy, closure of colostomy  Free of carcinoma<br />
</li>
<li>Pathology stage: ypT3N1a(cM0); Stage IIIB</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology: Adenocarcinoma<br />
</li>
<li>Histology Grade: Moderately differentiated<br />
</li>
<li>Depth of invasion: Perirectal soft tissue<br />
</li>
<li>Angiolymphatic invasion: Not identified<br />
</li>
<li>Perineural invasion: Present<br />
</li>
<li>Tumor cell budding: Intermediate<br />
</li>
<li>Circumferential (radial) margin of rectum: Uninvolved, 2 mm from the
margin<br />
</li>
<li>Lymph node metastasis, mesocolorectal: Metastatic adenocarcinoma
(1/12)</li>
<li>Extranodal involvement: Absent<br />
</li>
<li>Pathologic Stage Classification (pTNM, AJCC 8th Edition)
<ul>
<li>Primary Tumor (pT): ypT3 (Tumor invades pericolorectal
tissues)<br />
</li>
<li>Regional Lymph Nodes (pN): ypN1a (one regional lymph node
positive)<br />
</li>
<li>Distant Metastasis (pM): cM0<br />
</li>
</ul></li>
<li>Type of polyp in which invasive carcinoma arose: Not
identified<br />
</li>
<li>Additional pathologic findings: None identified<br />
</li>
<li>Tumor regression grading S/P CCRT: Partial response (score 2)<br />
</li>
<li>IHC: EGFR(+), MLH1(+), PMS2(+), MSH2(+), MSH6(+)<br />
</li>
<li>Specime labeled pelvic tumor margin: Necrosis and granulation
tissue, and free of carcinoma<br />
</li>
<li>T-colon colostomy: Free of carcinoma</li>
</ul></li>
</ul></li>
<li>2021-12-28 CT - abdomen, pelvis
<ul>
<li>Rectosigmoid colon cancer, size decreased.</li>
<li>Decreased size of pericolic lymph nodes.</li>
<li>Status post T-colostomy.</li>
<li>Right hydronephrosis and hydroureter.</li>
<li>Tiny subpleural nodules (&lt;0.5cm) at basal LLL. Suggest close
follow up.</li>
</ul></li>
<li>2021-12-28 Colonoscopy
<ul>
<li>compatible with colon cancer, 8cm AAV, with near lumen
obstruction.</li>
</ul></li>
<li>2021-09-16 CT - abdomen, pelvis
<ul>
<li>Imaging stage: T3N2aM0, stage IIIB</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-02-24
<ul>
<li>All RAS mutation not detected</li>
<li>BRAF mutation not detected</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-05
<ul>
<li>surgery
<ul>
<li>Hartmanns operation and closure of T-loop colostomy</li>
</ul></li>
<li>finding
<ul>
<li>Advanced rectal cancer obstruction s/p CCRT and the tumor was firmly
fixed to the pelvic cavity , clinically cant be resected
completely</li>
</ul></li>
</ul></li>
<li>2021-09-17
<ul>
<li>surgery
<ul>
<li>T loop colostomy</li>
</ul></li>
<li>finding
<ul>
<li>Rectal cancer with obstruction, cT3N2aM0 stage IIIB</li>
<li>RUQ stoma with stent</li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-09-28 ~ 2021-11-04 - pelvis: 45 Gy/ 25 fx. R-S colon tumor and
LAPs: 50.4 Gy/ 28 fx</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-02-22 ~ undergoing - FOLFOX plus bevacizumab</li>
<li>2021-11-29 ~ 2022-02-07 - FOLFOX</li>
<li>2021-10-04 ~ 2021-11-01 - 5-Fu + LV (CCRT)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Having been firmly embedded in the pelvic cavity, the tumor could
not be surgically resected fully (2022-01-05).</li>
<li>The patient receives FOLFOX since 2021-11-29 (plus bevacizumab since
2022-02-22) s/p T loop colostomy (2021-09-17) and CCRT (late Sep to
early Nov 2021).</li>
<li>According to laboratory data reported on 2022-04-06, there were no
obvious abnormalities; however, elevations in ALT (60 U/L) and AST (64
U/L) should be addressed, as these two readings had been normal prior to
the this last examination.</li>
<li>As metoclopramide is one of the potentially hepatotoxic drugs, some
silymarin as supplementation might be an optional add-on to mitigate the
potential hepatotoxicity.
<ul>
<li>reference
<ul>
<li>Hepatotoxicity by Drugs: The Most Common Implicated Agents. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783956/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783956/</a></li>
<li>A Pilot Study of Silymarin as Supplementation to Reduce Toxicities
in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI
Plus Bevacizumab. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420909/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420909/</a></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-424" class="section level1">
<h1>701342376</h1>
<div id="section-425" class="section level2">
<h2>220329</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-28 Colonoscopy
<ul>
<li>colon diverticulum, cecum, ascending colon</li>
</ul></li>
<li>2022-03-08 CT - abdomen, pelvis
<ul>
<li>S/P gastrectomy, splenectomy and pancreas operation. Fat stranding
of upper peritoneal cavity.</li>
</ul></li>
<li>2021-10-28 Patho - small intestine resction (not tumor)
<ul>
<li>Small intestine, distal ileum, segmental resection - Consistent with
Meckel diverticulum<br />
</li>
<li>Sections show ileal tissue with a diverticulum lined by gastric
mucosal tissue. The morphology is consistent with Meckel
diverticulum.<br />
</li>
</ul></li>
<li>2021-10-28 Patho - stomach subtotal/total (tumor)
<ul>
<li>pathologic diagnosis
<ul>
<li>Stomach, lesser curvature, total gastrectomy - Adenocarcinoma,
moderately differentiated</li>
<li>Esophagus, total gastrectomy - Adenocarcinoma, by direct invasion
with negative resection margin</li>
<li>Duodenum, total gastrectomy - Negative for malignancy<br />
</li>
<li>Liver, left lateral segment, segmentectomy - Negative for malignancy
- Acute suppurative inflammation<br />
</li>
<li>Pancreas, distal, distal pancreatectomy - Negative for
malignancy</li>
<li>Spleen, splenectomy - Negative for malignancy<br />
</li>
<li>Omentum, omentectomy - Negative for malignancy<br />
</li>
<li>Liver, caudate lobe, specimen B, resection - Negative for malignancy
- Acute suppurative inflammation<br />
</li>
<li>Proximal esophagus, specimen C, resection - Negative for
malignancy<br />
</li>
<li>Margin: free<br />
</li>
<li>Lymph node, lesser curvature, dissection - Negative for malignancy
(0/8)<br />
</li>
<li>Lymph node, greater curvature, dissection - Negative for malignancy
(0/14)<br />
</li>
<li>Lymph node, peri-pancreatic, dissection - Negative for malignancy
(0/12)<br />
</li>
<li>AJCC 8th edition pT4aN0 (if cM0) pStage IIB,<br />
</li>
<li>F2021-423: Esophagus, resection margin, excision - Negative for
malignancy<br />
</li>
</ul></li>
<li>microscopic examnation
<ul>
<li>Histologic Type: Lauren classification of adenocarcinoma: Intestinal
(tubular) type; The immunohistochemical stain Her-2/neu (Ab) is
negative.</li>
<li>Histologic Grade: G2: Moderately differentiated<br />
</li>
<li>Tumor Extension: Tumor invades esophagus, the serosa (visceral
peritoneum) and attached to the liver and pancreas capsule. No direct
invasion in the liver and pancreas parenchyma is found. The subserosal
liver parenchyma reveals acute suppurative inflammation. The
immunohistocehmical stain of CK reveals no invasive tumor. The spleen,
duodenum and omentum are free of tumor.<br />
</li>
<li>Additional Pathologic Findings
<ul>
<li>Intestinal metaplasia: absent<br />
</li>
<li>Low-grade dysplasia: absent<br />
</li>
<li>High-grade dysplasia: present<br />
</li>
<li>Helicobacter pylori-type gastritis<br />
</li>
<li>Autoimmune atrophic chronic gastritis: absent<br />
</li>
<li>Polyp(s): absent</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-10-27
<ul>
<li>Total gastrectomy with D2+ LN dissection
<ul>
<li>En-block left lateral segmentectomy with caudate loberesection with
distal pancreatectomy with splenectomy</li>
</ul></li>
<li>Distalsmallbowel segmental resection with anastomsois</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2021-12-02 ~ 2021-12-06 - 540cGy/3 fractions (15 MV photon) to
anastomosis and regional lymphatics</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-24, -02-07, -02-22, -03-09, -03-28 - FOLFOX</li>
<li>2021-12-08, -12-13, -12-20, -12-27, 2022-01-03 - 5-FU</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>gastric cancer pT4aN0 cM0 stage IIB s/p gastrectomy with D2+ LN
dissection (2021-10-27) followed by post-Op CCRT (5-FU, early Dec 2021
to early Jan 2022) and adjuvant chemotherapy (FOLFOX, since late Jan
2022).</li>
<li>tumor pathology (2021-10-28) showed Her-2/neu (Ab) negative. no
MSI/MMR, PD-L1 results found in HIS5</li>
<li>patients who have undergone primary D2 lymph node dissection are
preferred to receive [capecitabine + oxaliplatin] and [fluorouracil +
oxaliplatin], the latter is what the patient is getting now.</li>
<li>no adverse reaction found in nursing note for now during this
hospital stay. no issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-426" class="section level1">
<h1>701345193</h1>
<div id="section-427" class="section level2">
<h2>220506</h2>
<p>{ovarian clear cell carcinoma stage IA}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-17 Gynecologic ultrasonography
<ul>
<li>No obvious uterine or ovarian lesion</li>
</ul></li>
<li>2021-12-06 Patho
<ul>
<li>debulking surgery
<ul>
<li>total abdominal hysterectomy + bilateral salpingo-oophorectomy +
omentectomy + bilateral pelvic lymphnode dissection</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Ovary, right, oophorectomy - clear cell carcinoma; AJCC 8th edition:
pStage IA, pT1aN0(if cM0); FIGO stage: IA<br />
</li>
<li>Ovary,left, oophorectomy - Endometrioma<br />
</li>
<li>Histologic Type: Clear cell carcinoma</li>
<li>IHC: Napsin A(focal +), PAX8(+), WT-1(-), p53(wild type), and
PR(-).<br />
</li>
<li>Histologic Grade: Clear cell carcinoma is not graded.<br />
</li>
</ul></li>
</ul></li>
<li>2021-11-03 CT
<ul>
<li>Cystic adenocarcinoma of the left ovary is suspected.<br />
</li>
<li>Small ground-glass opacity 3.5 mm in LLL of the lung, nature?</li>
<li>The differential diagnoses include primary lung cancer, metastasis,
or benign lesion?</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>S-GPT/ALT
<ul>
<li>2022-05-05 71 U/L</li>
<li>2022-04-28 47 U/L</li>
<li>2022-04-21 66 U/L</li>
<li>2022-04-06 58 U/L</li>
<li>2022-03-24 29 U/L</li>
<li>2022-03-09 38 U/L</li>
<li>2022-02-24 33 U/L</li>
<li>2022-02-15 38 U/L</li>
<li>2022-01-25 26 U/L</li>
<li>2022-01-13 34 U/L</li>
<li>2021-12-23 39 U/L</li>
<li>2021-12-01 17 U/L</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-03 debulking surgery (total abdominal hysterectomy +
bilateral salpingo-oophorectomy + omentectomy + Bilateral Pelvic
Lymphnode Dissection) + enterolysis</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-04 ~ undergoing - paclitaxel + carboplatin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>S-GPT/ALT has been elevated above the normal range since April 2022
<ul>
<li>2022-05-05 71 U/L</li>
<li>2022-04-28 47 U/L</li>
<li>2022-04-21 66 U/L</li>
<li>2022-04-06 58 U/L</li>
<li>2022-03-24 29 U/L</li>
<li>2022-03-09 38 U/L</li>
<li>2022-02-24 33 U/L</li>
<li>2022-02-15 38 U/L</li>
<li>2022-01-25 26 U/L</li>
</ul></li>
<li>The infusion of 3-hour infusion paclitaxel in the current regimen
might have to be adjusted to 135 mg/m2 if ransaminases less than 10
times ULN and bilirubin levels are 1.26 to 2 times ULN.</li>
</ul>
</div>
<div id="section-428" class="section level2">
<h2>220412</h2>
<p>[assessment]</p>
<ul>
<li>For this ovarian clear cell carcinoma stage IA patient, IV
platinum-based therapy could serve as preferred first-line treatment,
specifically speaking paclitaxel + carboplatin Q3W, this is just the
treatment the patient receiving now, as from early Jan 2022.</li>
<li>The patient tolerates the current regimen well according to nursing
notes. Alternatively, albumin-bound paclitaxel may be considered if the
patient experiences hypersensitivity to paclitaxel.</li>
<li>Three months after the debulking surgery on 2021-12-03, a
gynecologic ultrasonography on 2022-03-17 found no evidence of uterine
or ovarian lesions. So far, so good.</li>
</ul>
</div>
<div id="section-429" class="section level2">
<h2>220126</h2>
<p>{ovarian clear cell carcinoma stage IA}</p>
<p>[objective]</p>
<ul>
<li>2021-12-06 Patho
<ul>
<li>debulking surgery
<ul>
<li>total abdominal hysterectomy + bilateral salpingo-oophorectomy +
omentectomy + bilateral pelvic lymphnode dissection - ROV - 20x18cm:
multiple (13-14#) solid mass, 2cm for each, with 1700c.c brown fluid in
cyst</li>
</ul></li>
<li>Diagnosis
<ul>
<li>Ovary, right, oophorectomy - clear cell carcinoma; AJCC 8th edition:
pStage IA, pT1aN0(if cM0); FIGO stage: IA<br />
</li>
<li>Ovary,left, oophorectomy - Endometrioma<br />
</li>
<li>Histologic Type: Clear cell carcinoma</li>
<li>IHC: Napsin A(focal +), PAX8(+), WT-1(-), p53(wild type), and
PR(-).<br />
</li>
<li>Histologic Grade: Clear cell carcinoma is not graded.<br />
</li>
</ul></li>
</ul></li>
<li>2021-11-03 CT
<ul>
<li>Cystic adenocarcinoma of the left ovary is suspected.<br />
</li>
<li>Small ground-glass opacity 3.5 mm in LLL of the lung, nature?</li>
<li>The differential diagnoses include primary lung cancer, metastasis,
or benign lesion?</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>for this ovarian clear cell carcinoma stage IA patient, IV
platinum-based therapy could serve as preferred first-line treatment,
specifically speaking Paclitaxel + Carboplatin Q3W, this is just the
treatment the patient receiving now, as from early Jan 2022.</li>
<li>if patient experienced a hypersensitivity reaction to paclitaxel,
then albumin-bound paclitaxel might be considered as an
alternative.</li>
<li>no apparent intolerence observed during this hospitalization.</li>
<li>no issue found in active medication.</li>
</ul>
</div>
</div>
<div id="section-430" class="section level1">
<h1>701346431</h1>
<div id="section-431" class="section level2">
<h2>220309</h2>
<p>{malignant neoplasm of unspecified site of left female breast,
cT4aN3M1, stage IV}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-01-19 Cell Block
<ul>
<li>Smears and cell blockshow lymphocytes, reactive mesothelial cells,
and clusters of large, pleomorphic tumor cells.</li>
<li>IHC: CK(+), GATA3(+), and Calretinin(-).</li>
<li>The results are consistent with metastatic breast carcinoma.</li>
</ul></li>
<li>2021-12-28 Pleural Effusion
<ul>
<li>50 cc yellow cloudy pleural effusion</li>
<li>The smears show lymphocytes, reactive mesothelial cells and a few
hyperchromatic atypical cell clusters, compatible with metastatic
carcinoma.</li>
</ul></li>
<li>2021-11-09 Patho - breast biopsy
<ul>
<li>pathologic diagnosis
<ul>
<li>Breast, right, biopsy - Invasive carcinoma of no special type<br />
</li>
<li>The sections show invasive carcinoma of no special type, composed of
breast tissue with nests and cords of polygonal neoplastic cells,
embedded in fibrous stroma.</li>
<li>IHC:
<ul>
<li>ER (Ab): Negative</li>
<li>PR (Ab): Negative</li>
<li>HER-2/Neu (Ab): Positive (score= 3+)</li>
<li>Ki-67: 25%</li>
</ul></li>
</ul></li>
</ul></li>
<li>2021-11-08 Tc-99m MDP whole body bone scan with SPECT
<ul>
<li>The scintigraphic findings suggest multiple bone metastases in the
skull, some T- and L-spine, sacrum, sternum, left scapula, bilateral
multiple ribs, multiple pelvic bones, S-I joints, and femurs.</li>
<li>Increased tracer uptake at bilateral shoulders, the nature is to be
determined (bone mets, DJD, or other nature ?)</li>
</ul></li>
<li>2021-11-08 SONO - Breast
<ul>
<li>Bilateral breast tumors with left axillary lymph node, suspected
malignancy.</li>
<li>BI-RADS: Category 5 - highly suggestive of malignancy, appropriate
action should be taken.</li>
</ul></li>
<li>2021-11-04 Pleural Effusion
<ul>
<li>diagnosis: Adenocarcinoma</li>
<li>smears show tumr cells with large hyperchromatic nuclei,
pleomorphism, prominent nucleoli and mitoses.</li>
</ul></li>
</ul></li>
<li>medication
<ul>
<li>2022-02-11 ~ ongoing: docetaxel + trastuzumab + pertuzumab (Q3W, the
latter two started on 2022-03-08)</li>
<li>2021-11-12 ~ 2022-01-20: doxorubicin + cyclophosphamide (AC),
Q3W</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient is diagnosed with breast cancer cT4aN3M1 stage IV and
bone mets, and she is fitted with AC followed by docetaxelc +
trastuzumab + pertuzumab regimen (the latter two drugs started on
2022-03-08).</li>
</ul>
</div>
</div>
<div id="section-432" class="section level1">
<h1>701346860</h1>
<div id="section-433" class="section level2">
<h2>220426</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-24 Hearing Test
<ul>
<li>PTA, Pure-tone Audiometry
<ul>
<li>Reliability FAIR</li>
<li>Average Rt 23 dB HL // Lt 21 dB HL</li>
<li>Bil normal to moderately severe SNHL</li>
</ul></li>
</ul></li>
<li>2022-01-27 KUB
<ul>
<li>Diffuse bowel dilatation with barium retention. Stationary.</li>
</ul></li>
<li>2022-01-21 KUB
<ul>
<li>Diffuse small bowel dilatation.</li>
<li>Retention of barium in the bowel loops.</li>
</ul></li>
<li>2022-01-19 Small intestine
<ul>
<li>Small bowel ileus.</li>
<li>The passage time is more than 24 hours.</li>
</ul></li>
<li>2021-12-22 Patho - uterus (with or without SO) neoplastic
<ul>
<li>Pathologic diagnosis
<ul>
<li>Uterus, endometrium, staging surgery  Serous carcinoma,
high-grade<br />
</li>
<li>Uterus, myometrium, total hysterectomy
<ul>
<li> Involved by serous carcinoma (&lt; 1/2 thickness)<br />
</li>
<li> Intramural myoma<br />
</li>
</ul></li>
<li>Uterus, cervix, total hysterectomy
<ul>
<li> Endocervix involved by tumor<br />
</li>
<li> Cervical stromal not involvement<br />
</li>
<li> Free of cervical margin<br />
</li>
</ul></li>
<li>AJCC 8th edition Pathology stage: pT1aN0(if cM0); FIGO IA; AJCC
stage IA</li>
</ul></li>
<li>Microscopic Examination
<ul>
<li>Histology type: Serous carcinoma<br />
</li>
<li>Histology grade: High-grade<br />
</li>
<li>Depth of invasion: 2 mm (invade &lt;1/2 thickness of the myometrial
wall)<br />
</li>
</ul></li>
</ul></li>
<li>2021-12-10 Patho - endometrium curretage/biopsy
<ul>
<li>Uterus, endometrium, EM sampling  serous adenocarcinoma, high
grade</li>
<li>IHC stains: p53 (aberrant type), WT-1 (+), CK20 (-), PAX-8 (-), ER
(-, 0%), PR (-, 0%).<br />
</li>
</ul></li>
<li>2021-12-09 Gynecologic ultrasonography
<ul>
<li>Endometrial hyperplasia(EM:30.1mm), suspected endometrial
malignancy</li>
<li>thickness of the posterior wall: 0.47cm</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2021-12-22 Staging surgery (ATH + BSO + bilateral pelvic lymphnode
dissection + paraaortic lyphnode dissection)</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02-22 ~ 2022-03-31 - 4500cGy/25 fractions (15 MV photon) of the
pelvic area. (CCRT)</li>
</ul></li>
<li>chemoimmunotherapy
<ul>
<li>2022-04-25 - undergoing - paclitaxel + carboplatin</li>
<li>2022-02-24 ~ 2022-03-30 - cisplatin (CCRT)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient has endometrial serous carcinoma of high grade, s/p
surgery on 2021-12-22, and CCRT during late February to the end of March
in 2022. She has been administered paclitaxel + carboplatin as of this
hospital stay.</li>
<li>The CBC and WBC results reported on 2022-04-20 and liver and kidney
function, serum electrolytes reported on 2022-04-13 were grossly normal.
Chronic viral hepatitis B is managed with Baraclude (entecavir) 0.5mg
QDAC.</li>
<li>For those with human epidermal growth factor receptor
2-overexpressing (HER2 data not found yet), addition of trastuzumab to
current chemotherapy might be considered optionally.</li>
</ul>
</div>
</div>
<div id="section-434" class="section level1">
<h1>701349358</h1>
<div id="section-435" class="section level2">
<h2>220215</h2>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2021-12-02 Patho - stomach subtotal/total (tumor)
<ul>
<li>stomach, antrum, subtotal gastrectomy - signet-ring cell
carcinoma</li>
<li>small intestine, duodenum, subtotal gastrectomy - signet-ring cell
carcinoma, by direct invasion</li>
<li>omentum, omentectomy - negative for malignancy</li>
<li>lymph node - signet-ring cell carcinoma, metastatic</li>
<li>pT2N3b(if cM0), pStage IIIB</li>
<li>gross configuration: for advanced carcinoma (Borrmann
classification): Type III
<ul>
<li>ulcerated with poorly defined infiltrative margins</li>
</ul></li>
<li>histologic type: adenocarcinoma, Lauren classification of
adenocarcinoma: diffuse type</li>
<li>histologic grade: G3 - poorly differentiated, undifferentiated</li>
<li>tumor extension: tumor invades the muscularis propria</li>
<li>lymphovascular Invasion, perineural invasion, intestinal metaplasia,
high-grade dysplasia, polyps: absent</li>
</ul></li>
<li>2021-11-30 Patho - stomach biopsy
<ul>
<li>stomach, antrum, biopsy  signet-ring cell carcinoma<br />
</li>
<li>IHC: CK(+), Her-2/neu (Ab)(-).<br />
</li>
</ul></li>
<li>2021-11-30 Esophagogastroduodenoscopy
<ul>
<li>highly suspected gastric cancer, antrum, Borrmann type 3, sp
biopsy</li>
</ul></li>
<li>2021-11-29 CT - abdomen gastric filling with water
<ul>
<li>T2N2M0, stage IIA</li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02 Adjuvant RT to anastomosis and regional lymphatics for
4500cGy/25fx is suggested for locoregional control.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-14 starts 5-FU</li>
</ul></li>
</ul>
</div>
</div>
<div id="section-436" class="section level1">
<h1>701353650</h1>
<div id="section-437" class="section level2">
<h2>220217</h2>
<p>[subjective]</p>
<ul>
<li>bloody stool since 2021-02</li>
<li>tenesmus since 2021-03</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2021-12-29 CT
<ul>
<li>There is wall thickening at the rectum measuring 2 cm in wall
thickness that is c/w adenocarcinoma.
<ul>
<li>In addition, at least six enlarged lymph nodes in the perirectal
space and adjacent mesocolon are noted.</li>
</ul></li>
<li>There are several hepatic cysts in left lobe and the largest one 3.7
cm in size at S2/4.</li>
<li>Impression (Imaging stage): T3N2aM0, stage IIIB</li>
</ul></li>
<li>2021-12-24 Patho - colon biopsy
<ul>
<li>Rectum , 4 cm from AV, biopsy - Adenocarcinoma.</li>
<li>IHC: EGFR(+); PMS2(+), MSH6(+), MSH2(+), MLH1(+).</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>CEA
<ul>
<li>2022-02-16 4.6 ng/mL (normal &lt; 5)</li>
<li>2021-12-24 4.5</li>
</ul></li>
<li>CA199
<ul>
<li>2022-02-16 14 U/mL (normal &lt; 35)</li>
</ul></li>
</ul></li>
<li>treatment
<ul>
<li>2022-01-13 ~ until now - preOP CCRT
<ul>
<li>Radiotherapy 3060cGy/17fx to pelvic area.</li>
<li>Chemotherapy HDFL</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>current treatment introduced just about a month, have to wait and
see the response.</li>
<li>available CEA, CA199 readings never outranged normal limits, might
not sensible enough for this patient.</li>
<li>Zoloft (sertraline 50mg QD) and Rivotril (clonazepam 0.5mg HS) are
prescribed for the anxiety.</li>
<li>no drug allergy recorded in database, no issue with current
medication.</li>
</ul>
</div>
</div>
<div id="section-438" class="section level1">
<h1>701355468</h1>
<div id="section-439" class="section level2">
<h2>220322</h2>
<p>{Malignant neoplasm of rectosigmoid junction, stage cT3N0M0, stage
IIA}</p>
<p>[objective]</p>
<ul>
<li>radiotherapy
<ul>
<li>2022-01-17 ~ 2022-03-07 - 4500cGy/25 fractions (15 MV photon) of the
pelvic, and 5040cGy/28 fractions of the rectal tumor bed area.</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>On 2022-01-11, the cancer multidisciplinary meeting recommended
pre-operative CCRT for this patient.</li>
<li>The patient has been undergoing CCRT treatment since mid-January
2022, and has started the FOLFOX regimen during this hospital stay.</li>
<li>There were no extreme anomalies in the laboratory data reported on
2022-03-17, 18, 21.</li>
<li>In nursing notes, adverse events of grade 0 have been recorded at
11:55 on 2022-03-22.</li>
<li>No issue with current medication.</li>
</ul>
</div>
<div id="section-440" class="section level2">
<h2>220222</h2>
<p>{Malignant neoplasm of rectosigmoid junction, stage cT3N0M0, stage
IIA}</p>
<p>[objective]</p>
<ul>
<li>exam findings
<ul>
<li>2022-01-07 Patho - colorectal polyp
<ul>
<li>Intestine, large, rectum, 8 cm from anal verge, biopsy -
Adenocarcinoma<br />
</li>
<li>IHC: EGFR(+), PMS2(+), MLH-1(+), MSH-2(+), MSH-6(+)<br />
</li>
<li>Microscopically, it shows adenocarcinoma composed of a proliferation
of irregular neoplastic glands with areas of cribriform architecture,
and infiltrative growth pattern. The tumor cells display hyperchromatic
nuclei with pleomorphism, prominent nucleoli, high N/C ratio and mitotic
figures.<br />
</li>
</ul></li>
<li>2022-01-06 Colonoscopy
<ul>
<li>Diagnosis: Rectal cancer s/p biopsy</li>
<li>Suggestion: CCRT then Op</li>
</ul></li>
</ul></li>
<li>treatment plan
<ul>
<li>preOp CCRT</li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-01-17 ~ - 3060cGy/17 fractions (15 MV photon) of the pelvic
area.</li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-01-18, -01-24, -02-21 - FL (biweekly 5-Fu + Lv)</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>this 78-year-old male diagnosed with malignant neoplasm of
rectosigmoid junction in early Jan 2022 is on pre-Op CCRT since
mid-Jan.</li>
<li>lab data reported on 2022-02-16 showed no dysfunction of liver and
kidney, and slightly lower blood counts.</li>
<li>hypertension, gout and HBV are under treatment of corresponding
self-carried drugs
<ul>
<li>bisoprolol, valsartan</li>
<li>febuxostat</li>
<li>entecavir</li>
</ul></li>
<li>no issue with current medication.</li>
</ul>
</div>
</div>
<div id="section-441" class="section level1">
<h1>701356176</h1>
<div id="section-442" class="section level2">
<h2>220110</h2>
<p>[Objective]</p>
<p>Lab data reported on 2022-01-10 and some prescribed medication: - CRP
9.17mg/dL (normal &lt;1), WBC 166*10^3/uL (normal 3.9~10.6) &lt;=
Tapimycin (Piperacillin + Tazobactam) - Blood Uric Acid 16.3mg/dL
(normal 4.4~7.6) &lt;= Fasturtec (Rasburicase) - Calcium 4.04 mmol/L
(normal 2.2~2.65) &lt;= Miacalcic (Calcitonin) - Magnesium 1.4mg/dL
(normal 1.9~2.7) - Triglyceride (TG) 524mg/dL (normal &lt;150), HDL-C
5mg/dL (normal &gt;40) - Benz(BZO) intoxication positive (normal
negative)</p>
<p>[Assessment/Suggestion]</p>
<ul>
<li>MgO might be considered for hypomagnesemia.</li>
<li>Flumazenil might be considered for benzodiazepine intoxication.
<ul>
<li>Unable to access PharmaCloud now, might need to find out why
intoxication happened.</li>
</ul></li>
<li>Statins might be considered for hypertriglyceridemia later after
acute symptoms been controlled.</li>
</ul>
</div>
</div>
<div id="section-443" class="section level1">
<h1>701356390</h1>
<div id="section-444" class="section level2">
<h2>220408</h2>
<p>{TNBC with brain mets}</p>
<p>[history]</p>
<ul>
<li>Underlying disease of left breast cancer about 11 years ago (as of
2022 Jan), post-radiotherapy.</li>
<li>Left clavicle metastasis.</li>
<li>Left lymph node mets s/p biospy, about 2 year ago (ER+, HER2-),
under hormones and targeted therapy (Letrozole + Palbociclib).</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-25 Ventricular ejaction fraction and wall motion study
<ul>
<li>The RVEF and LVEF were 63% and 65% respectively.</li>
<li>Normal wall motion of the LV.</li>
</ul></li>
<li>2022-02-14 Tc-99m MDP whole body bone scan
<ul>
<li>Two hot spots in bilateral fronto-parietal region of the skull,
respectively, and increased activity in the sternum, the nature is to be
determined (post-traumatic change, early bone mets or other nature ?),
suggesting follow-up with bone scan in 3 months for further
evaluation.</li>
<li>Suspected benign lesions in lower L-spine, sacrum, bilateral
shoulders, S-I joints, and hips.</li>
</ul></li>
<li>2022-02-11 CT - whole abdomen, pelvis
<ul>
<li>S/P Mastectomy, left.</li>
<li>There is soft tissue swelling at the left upper anterior
mediastinum, nature?</li>
</ul></li>
<li>2022-01-13 Patho - brain biopsy
<ul>
<li>Brain tumor, rt frontal area, frozen section and biopsy -
Metastatic carcinoma, breast origin</li>
<li>IHC: CK(+), GATA-3(+), ER(-), PR(-) and HER2(2+, equivocal) for
tumor cells, compatible with metastatic breast carcinoma.
<ul>
<li>There is NO amplification of HER2 detected by FISH assay in Taipei
Institute of Pathology</li>
</ul></li>
</ul></li>
<li>2022-01-13 Frozen section
<ul>
<li>Tumor, brain, frozen section - Malignancy,
poorly-differentiated.</li>
</ul></li>
<li>2022-01-12 CT - Brain for navigator
<ul>
<li>Multiple brain metasatses with mass effect. S/P markers for
stereostatic surgery.</li>
</ul></li>
<li>2022-01-10 MRI - Brain for navigator
<ul>
<li>Intra-axial lesions, suspected brain metastasis</li>
</ul></li>
<li>2022-01-10 CT - Brain
<ul>
<li>c/w brain metastasis</li>
<li>Midline shift, 8mm</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-13 Stereotactic biopsy and aspiration for right PO cystic
lesion and left frontal deep tumor; breast cancer history(+);
<ul>
<li>finding
<ul>
<li>OP 1:
<ul>
<li>Two pieces white-grayish soft tumor was harvest at left forntal deep
brain.</li>
<li>Frozen section: Tumor, brain, frozen section - Malignancy,
poorly-differentiated.</li>
</ul></li>
<li>OP 2:
<ul>
<li>Xanthochromic then light reddish fluid about 40cc was apirated at
right PO area.</li>
<li>sent for cytology/culture and CSF profile.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02-07 medrec plan to deliver 30 Gy/ 10 fx to the whole brain.
<ul>
<li>2022-01-24 ~ RT to the whole brain: 21 Gy/ 7 fx. (what does this
mean?)</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-24, -03-16, -04-07 - doxorubicin + cyclophosphamide</li>
<li>2022-03-24 - denosumab</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient has TNBC with brain mets and is being treated with
doxorubicin and cyclophosphamide as from late February 2022.</li>
<li>In lab results reported on 2022-04-06, liver and kidney functions
were normal, and no obvious abnormalities were noted in the CBC or WBC
levels.</li>
<li>If the current regimen fails to produce satisfactory outcome,
capecitabine might be a subsequential alternative.</li>
<li>Olaparib or talazoparib might be an optional add-on if the BRCA1/2
mutation germline sequencing result is positive.</li>
<li>Phase III KEYNOTE-355 trial demonstrated the benefits of
pembrolizumab added to chemotherapy in locally advanced or metastatic
triple-negative breast cancer.
<ul>
<li>Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced
or Metastatic Triple-Negative Breast Cancer.</li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/35348777/" class="uri">https://pubmed.ncbi.nlm.nih.gov/35348777/</a></li>
</ul></li>
</ul>
</div>
<div id="section-445" class="section level2">
<h2>220317</h2>
<p>{TNBC with brain mets}</p>
<p>[history]</p>
<ul>
<li>Underlying disease of left breast cancer about 11 years ago (as of
2022 Jan), post-radiotherapy.</li>
<li>Left clavicle metastasis.</li>
<li>Left lymph node mets s/p biospy, about 2 year ago (ER+,HER2-), under
hormones and targeted therapy (Letrozole + Palbociclib).</li>
</ul>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-02-25 Ventricular ejaction fraction and wall motion study
<ul>
<li>The RVEF and LVEF were 63% and 65% respectively.</li>
<li>Normal wall motion of the LV.</li>
</ul></li>
<li>2022-02-14 Tc-99m MDP whole body bone scan
<ul>
<li>Two hot spots in bilateral fronto-parietal region of the skull,
respectively, and increased activity in the sternum, the nature is to be
determined (post-traumatic change, early bone mets or other nature ?),
suggesting follow-up with bone scan in 3 months for further
evaluation.</li>
<li>Suspected benign lesions in lower L-spine, sacrum, bilateral
shoulders, S-I joints, and hips.</li>
</ul></li>
<li>2022-02-11 CT - whole abdomen, pelvis
<ul>
<li>S/P Mastectomy, left.</li>
<li>There is soft tissue swelling at the left upper anterior
mediastinum, nature?</li>
</ul></li>
<li>2022-01-13 Patho - brain biopsy
<ul>
<li>Brain tumor, rt frontal area, frozen section and biopsy -
Metastatic carcinoma, breast origin</li>
<li>IHC: CK(+), GATA-3(+), ER(-), PR(-) and HER2(2+, equivocal) for
tumor cells, compatible with metastatic breast carcinoma.
<ul>
<li>There is NO amplification of HER2 detected by FISH assay in Taipei
Institute of Pathology</li>
</ul></li>
</ul></li>
<li>2022-01-13 Frozen section
<ul>
<li>Tumor, brain, frozen section - Malignancy,
poorly-differentiated.</li>
</ul></li>
<li>2022-01-12 CT - Brain for navigator
<ul>
<li>Multiple brain metasatses with mass effect. S/P markers for
stereostatic surgery.</li>
</ul></li>
<li>2022-01-10 MRI - Brain for navigator
<ul>
<li>Intra-axial lesions, suspected brain metastasis</li>
</ul></li>
<li>2022-01-10 CT - Brain
<ul>
<li>c/w brain metastasis</li>
<li>Midline shift, 8mm</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-01-13 Stereotactic biopsy and aspiration for right PO cystic
lesion and left frontal deep tumor; breast cancer history(+);
<ul>
<li>finding
<ul>
<li>OP 1:
<ul>
<li>Two pieces white-grayish soft tumor was harvest at left forntal deep
brain.</li>
<li>Frozen section: Tumor, brain, frozen section - Malignancy,
poorly-differentiated.</li>
</ul></li>
<li>OP 2:
<ul>
<li>Xanthochromic then light reddish fluid about 40cc was apirated at
right PO area.</li>
<li>sent for cytology/culture and CSF profile.</li>
</ul></li>
</ul></li>
</ul></li>
</ul></li>
<li>radiotherapy
<ul>
<li>2022-02-07 medrec plan to deliver 30 Gy/ 10 fx to the whole brain.
<ul>
<li>2022-01-24 ~ RT to the whole brain: 21 Gy/ 7 fx. (what does this
mean?)</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-02-24, -03-16: doxorubicin + cyclophosphamide</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient has TNBC with brain mets and is being treated with
doxorubicin and cyclophosphamide as from late February 2022.</li>
<li>In the event that the results do not meet expectations, capecitabine
might be an alternative.
<ul>
<li>reference:
<ul>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/17611719/" class="uri">https://pubmed.ncbi.nlm.nih.gov/17611719/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/16005228/" class="uri">https://pubmed.ncbi.nlm.nih.gov/16005228/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/14650117/" class="uri">https://pubmed.ncbi.nlm.nih.gov/14650117/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/16777702/" class="uri">https://pubmed.ncbi.nlm.nih.gov/16777702/</a></li>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/16909414/" class="uri">https://pubmed.ncbi.nlm.nih.gov/16909414/</a></li>
</ul></li>
</ul></li>
</ul>
</div>
</div>
<div id="section-446" class="section level1">
<h1>701358139</h1>
<div id="section-447" class="section level2">
<h2>220124</h2>
<p>[objective]</p>
<p>This is a patient diagnosed by TSGH with poorly differential gastric
adenocarcinoma with carcinomatosis and metastatic lymphadenopathy and
bone metastasis, cT4aN3aM1, stage IV, seeking for second opinion on
2022-01-21.</p>
<ul>
<li>Lab readings:
<ul>
<li>2022-01-22 Urine: Bacteria 2+</li>
<li>2022-01-22 Abdomen - standing diaphragm: Ascites is highly
suspected.</li>
<li>2022-01-22 Chest PA - erect view:
<ul>
<li>Blunting of right and left costal-phrenic angle is noted, which may
be due to pleura effusion or thickening?</li>
<li>Discoid atelectasis in LLL of the lung is suspected.</li>
</ul></li>
<li>2022-01-21 Blood K 3.0mmol</li>
<li>2022-01-21 Blood gas - vein:
<ul>
<li>PO2 65mmHg</li>
<li>O2 Saturation 92%</li>
</ul></li>
</ul></li>
<li>Medication
<ul>
<li>fluid balance, hypokalemia
<ul>
<li>NAKO No.5</li>
<li>KCl inj</li>
<li>Radi-K</li>
<li>Spironolactone</li>
</ul></li>
</ul></li>
</ul>
<p>[Assessment]</p>
<ul>
<li>Empirical ABX might be considered if applicable based on symptoms
prior to culture outcome.</li>
<li>The following tests could be optionally ordered for future therapy
choice if no related data gathered from TSGH.
<ul>
<li>Microsatellite Instability (MSI) or Mismatch Repair (MMR)</li>
<li>PD-L1</li>
<li>HER2, high tumor mutation burden, NTRK gene fusion</li>
</ul></li>
<li>Mirabegron (beta-3 agonist) might diminish the antihypertensive
effect of Doxazosin (alpha-1 blocker).</li>
<li>The mirabegron prescribing information reports dose-dependent
increases in blood pressure with use. In healthy volunteers mirabegron
(at doses of up to 50 mg) produced mean maximum increases in
systolic/diastolic blood pressure of 3.5/1.5 mm Hg versus placebo.
However, in overactive bladder (OAB) patients, including those with
pre-existing hypertension, receiving a maximum dose of mirabegron 50 mg,
the systolic/diastolic blood pressure was only 0.5 to 1 mm Hg greater
than placebo. OAB patients infrequently reported worsening of
pre-existing hypertension with mirabegron. Both systolic and diastolic
blood pressure increases were reversible with the discontinuation of
mirabegron.</li>
<li>Lab data serum potassium 3.0mmol/L reported on 2022-01-24 showed the
reading below normal range (3.5~5.1), KCl inj and potassium sparing
diuretic Spironolactone have been prescribed.</li>
</ul>
</div>
</div>
<div id="section-448" class="section level1">
<h1>701359667</h1>
<div id="section-449" class="section level2">
<h2>220503</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-07 Pure tone audiometry, PTA
<ul>
<li>Reliability FAIR</li>
<li>Average RE 43 dB HL; LE 111 dB HL.</li>
<li>Rt mild to moderately severe SNHL.</li>
<li>Lt moderately severe to profound mixed type HL.</li>
</ul></li>
<li>2022-02-14 Patho - uterus with or without SO non-neoplastic/prolapse
<ul>
<li>PATHOLOGIC DIAGNOSIS
<ul>
<li>Uterus, endometrium, total hysterectomy  Neuroendocrine
carcinoma.</li>
<li>Uterus, myometrium, total hysterectomy  Neuroendocrine carcinoma.
Invading &gt; 1/2 thickness of the myometrium and 0.4 cm from serosal
surface.</li>
<li>Uterus, cervix, total hysterectomy  Neuroendocrine carcinoma.
Invading endocervix.</li>
<li>Ovaries and fallopian tubes, bilateral, BSO  Free</li>
<li>Lymph node, bilateral pelvic and para-aortic, dissection 
Free<br />
</li>
<li>pT2 pN0 (if cM0) AJCC 8th edition Pathology FIGO stage: II, at
least.<br />
</li>
</ul></li>
<li>MACROSCOPIC EXAMINATION
<ul>
<li>Operation Procedure: Staging surgery(ATH + BSO + omentectomy + LN
dissection)<br />
</li>
<li>Specimens include: uterus, bilateral adnexae, bilateral pelvic and
para-aortic lymph nodes.</li>
</ul></li>
<li>MICROSCOPIC EXAMINATION
<ul>
<li>Histology type: Large cell neuroendocrine carcinoma</li>
<li>Histology grade: high grade.</li>
<li>Depth of invasion: invade &gt; 1/2 thickness of the myometrial
wall<br />
</li>
<li>Uterine Serosa Involvement - Not identified</li>
<li>Cervical Stromal Involvement - Present</li>
<li>Other Tissue/ Organ Involvement - Not identified</li>
<li>Bilateral, ovary: free</li>
<li>Bilateral, fallopian tube: free</li>
<li>Omentum: free</li>
<li>Margins (required only if cervix and/or parametrium/paracervix is
involved by carcinoma)
<ul>
<li>Ectocervical/Vaginal Cuff Margin: Free 2.5 cm away</li>
</ul></li>
</ul></li>
<li>Parametrial/Paracervical Margin: Free
<ul>
<li>Lymphovascular Invasion: Present</li>
<li>Regional Lymph Nodes: free</li>
<li>Ancillary Studies - S2022-02021: IHC stains: CD56 (+), Ki-67:
30-40%, p40 (-), WT-1 (-), vimentin (focal +), p16: &lt;70%.</li>
</ul></li>
</ul></li>
<li>2022-02-11 Whole body PET scan
<ul>
<li>A prominent glucose hypermetabolic lesion in the uterus, compatible
with primary endometrial malignancy.</li>
<li>A small focal area of mildly increased FDG uptake in the right
lateral aspect of the pelvic cavity. The nature is to be determined (a
metastatic lymph node of low FDG uptake? other nature such as
inflammation?). Please correlate with other imaging modalities for
further evaluation.</li>
<li>Increased FDG accumulation in both kidneys, right ureter and
intestine. Physiological FDG accumulation is more likely.</li>
</ul></li>
<li>2022-02-09 Patho - endometrium curretage/biopsy
<ul>
<li>Uterus, endometrium, D&amp;C  Neuroendocrine carcinoma.</li>
<li>IHC stains: CD56 (+), Ki-67: 30-40%, p40 (-), WT-1 (-), vimentin
(focal +), p16: &lt;70%.</li>
<li>Section show(s) piece(s) of markedly necrotic tissue with
infiltration of sheets, nests, and trabeculae of round blue neoplastic
cells demonstrating pleomorphic nuceli.</li>
</ul></li>
<li>2022-02-07 MRI - pelvis
<ul>
<li>Suspected endometrial malignancy, cstage T1bN2M0. IIIc.</li>
<li>Uterine myoma, in cervical region.</li>
</ul></li>
<li>2022-02-04 Gynecologic ultrasonography
<ul>
<li>Endometrial thickening (EM:43.8mm)</li>
<li>Uterine myoma</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-02-26 Chromogranin A 52.1 ng/mL<br />
</li>
<li>2022-02-24
<ul>
<li>Anti-HBs 9.49 mIU/mL<br />
</li>
<li>Anti-HBc Reactive<br />
</li>
<li>Anti-HBc-Value 4.50 S/CO<br />
</li>
<li>Anti-HCV Nonreactive<br />
</li>
<li>Anti-HCV Value 0.02 S/CO<br />
</li>
<li>HBsAg Nonreactive<br />
</li>
<li>HBsAg (Value) 0.35 S/CO<br />
</li>
</ul></li>
<li>2022-02-13
<ul>
<li>Blood type ABO B<br />
</li>
<li>RH(D) Positive</li>
</ul></li>
</ul></li>
<li>surgical operation
<ul>
<li>2022-02-14
<ul>
<li>Surgery
<ul>
<li>Diagnosis: endometrial malignancy, staging surgery. suspected
endometrial malignancy, cstage T1bN2M0. III</li>
<li>Operation: Staging surgery (ATH + BSO + omentectomy + LN dissection)
- Finding</li>
<li>Supraumbilical midline vertical skin incision</li>
<li>Uterus: normal size, tense contact with bladder, peritoneum dut to
tumor mass accupied.</li>
<li>Adnexa:
<ul>
<li>LOV: 3x2x2cm, grossly normal</li>
<li>ROV: 2x2x2cm, grossly normal</li>
<li>Fallopian tube: bilateral grossly normal</li>
<li>CDS: mild adhesion</li>
<li>Ascites: 10 ml</li>
<li>Bilateralpelvic lymph nodes: normal(-), enlarged(-), indurated(+,
right para aortic area)</li>
<li>Omentum: grossly normal</li>
<li>Liver: grossly normal and smooth</li>
<li>Appendix: not seen</li>
<li>After the operation, optimal debulking surgery was achieved.</li>
<li>Residue tumor: R0, No residual tissued left as we seen.</li>
<li>Estimated blood loss: 400ml</li>
<li>Blood transfusion: nil</li>
<li>Complication: nil</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-09
<ul>
<li>Surgery
<ul>
<li>Diagnosis: MRI reported suspect EM malignancy, cstage T1bN2M0</li>
<li>Operation: Diagnostic dilatation and curettage for pathology -
Finding</li>
<li>Uterus: anteversion/retroversion, sounding: 8 cm, dilatation to
Hegar No.9.</li>
<li>Some endometrial tissus was curetted from endometrial cavity.</li>
<li>Estimated blood loss: 3 ml , Blood transfusion: nil, Complication:
nil.</li>
</ul></li>
</ul></li>
</ul></li>
<li>Radiotherapy
<ul>
<li>2022-03-18 ~ - 4500cGy/25 fractions of the pelvic area.</li>
</ul></li>
<li>Chemoimmunotherapy
<ul>
<li>2022-03-09 ~ undergoing - etoposide + cisplatin</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Estrogen receptor (ER) testing is recommended in the settings of
stage III, stage IV, and recurrent disease.</li>
<li>HER2 immunohistochemistry (IHC) testing is recommended for possible
treatment of advanced-stage or recurrent serous endometrial carcinoma or
carcinosarcoma.</li>
<li>Consider HER2 IHC testing in TP53-aberrant endometrial carcinoma
regarless of histotyping.</li>
<li>Molecular analysis of endometrial carcinoma has identified four
clinically significant molecular subgroups with differing clinical
prognoses: POLE mutations, microsatellite instability-high (MSI-H), copy
number low, and copy number high.</li>
<li>Ancillary studies for POLE mutations, mismatch repair (MMR)/MSI, and
aberrant p53 expression are encouraged to complement morphologic
assessment of histologic tumor type.</li>
<li>Universal testing of endometrial carcinomas for MMR proteins is
recommended (MSI testing if results equivocal).</li>
<li>Consider NTRK gene fusion testing for metastatic or recurrent
endometrial carcinoma.</li>
</ul>
</div>
</div>
<div id="section-450" class="section level1">
<h1>701361740</h1>
<div id="section-451" class="section level2">
<h2>220415</h2>
<p>{Acute myeloid leukemia}</p>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-22 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, iliac bone, biopsy  Acute myeloid leukemia</li>
<li>Microscopically, the sections show a picture of acute myeloid
leukemia, no remission, composed of hypocellular marrow for her age
(20-30%). The blasts are small-sized with round nuclei, and small amount
of cytoplasm, 70-80% of nucleated cells.</li>
<li>Immunohistochemistry shows CD34(+), CD117(+) and MPO(-) for blast,
CD61(+, megakaryocytes) and CD71(+, erythroid series) revealed
hypoplasia of megakaryocyte and erythroid series.</li>
</ul></li>
<li>2022-02-22 Abdominal Ultrasonography
<ul>
<li>Indication: pancytopenia</li>
<li>Diagnosis: possible liver lesion or false lesion, S5/8</li>
</ul></li>
<li>2022-02-21 Patho - bone marrow biopsy
<ul>
<li>Bone marrow, biopsy  Compatible with acute myeloid leukemia</li>
<li>The sections show normocellular marrow (35%). The marrow space is
partially replaced by a population of medium-sized immature cells with
oval nucleus and high N/C ratio, constitue 50% of marrow cells.</li>
<li>IHC, the immture cells reveal: CD34(+), CD117(+), TdT(rare+),
CD3(-), CD20(-), CD79a(-). The finding is compatible with acute myeloid
leukemia. Suggest bone marrow smear study and flow cytometry
evaluation.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-03-11
<ul>
<li>HLA A-high 11:01</li>
<li>HLA B-high 39:01</li>
<li>HLA C-high 07:02</li>
<li>HLA DRB1
<ul>
<li>HLA DQ-high 04:02, 06:01</li>
<li>HLA DQ-high 04:10, 08:03</li>
</ul></li>
</ul></li>
<li>2022-03-04
<ul>
<li>FLT3/ITD mutation undetectable</li>
<li>NPM1 mutation undetectable</li>
</ul></li>
<li>2022-03-03 Aspiration
<ul>
<li>CD2 NA</li>
<li>CD3 1.53</li>
<li>CD4 NA</li>
<li>CD5 0.25</li>
<li>CD7 0.15</li>
<li>CD8 NA</li>
<li>CD10 0.82</li>
<li>CD11b 59.4</li>
<li>CD13 76.3</li>
<li>CD14 0.13</li>
<li>CD15 NA</li>
<li>CD16 0.9</li>
<li>CD19 19.16</li>
<li>CD19/kappa NA</li>
<li>CD19/Lambda NA</li>
<li>CD20 0.23</li>
<li>CD23 NA</li>
<li>CD25 NA</li>
<li>CD33 87.26</li>
<li>CD34 98</li>
<li>CD38 NA</li>
<li>CD56 0.15</li>
<li>CD103 NA</li>
<li>CD117 0.04</li>
<li>CD138 NA</li>
<li>FMC7 NA</li>
<li>HLA-DR 99.76</li>
<li>MPO NA</li>
<li>TdT NA</li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-04 ~ undergoing - idarubicin + cytarabine, 3 + 7</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>The patient almost 60 was recently diagnosed with AML and has been
receiving idarubicin and cytarabine (3 + 7) since 2022-03-04.</li>
<li>For patients with AML, FLT3/ITD marks poor survival in younger
(&lt;60 years) but not in older (60-74 years) and NPM1 mutation marks
good survival in older, but not younger. reference: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094014/" class="uri">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094014/</a></li>
<li>The patients lab results of FLT3/ITD and NPM1 were undetectable
(2022-03-04), not revealing much direction in terms of risk
stratification.</li>
<li>Neutropenic fever and HBV are treated with corresponding ABX and
entecavir, respectively. No issue with current medication.</li>
</ul>
</div>
<div id="section-452" class="section level2">
<h2>220323</h2>
<p>{Quinolones-Antacids Interactions}</p>
<p>[objective]</p>
<ul>
<li>Drugs listed in current medication
<ul>
<li>Cravit (levofloxacin 500mg/tab) 1.5 tab PO QDAC</li>
<li>Strocain (oxethazaine, polymigel i.e.aluminum hydroxide + calcium
carbonate + magnesium carbonate) 5mg/tab 1 tab PO TIDAC</li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Antacids may decrease the absorption of quinolones in the setting of
oral administration of quinolones.
<ul>
<li>Antacids interacting members: Almagate, Aluminum Hydroxide, Calcium
Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium
Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate
<ul>
<li>Exception: Sodium Bicarbonate</li>
</ul></li>
<li>Quinolones interacting members: Ciprofloxacin (Systemic),
Delafloxacin, Enoxacin, Gemifloxacin, Levofloxacin (Systemic),
Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin,
Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin,
Zabofloxacin
<ul>
<li>Exception: Levofloxacin (Oral Inhalation)</li>
</ul></li>
</ul></li>
</ul>
<p>[suggestion]</p>
<ul>
<li>Either administration of Cravit 30 minutes before Strocain or
lowering of Strocain to QLAC + QNAC is recommended.</li>
</ul>
</div>
</div>
<div id="section-453" class="section level1">
<h1>701361784</h1>
<div id="section-454" class="section level2">
<h2>220429</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-03-27 Chest
<ul>
<li>Lung markings: emphysematous change in the bilateral lung
fields</li>
</ul></li>
<li>2022-03-26
<ul>
<li>Fecal material store in the colon.</li>
<li>Spondylosis of the L-spine is noted.</li>
</ul></li>
<li>2022-03-26 Femur LT
<ul>
<li>Left femoral intersubtrochanteric fracture, s/p ORIF</li>
</ul></li>
<li>2022-03-14 Chest
<ul>
<li>Atherosclerosis of the aorta.</li>
</ul></li>
<li>2022-03-08 Whole body PET scan
<ul>
<li>The FDG PET findings are compatible with lymphoma involving multiple
lymph nodes on both sides of the diaphragm, spleen, stomach and
bones/bone marrow (stage IV).</li>
</ul></li>
<li>2022-03-07 Bone densitometry - hip
<ul>
<li>Right hip, BMD is 0.537 gms/cm2, about 2.8 SD below the peak bone
mass (63%) and 0.3 SD below the mean of age-matched people (95%).</li>
<li>Osteoporosis</li>
</ul></li>
<li>2022-02-25 Patho - lymphnode biopsy
<ul>
<li>pathologic diagnosis
<ul>
<li>Left subhepatic lesion, CT-guide biopsy  High grade B cell
lymphoma, favor diffuse large B-cell lymphoma<br />
</li>
</ul></li>
<li>microscopic examination
<ul>
<li>Histology type: high grade B cell lymphoma shows medium to large
atypical lymphoid cells with nucleoli, frequent apoptosis and focal
tumor necrosis.</li>
<li>Immunohistochemistry: CK(-), CD3(-), CD20(+), Bcl-2(-), CD30(-),
CD10(+), Bcl-6(+), C-MYC(+, 80%), cyclin-D1(-) and Ki-67:&gt;90% for
tumor. According to all above histopathologic findings, it is in favor
of diffuse large B-cell lymphoma, and Burkitts lymphoma is less likely,
but can not be entirely excluded due to limited specimen.</li>
</ul></li>
</ul></li>
<li>2022-02-18 MRI - liver, spleen (non-contrast)
<ul>
<li>Non-contrast MRI has limitation in diagnosis of solid organ
pathology, bowel loop lesion, and vascular system abnormality. We
recommend contrast enhanced MRI if patients renal function can tolerate
Gd-DTPA injection.
<ul>
<li>There are several lobulated soft tissue masses in the hepatic hilum,
gastrohepatic ligament, hepatoduodenal ligament, aortocaval space, and
right perirenal space. In addition, One enlarged node measuring 1.9 x
1.4 cm in right supradiaphram cardiac-phrenic space is noted. Three soft
tissue masses in the omentum are noted. Malignant lymphoma is highly
suspected.</li>
<li>There is a well-defined heterogeneous mass measuring 5 x 3.2 cm in
the submucosal layer of the gastric body that may be lymphoma. Please
correlate with gastroscopy.</li>
<li>There is edematous wall thickening and distension of the
gallbladder, and mild dilatations of IHDs and CHD. Please correlate with
clinical condition.</li>
<li>Both kidney show small size and thin renal parenchyma that are
compatible with chronic renal disease. Please correlate with renal
function.</li>
<li>Mild ascites is noted.</li>
<li>Mild right side pleura effusion is noted.</li>
<li>There is no focal abnormality in the pancreas and spleen.</li>
<li>The abdominal aorta and IVC are grossly unremarkable.<br />
</li>
</ul></li>
<li>Malignant lymphoma is highly suspected. Please correlate with biopsy
and serum LDH level.</li>
</ul></li>
</ul></li>
<li>lab data
<ul>
<li>2022-02-17
<ul>
<li>Anti-HBc reactive, 4.57 S/CO</li>
<li>Anti-HCV nonreactive, 0.10 S/CO</li>
<li>HBsAg nonreactive, 0.34 S/CO</li>
</ul></li>
</ul></li>
<li>consultation
<ul>
<li>2022-04-19 cardiology
<ul>
<li>Q
<ul>
<li>For hypertension poor control</li>
<li>This 72-year-old female, a pt of double-hit DLBCL at troperitoneal
fossa, Lugano stage IV Dx in Feb 2022 S/P C/T. She was admitted for
chemotherapy. Owing to high blood perssure was noted (195/91 mmHg) and
anti-hypertensive agent was given but still poor control. We need
expertise to evaluate her condition thanks!</li>
</ul></li>
<li>A
<ul>
<li>This is a 72 years old lady who was admitted for Diffuse large B
cell lymphoma under R-DA-EPOCH therapy. We were consulted for poor
control BP</li>
<li>Current medication
<ul>
<li>concor 5mg 1# qd</li>
<li>hyzaar 1# qd</li>
</ul></li>
<li>exam
<ul>
<li>BP: 195/91 (most of the day: SBP&gt;160)</li>
<li>HR: 80</li>
<li>EKG: LVH pattern</li>
<li>CXR: normal heart size</li>
<li>Cr 2.0</li>
<li>UA 10.5;</li>
</ul></li>
<li>Impression
<ul>
<li>Hypertensive cardiovascular disease with poor cpntrol; suspected C/T
induced.</li>
</ul></li>
<li>Suggestion
<ul>
<li>May add sevikar 1# qd; regular use of apresoline if SBP still
&gt;160 mmHg.</li>
<li>DC hyzare due to significant hyperuricemia.</li>
<li>Check chemotherapy side effect (whether using tyrosine kinase
inhibitor? VEGF inhibitor?), and change regimen if feasible.</li>
</ul></li>
</ul></li>
</ul></li>
<li>2022-02-25 cardiology
<ul>
<li>S: abdominal pain</li>
<li>O:
<ul>
<li>Labs
<ul>
<li>Cr: 1.75 -&gt; 2.43 -&gt; 1.2</li>
<li>CRP: 4</li>
<li>Na/K: 136/4.2</li>
</ul></li>
<li>Cardiac echo: EF: 70%
<ul>
<li>Normal LV systolic function with normal wall motion.</li>
<li>Hypertrophic cardiomyopathy without outflow tract obstruction; LV
diastolic dysfunction Gr 1.</li>
</ul></li>
<li>Current BP medications
<ul>
<li>PO concor and po hyzaar</li>
</ul></li>
</ul></li>
<li>Impression:
<ul>
<li>Hypertensive cardiovascular disease, without acute hypertensive
crisis</li>
<li>Hypertrophic cardiomyopathy without outflow tract obstruction</li>
<li>Suspected cholangiocarcinoma or suspected lymphoma</li>
</ul></li>
<li>Suggestion:
<ul>
<li>Adequate pain control if patient is in pain due to fracture or
abdominal pain.</li>
<li>Add norvasc 1# qd - bid.</li>
<li>to keep concor 5 mg qd</li>
</ul></li>
</ul></li>
<li>2022-02-23 radiological diagnosis
<ul>
<li>According to the clinical condition and imaging findings, biopsy is
indicated.</li>
</ul></li>
<li>2022-02-16 surgery
<ul>
<li>a huge tumor near liver hilum, liver origin? pancreatic origin? or
lymphoma
<ul>
<li>admission for tumor survey</li>
<li>check MRI and tumor markers after admission</li>
<li>check HBsAg, anti-HCV, anti-HBs, anti-HBc</li>
</ul></li>
</ul></li>
</ul></li>
<li>chemotherapy
<ul>
<li>2022-03-15 ~ undergoing - R-DA-EPOCH, Dose-adjusted EPOCH-R,
<ul>
<li>etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin,
plus rituximab
<ul>
<li><a href="https://www.uptodate.com/contents/image?imageKey=ONC%2F88411" class="uri">https://www.uptodate.com/contents/image?imageKey=ONC%2F88411</a></li>
<li>drugs
<ul>
<li>Rituximab, 375 mg/m2 IV, Day 0 or 1</li>
<li>Etoposide, 50 mg/m2 per day IV, Days 1 to 4 (96 hours)</li>
<li>Doxorubicin, 10 mg/m2 per day IV, Days 1 to 4 (96 hours)</li>
<li>Vincristine, 0.4 mg/m2 per day IV (dose not capped), Days 1 to 4 (96
hours)</li>
<li>Cyclophosphamide, 750 mg/m2 IV, Day 5</li>
<li>Prednisone, 60 mg/m2 orally twice daily, Administer first dose 30
minutes prior to chemotherapy on day 1., Days 1 to 5</li>
<li>Granulocyte colony stimulating factor (G-CSF), Start day 6</li>
</ul></li>
</ul></li>
<li>Pretreatment considerations:
<ul>
<li>Hydration
<ul>
<li>Patients receiving cyclophosphamide should maintain adequate oral
hydration (2 to 3 L/day) and void frequently to reduce risk of
hemorrhagic cystitis.</li>
</ul></li>
<li>Emesis risk
<ul>
<li>MODERATE.</li>
</ul></li>
<li>Prophylaxis for infusion reactions
<ul>
<li>Premedicate with acetaminophen and diphenhydramine, with or without
an H2 receptor blocker, 30 minutes prior to at least the first and
second infusions of rituximab.</li>
</ul></li>
<li>Vesicant/irritant properties
<ul>
<li>Doxorubicin and vincristine are vesicants; avoid extravasation.
Etoposide is an irritant.</li>
</ul></li>
<li>Infection prophylaxis
<ul>
<li>Primary prophylaxis with hematopoietic growth factors is an
essential component of this regimen. Regular or pegylated G-CSF may be
used according to center policy. In addition, due to the risk of
developing Pneumocystis jiroveci pneumonia and other opportunistic
infections, consider the use of antimicrobial prophylaxis.</li>
</ul></li>
<li>Dose adjustment for baseline liver or renal dysfunction
<ul>
<li>Adjustment of initial cyclophosphamide, doxorubicin, etoposide, and
vincristine doses may be needed for preexisting liver dysfunction. In
addition, dose adjustment of etoposide and cyclophosphamide may be
required for renal dysfunction.</li>
</ul></li>
<li>Hepatitis screening
<ul>
<li>Patients should be screened for hepatitis B and C prior to starting
rituximab, and, if positive, considered for antiviral prophylaxis.</li>
</ul></li>
<li>Cardiac screening
<ul>
<li>Doxorubicin is associated with cardiomyopathy, the incidence of
which is related to cumulative dose. Assess baseline LVEF prior to
initiation of therapy. Dose alterations should be considered for LVEF
&lt;50%, and doxorubicin therapy is contraindicated in patients with
LVEF &lt;30% at initiation, those with recent myocardial infarction,
severe myocardial dysfunction, severe arrhythmia, or previous therapy
with high cumulative doses of doxorubicin or any other
anthracyclines.</li>
</ul></li>
<li>CNS prophylaxis
<ul>
<li>The need for CNS prophylaxis is determined based upon the
aggressiveness of the tumor reflected in the histology, organ
involvement, and presence or absence of high risk features.</li>
</ul></li>
<li>HIV screening
<ul>
<li>Patients should be screened for HIV prior to starting therapy.
Consider reducing the initial dose of cyclophosphamide to 187 mg/m2 if
CD4 &lt;100/microL at diagnosis.</li>
</ul></li>
<li>Neurotoxicity
<ul>
<li>Vincristine may cause constipation, and in severe cases, paralytic
ileus. A routine prophylactic regimen against constipation is
recommended in all patients receiving vincristine.</li>
</ul></li>
</ul></li>
<li>Monitoring parameters:
<ul>
<li>CBC with differential and platelet count twice weekly during
treatment.</li>
<li>Assess basic metabolic panel (creatinine and electrolytes) and liver
function prior to each subsequent treatment cycle.</li>
<li>Monitor cumulative doxorubicin dose. Reassess LVEF periodically
during dose-adjusted EPOCH-R therapy, as clinically indicated.</li>
<li>Carriers of hepatitis B or C should be monitored for clinical and
laboratory signs of active infection during and following completion of
therapy. Rituximab should be discontinued if reactivation occurs.</li>
</ul></li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>SBP 190~140 (most times &gt; 150), DBP 65~90, HR no less than 100
pulse per minite since 2022-04-28 this hospitalization so far, under
Concor (bisoprolol 5mg, QD), Sevikar (amlodipine 5mg + olmesartan 20mg,
QD) prescribed as self-carried drugs since 2022-04-29. Chemotherapy has
not yet been administered for now in this hospital stay.</li>
<li>WBC 310/uL, Neutrophil 18%, CRP 5.24 mg/dL, RBC 2.6<em>10^6/uL, HGB
8.0g/dL, PLT 43</em>10^3/uL, normal urine exam results on 2022-04-28,
body temperature 39.3 degree Celsius at 07:41 2022-04-29.</li>
<li>Primary prophylaxis with hematopoietic growth factors should be a
component of the R-DA-EPOCH regimen. Chemotherapy induced cytopenia is
managed with Granocyte (lenograstim 250mcg, QD). Elevations of CRP occur
in association with acute and chronic inflammation due to a range of
causes, including infectious diseases and noninfectious inflammatory
disorders. Elevated CRP with fever is managed with Tapimycin
(piperacillin 2g + tazobactam 0.25g, Q8H). Due to the risk of developing
Pneumocystis jiroveci pneumonia and other opportunistic infections, the
use of antimicrobial prophylaxis might be necessary. reference: <a href="https://pubmed.ncbi.nlm.nih.gov/11929754/" class="uri">https://pubmed.ncbi.nlm.nih.gov/11929754/</a></li>
<li>Doxorubicin is associated with cardiomyopathy, the incidence of
which is related to cumulative dose. The baseline LVEF prior to
chemotherapy initiation on 2022-02-22 was 70%, this does not suggest a
dose alteration.</li>
<li>The patient was screened for hepatitis B and C prior to starting
rituximab and is now receiving Vemlidy (tenofovir alafenamide 25mg QDCC)
for her HBV infection.</li>
</ul>
</div>
<div id="section-455" class="section level2">
<h2>220418</h2>
<p>[assessment]</p>
<ul>
<li>Pathology on 2022-02-25 revealed that C-MYC(+, 80%), BCL-2(-),
BCL-6(+), high-grade B-cell lymphoma (HGBL) with translocations of MYC
and BCL6, also known as double-hit lymphoma, is frequently associated
with poor prognostic factors, including elevated LDH, bone marrow and
central nervous system involvement, and high IPI score.</li>
<li>PET on 2022-03-08 indiated involvement of multiple lymph nodes on
both sides of the diaphragm, spleen, stomach and bones/bone marrow,
stage IV.</li>
<li>DA-EPOCH-R has been in use since 2022-03-15, the LDH has decreased
to 181 U/L (2022-04-15, WNL) from its peak of 1364 U/L (2022-03-16),
which might hint an improvement, and no evidence of CNS involvement has
yet been confirmed.</li>
<li>Vincristine may cause constipation, and in severe cases, paralytic
ileus. A routine prophylactic regimen against constipation is
recommended in all patients receiving vincristine. Metoclopramide and
sennoside have been prescribed.</li>
<li>Hypomagnesemia (1.4 mg/dL 2022-04-18) is treated with MgSO4 10% 20mL
IVD QD currently.</li>
</ul>
</div>
</div>
<div id="section-456" class="section level1">
<h1>701365869</h1>
<div id="section-457" class="section level2">
<h2>999999</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-04-19 Cell block - suspected malignant pleural effusion
<ul>
<li>SMEARS and CELLBLOCK: Many clusters of neoplastic cells
present.</li>
</ul></li>
<li>2022-03-25 MRI - brain
<ul>
<li>No evidence of brain metastasis.</li>
</ul></li>
<li>2022-03-23 PD-L1 (SP142) Assay (Ventana) S2022-4656
<ul>
<li>Result:
<ul>
<li>Tumor cell (TC) staining assessment: TC category: TC  1%</li>
<li>Tumor-infiltrating immune cell (IC) staining assessment: IC
category: IC  1%</li>
</ul></li>
<li>Note:
<ul>
<li>TC scoring: TC are scored as the percentage of viable tumor cells
showing membrane staining of any intensity.</li>
<li>IC scoring: IC are scored as the proportion of tumor area (including
associated intratumoral and contiguous peritumoral stroma) that is
occupied by discernible staining of any intensity of tumor-infiltrating
immune cells.</li>
</ul></li>
</ul></li>
<li>2022-03-24 Tc-99m MDP whole body bone scan
<ul>
<li>Increased activity in the lower L-spines. Degenerative change may
show this picture. Please correlate with other imaging modalities for
further evaluation.</li>
<li>Increased activity in the maxilla. Dental problem and/or sinusitis
may show this picture.</li>
<li>Some faint hot spots in the skull and bilateral rib cages. The
nature is to be determined (post-traumatic change? other nature?).
Please follow up bone scan for further evaluation.</li>
<li>Increased activity in bilateral shoulders and hips, compatible with
benign joint lesions.</li>
</ul></li>
<li>2022-03-21 Patho - pleural/pericardial biopsy
<ul>
<li>Lung, right, CT-guide biopsy  adenocarcinoma, moderately
differentiated</li>
<li>Sections show acinar glandular tumor cells infiltrating in a
fibrotic stroma.</li>
</ul></li>
<li>2022-03-19 Chest PA/AP view
<ul>
<li>There are few nodular opacity projecting in right lung that may be
metastases. Please correlate with CT.</li>
<li>Blunting of right costal-phrenic angle is noted, which may be due to
pleura effusion or thickening?</li>
<li>Atherosclerotic change of aortic arch</li>
<li>Enlargement of cardiac silhouette.</li>
</ul></li>
<li>2022-03-19 MRI - pelvis
<ul>
<li>Soft tissue tumors in bilateral adnexa and uterus (surface region),
r/o carcinomatosis. Prominent right lower abdomen soft tissue, r/o
carcinomatosis (appendix origin?)</li>
<li>Prominent ascites and bowel ileus.</li>
<li>Right pleural seeding with effusion.</li>
</ul></li>
<li>2022-03-15 Cell block
<ul>
<li>SMEARS and CELLBLOCK: Many clusters of adenocarcinoma present.</li>
<li>IHC stains:
<ul>
<li>TTF-1(+), Napsin-A(+): favor pulmonary origin;</li>
<li>CK20(-): dis-favor GI origin;</li>
<li>GATA-3(-): dis-favor breast origin;</li>
<li>PAX-8 (-): dis-favor ovarain origin.</li>
</ul></li>
</ul></li>
<li>2022-03-15 Gynecologic ultrasonography
<ul>
<li>Ascites(+)</li>
<li>A mass 9.2x8.9mm in uterus</li>
</ul></li>
<li>2022-03-12 Chest PA (erect) view
<ul>
<li>Consolidation and pleural effusion in right chest</li>
</ul></li>
</ul></li>
</ul>
<p>The patient suffered from SOB, air hunger, cold sweat, and the cold
of four limbs, the 12 lead EKG: sinus tachycardia, the heart rate from
139bpm to 58bpm, the blood oxygen drop, changed the oxygen support with
NRM O2 fll, the SpO2 97%, then we cant measure blood pressure, and the
patient consciousness become drowsy and the blood oxygen drop again,
under the NRM O2 full. The VS talks about the patients condition to
the family, so gave the endo inserting, on levophed and Dopamin high
dose will be transferred to MICU.</p>
</div>
</div>
<div id="section-458" class="section level1">
<h1>701374584</h1>
<div id="section-459" class="section level2">
<h2>220506</h2>
<p>[objective]</p>
<ul>
<li>exam finding
<ul>
<li>2022-05-05 CT - abdomen, pelvis
<ul>
<li>Massive ascites.</li>
<li>Swelling of pancreas.</li>
<li>General subcutaneous edema.</li>
</ul></li>
<li>2022-05-05 KUB
<ul>
<li>Some calcifications in pelvic cavity.</li>
<li>Presence of ileus.</li>
<li>Intact bony structure(s).</li>
</ul></li>
<li>2022-05-05 Chest PA erect view
<ul>
<li>Essential negative findings of the air way, mediastinum, heart,
lungs, pleura, diaphragm and thoracic cage.</li>
</ul></li>
</ul></li>
</ul>
<p>[assessment]</p>
<ul>
<li>Items in active problem list were treated with corresponding agents
<ul>
<li>metabolic acidosis - sodium bicarbonate</li>
<li>hyperkalemia - calcium polystyrene sulfonate</li>
<li>hypertension - nifedipine, clonide, doxazosin, carvedilol</li>
<li>type II diabetes - linagliptin, repaglinide</li>
</ul></li>
<li>Beta-blockers can potentially increase blood glucose concentrations
and antagonize the action of oral hypoglycemic drugs, however the odds
are greater for selective beta blockers than for carvedilol. reference:
<a href="https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0967-1" class="uri">https://cardiab.biomedcentral.com/articles/10.1186/s12933-019-0967-1</a></li>
<li>There are no records of drug allergies in the database. There are no
issues with the current medication.</li>
</ul>
</div>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
